
<html lang="en"     class="pb-page"  data-request-id="898f47e4-fe74-4a02-b5fb-a04963ed70ec"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c01336"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Cancer Stem Cell (CSC) Inhibitors in Oncology—A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives" /></meta><meta name="dc.Creator" content="Prashant S.  Kharkar" /></meta><meta name="dc.Description" content="Cancer stem cells (CSCs), a subpopulation of cancer cells endowed with self-renewal, tumorigenicity, pluripotency, chemoresistance, differentiation, invasive ability, and plasticity, reside in spec..." /></meta><meta name="Description" content="Cancer stem cells (CSCs), a subpopulation of cancer cells endowed with self-renewal, tumorigenicity, pluripotency, chemoresistance, differentiation, invasive ability, and plasticity, reside in spec..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 16, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01336" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01336" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01336" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01336" /></link>
        
    
    

<title>Cancer Stem Cell (CSC) Inhibitors in Oncology—A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01336" /></meta><meta property="og:title" content="Cancer Stem Cell (CSC) Inhibitors in Oncology—A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0012.jpeg" /></meta><meta property="og:description" content="Cancer stem cells (CSCs), a subpopulation of cancer cells endowed with self-renewal, tumorigenicity, pluripotency, chemoresistance, differentiation, invasive ability, and plasticity, reside in specialized tumor niches and are responsible for tumor maintenance, metastasis, therapy resistance, and tumor relapse. The new-age “hierarchical or CSC” model of tumor heterogeneity is based on the concept of eradicating CSCs to prevent tumor relapse and therapy resistance. Small-molecular entities and biologics acting on various stemness signaling pathways, surface markers, efflux transporters, or components of complex tumor microenvironment are under intense investigation as potential anti-CSC agents. In addition, smart nanotherapeutic tools have proved their utility in achieving CSC targeting. Several CSC inhibitors in clinical development have shown promise, either as mono- or combination therapy, in refractory and difficult-to-treat cancers. Clinical investigations with CSC marker follow-up as a measure of clinical efficacy are needed to turn the “hype” into the “hope” these new-age oncology therapeutics have to offer." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01336"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01336">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01336&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01336&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01336&amp;href=/doi/10.1021/acs.jmedchem.0c01336" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 15279-15307</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01304" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01337" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Cancer Stem Cell (CSC) Inhibitors in Oncology—A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Prashant S. Kharkar</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Prashant S. Kharkar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga, Mumbai 400 019, India</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#5121227f3a3930233a3023113832253c243c3330387f3435247f383f"><span class="__cf_email__" data-cfemail="b3c3c09dd8dbd2c1d8d2c1f3dad0c7dec6ded1d2da9dd6d7c69ddadd">[email protected]</span></a>. Tel: +91-22-3362225.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Prashant+S.++Kharkar">Prashant S. Kharkar</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1955-7223" title="Orcid link">http://orcid.org/0000-0003-1955-7223</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01336&amp;href=/doi/10.1021%2Facs.jmedchem.0c01336" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 15279–15307</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 16, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 July 2020</li><li><span class="item_label"><b>Published</b> online</span>16 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01336" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01336</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D15279%26pageCount%3D29%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPrashant%2BS.%2BKharkar%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D24%26contentID%3Dacs.jmedchem.0c01336%26title%3DCancer%2BStem%2BCell%2B%2528CSC%2529%2BInhibitors%2Bin%2BOncology%25E2%2580%2594A%2BPromise%2Bfor%2Ba%2BBetter%2BTherapeutic%2BOutcome%253A%2BState%2Bof%2Bthe%2BArt%2Band%2BFuture%2BPerspectives%26numPages%3D29%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D15307%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01336"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1031</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01336" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Cancer Stem Cell (CSC) Inhibitors in Oncology—A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Prashant&quot;,&quot;last_name&quot;:&quot;S. Kharkar&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15279-15307&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01336&quot;},&quot;abstract&quot;:&quot;Cancer stem cells (CSCs), a subpopulation of cancer cells endowed with self-renewal, tumorigenicity, pluripotency, chemoresistance, differentiation, invasive ability, and plasticity, reside in specialized tumor niches and are responsible for tumor maintenance, metastasis, therapy resistance, and tumor relapse. The new-age “hierarchical or CSC” model of tumor heterogeneity is based on the concept of eradicating CSCs to prevent tumor relapse and therapy resistance. Small-molecular entities and biologics acting on various stemness signaling pathways, surface markers, efflux transporters, or components of complex tumor microenvironment are under intense investigation as potential anti-CSC agents. In addition, smart nanotherapeutic tools have proved their utility in achieving CSC targeting. Several CSC inhibitors in clinical development have shown promise, either as mono- or combination therapy, in refractory and difficult-to-treat cancers. Clinical investigations with CSC marker follow-up as a measure of clinical&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01336&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01336" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01336&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01336" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01336&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01336" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01336&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01336&amp;href=/doi/10.1021/acs.jmedchem.0c01336" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01336" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01336" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01336%26sid%3Dliteratum%253Aachs%26pmid%3D33325699%26genre%3Darticle%26aulast%3DKharkar%26date%3D2020%26atitle%3DCancer%2BStem%2BCell%2B%2528CSC%2529%2BInhibitors%2Bin%2BOncology%25E2%2580%2594A%2BPromise%2Bfor%2Ba%2BBetter%2BTherapeutic%2BOutcome%253A%2BState%2Bof%2Bthe%2BArt%2Band%2BFuture%2BPerspectives%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D24%26spage%3D15279%26epage%3D15307%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292519" title="Cancer therapy">Cancer therapy</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291081" title="Immunotherapy">Immunotherapy</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/jmcmar.2020.63.issue-24/20201224/jmcmar.2020.63.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Cancer stem cells (CSCs), a subpopulation of cancer cells endowed with self-renewal, tumorigenicity, pluripotency, chemoresistance, differentiation, invasive ability, and plasticity, reside in specialized tumor niches and are responsible for tumor maintenance, metastasis, therapy resistance, and tumor relapse. The new-age “hierarchical or CSC” model of tumor heterogeneity is based on the concept of eradicating CSCs to prevent tumor relapse and therapy resistance. Small-molecular entities and biologics acting on various stemness signaling pathways, surface markers, efflux transporters, or components of complex tumor microenvironment are under intense investigation as potential anti-CSC agents. In addition, smart nanotherapeutic tools have proved their utility in achieving CSC targeting. Several CSC inhibitors in clinical development have shown promise, either as mono- or combination therapy, in refractory and difficult-to-treat cancers. Clinical investigations with CSC marker follow-up as a measure of clinical efficacy are needed to turn the “hype” into the “hope” these new-age oncology therapeutics have to offer.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03710" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03710" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Novel oncology therapeutics targeting cancer stem cells (CSCs) is one of the most admired 21st century expeditions. Initially viewed by critics with skepticism, the field has come a long way, from naı̈ve concepts in the early days to the most recent clinical trials featuring promising anti-CSC agents. Even though countless scientific studies have reiterated the importance of CSCs in tumor initiation, progression, chemoresistance, and finally relapse, it would not be an understatement to say, “the field is still in its infancy”. The modern-day scientific community is aware of the potential offered by the anti-CSC therapeutics in radically transforming the oncology arena.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Higher incidence rates of several cancers such as lung, breast, prostate, colorectal, and many others have complicated the treatment regimens and modalities. The higher prevalence of multidrug resistance, the lower or marginally better response rates even with costly immuno- and molecularly targeted therapies, the humongous R&D spending, the lack of reliable preclinical models, and the never-ending quest for the so-called “better oncology drug” have contributed to the present-day realistic and abysmally frustrating picture of oncology drug discovery and development. The CSC hypothesis, “intratumoral presence of a subpopulation of cells with self-renewal, tumorigenesis and invasive characteristics, which maintains the cellular heterogeneity within a tumor in hierarchical manner”, improved our understanding of the origin of tumors and the complex tumor microenvironment (TME). The age-old mysteries in oncology are being unfolded with this relatively newer school of thought, strongly aided by the solid scientific foundation. The debate concerning the “CSC hypothesis” and the well-respected “clonal or stochastic model of cancer” has been going on for quite some time.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> We are standing at the crossroads and witnessing an important era in oncology research. We either “believe it” or “leave it”! The rightful choice will be evident only after we take a plunge in the vast sea of the biomedical literature centered on CSCs.</div><div class="NLM_p">In this regard, a PubMed<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> search (conducted on 2020-10-19) for articles on “Cancer Stem Cells” published during 1983–2021 yielded 83 672 hits, with ∼47% of the articles published between 2015 and 2021 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). An exploratory analysis of these data led to interesting observations. Approximately 2% of the articles were on “Clinical Trial”, “Randomized Controlled Trial”, and “Meta-Analysis”, with a peak appearing in 2018, whereas ∼20% of the articles belonged to the “Review” and “Systematic Review” categories. Similar trends were unveiled by the SciFinder<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> search (conducted on 2020-10-19), wherein ∼50% of the articles were published and 451 patent applications/patents were filed/published/granted between 2015 and 2020, with a record 95 patent applications/patents in 2016. To conclude, the publications and patent data clearly emphasized the exponentially growing interest of the scientific community and the pharmaceutical industry in this field.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Distribution of number of articles in PubMed on “Cancer Stem Cells” (1983–2021).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">CSCs reside in an anatomically distinct part of the heterogeneous TME, that is, the CSC niche.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> These cells are capable of producing diverse factors that endow them the ability to self-renew, induce angiogenesis, catalyze further sequences of events leading to immune and other stromal cell recruitment, and ultimately promote tumor cell invasion and metastasis. In brief, the CSC niche contributes to the heterogeneous cancer cell lineages, which make up most of the tumor mass.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The CSCs undergo symmetric self-renewal (producing two CSCs), asymmetric division (leading to one CSC and one differentiated cell), or symmetric differentiation (generating two differentiated cells) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Logically, the symmetric self-renewal can contribute to the excessive cell growth required for tumor formation. The models of tumorigenesis—the CSC or hierarchical model (designating CSCs as malignant tumor-propagating cells) and the stochastic model (designating every tumor cell that is capable of tumor initiation and progression)—are unified by cellular plasticity. It is the capacity of the cancer cell population to interconvert between the differentiated and the stem-like states.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5−7)</a> Normal stem cells (NSCs) heavily rely on cellular plasticity to maintain the intricate balance between the parental stemness and the progeny cells differentiating into multiple cell lineages. Oncogenic transformations and the ensuing cellular reprogramming derail the critical homeostatic mechanisms and contribute to the dedifferentiation of non-CSCs into CSCs. Tumorigenesis kicks in.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cell division fate of CSCs: (a) asymmetric division, (b) symmetric division, and (c) symmetric differentiation. Adapted from ref <a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a>. Copyright 2016 G. Lee et al.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Stemness Characteristics: A Closer Look at CSCs and NSCs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81851" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81851" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The curious reader is now poised with a relevant question, “How are CSCs distinct from NSCs?” The cell division, be it symmetric or asymmetric, is tightly controlled in NSCs for obvious reasons, whereas the dysregulation of the dynamic balance between cells with stem-like characteristics and the normal cancer cells coupled to erroneous cellular plasticity results in abnormal cell division in CSCs.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Unlike the organogenic NSCs, which are majorly quiescent and are rare in normal adult tissues, tumorigenic CSCs are infrequently found within tumors. Moreover, they are mitotically less active than the bulk of the tumor cells. The NSC karyotypes are normal, whereas the CSC ones are abnormal. Both cell types share appreciable similarities such as (i) signaling pathways regulating self-renewal, angiogenesis, and other critical processes; (ii) surface receptors; (iii) regulation of telomeres and telomerase activity; and (iv) dependence on secreted cytokines and growth factors, among others.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Because of these factors, the therapeutic targeting of CSCs presents appreciable challenges. As we discover more about CSC biology, precise anti-CSC strategies will be articulated in the years to come.</div><div class="NLM_p">Resistance to chemo- and radiotherapies is one of the prominent features of both, NSCs and CSCs.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The ATP-binding cassette (ABC) transporters, ABCB1 (P-glycoprotein 1 (P-gp)) and ABCG2 (breast cancer resistance protein (BCRP)), are overexpressed in both cell types.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> These transporters majorly contribute to the maintenance of stemness and protect the cells from cellular toxins.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Muriithi et al. (2020) extensively reviewed the roles of ABC transporters in cancer aggressiveness beyond multidrug resistance (MDR).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The new line of evidence strongly indicated the critical role played by these proteins in transporting tumor-promoting molecules and mediating important protein–protein interactions that affect tumor aggressiveness, progression, and patient prognosis. It is now well known that CSCs are inherently resistant to radiotherapy. In fact, CSCs are enriched postradiation exposure, for example, glioblastoma<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and oral cancer.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">Pluripotency, or multipotency, a distinct stemness property, refers to the ability of a cell to differentiate into many derivatives, giving rise to most cells of the embryo.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Embryonic stem cells (ESCs) undergo unlimited proliferation just like CSCs. Both cell types share similar regulatory mechanisms, for example, pluripotent transcription factors (TFs)—octamer-binding transcription factor 4 (Oct4), NANOG, and sex determining region Y-box 2 (Sox2)—not only catalyze the somatic cells reprogramming into an ESC-like state but also maintain ESC self-renewal and pluripotency.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The criticality lies in the fact that these TFs, well in advance, prevent the division of ESCs into the wrong cell type. In CSCs, the scenario is a bit different, wherein the overexpression of <i>OCT4</i>, <i>NANOG</i>, and <i>SOX2</i> leads to the inhibition of apoptosis via the modulation of several signaling pathways, for example, the Oct4/Tcl1/Akt1 pathway and the Sox2/ORAIL/STIM1 pathway. A detailed discussion of these pathways is beyond the scope of the present Perspective. Li et al. (2017) proposed a dual Oct4/Akt inhibition strategy using metformin and Akt 1/2 inhibitor to curtail the CSC and bulk cancer cell proliferation.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Efremov et al. (2019) showed that malignancy and stemness were deeply interlinked and that there existed a mechanism contributing to the <i>de novo</i> formation of a pluripotent phenotype in the subpopulation of so-called “committed” tumor cells.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Substantial overlap between the CSCs and NSCs with reference to the stemness genes led to a conclusive definition of malignancy as the capability to maintain a stemness gene expression profile, aided by invasion, metastasis, and multidrug resistance.</div><div class="NLM_p">The epithelial (polar phenotype)–mesenchymal (invasive phenotype) transition (EMT) is inseparable from CSCs. A variety of cellular processes, for example, migration, invasion, metastasis, alteration of the extracellular matrix (ECM), and apoptosis, are all controlled by the EMT. In fact, EMT-exhibiting cells present in the CSC population contribute to drug resistance. Thus CSCs with the EMT feature survive drug treatment, which ultimately results in tumor relapse. Tanabe et al. (2020) stupendously reviewed the linkage between the EMT and CSCs on various fronts such as the regulation of signaling pathways (e.g., Wnt/β-catenin, Notch, Janus kinase/signal transducer and activator of transcription (JAK/STAT), transforming growth factor beta (TGF-β), and others), hypoxia, and plasticity.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> An in-depth discussion on these pathways is beyond the scope of this Perspective. Du and Shim (2016) studied the mechanisms leading to EMT-induced drug resistance, followed by the strategies to overcome it via EMT targeting.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> A brief update on microRNA (miRNA)-based therapeutics for the reversal of EMT-induced drug resistance was provided. To conclude, the EMT-activating TFs—snail, slug, twist-related protein 1, zinc-finger E-box-binding homeobox 1 (ZEB1), and ZEB2—are all linked to the induction of stemness, survival, and altered cellular metabolism. The stopover, that is, the partial EMT en route to the motile mesenchymal phenotype, bestows the roaring cancer cells with the impetus they need—motility, stemness, tumorigenicity, and chemo- and radioresistance. Targeting EMT pathways in CSCs with appropriate inhibitors, for example, curcumin and metformin, could potentially reverse chemoresistance. Kindly refer to both of the articles (refs <a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18and19)</a>) for a detailed description of the diverse signaling pathways in the EMT and related events.</div><div class="NLM_p">The expression of stemness-related markers by CSCs, similar to the ESCs and NSCs, is critical for the regulation of their stemness. Interestingly, these markers are absent in normal somatic cells. A precise understanding of the CSC “stemness” phenotype and its involvement in the tumorigenesis is critical for elucidating the underlying mechanisms and therapeutic targeting of CSCs. For example, if we could detect the expression levels of stemness-related TFs in patient tumor samples, then the quality of patient prognosis assessment, tumor diagnosis, classification, and treatment strategies could be greatly improved. Zhao et al. (2017) published an exhaustive list of stemness-related TFs and surface markers in multiple human cancers.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> No attempt was made to provide such an ever-expanding list in the present Perspective. The discovery of CSC-specific TFs and markers is an active area of research.<a onclick="showRef(event, 'cit21a cit21c'); return false;" href="javascript:void(0);" class="ref cit21a cit21c">(21a–c)</a> The ensuing curiosity in this field led to real ground-breaking research in oncology.</div><div class="NLM_p">The researchers were obviously intrigued by a simple question: How does one distinguish CSC-specific markers from their NSC counterparts? A large number of stem-cell markers common to CSCs and NSCs were eventually identified, for example, aldehyde dehydrogenase 1 (ALDH1), Bmi-1, CD44, CD133, and many others. The quest for CSC-specific markers continued. Pádua et al. (2020) systematically reviewed the relevance of TFs in gastric and colorectal CSCs.<a onclick="showRef(event, 'cit21a'); return false;" href="javascript:void(0);" class="ref cit21a">(21a)</a> Major surface markers for gastric cancer (GC) include transmembrane glycoprotein CD44, CD54 (intercellular adhesion molecule 1 (ICAM-1)), signal transducer CD24, epithelial cell adhesion molecule (EpCAM), CD49f (integrin α6 (ITGA6)), transferrin receptor protein 1 (CD71), and a few others. The CSC populations with varied phenotypes, for example, CD44<sup>+</sup>, CD49f<sup>+</sup>, CD44<sup>+</sup>CD24<sup>+</sup>, EpCAM<sup>+</sup>/CD44<sup>+</sup>, and so on, were isolated and extensively studied in vitro and in vivo. Interestingly, a few markers, such as leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5), were considered as prognostic factors for colorectal cancer (CRC). Along similar lines, TFs were explored for the identification and targeting of various CSCs. Readers are encouraged to read ref <a onclick="showRef(event, 'cit21a'); return false;" href="javascript:void(0);" class="ref cit21a">(21a)</a> for a thorough overview on this topic.</div><div class="NLM_p last">Karsten and Goletz (2013) looked at the above challenge from a slightly different perspective.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> They mainly focused on alterations in the glycosylation patterns of stem-cell glycoprotein markers during the malignant transformation of NSC/progenitor cell into CSC. Their work on the Thomsen–Friedenreich antigen or epitope (TF, CD176) led to the identification of CD176 as an exceptionally specific tumor marker. Recently, the expression of Oct4 and CD133 was studied as a prognostic factor for identifying malignant gall bladder lesions from the nonmalignant ones.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The investigators could positively correlate the higher expression levels of Oct4 and CD133 with the malignant lesions. The profiles were significantly associated with tumor grading, staging, and liver metastasis. A high expression of only Oct4 correlated well with the reduced survival. Along similar lines, Feng et al. (2019) used transcriptome sequencing for SK-BR-3 and MDA-MB-231 cells to identify new CSC markers and signaling pathways as a prognostic measure in human epidermal growth factor receptor 2 (HER2)-positive breast cancer.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The two cell lines differed from each other with respect to CD44<sup>+</sup>/CD24<sup>–/low</sup>, the most commonly used marker for breast CSCs. The SK-BR-3 cell line contained almost no CD44<sup>+</sup>/CD24<sup>–/low</sup> cells, whereas the MDA-MB-231 cell line had >90% of this phenotype. Furthermore, a higher expression of ALDH 1A3, CD164, and EpCAM was observed in SK-BR-3 cells. β-Catenin expression in the canonical Wnt signaling pathway was reduced in this cell line compared with the MDA-MB-231. Such thought-provoking studies are important for the meaningful translation of the generated results to the clinic. In conclusion, the ever-expanding field of stem-cell markers, TFs, and their applications in prognosis as well as therapeutic CSC targeting will amuse us for quite some time.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Cell Cycle, Epigenetics, and Autophagy: Relevance to CSCs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17646" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17646" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The cell cycle is a tightly controlled and well-orchestrated chain of events leading to two daughter cells post-mitosis. “Switching-on and -off” instances are precisely and intricately executed by cell-cycle checkpoints. Uncontrolled cell division in a cancerous cell, one of the major hallmarks of cancer, is a direct implication of the alterations in the cell-cycle genes by disrupting these switch mechanisms.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The study of the precise association between the deregulated cell cycle in CSCs and one of their signature features, tumorigenicity, is an active area of research.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The CSCs are derived from various sources such as stem cells, completely differentiated cells, and hybrid cells arising out of their fusion<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and exhibit marked variations in the cell-cycle gene-expression profiles compared with the bulk tumor cells. Various CSC phenotypes (quiescent, slow-cycling, or rapidly proliferating) are supposedly different from the cancer cells.</div><div class="NLM_p">Speaking of cellular quiescence, the NSC subtypes reside in tissues in the quiescent state. It is a dormant, that is, nondividing and reversible state (G<sub>0</sub> stage of the cell cycle). Upon tissue injury, these quiescent cells are reactivated to restore the homeostasis. Obviously, cellular quiescence is crucial for regeneration, long-term tissue maintenance, and survival. The deregulation of quiescence leads to pathological conditions such as cancer, wherein the quiescent CSCs contribute largely to the tumor maintenance. Cho et al. (2019) revisited the mechanisms, hallmarks, and implications of stem-cell quiescence.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Similar to NSCs, CSCs respond to several intrinsic and extrinsic signals and shuttle between the quiescent state and the symmetric/asymmetric division to conserve their population. Understanding the intricate details of this process and the critical role played by the cell-cycle machinery is crucial for selective CSC targeting. In other words, a precise understanding of the regulatory mechanisms governing the entry into and exit from the quiescent state is helpful for designing CSC-specific therapeutic strategies. A related article featured various facets of the cell-cycle dynamics in glioma CSCs.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The idea was to determine the relative distribution of cells in the G<sub>0</sub>/G<sub>1</sub>, S, and G<sub>2</sub>/M phases of the cell cycle. Surface markers CD133, CD15, and CD44 were used to identify cells with stem-like characters in established gliobastoma multiforme (GBM) cell lines and primary patient-derived tumor cell lines. The results of such studies could potentially guide the treatment strategies for the notorious GBM. Along similar lines, Takeishi and Nakayama (2016) reviewed an interesting strategy based on targeting the switch controlling CSC quiescence and proliferation, that is, either promote (lock-out) or prevent (lock-in) CSC entry into the cell cycle for anti-CSC efficacy.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The lock-out mode would lead to enhanced proliferation and differentiation, which could be targeted by the cytotoxic drugs. The lock-in mode would re-establish the cellular quiescence and thereby prevent aberrant proliferation and differentiation, putting the brakes on the tumor growth and metastasis.</div><div class="NLM_p">The crooked cell-cycle genes can eventually push a differentiated normal cell toward genomic instability, as evidenced by the genetic and epigenetic changes transforming NSCs into CSCs.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Surprisingly, the positive or negative cross-talk between (i) mitogen-activated protein kinase kinase/extracellular-signal-regulated kinase (MEK/ERK) pathways, which are stimulated by the growth factors and contribute to mitogenic activity, and (ii) the phosphatidylinositol-3-kinase (PI3K) pathway, which is mostly responsible for the stemness maintenance, could fasten the conversion of NSCs into CSCs. Hassan et al. (2020) proposed a mechanism for the conversion of induced pluripotent stem cells (iPSCs) to tissue-specific (e.g., lung, liver, etc.) CSCs via the inhibition of the MEK/ERK pathway and the stimulation of the PI3K/Akt pathway using conditioned media sourced from the cancer cell lines.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Such studies are likely to aid further investigations related to the tumorigenesis mechanisms in CSCs and drug screening for precision medicine or individualized therapy. Along similar lines, Liao et al. (2018) proposed a novel method to generate CSCs to address the impediment to isolate pure CSCs for basic research and drug screening.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The authors utilized a strategy involving the synergistic inhibition of glycogen synthase kinase-3 beta (GSK3β) and MEK using small molecules, CHIR99021 and PD184352, respectively, in immortalized human mammary epithelial (HMLE) cells. The treatment led to the expression of EMT markers, the shift of the cell cycle from the G<sub>0</sub>/G<sub>1</sub> to the G<sub>2</sub>/M phase, and the suppression of the apoptosis rate in the HMLE cells. In addition, the mammosphere-forming ability of the stimulated HMLE cells was enhanced, leading to the regeneration of the tumor. It is worth mentioning that appreciable chemoresistance was noted as well. The in vivo studies corroborated the in vitro results. Mechanistically, GSK3β is a master regulator of diverse cellular pathways including Wnt/β-catenin signaling. The inhibition of GSK3β resulted in the activation of the canonical Wnt pathway,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> leading to self-renewal, in this case, of HMLE cells. On the other side, MEK inhibition led to the accumulation of β-catenin, which, in turn, activated ERK and upregulated c-myc and Ras oncogenes. In brief, the HMLE cells were transformed into CSCs following small-molecule exposure, which could then be used to screen potential CSC inhibitors.</div><div class="NLM_p">The PI3K/Akt/mammalian target of the rapamycin (mTOR) signaling pathway is critical from the cell-cycle regulation, quiescence, and proliferation aspects. Highly chemoresistant epithelial ovarian cancer (EOC) cells exhibit increased EMT and CSC marker expression, alongside activation of the PI3K/Akt/mTOR pathway.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The treatment of EOC cells with a dual PI3K/mTOR inhibitor such as BEZ235 in combination with cisplatin led to significantly higher reactive oxygen species (ROS) levels and apoptosis in the EOC cells. The compromised colony formation ability in combination-treated EOC cells clearly demonstrated the PI3K/Akt/mTOR pathway inhibition, EMT reversal, and reduced CSC marker expression.</div><div class="NLM_p">From a different standpoint, the PI3K/Akt pathway, mitogen-activated protein kinase (MAPK), and other kinases regulate GSK3β through phosphorylation; GSK3β, in turn, is vital for cyclin D1 turnover, which is necessary for cell-cycle progression. In addition, GSK3β also contributes to the migratory properties of cancer cells. Vijay et al. (2019) explored the precise role of GSK3β inhibitors in EMT and CSC properties in triple-negative breast cancer (TNBC).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The authors screened a small-molecule library for potential EMT inhibitors in cells with mesenchymal phenotype and identified three GSK3β inhibitors. The stem-like properties of the cell types with the mesenchymal phenotype were reduced by the identified inhibitors. The most intriguing part of the study was the demonstration of the selective killing of cells with mesenchymal properties while cells with epithelial attributes were spared. Overall, the utility of GSK3β inhibitor monotherapy for TNBC treatment was confirmed.</div><div class="NLM_p">Referring to the previous concept of differentiation therapy, that is, pushing CSCs to enter the cell cycle from their favored quiescent state, the complicated gain-of-stemness characteristics by CSCs may involve epigenetic reprogramming due to its relevance in the differentiation of stem cells into various tissue-specific subtypes. Shukla and Meeran (2014) reviewed the distinct roles played by DNA methylation, chromatin remodeling, and miRNAs in CSC epigenetic reprogramming.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Active DNA methylation is a prerequisite for regaining stem-like properties during the induction of pluripotency. Hence inhibitors of DNA methylation can push CSCs toward differentiation. Chromatin remodeling is also crucial for the silencing of differentiation-specific genes and the expression of stemness-specific genes during pluripotency induction. Along similar lines, oncogenic miRNAs, for example, miR-21, play their part in gain-of-stemness, the EMT, and related processes. Turdo et al. (2019)<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> comprehensively summarized several innovative anti-CSC strategies such as differentiation therapy, the inhibition of epigenetic enzymes, metabolic processes like oxidative phosphorylation (OXPHOS), among others. Targeting the metabostemness, that is, the induction of epigenetic reprogramming due to metabolic insults, was of particular interest. Overall, epigenetics and associated processes could be exploited to eradicate CSCs.</div><div class="NLM_p">In addition to epigenetics, autophagy plays a crucial role in cellular fate and ultimately homeostasis under physiological conditions by clearing the cellular debris (unwanted or dysfunctional cytoplasmic components). The scenario in cancer is slightly altered. At times, autophagy clears off tumorigenesis completely, whereas in a complete turn-around instance, it adopts a protective role, rescuing the cancer cells under stressful conditions. Bhol et al. (2019) tried to take a closer look at the CSC maintenance mechanisms governed by the epigenetic modification of autophagy in cancer to unveil newer therapeutic, prognostic, and diagnostic opportunities.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Several signaling pathways are involved in both the tumor promotion and suppression processes mediated via regulatory elements of autophagy. Representative examples of such pathways in tumor promotion include (i) miR-21-induced autophagy inhibition in cervical cancer, leading to increased radioresistance through the Akt-mTOR pathway, and (ii) miR-32-stimulated autophagy promotion with observed radioresistance in prostate cancer (PC) cells through the TOR-S6K pathway. Similar examples of tumor-suppressive pathways are (i) the miR-34-induced downregulation of autophagy, leading to enhanced chemosensitivity in PC via the AMP-activated protein kinase (AMPK)/mTOR pathway, and (ii) the miR-338-promoted autophagy downregulation in cervical cancer through the PI3K/Akt/mTOR pathway. Many of these studies were reported after 2015. The research on autophagy in cancer is expanding at record speed and is likely to provide answers to many questions related to CSC existence and functions in near future.</div><div class="NLM_p last">The known facets of CSC biology, with all its appendages, are eventually required to be translated to the clinic. The last decade has witnessed a spike in CSC-specific therapeutic approaches in a variety of cancers including solid tumors and hematologic malignancies. Countless patents, research articles, books, and book chapters have appeared in the scientific literature covering intricate aspects of this complicated field. Few of these cherry-picked reports in the last 2 years (2019–2020) are likely to provide an in-depth understanding of the field for the interested reader.<a onclick="showRef(event, 'ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47 ref48">(39−48)</a> As our knowledge of CSC biology is updated in due time, we will witness the dominance of a few exceptionally promising strategies over others. We will be here to witness it at least for the next few decades! The present Perspective is focused on small-molecule CSC inhibitors including synthetic chemicals and phytochemicals in “Biological Testing”, “Preclinical”, or “Clinical” development. An apt discussion on completed/ongoing clinical trials of anti-CSC therapeutics is provided to appreciate the challenges and limitations of these agents on the battlefield, that is, the clinic. Selective tumor targeting, in general, and CSCs, in particular, by nanotechnology and allied approaches are briefly touched upon to appreciate the importance of delivery technologies in further strengthening the therapeutic potential of promising candidates. A brief account of macromolecular therapeutics or biologics, for example, monoclonal antibodies (mAbs), vaccines, cell-based therapies, aptamers, and others, including their use as combination therapy, is presented.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">CSC Inhibitors: A Broad Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64677" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64677" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To get a 360° view of the anti-CSC drug discovery and development landscape, we searched the Cortellis Drug Discovery Intelligence platform<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> using the “Mechanism of Action” as “Drugs Targeting Cancer Stem Cells” phrase. A total of 39 hits in “Biological Testing”, “Preclinical”, and “Clinical” phases were obtained. Representative structures from the hit list (<b>1</b>–<b>14</b>) are given in <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>. Additional details such as the Product Category, Therapeutic Group, Organization, and so on of these and a few macromolecular hits are listed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Interested readers are encouraged to refer the latest reports<a onclick="showRef(event, 'ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47 ref48">(39−48)</a> for more information on the various signaling pathways involved in CSC biology and the associated therapeutic intervention by several clinical candidates or drugs, either alone or in combination with chemotherapeutic agents. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> outlines the major CSC pathways and lists the representative promising therapeutics with mechanistic participation in these pathways. <a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a> depicts the molecular structures of additional small-molecule clinical candidates or approved drugs (<b>15</b>–<b>25</b>) mentioned in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>.<a onclick="showRef(event, 'ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47 ref48">(39−48)</a></div><figure id="cht1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Structurally Diverse CSC Inhibitors under Various Phases of Discovery and Development</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Phase 3.</p><p><span class="fn-label"><sup>b</sup></span>Phase 2.</p><p><span class="fn-label"><sup>c</sup></span>Preclinical.</p><p class="last"><span class="fn-label"><sup>d</sup></span>Biological testing.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Details of Representative “Drugs Targeting Cancer Stem Cells” Obtained from the Cortellis Drug Discovery Intelligence Search</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound no.<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">code name (INN<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a>)</th><th class="colsep0 rowsep0" align="center">product category</th><th class="colsep0 rowsep0" align="center">therapeutic group</th><th class="colsep0 rowsep0" align="center">mechanism of action</th><th class="colsep0 rowsep0" align="center">organization</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">BIB-608; GB-201; Z1HHM49K7O (napabucasin)</td><td class="colsep0 rowsep0" align="left">Natural Products</td><td class="colsep0 rowsep0" align="left">CRC Therapy; GC Therapy; GBM Therapy; Hematological Cancer Therapy; Non-Small Cell Lung Cancer Therapy; Respiratory/Thoracic Cancer Therapy; Solid Tumors Therapy; Pancreatic Cancer Therapy; Liver Cancer Therapy</td><td class="colsep0 rowsep0" align="left">Drugs Targeting Cancer Stem Cells; Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors; Signal Transduction Modulators</td><td class="colsep0 rowsep0" align="left">Boston Biomedical (Sumitomo Dainippon Pharma Global Oncology)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">PF-04554878; PF-4554878; VS-6063 (defactinib HCl)</td><td class="colsep0 rowsep0" align="left">Synthetic Small-Molecule</td><td class="colsep0 rowsep0" align="left">Cancer of Unspecified Body Location/System; Non-Small Cell Lung Cancer Therapy; Ovarian Cancer Therapy; Pancreatic Cancer Therapy; Solid Tumors Therapy; Respiratory/Thoracic Cancer Therapy</td><td class="colsep0 rowsep0" align="left">Drugs Targeting Cancer Stem Cells; Focal Adhesion Kinase 1 (FADK1; PTK2) Inhibitors; Focal Adhesion Kinase 2 (FADK2; PTK2B; PYK2) Inhibitors; Signal Transduction Modulators</td><td class="colsep0 rowsep0" align="left">Pfizer (Originator) Verastem</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b>, <b>4</b></td><td class="colsep0 rowsep0" align="left">15a, 24a</td><td class="colsep0 rowsep0" align="left">Synthetic Small-Molecule</td><td class="colsep0 rowsep0" align="left">Oncolytic Drugs</td><td class="colsep0 rowsep0" align="left">Drugs Targeting Cancer Stem Cells</td><td class="colsep0 rowsep0" align="left">Tianjin Int Joint Acad Biotechnol Med (Originator)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">Synthetic Small-Molecule</td><td class="colsep0 rowsep0" align="left">Non-Small Cell Lung Cancer Therapy</td><td class="colsep0 rowsep0" align="left">Apoptosis Inducers; CDK9/Cyclin T1 Inhibitors; Drugs Targeting Cancer Stem Cells; Signal Transduction Modulators</td><td class="colsep0 rowsep0" align="left">Nankai University (Originator)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">NMK-T-057</td><td class="colsep0 rowsep0" align="left">Synthetic Small-Molecule</td><td class="colsep0 rowsep0" align="left">Breast Cancer (BC) Therapy</td><td class="colsep0 rowsep0" align="left">Apoptosis Inducers; Autophagy Inducers; Drugs Targeting Cancer Stem Cells; gamma-Secretase Inhibitors</td><td class="colsep0 rowsep0" align="left">multiple</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">FND-4b</td><td class="colsep0 rowsep0" align="left">Synthetic Small-Molecule</td><td class="colsep0 rowsep0" align="left">Oncolytic Drugs</td><td class="colsep0 rowsep0" align="left">AMPK Activators; Apoptosis Inducers; Drugs Targeting Cancer Stem Cells; Signal Transduction Modulators</td><td class="colsep0 rowsep0" align="left">University of Kentucky (Originator)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">Chemosensitizers</td><td class="colsep0 rowsep0" align="left">Antineoplastic Enhancing Agents</td><td class="colsep0 rowsep0" align="left">Drugs Targeting Cancer Stem Cells; P-Glycoprotein (MDR-1; ABCB1) Inhibitors</td><td class="colsep0 rowsep0" align="left">Universita degli Studi di Bari</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">RIPGBM</td><td class="colsep0 rowsep0" align="left">Prodrugs</td><td class="colsep0 rowsep0" align="left">Glioblastoma Multiforme Therapy</td><td class="colsep0 rowsep0" align="left">Apoptosis Inducers; Drugs Targeting Cancer Stem Cells; Receptor-Interacting Serine/Threonine-Protein (RIP-2) Kinase 2 Inhibitors; Signal Transduction Modulators</td><td class="colsep0 rowsep0" align="left">multiple</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">Synthetic Small-Molecule</td><td class="colsep0 rowsep0" align="left">Ovarian Cancer Therapy</td><td class="colsep0 rowsep0" align="left">Apoptosis Inducers; Drugs Targeting Cancer Stem Cells</td><td class="colsep0 rowsep0" align="left">Liaocheng University (Originator)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">Synthetic Small-Molecule</td><td class="colsep0 rowsep0" align="left">CRC Therapy</td><td class="colsep0 rowsep0" align="left">Na<sup>+</sup>/H<sup>+</sup> Exchange Regulatory Cofactor NHE-RF1 (NHERF-1) Inhibitors; Drugs Targeting Cancer Stem Cells</td><td class="colsep0 rowsep0" align="left">Multiple</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">Synthetic Small-Molecule</td><td class="colsep0 rowsep0" align="left">CRC Therapy</td><td class="colsep0 rowsep0" align="left">β-Catenin (CTNNB1) Inhibitors; Drugs Targeting Cancer Stem Cells; Wnt Signaling Inhibitors</td><td class="colsep0 rowsep0" align="left">multiple</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">Prestw-1013 (deptropin, as citrate salt)</td><td class="colsep0 rowsep0" align="left">Synthetic Small-Molecule</td><td class="colsep0 rowsep0" align="left">Anti-Hepatitis E Virus Drugs; Oncolytic Drugs</td><td class="colsep0 rowsep0" align="left">Drugs Targeting Cancer Stem Cells; Histamine H<sub>1</sub> Receptor Antagonists; Signal Transduction Modulators</td><td class="colsep0 rowsep0" align="left">ETH Zürich</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">AG-205, AG-205 PGRMC1 Inhibitor</td><td class="colsep0 rowsep0" align="left">Synthetic Small-Molecule</td><td class="colsep0 rowsep0" align="left">Oncolytic Drugs</td><td class="colsep0 rowsep0" align="left">Apoptosis Inducers; Drugs Targeting Cancer Stem Cells Membrane-Associated Progesterone Receptor Component 1 (PGRMC1) Antagonists; Signal Transduction Modulators</td><td class="colsep0 rowsep0" align="left">University of Kentucky</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">CC-188<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">Cancer Immunotherapy; Murine Monoclonal Antibodies; Nuclear Imaging Agents; Radiopharmaceuticals</td><td class="colsep0 rowsep0" align="left">Diagnosis of Cancer</td><td class="colsep0 rowsep0" align="left">Drugs Targeting Cancer Stem Cells</td><td class="colsep0 rowsep0" align="left">Washington University (Originator)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">13M57<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">Cancer Immunotherapy; Monoclonal Antibodies</td><td class="colsep0 rowsep0" align="left">Diagnosis of Cancer Oncolytic Drugs</td><td class="colsep0 rowsep0" align="left">Anti-Notch1 (Neurogenic Locus Notch Homologue Protein 1); Drugs Targeting Cancer Stem Cells</td><td class="colsep0 rowsep0" align="left">OncoMed Pharmaceuticals (Originator)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">scFv:EGFRvIII/scFv:AC133<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">Bispecific Antibodies; Cancer Immunotherapy; Single-Chain V-Domain Antibody Fragment (scFv)</td><td class="colsep0 rowsep0" align="left">Diagnosis of Cancer; Glioblastoma Multiforme Therapy</td><td class="colsep0 rowsep0" align="left">Anti-EGFR; Anti-PROM1 (Prominin-1; CD133); Drugs Targeting Cancer Stem Cells; Signal Transduction Modulators</td><td class="colsep0 rowsep0" align="left">Stanford University (Originator)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">See <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a> for structures.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">International nonproprietary name.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Preclinical.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Biological testing.</p></div></div></div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Major signaling pathways in CSCs and representative therapeutics targeting them.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="cht2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Molecular Structures of Additional Clinical Candidates or Drugs Discussed in Recent Reports<a onclick="showRef(event, 'ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47 ref48">(39−48)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Phase 1.</p><p><span class="fn-label"><sup>b</sup></span>Phase 2.</p><p class="last"><span class="fn-label"><sup>c</sup></span>Phase 1/2.</p></p></figure><div class="NLM_p">Despite the fact that a large number of small and macromolecular candidates targeting CSCs are under active clinical development, their efficacy in eradicating CSCs is a little doubtful because several of these trials lack CSC-specific readouts. Who is to be blamed for this irony? The scientific community? The exhausted and possibly despondent CSC researcher? Or the ignorant oncologist? Probably no one! All of us, true believers of CSC philosophy, are just part of a spectacular and wondrous journey from a starting point called “hype” to a destination named “hope”! Increasing the awareness of CSC therapeutics and gathering clinical evidence will fuel definitive growth in the number of formal and deliberate attempts to map the CSC involvement in clinical trial designs.</div><div class="NLM_p last">On the basis of the source (natural/synthetic/repurposed drug) and chemical nature (small-/macromolecule), the known anti-CSC agents (including clinical candidates and a few approved drugs) are tentatively classified into: (i) phytochemicals and their semisynthetic analogs, (ii) repurposed drugs, (iii) synthetic new chemical entities (NCEs), (iv) biologics (mAbs, aptamers, proteins and peptides, vaccines, miRNA-based and therapeutics, among others), and (v) nanotherapeutics, including tumor-targeted approaches such as antibody–drug conjugates (ADCs). The latest critical updates and future perspectives on these classes are important to realize the potential offered by CSC-directed agents and the strategies for radicalizing the oncology field.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Phytochemicals as Anti-CSC Therapeutics</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11644" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11644" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">During the past decade or so, select few phytochemicals significantly enriched our understanding of CSC biology by serving as lead molecules or probes. <a class="ref internalNav" href="#cht3" aria-label="Chart 3">Chart 3</a> lists many of these agents (<b>26</b>–<b>38</b>) with potent CSC inhibitory activity. Very recently, Naujokat and McKee (2020) elaborated on the CSC inhibitory potential of the “big five” phytochemicals, curcumin (<b>26</b>), epigallocatechin 3-gallate (EGCG, <b>27</b>), sulforaphane (<b>28</b>), resveratrol (<b>29</b>), and genistein (<b>30</b>), by interfering with intrinsic CSC pathways.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Interestingly, these molecules were efficacious in clinical trials of several cancers, either alone or in combination with conventional chemotherapeutic agents. Along similar lines, Liskova et al. (2019) reviewed several other dietary phytochemicals targeting CSCs.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Younas et al. (2018) systematically discussed the mechanistic aspects of BC chemoprevention by phytochemicals belonging to alkaloids, polyphenols, terpenes, organosulfur compounds, and other classes.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Perhaps one of the most admired phytochemicals is napabucasin (<b>1</b>, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>), a first-in-class cancer stemness inhibitor currently in Phase 3 clinical trials. In addition, in-depth discussions on resveratrol (<b>29</b>), a relatively more explored phytochemical from the “big five” list,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> and garcinol (<b>37</b>), an emerging anti-CSC lead, are provided.</div><figure id="cht3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Chart 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 3. Molecular Structures of CSC Inhibitory Phytochemicals</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=cht3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Curcumin.</p><p><span class="fn-label"><sup>b</sup></span>Epigallocatechin gallate.</p><p><span class="fn-label"><sup>c</sup></span>Sulforaphane.</p><p><span class="fn-label"><sup>d</sup></span>Resveratrol.</p><p><span class="fn-label"><sup>e</sup></span>Genistein.</p><p><span class="fn-label"><sup>f</sup></span>Pterostilbene.</p><p><span class="fn-label"><sup>g</sup></span>Berberine.</p><p><span class="fn-label"><sup>h</sup></span>Quercetin.</p><p><span class="fn-label"><sup>i</sup></span>Ellagic acid.</p><p><span class="fn-label"><sup>j</sup></span>Koenimbine.</p><p><span class="fn-label"><sup>k</sup></span>Isonapabucasin (synthetic regioisomer of napabucasin).</p><p><span class="fn-label"><sup>l</sup></span>Garcinol.</p><p class="last"><span class="fn-label"><sup>m</sup></span>Isogarcinol.</p></p></figure><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Napabucasin (<b>1</b>)</h3><div class="NLM_p">Originally isolated in the early 1980s from the inner bark of <i>Handroanthus impetiginosus</i> (Family: Bignoniaceae), <b>1</b> (2-acetylnaphtho[2,3-<i>b</i>]furan-4,9-dione) was one of the six active constituents with potent cytotoxicity against the KB cell line.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Arduous mechanistic investigations into homogeneous time-resolved fluorescence (HTRF) and other assays using MDA-MB-231 (breast adenocarcinoma) cells revealed that the STAT3 phosphorylation inhibition by <b>1</b> (EC<sub>50</sub> = 2 μM) led to the suppression of STAT3 activation.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Molecular modeling studies predicted the binding mode of <b>1</b> in the Src Homology 2 (SH2) domain of STAT3. The SH2 domain is required for the receptor binding and activation of STAT3 by tyrosine kinases. Alternatively, the naphthoquinone core of <b>1</b> was found to induce ROS generation due to high-affinity binding to NAD(P)H:quinone oxidoreductase-1 (NQO1), an enzyme responsible for catalyzing the two-electron-transfer reduction of quinones via the semiquinone biradical intermediate.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The bioactivation of <b>1</b> by NQO1 and, to some extent, by cytochrome P450 oxidoreductase (POR) led to ROS-guided DNA damage and reduced STAT3 phosphorylation and cell death. The mechanistic rationale based on phosphorylated STAT3 (pSTAT3) prompted the investigators to propose the use of pSTAT3 as a potential biomarker for predicting the patient response to <b>1</b>.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><div class="NLM_p">Interestingly, the angular regioisomer of <b>1</b>, that is, isonapabucasin (<b>36</b>, <a class="ref internalNav" href="#cht3" aria-label="Chart 3">Chart 3</a>) was chemically synthesized and extensively evaluated in vitro, along with <b>1</b>, for anticancer activity and the underlying mechanistic details in MDA-MB-231 and K562 (chronic myelogenous leukemia (CML)) cell lines.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Compound <b>36</b> exhibited more potent antiproliferative activity against MDA-MB-231 cells (IC<sub>50</sub> = 0.74 μM), induced apoptosis, and underwent bioactivation by NQO1 via either one- or two-electron reduction, leading to semiquinone and catechol forms, respectively, with the profuse induction of ROS generation and the subsequent DNA damage. In HTRF assays, <b>36</b> potently inhibited STAT3 phosphorylation (EC<sub>50</sub> = 0.87 μM). The molecular docking experiments corroborated the in vitro potency data based on the observation that the angular <b>36</b> was able to bind favorably in the STAT3 SH2 domain, leading to additional H-bond formation with crucial residues lining the westward pocket.</div><div class="NLM_p">Recent findings demonstrated the STAT3 inhibitory potential of <b>1</b> in GC and glioblastoma.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Yang et al. (2019) reviewed the scope of STAT3 inhibitors in cancer with a particular emphasis on the early- and late-stage clinical trials of <b>1</b> in solid tumors and hematologic malignancies, either alone or in combination with established cytotoxic drugs.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> A total of 22 trials, phases 1 (8), 1/2 (7), and 3 (7), were listed for metastatic pancreatic ductal adenocarcinoma (PDAC), CRC, previously treated metastatic CRC, advanced malignancies, gastric and gastroeophageal junction cancers, hematologic malignancies, and advanced solid tumors, including hepatocellular carcinoma (HCC) and glioblastoma. One of the most aspiring phase 3 trials, CanStem111P (NCT02993731), <b>1</b> plus Nab-paclitaxel with gemcitabine in adult patients with metastatic PDA (Primary outcome measure – Overall Survival (OS)), came to a halt due to futility.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The reasons for trial failure could be manifold including: (i) the highly aggressive nature and dismal prognosis of PDA; (ii) issues related to patient inclusion criteria, for example, “the patient must not have previously received chemotherapy or any investigational agent for the treatment of PDAC” (although treatment with fluoropyrimidine or gemcitabine administered as a radiation sensitizer >6 months prior to randomization was allowed); (iii) the major involvement of the oncogenic activation of <i>KRAS</i> with the lesser involvement of BRAF–MAPK and PI3K–Akt pathways in PDA, and possibly (iv) the inappropriate or lack of consideration given to PDA epithelial subtypes<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> while enrolling patients in the trial. These include poorly differentiated basal-like/squamous/quasimesenchymal and well-differentiated classical/pro-genitor as well as activated stromal subtypes—immune signaling and matricellular fibrosis. The PDA subtypes could have responded differentially to the treatment, compromising the therapeutic outcome.</div><div class="NLM_p">In a randomized, placebo-controlled phase 3 trial of <b>1</b> in refractory advanced CRC (NCT01830621), there was no significant difference in the median OS between the two groups from the overall unselected population, whereas in patients with the prespecified pSTAT3 biomarker (pSTAT3-positive), the OS was longer (5.1 months) in the treatment than in the placebo group (3.0 months).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> This interesting observation reiterated the exemplary need for careful biomarker profiling during patient inclusion in the trial for a meaningful outcome. In addition, the combination therapeutics require deliberative selection, too. In several cancers, the lack of definitive point-of-care treatment options is a major concern, which spreads over the trials involving such cancer types.</div><div class="NLM_p">In a related international, randomized, double-blind, placebo-controlled phase 3 trial, BRIGHTER (NCT02178956), of <b>1</b> with paclitaxel in patients with pretreated advanced gastric and gastroesophageal junction adenocarcinoma, the effect of the combination of overall survival (OS) and progression-free survival (PFS) was insignificant, even though the combination was tolerable.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Despite the promising synergistic activity of the combination in preclinical and early clinical settings, the trial failed. The potential reasons leading to the failure could be similar to those of the previous CanStem111P trial. The naphthoquinone core flanked by a ketonic functionality of <b>1</b> could be the culprit, compromising its integrity in the highly redox-imbalanced TME in vivo before its pharmacodynamic (PD) effects were apparent. In brief, even though targeting cancer stemness is a promising approach, better agents capable of executing the strategy with the utmost precision are desperately needed.</div><div class="NLM_p">A recently concluded phase 1 study of <b>1</b> in Japanese patients with advanced solid tumors (JapicCTI-132152) demonstrated its tolerability up to 1.4 g/day with a similar pharmacokinetic (PK) profile as the previous phase 1 trials in healthy human volunteers or cancer patients.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Presently, <b>1</b> is the subject matter of six ongoing/completed trials:<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> (i) CanStem 303C: Combination therapy with standard biweekly FOLFIRI (leucovorin + fluorouracil + irinotecan) and bevacizumab in adult patients with previously treated metastatic CRC – phase 3 (NCT02753127) (Recruitment Status – Active, not recruiting); (ii) immune checkpoint inhibitor combination (ipilimumab, nivolumab, or pembrolizumab) in adult patients for advanced solid tumors – phase 1b/2 (NCT02467361) (Status – Completed, no results posted yet); (iii) paclitaxel combination for advanced solid tumors – phase 1/2 (NCT01325441) (Recruitment Status – Recruiting); (iv) combination therapy (fluorouracil, oxaliplatin, leucovorin, irinoteca, bevacizumab, capecitabine, or regorafenib) for advanced gastrointestinal cancer – phase 1b/2 (NCT02024607) (Status – Completed) (improved efficacy observed in patients with metastatic CRC, including patients who received FOLFIRI ± bevacizumab);<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> (v) Combination therapy (<b>1</b> with sorafenib) versus amcasertib with sorafenib for HCC – phase 1/2 (NCT02279719) (Status – Completed, no results posted yet); and (vi) rollover study with continued access to <b>1</b> for previously enrolled patients (Boston Biomedical-sponsored protocols) as monotherapy or combination (Nab-paclitaxel, gemcitabine, nivolumab, paclitaxel, irinotecan, leucovorin, 5-FU, or bevacizumab) for advanced solid tumors – phase 1 (NCT04299880) (Status – Enrolling by invitation).</div><div class="NLM_p">While we wait for the outcome of several clinical trials of <b>1</b>, the adrenaline rush is on to speculate what the future holds for the cancer stemness inhibition strategy—a positive result or yet another disappointment? On the brighter side, the results from NCT02024607<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> clearly demonstrated the sensitization of chemorefractory CRC by <b>1</b> to FOLFIRI ± bevacizumab, irrespective of the pSTAT3 status. We definitely need better clinical trial protocols, better agents (including combination therapeutics), better biomarkers to select the “right” patient population, and, most importantly, the “right” cancer type. The search is on, and we will definitely get there with newer arsenals and well-understood cancer-type characteristics. Concerted efforts are needed from medicinal chemists, biologists, crystallographers, bioinformaticians, toxicologists, geneticists, and many more professionals to take this field to the next level.</div><div class="NLM_p">DSP-0337, an oral prodrug of <b>1</b>, is in the early stage, that is, phase 1 clinical development, in adults as a monotherapy for advanced solid tumors refractory to conventional treatment (NCT03416816) (Recruitment Status – Recruiting).<a onclick="showRef(event, 'ref63 ref66'); return false;" href="javascript:void(0);" class="ref ref63 ref66">(63,66)</a> Intrigued by this report, we searched for napabucasin prodrugs in the Cortellis Drug Discovery Intelligence platform under the “Related Drugs” category. The molecular structures of the hits (<b>39</b>–<b>49</b>) listed as “Highest Phase: Biological Testing” are given in <a class="ref internalNav" href="#cht4" aria-label="Chart 4">Chart 4</a>. Hits <b>39</b>–<b>41</b> were reported as water-soluble prodrugs of <b>1</b> in a patent application.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Other prodrugs (<b>42</b>–<b>49</b>) were reported in a United States patent filed jointly by Kyoto Pharmaceutical Industries and Sumitomo Dainippon Pharma, Japan.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> There is considerable interest in extending the product pipeline based on <b>1</b> by suitable structural modifications, for example, converting <b>1</b> to its prodrugs, to overcome underlying PK/PD issues, if any.</div><figure id="cht4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Chart 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 4. Napabucasin (<b>1</b>) Prodrugs Currently in the “Biological Testing” Phase</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=cht4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Resveratrol (<b>29</b>)</h3><div class="NLM_p">It is a polyphenolic stilbene antioxidant found in several plants and is well known for its potent anticancer, anti-inflammatory, neuroprotective, and immunomodulatory properties.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> The enhanced therapeutic efficacy of chemotherapeutic drugs and the sensitization of pancreatic cancer (PaC) cells to chemo- and radiotherapy on treatment with <b>29</b> prompted further investigations of the molecular mechanisms behind CSC regulation, if any, by <b>29</b>. The dose-dependent (0–30 μM) inhibitory effect of <b>29</b> on the viability of pancreatic CSCs and the growth of primary and secondary spheroids derived from them were assuring. Interestingly, the treatment of pancreatic CSCs with <b>29</b> led to growth arrest due to cyclin D1 inhibition and the induction of apoptosis via the inhibition of apoptosis-related proteins, XIAP and Bcl-2. The expression of EMT-promoting transcription factors, Zeb-1, Snail, and Slug, was inhibited in pancreatic CSCs along with the expression of pluripotency TFs, Nanog, Sox-2, and Oct4. The further evaluation of <b>29</b> in the colony-formation assay confirmed its potential in ablating the self-renewal capacity of the pancreatic CSCs in a dose-dependent manner (0–30 μM).<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> In efficacy studies in Kras<sup>G12D</sup> transgenic mice (which present disease manifestation similar to the human PaC), <b>29</b> inhibited not only the growth and development of PaC but also the self-renewal capacity of Kras<sup>G12D</sup> mice-derived pancreatic CSCs. To summarize, the crucial mechanistic involvement of <b>29</b> in eliminating pancreatic CSCs was clearly shown, thereby opening newer avenues for therapeutic intervention.</div><div class="NLM_p">Along similar lines, <b>29</b> caused selective cytotoxicity to osteosarcoma cell lines, MG-63 (IC<sub>50</sub> = 28.58 μM) and MNNG/HOS (IC<sub>50</sub> = 20.57 μM), with >40-fold selectivity over the human normal osteoblastic cell line hFOB 1.19.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Xenograft studies in athymic nude mice clearly indicated the superior antiosteosarcoma activity of <b>29</b>. Immunohistochemical staining of the xenografts precisely picked up increased bcl-2 expression and reduced CD133 and pSTAT3 expression. Sphere assays involving the primary and secondary spheroids generated from MG-63 and MNNG/HOS cells confirmed the significant reduction in the number and volume of spheres on treatment with <b>29</b> (40 μM). Overall, <b>29</b> could inhibit the osteosarcoma stem cells (CD133<sup>+</sup> subpopulation). Further mechanistic investigations identified reduced oncostatin M, STAT3, and JAK2 phosphorylation alongside decreased phosphorylated PI3K, phosphorylated Akt, and NF-κB (components of the downstream PI3K/Akt/NF-κB signaling cascade) expression levels in both MG-63 and MNNG/HOS cell lines on treatment with <b>29</b> (40 μM for 48 h). The results were significant in validating the potential utility of <b>29</b> via STAT3 inhibition in tackling metastasis and recurrence in osteosarcoma, which is presently an unmet medical need.</div><div class="NLM_p last">Honari et al. (2019) presented a line of evidence in support of <b>29</b> for CRC prevention and treatment.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> A summary of phase 1 and 2 trials in CRC, PC, BC, and multiple myeloma is given with mixed results. Because of the intrinsic issues with its bioavailability, higher doses of <b>29</b> (up to 5 g/day) were tried in clinical trials. The CRC trials were hopeful, but several questions needed to be answered before a meaningful translation to the clinic could happen. Achieving optimal therapeutic concentrations of <b>29</b> is a daunting challenge. If the bioavailability could be drastically improved, then <b>29</b> may prove its utility in targeting CSCs beyond in vitro and preclinical investigations in various cancers.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Garcinol (<b>37</b>)</h3><div class="NLM_p">As a phytochemical belonging to the polyisoprenylated benzophenone class and majorly obtained from the fruit rinds of <i>Garcinia indica</i> (Family: Clusiaceae), garcinol (<b>37</b>, <a class="ref internalNav" href="#cht3" aria-label="Chart 3">Chart 3</a>), is at the epicenter of a cluster of natural products that are potentially interesting to the oncology field due to their ability to target CSCs and their signaling pathways. Both <b>37</b> and its constitutional isomer, isogarcinol (<b>38</b>), are reported to possess potent anticancer, anti-infective, antioxidant, and anti-inflammatory activities.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Very recently, Schobert and Biersack (2019) thoroughly reviewed the latest developments in the chemical and biological aspects of <b>37</b> and <b>38</b>, in particular, the newer biological sources, improvised chemical synthesis, and molecular pharmacological aspects of their therapeutic benefits.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Along similar lines, Aggarwal et al. (2020) summarized the potential of <b>37</b> in targeting varied oncogenic factors in tumor milieu and its implications in the ensuing antineoplastic efficacy.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> The observed antitumor activity was mainly attributed to its effect on NF-κB and JAK/STAT3 pathways.</div><div class="NLM_p">Previously, Ahmad et al. (2012) reported the in vitro and in vivo anticancer activity of <b>37</b> against highly aggressive, invasive, TNBC cell lines, MDA-MB-231 and BT-549. The observed anticancer effects were partly attributed to the EMT reversal via derailed miRNA-200s, let-7s, NF-kB, and Wnt signaling pathways.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> In vivo studies were carried out in female severe combined immunodeficiency (SCID) mice bearing MDA-MB-231 xenografts. The dosage regimen of orally administered <b>37</b> was 5 mg/day/animal for 6 days/week for 4 weeks. The study demonstrated its nontoxic nature in mice, as inferred from the insignificant weight loss and the absence of any adverse effects. In a follow-up study, the same research group tried to unravel the molecular mystery behind the cell proliferation inhibition and apoptosis induction in BC, PC, and PaC.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> This pioneering study provided conclusive evidence that <b>37</b> targeted the STAT3 signaling pathway, wherein total and pSTAT3 along with interleukin 6 (IL-6)-induced STAT3 phosphorylation were inhibited in a dose-dependent manner in all three cell types tested. The inhibition of cell invasion was due to the diminished production of urokinase, vascular endothelial growth factor (VEGF), and matrix metalloproteinase-9 (MMP-9). Significant tumor growth inhibition and scarce STAT3 expression and activation were observed in female SCID mice (MDA-MB-231 xenografts) following the oral administration of <b>37</b> (5 mg/day as a preparation in sesame oil for 5 days/week for 4 weeks).</div><div class="NLM_p">Previous results indicated that <b>37</b> could sensitize chemotherapy-resistant cancer cells by targeting CSC-like cells. In particular, <b>37</b> sensitized the human head and neck carcinoma cells to cisplatin treatment<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> and human pancreatic adenocarcinoma cells to the standard-care gemcitabine treatment.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Taking a clue from the literature, Wang et al. (2017) investigated the sensitivity of a panel of non-small-cell lung cancer (NSCLC) cell lines to <b>37</b> and found that the A549 (adenocarcinomatic human alveolar basal epithelial) cell line was the most sensitive due to the decreased transcriptional expression of <i>ALDH1A1</i>, which is otherwise highly expressed in A549 cells.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Further investigation identified the precise molecular mechanism of the <i>ALDH1A1</i> downregulation. Garcinol interfered with the binding of CCAAT enhancer binding protein β (C/EBPβ) (crucial for <i>ALDH1A1</i> mRNA expression) with the <i>ALDH1A1</i> promoter region. This was due to the upregulation of the stress responder DNA damage-inducible transcript 3 (DDIT3) mRNA, leading to increased protein expression levels on treatment with <b>37</b>. The increased DDIT3 interacted with C/EBPβ, depleting it for its possible interaction with the <i>ALDH1A1</i> promoter region. Similar effects were demonstrated in the tumor tissues in xenograft mice models, thereby validating the in vitro observations.</div><div class="NLM_p">In a related study, Farhan et al. (2019) explored the role of the miRNA-regulated EMT in acquired resistance to erlotinib and cisplatin, standard therapies for NSCLC.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> The authors exposed the A549 cells to TGF-β1, generating the mesenchymal and drug-resistant phenotype (A549M). Surprisingly, a remarkable sensitization of the resistant cells with the mesenchymal phenotype to erlotinib and cisplatin was observed, as seen from the much lower IC<sub>50</sub> values for both drugs. The study unequivocally confirmed the key roles played by the EMT-regulating miRNAs, miR-200c and let-7c, in EMT reversal on treatment with <b>37</b> and the subsequent sensitization of the NSCLC cells to erlotinib and cisplatin. <b>37</b> upregulated these key miRNAs.</div><div class="NLM_p">Wang et al. (2019) reviewed the key structural features of <b>37</b> for anticancer activity via the specific/nonspecific inhibition of (i) 5-lipoxygenase (5-LO), a key enzyme in oral cancers, and (ii) p300 histone acetyltransferase (HAT) by various analogs of <b>37</b> due to their binding at the allosteric and acetyl-CoA binding sites.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> The authors also summarized the anticancer effect of <b>37</b> via CSC suppression. In a study involving the lung CSC phenotype of human NSCLC, <b>37</b> inhibited the viability in NSCLC cell lines, H441 and A549, induced their apoptosis, and compromised their ability to form colonies in a functional assay along with abolished sphere formation.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> There was little to no toxicity to the noncancerous human bronchial epithelial BEAS-2B cells. Further mechanistic investigations clearly showed that the impaired phosphorylation of low-density lipoprotein receptor-related protein 6 (LRP6) and the downregulation of β-catenin, dishevelled segment polarity protein 2 (Dvl2), axis inhibition protein 2 (Axin2), and cyclin D1 expressions in NSCLC-sourced spheres were responsible for the anti-CSC effect of <b>37</b>. Also, the IL-6-inducible JAK2/STAT3 and MAPK signaling pathways were inhibited by <b>37</b> in H441 cells. The efficacy studies in NOD/SCID mice (5 mg/kg, i.p., 5 injections/week) xenografted with H441 tumor spheres showed significantly delayed tumor-initiation ability post-15 weeks of administration. In short, <b>37</b> majorly affected the Wnt/β-catenin signaling pathway and caused STAT3 inactivation.</div><div class="NLM_p last">Kharkar et al. (2020) evaluated the in vitro anti-CSC potential of <b>37</b> in a battery of assays including cell proliferation, soft-agar, and sphere assays in BC (MDA-MB-231) and PC (DU-145 and PC-3) cell lines.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Cisplatin and sunitinib were used as positive controls representing the conventional chemotherapeutic and anti-CSC therapeutic agents, respectively. The corresponding IC<sub>50</sub> values of <b>37</b> were: MTT assay, MDA-MB-231: 2.43 ± 0.01 μM; DU-145: 2.87 ± 0.10 μM; PC-3: 2.86 ± 0.08 μM; soft-agar assay: MDA-MB-231: 2.13 ± 0.02 μM; PC-3: 3.46 ± 0.55 μM. There was no significant difference between the <b>37</b> and sunitinib IC<sub>50</sub> values in both the assays. In the sphere assay, <b>37</b> demonstrated the dose-dependent (0.025–2.5 μM) inhibition of sphere formation in MDA-MB-231 and PC-3 cell lines. Compared with sunitinib, <b>37</b> was well tolerated by human peripheral blood mononuclear cells (<i>h</i>PBMCs). Overall, <b>37</b> is an emerging phytochemical with remarkable CSC inhibitory potential that warrants further clinical investigation and subsequent development.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Drug Repurposing for CSC Targeting</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38841" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38841" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Drug repurposing is a rewarding strategy for the identification of promising anti-CSC therapeutics. <a class="ref internalNav" href="#cht5" aria-label="Chart 5">Chart 5</a> includes representative drug-repurposing candidates <b>50</b>–<b>58</b>. Vásquez-Bochm et al. (2019) relied on transcriptomic analyses to screen a data set of 1300 bioactive compounds and subsequently identify breast CSC-targeting leads.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The idea was to compare the disease-induced gene signatures against the postdrug treatment expression profile to identify potential connections linking drugs to the disease state; a negative correlation was sought to propose the drug for repurposing. The authors utilized a bioinformatics approach wherein a breast CSC-specific consensus gene signature (25 upregulated and 14 downregulated genes) was employed to query the Connectivity Map (CMap) database.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Five identified hits were then experimentally evaluated in TNBC cell lines MDA-MB-231 and Hs578T. One of the hits, lovastatin (<b>50</b>, <a class="ref internalNav" href="#cht5" aria-label="Chart 5">Chart 5</a>), downregulated the genes regulating stemness and invasiveness in mammary tumors. The CSC targeting was mediated by its original mechanism of action, that is, the inhibition of hydroxymethylglutaryl–coenzyme A (HMG–CoA) reductase.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The study proved crucial for garnering the evidence-based repurposing of other statins as anti-CSC therapeutics.<a onclick="showRef(event, 'ref86 ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref86 ref87 ref88">(86−88)</a></div><figure id="cht5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Chart 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 5. Molecular Structures of Drug Repurposing Candidates as CSC Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=cht5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Lovastatin.</p><p><span class="fn-label"><sup>b</sup></span>Phenformin.</p><p><span class="fn-label"><sup>c</sup></span>Menadione.</p><p><span class="fn-label"><sup>d</sup></span>Selegiline.</p><p><span class="fn-label"><sup>e</sup></span>Thioridazine.</p><p><span class="fn-label"><sup>f</sup></span>Sulfasalazine.</p><p><span class="fn-label"><sup>g</sup></span>Aurinafin.</p><p><span class="fn-label"><sup>h</sup></span>Celecoxib.</p><p class="last"><span class="fn-label"><sup>i</sup></span>Omeprazole.</p></p></figure><div class="NLM_p">Targeting CSC metabolism by drugs is yet another fascinating avenue for repurposing. Jagust et al. (2019) reviewed the metabolism-based strategies for discovering anti-CSC agents.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> The intricate involvement of cellular metabolism and stemness in development and cancer is partially responsible for the distinct metabolic signatures in CSCs, which, in a way, could be exploited for selective CSC targeting. A few well-known drugs such as metformin (<b>20</b>, <a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>), phenformin (<b>51</b>, <a class="ref internalNav" href="#cht5" aria-label="Chart 5">Chart 5</a>), menadione (<b>52</b>), and selegiline (<b>53</b>) inhibited mitochondrial respiration by blocking the electron transport chain (ETC) (OXPHOS) in nutrient-deprived tumor cells. Targeting of ETC complex I by <b>20</b> led to apoptosis induction in PDAC CD133<sup>+</sup> cells and CD44<sup>high</sup>/CD24<sup>low</sup> mammospheres. Compared with <b>20</b>, the highly lipophilic congener <b>51</b> was delivered more efficiently to the mitochondria, where it inhibited ETC complex I and induced reactive oxygen species (ROS). Ironically, resistance development to <b>20</b> (as monotherapy) was routinely observed. Hit <b>53</b> caused apoptotic cell death in acute myeloid leukemia (AML) CSCs via the reduced expression of ETC and glycolysis-related genes.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Quite a few antibiotics, such as antimycin A, oligomycin, bedaquiline, and others affect ETC in various complexes, thereby selectively decreasing the CSC numbers. Doxycycline, azithromycin, and a few others target mitochondrial translation and biogenesis. An elaborate discussion on drugs acting in various stages in CSC glycolysis, lipid and redox metabolism, and their molecular targets, is beyond the scope of the present Perspective and can be found elsewhere.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div><div class="NLM_p">Thioridazine (<b>54</b>), a potent dopamine D<sub>2</sub> receptor (D<sub>2</sub>R) antagonist clinically used as an antipsychotic, has shown potent activity against colorectal CSCs isolated from HCT116 spheres.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Following a 24 h treatment with <b>54</b>, both the proliferation and invasion of CSCs were significantly inhibited at a therapeutically achievable, that is, <10 μM, concentration. Apoptosis induction by the upregulation of <i>caspase-3</i> and <i>Bax</i> genes and the downregulation of the antiapoptotic <i>Bcl-2</i> gene were observed. The mechanism of the anti-CSC action of <b>54</b> was related to the mitochondrial pathway due to its effect on the mitochondrial membrane potential.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Recently, <b>54</b> demonstrated P62-mediated autophagy and apoptosis in GBM cell lines with the major involvement of the Wnt/β-catenin pathway.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> These results are significant for the potential repositioning of <b>54</b>, a BBB-permeable drug for GBM treatment. In a related article, Weissenrieder et al. (2020) explored the potential role of D2R in the spheroid phenotype in the GBM cell line, U87 MG. They concluded that the observed involvement was due to the factors related to cell–cell adhesion or EGFR signaling and not to the varied stemness marker expressions.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> The authors utilized D<sub>2</sub>R antagonists such as <b>54</b>, pimozide, haloperidol, and remoxipride, alongside D2R agonists PHNO, sumanirole, and ropinirole, each at 100 nM concentration. The D2R antagonists decreased, whereas the agonists increased, the spheroid formation. Varga et al. (2017) reviewed the possible biological and clinical applications of phenothiazines in a variety of diseases and conditions including cancer.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div><div class="NLM_p">Sulfasalazine (<b>55</b>), a prodrug originally prescribed for inflammatory bowel disease, exhibited potent activity against metastatic bladder cancer in combination with cisplatin.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> The multiple effects of <b>55</b> on MBT-2V cells resulting from its synergistic combination with cisplatin included the depletion of glutathione (GSH) levels by the inhibition of the system x<sub>c</sub><sup>–</sup> transporter (xCT), the induction of ROS production alongside the inhibition of CD44v9 (a variant isoform of CD44 and a new CSC surface marker) expression, and the upregulation of phospho-p38<sup>MAPK</sup> expression. A related study investigated the effectiveness of the same combination in cisplatin-resistant, CD44v9-expressing HCC cells derived from patients as well as cell lines HAK-1A and HAK-1B.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> The in vitro and in vivo animal efficacy studies confirmed the superior activity of the combination in overcoming the drug resistance in the HCC cells.</div><div class="NLM_p">One way to improve the response to anticancer agents is to overcome the onset of resistance by causing pro-oxidative overload. Ralph et al. (2019) explored the possibility of repurposing auranofin (<b>56</b>), a potent and specific thioreductase inhibitor, and celecoxib (<b>57</b>), a selective cyclooxygenase-2 (COX-2) inhibitor.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> The metastatic-cancer-cell- and CSC-killing properties of <b>56</b> and <b>57</b> were mainly attributed to their ability to promote mitochondrial ROS, thereby activating the intrinsic pathway to programmed cell death. The authors warranted the clinical validation of these and related drugs in cancer patients. Hashemi Goradel et al. (2019) reviewed the connection between COX-2 and cancer as well as its involvement in CSC induction and the promotion of apoptotic resistance.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> In cancer cells, multiple effects of COX-2 such as invasion, metastasis, inflammation, and angiogenesis, are mostly mediated via prostaglandin E<sub>2</sub> (PGE<sub>2</sub>). Members of the MAPK, EGFR, and NF-κB families act as upstream modulators of COX-2. Treatment with its inhibitors would reverse these deleterious events and sensitize the cancer cells and CSCs to the chemo- and radiotherapy.</div><div class="NLM_p">A Chinese patent application (2018) listed omeprazole (<b>58</b>), a blockbuster proton pump inhibitor (PPI) drug, as a major ingredient of a cocktail (<b>58</b> + catechin + paromomycin sulfate + ribavirin in mass ratio 23:1:3:8) exhibiting potent liver CSC inhibitory activity.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> The inventors claimed that the cocktail decreased the proliferation rate of solid tumors and mitigated the oxidative and inflammatory damage caused by liver cancer. The in vitro observations were subsequently confirmed in vivo. The author tried to understand the logic behind the anti-CSC effects of the cocktail. Pantoprazole, a congener of <b>58</b>, is known to have effects on gastric CSCs via EMT/β-catenin pathways.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Catechin is a catechol-containing antioxidant that is highly prone to oxidation under mild conditions. One of most abundant catechins, ECGC (<b>27</b>, <a class="ref internalNav" href="#cht3" aria-label="Chart 3">Chart 3</a>), is reported to affect the CSCs by binding to its transmembrane receptor 67LR, which, in turn, is a master regulator of CSC activity.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Paromomycin sulfate is an aminoglycoside antibiotic used as an antiprotozoal agent. Its mechanism of action involves faulty protein synthesis. Ribavirin is a nucleoside inhibitor of the inosine 5′-monophosphate dehydrogenase (IMPDH) enzyme that catalyzes a crucial step in guanine nucleotide biosynthesis. The inhibition of IMPDH by ribavirin would lead to the depletion of guanine nucleotides, hampering the de novo biosynthesis of nucleic acids. Lately, non-nucleoside inhibitors of human IMPDH isoform 2 (<i>h</i>IMPDH2) have been explored in BC, PC, and the GBM.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> In conclusion, the cocktail ingredients would work in synergy, affecting various aspects of cell proliferation.</div><div class="NLM_p last">Overall, drug repurposing presents a safe, more realistic, and quicker approach to discover potential anti-CSC leads for several cancer types. More research is needed to further expand the scope of this field.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Synthetic Organic Molecules/NCEs as Anti-CSC Agents</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01770" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01770" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Small-molecule drug candidates and NCEs act as CSC inhibitors by interfering with a large number of signaling pathways. Tyrosine kinase inhibitors (TKIs) are at the forefront of these agents. Very recently, Talukdar et al. (2020) reiterated the role of EGFR, a receptor tyrosine kinase (RTK) in CSC regulation.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> In particular, CSC characteristics such as the stemness, chemoresistance, quiescence, metabolism, and immunomodulatory activity are intricately controlled by EGFR. Clinically used EGFR and other kinase inhibitors eventually become inefficacious due to acquired drug resistance by the CSCs.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> The authors discussed the need to combine EGFR inhibitors with inhibitors of other crucial signaling cascades such as STAT3 to improve the therapeutic outcome. Jin (2020) reviewed the critical role of nonreceptor tyrosine kinase (NRTK) Src family kinases in CSC generation and the overall development of CRC and discussed the clinical implications of their inhibition.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> The activation of Src in CRC by several membrane receptors such as EGFR, vascular endothelial growth factor receptor (VEGFR), IL-13Rα2, and others as well as by modulators like aryl hydrocarbon receptor (AhR) signaling and receptor-like protein tyrosine phosphatase (PTPR) and the downstream activation of Src substrates like focal adhesion kinase (FAK) and many others contribute to the CRC progression. In addition, the Src family kinases induce the EMT by increasing β-catenin/E-cadherin phosphorylation. Overall, Src plays a central role in inducing and maintaining CRC CSCs, which could be targeted at various locations to ameliorate the CRC.</div><div class="NLM_p">The FAK or protein tyrosine kinase 2 (PTK2) is a key NRTK integrating signal from the growth factors and cell adhesion. In cancer, FAK is instrumental in enforcing adhesion to the tumor stroma and ECM.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Barnawi et al. (2020) investigated the role of FAK activation by the actin-bundling protein, fascin, and its effect on the breast CSCs via β-catenin downstream targets. Extensive profiling of the fascin–FAK−β-catenin downstream targets in BC patients led to the proposed targeting of this pathway for breast CSC eradication.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Anti-CSC discovery programs on targets such as FAK are desperately needed.</div><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Defactinib (<b>2</b>)</h3><div class="NLM_p last">Previously, <b>2</b> (VS-6063, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>), an oral FADK1 and FADK2 inhibitor, was shown to target CSCs and downstream Wnt/β-catenin reporter activity.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Verastem Oncology<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> has an active clinical development program for <b>2</b> for KRAS-mutated NSCLC, recurrent or refractory stage III–IV epithelial ovarian, fallopian tube, or peritoneal cancer, and other advanced cancers. Currently, it is being evaluated in six different clinical trials: (i) NCT04201145 (pembrolizumab + <b>2</b> in pleural mesothelioma; Phase 1); (ii) NCT04439331 (<b>2</b> in cancers with neurofibromatosis type 2 (NF2) genetic changes; Phase 2); (iii) NCT03875820 (<b>2</b> + RO5126766 (dual RAF/MEK inhibitor) for NSCLC, CRC, low-grade serous ovarian cancer, and solid tumor; Phase 1); (iv) NCT02758587 (pembrolizumab + <b>2</b> in NSCLC, pancreatic neoplasms and mesothelioma; Phase 1/2); (v) NCT03727880 (pembrolizumab ± <b>2</b> in resectable PDAC; Phase 2), and (vi) NCT02546531 (pembrolizumab + <b>2</b> + gemcitabine in advanced cancers; Phase 1). Clinical candidate <b>2</b> was granted Orphan Drug Designation in the USA and the EU for malignant mesothelioma and OC. Overall, the results from previous and ongoing clinical trials of <b>2</b> as monotherapy or in combination are encouraging. The ultimate clinical success will seal the deal.</div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Dasatinib Analogs</h3><div class="NLM_p">Dasatinib (<b>59</b>, <a class="ref internalNav" href="#cht6" aria-label="Chart 6">Chart 6</a>) is a highly potent, small-molecule Src and Bcr-Abl kinase inhibitor launched in 2006 for the treatment of CML and acute lymphoblastic leukemia (ALL). The originator, Bristol-Myers Squibb, is conducting several clinical trials of <b>59</b> for refractory cancers. A recent phase 2b DASCERN trial (NCT01593254) compared <b>59</b> with imatinib in patients with CML in the chronic phase and concluded that if an optimal response to imatinib could not be seen in 3 months, then switching to <b>59</b> might be beneficial.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Previously, Tian et al. (2018) convincingly proved that <b>59</b> blocked paclitaxel-induced breast CSC enrichment and Src activation in both native and paclitaxel-resistant TNBC cells and enhanced sensitivity to paclitaxel.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><figure id="cht6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Chart 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 6. Dasatinib Analogs Currently in the “Biological Testing” Phase</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=cht6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Dasatinib.</p></p></figure><div class="NLM_p last">Moving ahead, the author searched the Cortellis Drug Discovery Intelligence platform for “Related Drugs”, using <b>59</b> as query, which featured two reports<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112,113)</a> describing its analogs. Presently, <b>3</b> and <b>4</b> (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) are in the “Preclinical” phase, whereas others, <b>60</b>–<b>65</b> (<a class="ref internalNav" href="#cht6" aria-label="Chart 6">Chart 6</a>), are under “Biological Testing”. Both reports highlighted the effects of the bioisosteric replacement of the distal “–CONH–” group or the proximal substituent on the piperazine “N” on the anticancer activity against leukemia cell lines K562 and HL60. A few of these analogs had covalent warheads such as a vinyl moiety. The acrylamide derivatives <b>62</b> and <b>64</b> were equipotent as <b>59</b>. The bioisosteric replacements yielded less potent analogs of <b>59</b> in related assays and were less toxic in vivo following single-dose oral administration.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> To summarize, a simple and effective strategy based on the “active chemical analog” approach for the structural modifications of an established drug was presented for fine-tuning the anticancer and anti-CSC activity.</div></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Cyclin-Dependent Kinase (CDK) Inhibitors</h3><div class="NLM_p">Hit <b>5</b> (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) was designed as a pharmacophoric hybrid version of “ribociclib” (cyclin D1/CDK4 and CDK6 inhibitor) and <b>28</b> (<a class="ref internalNav" href="#cht3" aria-label="Chart 3">Chart 3</a>) to discover selective CDK9 inhibitors.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Detailed biological evaluations in NSCLC-specific assays identified <b>5</b> as a potent and selective CDK9 inhibitor (CDK9/cyclin T IC<sub>50</sub> = 11 nM; >12-fold selective over CDK4/cyclin D and CDK6/cyclin D) with submicromolar potency in cell viability assays. Furthermore, <b>5</b> downregulated the NSCLC stem cells in CSC assays and exhibited in vivo efficacy in the H1299 xenograft model in a dose-dependent manner. Mechanistically, <b>5</b> inhibited the phosphorylation of retinoblastoma tumor suppressor protein (Rb) and RNA polymerase II carboxy-terminal domain (RNAP II CTD) in addition to the decreased expression of stemness marker Oct4. Overall, <b>5</b> emerged as a potential lead for the further design and development of selective CDK9/cyclin T inhibitors for anti-CSC activity.</div><div class="NLM_p last">At the present, the CDK4/6 involvement in CSC biology is of a speculative nature. The observations on pluripotent stem cells are extrapolated to CSCs. It is believed that CDK 4/6 along with CDK2 could affect the direct phosphorylation of Oct4, Sox2, and Nanog, leading to their stabilization.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Alternatively, the activation of Nanog expression through the Rb phosphorylation pathway could be operative. Nonetheless, the crucial role of CDKs in the cell-cycle machinery and the availability of several selective inhibitors will unveil the potential these drugs hold in the anti-CSC therapeutics field.</div></div><div id="sec7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> γ-Secretase Inhibitors</h3><div class="NLM_p last">The CSCs are in a state of dysregulated autophagy. Its modulation has a long-standing impact on CSC properties. The inhibition or activation of autophagy can potentially be used for sensitizing CSCs to chemotherapy.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Das et al. (2019) profiled NMK-T-057 (<b>6</b>, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) as an inducer of autophagy, causing cell death via the inhibition of the γ-secretase-mediated activation of Notch signaling in BC cell lines representing clinical phenotypes MDA-MB-231, MDA-MB-468, 4T1, and MCF-7.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Hit <b>6</b> could inhibit colony formation, as assessed by the clonogenic assay, reduce the secondary spheroids obtained from the treated primary spheroids in the sphere assay, induce apoptosis in a dose-dependent manner, prevent the migratory aptitude of BC cells, and attenuate stemness in TNBC cells and was found to be nontoxic in animal toxicity studies following a 7 day treatment. Interestingly, <b>6</b> reversed the EMT in highly aggressive and invasive MDA-MB-231 cells. Further mechanistic revelation confirmed the downregulation of the Notch/Akt axis with a direct effect on Notch-1, <i>Hes-1</i> (Notch target gene), and the phosphorylation status of Akt. Deeper insights in this direction led to the identification of γ-secretase inhibition by <b>6</b> accompanied by binding to the γ-secretase complex interface as its primary mechanism of action. In 4T1 xenograft models, <b>6</b> inhibited the progression of breast tumors. A drastic reduction in active Notch was seen in treated tumors. In summary, the arduous biological studies reiterated the importance of Notch signaling inhibition as a rewarding strategy for targeting CSCs.</div></div><div id="sec7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> AMPK Modulators</h3><div class="NLM_p">Oncogenic transformation involves major cellular reprogramming to meet the energy requirement due to increased metabolism. Here AMPK, a cellular energy sensor, plays a crucial role. Its activation due to ATP depletion leads to reduced cell proliferation, inhibition of oncogenic pathways, and induction of apoptosis, among others. Previously, Kim and He discussed the targeting of AMPK in various cancer cell lines and animal models of cancer.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Along these lines, Johnson et al. (2019) evaluated FND-4b (<b>7</b>, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) for its AMPK activation and the downstream events resulting in decreased cell growth and increased apoptosis in three BC phenotypes, estrogen receptor (ER)<sup>+</sup>, TNBC, and CSCs.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> The observations were in line with the expectations. The decreased cell growth was attributed to the AMPK activation, reduced fatty acid synthesis, mTOR signaling, and cyclin D1 levels. The study and the associated strategy based on the AMPK activation were important from the TNBC treatment point of view because these patients present a low expression of AMPK. Compound <b>7</b> is thus a valuable anti-CSC agent awaiting further progression in the drug discovery and development cycle. Bort et al. (2019) demonstrated the utility of the therapeutic activation of AMPK to overcome chemoresistance in HCC.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></div><div class="NLM_p last">The other school of thought centered on AMPK inhibitors contradicts this previous belief. In this regard, Bonini and Gantner critically reviewed the controversial and contextual role of AMPK as either a tumor suppressor or tumor promoter.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> It is now agreed that the role of AMPK in the constituents of the complex TME would be governed by a large number of factors such as the level of hypoxia, the availability of nutrients, cell–cell interactions, the exposure to cytokines, and many others. As the precise details of AMPK biochemistry are understood, appropriate therapeutic strategies could be devised. A few recent reports emphasized the need to target CSCs via AMPK inhibition in PC<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> and CRC.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></div></div><div id="sec7_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> P-gp Modulators</h3><div class="NLM_p last">The overexpression of P-gp is the single most important factor contributing to MDR in cancer. The CSC hypothesis rejuvenated the MDR research and led to several important discoveries. The translation of these findings to the clinic is on course.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Pati et al. (2015) explored the “collateral sensitivity” (CS) strategy for modulating the cellular energy equilibrium, ultimately leading to profuse ROS generation with simultaneous hypersensitivity to the altered energy levels.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Implementing CS is possible with or without direct interaction at the P-gp. In brief, the first type of agent exhibiting the CS phenomenon, for example, P-gp substrates, would undergo ATP-dependent efflux by P-gp. The ensuing ATP depletion would result in ROS production, whereas the second type would do so without the direct involvement with P-gp. Such agents could be transition-metal chelators wherein the metal ions shuttle between two or more redox states. The authors designed a set of “hybrid” ligands comprising a σ<sub>2</sub> receptor (overexpressed in many cancers) ligand, a P-gp substrate, and, additionally, a metal-chelating framework exemplified by <b>8</b> (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>). A detailed biological evaluation in MCF-7 and A549 cell lines and their corresponding doxorubicin-resistant versions led to varied hit profiles. Compound <b>8</b> turned out to be a nanomolar P-gp inhibitor with moderate antiproliferative activity in A549 and A549dx cells. A few molecules predominantly showed the CS phenomenon. Overall, such a multipronged strategy is likely to be useful in the refractory tumors. Further evidence in context with CSCs is warranted.</div></div><div id="sec7_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Apoptosis Inducers</h3><div class="NLM_p">Dysregulated apoptosis is central to cancer development, progression, metastasis, and regression. The induction of apoptosis to eradicate cancer cells and CSCs is an emerging strategy in oncology.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Lucki et al. (2019) performed a cell-based chemical genetics screening with 10<sup>6</sup> molecules and identified a small-molecule hit <b>9</b> (RIPGBM, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>), which uniquely induced apoptosis in multipotent GBM CSCs.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> The conversion of <b>9</b> to its proapoptotic tricyclic analog cRIPGBM, specifically generated via intramolecular cyclization in a redox-dependent pathway in GBM CSCs, was partly responsible for its cell-type selectivity. Accumulated mechanistic details placed cRIPGBM as a binding partner of receptor-interacting protein kinase 2 (RIPK2), which led to the formation of a proapoptotic RIPK2/caspase 1 complex. In vivo efficacy studies of <b>9</b> in an orthotopic intracranial, patient-derived GBM CSC tumor xenograft mouse model corroborated the cellular assay results. Significant inhibition of in vivo tumor growth was observed. Overall, a lead molecule acting at a novel target for a medical condition with an unmet medical need was discovered, potentially opening up newer avenues for CSC targeting.</div><div class="NLM_p last">In another study, celastrol, a quinone methide, was used as a lead compound for further derivatization to discover more potent and reasonably bioavailable ovarian CSC inhibitors.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Hit <b>10</b> (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) was perhaps the best compound in the series with IC<sub>50</sub> of 0.62 to 0.68 μM in the SKOV3, OVCAR3, and A2780 OC cell lines (selectivity index = 3.68 based on the normal ovarian epithelial cell line IOSE80). In addition, <b>10</b> induced profuse apoptosis and inhibited migration, colony formation, and sphere formation in the tested cell lines. Specifically, reduction in CSC markers CD44 and CD133 and the percentage of ALDH<sup>+</sup> OC cells was observed. Thus the authors successfully discovered a more potent semisynthetic derivative of a pentacyclic triterpenoid phytochemical with promising activity.</div></div><div id="sec7_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> NHERF1 Inhibitors</h3><div class="NLM_p last">Following the therapeutic inhibition of the Wnt/β-catenin pathway, the resulting cytoprotective autophagic response is majorly driven by NHERF1, which is overexpressed in highly aggressive and metastatic cancers. The postsynaptic density 95/discs large/zona occludens 1 (PDZ1) and PDZ2 domains of NHERF1 bind to target proteins, β-catenin and PTEN, at specific C-terminal motifs.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> These observations favored dual β-catenin/NHERF1 inhibition as a promising strategy for inducing apoptotic death in cancer cells. Coluccia et al. (2019) adopted a structure-based pharmacophore screening strategy to discover potent NHERF1 PDZ1 inhibitors.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> To exploit the oncogenic activity of NHERF1 (dictated by its subcellular localization) for targeting CRC cells, novel, first-in-class NHERF1 PDZ1 domain inhibitors were designed and evaluated in combination with β-catenin inhibitors for their ability to induce apoptotic cell death in CRC cells refractory to known Wnt/β-catenin pathway inhibitors. The discovery of the potent activity of <b>11</b> as an NHERF1 inhibitor and <b>12</b> as a specific β-catenin inhibitor and their synergistic cell growth inhibition was a significant achievement, clearing the path for next-generation agents acting by similar mechanisms.</div></div><div id="sec7_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Miscellaneous</h3><div class="NLM_p">Deptropine (<b>13</b>, as citrate, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) is a marketed H<sub>1</sub>-receptor antagonist with significant antimuscarinic activity. It is an inhibitor of ALDH with potent activity against breast CSCs.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> In a recently concluded study, <b>13</b> induced hepatoma cell death by blocking autophagosome–lysososome fusion, that is, it initiated autophagy, but failed to complete its maturation.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> In addition, <b>13</b> moderately activated caspase-3, -8, and -9 and partially contributed to the cell death via apoptosis activation. Furthermore, Hep3B tumor xenograft studies in athymic mice showed a significant reduction in the tumor volume, thereby supporting the in vitro observations. It is interesting to see a definitive trend in specific chemotypes, in this case, 10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>]-cycloheptene, in inheriting anticancer and anti-CSC activities.</div><div class="NLM_p">Progesterone receptor membrane component 1 (PGRMC1) is a heme-binding protein with high homology to cytochrome <i>b</i><sub>5</sub>. Accumulated scientific evidence confirmed <i>PGRMC1</i> as a candidate oncogene for head and neck cancers.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> It is often overexpressed in several cancers and presents great potential as a biomarker. In damaged BC cells struggling to survive, PGRMC1 promotes Akt activation and helps in sustaining signaling. Small-molecule ligands that displace heme from its binding site on PGRMC1 disrupt the downstream events, for example, the stability of EGFR. AG-205 (<b>14</b>, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) could bind to PGRMC1 and related proteins crucial for maintaining cancer cell viability. Surprisingly, <b>14</b> was more active against cell lines expressing wild-type EGFR than its mutant form, ΔE746-A750.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Overall, treatment with <b>14</b> alone or in combination was effective in cancer cell growth inhibition.</div><div class="NLM_p">Padhariya et al. (2020) evaluated a series of substituted chloroacetamides as potential inhibitors of breast, prostate, and oral CSCs.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> The assay panel comprised cell viability, soft-agar, and sphere assays using breast (MDA-MB-231, MCF7, and T47D), prostate (DU145, LNCaP, and PC-3), and oral (KB, KB-3-1, KBChR-8-5) cancer cell lines. Of all of the compounds tested, <b>66</b> and <b>67</b> (<a class="ref internalNav" href="#cht7" aria-label="Chart 7">Chart 7</a>) were the most potent (<b>66</b>: MTT IC<sub>50</sub> T47D: 0.33 ± 0.01 μM; soft-agar IC<sub>50</sub> DU145: 0.27 ± 0.03 μM; sphere assay PC3: >50% inhibition at 25 nM; <b>67</b>: MTT IC<sub>50</sub> MDA-MB-231: 0.73 ± 0.11 μM; soft-agar IC<sub>50</sub> DU145: 1.16 ± 0.06 μM; sphere assay PC3: >50% inhibition at 25 nM). Whereas <b>66</b> was toxic to <i>h</i>PBMCs, <b>67</b> was well-tolerated. No mechanistic studies were carried out. Overall, the preliminary investigations led to the discovery of potent breast and prostate CSC inhibitors.</div><figure id="cht7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Chart 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 7. Representative CSC Inhibitors Reported in the Literature</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=cht7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Extending the previous work on electrophilic chloroacetamides, Padhariya et al. (2020) set out with the sole aim of discovering more drug-like and nontoxic hits by building up on the previous hits <b>66</b> and <b>67</b>. The search culminated in a new series of 1,2,3-triazoles.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Initial cell viability assays for 30 NCEs were performed using breast (MDA-MB-231), prostate (PC-3), and glioma (U87 MG) cell lines along with cervical (SiHa) and lung (A549) cell lines. Furthermore, five potent hits were tested in soft-agar and sphere assays (MDA-MB-231 and PC-3). Two hits, <b>68</b> and <b>69</b>, were the best in the series (<b>68</b>: MTT IC<sub>50</sub> MDA-MB-231: 2.16 ± 0.16 μM; soft-agar IC<sub>50</sub> PC-3: 2.9 ± 0.22 μM; sphere assay PC-3: ∼50% inhibition at 2.5 μM; <b>69</b>: MTT IC<sub>50</sub> MDA-MB-231: 1.47 ± 0.07 μM; soft-agar IC<sub>50</sub> PC-3: 12.13 ± 0.18 μM; sphere assay MDA-MB-231: >50% inhibition at 250 nM). Both hits were well tolerated in the <i>h</i>PBMC assay (IC<sub>50</sub> > 100 μM). In conclusion, the concerted efforts led to the discovery of moderately potent CSC inhibitors, which will be mechanistically studied in the future.</div><div class="NLM_p">Quattrini et al. (2020) reported a series of novel imidazo[1,2-<i>a</i>]pyridine derivatives as ALDH1A3 inhibitors with picomolar efficacy against patient-derived GBM stem-like cells.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Mesenchymal (MES) glioma stem-like cells, one of the two subpopulations, are characterized by relatively higher levels of ALDH1A3, which is crucial for their viability. Starting from a previously identified lead, the authors further optimized it using structure-based drug design. The most potent compound, <b>70</b> (<a class="ref internalNav" href="#cht7" aria-label="Chart 7">Chart 7</a>), demonstrated high selectivity at the 1A3 isoform and exceptionally potent activity in patient-derived glioma sphere samples: IC<sub>50</sub> values: 25.2 nM (MES-157), 63.4 nM (MES-267), and 2.58 pM (MES-374). Further in vivo validation of <b>70</b> is pending. Nonetheless, the identification of such a potent, selective, and functional inhibitor of ALDH1A3 is likely to generate interest in the scientific community for further exploration.</div><div class="NLM_p">In the follow-up study, systematic structure–activity relationship (SAR) studies of imidazo[1,2-<i>a</i>]pyridine derivatives led to the discovery of the angular hit <b>71</b> as a selective, submicromolar inhibitor of ALDH1A3 (IC<sub>50</sub> = 0.66 ± 1.3 μM).<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Molecular docking studies confirmed the binding mode in the enzyme active site. The −COOMe group was involved in the solvent-mediated H bond in one of the top-scoring poses. Overall, the medicinal chemistry efforts contributed to the thorough understanding of the design principles; for example, linear analog (<b>70</b>) was far more potent than the sharply angular one (<b>71</b>).</div><div class="NLM_p last">Very recently, on the basis of proof-of-concept (PoC)-generating liposomal studies, a unique idea of selectively altering the K<sup>+</sup>/H<sup>+</sup> transport across organelle membranes, such as mitochondria and lysosomes, by small molecules was put forth.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The critical design aspect, that is, the infusion of K<sup>+</sup>-binding capacity, was addressed by introducing an N–O–alkylamide moiety capable of binding to K<sup>+</sup> (<b>72</b>, <a class="ref internalNav" href="#cht7" aria-label="Chart 7">Chart 7</a>) at pH 8.0 (liposomal exterior) due to a unique resonance-assisted H-bond form (O<sup>–</sup>–C(Ar)═N–O–C(R)–C═O). At pH 6.8, it dissociated inside the liposome, thereby releasing the bound K<sup>+</sup>. On its way back, that is, out of liposome, the free form (−N<b>H</b>CO−) transported H<sup>+</sup> and again bound to K<sup>+</sup>. The PoC was validated in human OC HEYA8 cells. Subsequently, the selective killing of salinomycin-resistant ovarian CSCs by <b>72</b> was observed in vitro at 5 μM concentration. Cells treated with <b>72</b> were less capable of tumorigenesis, and the resulting tumor size was significantly lower than that of the control. Mechanistically, <b>72</b> damaged the mitochondrial and lysosomal compartments via apoptosis induction and autophagy suppression. As a novel class of anti-CSC agents, the synthetic cation transporters exhibited promise to warrant further research.</div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Biologics</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24411" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24411" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In addition to small molecules, macromolecular entities serve as a great source of anti-CSC therapeutics. The so-called biologics or their semisynthetic versions target CSCs with high precision and accuracy. Peculiar characteristics can be infused into these agents to induce/block specific targets and the associated events. Most of these agents suffer from the obvious disadvantages related to cost, manufacturing, route of administration, and adverse effects, which could limit their therapeutic use. Nonetheless, biologics are still preferred over small-molecular drugs for debilitating diseases and disorders such as rheumatoid arthritis, cancer, and so on due to the promise they offer. Several structural and functional versions of these agents exist in the clinic. Novel modalities based on macromolecular agents are under investigation and active development. Apart from their use as therapeutic agents, some are used to deliver the “active” cargo at specific locations in the body. These “heavy weights” are truly valuable and indispensable for basic research in CSCs as well. Thus a short trip to the wonderland called “biologics”, in particular, for CSC targeting, is worthwhile.</div><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Anti-CSC mAbs</h3><div class="NLM_p">The complex CSC biology presents distinct interventional targets for mAb therapeutics. The wishlist is too long, including CSC markers, members of the signaling pathways, diverse factors in the TME, the CSC niche, and what not. Santamaria et al. (2017) questioned the feasibility of mAb therapeutics for CSC targeting in their review.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> The stupendous success of antitumor mAbs, including the recent addition of immune checkpoint inhibitors, may be extrapolated to CSCs, keeping in mind their unique nature and characteristics—quiescent, migratory, chemoresistant, plasticity, and so on. The molecular targets previously exploited for CSC-specific effects, for example, the STAT3 pathway, P-gp, and many others, could be the potential candidates for mAb development. Zhang et al. (2019) described the utility of humanized antireceptor tyrosine kinase-like orphan receptor 1 (ROR1) mAb and cirmtuzumab in eliminating highly chemoresistant breast CSCs.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> The increased expression of ROR1 following chemotherapy was found to impart major stemness characteristics to the BC cells, which were selectively put to use to eradicate them.</div><div class="NLM_p">Targeting CSCs by mAbs against surface markers could be, at times, problematic due to the presence of similar markers on the NSCs. In addition, there could be efficacy issues with mAb monotherapy. Thus multipronged strategies involving combination with other mAbs, for example, antiprogrammed cell death protein 1 (PD-1) or antiprogrammed death-ligand 1 (PD-L1) mAbs, or chemotherapeutic agents may increase the therapy outcome. Previously, several preclinical investigations and clinical trials of agents targeting delta-like ligand (DLL), one of the Notch signaling canonical ligands, were conducted.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Recently, Moore et al. (2020) provided an extensive overview of the Notch-targeting strategies in cancer, with a particular emphasis on anti-DLL4 mAbs (demcizumab and enoticumab) and Notch receptor mAbs (brontictuzumab and tarextumab).<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></div><div class="NLM_p">Brontictuzumab (OMP52M51), a humanized IgG2 Ab, acts by inhibiting Notch1 signaling. In vivo efficacy studies confirmed the tumor growth inhibition via direct actions on the tumor cells and CSCs alongside tumor angiogenesis. In a dose-escalation study (NCT01703572), intravenously administered brontictuzumab showed acceptable tolerability and moderate efficacy in patients with hematologic malignancies.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Another Ab candidate, tarextumab (OMP59R5), selectively inhibited Notch2 and Notch3 signaling and was evaluated in a phase 1 dose escalation and expansion study for solid tumors with demonstrated Notch signaling inhibition.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Demcizumab (OMP-21M18) was evaluated in combination with several chemotherapeutic drugs in various phase 1/1b trials for advanced or metastatic solid tumors (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Another fully humanized anti-DLL4 mAb, enoticumab (REGN421, SAR153192), underwent a safety and tolerability evaluation in a phase 1 trial (NCT00871559). No results are posted yet. Along a similar line, navicixizumab (OMP-305B83), a humanized bispecific anti-DLL4/anti-VEGF mAb, demonstrated safety, tolerability, and efficacy in a phase 1a study conducted in patients with previously treated multiple solid tumors. The most promising efficacy was seen against ovarian cancer.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> In April 2020, a phase 1b study of navicixizumab in combination with paclitaxel was completed. The results are yet to be posted (NCT03030287). Another phase 1 trial of navicixizumab with FOLFIRI and FOLFOX for metastatic CRC was terminated with no results posted (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Overall, mAb development for CSC targeting is still an active research area with mixed feelings due to the inherent complexities in CSC biology compromising acceptable translation to the clinic.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Clinical Trials Involving CSC-Targeting Strategies Based on Combination Therapy</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">sr. no.</th><th class="colsep0 rowsep0" align="center">details</th><th class="colsep0 rowsep0" align="center">NCT no. (phase/status)</th><th class="colsep0 rowsep0" align="center">indication</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">Breast Cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.</td><td class="colsep0 rowsep0" align="left">ruxolitinib + chemotherapy (paclitaxel, doxorubicin, cyclophosphamide)</td><td class="colsep0 rowsep0" align="left">NCT02876302 (2/ongoing)</td><td class="colsep0 rowsep0" align="left">preoperative chemotherapy for TNBC</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2.</td><td class="colsep0 rowsep0" align="left">MK-0752 + docetaxel + pegfilgrastim</td><td class="colsep0 rowsep0" align="left">NCT00645333 (2/completed)</td><td class="colsep0 rowsep0" align="left">advanced or metastatic BC<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3.</td><td class="colsep0 rowsep0" align="left">paclitaxel + reparixin</td><td class="colsep0 rowsep0" align="left">NCT02370238 (2/unknown)</td><td class="colsep0 rowsep0" align="left">metastatic TNBC</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4.</td><td class="colsep0 rowsep0" align="left">OMP-305B83 + FOLFIRI + FOLFOX</td><td class="colsep0 rowsep0" align="left">NCT03035253 (1/terminated)</td><td class="colsep0 rowsep0" align="left">metastatic CRC</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5.</td><td class="colsep0 rowsep0" align="left">demcizumab (OMP-21M18)</td><td class="colsep0 rowsep0" align="left">NCT01189942 (1/completed)</td><td class="colsep0 rowsep0" align="left">metastatic CRC</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">Prostate Cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6.</td><td class="colsep0 rowsep0" align="left">demcizumab + abraxane + gemcitabine</td><td class="colsep0 rowsep0" align="left">NCT01189929 (1/completed)</td><td class="colsep0 rowsep0" align="left">locally advanced or metastatic PaC<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7.</td><td class="colsep0 rowsep0" align="left">gamma-secretase/notch signaling pathway inhibitor RO4929097</td><td class="colsep0 rowsep0" align="left">NCT01192763 (1/terminated)</td><td class="colsep0 rowsep0" align="left">pancreatic cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">Ovarian Cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8.</td><td class="colsep0 rowsep0" align="left">carboplatin + paclitaxel + ruxolitinib + ruxolitinib phosphate</td><td class="colsep0 rowsep0" align="left">NCT02713386 (1/2; ongoing)</td><td class="colsep0 rowsep0" align="left">stages III–IV epithelial ovarian, fallopian tube, or primary peritoneal cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">9.</td><td class="colsep0 rowsep0" align="left">bevacizumab + chemotherapy guided by CSC test</td><td class="colsep0 rowsep0" align="left">NCT03632798 (3/ongoing)</td><td class="colsep0 rowsep0" align="left">recurrent ovarian cancer, fallopian tube, or primary peritoneal cancer</td></tr></tbody></table></div></div></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Anti-CSC Antibody–Drug Conjugates</h3><div class="NLM_p">The fascination with ADCs is as old as it is with the anti-CSC therapeutics, which is clearly evident from the literature reports on the design and evaluation of anti-CSC ADCs. Marcucci et al. (2019) reviewed the anti-CSC ADCs disclosed so far to the scientific community.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Interestingly, most of these target CSC markers, and a few just happen to exhibit anti-CSC activity in addition to their antitumor efficacy. The most notable of these ADCs are: (i) anti-DLL3 ADC (rovalpituzumab tesirine: anti-DLL3 mAb–Val–Ala–pyrrolo-benzodiazepine dimer – Phase 3); (ii) anti-PTK7 ADC (PF-06647020: humanized anti-PTK7 mAb–Val–Cit–Aur0101 – Phase 1), and (iii) anti-HER2 ADC (ado-trastuzumab emtansine: trastuzumab–noncleavable linker–maytansine – approved for HER2-positive metastatic BC).</div><div class="NLM_p last">Although six ADCs have been approved for cancer indication, we are yet to develop ADCs that specifically target CSCs. Despite the overstated hope, major issues remain. The anti-CSC ADC development is hampered by: (i) the complicated CSC biology, partially dependent on their state (proliferating versus quiescent autophagic) and location in the tumor tissue, (ii) the selection of an appropriate cytotoxic payload (cell-cycle-independent versus cell-cycle-dependent agents), (iii) the CSC plasticity along with complications related to intra- and intertumoral CSC fractions, and (iv) the poor translation from preclinical animal models to clinical settings. There have been setbacks in promulgating the PoC. Concerted efforts are needed to realize clinical success in the future as we learn more about CSC biology. Parallel efforts on both fronts, that is, ADC conjugation chemistry and appropriate anti-CSC agents, will greatly assist in realizing this, by today’s measures, a relatively distant dream. In their recent review article, Ponziani et al. (2020) provided the latest updates on chemotherapeutic ADCs with reference to the conjugation strategies, chemistry, payload selection, and clinically approved agents.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div></div><div id="sec8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> CSC-Targeted Vaccines</h3><div class="NLM_p last">In 2012, Ning et al. developed a dendritic-cell (DC)-based vaccine that selectively targeted CSCs and conferred antitumor immunity.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Recent progress in the CSC vaccine development field was recently abstracted to outline the strategies, issues, and challenges by Lin et al. (2017).<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Logically speaking, relatively rare occurrence of CSCs in tumors could be problematic for vaccine efficacy. Szaryńska et al. (2018) applied a similar approach for a DC vaccination for CRC.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> The combined use of a CSC vaccine postsurgery or radiation therapy with other immunotherapeutic options could be advantageous over monotherapy. In one such study, a CSC vaccination along with PD-L1- and CLTA-4-mediated immune checkpoint inhibition led to the definitive eradication of melanoma stem cells in a mouse tumor model.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Another issue with this approach is the availability of suitable tumor antigens. One report proposed the use of Nanog peptides for DC loading to evoke a cytotoxic T-cell response against CSCs.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Rigorous attempts to design and develop a CSC-specific DC or other type of vaccine would continue despite the roadblocks.</div></div><div id="sec8_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> miRNA-based Therapeutics</h3><div class="NLM_p last">Research on miRNAs, in particular, in cancer biology, has advanced our understanding of these noncoding RNAs and their important roles in tumorigenesis (e.g., Let-7 and miR-600 (BC)) chemoresistance (e.g., miR-377 (CML)), and metastasis (e.g., 135b (colon cancer) and Ex-miR-105 (BC)).<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Various miRNA-based therapeutic strategies are reported in the literature. The choice of a particular mode depends on whether onco-miRNAs (upregulated during malignant transformation in tumor tissue) are to be antagonized/knocked-down or TS-miRNAs (downregulated during malignant transformation) are to be replaced. The expected outcome or the end result is the sensitization of cancer cells to conventional chemotherapy. Toden et al. (2019) identified a unique miRNA panel in colorectal CD44v6<sup>+</sup> CSCs, for example, overexpressed miR-1246.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Such patient and tumor-type specific data can be further fine-tuned depending on the onco- or TS-miRNA-based approach for personalized/tailor-made therapy using a variety of modalities, for example, small-molecules, small-interfering RNAs (siRNAs), miRNAs, aptamers, and many others, to increase the overall and disease-free survival in patients. The combined use of miRNA therapy and cytotoxic drugs would offer synergistic output for the obvious reasons.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div></div><div id="sec8_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> DNA/RNA Aptamers (“Chemical Antibodies”)</h3><div class="NLM_p last">These are short, noncoding, single-stranded (deoxy)/oligonucleotides that can bind to their putative targets with high affinity due to their unique, sequence-specific 3D structrue.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Interestingly, large aptamer libraries can be built due to the ease of nucleotide synthesis. Previously, aptamers targeting specific markers on BC cells were explored for potential diagnostic and therapeutic applications, in addition to the targeted delivery of the drug–aptamer conjugates.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Zhou et al. (2017) revisited the aptamer-based therapeutic approaches for CSC targeting.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> The selection of aptamers from a large random library of (deoxy)/oligonucleotides based on the systematic evolution of ligands by the exponential enrichment (SELEX) process forms the core of this approach. Various investigational agents have demonstrated promising anti-CSC potential in the preclinical studies.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> A noteworthy problem with aptamers is the collateral damage to the healthy cells resulting from aptamer-mediated blocking of essential targets, just like chemotherapy. Binding of these agents to the overtly overexpressed targets in the cancer cells could provide some respite from their toxicity. Several aptamers are in cancer clinical trials for diagnostic or treatment purposes.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Hopefully, these versatile agents will soon reach the market after rigorous clinical investigations. Extremely large aptamer libraries resulting from the exponential combinations of the (deoxy)/oligonucleotides, for example, 10<sup>15</sup> sequences, could offer a valuable resource for the discovery of anti-CSC agents.</div></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">Drug Combinations for Targeting CSCs and Bulk Tumor Cells</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81073" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81073" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The elaborate discussion so far on CSC biology, therapeutic approaches for targeting CSC-specific pathways, and the crucial clinical trials of cancer stemness inhibitors has highlighted the utility of this approach in oncology. The moderate success in clinical development is a bit worrisome, which brings us back to the relevant questions: “When is the right time to use CSC-specific agents? Which type of cancer do we need to study? Which drug combinations are to be used?” As discussed previously, the right mix of these critical parameters along with highly efficacious anti-CSC therapeutics for defining therapeutic success is yet to be discovered. More trials, better agents, and a clear understanding of their PD for the given cancer type, in particular, in late-stage clinical trials, are needed.</div><div class="NLM_p">A CSC-targeted agent is more beneficial in the early stages of cancer (including the neo-adjuvant and adjuvant scenarios), whereas the conventional modalities (chemo- and radiotherapies) are best suited for the advanced stages of cancer because they eradicate bulk tumor cells.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Anti-CSC agents are known to work the best when combined with conventional cytostatic drugs.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Several strategies could be used for selecting the anti-CSC component of the combination such as: (i) the direct inhibition of CSC stemness properties, for example, self-renewal, (ii) the indirect modulation of the TME to affect the CSC niche, (iii) the promotion of CSC differentiation so that they could be eliminated by the chemotherapeutic drugs, (iv) immunotherapy and oncolytic viruses, and many others.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Dzobo et al. (2020) outlined the recent advances in CSC targeting within the TME in various cancers and listed the clinical trials of various drugs in combination with the chemo- and radiotherapies.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> A few representative clinical studies based on various combination strategies in major cancer types with a particular emphasis on CSC targeting are given in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. The mechanistic aspects of these drugs or drug candidates in combination need a closer look to fully understand the rationale and justify their selection.</div><div class="NLM_p">Ruxolitinib (Jakafi), a selective JAK1/JAK2 inhibitor, is indicated for the treatment of intermediate or high-risk myelofibrosis. Issues mainly related to tolerance and drug resistance limit its therapeutic use. The involvement of the JAK/STAT pathway in solid tumors led to several clinical trials of JAK inhibitors either as mono- or combination therapy for solid malignancies such as PDAC, BC, CRC, OC, PC, among others.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> MK-0752 is a γ-secretase and pan-Notch inhibitor evaluated in several cancers. In one study, treatment with MK-0752 led to a reduction in tumor growth along with the increased population of breast CSCs, in particular, in Notch3-expressing BC cells, owing to IL-6 induction.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> The combination of the interleukin-6 (IL-6) inhibitor tocilizumab with MK-0752 resulted in the desired reduction in breast CSCs and tumor growth. Reparixin is an investigational agent acting via the allosteric modulation of C–X–C chemokine receptor types 1/2 (CXCR1/2) and receptors for C–X–C motif chemokine ligand 8 (CXCL8, IL-8). The CXCL8–CXCR1/2 axis is a promising target in breast CSCs.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> In a recent phase 2 study in operable HER-2-negative BC patients (NCT01861054), reparixin was found to be safe and well-tolerated. The breast CSCs were reduced in many patients, as measured by flow cytometry, confirming the CXCR1 targeting.</div><div class="NLM_p last">Overall, countless strategies based on approved/investigational agents combined with other treatment modalities could be employed to yield the desired therapeutic outcome. The greater the molecular level information (e.g, biomarkers) about the cancer type in patients participating in trials and the data available from preclinical and early clinical studies, the better it is for designing the optimal clinical trial protocol and therapeutic regimen. A huge pile of data from varied sources could be problematic, too. Data mining using machine learning and deep learning could be useful for complicated tasks like the selection of a better drug combination for one cancer type over the other based on “big” data from a large number of functionally diverse biological assays. In a recent study, Chen et al. (2020) used an image analysis to expedite a sphere assay of SUM159 BC cells. They used single-cell images taken on day 4 to predict the sphere formation rate on day 14 using a convolutional neural network based on 1710 single-cell events as input.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Such intelligent and serious efforts are needed to advance our understanding of CSCs to develop “useful” treatment options.</div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">Nanotherapeutics for CSC Targeting</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43548" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43548" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The complex TME, CSC niche, tumor heterogeneity, hypoxic state, altered metabolism, overexpressed efflux transporters, and other factors impede the delivery of therapeutic arsenal to the site of action, resulting in a suboptimal clinical outcome. Preclinical models at times fail to represent the disease state, which is partially responsible for the poor translation to the clinic despite encouraging in vitro results. Overall, the targeted delivery of the therapeutic cargo is crucial for observing the expected outcome. Nanotherapeutics provide solutions for many, if not all, of these problems.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> The distinct features of the cancerous tissue such as the hypoxic state, acidosis, and abnormal vasculature could be exploited to design innovative delivery technologies. Interactions between the TME and the nanodelivery system, drug PK/PD, limitations of the delivery mechanism, target location, and formulation characteristics could significantly affect the drug penetration. A deeper understanding and knowledge of the underlying issues and mitigation strategies to convert these challenges into opportunities could turn the tables.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Feng et al. (2019) extensively reviewed various nanotherapeutic strategies, for example, nanoparticle (NP) formulations for overcoming hypoxia-mediated tumor progression.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Liposomes, mesoporous silica, nanomicelles, lipid polymers, metal NPs, β-cyclodextrin, poly(lactic-<i>co</i>-glycolic acid) (PLGA), polyethylene glycol–polylactic acid (PEG–PLA), and many other formulations containing drugs such as salinomycin, doxorubicin, paclitaxel, cisplatin, and investigational signaling pathways inhibitors, with or without targeting moieties—target-specific mAbs and aptamers, siRNAs, miRNAs, and polymers—were utilized to target CSC-specific markers, efflux transporters, and signaling pathways. The listed indications and measured anti-CSC effects of the targeted NP formulations were optimal, reaffirming the immense potential nanotherapeutics hold.</div><div class="NLM_p">In a related report, Wang et al. (2020) reviewed the utility of cell membrane biomimetic NPs for cancer targeting due to the homing ability of the cell-membrane proteins.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> The camouflaged NPs evade elimination by the reticuloendothelial system, remain in the circulation for a long time, and are targeted to particular regions of the cancerous tissue. Su et al. (2018) arduously evaluated the capacity of a set of CSC-homing peptides for targeting breast, colon, liver, and pancreatic CSCs.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> The promising peptides could associate strongly with the glycan epitopes of known CSC/NSC markers, opening up newer opportunities for CSC targeting. Chuang et al. (2017) described CSC-targeting synthetic peptides and their conjugates with cytotoxic cargo along with a method of screening for CSC-targeting peptides using phage display technology.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><div class="NLM_p">The drug-delivery modalities may have a stupendous effect on the therapeutic outcome. In an attempt to rationalize the superior efficacy of albumin NPs of paclitaxel (Abraxane) over Taxol (a micellar formulation of paclitaxel) in metastatic BC in humans, Yuan et al. (2020) observed a higher intracellular uptake of Abraxane in human TNBC (SUM149) cells, that is, both CSCs and differentiated cells.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> Surprisingly, Taxol increased the CSCs, whereas Abraxane significantly reduced them. Higher cellular uptake and efficacy at the CSCs could lead to the desired outcome. In conclusion, the nanotherapeutic strategy played a crucial role in modulating the anti-CSC efficacy of the cytotoxic cargo.</div><div class="NLM_p">Lopez-Bertoni et al. (2018) ventured into an ambitious project wherein novel CSC inhibitory miRNA mimics were packaged into self-assembled, bioreducible poly(β-amino ester) NPs. The delivery system safely released the cargo intracellularly to the GBM CSCs under a reducing cytosolic environment on intratumoral administration in the orthotopic brain-tumor xenograft model.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> The significant inhibition of tumor growth coupled to prolonged survival was observed in the treatment group. The lone study simultaneously addressed both of the challenges, novel anti-GBM CSC therapeutics and its targeted delivery at the site of action. A countless number of articles were published in the recent past on nanotherapeutics for CSC targeting. A detailed discussion on each of these reports is beyond the scope of the present Perspective. <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> lists a few interesting studies on nanotherapeutic strategies for the targeted delivery of anti-CSC agents.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Recent Reports on Various Nanotherapeutics for CSC Targeting</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">sr. no.</th><th class="colsep0 rowsep0" align="center">description</th><th class="colsep0 rowsep0" align="center">year</th><th class="colsep0 rowsep0" align="center">outcome</th><th class="colsep0 rowsep0" align="center">additional comments, if any</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.</td><td class="colsep0 rowsep0" align="left">salinomycin-loaded gold NPs</td><td class="colsep0 rowsep0" align="left">2019</td><td class="colsep0 rowsep0" align="left">high sensitivity of breast CSCs to NPs</td><td class="colsep0 rowsep0" align="left">cell death due to iron accumulation, leading to ROS generation, mitochondrial dysfunction, and lipid oxidation</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2.</td><td class="colsep0 rowsep0" align="left">anti-CD133 Ab-conjugated topoisomerase inhibitor NPs</td><td class="colsep0 rowsep0" align="left">2016</td><td class="colsep0 rowsep0" align="left">eradication of CRC CSCs in vitro and in vivo due to CD133-targeted delivery</td><td class="colsep0 rowsep0" align="left">greater cytotoxic efficacy compared with the nontargeted NPs</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3.</td><td class="colsep0 rowsep0" align="left">gene encoding plasmid and cisplatin delivery by mesoporous silica NPs</td><td class="colsep0 rowsep0" align="left">2019</td><td class="colsep0 rowsep0" align="left">reduced hepatoma cell proliferation, no. of CSCs and downregulation of stemness genes in vitro and in vivo</td><td class="colsep0 rowsep0" align="left">Huh7 cells blocked in the S-phase of the cell cycle leading to apoptosis</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4.</td><td class="colsep0 rowsep0" align="left">NPs containing self-assembled polypeptides</td><td class="colsep0 rowsep0" align="left">2020</td><td class="colsep0 rowsep0" align="left">highly cytotoxic, TNBC-targeted peptide nanocostructs</td><td class="colsep0 rowsep0" align="left">nucleolin (cell surface receptor on TNBC cells)-dependent cell penetration</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5.</td><td class="colsep0 rowsep0" align="left">polymerosomes for selective pancreatic tumor targeting</td><td class="colsep0 rowsep0" align="left">2020</td><td class="colsep0 rowsep0" align="left">increased cellular uptake and cytotoxicity under hypoxic conditions in vitro; reduced tumor growth and increased intratumoral necrosis in vivo</td><td class="colsep0 rowsep0" align="left">selective targeting to hypoxic niche, drug release due to destabilization</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6.</td><td class="colsep0 rowsep0" align="left">graphene oxide-silver nanocomposites of saliomycin for human ovarian CSC targeting</td><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">reduced cell viability via ROS generation, mitochondrial dysfunction, and induction of apoptosis</td><td class="colsep0 rowsep0" align="left">five times higher levels of apoptosis than salinomycin or nanocomposites alone, reduced mitochondrial membrane potential, and enhanced expression of apoptotic genes</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7.</td><td class="colsep0 rowsep0" align="left">engineered biological nanoparticles for targeting liver CSCs</td><td class="colsep0 rowsep0" align="left">2020</td><td class="colsep0 rowsep0" align="left">decreased cell proliferation after treatment with milk-derived nanovesicles containing siRNA of β-catenin</td><td class="colsep0 rowsep0" align="left">nanovesicles decorated with RNA scaffolds to include RNA aptamers for selective binding with epithelial cell adhesion molecule (EpCAM), marker present on liver CSCs</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8.</td><td class="colsep0 rowsep0" align="left">lipid-polymer hybrid NPs for targeted delivery of norcantharidin for breast CSCs</td><td class="colsep0 rowsep0" align="left">2019</td><td class="colsep0 rowsep0" align="left">reduced growth of orthotopic mammary TNBC tumors and metastasis</td><td class="colsep0 rowsep0" align="left">NPs containing integrin α5 ligand for selective targeting of breast CSCs</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">9.</td><td class="colsep0 rowsep0" align="left">quantum dots containing doxorubicin for CSC-targeted delivery</td><td class="colsep0 rowsep0" align="left">2020</td><td class="colsep0 rowsep0" align="left">significant cell killing effect due to efficient nuclear delivery of doxorubicin coated onto quantum dots</td><td class="colsep0 rowsep0" align="left">doxorubicin transported into the nuclei of cancer cells and CSCs owing to the chemical composition of the quantum dots</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10.</td><td class="colsep0 rowsep0" align="left">hybrid gold NPs containing quinacrine for oral CSC targeting</td><td class="colsep0 rowsep0" align="left">2020</td><td class="colsep0 rowsep0" align="left">excellent oral CSC growth inhibitory potential mostly via induction of apoptosis</td><td class="colsep0 rowsep0" align="left">excessive DNA damage by the hybrid gold NPs containing quinacrine by inhibition of DNA repair machinery</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a></td></tr></tbody></table></div></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87320" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87320" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Most of the ground-breaking research in the CSC field has been carried out in the past decade or so. The scientific community took keen interest in the latest developments and emerging trends in this naı̈ve discipline of oncology standing on the shoulders of the CSC hypothesis. Advances in the basic research on stemness properties, strongly supported by the availability of improved tools and techniques for studying molecular-level interactions, improved our understanding of the intricate and complicated signaling pathways. It was possible to study interactions among various crucial players and to identify CSC-specific targets. Most importantly, the availability of unique anti-CSC agents and the nanotherapeutic technologies for delivering them to the extremely complicated TME, in particular the CSC niche, majorly contributed to the present-day situation where “hope” has dominated “hype”. Countless completed and ongoing clinical trials have investigated promising anti-CSC agents either as monotherapy or in combination with conventional chemotherapeutic drugs under adjuvant or neoadjuvant settings in otherwise refractory or untreatable cancer types. The idea was simple: Chemotherapy would kill the bulk of the tumor, and the CSC inhibitor would eradicate therapy-resistant CSCs. Significantly improved overall and progression-free survival would be the ultimate measure of success. The discovery of newer, promising anti-CSC agents is highly desirable for expanding the scope of treatment from solid tumors to hematologic malignancies, from melanoma to the highly inaccessible GBM, and of course, to rare cancers. Simultaneously, advances in the nanotherapeutics-based approaches for CSC targeting are crucial for the site-specific delivery of the arsenal to ensure improved efficacy and reduced toxicity. Both fields are advancing in parallel and creating unprecedented opportunities by crossover permutations and combinations.</div><div class="NLM_p">Cancer treatment is moving toward a personalized approach to increase the chances of a cure. The addition of a new dimension, that is, CSCs, to the previous cancer treatment strategies and beliefs, coupled to the practices of precision medicine will lead to an exceptionally higher cure rate for the majority of cancers, including those with unmet medical need. The identification of tissue-specific CSC markers in patients can potentially guide the selection of appropriate anti-CSC entities (small molecules or biologics) and their combination with cytotoxic agents for optimal results. The incorporation of CSC-specific markers in the trial design is desperately needed. Systematic planning is the key to establish the ultimate utility of these “new-age” oncology drugs. Perhaps we are in a phase witnessing the end of the generalized chemotherapy era and transitioning into an era of personalized medicine dominated by the CSC inhibitors.</div><div class="NLM_p">The main focus of the “anti-CSC therapeutics” era will be on the modulation of CSC characteristics: self-renewal, pluripotency, chemoresistance, plasticity, the EMT, and differentiation. <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> depicts the important terms in the form of a word cloud generated from the content of this Perspective. The signaling pathways involved in conferring these characteristic to a subpopulation of cells residing in specialized niches within the tumor mass will be extensively explored for drug discovery and development. The repurposing of several drugs and phytochemicals will continue to provide quality leads for further exploration. The incidence rate of particular cancer types in developed nations will dictate the majority of these investigations. Nonetheless, such studies will further enrich our understanding of CSC biology, which, in turn, could be extrapolated to the cancers that are more prevalent in developing and underdeveloped nations. The origin of tumors will be better understood with these advances so that definitive preventive measures such as nutraceuticals and lifestyle changes, among others, would be put into proper perspective with confidence. Hopefully, the mysteries relating cancer to other metabolic and inflammatory diseases including diabetes, obesity, hypertension, and so on will unfold, which will promulgate the ground-breaking discoveries in those therapeutic domains as well. The optimism is never-ending, and so is the promise offered by the anti-CSC therapeutics.</div><figure id="fig4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0011.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Word cloud representing the contents of the Perspective.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Moving forward, clinical trials will majorly guide the in vitro and preclinical studies in retrospect. At present, the clinical trial scenario concerning the anti-CSC agents is not exactly encouraging, but this is temporary. Agents with a unique mode of action are definitely needed to deal with the MDR problem firsthand. Surprisingly, the advances in CSC research have rejuvenated the interest in the MDR field. Chemosensitization by agents meddling with the CSC stemness properties such as differentiation appear as “low-hanging” fruits. Once we reverse drug resistance, cancer treatment is simplified. Clinical validation of the appropriate drug combinations for specific cancer types is a daunting task. As the in vitro, preclinical, and early clinical data accumulate, finding patterns, extracting useful associations, and extrapolating them to future instances, that is, data mining and predictive analytics, take the center stage. In this regard, the machine- and deep-learning tools could be helpful for connecting the dots. In conclusion, the field is moving in the right direction at a reasonable speed. It is just that we are unaware of the “unknown unknowns” and to some extent the “known unknowns”. Despite that, the journey has been so very spectacular so far.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01336" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61277" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61277" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Prashant S. Kharkar</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga, Mumbai 400 019, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1955-7223" title="Orcid link">http://orcid.org/0000-0003-1955-7223</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1b6b683570737a69707a695b72786f766e76797a72357e7f6e357275"><span class="__cf_email__" data-cfemail="7404075a1f1c15061f1506341d170019011916151d5a1110015a1d1a">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The author declares no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52537" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52537" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Prashant S. Kharkar</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=BIO-d7e3519-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Prashant S. Kharkar</b> received his B. Pharm. degree in 1998. He obtained his M. Pharm. Sci. (2000) and Ph.D. (Tech.) (2004), both in Pharmaceutical Chemistry, from Institute of Chemical Technology (ICT), Mumbai, India. Dr. Kharkar completed his postdoctoral research (2006–2009) on neurodegenerative diseases and disorders with Prof. Aloke Dutta at Wayne State University, Detroit, MI. Previously, Dr. Kharkar worked in Indian and Foreign Multinational Drug Discovery companies such as Piramal Life Sciences, Reliance Life Sciences, and Nycomed Pharma Pvt. Ltd. Currently he is working as a Professor of Medicinal Chemistry at ICT. His research is focused on the design and development of small-molecule cancer stem cell inhibitors for triple-negative breast cancer (TNBC), prostate cancer, and glioblastoma multiforme (GBM). He has active discovery programs on antitubercular and anti-SARS-CoV-2 agents.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14545" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14545" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The author thanks Anubhav P. Kharkar for his help with the figures. The support and encouragement by Prof. Aniruddha B. Pandit, Vice Chancellor, ICT and Prof. Shreerang V. Joshi, Head, DPST, ICT, Mumbai are highly acknowledged.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">ATP-binding cassette</p></td></tr><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody-drug conjugate</p></td></tr><tr><td class="NLM_term">AhR</td><td class="NLM_def"><p class="first last">aryl hydrocarbon receptor</p></td></tr><tr><td class="NLM_term">ALDH</td><td class="NLM_def"><p class="first last">aldehyde dehydrogenase</p></td></tr><tr><td class="NLM_term">ALL</td><td class="NLM_def"><p class="first last">acute lymphoblastic leukemia</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">AMPK</td><td class="NLM_def"><p class="first last">AMP-activated protein kinase</p></td></tr><tr><td class="NLM_term">Axin2</td><td class="NLM_def"><p class="first last">axis inhibition protein 2</p></td></tr><tr><td class="NLM_term">BC</td><td class="NLM_def"><p class="first last">breast cancer</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">C/EBPβ</td><td class="NLM_def"><p class="first last">CCAAT enhancer binding protein β</p></td></tr><tr><td class="NLM_term">COX-2</td><td class="NLM_def"><p class="first last">cyclooxygenase-2</p></td></tr><tr><td class="NLM_term">CRC</td><td class="NLM_def"><p class="first last">colorectal cancer</p></td></tr><tr><td class="NLM_term">CSC</td><td class="NLM_def"><p class="first last">cancer stem cell</p></td></tr><tr><td class="NLM_term">DC</td><td class="NLM_def"><p class="first last">dendritic cell</p></td></tr><tr><td class="NLM_term">CXCL8</td><td class="NLM_def"><p class="first last">C-X-C chemokine ligand 8</p></td></tr><tr><td class="NLM_term">CXCR1</td><td class="NLM_def"><p class="first last">C-X-C chemokine receptor type 1</p></td></tr><tr><td class="NLM_term">DDIT3</td><td class="NLM_def"><p class="first last">DNA damage-inducible transcript 3</p></td></tr><tr><td class="NLM_term">D<sub>2</sub>R</td><td class="NLM_def"><p class="first last">dopamine D<sub>2</sub> receptor</p></td></tr><tr><td class="NLM_term">DLL</td><td class="NLM_def"><p class="first last">delta-like ligand</p></td></tr><tr><td class="NLM_term">Dvl2</td><td class="NLM_def"><p class="first last">dishevelled segment polarity protein 2</p></td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">extracellular matrix</p></td></tr><tr><td class="NLM_term">EOC</td><td class="NLM_def"><p class="first last">epithelial ovarian cancer</p></td></tr><tr><td class="NLM_term">EpCAM</td><td class="NLM_def"><p class="first last">epithelial cell adhesion molecule</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">ETC</td><td class="NLM_def"><p class="first last">electron transport chain</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">GBM</td><td class="NLM_def"><p class="first last">gliobastoma multiforme</p></td></tr><tr><td class="NLM_term">GC</td><td class="NLM_def"><p class="first last">gastric cancer</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">GSK3β</td><td class="NLM_def"><p class="first last">glycogen synthase kinase-3 beta</p></td></tr><tr><td class="NLM_term">HAT</td><td class="NLM_def"><p class="first last">histone acetyltransferase</p></td></tr><tr><td class="NLM_term">HMG-CoA</td><td class="NLM_def"><p class="first last">hydroxymethylglutaryl-coenzyme A</p></td></tr><tr><td class="NLM_term">HCC</td><td class="NLM_def"><p class="first last">hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term"><i>h</i>PBMCs</td><td class="NLM_def"><p class="first last">human peripheral blood mononuclear cells</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">ICAM-1</td><td class="NLM_def"><p class="first last">intercellular adhesion molecule 1</p></td></tr><tr><td class="NLM_term">ITGA6</td><td class="NLM_def"><p class="first last">integrin α6</p></td></tr><tr><td class="NLM_term">JAK/STAT</td><td class="NLM_def"><p class="first last">Janus kinase/signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">Lgr5</td><td class="NLM_def"><p class="first last">leucine-rich repeat-containing G-protein coupled receptor 5</p></td></tr><tr><td class="NLM_term">5-LO</td><td class="NLM_def"><p class="first last">5-lipoxygenase</p></td></tr><tr><td class="NLM_term">LRP6</td><td class="NLM_def"><p class="first last">low-density lipoprotein receptor-related protein 6</p></td></tr><tr><td class="NLM_term">mAbs</td><td class="NLM_def"><p class="first last">monoclonal antibodies</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistance</p></td></tr><tr><td class="NLM_term">MEK/ERK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase/extracellular-signal-regulated kinase</p></td></tr><tr><td class="NLM_term">miRNA</td><td class="NLM_def"><p class="first last">micro RNA</p></td></tr><tr><td class="NLM_term">MMP-9</td><td class="NLM_def"><p class="first last">matrix metalloproteinase-9</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">NHERF-1</td><td class="NLM_def"><p class="first last">Na<sup>+</sup>/H<sup>+</sup> exchange regulatory cofactor</p></td></tr><tr><td class="NLM_term">NOD</td><td class="NLM_def"><p class="first last">nonobese diabetic</p></td></tr><tr><td class="NLM_term">NQO1</td><td class="NLM_def"><p class="first last">NAD(P)H:quinone oxidoreductase-1</p></td></tr><tr><td class="NLM_term">NP</td><td class="NLM_def"><p class="first last">nanoparticle</p></td></tr><tr><td class="NLM_term">NRTK</td><td class="NLM_def"><p class="first last">nonreceptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">NSC</td><td class="NLM_def"><p class="first last">normal stem cell</p></td></tr><tr><td class="NLM_term">OC</td><td class="NLM_def"><p class="first last">ovarian cancer</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">Oct4</td><td class="NLM_def"><p class="first last">octamer-binding transcription factor 4</p></td></tr><tr><td class="NLM_term">OS</td><td class="NLM_def"><p class="first last">overall survival</p></td></tr><tr><td class="NLM_term">OXPHOS</td><td class="NLM_def"><p class="first last">oxidative phosphorylation</p></td></tr><tr><td class="NLM_term">PC</td><td class="NLM_def"><p class="first last">prostate cancer</p></td></tr><tr><td class="NLM_term">PaC</td><td class="NLM_def"><p class="first last">pancreatic cancer</p></td></tr><tr><td class="NLM_term">PDAC</td><td class="NLM_def"><p class="first last">pancreatic ductal adenocarcinoma</p></td></tr><tr><td class="NLM_term">PDZ1</td><td class="NLM_def"><p class="first last">postsynaptic density 95/discs large/zona occludens 1</p></td></tr><tr><td class="NLM_term">PFS</td><td class="NLM_def"><p class="first last">progression-free survival</p></td></tr><tr><td class="NLM_term">PGE<sub>2</sub></td><td class="NLM_def"><p class="first last">prostaglandin E<sub>2</sub></p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein 1</p></td></tr><tr><td class="NLM_term">PGRMC1</td><td class="NLM_def"><p class="first last">membrane-associated progesterone receptor component 1</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol-3-kinase</p></td></tr><tr><td class="NLM_term">PoC</td><td class="NLM_def"><p class="first last">proof-of-concept</p></td></tr><tr><td class="NLM_term">POR</td><td class="NLM_def"><p class="first last">cytochrome P450 oxidoreductase</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">proton pump inhibitor</p></td></tr><tr><td class="NLM_term">PTK</td><td class="NLM_def"><p class="first last">protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">PTPR</td><td class="NLM_def"><p class="first last">receptor-like protein tyrosine phosphatase</p></td></tr><tr><td class="NLM_term">RIP-2</td><td class="NLM_def"><p class="first last">receptor-interacting serine/threonine-protein kinase 2</p></td></tr><tr><td class="NLM_term">RIPK2</td><td class="NLM_def"><p class="first last">receptor-interacting protein kinase 2</p></td></tr><tr><td class="NLM_term">RNAP II CTD</td><td class="NLM_def"><p class="first last">RNA polymerase II carboxy-terminal domain</p></td></tr><tr><td class="NLM_term">ROR1</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase-like orphan receptor 1</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SH2</td><td class="NLM_def"><p class="first last">Src homology 2</p></td></tr><tr><td class="NLM_term">SCID</td><td class="NLM_def"><p class="first last">severe combined immunodeficiency</p></td></tr><tr><td class="NLM_term">siRNA</td><td class="NLM_def"><p class="first last">small-interfering RNA</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term">TF</td><td class="NLM_def"><p class="first last">Thomsen–Friedenreich antigen or epitope</p></td></tr><tr><td class="NLM_term">TFs</td><td class="NLM_def"><p class="first last">transcription factors</p></td></tr><tr><td class="NLM_term">TGF-β</td><td class="NLM_def"><p class="first last">transforming growth factor beta</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">TME</td><td class="NLM_def"><p class="first last">tumor microenvironment</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">ZEB1</td><td class="NLM_def"><p class="first last">zinc-finger E-box-binding homeobox 1</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70613" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70613" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 186 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brower, V.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cell hypothesis evolves with emerging research</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>, <span class="NLM_elocation-id">djw139</span> <span class="refDoi"> DOI: 10.1093/jnci/djw139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1093%2Fjnci%2Fdjw139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=27130920" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&author=V.+Brower&title=Cancer+stem+cell+hypothesis+evolves+with+emerging+research&doi=10.1093%2Fjnci%2Fdjw139"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjw139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjw139%26sid%3Dliteratum%253Aachs%26aulast%3DBrower%26aufirst%3DV.%26atitle%3DCancer%2520stem%2520cell%2520hypothesis%2520evolves%2520with%2520emerging%2520research%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2016%26volume%3D108%26doi%3D10.1093%2Fjnci%2Fdjw139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartram, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeschke, J. M.</span></span> <span> </span><span class="NLM_article-title">Do cancer stem cells exist? a pilot study combining a systematic review with the hierarchy-of-hypotheses approach</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e0225898</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0225898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1371%2Fjournal.pone.0225898" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31834886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitV2ksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&author=I.+Bartramauthor=J.+M.+Jeschke&title=Do+cancer+stem+cells+exist%3F+a+pilot+study+combining+a+systematic+review+with+the+hierarchy-of-hypotheses+approach&doi=10.1371%2Fjournal.pone.0225898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Do cancer stem cells exist? A pilot study combining a systematic review with the hierarchy-of-hypotheses approach</span></div><div class="casAuthors">Bartram, Isabelle; Jeschke, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e0225898</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">A review.  The phenomenon of cancer cell heterogeneity has been explained by different hypotheses, each entailing different therapy strategies.  The most recent is the cancer stem cell model, which says that tumorigenicity and self-renewal are restricted to rare stem cell-like cancer cells.  Since its conception, conflicting evidence has been published.  In this study, we tested the applicability of a new approach developed in the field of ecol., the hierarchy-of-hypotheses approach, for the Cancer Stem Cell hypothesis.  This approach allows to structure a broad concept into more specific sub-hypotheses, which in turn can be connected to available empirical studies.  To generate a dataset with empirical studies, we conducted a systematic literature review in the Web of Science limited to the first 1000 publications returned by the search.  From this pool, 51 publications were identified that tested whether a cell sub-population had cancer stem cell properties.  By classifying the studies according to: (1) assessed indicators, (2) exptl. assays and (3) model cancer cells used, we built a hierarchical structure of sub-hypotheses.  The empirical tests from the selected studies were subsequently assigned to this hierarchy of hypotheses, and the percentage of supporting, undecided and questioning evidence was calcd. for each sub-hypothesis, as well as addnl. exptl. characteristics.  Our approach successfully allowed us to det. that within our dataset, the empirical support for the CSC hypothesis was only 49.0%.  The support of different sub-hypotheses was highly variable.  Most noticeable, the conception that putative cancer stem cells are a rare subset of cells could not be confirmed by most studies (13.5% support).  The empirical support varied also between types of cancer, animal models and cell isolation method used.  For the first time, this study showed the applicability of the hierarchy-of-hypotheses approach for synthesizing and evaluating empirical evidence for a broad hypothesis in the field of bio-medical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Eyzx9U1fSrVg90H21EOLACvtfcHk0lgOKTkO3FrW8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitV2ksL0%253D&md5=ce37534e2883a2ec2dbdd32fafd31a4e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0225898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0225898%26sid%3Dliteratum%253Aachs%26aulast%3DBartram%26aufirst%3DI.%26aulast%3DJeschke%26aufirst%3DJ.%2BM.%26atitle%3DDo%2520cancer%2520stem%2520cells%2520exist%253F%2520a%2520pilot%2520study%2520combining%2520a%2520systematic%2520review%2520with%2520the%2520hierarchy-of-hypotheses%2520approach%26jtitle%3DPLoS%2520One%26date%3D2019%26volume%3D14%26doi%3D10.1371%2Fjournal.pone.0225898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">NCBI Resource Coordinators</span> <span> </span><span class="NLM_article-title">Database resources of the National
Center for Biotechnology Information</span>. <i>Nucleic
Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">D8</span>– <span class="NLM_lpage">D13</span>, <span class="refDoi"> DOI: 10.1093/nar/gkx1095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1093%2Fnar%2Fgkx1095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29140470" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=D8-D13&author=NCBI+Resource+Coordinators&title=Database+resources+of+the+National%0ACenter+for+Biotechnology+Information&doi=10.1093%2Fnar%2Fgkx1095"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkx1095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkx1095%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DDatabase%2520resources%2520of%2520the%2520National%250ACenter%2520for%2520Biotechnology%2520Information%26jtitle%3DNucleic%250AAcids%2520Res.%26date%3D2018%26volume%3D46%26spage%3DD8%26epage%3DD13%26doi%3D10.1093%2Fnar%2Fgkx1095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span> <i>SciFinder</i>, version
2020; <span class="NLM_publisher-name">Chemical Abstracts Service (CAS)</span>: <span class="NLM_publisher-loc">Columbus, OH</span>, <span class="NLM_year">2020</span> (accessed
2020-10-19).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+SciFinder%2C+version%0A2020%3B+Chemical+Abstracts+Service+%28CAS%29%3A+Columbus%2C+OH%2C+2020+%28accessed%0A2020-10-19%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DSciFinder%26pub%3DChemical%2520Abstracts%2520Service%2520%2528CAS%2529%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plaks, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span> <span> </span><span class="NLM_article-title">The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?</span>. <i>Cell Stem Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1016/j.stem.2015.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.stem.2015.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=25748930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtlGjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=225-238&author=V.+Plaksauthor=N.+Kongauthor=Z.+Werb&title=The+cancer+stem+cell+niche%3A+how+essential+is+the+niche+in+regulating+stemness+of+tumor+cells%3F&doi=10.1016%2Fj.stem.2015.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?</span></div><div class="casAuthors">Plaks, Vicki; Kong, Niwen; Werb, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Cell Stem Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-238</span>CODEN:
                <span class="NLM_cas:coden">CSCEC4</span>;
        ISSN:<span class="NLM_cas:issn">1875-9777</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Cancer stem cells (CSCs) are tumor cells that have the principal properties of self-renewal, clonal tumor initiation capacity, and clonal long-term repopulation potential.  CSCs reside in niches, which are anatomically distinct regions within the tumor microenvironment.  These niches maintain the principle properties of CSCs, preserve their phenotypic plasticity, protect them from the immune system, and facilitate their metastatic potential.  In this perspective, we focus on the CSC niche and discuss its contribution to tumor initiation and progression.  Since CSCs survive many commonly employed cancer therapies, we examine the prospects of targeting the niche components as preferable therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbJz89_n-_IbVg90H21EOLACvtfcHk0lgffpp7gfPU4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtlGjsr0%253D&md5=88070b21b2922fc2f726d5979462443f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.stem.2015.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.stem.2015.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DPlaks%26aufirst%3DV.%26aulast%3DKong%26aufirst%3DN.%26aulast%3DWerb%26aufirst%3DZ.%26atitle%3DThe%2520cancer%2520stem%2520cell%2520niche%253A%2520how%2520essential%2520is%2520the%2520niche%2520in%2520regulating%2520stemness%2520of%2520tumor%2520cells%253F%26jtitle%3DCell%2520Stem%2520Cell%26date%3D2015%26volume%3D16%26spage%3D225%26epage%3D238%26doi%3D10.1016%2Fj.stem.2015.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayob, A. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramasamy, T. S.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells as key drivers of tumour progression</span>. <i>J. Biomed. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">20</span>, <span class="refDoi"> DOI: 10.1186/s12929-018-0426-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2Fs12929-018-0426-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29506506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Sku7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=20&author=A.+Z.+Ayobauthor=T.+S.+Ramasamy&title=Cancer+stem+cells+as+key+drivers+of+tumour+progression&doi=10.1186%2Fs12929-018-0426-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells as key drivers of tumour progression</span></div><div class="casAuthors">Ayob, Ain Zubaidah; Ramasamy, Thamil Selvee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomedical Science (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20/1-20/18</span>CODEN:
                <span class="NLM_cas:coden">JBCIEA</span>;
        ISSN:<span class="NLM_cas:issn">1423-0127</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background:Cancer stem cells (CSCs) are subpopulations of cancer cells sharing similar characteristics as normal stem or progenitor cells such as self-renewal ability and multi-lineage differentiation to drive tumor growth and heterogeneity.  Throughout the cancer progression, CSC can further be induced from differentiated cancer cells via the adaptation and cross-talks with the tumor microenvironment as well as a response from therapeutic pressures, therefore contributes to their heterogeneous phenotypes.  Challengingly, conventional cancer treatments target the bulk of the tumor and are unable to target CSCs due to their highly resistance nature, leading to metastasis and tumor recurrence.  Main body: This review highlights the roles of CSCs in tumor initiation, progression and metastasis with a focus on the cellular and mol. regulators that influence their phenotypical changes and behaviors in the different stages of cancer progression.  We delineate the cross-talks between CSCs with the tumor microenvironment that support their intrinsic properties including survival, stemness, quiescence and their cellular and mol. adaptation in response to therapeutic pressure.  An insight into the distinct roles of CSCs in promoting angiogenesis and metastasis has been captured based on in vitro and in vivo evidences.  Conclusion: Given dynamic cellular events along the cancer progression and contributions of resistance nature by CSCs, understanding their mol. and cellular regulatory mechanism in a heterogeneous nature, provides significant cornerstone for the development of CSC-specific therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3nTnY6lOWyLVg90H21EOLACvtfcHk0lgffpp7gfPU4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Sku7zL&md5=a4700e44e5f5cb9be8de6d03c823ad75</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1186%2Fs12929-018-0426-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12929-018-0426-4%26sid%3Dliteratum%253Aachs%26aulast%3DAyob%26aufirst%3DA.%2BZ.%26aulast%3DRamasamy%26aufirst%3DT.%2BS.%26atitle%3DCancer%2520stem%2520cells%2520as%2520key%2520drivers%2520of%2520tumour%2520progression%26jtitle%3DJ.%2520Biomed.%2520Sci.%26date%3D2018%26volume%3D25%26spage%3D20%26doi%3D10.1186%2Fs12929-018-0426-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, R. R.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, A. U.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells: cellular plasticity, niche, and its clinical relevance</span>. <i>J. Stem Cell Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">363</span>, <span class="refDoi"> DOI: 10.4172/2157-7633.1000363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.4172%2F2157-7633.1000363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=27891292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOlt7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=363&author=G.+Leeauthor=R.+R.+Hallauthor=A.+U.+Ahmed&title=Cancer+stem+cells%3A+cellular+plasticity%2C+niche%2C+and+its+clinical+relevance&doi=10.4172%2F2157-7633.1000363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells: cellular plasticity, niche, and its clinical relevance</span></div><div class="casAuthors">Lee, Gina; Hall, Robert R., III; Ahmed, Atique U.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Stem Cell Research & Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">363/1-363/9</span>CODEN:
                <span class="NLM_cas:coden">JSCRCI</span>;
        ISSN:<span class="NLM_cas:issn">2157-7633</span>.
    
            (<span class="NLM_cas:orgname">OMICS International</span>)
        </div><div class="casAbstract">Cancer handles an estd. 7.6 million deaths worldwide per annum.  A recent theory focuses on the role Cancer Stem Cells (CSCs) in driving tumorigenesis and disease progression.  This theory hypothesizes that a population of the tumor cell with similar functional and phenotypic characteristics as normal tissue stem cells are responsible for formation and advancement of many human cancers.  The CSCs subpopulation can differentiate into non-CSC tumor cells and promote phenotypic and functional heterogeneity within the tumor.  The presence of CSCs has been reported in a no. of human cancers including blood, breast, brain, colon, lung, pancreas prostate and liver.  Although the origin of CSCs remains a mystery, recent reports suggest that the phenotypic characteristics of CSCs may be plastic and are influenced by the microenvironment specific for the individual tumor.  Such factors unique to each tumor preserve the dynamic balance between CSCs to non-CSCs cell fate, as well as maintain the proper equil.  Alternating such equil. via dedifferentiation can result in aggressiveness, as CSCs are considered to be more resistant to the conventional cancer treatments of chemotherapy and radiation.  Understanding how the tumoral microenvironment affects the plasticity driven CSC niche will be crit. for developing a more effective treatment for cancer by eliminating its aggressive and recurring nature that now is believed to be perpetuated by CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEyyC8Qu2kmLVg90H21EOLACvtfcHk0lgffpp7gfPU4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOlt7vL&md5=404451733e2940c236e8c93d4a2e37e0</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.4172%2F2157-7633.1000363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2157-7633.1000363%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DG.%26aulast%3DHall%26aufirst%3DR.%2BR.%26aulast%3DAhmed%26aufirst%3DA.%2BU.%26atitle%3DCancer%2520stem%2520cells%253A%2520cellular%2520plasticity%252C%2520niche%252C%2520and%2520its%2520clinical%2520relevance%26jtitle%3DJ.%2520Stem%2520Cell%2520Res.%2520Ther.%26date%3D2016%26volume%3D6%26spage%3D363%26doi%3D10.4172%2F2157-7633.1000363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lytle, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reya, T.</span></span> <span> </span><span class="NLM_article-title">Stem cell fate in cancer growth, progression and therapy resistance</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.1038/s41568-018-0056-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fs41568-018-0056-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30228301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCju77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=669-680&author=N.+K.+Lytleauthor=A.+G.+Barberauthor=T.+Reya&title=Stem+cell+fate+in+cancer+growth%2C+progression+and+therapy+resistance&doi=10.1038%2Fs41568-018-0056-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Stem cell fate in cancer growth, progression and therapy resistance</span></div><div class="casAuthors">Lytle, Nikki K.; Barber, Alison G.; Reya, Tannishtha</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">669-680</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Although we have come a long way in our understanding of the signals that drive cancer growth, and how these signals can be targeted, effective control of this disease remains a key scientific and medical challenge.  The therapy resistance and relapse that are commonly seen are driven in large part by the inherent heterogeneity within cancers that allows drugs to effectively eliminate some, but not all, malignant cells.  Here, we focus on the fundamental drivers of this heterogeneity by examg. emerging evidence that shows that these traits are often controlled by the disruption of normal cell fate and aberrant adoption of stem cell signals.  We discuss how undifferentiated cells are preferentially primed for transformation and often serve as the cell of origin for cancers.  We also consider evidence showing that activation of stem cell programs in cancers can lead to progression, therapy resistance and metastatic growth and that targeting these attributes may enable better control over a difficult disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS1xbXhKze1LVg90H21EOLACvtfcHk0lgffpp7gfPU4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslCju77O&md5=d3b2025797d58c408ed5d8862b07622e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fs41568-018-0056-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-018-0056-x%26sid%3Dliteratum%253Aachs%26aulast%3DLytle%26aufirst%3DN.%2BK.%26aulast%3DBarber%26aufirst%3DA.%2BG.%26aulast%3DReya%26aufirst%3DT.%26atitle%3DStem%2520cell%2520fate%2520in%2520cancer%2520growth%252C%2520progression%2520and%2520therapy%2520resistance%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2018%26volume%3D18%26spage%3D669%26epage%3D680%26doi%3D10.1038%2Fs41568-018-0056-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamil, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, K. M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asaduzzaman, S. M.</span></span> <span> </span><span class="NLM_article-title">Stem cell and cancer stem cell: a tale of two cells</span>. <i>Progr. Stem Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.15419/psc.v3i02.124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.15419%2Fpsc.v3i02.124" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=97-108&author=M.+Rahmanauthor=H.+M.+Jamilauthor=N.+Akhtarauthor=K.+M.+T.+Rahmanauthor=R.+Islamauthor=S.+M.+Asaduzzaman&title=Stem+cell+and+cancer+stem+cell%3A+a+tale+of+two+cells&doi=10.15419%2Fpsc.v3i02.124"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.15419%2Fpsc.v3i02.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15419%252Fpsc.v3i02.124%26sid%3Dliteratum%253Aachs%26aulast%3DRahman%26aufirst%3DM.%26aulast%3DJamil%26aufirst%3DH.%2BM.%26aulast%3DAkhtar%26aufirst%3DN.%26aulast%3DRahman%26aufirst%3DK.%2BM.%2BT.%26aulast%3DIslam%26aufirst%3DR.%26aulast%3DAsaduzzaman%26aufirst%3DS.%2BM.%26atitle%3DStem%2520cell%2520and%2520cancer%2520stem%2520cell%253A%2520a%2520tale%2520of%2520two%2520cells%26jtitle%3DProgr.%2520Stem%2520Cell%26date%3D2016%26volume%3D3%26spage%3D97%26epage%3D108%26doi%3D10.15419%2Fpsc.v3i02.124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunting, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colapietro, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagutina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosveld, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakauchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, B. P.</span></span> <span> </span><span class="NLM_article-title">The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1028</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1038/nm0901-1028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fnm0901-1028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=11533706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmvFOlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1028-1034&author=S.+Zhouauthor=J.+D.+Schuetzauthor=K.+D.+Buntingauthor=A.+M.+Colapietroauthor=J.+Sampathauthor=J.+J.+Morrisauthor=I.+Lagutinaauthor=G.+C.+Grosveldauthor=M.+Osawaauthor=H.+Nakauchiauthor=B.+P.+Sorrentino&title=The+ABC+transporter+Bcrp1%2FABCG2+is+expressed+in+a+wide+variety+of+stem+cells+and+is+a+molecular+determinant+of+the+side-population+phenotype&doi=10.1038%2Fnm0901-1028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype</span></div><div class="casAuthors">Zhou, Sheng; Schuetz, John D.; Bunting, Kevin D.; Colapietro, Anne-Marie; Sampath, Janardhan; Morris, John J.; Lagutina, Irina; Grosveld, Gerard C.; Osawa, Mitsujiro; Nakauchi, Hiromitsu; Sorrentino, Brian P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1028-1034</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Stem cells from bone marrow, skeletal muscle and possibly other tissues can be identified by the 'side-population' (SP) phenotype.  Although it has been assumed that expression of ABC transporters is responsible for this phenotype, the specific mols. involved have not been defined.  Here we show that expression of the Bcrp1 (also known as Abcg2 murine/ABCG2 human) gene is a conserved feature of stem cells from a wide variety of sources.  Bcrp1 mRNA was expressed at high levels in primitive murine hematopoietic stem cells, and was sharply down regulated with differentiation.  Enforced expression of the ABCG2 cDNA directly conferred the SP phenotype to bone-marrow cells and caused a redn. in maturing progeny both in vitro and in transplantation-based assays.  These results show that expression of the Bcrp1/ABCG2 gene is an important determinant of the SP phenotype, and that it might serve as a marker for stem cells from various sources.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIKAccL-V8ibVg90H21EOLACvtfcHk0liGR75JkqkgDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmvFOlsrk%253D&md5=3de78747ac288655cc31201553310056</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnm0901-1028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0901-1028%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DSchuetz%26aufirst%3DJ.%2BD.%26aulast%3DBunting%26aufirst%3DK.%2BD.%26aulast%3DColapietro%26aufirst%3DA.%2BM.%26aulast%3DSampath%26aufirst%3DJ.%26aulast%3DMorris%26aufirst%3DJ.%2BJ.%26aulast%3DLagutina%26aufirst%3DI.%26aulast%3DGrosveld%26aufirst%3DG.%2BC.%26aulast%3DOsawa%26aufirst%3DM.%26aulast%3DNakauchi%26aufirst%3DH.%26aulast%3DSorrentino%26aufirst%3DB.%2BP.%26atitle%3DThe%2520ABC%2520transporter%2520Bcrp1%252FABCG2%2520is%2520expressed%2520in%2520a%2520wide%2520variety%2520of%2520stem%2520cells%2520and%2520is%2520a%2520molecular%2520determinant%2520of%2520the%2520side-population%2520phenotype%26jtitle%3DNat.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D1028%26epage%3D1034%26doi%3D10.1038%2Fnm0901-1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floc’h, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flemington, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerrecher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span> <span> </span><span class="NLM_article-title">Challenges and opportunities in cancer drug resistance</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.0c00383</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.0c00383" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=R.+A.+Wardauthor=S.+Fawellauthor=N.+Floc%E2%80%99hauthor=V.+Flemingtonauthor=D.+McKerrecherauthor=P.+D.+Smith&title=Challenges+and+opportunities+in+cancer+drug+resistance&doi=10.1021%2Facs.chemrev.0c00383"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DFloc%25E2%2580%2599h%26aufirst%3DN.%26aulast%3DFlemington%26aufirst%3DV.%26aulast%3DMcKerrecher%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DChallenges%2520and%2520opportunities%2520in%2520cancer%2520drug%2520resistance%26jtitle%3DChem.%2520Rev.%26date%3D2020%26doi%3D10.1021%2Facs.chemrev.0c00383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Begicevic, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falasca, M.</span></span> <span> </span><span class="NLM_article-title">ABC transporters in cancer stem cells: beyond chemoresistance</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2362</span>, <span class="refDoi"> DOI: 10.3390/ijms18112362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fijms18112362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOgtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=2362&author=R.+R.+Begicevicauthor=M.+Falasca&title=ABC+transporters+in+cancer+stem+cells%3A+beyond+chemoresistance&doi=10.3390%2Fijms18112362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">ABC transporters in cancer stem cells: beyond chemoresistance</span></div><div class="casAuthors">Begicevic, Romana-Rea; Falasca, Marco</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2362/1-2362/23</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The efficacy of chemotherapy is one of the main challenges in cancer treatment and one of the major obstacles to overcome in achieving lasting remission and a definitive cure in patients with cancer is the emergence of cancer resistance.  Indeed, drug resistance is ultimately accountable for poor treatment outcomes and tumor relapse.  There are various mol. mechanisms involved in multidrug resistance, such as the change in the activity of membrane transporters primarily belonging to the ATP binding cassette (ABC) transporter family.  In addn., it has been proposed that this common feature could be attributed to a subpopulation of slow-cycling cancer stem cells (CSCs), endowed with enhanced tumorigenic potential and multidrug resistance.  CSCs are characterized by the overexpression of sp. surface markers that vary in different cancer cell types.  Overexpression of ABC transporters has been reported in several cancers and more predominantly in CSCs.  While the major focus on the role played by ABC transporters in cancer is polarized by their involvement in chemoresistance, emerging evidence supports a more active role of these proteins, in which they release specific bioactive mols. in the extracellular milieu.  This review will outline our current understanding of the role played by ABC transporters in CSCs, how their expression is regulated and how they support the malignant metabolic phenotype.  To summarize, we suggest that the increased expression of ABC transporters in CSCs may have precise functional roles and provide the opportunity to target, particularly these cells, by using specific ABC transporter inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOmUDkuiM2ZbVg90H21EOLACvtfcHk0liGR75JkqkgDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOgtb7O&md5=ed113cd4ed615f8867bfe13dcd76f146</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.3390%2Fijms18112362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18112362%26sid%3Dliteratum%253Aachs%26aulast%3DBegicevic%26aufirst%3DR.%2BR.%26aulast%3DFalasca%26aufirst%3DM.%26atitle%3DABC%2520transporters%2520in%2520cancer%2520stem%2520cells%253A%2520beyond%2520chemoresistance%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D2362%26doi%3D10.3390%2Fijms18112362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muriithi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macharia, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heming, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echevarria, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyachieo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filho, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neto, V. M.</span></span> <span> </span><span class="NLM_article-title">ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance</span>. <i>Cancer Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.20892/j.issn.2095-3941.2019.0284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.20892%2Fj.issn.2095-3941.2019.0284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32587767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlalsb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=253-269&issue=2&author=W.+Muriithiauthor=L.+W.+Machariaauthor=C.+P.+Hemingauthor=J.+L.+Echevarriaauthor=A.+Nyachieoauthor=P.+N.+Filhoauthor=V.+M.+Neto&title=ABC+transporters+and+the+hallmarks+of+cancer%3A+roles+in+cancer+aggressiveness+beyond+multidrug+resistance&doi=10.20892%2Fj.issn.2095-3941.2019.0284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance</span></div><div class="casAuthors">Muriithi, Wanjiru; Macharia, Lucy Wanjiku; Heming, Carlos Pilotto; Echevarria, Juliana Lima; Nyachieo, Atunga; Filho, Paulo Niemeyer; Neto, Vivaldo Moura</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">253-269</span>CODEN:
                <span class="NLM_cas:coden">CBMADQ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Tianjin Medical University Cancer Institute and Hospital</span>)
        </div><div class="casAbstract">The ATP-binding cassette transporters (ABC transporters) have been intensely studied over the past 50 years for their involvement in the multidrug resistance (MDR) phenotype, esp. in cancer.  They are frequently overexpressed in both naive and post-treatment tumors, and hinder effective chemotherapy by reducing drug accumulation in cancer cells.  In the last decade however, several studies have established that ABC transporters have addnl., fundamental roles in tumor biol.; there is strong evidence that these proteins are involved in transporting tumor-enhancing mols. and/or in protein-protein interactions that impact cancer aggressiveness, progression, and patient prognosis.  This review highlights these studies in relation to some well-described cancer hallmarks, in an effort to re-emphasize the need for further investigation into the physiol. functions of ABC transporters that are crit. for tumor development.  Unraveling these new roles offers an opportunity to define new strategies and targets for therapy, which would include endogenous substrates or signaling pathways that regulate these proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYzAkKELKFV7Vg90H21EOLACvtfcHk0ljrlILhu4WW8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlalsb7N&md5=a2a337daed796df412789dd797e33e73</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.20892%2Fj.issn.2095-3941.2019.0284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.20892%252Fj.issn.2095-3941.2019.0284%26sid%3Dliteratum%253Aachs%26aulast%3DMuriithi%26aufirst%3DW.%26aulast%3DMacharia%26aufirst%3DL.%2BW.%26aulast%3DHeming%26aufirst%3DC.%2BP.%26aulast%3DEchevarria%26aufirst%3DJ.%2BL.%26aulast%3DNyachieo%26aufirst%3DA.%26aulast%3DFilho%26aufirst%3DP.%2BN.%26aulast%3DNeto%26aufirst%3DV.%2BM.%26atitle%3DABC%2520transporters%2520and%2520the%2520hallmarks%2520of%2520cancer%253A%2520roles%2520in%2520cancer%2520aggressiveness%2520beyond%2520multidrug%2520resistance%26jtitle%3DCancer%2520Biol.%2520Med.%26date%3D2020%26volume%3D17%26issue%3D2%26spage%3D253%26epage%3D269%26doi%3D10.20892%2Fj.issn.2095-3941.2019.0284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span> <span> </span><span class="NLM_article-title">Radiotherapy targeting cancer stem cells “awakens” them to induce tumour relapse and metastasis in oral cancer</span>. <i>Int. J. Oral Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">19</span>, <span class="refDoi"> DOI: 10.1038/s41368-020-00087-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fs41368-020-00087-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32576817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB38njslaktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=19&author=Y.+Liuauthor=M.+Yangauthor=J.+Luoauthor=H.+Zhou&title=Radiotherapy+targeting+cancer+stem+cells+%E2%80%9Cawakens%E2%80%9D+them+to+induce+tumour+relapse+and+metastasis+in+oral+cancer&doi=10.1038%2Fs41368-020-00087-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Radiotherapy targeting cancer stem cells "awakens" them to induce tumour relapse and metastasis in oral cancer</span></div><div class="casAuthors">Liu Yangfan; Yang Miao; Zhou Hongmei; Luo Jingjing</div><div class="citationInfo"><span class="NLM_cas:title">International journal of oral science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Radiotherapy is one of the most common treatments for oral cancer.  However, in the clinic, recurrence and metastasis of oral cancer occur after radiotherapy, and the underlying mechanism remains unclear.  Cancer stem cells (CSCs), considered the "seeds" of cancer, have been confirmed to be in a quiescent state in most established tumours, with their innate radioresistance helping them survive more easily when exposed to radiation than differentiated cancer cells.  There is increasing evidence that CSCs play an important role in recurrence and metastasis post-radiotherapy in many cancers.  However, little is known about how oral CSCs cause tumour recurrence and metastasis post-radiotherapy.  In this review article, we will first summarise methods for the identification of oral CSCs and then focus on the characteristics of a CSC subpopulation induced by radiation, hereafter referred to as "awakened" CSCs, to highlight their response to radiotherapy and potential role in tumour recurrence and metastasis post-radiotherapy as well as potential therapeutics targeting CSCs.  In addition, we explore potential therapeutic strategies targeting these "awakened" CSCs to solve the serious clinical challenges of recurrence and metastasis in oral cancer after radiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQlVED3Wn4etenUz0lpNqnfW6udTcc2eZw3rBIguV2trntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38njslaktQ%253D%253D&md5=32eb4c977bc9e164c08ae88bd36f7ddb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fs41368-020-00087-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41368-020-00087-0%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DH.%26atitle%3DRadiotherapy%2520targeting%2520cancer%2520stem%2520cells%2520%25E2%2580%259Cawakens%25E2%2580%259D%2520them%2520to%2520induce%2520tumour%2520relapse%2520and%2520metastasis%2520in%2520oral%2520cancer%26jtitle%3DInt.%2520J.%2520Oral%2520Sci.%26date%3D2020%26volume%3D12%26spage%3D19%26doi%3D10.1038%2Fs41368-020-00087-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tracey, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, M. J.</span></span> <span> </span><span class="NLM_article-title">Off to a bad start: Cancer initiation by pluripotency regulator PRDM14</span>. <i>Trends Genet.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1016/j.tig.2019.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.tig.2019.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31130394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpsVOrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2019&pages=489-500&author=L.+J.+Traceyauthor=M.+J.+Justice&title=Off+to+a+bad+start%3A+Cancer+initiation+by+pluripotency+regulator+PRDM14&doi=10.1016%2Fj.tig.2019.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Off to a Bad Start: Cancer Initiation by Pluripotency Regulator PRDM14</span></div><div class="casAuthors">Tracey, Lauren J.; Justice, Monica J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Genetics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-500</span>CODEN:
                <span class="NLM_cas:coden">TRGEE2</span>;
        ISSN:<span class="NLM_cas:issn">0168-9525</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite advances in chemotherapies that improve cancer survival, most patients who relapse succumb to the disease due to the presence of cancer stem cells (CSCs), which are highly chemoresistant.  The pluripotency factor PR domain 14 (PRDM14) has a key role in initiating many types of cancer.  Normally, PRDM14 uses epigenetic mechanisms to establish and maintain the pluripotency of embryonic cells, and its role in cancer is similar.  This important link between cancer and induced pluripotency is a key revelation for how CSCs may form: pluripotency genes, such as PRDM14, can expand stem-like cells as they promote ongoing DNA damage.  PRDM14 and its protein-binding partners, the ETO/CBFA2T family, are ideal candidates for eliminating CSCs from relevant cancers, preventing relapse and improving long-term survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcfUsY53H3MLVg90H21EOLACvtfcHk0ljB0iTjOEFmpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpsVOrsbY%253D&md5=8dbba083bc11951a651139720ccb2b78</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.tig.2019.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tig.2019.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DTracey%26aufirst%3DL.%2BJ.%26aulast%3DJustice%26aufirst%3DM.%2BJ.%26atitle%3DOff%2520to%2520a%2520bad%2520start%253A%2520Cancer%2520initiation%2520by%2520pluripotency%2520regulator%2520PRDM14%26jtitle%3DTrends%2520Genet.%26date%3D2019%26volume%3D35%26spage%3D489%26epage%3D500%26doi%3D10.1016%2Fj.tig.2019.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span> <span> </span><span class="NLM_article-title">Pluripotency transcription factors and cancer stem cells: small genes make a big difference</span>. <i>Aizheng</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.5732/cjc.012.10282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.5732%2Fcjc.012.10282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=23419197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVyitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=483-487&author=A.+Liuauthor=X.+Yuauthor=S.+Liu&title=Pluripotency+transcription+factors+and+cancer+stem+cells%3A+small+genes+make+a+big+difference&doi=10.5732%2Fcjc.012.10282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Pluripotency transcription factors and cancer stem cells: small genes make a big difference</span></div><div class="casAuthors">Liu, Anfei; Yu, Xiya; Liu, Shangrong</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">483-487</span>CODEN:
                <span class="NLM_cas:coden">CJCHDJ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Sun Yat-sen University Cancer Center</span>)
        </div><div class="casAbstract">A review.  Cancer stem cells (CSCs) are thought to drive uncontrolled tumor growth, and the existence of CSCs has recently been proven by direct exptl. evidence, including tracing cell lineages within a growing tumor.  However, CSCs must be analyzed in addnl. cancer types.  Cancer stem cell-like cells (CSCLCs) are a good alternative system for the study of CSCs, which hold great promise for clin. applications.  OCT4, NANOG and SOX2 are three basic transcription factors that are expressed in both CSCLCs and embryonic stem cells (ESCs).  These transcription factors play crit. roles in maintaining the pluripotence and self-renewal characteristics of CSCLCs and ESCs.  In this review, we discuss the aberrant expression, isoforms, and pseudogenes of OCT4, NANOG, and SOX2 in the CSCLC niche, which contribute to the major differences between CSCLCs and ESCs.  We also highlight an anticancer therapy that involves killing specific cancer cells directly by repressing the expression of OCT4, NANOG, or SOX2.  Importantly, OCT4, NANOG, and SOX2 provide great promise for clin. applications because reducing their expression or blocking the pathways in which they function may inhibit tumor growth and turn-off the cancer 'switch'.  In the future, a clear understanding of transcription actor regulation will be essential for elucidating the roles of OCT4, NANOG, and SOX2 in tumorigenesis, as well as exploring their use for diagnostic and therapeutic purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohrpR4CUtaI7Vg90H21EOLACvtfcHk0ljB0iTjOEFmpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVyitbg%253D&md5=96890ecefd851117efd68bffde52e328</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.5732%2Fcjc.012.10282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5732%252Fcjc.012.10282%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26atitle%3DPluripotency%2520transcription%2520factors%2520and%2520cancer%2520stem%2520cells%253A%2520small%2520genes%2520make%2520a%2520big%2520difference%26jtitle%3DAizheng%26date%3D2013%26volume%3D32%26spage%3D483%26epage%3D487%26doi%3D10.5732%2Fcjc.012.10282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span> <span> </span><span class="NLM_article-title">Dual inhibiting OCT4 and AKT potently suppresses the propagation of human cancer cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">46246</span>, <span class="refDoi"> DOI: 10.1038/srep46246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fsrep46246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=28383051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvFyiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=46246&author=W.+Liauthor=Y.+Zhouauthor=X.+Zhangauthor=Y.+Yangauthor=S.+Danauthor=T.+Suauthor=S.+Sheauthor=W.+Dongauthor=Q.+Zhaoauthor=J.+Jiaauthor=H.+Yaoauthor=M.+Zhengauthor=B.+Kangauthor=Y.+J.+Wang&title=Dual+inhibiting+OCT4+and+AKT+potently+suppresses+the+propagation+of+human+cancer+cells&doi=10.1038%2Fsrep46246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibiting OCT4 and AKT potently suppresses the propagation of human cancer cells</span></div><div class="casAuthors">Li, Wenxin; Zhou, Yanwen; Zhang, Xiaoqian; Yang, Ying; Dan, Songsong; Su, Tong; She, Shiqi; Dong, Weilai; Zhao, Qingwei; Jia, Jia; Yao, Hangping; Zheng, Min; Kang, Bo; Wang, Ying-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46246</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">AKT serves as an epigenetic modulator that links epigenetic regulation to cell survival and proliferation while the epigenetic mediator OCT4 critically controls stem cell pluripotency and self-renewal.  Emerging evidence indicated their complicated interplays in cancer cells and cancer stem cells (CSCs), and inhibiting either one may activate the other.  Thus, in this study, we propose a strategy to targeting both factors simultaneously.  Firstly, a combination of an OCT4-specific shRNA and the specific AKT inhibitor Akti-1/2 potently suppressed the propagation of human embryonal carcinoma cells, adherent cancer cells and stem-like cancer cells, establishing the proof-of-concept that dual inhibiting OCT4 and AKT can effectively target various cancer cells.  Next, we combined Akti-1/2 with metformin, a widely-prescribed drug for treating type 2 diabetes, which was reported to down-regulate OCT4 expression.  The metformin + Akti-1/2 combo significantly altered multiple signaling and epigenetic pathways, induced growth arrest and cell death of adherent and stem-like glioblastoma U87 cells, and attenuated their tumorigenicity in vivo.  Taken together, we demonstrate here that simultaneously targeting an epigenetic mediator and an epigenetic modulator, by dual inhibiting OCT4 and AKT, can have significantly improved efficacies over single treatment in suppressing the propagation of CSCs as well as the entire bulk of differentiated cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu8VxfE5dNJbVg90H21EOLACvtfcHk0ljB0iTjOEFmpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvFyiu7g%253D&md5=67aa8d55d95877f148531b416123ac36</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fsrep46246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep46246%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DDan%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DT.%26aulast%3DShe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DKang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26atitle%3DDual%2520inhibiting%2520OCT4%2520and%2520AKT%2520potently%2520suppresses%2520the%2520propagation%2520of%2520human%2520cancer%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D46246%26doi%3D10.1038%2Fsrep46246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proskurina, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremova, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taranov, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostanin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernykh, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolchanov, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogachev, S. S.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells: emergent nature of tumor emergency</span>. <i>Front. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">544</span>, <span class="refDoi"> DOI: 10.3389/fgene.2018.00544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffgene.2018.00544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30505319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVems7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=544&author=Y.+R.+Efremovauthor=A.+S.+Proskurinaauthor=E.+A.+Potterauthor=E.+V.+Dolgovaauthor=O.+V.+Efremovaauthor=O.+S.+Taranovauthor=A.+A.+Ostaninauthor=E.+R.+Chernykhauthor=N.+A.+Kolchanovauthor=S.+S.+Bogachev&title=Cancer+stem+cells%3A+emergent+nature+of+tumor+emergency&doi=10.3389%2Ffgene.2018.00544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells: emergent nature of tumor emergency</span></div><div class="casAuthors">Efremov, Yaroslav R.; Proskurina, Anastasia S.; Potter, Ekaterina A.; Dolgova, Evgenia V.; Efremova, Oksana V.; Taranov, Oleg S.; Ostanin, Aleksandr A.; Chernykh, Elena R.; Kolchanov, Nikolay A.; Bogachev, Sergey S.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Genetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">544</span>CODEN:
                <span class="NLM_cas:coden">FGREBR</span>;
        ISSN:<span class="NLM_cas:issn">1664-8021</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  A functional anal. of 167 genes overexpressed in Krebs-2 tumor initiating cells was performed.  In the first part of the study, the genes were analyzed for their belonging to one or more of the three groups, which represent the three major phenotypic manifestation of malignancy of cancer cells, namely (1) proliferative self-sufficiency, (2) invasive growth and metastasis, and (3) multiple drug resistance. 96 genes out of 167 were identified as possible contributors to at least one of these fundamental properties.  It was also found that substantial part of these genes are also known as genes responsible for formation and/or maintenance of the stemness of normal pluri-/multipotent stem cells.  These results suggest that the malignancy is simply the ability to maintain the stem cell specific genes expression profile, and, as a consequence, the stemness itself regardless of the controlling effect of stem niches.  In the second part of the study, three stress factors combined into the single concept of "generalized cellular stress," which are assumed to activate the expression of these genes, were defined.  In addn., possible mechanisms for such activation were identified.  The data obtained suggest the existence of a mechanism for the de novo formation of a pluripotent/stem phenotype in the subpopulation of "committed" tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpia0s4hhtKWrVg90H21EOLACvtfcHk0ljWG6hKI_igmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVems7fP&md5=71f538a53566d49d2d7bdcd91b4860e3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3389%2Ffgene.2018.00544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffgene.2018.00544%26sid%3Dliteratum%253Aachs%26aulast%3DEfremov%26aufirst%3DY.%2BR.%26aulast%3DProskurina%26aufirst%3DA.%2BS.%26aulast%3DPotter%26aufirst%3DE.%2BA.%26aulast%3DDolgova%26aufirst%3DE.%2BV.%26aulast%3DEfremova%26aufirst%3DO.%2BV.%26aulast%3DTaranov%26aufirst%3DO.%2BS.%26aulast%3DOstanin%26aufirst%3DA.%2BA.%26aulast%3DChernykh%26aufirst%3DE.%2BR.%26aulast%3DKolchanov%26aufirst%3DN.%2BA.%26aulast%3DBogachev%26aufirst%3DS.%2BS.%26atitle%3DCancer%2520stem%2520cells%253A%2520emergent%2520nature%2520of%2520tumor%2520emergency%26jtitle%3DFront.%2520Genet.%26date%3D2018%26volume%3D9%26spage%3D544%26doi%3D10.3389%2Ffgene.2018.00544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quader, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, R.</span></span> <span> </span><span class="NLM_article-title">Interplay of EMT and CSC in cancer and the potential therapeutic strategies</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">904</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.00904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffphar.2020.00904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32625096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVWgtbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=904&author=S.+Tanabeauthor=S.+Quaderauthor=H.+Cabralauthor=R.+Ono&title=Interplay+of+EMT+and+CSC+in+cancer+and+the+potential+therapeutic+strategies&doi=10.3389%2Ffphar.2020.00904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Interplay of EMT and CSC in cancer and the potential therapeutic strategies</span></div><div class="casAuthors">Tanabe, Shihori; Quader, Sabina; Cabral, Horacio; Ono, Ryuichi</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">904</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The mechanism of epithelial-mesenchymal transition (EMT) consists of the cellular</div> phenotypic transition from epithelial to mesenchymal status.  The cells exhibiting EMT</div> exist in cancer stem cell (CSC) population, which is involved in drug resistance.  CSCs</div> demonstrating EMT feature remain after cancer treatment, which leads to drug resistance,</div> recurrence, metastasis and malignancy of cancer.  In this context, the recent advance of</div> nanotechnol. in the medical application has ascended the possibility to target CSCs</div> using nanomedicines.  In this review article, we focused on the mechanism of CSCs and</div> EMT, esp. into the signaling pathways in EMT, regulation of EMT and CSCs by</div> microRNAs and nanomedicine-based approaches to target CSCs.</div>.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjPY5-iyR5GLVg90H21EOLACvtfcHk0ljWG6hKI_igmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVWgtbfM&md5=2c59357d85d761af3c5ab92de856b904</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.00904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.00904%26sid%3Dliteratum%253Aachs%26aulast%3DTanabe%26aufirst%3DS.%26aulast%3DQuader%26aufirst%3DS.%26aulast%3DCabral%26aufirst%3DH.%26aulast%3DOno%26aufirst%3DR.%26atitle%3DInterplay%2520of%2520EMT%2520and%2520CSC%2520in%2520cancer%2520and%2520the%2520potential%2520therapeutic%2520strategies%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D904%26doi%3D10.3389%2Ffphar.2020.00904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J. S.</span></span> <span> </span><span class="NLM_article-title">Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">965</span>, <span class="refDoi"> DOI: 10.3390/molecules21070965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fmolecules21070965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVWkt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=965&author=B.+Duauthor=J.+S.+Shim&title=Targeting+epithelial-mesenchymal+transition+%28EMT%29+to+overcome+drug+resistance+in+cancer&doi=10.3390%2Fmolecules21070965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer</span></div><div class="casAuthors">Du, Bowen; Shim, Joong Sup</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">965/1-965/15</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Epithelial-mesenchymal transition (EMT) is known to play an important role in cancer progression, metastasis and drug resistance.  Although there are controversies surrounding the causal relationship between EMT and cancer metastasis, the role of EMT in cancer drug resistance has been increasingly recognized.  Numerous EMT-related signaling pathways are involved in drug resistance in cancer cells.  Cells undergoing EMT show a feature similar to cancer stem cells (CSCs), such as an increase in drug efflux pumps and anti-apoptotic effects.  Therefore, targeting EMT has been considered a novel opportunity to overcome cancer drug resistance.  This review describes the mechanism by which EMT contributes to drug resistance in cancer cells and summarizes new advances in research in EMT-assocd. drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLrVX8vkTNGLVg90H21EOLACvtfcHk0ljWG6hKI_igmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVWkt7rJ&md5=74f02736256323d38e647ff1416d8790</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21070965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21070965%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DB.%26aulast%3DShim%26aufirst%3DJ.%2BS.%26atitle%3DTargeting%2520epithelial-mesenchymal%2520transition%2520%2528EMT%2529%2520to%2520overcome%2520drug%2520resistance%2520in%2520cancer%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26spage%3D965%26doi%3D10.3390%2Fmolecules21070965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Stemness-related markers in cancer</span>. <i>Cancer Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.4103/ctm.ctm_69_16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.4103%2Fctm.ctm_69_16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29276782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOht7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=87-95&author=W.+Zhaoauthor=Y.+Liauthor=X.+Zhang&title=Stemness-related+markers+in+cancer&doi=10.4103%2Fctm.ctm_69_16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Stemness-related Markers in Cancer</span></div><div class="casAuthors">Zhao, Wenxiu; Li, Yvonne; Zhang, Xun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Translational Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">CTMABE</span>;
        ISSN:<span class="NLM_cas:issn">2395-3012</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs), with their self-renewal ability and multilineage differentiation potential, are a crit. subpopulation of tumor cells that can drive tumor initiation, growth, and resistance to therapy.  Like embryonic and adult stem cells, CSCs express markers that are not expressed in normal somatic cells and are thus thought to contribute toward a "stemness" phenotype.  This review summarizes the current knowledge of stemness-related markers in human cancers, with a particular focus on important transcription factors, protein surface markers, and signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQUfdLZo7mS7Vg90H21EOLACvtfcHk0lgnq0JTtpcclw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOht7fE&md5=4408ed4c8b31c8f818404c7cc712cd04</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.4103%2Fctm.ctm_69_16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252Fctm.ctm_69_16%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DStemness-related%2520markers%2520in%2520cancer%26jtitle%3DCancer%2520Transl.%2520Med.%26date%3D2017%26volume%3D3%26spage%3D87%26epage%3D95%26doi%3D10.4103%2Fctm.ctm_69_16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pádua, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueira, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesquita, P.</span></span> <span> </span><span class="NLM_article-title">The relevance of transcription factors in gastric and colorectal cancer stem cells identification and eradication</span>. <i>Front. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">442</span>, <span class="refDoi"> DOI: 10.3389/fcell.2020.00442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffcell.2020.00442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32626705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB38noslShtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=442&author=D.+P%C3%A1duaauthor=P.+Figueiraauthor=I.+Ribeiroauthor=R.+Almeidaauthor=P.+Mesquita&title=The+relevance+of+transcription+factors+in+gastric+and+colorectal+cancer+stem+cells+identification+and+eradication&doi=10.3389%2Ffcell.2020.00442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication</span></div><div class="casAuthors">Padua Diana; Figueira Paula; Ribeiro Ines; Almeida Raquel; Mesquita Patricia; Padua Diana; Figueira Paula; Ribeiro Ines; Almeida Raquel; Mesquita Patricia; Almeida Raquel; Almeida Raquel</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in cell and developmental biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">442</span>
        ISSN:<span class="NLM_cas:issn">2296-634X</span>.
    </div><div class="casAbstract">Gastric and colorectal cancers have a high incidence and mortality worldwide.  The presence of cancer stem cells (CSCs) within the tumor mass has been indicated as the main reason for tumor relapse, metastasis and therapy resistance, leading to poor overall survival.  Thus, the elimination of CSCs became a crucial goal for cancer treatment.  The identification of these cells has been performed by using cell-surface markers, a reliable approach, however it lacks specificity and usually differs among tumor type and in some cases even within the same type.  In theory, the ideal CSC markers are those that are required to maintain their stemness features.  The knowledge that CSCs exhibit characteristics comparable to normal stem cells that could be associated with the expression of similar transcription factors (TFs) including SOX2, OCT4, NANOG, KLF4 and c-Myc, and signaling pathways such as the Wnt/β-catenin, Hedgehog (Hh), Notch and PI3K/AKT/mTOR directed the attention to the use of these similarities to identify and target CSCs in different tumor types.  Several studies have demonstrated that the abnormal expression of some TFs and the dysregulation of signaling pathways are associated with tumorigenesis and CSC phenotype.  The disclosure of common and appropriate biomarkers for CSCs will provide an incredible tool for cancer prognosis and treatment.  Therefore, this review aims to gather the new insights in gastric and colorectal CSC identification specially by using TFs as biomarkers and divulge promising drugs that have been found and tested for targeting these cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKnSTGbtpJaq__Jf7-eMvJfW6udTcc2eZaeGtqT14jg7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38noslShtA%253D%253D&md5=716a3753e3b228858d1b05322f2b78ce</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.3389%2Ffcell.2020.00442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcell.2020.00442%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A1dua%26aufirst%3DD.%26aulast%3DFigueira%26aufirst%3DP.%26aulast%3DRibeiro%26aufirst%3DI.%26aulast%3DAlmeida%26aufirst%3DR.%26aulast%3DMesquita%26aufirst%3DP.%26atitle%3DThe%2520relevance%2520of%2520transcription%2520factors%2520in%2520gastric%2520and%2520colorectal%2520cancer%2520stem%2520cells%2520identification%2520and%2520eradication%26jtitle%3DFront.%2520Cell%2520Dev.%2520Biol.%26date%3D2020%26volume%3D8%26spage%3D442%26doi%3D10.3389%2Ffcell.2020.00442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muralikrishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nephew, K. P.</span></span> <span> </span><span class="NLM_article-title">Targeting aldehyde dehydrogenases to eliminate cancer stem cells in gynecologic malignancies</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">961</span>, <span class="refDoi"> DOI: 10.3390/cancers12040961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcancers12040961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKgtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=961&author=V.+Muralikrishnanauthor=T.+D.+Hurleyauthor=K.+P.+Nephew&title=Targeting+aldehyde+dehydrogenases+to+eliminate+cancer+stem+cells+in+gynecologic+malignancies&doi=10.3390%2Fcancers12040961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting aldehyde dehydrogenases to eliminatecancer stem cells in gynecologic malignancies</span></div><div class="casAuthors">Muralikrishnan, Vaishnavi; Hurley, Thomas D.; Nephew, Kenneth P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">961</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Gynecol. cancers cause over 600,000 deaths annually in women worldwide.  The development of chemoresistance after initial rounds of chemotherapy contributes to tumor relapse and death due to gynecol. malignancies.  In this regard, cancer stem cells (CSCs), a subpopulation of stem cells with the ability to undergo self-renewal and clonal evolution, play a key role in tumor progression and drug resistance.  Aldehyde dehydrogenases (ALDH) are a group of enzymes shown to be robust CSC markers in gynecol. and other malignancies.  These enzymes also play functional roles in CSCs, including detoxification of aldehydes, scavenging of reactive oxygen species (ROS), and retinoic acid (RA) signaling, making ALDH an attractive therapeutic target in various clin. scenarios.  In this review, we discuss the crit. roles of the ALDH in driving stemness in different gynecol. malignancies.  We review inhibitors of ALDH, both general and isoform-specific, which have been used to target CSCs in gynecol. cancers.  Many of these inhibitors have been shown to be effective in preclin. models of gynecol. malignancies, supporting further development in the clinic.  Furthermore, ALDH inhibitors, including 673A and CM037, synergize with chemotherapy to reduce tumor growth.  Thus, ALDH-targeted therapies hold promise for improving patient outcomes in gynecol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0YbLEdolnPLVg90H21EOLACvtfcHk0lgnq0JTtpcclw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKgtrnL&md5=98b2a7d09d7bfe5e10b93c3990ec9a81</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.3390%2Fcancers12040961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12040961%26sid%3Dliteratum%253Aachs%26aulast%3DMuralikrishnan%26aufirst%3DV.%26aulast%3DHurley%26aufirst%3DT.%2BD.%26aulast%3DNephew%26aufirst%3DK.%2BP.%26atitle%3DTargeting%2520aldehyde%2520dehydrogenases%2520to%2520eliminate%2520cancer%2520stem%2520cells%2520in%2520gynecologic%2520malignancies%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D961%26doi%3D10.3390%2Fcancers12040961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit21c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo-Guzmán, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Gallegos, Á. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Sánchez, E.</span></span> <span> </span><span class="NLM_article-title">ALDH as a stem cell marker in solid tumors</span>. <i>Curr. Stem Cell Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.2174/1574888X13666180810120012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.2174%2F1574888X13666180810120012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30095061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3c7mvVenuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=375-388&author=M.+E.+Toledo-Guzm%C3%A1nauthor=M.+I.+Hern%C3%A1ndezauthor=%C3%81.+A.+G%C3%B3mez-Gallegosauthor=E.+Ortiz-S%C3%A1nchez&title=ALDH+as+a+stem+cell+marker+in+solid+tumors&doi=10.2174%2F1574888X13666180810120012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21cR"><div class="casContent"><span class="casTitleNuber">21c</span><div class="casTitle"><span class="NLM_cas:atitle">ALDH as a Stem Cell Marker in Solid Tumors</span></div><div class="casAuthors">Toledo-Guzman Mariel E; Hernandez Miguel Ibanez; Toledo-Guzman Mariel E; Gomez-Gallegos Angel A; Ortiz-Sanchez Elizabeth; Gomez-Gallegos Angel A</div><div class="citationInfo"><span class="NLM_cas:title">Current stem cell research & therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">375-388</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aldehyde dehydrogenase (ALDH) is an enzyme that participates in important cellular mechanisms as aldehyde detoxification and retinoic acid synthesis; moreover, ALDH activity is involved in drug resistance, a characteristic of cancer stem cells (CSCs).  Even though ALDH is found in stem cells, CSCs and progenitor cells, this enzyme has been successfully used to identify and isolate cell populations with CSC properties from several tumor origins.  ALDH is allegedly involved in cell differentiation through its product, retinoic acid.  However, direct or indirect ALDH inhibition, using specific inhibitors or retinoic acid, has shown a reduction in ALDH activity, along with the loss of stem cell traits, reduction of cell proliferation, invasion, and drug sensitization.  For these reasons, ALDH and retinoic acid are promising therapeutic targets.  This review summarizes the current evidence for ALDH as a CSCs marker in solid tumors, as well as current knowledge about the functional roles of ALDH in CSCs.  We discuss the controversy of ALDH activity to maintain CSC stemness, or conversely, to promote cell differentiation.  Finally, we review the advances in using ALDH inhibitors as anti-cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQUklA8IheHWM25P7XSLhESfW6udTcc2eZaeGtqT14jg7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7mvVenuw%253D%253D&md5=ed1c99e325755b02e7ad7e9e396bc0e7</span></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.2174%2F1574888X13666180810120012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1574888X13666180810120012%26sid%3Dliteratum%253Aachs%26aulast%3DToledo-Guzm%25C3%25A1n%26aufirst%3DM.%2BE.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DM.%2BI.%26aulast%3DG%25C3%25B3mez-Gallegos%26aufirst%3D%25C3%2581.%2BA.%26aulast%3DOrtiz-S%25C3%25A1nchez%26aufirst%3DE.%26atitle%3DALDH%2520as%2520a%2520stem%2520cell%2520marker%2520in%2520solid%2520tumors%26jtitle%3DCurr.%2520Stem%2520Cell%2520Res.%2520Ther.%26date%3D2019%26volume%3D14%26spage%3D375%26epage%3D388%26doi%3D10.2174%2F1574888X13666180810120012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karsten, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goletz, S.</span></span> <span> </span><span class="NLM_article-title">What makes cancer stem cell markers different?</span>. <i>SpringerPlus</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">301</span>, <span class="refDoi"> DOI: 10.1186/2193-1801-2-301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2F2193-1801-2-301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=23888272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Wiu7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=301&author=U.+Karstenauthor=S.+Goletz&title=What+makes+cancer+stem+cell+markers+different%3F&doi=10.1186%2F2193-1801-2-301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">What makes cancer stem cell markers different?</span></div><div class="casAuthors">Karsten, Uwe; Goletz, Steffen</div><div class="citationInfo"><span class="NLM_cas:title">SpringerPlus</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">301/1-301/8, 8</span>CODEN:
                <span class="NLM_cas:coden">SPRIFB</span>;
        ISSN:<span class="NLM_cas:issn">2193-1801</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Since the cancer stem cell concept has been widely accepted, several strategies have been proposed to attack cancer stem cells (CSC).  Accordingly, stem cell markers are now preferred therapeutic targets.  However, the problem of tumor specificity has not disappeared but shifted to another question: how can cancer stem cells be distinguished from normal stem cells, or more specifically, how do CSC markers differ from normal stem cell markers.  A hypothesis is proposed which might help to solve this problem in at least a subgroup of stem cell markers.  Glycosylation may provide the key.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp0Vy6CjVTmbVg90H21EOLACvtfcHk0li9L342gPSYUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Wiu7%252FF&md5=b76e43970db39972f766e5cb1f3f2bd8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1186%2F2193-1801-2-301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2193-1801-2-301%26sid%3Dliteratum%253Aachs%26aulast%3DKarsten%26aufirst%3DU.%26aulast%3DGoletz%26aufirst%3DS.%26atitle%3DWhat%2520makes%2520cancer%2520stem%2520cell%2520markers%2520different%253F%26jtitle%3DSpringerPlus%26date%3D2013%26volume%3D2%26spage%3D301%26doi%3D10.1186%2F2193-1801-2-301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fatima, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span> <span> </span><span class="NLM_article-title">Clinicopathological correlation of cancer stem cell markers Oct-4 and CD133 expression as prognostic factor in malignant lesions of gallbladder: An immunohistochemical study</span>. <i>Indian J. Pathol. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.4103/IJPM.IJPM_134_19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.4103%2FIJPM.IJPM_134_19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31361225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3MvivVKmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=384-390&author=N.+Fatimaauthor=A.+N.+Srivastavaauthor=J.+Nigamauthor=N.+Tandonauthor=R.+Ahmadauthor=V.+Kumar&title=Clinicopathological+correlation+of+cancer+stem+cell+markers+Oct-4+and+CD133+expression+as+prognostic+factor+in+malignant+lesions+of+gallbladder%3A+An+immunohistochemical+study&doi=10.4103%2FIJPM.IJPM_134_19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Clinicopathological correlation of cancer stem cell markers Oct-4 and CD133 expression as prognostic factor in malignant lesions of gallbladder: An immunohistochemical study</span></div><div class="casAuthors">Fatima Naseem; Srivastava Anand Narain; Tandon Nishi; Nigam Jaya; Ahmad Rumana; Kumar Vijay</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of pathology & microbiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">384-390</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Gallbladder cancer (GBC) is the most frequent biliary tract cancer, with high morbidity and poor prognosis, and shows early metastasis and invasiveness.  No reliable biomarkers are available for detection of GBC progression.  Aim:  To investigate the immunohistochemical expression of Oct-4 and CD133 in malignant and nonneoplastic lesions of gallbladder and to analyze the clinical significance of the expressions related to clinicopathological parameters.  Settings and Design:  This is a prospective case control study, conducted in medical college background.  Materials and Methods:  A total of 103 cases of gallbladder were grouped into malignant lesions (n = 48) and nonneoplastic lesions (simple epithelial hyperplasia; n = 35 and chronic cholecystitis; n = 20).  All tissue samples were evaluated for expression of Oct-4 and CD133 using immunohistochemistry in an effort to elucidate the correlation between their expressions with clinicopathological parameters.  Statistical Analysis:  The final score was calculated by multiplying the intensity to the percentage of positive cells.  The scores ≥2 were considered as positive.  Results:  Significant positive correlation of higher expression levels of Oct-4 and CD133 were observed in malignant as compared to nonneoplastic lesions of gallbladder (P < 0.0001).  High expression of Oct-4 and CD133 were significantly associated with tumor grading (Oct-4, P = 0.04; CD133, P = 0.02), staging (Oct-4, P = 0.03; CD133, P = 0.02), and liver metastasis (Oct-4, P = 0.01; CD133, P = 0.007).  Significantly reduced survival was observed with high expression of Oct-4 (P = 0.002).  No significant correction was observed between CD 133 and survival.  Conclusion:  This study revealed that high expression level of Oct-4 may provide a new insight for the prognosis of the disease in terms of clinical staging and grade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTMu_8lyKCw9ZSWdIdmEou5fW6udTcc2eaJXWFMFXga6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvivVKmsw%253D%253D&md5=bb7d87c8097d28cbe07ead5d0c82ce09</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.4103%2FIJPM.IJPM_134_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252FIJPM.IJPM_134_19%26sid%3Dliteratum%253Aachs%26aulast%3DFatima%26aufirst%3DN.%26aulast%3DSrivastava%26aufirst%3DA.%2BN.%26aulast%3DNigam%26aufirst%3DJ.%26aulast%3DTandon%26aufirst%3DN.%26aulast%3DAhmad%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DV.%26atitle%3DClinicopathological%2520correlation%2520of%2520cancer%2520stem%2520cell%2520markers%2520Oct-4%2520and%2520CD133%2520expression%2520as%2520prognostic%2520factor%2520in%2520malignant%2520lesions%2520of%2520gallbladder%253A%2520An%2520immunohistochemical%2520study%26jtitle%3DIndian%2520J.%2520Pathol.%2520Microbiol.%26date%3D2019%26volume%3D62%26spage%3D384%26epage%3D390%26doi%3D10.4103%2FIJPM.IJPM_134_19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span> <span> </span><span class="NLM_article-title">Identification of new cancer stem cell markers and signaling pathways in HER-2-positive breast cancer by transcriptome sequencing</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1003</span>– <span class="NLM_lpage">1018</span>, <span class="refDoi"> DOI: 10.3892/ijo.2019.4876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3892%2Fijo.2019.4876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31545416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltVeku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=1003-1018&author=L.+Fengauthor=S.+Huangauthor=G.+Anauthor=G.+Wangauthor=S.+Guauthor=X.+Zhao&title=Identification+of+new+cancer+stem+cell+markers+and+signaling+pathways+in+HER-2-positive+breast+cancer+by+transcriptome+sequencing&doi=10.3892%2Fijo.2019.4876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of new cancer stem cell markers and signaling pathways in HER-2-positive breast cancer by transcriptome sequencing</span></div><div class="casAuthors">Feng, Lu; Huang, Shangke; An, Gaili; Wang, Guanying; Gu, Shanzhi; Zhao, Xinhan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1003-1018</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Human epidermal growth factor receptor (HER)-2-pos. breast cancer accounts for ∼25% of all breast cancer cases, and is assocd. with a poor prognosis.  In the present study, the ratio of CD44+/CD24-/low cells was almost zero in SK-BR-3 cells; however, it was >90% in MDA-MB-231 cells, as detd. by flow cytometry.  Since SK-BR-3 and MDA-MB-231 cells both exhibit a strong propensity for invasion and migration, it was hypothesized that there may be other markers of CSCs in SK-BR-3 cells.  Therefore, transcriptome sequencing was performed for SK-BR-3 and MDA-MB-231 cells.  It was obsd. that several leukocyte differentiation antigens and other CSC markers were significantly more highly expressed in SK-BR-3 cells.  Furthermore, the expression of aldehyde dehydrogenase (ALDH)1A3, CD164 and epithelial cell adhesion mol. (EpCAM) was higher in SK-BR-3 cells compared with in other subtypes of breast cell lines, as detd. by reverse transcription-polymerase chain reaction and western blot anal.  In addn., the expression levels of ALDH1A3, ALDH3B2 and EpCAM were higher in HER-2-pos. breast cancer compared with in paracancerous tissues and other subtypes of breast cancer, as detd. by immunohistochem.  The expression of β-catenin in the Wnt signaling pathway was lower in SK-BR-3 cells compared with in MDA-MB-231 cells, which may be used as a prognostic indicator for breast cancer.  These findings may help identify novel CSC markers and therapeutic targets for HER-2-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdzDidqFCAr7Vg90H21EOLACvtfcHk0li9L342gPSYUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltVeku78%253D&md5=ad585fbf4b88f7ecfd227e2617da9f62</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3892%2Fijo.2019.4876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2019.4876%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DAn%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DGu%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26atitle%3DIdentification%2520of%2520new%2520cancer%2520stem%2520cell%2520markers%2520and%2520signaling%2520pathways%2520in%2520HER-2-positive%2520breast%2520cancer%2520by%2520transcriptome%2520sequencing%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2019%26volume%3D55%26spage%3D1003%26epage%3D1018%26doi%3D10.3892%2Fijo.2019.4876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caglar, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biray Avci, C.</span></span> <span> </span><span class="NLM_article-title">Alterations of cell cycle genes in cancer: unmasking the role of cancer stem cells</span>. <i>Mol. Biol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">3065</span>– <span class="NLM_lpage">3076</span>, <span class="refDoi"> DOI: 10.1007/s11033-020-05341-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1007%2Fs11033-020-05341-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32112300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktFeksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2020&pages=3065-3076&author=H.+O.+Caglarauthor=C.+Biray+Avci&title=Alterations+of+cell+cycle+genes+in+cancer%3A+unmasking+the+role+of+cancer+stem+cells&doi=10.1007%2Fs11033-020-05341-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Alterations of cell cycle genes in cancer: unmasking the role of cancer stem cells</span></div><div class="casAuthors">Caglar, Hasan Onur; Biray Avci, Cigir</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">3065-3076</span>CODEN:
                <span class="NLM_cas:coden">MLBRBU</span>;
        ISSN:<span class="NLM_cas:issn">0301-4851</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Abstr.: The cell cycle is a complex and strictly controlled process, consisting of different phases.  Cell cycle regulation depends on phase-specific transcriptions of cell cycle genes.  The alterations of cell cycle genes can predispose normal cells to have a cancerous phenotype.  Indeed, several mechanisms underlying the deregulation of the cell cycle have been identified in different types of cancer.  Cancer stem cells (CSCs), a fraction of tumor cells, are selectively capable of initiating tumor development.  However, the deregulation of the cell cycle progression in CSCs still remains incompletely understood.  This review describes epigenetic alterations and aberrant transcriptional regulation of cell cycle genes in CSCs as well as cell cycle patterns of CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2T2oL7_SUvbVg90H21EOLACvtfcHk0liQgx93Rs_mJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktFeksr8%253D&md5=3cbe30a384ce330f3c20658530bf02e5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs11033-020-05341-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11033-020-05341-6%26sid%3Dliteratum%253Aachs%26aulast%3DCaglar%26aufirst%3DH.%2BO.%26aulast%3DBiray%2BAvci%26aufirst%3DC.%26atitle%3DAlterations%2520of%2520cell%2520cycle%2520genes%2520in%2520cancer%253A%2520unmasking%2520the%2520role%2520of%2520cancer%2520stem%2520cells%26jtitle%3DMol.%2520Biol.%2520Rep.%26date%3D2020%26volume%3D47%26spage%3D3065%26epage%3D3076%26doi%3D10.1007%2Fs11033-020-05341-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayob, A. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramasamy, T. S.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells as key drivers of tumour progression</span>. <i>J. Biomed. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">20</span>, <span class="refDoi"> DOI: 10.1186/s12929-018-0426-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2Fs12929-018-0426-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29506506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Sku7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=20&author=A.+Z.+Ayobauthor=T.+S.+Ramasamy&title=Cancer+stem+cells+as+key+drivers+of+tumour+progression&doi=10.1186%2Fs12929-018-0426-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells as key drivers of tumour progression</span></div><div class="casAuthors">Ayob, Ain Zubaidah; Ramasamy, Thamil Selvee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomedical Science (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20/1-20/18</span>CODEN:
                <span class="NLM_cas:coden">JBCIEA</span>;
        ISSN:<span class="NLM_cas:issn">1423-0127</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background:Cancer stem cells (CSCs) are subpopulations of cancer cells sharing similar characteristics as normal stem or progenitor cells such as self-renewal ability and multi-lineage differentiation to drive tumor growth and heterogeneity.  Throughout the cancer progression, CSC can further be induced from differentiated cancer cells via the adaptation and cross-talks with the tumor microenvironment as well as a response from therapeutic pressures, therefore contributes to their heterogeneous phenotypes.  Challengingly, conventional cancer treatments target the bulk of the tumor and are unable to target CSCs due to their highly resistance nature, leading to metastasis and tumor recurrence.  Main body: This review highlights the roles of CSCs in tumor initiation, progression and metastasis with a focus on the cellular and mol. regulators that influence their phenotypical changes and behaviors in the different stages of cancer progression.  We delineate the cross-talks between CSCs with the tumor microenvironment that support their intrinsic properties including survival, stemness, quiescence and their cellular and mol. adaptation in response to therapeutic pressure.  An insight into the distinct roles of CSCs in promoting angiogenesis and metastasis has been captured based on in vitro and in vivo evidences.  Conclusion: Given dynamic cellular events along the cancer progression and contributions of resistance nature by CSCs, understanding their mol. and cellular regulatory mechanism in a heterogeneous nature, provides significant cornerstone for the development of CSC-specific therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3nTnY6lOWyLVg90H21EOLACvtfcHk0liQgx93Rs_mJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Sku7zL&md5=a4700e44e5f5cb9be8de6d03c823ad75</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1186%2Fs12929-018-0426-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12929-018-0426-4%26sid%3Dliteratum%253Aachs%26aulast%3DAyob%26aufirst%3DA.%2BZ.%26aulast%3DRamasamy%26aufirst%3DT.%2BS.%26atitle%3DCancer%2520stem%2520cells%2520as%2520key%2520drivers%2520of%2520tumour%2520progression%26jtitle%3DJ.%2520Biomed.%2520Sci.%26date%3D2018%26volume%3D25%26spage%3D20%26doi%3D10.1186%2Fs12929-018-0426-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">López-Lázaro, M.</span></span> <span> </span><span class="NLM_article-title">The stem cell division theory of cancer</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2018.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.critrevonc.2018.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29482784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC1MrlsFCgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2018&pages=95-113&author=M.+L%C3%B3pez-L%C3%A1zaro&title=The+stem+cell+division+theory+of+cancer&doi=10.1016%2Fj.critrevonc.2018.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The stem cell division theory of cancer</span></div><div class="casAuthors">Lopez-Lazaro Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">95-113</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">All cancer registries constantly show striking differences in cancer incidence by age and among tissues.  For example, lung cancer is diagnosed hundreds of times more often at age 70 than at age 20, and lung cancer in nonsmokers occurs thousands of times more frequently than heart cancer in smokers.  An analysis of these differences using basic concepts in cell biology indicates that cancer is the end-result of the accumulation of cell divisions in stem cells.  In other words, the main determinant of carcinogenesis is the number of cell divisions that the DNA of a stem cell has accumulated in any type of cell from the zygote.  Cell division, process by which a cell copies and separates its cellular components to finally split into two cells, is necessary to produce the large number of cells required for living.  However, cell division can lead to a variety of cancer-promoting errors, such as mutations and epigenetic mistakes occurring during DNA replication, chromosome aberrations arising during mitosis, errors in the distribution of cell-fate determinants between the daughter cells, and failures to restore physical interactions with other tissue components.  Some of these errors are spontaneous, others are promoted by endogenous DNA damage occurring during quiescence, and others are influenced by pathological and environmental factors.  The cell divisions required for carcinogenesis are primarily caused by multiple local and systemic physiological signals rather than by errors in the DNA of the cells.  As carcinogenesis progresses, the accumulation of DNA errors promotes cell division and eventually triggers cell division under permissive extracellular environments.  The accumulation of cell divisions in stem cells drives not only the accumulation of the DNA alterations required for carcinogenesis, but also the formation and growth of the abnormal cell populations that characterize the disease.  This model of carcinogenesis provides a new framework for understanding the disease and has important implications for cancer prevention and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1aXaniitqqoqdXsLcGTEUfW6udTcc2ebaQH98wfXMqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrlsFCgug%253D%253D&md5=3348665d0e4e2c7172fbe3767b8a4321</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2018.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2018.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26atitle%3DThe%2520stem%2520cell%2520division%2520theory%2520of%2520cancer%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2018%26volume%3D123%26spage%3D95%26epage%3D113%26doi%3D10.1016%2Fj.critrevonc.2018.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lui, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obajdin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroukov, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spagnoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, F. M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms, hallmarks, and implications of stem cell quiescence</span>. <i>Stem Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1190</span>– <span class="NLM_lpage">1200</span>, <span class="refDoi"> DOI: 10.1016/j.stemcr.2019.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.stemcr.2019.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31189093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=1190-1200&author=I.+J.+Choauthor=P.+P.+Luiauthor=J.+Obajdinauthor=F.+Riccioauthor=W.+Stroukovauthor=T.+L.+Willisauthor=F.+Spagnoliauthor=F.+M.+Watt&title=Mechanisms%2C+hallmarks%2C+and+implications+of+stem+cell+quiescence&doi=10.1016%2Fj.stemcr.2019.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms, Hallmarks, and Implications of Stem Cell Quiescence</span></div><div class="casAuthors">Cho, Inchul J.; Lui, Prudence PokWai; Obajdin, Jana; Riccio, Federica; Stroukov, Wladislaw; Willis, Thea Louise; Spagnoli, Francesca; Watt, Fiona M.</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1190-1200</span>CODEN:
                <span class="NLM_cas:coden">SCRTFL</span>;
        ISSN:<span class="NLM_cas:issn">2213-6711</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Cellular quiescence is a dormant but reversible cellular state in which cell-cycle entry and proliferation are prevented.  Recent studies both in vivo and in vitro demonstrate that quiescence is actively maintained through synergistic interactions between intrinsic and extrinsic signals.  Subtypes of adult mammalian stem cells can be maintained in this poised, quiescent state, and subsequently reactivated upon tissue injury to restore homeostasis.  However, quiescence can become deregulated in pathol. settings.  In this review, we discuss the recent advances uncovering intracellular signaling pathways, transcriptional changes, and extracellular cues within the stem cell niche that control induction and exit from quiescence in tissue stem cells.  We discuss the implications of quiescence as well as the pharmacol. and genetic approaches that are being explored to either induce or prevent quiescence as a therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyjE-BlzTnArVg90H21EOLACvtfcHk0liQgx93Rs_mJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtbzI&md5=0ca821f9174662bf562862765a51a8bf</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.stemcr.2019.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.stemcr.2019.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DI.%2BJ.%26aulast%3DLui%26aufirst%3DP.%2BP.%26aulast%3DObajdin%26aufirst%3DJ.%26aulast%3DRiccio%26aufirst%3DF.%26aulast%3DStroukov%26aufirst%3DW.%26aulast%3DWillis%26aufirst%3DT.%2BL.%26aulast%3DSpagnoli%26aufirst%3DF.%26aulast%3DWatt%26aufirst%3DF.%2BM.%26atitle%3DMechanisms%252C%2520hallmarks%252C%2520and%2520implications%2520of%2520stem%2520cell%2520quiescence%26jtitle%3DStem%2520Cell%2520Rep.%26date%3D2019%26volume%3D12%26spage%3D1190%26epage%3D1200%26doi%3D10.1016%2Fj.stemcr.2019.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qemo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, L. A.</span></span> <span> </span><span class="NLM_article-title">Cell cycle dynamics in glioma cancer stem cells</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1869</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-8805-1_11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1007%2F978-1-4939-8805-1_11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30324519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFWhtLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1869&publication_year=2019&pages=117-126&author=I.+Qemoauthor=L.+A.+Porter&title=Cell+cycle+dynamics+in+glioma+cancer+stem+cells&doi=10.1007%2F978-1-4939-8805-1_11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle dynamics in glioma cancer stem cells</span></div><div class="casAuthors">Qemo, Ingrid; Porter, Lisa A.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1869</span>
        (<span class="NLM_cas:issue">Brain Tumor Stem Cells</span>),
    <span class="NLM_cas:pages">117-126</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Cancer stem cells, sometimes referred to as tumor initiating cells, play pivotal roles in tumor initiation, progression, metastasis, resistance to therapy, and relapse.  Understanding how these populations of cells expand in response to a host of conditions is crit. in detg. effective cancer therapeutics.  A defining feature of cancer stem cells is the ability to switch between modes of quiescence and sym./asym. division to protect and conserve the population, this feature is traditionally reserved for normal adult stem cell populations.  Understanding how the core cell cycle machinery responds to external cues to drive sym./asym. division vs. quiescence will reveal fundamental information about how cancer stem cell populations survive and expand.  This chapter will describe methods to study the cell cycle dynamics in brain cancer stem cell populations and how they compare to the other populations in a tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpioZEwbROLZrVg90H21EOLACvtfcHk0ljJxu-XBwtGDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFWhtLvJ&md5=9e23498568a00fee273e55f3b2972d57</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-8805-1_11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-8805-1_11%26sid%3Dliteratum%253Aachs%26aulast%3DQemo%26aufirst%3DI.%26aulast%3DPorter%26aufirst%3DL.%2BA.%26atitle%3DCell%2520cycle%2520dynamics%2520in%2520glioma%2520cancer%2520stem%2520cells%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2019%26volume%3D1869%26spage%3D117%26epage%3D126%26doi%3D10.1007%2F978-1-4939-8805-1_11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeishi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K. I.</span></span> <span> </span><span class="NLM_article-title">To wake up cancer stem cells, or to let them sleep, that is the question</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1111/cas.12958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1111%2Fcas.12958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=27116333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSgsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=875-881&author=S.+Takeishiauthor=K.+I.+Nakayama&title=To+wake+up+cancer+stem+cells%2C+or+to+let+them+sleep%2C+that+is+the+question&doi=10.1111%2Fcas.12958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">To wake up cancer stem cells, or to let them sleep, that is the question</span></div><div class="casAuthors">Takeishi, Shoichiro; Nakayama, Keiichi I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">875-881</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) generate transient-amplifying cells and thereby contribute to cancer propagation.  A fuller understanding of the biol. features of CSCs is expected to lead to the development of new anticancer therapies capable of eradicating this life-threatening disease.  Cancer stem cells are known to maintain a non-proliferative state and to enter the cell cycle only infrequently.  Given that conventional anticancer therapies preferentially target dividing cells, CSCs are resistant to such treatments, with those remaining after elimination of bulk cancer cells potentially giving rise to disease relapse and metastasis as they re-enter the cell cycle after a period of latency.  Targeting of the switch between quiescence and proliferation in CSCs is therefore a potential strategy for preventing the reinitiation of malignancy, underscoring the importance of elucidation of the mechanisms by which these cells are maintained in the quiescent state.  The fundamental properties of CSCs are thought to be governed cooperatively by internal mols. and cues from the external microenvironment (stem cell niche).  Several such intrinsic and extrinsic regulators are responsible for the control of cell cycle progression in CSCs.  In this review, we address two opposite approaches to the therapeutic targeting of CSCs - wake-up and hibernation therapies - that either promote or prevent the entry of CSCs into the cell cycle, resp., and we discuss the potential advantages and risks of each strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUgdRUXMfDcrVg90H21EOLACvtfcHk0ljJxu-XBwtGDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSgsb7K&md5=53222f246c6bd942dc3394446388e558</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1111%2Fcas.12958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12958%26sid%3Dliteratum%253Aachs%26aulast%3DTakeishi%26aufirst%3DS.%26aulast%3DNakayama%26aufirst%3DK.%2BI.%26atitle%3DTo%2520wake%2520up%2520cancer%2520stem%2520cells%252C%2520or%2520to%2520let%2520them%2520sleep%252C%2520that%2520is%2520the%2520question%26jtitle%3DCancer%2520Sci.%26date%3D2016%26volume%3D107%26spage%3D875%26epage%3D881%26doi%3D10.1111%2Fcas.12958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afify, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seno, M.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cell generation by silenced MAPK enhancing PI3K/AKT signaling</span>. <i>Med. Hypotheses</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">109742</span>, <span class="refDoi"> DOI: 10.1016/j.mehy.2020.109742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.mehy.2020.109742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32315923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXns1Cjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2020&pages=109742&author=G.+Hassanauthor=J.+Duauthor=S.+M.+Afifyauthor=A.+Senoauthor=M.+Seno&title=Cancer+stem+cell+generation+by+silenced+MAPK+enhancing+PI3K%2FAKT+signaling&doi=10.1016%2Fj.mehy.2020.109742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cell generation by silenced MAPK enhancing PI3K/AKT signaling.</span></div><div class="casAuthors">Hassan, Ghmkin; Du, Juan; Afify, Said M.; Seno, Akimasa; Seno, Masaharu</div><div class="citationInfo"><span class="NLM_cas:title">Medical Hypotheses</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109742</span>CODEN:
                <span class="NLM_cas:coden">MEHYDY</span>;
        ISSN:<span class="NLM_cas:issn">0306-9877</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cancer stem cells, which are defined by self-renewal, differentiation potential and tumorigenicity, are proposed to be responsible for cancer initiation and maintain the tumor mass.  Cancer stem cells are thought to be resistant to chemotherapy inhibiting different signaling pathways.  Typically, growth factors are known to stimulate MEK/ERK pathways, which is responsible for mitogenic activity, while the PI3K appears more related with the maintenance of stemness.  The cross-talk, even in pos. or neg. ways, between these two pathways could stimulate or accelerate the conversion of normal stem cells into cancer stem cells.  Here, we propose a new hypothesis of a mechanism for the conversion of stem cells or progenitors including induced pluripotent stem cells (iPSCs) to tissue-specific cancer stem cells.  This conversion could be prepd. by inhibiting MEK/ERK pathway and enhancing PI3K/AKT pathway exploiting conditioned media derived from cancer cell lines, which are good sources of many different cytokines, chemokines, tissues-specific factors, metabolites and so on, together with some inhibitors.  The feasibility of this combination will be explained in this hypothesis through the reports published somewhere.  Generation of cancer stem cells using embryonic stem cells/iPSCs will bring new theory in the mechanisms of tumorigenesis and assist drug screening that applies for the precision medicines for individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdAJA2g4xE7rVg90H21EOLACvtfcHk0ljJxu-XBwtGDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXns1Cjsr4%253D&md5=434416c02329c81792f038d09c3109a1</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.mehy.2020.109742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mehy.2020.109742%26sid%3Dliteratum%253Aachs%26aulast%3DHassan%26aufirst%3DG.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DAfify%26aufirst%3DS.%2BM.%26aulast%3DSeno%26aufirst%3DA.%26aulast%3DSeno%26aufirst%3DM.%26atitle%3DCancer%2520stem%2520cell%2520generation%2520by%2520silenced%2520MAPK%2520enhancing%2520PI3K%252FAKT%2520signaling%26jtitle%3DMed.%2520Hypotheses%26date%3D2020%26volume%3D141%26spage%3D109742%26doi%3D10.1016%2Fj.mehy.2020.109742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, Z.</span></span> <span> </span><span class="NLM_article-title">Inhibition of GSK3 and MEK induced cancer stem cell generation via the Wnt and MEK signaling pathways</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2013</span>, <span class="refDoi"> DOI: 10.3892/or.2018.6600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3892%2For.2018.6600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30066938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2msb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2018&pages=2005-2013&author=S.+Liaoauthor=L.+Ganauthor=W.+Qinauthor=C.+Liuauthor=Z.+Mei&title=Inhibition+of+GSK3+and+MEK+induced+cancer+stem+cell+generation+via+the+Wnt+and+MEK+signaling+pathways&doi=10.3892%2For.2018.6600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of gsk3 and mek induced cancer stem cell generation via the wnt and mek signaling pathways</span></div><div class="casAuthors">Liao, Shengtao; Gan, Li; Qin, Wanxiang; Liu, Chang; Mei, Zhechuan</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2005-2013</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are considered to be tumor-initiating cells, responsible for tumor invasive growth and dissemination to distant organ sites.  Typically, radiation treatment and chemotherapy should target CSCs.  However, current research investigating CSCs is impeded by the difficulty of isolating pure CSCs and maintaining them in vitro.  In the present study, the synergistic inhibition of glycogen synthase kinase 3 and mitogen-activated protein kinase kinase using small mols., CHIR99021 and PD184352, efficiently generated CSCs from immortalized human mammary epithelial cells (HMLEs) and resulted in the acquisition of mesenchymal traits and the expression of epithelial-mesenchymal transition markers.  The cell proliferation, invasion and migration of HMLE cells were significantly promoted by CHIR99021 and PD184352 (P<0.05).  Furthermore, the cell cycle was shifted from the G0/G1 phase to the G2/M phase, and the apoptotic rate was suppressed in HMLE cells following treatment with CHIR99021 and PD184352.  Compared with control group, the stimulated cells exhibited an increased ability to form mammospheres and regenerate a tumor.  In addn. to these properties, the induced cells also exhibited notable chemotherapy resistance.  In vivo, the treatment of cells with CHIR99021 and PD184352 promoted the growth of HMLE-engrafted tumor types.  These results provide a practical strategy for the generation of CSCs using small mols. in vitro, which provides a cell resource that may be used for drug screening.  Addnl., the present results addnl. highlighted the synergistic functions of Wnt and mitogen-activated protein kinase kinase signaling pathways in tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBe1TMiPAk4rVg90H21EOLACvtfcHk0lgNKZMv1B0pjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2msb3I&md5=32750dd6170cd7e7a2f304e185cf5500</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3892%2For.2018.6600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2018.6600%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DS.%26aulast%3DGan%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DMei%26aufirst%3DZ.%26atitle%3DInhibition%2520of%2520GSK3%2520and%2520MEK%2520induced%2520cancer%2520stem%2520cell%2520generation%2520via%2520the%2520Wnt%2520and%2520MEK%2520signaling%2520pathways%26jtitle%3DOncol.%2520Rep.%26date%3D2018%26volume%3D40%26spage%3D2005%26epage%3D2013%26doi%3D10.3892%2For.2018.6600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clevers, H.</span></span> <span> </span><span class="NLM_article-title">Wnt signalling in stem cells and cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>434</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">850</span>, <span class="refDoi"> DOI: 10.1038/nature03319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fnature03319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=15829953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=843-850&author=T.+Reyaauthor=H.+Clevers&title=Wnt+signalling+in+stem+cells+and+cancer&doi=10.1038%2Fnature03319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Wnt signalling in stem cells and cancer</span></div><div class="casAuthors">Reya, Tannishtha; Clevers, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">843-850</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The canonical Wnt cascade has emerged as a crit. regulator of stem cells.  In many tissues, activation of Wnt signaling has also been assocd. with cancer.  This has raised the possibility that the tightly regulated self-renewal mediated by Wnt signaling in stem and progenitor cells is subverted in cancer cells to allow malignant proliferation.  Insights gained from understanding how the Wnt pathway is integrally involved in both stem cell and cancer cell maintenance and growth in the intestinal, epidermal and hematopoietic systems may serve as a paradigm for understanding the dual nature of self-renewal signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfhAAsTCfqJbVg90H21EOLACvtfcHk0lgNKZMv1B0pjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrw%253D&md5=eeadde4e2da7fb4226164e4adfd8c8b0</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnature03319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03319%26sid%3Dliteratum%253Aachs%26aulast%3DReya%26aufirst%3DT.%26aulast%3DClevers%26aufirst%3DH.%26atitle%3DWnt%2520signalling%2520in%2520stem%2520cells%2520and%2520cancer%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D843%26epage%3D850%26doi%3D10.1038%2Fnature03319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beretov, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">618</span>, <span class="refDoi"> DOI: 10.1186/s12885-019-5824-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2Fs12885-019-5824-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31234823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3MzgtlShsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=618&author=J.+Dengauthor=X.+Baiauthor=X.+Fengauthor=J.+Niauthor=J.+Beretovauthor=P.+Grahamauthor=Y.+Li&title=Inhibition+of+PI3K%2FAkt%2FmTOR+signaling+pathway+alleviates+ovarian+cancer+chemoresistance+through+reversing+epithelial-mesenchymal+transition+and+decreasing+cancer+stem+cell+marker+expression&doi=10.1186%2Fs12885-019-5824-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression</span></div><div class="casAuthors">Deng Junli; Bai Xupeng; Feng Xiaojie; Ni Jie; Beretov Julia; Graham Peter; Li Yong; Deng Junli; Bai Xupeng; Feng Xiaojie; Ni Jie; Beretov Julia; Graham Peter; Li Yong; Deng Junli; Feng Xiaojie; Beretov Julia; Li Yong</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">618</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Ovarian cancer is the most common malignant tumor of the female reproductive tract.  Chemoresistance is a major challenge for current ovarian cancer therapy.  However, the mechanism underlying epithelial ovarian cancer (EOC) chemoresistance is not completely uncovered.  The phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling is an important intracellular pathway in regulating cell cycle, quiescence, and proliferation.  The aim of this study is to investigate the role of PI3K/Akt/mTOR signaling pathway and its association with epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) marker expression in EOC chemoresistance.  METHODS:  The expressions of EMT and CSC markers were detected by immunofluorescence, western blot, and quantitative real-time PCR.  BEZ235, a dual PI3K/mTOR inhibitor, was employed to investigate the role of PI3K/Akt/ mTOR signaling in regulating EMT and CSC marker expression.  Students' t test and one-way ANOVA with Tukey's post-hoc test were used to compare the data from different groups.  RESULTS:  We found that EMT and CSC marker expression were significantly enhanced in chemoresistant EOC cells, which was accompanied by the activation of PI3K/Akt/mTOR signaling.  Compared with single cisplatin treatment, combined treatment with BEZ235 and cisplatin significantly disrupted the colony formation ability, induced higher ROS level and more apoptosis in chemoresistant EOC cells.  Furthermore, the combination approach effectively inhibited PI3K/Akt/mTOR signaling pathway, reversed EMT, and decreased CSC marker expression in chemoresistant EOC cells compared with cisplatin mono-treatment.  CONCLUSIONS:  Our results first demonstrate that EMT and enhanced CSC marker expression triggered by activated PI3K/Akt/mTOR signaling are involved in the chemoresistance of EOC, and BEZ235 in combination with cisplatin might be a promising treatment option to reverse EOC chemoresistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7_gQlHibJTOLt9HypzAgQfW6udTcc2eYyNp5tN8D-WLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzgtlShsw%253D%253D&md5=e6be0ea91d642de6556e5c7e12689c47</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1186%2Fs12885-019-5824-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-019-5824-9%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DNi%26aufirst%3DJ.%26aulast%3DBeretov%26aufirst%3DJ.%26aulast%3DGraham%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DInhibition%2520of%2520PI3K%252FAkt%252FmTOR%2520signaling%2520pathway%2520alleviates%2520ovarian%2520cancer%2520chemoresistance%2520through%2520reversing%2520epithelial-mesenchymal%2520transition%2520and%2520decreasing%2520cancer%2520stem%2520cell%2520marker%2520expression%26jtitle%3DBMC%2520Cancer%26date%3D2019%26volume%3D19%26spage%3D618%26doi%3D10.1186%2Fs12885-019-5824-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vijay, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Den Hollander, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toneff, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietila, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez-Pena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werden, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shariati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobieski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sphyris, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soundararajan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S. A.</span></span> <span> </span><span class="NLM_article-title">GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">37</span>, <span class="refDoi"> DOI: 10.1186/s13058-019-1125-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2Fs13058-019-1125-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30845991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3cbhs1ansQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=37&author=G.+V.+Vijayauthor=N.+Zhaoauthor=P.+Den+Hollanderauthor=M.+J.+Toneffauthor=R.+Josephauthor=M.+Pietilaauthor=J.+H.+Taubeauthor=T.+R.+Sarkarauthor=E.+Ramirez-Penaauthor=S.+J.+Werdenauthor=M.+Shariatiauthor=R.+Gaoauthor=M.+Sobieskiauthor=C.+C.+Stephanauthor=N.+Sphyrisauthor=N.+Miuraauthor=P.+Daviesauthor=J.+T.+Changauthor=R.+Soundararajanauthor=J.+M.+Rosenauthor=S.+A.+Mani&title=GSK3%CE%B2+regulates+epithelial-mesenchymal+transition+and+cancer+stem+cell+properties+in+triple-negative+breast+cancer&doi=10.1186%2Fs13058-019-1125-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer</span></div><div class="casAuthors">Vijay Geraldine Vidhya; Den Hollander Petra; Joseph Robiya; Ramirez-Pena Esmeralda; Werden Steven J; Shariati Maryam; Sphyris Nathalie; Soundararajan Rama; Mani Sendurai A; Zhao Na; Toneff Mike J; Rosen Jeffrey M; Pietila Mika; Taube Joseph H; Sarkar Tapasree R; Gao Ruli; Sobieski Mary; Stephan Clifford C; Davies Peter; Miura Noayuki; Chang Jeffrey T; Chang Jeffrey T; Mani Sendurai A</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Triple-negative breast cancers (TNBCs), which lack receptors for estrogen, progesterone, and amplification of epidermal growth factor receptor 2, are highly aggressive.  Consequently, patients diagnosed with TNBCs have reduced overall and disease-free survival rates compared to patients with other subtypes of breast cancer.  TNBCs are characterized by the presence of cancer cells with mesenchymal properties, indicating that the epithelial to mesenchymal transition (EMT) plays a major role in the progression of this disease.  The EMT program has also been implicated in chemoresistance, tumor recurrence, and induction of cancer stem cell (CSC) properties.  Currently, there are no targeted therapies for TNBC, and hence, it is critical to identify the novel targets to treat TNBC.  METHODS:  A library of compounds was screened for their ability to inhibit EMT in cells with mesenchymal phenotype as assessed using the previously described Z-cad reporters.  Of the several drugs tested, GSK3β inhibitors were identified as EMT inhibitors.  The effects of GSK3β inhibitors on the properties of TNBC cells with a mesenchymal phenotype were assessed using qRT-PCR, flow cytometry, western blot, mammosphere, and migration and cell viability assays.  Publicly available datasets also were analyzed to examine if the expression of GSK3β correlates with the overall survival of breast cancer patients.  RESULTS:  We identified a GSK3β inhibitor, BIO, in a drug screen as one of the most potent inhibitors of EMT.  BIO and two other GSK3β inhibitors, TWS119 and LiCl, also decreased the expression of mesenchymal markers in several different cell lines with a mesenchymal phenotype.  Further, inhibition of GSK3β reduced EMT-related migratory properties of cells with mesenchymal properties.  To determine if GSK3β inhibitors target mesenchymal-like cells by affecting the CSC population, we employed mammosphere assays and profiled the stem cell-related cell surface marker CD44+/24- in cells after exposure to GSK3β inhibitors.  We found that GSK3β inhibitors indeed decreased the CSC properties of cell types with mesenchymal properties.  We treated cells with epithelial and mesenchymal properties with GSK3β inhibitors and found that GSK3β inhibitors selectively kill cells with mesenchymal attributes while sparing cells with epithelial properties.  We analyzed patient data to identify genes predictive of poor clinical outcome that could serve as novel therapeutic targets for TNBC.  The Wnt signaling pathway is critical to EMT, but among the various factors known to be involved in Wnt signaling, only the higher expression of GSK3β correlated with poorer overall patient survival.  CONCLUSIONS:  Taken together, our data demonstrate that GSK3β is a potential target for TNBCs and suggest that GSK3β inhibitors could serve as selective inhibitors of EMT and CSC properties for the treatment of a subset of aggressive TNBC.  GSK3β inhibitors should be tested for use in combination with standard-of-care drugs in preclinical TNBC models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfVPhSJgAa6b7NkxioyDXTfW6udTcc2eZ_FJVfcOO_27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbhs1ansQ%253D%253D&md5=87411c7f788208a247d10ab28803b773</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1186%2Fs13058-019-1125-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-019-1125-0%26sid%3Dliteratum%253Aachs%26aulast%3DVijay%26aufirst%3DG.%2BV.%26aulast%3DZhao%26aufirst%3DN.%26aulast%3DDen%2BHollander%26aufirst%3DP.%26aulast%3DToneff%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DR.%26aulast%3DPietila%26aufirst%3DM.%26aulast%3DTaube%26aufirst%3DJ.%2BH.%26aulast%3DSarkar%26aufirst%3DT.%2BR.%26aulast%3DRamirez-Pena%26aufirst%3DE.%26aulast%3DWerden%26aufirst%3DS.%2BJ.%26aulast%3DShariati%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DR.%26aulast%3DSobieski%26aufirst%3DM.%26aulast%3DStephan%26aufirst%3DC.%2BC.%26aulast%3DSphyris%26aufirst%3DN.%26aulast%3DMiura%26aufirst%3DN.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DJ.%2BT.%26aulast%3DSoundararajan%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DJ.%2BM.%26aulast%3DMani%26aufirst%3DS.%2BA.%26atitle%3DGSK3%25CE%25B2%2520regulates%2520epithelial-mesenchymal%2520transition%2520and%2520cancer%2520stem%2520cell%2520properties%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2019%26volume%3D21%26spage%3D37%26doi%3D10.1186%2Fs13058-019-1125-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeran, S. M.</span></span> <span> </span><span class="NLM_article-title">Epigenetics of cancer stem cells: pathways and therapeutics</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1840</i></span>,  <span class="NLM_fpage">3494</span>– <span class="NLM_lpage">3502</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2014.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.bbagen.2014.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyns7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1840&publication_year=2014&pages=3494-3502&author=S.+Shuklaauthor=S.+M.+Meeran&title=Epigenetics+of+cancer+stem+cells%3A+pathways+and+therapeutics&doi=10.1016%2Fj.bbagen.2014.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetics of cancer stem cells: Pathways and therapeutics</span></div><div class="casAuthors">Shukla, Samriddhi; Meeran, Syed Musthapa</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1840</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3494-3502</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Epigenetic alterations including DNA methylation and histone modifications are the key factors in the differentiation of stem cells into different tissue subtypes.  The generation of cancer stem cells (CSCs) in the process of carcinogenesis may also involve similar kind of epigenetic reprogramming where, in contrast, it leads to the loss of expression of genes specific to the differentiated state and regaining of stem cell-specific characteristics.  The most important predicament with treatment of cancers includes the non-responsive quiescent CSC.The distinctive capabilities of the CSCs make cancer treatment even more difficult as this population of cells tends to remain quiescent for longer intervals and then gets reactivated leading to tumor relapse.  Therefore, the current review is aimed to focus on recent advances in understanding the relation of epigenetic reprogramming to the generation, self-renewal and proliferation of CSCs.  CSC-targeted therapeutic approaches would improve the chances of patient survival by reducing the frequency of tumor relapse.  Differentiation therapy is an emerging therapeutic approach in which the CSCs are induced to differentiate from their quiescent state to a mature differentiated form, through activation of differentiation-related signaling pathways, miRNA-mediated alteration and epigenetic differentiation therapy.  Thus, understanding the origin of CSC and their epigenetic regulation is crucial to develop treatment strategy against not only for the heterogeneous population of cancer cells but also to CSCs.Characterizing the epigenetic marks of CSCs and the assocd. signaling cascades might help in developing therapeutic strategies against chemo-resistant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEAG2zhRP3ULVg90H21EOLACvtfcHk0lj5aCBN_A3ejQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyns7bO&md5=afa2da448755284fdac00bda3fb7c2cd</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2014.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2014.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DMeeran%26aufirst%3DS.%2BM.%26atitle%3DEpigenetics%2520of%2520cancer%2520stem%2520cells%253A%2520pathways%2520and%2520therapeutics%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2014%26volume%3D1840%26spage%3D3494%26epage%3D3502%26doi%3D10.1016%2Fj.bbagen.2014.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turdo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veschi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaggianesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnici, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianca, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stassi, G.</span></span> <span> </span><span class="NLM_article-title">Meeting the challenge of targeting cancer stem cells</span>. <i>Front. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">16</span>, <span class="refDoi"> DOI: 10.3389/fcell.2019.00016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffcell.2019.00016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30834247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgsVKjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=16&author=A.+Turdoauthor=V.+Veschiauthor=M.+Gaggianesiauthor=A.+Chinniciauthor=P.+Biancaauthor=M.+Todaroauthor=G.+Stassi&title=Meeting+the+challenge+of+targeting+cancer+stem+cells&doi=10.3389%2Ffcell.2019.00016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Meeting the Challenge of Targeting Cancer Stem Cells</span></div><div class="casAuthors">Turdo Alice; Veschi Veronica; Gaggianesi Miriam; Chinnici Aurora; Bianca Paola; Stassi Giorgio; Todaro Matilde</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in cell and developmental biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16</span>
        ISSN:<span class="NLM_cas:issn">2296-634X</span>.
    </div><div class="casAbstract">Notwithstanding cancer patients benefit from a plethora of therapeutic alternatives, drug resistance remains a critical hurdle.  Indeed, the high mortality rate is associated with metastatic disease, which is mostly incurable due to the refractoriness of metastatic cells to current treatments.  Increasing data demonstrate that tumors contain a small subpopulation of cancer stem cells (CSCs) able to establish primary tumor and metastasis.  CSCs are endowed with multiple treatment resistance capabilities comprising a highly efficient DNA damage repair machinery, the activation of survival pathways, enhanced cellular plasticity, immune evasion and the adaptation to a hostile microenvironment.  Due to the presence of distinct cell populations within a tumor, cancer research has to face the major challenge of targeting the intra-tumoral as well as inter-tumoral heterogeneity.  Thus, targeting molecular drivers operating in CSCs, in combination with standard treatments, may improve cancer patients' outcomes, yielding long-lasting responses.  Here, we report a comprehensive overview on the most significant therapeutic advances that have changed the known paradigms of cancer treatment with a particular emphasis on newly developed compounds that selectively affect the CSC population.  Specifically, we are focusing on innovative therapeutic approaches including differentiation therapy, anti-angiogenic compounds, immunotherapy and inhibition of epigenetic enzymes and microenvironmental cues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNWC6k0csi_sERNNga7KD-fW6udTcc2eZ_FJVfcOO_27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgsVKjuw%253D%253D&md5=afa42b46d117fed33f5cfed79b2936de</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3389%2Ffcell.2019.00016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcell.2019.00016%26sid%3Dliteratum%253Aachs%26aulast%3DTurdo%26aufirst%3DA.%26aulast%3DVeschi%26aufirst%3DV.%26aulast%3DGaggianesi%26aufirst%3DM.%26aulast%3DChinnici%26aufirst%3DA.%26aulast%3DBianca%26aufirst%3DP.%26aulast%3DTodaro%26aufirst%3DM.%26aulast%3DStassi%26aufirst%3DG.%26atitle%3DMeeting%2520the%2520challenge%2520of%2520targeting%2520cancer%2520stem%2520cells%26jtitle%3DFront.%2520Cell%2520Dev.%2520Biol.%26date%3D2019%26volume%3D7%26spage%3D16%26doi%3D10.3389%2Ffcell.2019.00016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhol, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panigrahi, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praharaj, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahapatra, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behera, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutia, S. K.</span></span> <span> </span><span class="NLM_article-title">Epigenetic modifications of autophagy in cancer and cancer therapeutics</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2019.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.semcancer.2019.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31158463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFyjtLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2020&pages=22-33&author=C.+S.+Bholauthor=D.+P.+Panigrahiauthor=P.+P.+Praharajauthor=K.+K.+Mahapatraauthor=S.+Patraauthor=S.+R.+Mishraauthor=B.+P.+Beheraauthor=S.+K.+Bhutia&title=Epigenetic+modifications+of+autophagy+in+cancer+and+cancer+therapeutics&doi=10.1016%2Fj.semcancer.2019.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic modifications of autophagy in cancer and cancer therapeutics</span></div><div class="casAuthors">Bhol, Chandra S.; Panigrahi, Debasna P.; Praharaj, Prakash P.; Mahapatra, Kewal K.; Patra, Srimanta; Mishra, Soumya R.; Behera, Bishnu P.; Bhutia, Sujit K.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22-33</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Epigenetic alterations, such as DNA methylation, histone modifications and miRNAs, have a significant role play in malignant cellular transformation and metastasis.  On the other hand, autophagy has been reported to perform context-dependent roles in cancer; at times, it becomes lethal and abolishes tumorigenesis, whereas, at other instances, it protects cancer cells by providing a rescue mechanism under adverse conditions.  Although epigenetics and autophagy are two important and independent cellular processes, various oncogenic and oncosuppressor proteins involve autophagy through epigenetic modifications and different signaling pathways, thereby regulating tumor growth and therapeutic response.  Moreover, the importance of epigenetic modification of autophagy in cancer is reflected through its involvement in cancer stem cell maintenance, which in turn, contributes to tumor cell viability during dormancy leading to tumor recurrence.  The effects of epigenetic modifications of autophagy in cancer is still ambiguous and less acknowledged; therefore, efforts have been made to understand its detail underlying mechanism to unveil new targets and avenues for better prognosis and diagnosis of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyB3OlPFlIy7Vg90H21EOLACvtfcHk0lhqFgMc-GVHwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFyjtLjL&md5=018af7507aa941ef03fdc9c8bc244508</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2019.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2019.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DBhol%26aufirst%3DC.%2BS.%26aulast%3DPanigrahi%26aufirst%3DD.%2BP.%26aulast%3DPraharaj%26aufirst%3DP.%2BP.%26aulast%3DMahapatra%26aufirst%3DK.%2BK.%26aulast%3DPatra%26aufirst%3DS.%26aulast%3DMishra%26aufirst%3DS.%2BR.%26aulast%3DBehera%26aufirst%3DB.%2BP.%26aulast%3DBhutia%26aufirst%3DS.%2BK.%26atitle%3DEpigenetic%2520modifications%2520of%2520autophagy%2520in%2520cancer%2520and%2520cancer%2520therapeutics%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2020%26volume%3D66%26spage%3D22%26epage%3D33%26doi%3D10.1016%2Fj.semcancer.2019.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span> <span> </span><span class="NLM_article-title">Targeting cancer stem cell pathways for cancer therapy</span>. <i>Signal Transduct. Target Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.1038/s41392-020-0110-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fs41392-020-0110-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32296030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB38jhtFyisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=8&author=L.+Yangauthor=P.+Shiauthor=G.+Zhaoauthor=J.+Xuauthor=W.+Pengauthor=J.+Zhangauthor=G.+Zhangauthor=X.+Wangauthor=Z.+Dongauthor=F.+Chenauthor=H.+Cui&title=Targeting+cancer+stem+cell+pathways+for+cancer+therapy&doi=10.1038%2Fs41392-020-0110-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer stem cell pathways for cancer therapy</span></div><div class="casAuthors">Yang Liqun; Shi Pengfei; Zhao Gaichao; Xu Jie; Peng Wen; Zhang Jiayi; Zhang Guanghui; Wang Xiaowen; Dong Zhen; Cui Hongjuan; Yang Liqun; Shi Pengfei; Zhao Gaichao; Xu Jie; Peng Wen; Zhang Jiayi; Zhang Guanghui; Wang Xiaowen; Dong Zhen; Cui Hongjuan; Chen Fei</div><div class="citationInfo"><span class="NLM_cas:title">Signal transduction and targeted therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been considered promising therapeutic targets for cancer therapy.  These cells have self-renewal capacity and differentiation potential and contribute to multiple tumor malignancies, such as recurrence, metastasis, heterogeneity, multidrug resistance, and radiation resistance.  The biological activities of CSCs are regulated by several pluripotent transcription factors, such as OCT4, Sox2, Nanog, KLF4, and MYC.  In addition, many intracellular signaling pathways, such as Wnt, NF-κB (nuclear factor-κB), Notch, Hedgehog, JAK-STAT (Janus kinase/signal transducers and activators of transcription), PI3K/AKT/mTOR (phosphoinositide 3-kinase/AKT/mammalian target of rapamycin), TGF (transforming growth factor)/SMAD, and PPAR (peroxisome proliferator-activated receptor), as well as extracellular factors, such as vascular niches, hypoxia, tumor-associated macrophages, cancer-associated fibroblasts, cancer-associated mesenchymal stem cells, extracellular matrix, and exosomes, have been shown to be very important regulators of CSCs.  Molecules, vaccines, antibodies, and CAR-T (chimeric antigen receptor T cell) cells have been developed to specifically target CSCs, and some of these factors are already undergoing clinical trials.  This review summarizes the characterization and identification of CSCs, depicts major factors and pathways that regulate CSC development, and discusses potential targeted therapy for CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpLB2lPAt1ijUE-swuRqsHfW6udTcc2eZi4CAmgffvC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38jhtFyisA%253D%253D&md5=6678de50a460f118ed9fb7446edb64df</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fs41392-020-0110-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41392-020-0110-5%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DCui%26aufirst%3DH.%26atitle%3DTargeting%2520cancer%2520stem%2520cell%2520pathways%2520for%2520cancer%2520therapy%26jtitle%3DSignal%2520Transduct.%2520Target%2520Ther.%26date%3D2020%26volume%3D5%26spage%3D8%26doi%3D10.1038%2Fs41392-020-0110-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saygin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majeti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reizes, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lathia, J. D.</span></span> <span> </span><span class="NLM_article-title">Targeting cancer stemness in the clinic: from hype to hope</span>. <i>Cell Stem Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1016/j.stem.2018.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.stem.2018.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30595497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntl2l" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=25-40&author=C.+Sayginauthor=D.+Mateiauthor=R.+Majetiauthor=O.+Reizesauthor=J.+D.+Lathia&title=Targeting+cancer+stemness+in+the+clinic%3A+from+hype+to+hope&doi=10.1016%2Fj.stem.2018.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Cancer Stemness in the Clinic: From Hype to Hope</span></div><div class="casAuthors">Saygin, Caner; Matei, Daniela; Majeti, Ravindra; Reizes, Ofer; Lathia, Justin D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Stem Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-40</span>CODEN:
                <span class="NLM_cas:coden">CSCEC4</span>;
        ISSN:<span class="NLM_cas:issn">1875-9777</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Tumors are composed of non-homogeneous cell populations exhibiting varying degrees of genetic and functional heterogeneity.  Cancer stem cells (CSCs) are capable of sustaining tumors by manipulating genetic and non-genetic factors to metastasize, resist treatment, and maintain the tumor microenvironment.  Understanding the key traits and mechanisms of CSC survival provides opportunities to improve patient outcomes via improved prognostic models and therapeutics.  Here, we review the clin. significance of CSCs and results of potential CSC-targeting therapies in various cancers.  We discuss barriers to translating cues from pre-clin. models into clin. applications and propose new strategies for rational design of future anti-CSC trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuGh67NSTJgbVg90H21EOLACvtfcHk0lhqFgMc-GVHwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntl2l&md5=32cd80d33130f24b9ad4accbca08f716</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.stem.2018.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.stem.2018.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DSaygin%26aufirst%3DC.%26aulast%3DMatei%26aufirst%3DD.%26aulast%3DMajeti%26aufirst%3DR.%26aulast%3DReizes%26aufirst%3DO.%26aulast%3DLathia%26aufirst%3DJ.%2BD.%26atitle%3DTargeting%2520cancer%2520stemness%2520in%2520the%2520clinic%253A%2520from%2520hype%2520to%2520hope%26jtitle%3DCell%2520Stem%2520Cell%26date%3D2019%26volume%3D24%26spage%3D25%26epage%3D40%26doi%3D10.1016%2Fj.stem.2018.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fayomi, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anyaeche, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckanovich, R. J.</span></span> <span> </span><span class="NLM_article-title">An evolving paradigm of cancer stem cell hierarchies: therapeutic implications</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3083</span>– <span class="NLM_lpage">3098</span>, <span class="refDoi"> DOI: 10.7150/thno.41647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.7150%2Fthno.41647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32194856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsl2mt7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=3083-3098&author=A.+J.+Coleauthor=A.+P.+Fayomiauthor=V.+I.+Anyaecheauthor=S.+Baiauthor=R.+J.+Buckanovich&title=An+evolving+paradigm+of+cancer+stem+cell+hierarchies%3A+therapeutic+implications&doi=10.7150%2Fthno.41647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">An evolving paradigm of cancer stem cell hierarchies: therapeutic implications</span></div><div class="casAuthors">Cole, Alexander J.; Fayomi, Adetunji P.; Anyaeche, Vivian I.; Bai, Shoumei; Buckanovich, Ronald J.</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3083-3098</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">A review.  Over a decade of research has confirmed the crit. role of cancer stem-like cells (CSCs) in tumor initiation, chemoresistance, and metastasis.  Increasingly, CSC hierarchies have begun to be defined with some recurring themes.  This includes evidence that these hierarchies are 'flexible,' with both cell state transitions and dedifferentiation events possible.  These findings pose therapeutic hurdles and opportunities.  Here, we review cancer stem cell hierarchies and their interactions with the tumor microenvironment.  We also discuss the current therapeutic approaches designed to target CSC hierarchies and initial clin. trial results for CSC targeting agents.  While cancer stem cell targeted therapies are still in their infancy, we are beginning to see encouraging results that suggest a pos. outlook for CSC-targeting approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDUUo-wF4qwrVg90H21EOLACvtfcHk0lgYfRKfsAdEnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsl2mt7jF&md5=64fa83142730948eee2340502a9dc218</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.7150%2Fthno.41647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.41647%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DA.%2BJ.%26aulast%3DFayomi%26aufirst%3DA.%2BP.%26aulast%3DAnyaeche%26aufirst%3DV.%2BI.%26aulast%3DBai%26aufirst%3DS.%26aulast%3DBuckanovich%26aufirst%3DR.%2BJ.%26atitle%3DAn%2520evolving%2520paradigm%2520of%2520cancer%2520stem%2520cell%2520hierarchies%253A%2520therapeutic%2520implications%26jtitle%3DTheranostics%26date%3D2020%26volume%3D10%26spage%3D3083%26epage%3D3098%26doi%3D10.7150%2Fthno.41647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. L.</span></span> <span> </span><span class="NLM_article-title">Targeting cancer stem cells in drug discovery: current state and future perspectives</span>. <i>World J. Stem Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">420</span>, <span class="refDoi"> DOI: 10.4252/wjsc.v11.i7.398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.4252%2Fwjsc.v11.i7.398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31396368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3MvmtlGluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=398-420&author=F.+Y.+Duauthor=Q.+F.+Zhouauthor=W.+J.+Sunauthor=G.+L.+Chen&title=Targeting+cancer+stem+cells+in+drug+discovery%3A+current+state+and+future+perspectives&doi=10.4252%2Fwjsc.v11.i7.398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer stem cells in drug discovery: Current state and future perspectives</span></div><div class="casAuthors">Du Fang-Yu; Zhou Qi-Fan; Sun Wen-Jiao; Chen Guo-Liang</div><div class="citationInfo"><span class="NLM_cas:title">World journal of stem cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">398-420</span>
        ISSN:<span class="NLM_cas:issn">1948-0210</span>.
    </div><div class="casAbstract">In recent decades, cancer stem cells (CSCs) have been increasingly identified in many malignancies.  CSC-related signaling pathways and their functions provide new strategies for treating cancer.  The aberrant activation of related signaling pathways (e.g., Wnt, Notch, and Hedgehog pathways) has been linked to multiple types of malignant tumors, which makes these pathways attractive targets for cancer therapy.  CSCs display many characteristic features, such as self-renewal, differentiation, high tumorigenicity, and drug resistance.  Therefore, there is an urgent need to develop new therapeutic strategies to target these pathways to control stem cell replication, survival, and differentiation.  Notable crosstalk occurs among different signaling pathways and potentially leads to compensatory escape.  Therefore, multitarget inhibitors will be one of the main methods to overcome the drug resistance of CSCs.  Many small molecule inhibitors of components of signaling pathways in CSCs have entered clinical trials, and some inhibitors, such as vismodegib, sonidegib, and glasdegib, have been approved.  Tumor cells are susceptible to sonidegib and vismodegib resistance due to mutations in the Smo protein.  The signal transducers and activators of transcription 3 (STAT3) inhibitor BBI608 is being evaluated in a phase III trial for a variety of cancers.  Structural derivatives of BBI608 are the main focus of STAT3 inhibitor development, which is another strategy for CSC therapy.  In addition to the potential pharmacological inhibitors targeting CSC-related signaling pathways, other methods of targeting CSCs are available, such as nano-drug delivery systems, mitochondrion targeting, autophagy, hyperthermia, immunotherapy, and CSC microenvironment targeting.  In addition, we summarize the latest advances in the clinical development of agents targeting CSC-related signaling pathways and other methods of targeting CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrJ96Nuqm0356KlWarZTAzfW6udTcc2eY27V8APE_wfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvmtlGluw%253D%253D&md5=09054c0eb04f640b8401d31e2b33506b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.4252%2Fwjsc.v11.i7.398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4252%252Fwjsc.v11.i7.398%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DF.%2BY.%26aulast%3DZhou%26aufirst%3DQ.%2BF.%26aulast%3DSun%26aufirst%3DW.%2BJ.%26aulast%3DChen%26aufirst%3DG.%2BL.%26atitle%3DTargeting%2520cancer%2520stem%2520cells%2520in%2520drug%2520discovery%253A%2520current%2520state%2520and%2520future%2520perspectives%26jtitle%3DWorld%2520J.%2520Stem%2520Cells%26date%3D2019%26volume%3D11%26spage%3D398%26epage%3D420%26doi%3D10.4252%2Fwjsc.v11.i7.398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajayi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavasolian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezalotfi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebrahimi, M.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells targeting; the lessons from the interaction of the immune system, the cancer stem cells and the tumor niche</span>. <i>Int. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1080/08830185.2019.1669593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1080%2F08830185.2019.1669593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31578892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSiu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=267-283&author=H.+Rajayiauthor=P.+Tavasolianauthor=A.+Rezalotfiauthor=M.+Ebrahimi&title=Cancer+stem+cells+targeting%3B+the+lessons+from+the+interaction+of+the+immune+system%2C+the+cancer+stem+cells+and+the+tumor+niche&doi=10.1080%2F08830185.2019.1669593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Stem Cells Targeting; the Lessons from the Interaction of the Immune System, the Cancer Stem Cells and the Tumor Niche</span></div><div class="casAuthors">Rajayi, Hajar; Tavasolian, Parsova; Rezalotfi, Alaleh; Ebrahimi, Marzieh</div><div class="citationInfo"><span class="NLM_cas:title">International Reviews of Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">267-283</span>CODEN:
                <span class="NLM_cas:coden">IRIMEH</span>;
        ISSN:<span class="NLM_cas:issn">0883-0185</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Failure of treatment strategies against cancers is major issue engaging many scientists to investigate the possible resistance factors.  Cancer stem cells (CSCs) subvert promising therapeutic methods by developing resistant cancers.  These pluripotent cells are located in individual microenvironments called cancer niche.  CSCs affect the immune cells and on the flip side, the immune cells in the cancer niche influence them.  Thereby, the interaction between CSCs and immune cells in cancer niche needs to be clearly studied in order to develop novel efficient methods of immune-based cancer treatment.  In this article, we review literature about the suggested methods of CSC escape from immune responses and the effect of cancer niche characteristics on the ability of CSCs to develop resistant strains of cancers.  Moreover, we discuss immune-mediated tumor targeting methods and bring in trials focused on CSC targeted therapies.  We aim to help physicians to reach a consensus about using CSC-targeted immunotherapy methods and emerge novel immunotherapy methods through disrupting the interaction between immune cells and CSCs in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlyJI0t88sQLVg90H21EOLACvtfcHk0lgYfRKfsAdEnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSiu73M&md5=75c96b20df4a4c26fea5dc2548f66e9e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1080%2F08830185.2019.1669593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F08830185.2019.1669593%26sid%3Dliteratum%253Aachs%26aulast%3DRajayi%26aufirst%3DH.%26aulast%3DTavasolian%26aufirst%3DP.%26aulast%3DRezalotfi%26aufirst%3DA.%26aulast%3DEbrahimi%26aufirst%3DM.%26atitle%3DCancer%2520stem%2520cells%2520targeting%253B%2520the%2520lessons%2520from%2520the%2520interaction%2520of%2520the%2520immune%2520system%252C%2520the%2520cancer%2520stem%2520cells%2520and%2520the%2520tumor%2520niche%26jtitle%3DInt.%2520Rev.%2520Immunol.%26date%3D2019%26volume%3D38%26spage%3D267%26epage%3D283%26doi%3D10.1080%2F08830185.2019.1669593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoque, M. O.</span></span> <span> </span><span class="NLM_article-title">Targeting cancer stem cells: a strategy for effective eradication of cancer</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">732</span>, <span class="refDoi"> DOI: 10.3390/cancers11050732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcancers11050732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitV2mur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=732&author=M.+Shibataauthor=M.+O.+Hoque&title=Targeting+cancer+stem+cells%3A+a+strategy+for+effective+eradication+of+cancer&doi=10.3390%2Fcancers11050732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer stem cells: a strategy for effective eradication of cancer</span></div><div class="casAuthors">Shibata, Masahiro; Hoque, Mohammad Obaidul</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">732</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are subpopulations of tumor cells with the ability to self-renew, differentiate, and initiate and maintain tumor growth, and they are considered to be the main drivers of intra- and inter-tumoral heterogeneity.  While conventional chemotherapy can eradicate the majority of non-CSC tumor cells, CSCs are often drug-resistant, leading to tumor recurrence and metastasis.  The heterogeneity of CSCs is the main challenge in developing CSC-targeting therapy; therefore, we and other investigators have focused on developing novel therapeutic strategies that combine conventional chemotherapy with inhibitors of CSC-regulating pathways.  Encouraging preclin. findings have suggested that CSC pathway blockade can indeed enhance cellular sensitivity to non-targeted conventional therapy, and this work has led to several ongoing clin. trials of CSC pathway inhibitors.  Our studies in bladder cancer and lung adenocarcinoma have demonstrated a crucial role of YAP1, a transcriptional regulator of genes that promote cell survival and proliferation, in regulating CSC phenotypes.  Moreover, using cell lines and patient-derived xenograft models, we showed that inhibition of YAP1 enhances the efficacy of conventional therapies by attenuating CSC stemness features.  In this review, we summarize the therapeutic strategies for targeting CSCs in several cancers and discuss the potential and challenges of the approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxzejZFp2WPrVg90H21EOLACvtfcHk0ljt-zokhjTXNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitV2mur4%253D&md5=dd913083e1567dfdb7ca4c4dc83101ac</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.3390%2Fcancers11050732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11050732%26sid%3Dliteratum%253Aachs%26aulast%3DShibata%26aufirst%3DM.%26aulast%3DHoque%26aufirst%3DM.%2BO.%26atitle%3DTargeting%2520cancer%2520stem%2520cells%253A%2520a%2520strategy%2520for%2520effective%2520eradication%2520of%2520cancer%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26spage%3D732%26doi%3D10.3390%2Fcancers11050732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jangili, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. S.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">7856</span>– <span class="NLM_lpage">7878</span>, <span class="refDoi"> DOI: 10.1039/D0CS00379D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1039%2FD0CS00379D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32633291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlagur3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2020&pages=7856-7878&author=J.+Hanauthor=M.+Wonauthor=J.+H.+Kimauthor=E.+Jungauthor=K.+Minauthor=P.+Jangiliauthor=J.+S.+Kim&title=Cancer+stem+cell-targeted+bio-imaging+and+chemotherapeutic+perspective&doi=10.1039%2FD0CS00379D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective</span></div><div class="casAuthors">Han, Jiyou; Won, Miae; Kim, Ji Hyeon; Jung, Eugeine; Min, Kyungim; Jangili, Paramesh; Kim, Jong Seung</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7856-7878</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs), also called tumor-initiating cells (TICs), have been studied intensively due to their rapid proliferation, migration, and role in the recurrence of cancer.  In general, CSC marker-pos. cells [CD133, CD44, CD166, aldehyde dehydrogenase (ALDH), and epithelial cell adhesion mol. (EpCAM)] exhibit a 100-fold increased capacity to initiate cancer.  Within a heterogeneous tumor mass, only approx. 0.05-3% of cells are suspected to be CSCs and able to proliferate under hypoxia.  Interestingly, CSCs, cancer cells, and normal stem cells share many cytochem. properties, such as inhibition of the redox system for reactive oxygen species (ROS) prodn. and high expression of drug resistance transporters.  However, compared to normal stem cells, CSCs develop unique metabolic flexibility, which involves switching between oxidative phosphorylation (OXPHOS) and glycolysis as their main source of energy.  Due to the similarities between CSCs and other cancer cells and normal stem cells, limited chemotherapeutic and bio-imaging reagents specific for CSCs have been developed.  In this short review, we address the current knowledge regarding CSCs with a focus on designing chemotherapeutic and bio-imaging reagents that target CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsMTmA_W7FdrVg90H21EOLACvtfcHk0ljt-zokhjTXNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlagur3N&md5=791fe87c313aea6f695e8368195ed4af</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1039%2FD0CS00379D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0CS00379D%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DWon%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DJung%26aufirst%3DE.%26aulast%3DMin%26aufirst%3DK.%26aulast%3DJangili%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DJ.%2BS.%26atitle%3DCancer%2520stem%2520cell-targeted%2520bio-imaging%2520and%2520chemotherapeutic%2520perspective%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2020%26volume%3D49%26spage%3D7856%26epage%3D7878%26doi%3D10.1039%2FD0CS00379D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zu, X.</span></span> <span> </span><span class="NLM_article-title">Self-renewal signalling pathway inhibitors: perspectives on therapeutic approaches for cancer stem cells</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.2147/OTT.S224465</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.2147%2FOTT.S224465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32021295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVWlsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=525-540&author=Q.+Zhuauthor=Y.+Shenauthor=X.+Chenauthor=J.+Heauthor=J.+Liuauthor=X.+Zu&title=Self-renewal+signalling+pathway+inhibitors%3A+perspectives+on+therapeutic+approaches+for+cancer+stem+cells&doi=10.2147%2FOTT.S224465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Self-renewal signalling pathway inhibitors: perspectives on therapeutic approaches for cancer stem cells</span></div><div class="casAuthors">Zhu, Qingyun; Shen, Yingying; Chen, Xiguang; He, Jun; Liu, Jianghua; Zu, Xuyu</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">525-540</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The poor survival and prognosis of individuals with cancer are often attributed to tumor relapse and metastasis, which may be due to the presence of cancer stem cells (CSCs).  CSCs have the characteristics of self-renewal, differentiation potential, high carcinogenicity, and drug resistance.  In addn., CSCs exhibit many characteristics similar to those of embryonic or tissue stem cells while displaying persistent abnormal activation of self-renewal pathways assocd. with development and tissue homeostasis, including the Wnt, Notch, Hedgehog (Hh), TGF-β, JAK/STAT3, and NF-κB pathways.  Therefore, we can eliminate CSCs by targeting these self-renewal pathways to constrain stem cell replication, survival and differentiation.  At the same time, we cannot neglect the ping-pong effect of the tumor microenvironment, which releases cytokines and promotes self-renewal pathways in CSCs.  Recently, meaningful progress has been made in the study of inhibitors of self-renewal pathways in tumors.  This review primarily summarizes several representative and novel agents targeting these self-renewal signalling pathways and the tumor microenvironment and that represent a promising strategy for treating refractory and recurrent cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7b-ZkJAj6F7Vg90H21EOLACvtfcHk0ljt-zokhjTXNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVWlsbrN&md5=7dedc038b7491b9b017c927236c51bf7</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2147%2FOTT.S224465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S224465%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZu%26aufirst%3DX.%26atitle%3DSelf-renewal%2520signalling%2520pathway%2520inhibitors%253A%2520perspectives%2520on%2520therapeutic%2520approaches%2520for%2520cancer%2520stem%2520cells%26jtitle%3DOncoTargets%2520Ther.%26date%3D2020%26volume%3D13%26spage%3D525%26epage%3D540%26doi%3D10.2147%2FOTT.S224465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span> <span> </span><span class="NLM_article-title">Current advance of therapeutic agents in clinical trials potentially targeting tumor plasticity</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">887</span>, <span class="refDoi"> DOI: 10.3389/fonc.2019.00887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffonc.2019.00887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31552191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvVKhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=887&author=X.+G.+Yangauthor=L.+C.+Zhuauthor=Y.+J.+Wangauthor=Y.+Y.+Liauthor=D.+Wang&title=Current+advance+of+therapeutic+agents+in+clinical+trials+potentially+targeting+tumor+plasticity&doi=10.3389%2Ffonc.2019.00887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity</span></div><div class="casAuthors">Yang Xiao-Guang; Zhu Lan-Cao; Wang Yan-Jun; Li Yan-Yu; Wang Dun</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">887</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Tumor plasticity refers to tumor cell's inherent property of transforming one type of cell to different types of cells.  Tumor plasticity is the main cause of tumor relapse, metastasis and drug resistance.  Cancer stem cell (CSC) model embodies the trait of tumor plasticity.  During carcinoma progression, epithelial-mesenchymal transition (EMT) plays crucial role in the formation of CSCs and vasculogenic mimicry (VM) based on epithelial-mesenchymal plasticity.  And the unique tumor microenvironment (TME) not only provides suitable niche for CSCs but promotes the building of CSCs and VM that nourishes tumor tissue together with neoplasm metabolism by affecting tumor plasticity.  Therapeutic strategies targeting tumor plasticity are promising ways to treat malignant tumor.  In this article, we discuss the recent developments of potential drug targets related to CSCs, EMT, TME, VM, and metabolic pathways and summarize drugs that target these areas in clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSSH6BJPImEXQvupmecNw_lfW6udTcc2eZyo27UFpGur7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvVKhsA%253D%253D&md5=ca4f0603b062b3a9a8489c48496c5ed2</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2019.00887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2019.00887%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%2BG.%26aulast%3DZhu%26aufirst%3DL.%2BC.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BY.%26aulast%3DWang%26aufirst%3DD.%26atitle%3DCurrent%2520advance%2520of%2520therapeutic%2520agents%2520in%2520clinical%2520trials%2520potentially%2520targeting%2520tumor%2520plasticity%26jtitle%3DFront.%2520Oncol.%26date%3D2019%26volume%3D9%26spage%3D887%26doi%3D10.3389%2Ffonc.2019.00887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerson, S. L.</span></span> <span> </span><span class="NLM_article-title">Concise reviews: cancer stem cell targeted therapies: toward clinical success</span>. <i>Stem Cells Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1002/sctm.18-0123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fsctm.18-0123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30328686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3cvgtV2iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=75-81&author=A.+Desaiauthor=Y.+Yanauthor=S.+L.+Gerson&title=Concise+reviews%3A+cancer+stem+cell+targeted+therapies%3A+toward+clinical+success&doi=10.1002%2Fsctm.18-0123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success</span></div><div class="casAuthors">Desai Amar; Yan Yan; Gerson Stanton L; Desai Amar; Yan Yan; Gerson Stanton L</div><div class="citationInfo"><span class="NLM_cas:title">Stem cells translational medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-81</span>
        ISSN:<span class="NLM_cas:issn">2157-6564</span>.
    </div><div class="casAbstract">Cancer stem cells (CSCs) are a subpopulation of cells within tumors that possess the stem cell characteristics of self-renewal, quiescence, differentiation, and the ability to recapitulate the parental tumor when transplanted into a host.  CSCs are correlated with poor clinical outcome due to their contribution to chemotherapy resistance and metastasis.  Multiple cell surface and enzymatic markers have been characterized to identify CSCs within a heterogeneous tumor, and here we summarize ongoing preclinical and clinical efforts to therapeutically target these cells and improve patient outcomes.  Stem Cells Translational Medicine 2019;8:75-81.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRakWyb4NBDdQ20zIbnCCI3fW6udTcc2eYfQbse-2JbwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvgtV2iug%253D%253D&md5=abff02751ed183315ebab6ddc9994752</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Fsctm.18-0123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsctm.18-0123%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DA.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DGerson%26aufirst%3DS.%2BL.%26atitle%3DConcise%2520reviews%253A%2520cancer%2520stem%2520cell%2520targeted%2520therapies%253A%2520toward%2520clinical%2520success%26jtitle%3DStem%2520Cells%2520Transl.%2520Med.%26date%3D2019%26volume%3D8%26spage%3D75%26epage%3D81%26doi%3D10.1002%2Fsctm.18-0123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Cortellis</span> <span> </span><span class="NLM_article-title">Drug Discovery Intelligence</span>. <span class="NLM_publisher-name">Clarivate Analytics</span>, <span class="NLM_year">2020</span>. <a href="http://cortellis.com/drugdiscovery/home?locale=en-US" class="extLink">http://cortellis.com/drugdiscovery/home?locale=en-US</a> (accessed
2020-07-27).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Cortellis&title=Drug+Discovery+Intelligence"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DDrug%2520Discovery%2520Intelligence%26pub%3DClarivate%2520Analytics%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naujokat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, D. L.</span></span> <span> </span><span class="NLM_article-title">The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.2174/0929867327666200228110738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.2174%2F0929867327666200228110738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32107991" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=C.+Naujokatauthor=D.+L.+McKee&title=The+%E2%80%9CBig+Five%E2%80%9D+Phytochemicals+Targeting+Cancer+Stem+Cells%3A+Curcumin%2C+EGCG%2C+Sulforaphane%2C+Resveratrol+and+Genistein&doi=10.2174%2F0929867327666200228110738"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2174%2F0929867327666200228110738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867327666200228110738%26sid%3Dliteratum%253Aachs%26aulast%3DNaujokat%26aufirst%3DC.%26aulast%3DMcKee%26aufirst%3DD.%2BL.%26atitle%3DThe%2520%25E2%2580%259CBig%2520Five%25E2%2580%259D%2520Phytochemicals%2520Targeting%2520Cancer%2520Stem%2520Cells%253A%2520Curcumin%252C%2520EGCG%252C%2520Sulforaphane%252C%2520Resveratrol%2520and%2520Genistein%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.2174%2F0929867327666200228110738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liskova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubatka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlyncek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Büsselberg, D.</span></span> <span> </span><span class="NLM_article-title">Dietary phytochemicals targeting cancer stem cells</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">899</span>, <span class="refDoi"> DOI: 10.3390/molecules24050899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fmolecules24050899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos1elsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=899&author=A.+Liskovaauthor=P.+Kubatkaauthor=M.+Samecauthor=P.+Zuborauthor=M.+Mlyncekauthor=T.+Bielikauthor=S.+M.+Samuelauthor=A.+Zulliauthor=T.+K.+Kwonauthor=D.+B%C3%BCsselberg&title=Dietary+phytochemicals+targeting+cancer+stem+cells&doi=10.3390%2Fmolecules24050899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Dietary phytochemicals targeting cancer stem cells</span></div><div class="casAuthors">Liskova, Alena; Kubatka, Peter; Samec, Marek; Zubor, Pavol; Mlyncek, Milos; Bielik, Tibor; Samuel, Samson Mathews; Zulli, Anthony; Kwon, Taeg Kyu; Buesselberg, Dietrich</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">899/1-899/19</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  There is an increasing awareness of the importance of a diet rich in fruits and vegetables for human health.  Cancer stem cells (CSCs) are characterized as a subpopulation of cancer cells with aberrant regulation of self-renewal, proliferation or apoptosis leading to cancer progression, invasiveness, metastasis formation, and therapy resistance.  Anticancer effects of phytochems. are also directed to target CSCs.  Here we provide a comprehensive review of dietary phytochems. targeting CSCs.  Moreover, we evaluate and summarize studies dealing with effects of dietary phytochems. on CSCs of various malignancies in preclin. and clin. research.  Dietary phytochems. have a significant impact on CSCs which may be applied in cancer prevention and treatment.  However, anticancer effects of plant derived compds. have not yet been fully investigated in clin. research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovgRRecCNC07Vg90H21EOLACvtfcHk0lgDsP__jBqU3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos1elsbw%253D&md5=70c9a31d603166936c01cb5a789a7108</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24050899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24050899%26sid%3Dliteratum%253Aachs%26aulast%3DLiskova%26aufirst%3DA.%26aulast%3DKubatka%26aufirst%3DP.%26aulast%3DSamec%26aufirst%3DM.%26aulast%3DZubor%26aufirst%3DP.%26aulast%3DMlyncek%26aufirst%3DM.%26aulast%3DBielik%26aufirst%3DT.%26aulast%3DSamuel%26aufirst%3DS.%2BM.%26aulast%3DZulli%26aufirst%3DA.%26aulast%3DKwon%26aufirst%3DT.%2BK.%26aulast%3DB%25C3%25BCsselberg%26aufirst%3DD.%26atitle%3DDietary%2520phytochemicals%2520targeting%2520cancer%2520stem%2520cells%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D899%26doi%3D10.3390%2Fmolecules24050899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giglioli-Guivarc’h, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbasi, B. H.</span></span> <span> </span><span class="NLM_article-title">Mechanistic evaluation of phytochemicals in breast cancer remedy: current understanding and future perspectives</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">29714</span>– <span class="NLM_lpage">29744</span>, <span class="refDoi"> DOI: 10.1039/C8RA04879G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1039%2FC8RA04879G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFGlsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=29714-29744&author=M.+Younasauthor=C.+Hanoauthor=N.+Giglioli-Guivarc%E2%80%99hauthor=B.+H.+Abbasi&title=Mechanistic+evaluation+of+phytochemicals+in+breast+cancer+remedy%3A+current+understanding+and+future+perspectives&doi=10.1039%2FC8RA04879G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic evaluation of phytochemicals in breast cancer remedy: current understanding and future perspectives</span></div><div class="casAuthors">Younas, Muhammad; Hano, Christophe; Giglioli-Guivarc'h, Nathalie; Abbasi, Bilal Haider</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">29714-29744</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Breast cancer is one of the most commonly diagnosed cancers around the globe and accounts for a large proportion of fatalities in women.  Despite the advancement in therapeutic and diagnostic procedures, breast cancer still represents a major challenge.  Current anti-breast cancer approaches include surgical removal, radiotherapy, hormonal therapy and the use of various chemotherapeutic drugs.  However, drug resistance, assocd. serious adverse effects, metastasis and recurrence complications still need to be resolved which demand safe and alternative strategies.  In this scenario, phytochems. have recently gained huge attention due to their safety profile and cost-effectiveness.  These phytochems. modulate various genes, gene products and signalling pathways, thereby inhibiting breast cancer cell proliferation, invasion, angiogenesis and metastasis and inducing apoptosis.  Moreover, they also target breast cancer stem cells and overcome drug resistance problems in breast carcinomas.  Phytochems. as adjuvants with chemotherapeutic drugs have greatly enhanced their therapeutic efficacy.  This review focuses on the recently recognized mol. mechanisms underlying breast cancer chemoprevention with the use of phytochems. such as curcumin, resveratrol, silibinin, genistein, epigallocatechin gallate, secoisolariciresinol, thymoquinone, kaempferol, quercetin, parthenolide, sulforaphane, ginsenosides, naringenin, isoliquiritigenin, luteolin, benzyl isothiocyanate, α-mangostin, 3,3'-diindolylmethane, pterostilbene, vinca alkaloids and apigenin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFvkmoCMvmIrVg90H21EOLACvtfcHk0lg_NVPmE3DzAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFGlsb3O&md5=41e77c9e49bb5789b3dd1365637411a6</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1039%2FC8RA04879G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8RA04879G%26sid%3Dliteratum%253Aachs%26aulast%3DYounas%26aufirst%3DM.%26aulast%3DHano%26aufirst%3DC.%26aulast%3DGiglioli-Guivarc%25E2%2580%2599h%26aufirst%3DN.%26aulast%3DAbbasi%26aufirst%3DB.%2BH.%26atitle%3DMechanistic%2520evaluation%2520of%2520phytochemicals%2520in%2520breast%2520cancer%2520remedy%253A%2520current%2520understanding%2520and%2520future%2520perspectives%26jtitle%3DRSC%2520Adv.%26date%3D2018%26volume%3D8%26spage%3D29714%26epage%3D29744%26doi%3D10.1039%2FC8RA04879G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Löcken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clamor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span> <span> </span><span class="NLM_article-title">Napabucasin and related heterocycle-fused naphthoquinones as STAT3 inhibitors with antiproliferative activity against cancer cells</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">1636</span>– <span class="NLM_lpage">1644</span>, <span class="refDoi"> DOI: 10.1021/acs.jnatprod.8b00247</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.8b00247" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FnslKisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=1636-1644&author=H.+L%C3%B6ckenauthor=C.+Clamorauthor=K.+M%C3%BCller&title=Napabucasin+and+related+heterocycle-fused+naphthoquinones+as+STAT3+inhibitors+with+antiproliferative+activity+against+cancer+cells&doi=10.1021%2Facs.jnatprod.8b00247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells</span></div><div class="casAuthors">Locken Hauke; Clamor Cinzia; Muller Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of natural products</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1636-1644</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Napabucasin (6) and its angularly anellated isomer (7), for which the synthesis is described, together with related plant-derived naphthoquinones, were evaluated in vitro against human breast cancer (MDA-MB-231) and chronic myelogenous leukemia (K562) cells.  As observed for β-lapachone (3), the active naphthoquinones all induced apoptosis in a cell-cycle-independent fashion.  In contrast to the pyran-fused β-lapachone (3), however, the most potent furan-fused naphthoquinones were able to redox cycle and generate superoxide in cell-based assays, which was independent of NAD(P)H:quinone oxido-reductase 1.  In a homogeneous time-resolved fluorescence (HTRF) assays with MDA-MB-231 cells, both napabucasin (6) and isonapabucasin (7) were identified as targeting STAT3 phosphorylation.  In addition, drug affinity responsive target stability assays were performed to validate a direct interaction of the naphthoquinones with STAT3.  Isonapabucasin (7) turned out to be twice as potent against STAT3 as napabucasin (6) in the HTRF assay, with an EC50 in the submicromolar range, which was in excellent agreement with the potency of both agents to inhibit the growth of MDA-MB-231 cells.  Moreover, molecular docking experiments predicted different binding modes to the STAT3 SH2 domain for the linearly anellated napabucasin (6) and its angularly anellated isomer (7).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSQACUhahgsEEgZCMqtRBifW6udTcc2ea9_0FTYZ0B5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FnslKisw%253D%253D&md5=f7b8eca5ba22354ee3c13457409262f4</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.8b00247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.8b00247%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6cken%26aufirst%3DH.%26aulast%3DClamor%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DNapabucasin%2520and%2520related%2520heterocycle-fused%2520naphthoquinones%2520as%2520STAT3%2520inhibitors%2520with%2520antiproliferative%2520activity%2520against%2520cancer%2520cells%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2018%26volume%3D81%26spage%3D1636%26epage%3D1644%26doi%3D10.1021%2Facs.jnatprod.8b00247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Froeling, F. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swamynathan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschênes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chio, I. I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosnan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alagesan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotman, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belleau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogoff, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D. A.</span></span> <span> </span><span class="NLM_article-title">Bioactivation of napabucasin triggers reactive oxygen species-mediated cancer cell death</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">7162</span>– <span class="NLM_lpage">7174</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-0302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1158%2F1078-0432.CCR-19-0302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31527169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslWitLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=7162-7174&author=F.+E.+M.+Froelingauthor=M.+M.+Swamynathanauthor=A.+Desch%C3%AAnesauthor=I.+I.+C.+Chioauthor=E.+Brosnanauthor=M.+A.+Yaoauthor=P.+Alagesanauthor=M.+Lucitoauthor=J.+Liauthor=A.+Y.+Changauthor=L.+C.+Trotmanauthor=P.+Belleauauthor=Y.+Parkauthor=H.+A.+Rogoffauthor=J.+D.+Watsonauthor=D.+A.+Tuveson&title=Bioactivation+of+napabucasin+triggers+reactive+oxygen+species-mediated+cancer+cell+death&doi=10.1158%2F1078-0432.CCR-19-0302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactivation of napabucasin triggers reactive oxygen species-mediated cancer cell death</span></div><div class="casAuthors">Froeling, Fieke E. M.; Swamynathan, Manojit Mosur; Deschenes, Astrid; Chio, Iok In Christine; Brosnan, Erin; Yao, Melissa A.; Alagesan, Priya; Lucito, Matthew; Li, Juying; Chang, An-Yun; Trotman, Lloyd C.; Belleau, Pascal; Park, Youngkyu; Rogoff, Harry A.; Watson, James D.; Tuveson, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7162-7174</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Napabucasin (2-acetylfuro-1,4-naphthoquinone or BBI-608) is a small mol. currently being clin. evaluated in various cancer types.  It has mostly been recognized for its ability to inhibit STAT3 signaling.  However, based on its chem. structure, we hypothesized that napabucasin is a substrate for intracellular oxidoreductases and therefore may exert its anticancer effect through redox cycling, resulting in reactive oxygen species (ROS) prodn. and cell death.  Exptl. Design: Binding of napabucasin to NAD(P)H:quinone oxidoreductase-1 (NQO1), and other oxidoreductases, was measured.  Pancreatic cancer cell lines were treated with napabucasin, and cell survival, ROS generation, DNA damage, transcriptomic changes, and alterations in STAT3 activation were assayed in vitro and in vivo.  Genetic knockout or pharmacol. inhibition with dicoumarol was used to evaluate the dependency on NQO1.  Results: Napabucasin was found to bind with high affinity to NQO1 and to a lesser degree to cytochrome P 450 oxidoreductase (POR).  Treatment resulted in marked induction of ROS and DNA damage with an NQO1- and ROS-dependent decrease in STAT3 phosphorylation.  Differential cytotoxic effects were obsd., where NQO1-expressing cells generating cytotoxic levels of ROS at low napabucasin concns. were more sensitive.  Cells with low or no baseline NQO1 expression also produced ROS in response to napabucasin, albeit to a lesser extent, through the one-electron reductase POR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobkyO7Js1b7LVg90H21EOLACvtfcHk0lg_NVPmE3DzAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslWitLvN&md5=f2bbfdc3e8673c095f1118e361e6f81d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-0302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-0302%26sid%3Dliteratum%253Aachs%26aulast%3DFroeling%26aufirst%3DF.%2BE.%2BM.%26aulast%3DSwamynathan%26aufirst%3DM.%2BM.%26aulast%3DDesch%25C3%25AAnes%26aufirst%3DA.%26aulast%3DChio%26aufirst%3DI.%2BI.%2BC.%26aulast%3DBrosnan%26aufirst%3DE.%26aulast%3DYao%26aufirst%3DM.%2BA.%26aulast%3DAlagesan%26aufirst%3DP.%26aulast%3DLucito%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DA.%2BY.%26aulast%3DTrotman%26aufirst%3DL.%2BC.%26aulast%3DBelleau%26aufirst%3DP.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DRogoff%26aufirst%3DH.%2BA.%26aulast%3DWatson%26aufirst%3DJ.%2BD.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26atitle%3DBioactivation%2520of%2520napabucasin%2520triggers%2520reactive%2520oxygen%2520species-mediated%2520cancer%2520cell%2520death%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D7162%26epage%3D7174%26doi%3D10.1158%2F1078-0432.CCR-19-0302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogoff, H. A.</span></span> <span> </span><span class="NLM_article-title">Evaluation of tumor cell-tumor microenvironment component interactions as potential predictors of patient response to napabucasin</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1429</span>– <span class="NLM_lpage">1434</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-18-1242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1158%2F1541-7786.MCR-18-1242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31043490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1KjsL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=1429-1434&author=A.+Y.+Changauthor=E.+Hsuauthor=J.+Patelauthor=Y.+Liauthor=M.+Zhangauthor=H.+Iguchiauthor=H.+A.+Rogoff&title=Evaluation+of+tumor+cell-tumor+microenvironment+component+interactions+as+potential+predictors+of+patient+response+to+napabucasin&doi=10.1158%2F1541-7786.MCR-18-1242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of tumor cell-tumor microenvironment component interactions as potential predictors of patient response to napabucasin</span></div><div class="casAuthors">Chang, An-Yun; Hsu, Eric; Patel, Jaimin; Li, Yiqun; Zhang, Minjie; Iguchi, Haruhisa; Rogoff, Harry A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1429-1434</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Napabucasin is an NAD(P)H:quinone oxidoreductase 1 (NQO1)-bioactivatable small mol. hypothesized to affect multiple oncogenic pathways.  In a prespecified, retrospective anal. of the napabucasin phase III CO.23 study, overall survival was longer for napabucasin vs. placebo in patients expressing phosphorylated STAT3 (pSTAT3) in tumor cells and cells of the tumor microenvironment (TME).  We hypothesized that a connection may exist between NQO1 expression in cancer cells and pSTAT3 in tumor cells and the TME.  In 3D spheroid cocultures of cancer cells and cancer-assocd. fibroblasts, the antitumor activity of napabucasin was NQO1 dependent.  The levels of cytokines such as IL6, CXCL10, and GM-CSF were higher in NQO1-pos. vs. NQO1-deleted cocultures.  These differentially secreted cytokines promoted STAT3 phosphorylation in tumor cells and the TME.  NQO1-expressing, napabucasin-sensitive tumor cells can modify tumor cells and the TME to promote STAT3 phosphorylation, suggesting that pSTAT3 may be used to identify a subpopulation of patients who would likely respond to napabucasin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRjLHe-89V9bVg90H21EOLACvtfcHk0liSiJVhb1BAFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1KjsL3O&md5=2788fe3d367fd97f4e1efb447be5d225</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-18-1242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-18-1242%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DA.%2BY.%26aulast%3DHsu%26aufirst%3DE.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DIguchi%26aufirst%3DH.%26aulast%3DRogoff%26aufirst%3DH.%2BA.%26atitle%3DEvaluation%2520of%2520tumor%2520cell-tumor%2520microenvironment%2520component%2520interactions%2520as%2520potential%2520predictors%2520of%2520patient%2520response%2520to%2520napabucasin%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2019%26volume%3D17%26spage%3D1429%26epage%3D1434%26doi%3D10.1158%2F1541-7786.MCR-18-1242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.</span></span> <span> </span><span class="NLM_article-title">Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">289</span>, <span class="refDoi"> DOI: 10.1186/s13046-019-1289-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2Fs13046-019-1289-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31277685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3MzksFOkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=289&author=D.+Hanauthor=T.+Yuauthor=N.+Dongauthor=B.+Wangauthor=F.+Sunauthor=D.+Jiang&title=Napabucasin%2C+a+novel+STAT3+inhibitor+suppresses+proliferation%2C+invasion+and+stemness+of+glioblastoma+cells&doi=10.1186%2Fs13046-019-1289-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56aR"><div class="casContent"><span class="casTitleNuber">56a</span><div class="casTitle"><span class="NLM_cas:atitle">Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells</span></div><div class="casAuthors">Han Dongfeng; Dong Nan; Wang Bo; Sun Fei; Jiang Dehua; Yu Tianfu; Yu Tianfu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">289</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Glioblastoma (GBM) cells with stem cell-like properties are called glioma stem cells (GSCs).  GSCs display highly treatment resistance and are responsible for tumor recurrence.  Napabucasin (BBI608), a novel small molecule inhibitor of STAT3, has been identified to eliminate stemness-like tumor cells in some cancers.  However, the influence of Napabucasin on GBM cells, especially on GSCs, is currently unclear.  In this study, we explored the influence and underlying mechanisms of Napabucasin on GBM cells.  METHODS:  STAT3 expression and its correlation with the glioma grade and patient survival were analyzed using CGGA and TCGA glioma databases.  The influence of Napabucasin on proliferation, stemness, the cell cycle, apoptosis, and invasion of human GBM cell lines U87MG and LN229 was tested by CCK8, EdU incorporation, colony formation, Transwell invasion, and three-dimensional spheroid assays as well as flow cytometry, qPCR, and western blot analysis.  The ability of Napabucasin to inhibit cell proliferation of U87MG tumor xenografts in mice was assessed using a live animal bioluminescence imaging system and immunohistochemistry.  RESULTS:  Napabucasin suppressed the proliferation, colony formation, and invasion of U87MG and LN229 cells.  Furthermore, Napabucasin induced cell cycle arrest and apoptosis.  More importantly, Napabucasin treatment obviously inhibited expression of stemness-associated genes including STAT3 and suppressed the spheroid formation of glioma cells in vitro.  Napabucasin also disrupted the NF-κB signaling pathway via downregulation of RelA (p65).  Finally, glioma growth was effectively impaired by Napabucasin in nude mice bearing intracranial glioma xenografts.  CONCLUSIONS:  Napabucasin treatment may be a novel approach for the treatment of GBM, particularly GSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRIKHLY7Pb48yail4HZd-ifW6udTcc2eYgbnWQR1fzQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzksFOkuw%253D%253D&md5=8a941303a4a70d3ba1400170ab2054ee</span></div><a href="/servlet/linkout?suffix=cit56a&amp;dbid=16384&amp;doi=10.1186%2Fs13046-019-1289-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-019-1289-6%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DDong%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DD.%26atitle%3DNapabucasin%252C%2520a%2520novel%2520STAT3%2520inhibitor%2520suppresses%2520proliferation%252C%2520invasion%2520and%2520stemness%2520of%2520glioblastoma%2520cells%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D38%26spage%3D289%26doi%3D10.1186%2Fs13046-019-1289-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit56b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cafferkey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, I.</span></span> <span> </span><span class="NLM_article-title">Novel STAT 3 inhibitors for treating gastric cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1031</span>, <span class="refDoi"> DOI: 10.1080/13543784.2016.1195807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1080%2F13543784.2016.1195807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=27322026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVekurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=1023-1031&author=C.+Cafferkeyauthor=I.+Chau&title=Novel+STAT+3+inhibitors+for+treating+gastric+cancer&doi=10.1080%2F13543784.2016.1195807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56bR"><div class="casContent"><span class="casTitleNuber">56b</span><div class="casTitle"><span class="NLM_cas:atitle">Novel STAT 3 inhibitors for treating gastric cancer</span></div><div class="casAuthors">Cafferkey, Catherine; Chau, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1023-1031</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Advanced gastric cancer has a poor prognosis, with a median survival of approx. 12 mo.  There is a continued need to explore the use of novel treatments for this disease.  STAT3 inhibitors are under evaluation in a no. of early phase trials, some showing promise in gastric cancer.  This article explores the role of STAT 3 in gastric cancer and highlights some early phase clin. trials on STAT3 inhibition.  The STAT3 protein and signalling pathway are discussed.  STAT3 in the pathogenesis of gastric cancer is reviewed; pre-clin. data on the role of STAT3 in the development of cancer is presented together with early and emerging data on STAT3 inhibitors under investigation in the clin. setting.  In this review, the authors searched PubMed, clinicaltrials.gov and ASCO abstrs. on STAT3 inhibitors, focusing on trials recruiting gastric cancer patients.  Activated STAT3 in gastric cancer is correlated with poor survival.  It plays a crit. role in regulating tumor growth and metastases.  STAT3 inhibitors are emerging as an interesting drug in gastric cancer.  However, trials utilizing these agents remain in their early phase with one agent currently under evaluation in the phase III setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOJe8WolbYlbVg90H21EOLACvtfcHk0liSiJVhb1BAFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVekurvL&md5=abbe6909fd28a5f6ea39a6c5c8aff43d</span></div><a href="/servlet/linkout?suffix=cit56b&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1195807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1195807%26sid%3Dliteratum%253Aachs%26aulast%3DCafferkey%26aufirst%3DC.%26aulast%3DChau%26aufirst%3DI.%26atitle%3DNovel%2520STAT%25203%2520inhibitors%2520for%2520treating%2520gastric%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D1023%26epage%3D1031%26doi%3D10.1080%2F13543784.2016.1195807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span> <span> </span><span class="NLM_article-title">Novel activators and small-molecule inhibitors of STAT3 in cancer</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2019.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.cytogfr.2019.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31677966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2hur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2019&pages=10-22&author=L.+Yangauthor=S.+Linauthor=L.+Xuauthor=J.+Linauthor=C.+Zhaoauthor=X.+Huang&title=Novel+activators+and+small-molecule+inhibitors+of+STAT3+in+cancer&doi=10.1016%2Fj.cytogfr.2019.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Novel activators and small-molecule inhibitors of STAT3 in cancer</span></div><div class="casAuthors">Yang, Lehe; Lin, Shichong; Xu, Lingyuan; Lin, Jiayuh; Zhao, Chengguang; Huang, Xiaoying</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-22</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Excessive activation of signal transducer and activator of transcription 3 (STAT3) signaling is obsd. in a subset of many cancers, making activated STAT3 a highly promising potential therapeutic target supported by multiple preclin. and clin. studies.  However, early-phase clin. trials have produced mixed results with STAT3-targeted cancer therapies, revealing substantial complexity to targeting aberrant STAT3 signaling.  This review discusses the diverse mechanisms of oncogenic activation of STAT3, and the small mol. inhibitors of STAT3 in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCBnwMn0yKlrVg90H21EOLACvtfcHk0ljpTn_q9Im1rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2hur7L&md5=f84f806071ba818d9056322425bf4c41</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2019.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2019.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DX.%26atitle%3DNovel%2520activators%2520and%2520small-molecule%2520inhibitors%2520of%2520STAT3%2520in%2520cancer%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2019%26volume%3D49%26spage%3D10%26epage%3D22%26doi%3D10.1016%2Fj.cytogfr.2019.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span> </span><span class="NLM_article-title">Sumitomo
Dainippon Pharma Announces Discontinuation of Phase 3 CanStem111P
Study of Investigational Anti-Cancer Agent Napabucasin in Patients
with Pancreatic Cancer Following Interim Analysis</span>; <span class="NLM_publisher-name">Sumitomo Dainippon Pharma Co., Ltd.</span>, <span class="NLM_year">2019</span>. <a href="https://www.ds-pharma.com/ir/news/2019/20190702.html" class="extLink">https://www.ds-pharma.com/ir/news/2019/20190702.html</a> (accessed
2020-10-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Sumitomo%0ADainippon+Pharma+Announces+Discontinuation+of+Phase+3+CanStem111P%0AStudy+of+Investigational+Anti-Cancer+Agent+Napabucasin+in+Patients%0Awith+Pancreatic+Cancer+Following+Interim+Analysis%3B+Sumitomo+Dainippon+Pharma+Co.%2C+Ltd.%2C+2019.+https%3A%2F%2Fwww.ds-pharma.com%2Fir%2Fnews%2F2019%2F20190702.html+%28accessed%0A2020-10-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DSumitomo%250ADainippon%2520Pharma%2520Announces%2520Discontinuation%2520of%2520Phase%25203%2520CanStem111P%250AStudy%2520of%2520Investigational%2520Anti-Cancer%2520Agent%2520Napabucasin%2520in%2520Patients%250Awith%2520Pancreatic%2520Cancer%2520Following%2520Interim%2520Analysis%26pub%3DSumitomo%2520Dainippon%2520Pharma%2520Co.%252C%2520Ltd%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayres Pereira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chio, I. I. C.</span></span> <span> </span><span class="NLM_article-title">Metastasis in pancreatic ductal adenocarcinoma: current standing and methodologies</span>. <i>Genes</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi"> DOI: 10.3390/genes11010006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fgenes11010006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=6&author=M.+Ayres+Pereiraauthor=I.+I.+C.+Chio&title=Metastasis+in+pancreatic+ductal+adenocarcinoma%3A+current+standing+and+methodologies&doi=10.3390%2Fgenes11010006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.3390%2Fgenes11010006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fgenes11010006%26sid%3Dliteratum%253Aachs%26aulast%3DAyres%2BPereira%26aufirst%3DM.%26aulast%3DChio%26aufirst%3DI.%2BI.%2BC.%26atitle%3DMetastasis%2520in%2520pancreatic%2520ductal%2520adenocarcinoma%253A%2520current%2520standing%2520and%2520methodologies%26jtitle%3DGenes%26date%3D2020%26volume%3D11%26spage%3D6%26doi%3D10.3390%2Fgenes11010006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nott, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalcberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickers, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebbutt, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magoski, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Callaghan, C. J.</span></span> <span> </span><span class="NLM_article-title">Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial</span>. <i>Lancet Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1016/S2468-1253(18)30009-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2FS2468-1253%2818%2930009-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29397354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC1MvntVehtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=263-270&author=D.+J.+Jonkerauthor=L.+Nottauthor=T.+Yoshinoauthor=S.+Gillauthor=J.+Shapiroauthor=A.+Ohtsuauthor=J.+Zalcbergauthor=M.+M.+Vickersauthor=A.+C.+Weiauthor=Y.+Gaoauthor=N.+C.+Tebbuttauthor=B.+Markmanauthor=T.+Priceauthor=T.+Esakiauthor=S.+Koskiauthor=M.+Hitronauthor=W.+Liauthor=Y.+Liauthor=N.+M.+Magoskiauthor=C.+J.+Liauthor=J.+Simesauthor=D.+Tuauthor=C.+J.+O%E2%80%99Callaghan&title=Napabucasin+versus+placebo+in+refractory+advanced+colorectal+cancer%3A+a+randomised+phase+3+trial&doi=10.1016%2FS2468-1253%2818%2930009-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60aR"><div class="casContent"><span class="casTitleNuber">60a</span><div class="casTitle"><span class="NLM_cas:atitle">Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial</span></div><div class="casAuthors">Jonker Derek J; Nott Louise; Yoshino Takayuki; Gill Sharlene; Shapiro Jeremy; Ohtsu Atsushi; Zalcberg John; Vickers Michael M; Wei Alice C; Gao Yuan; Hitron Matthew; Li Wei; Li Youzhi; Tebbutt Niall C; Markman Ben; Price Timothy; Esaki Taito; Koski Sheryl; Magoski Nadine M; Li Chiang J; Simes John; Tu Dongsheng; O'Callaghan Christopher J</div><div class="citationInfo"><span class="NLM_cas:title">The lancet. Gastroenterology & hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263-270</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Napabucasin is a first-in-class cancer stemness inhibitor that targets STAT3, which is a poor prognostic factor in colorectal cancer.  This study aimed to test napabucasin in advanced colorectal cancer.  METHODS:  This study was a double-blind randomised phase 3 trial done at 68 centres in Canada, Australia, New Zealand, and Japan.  Patients with advanced colorectal cancer with a good Eastern Cooperative Oncology Group (ECOG) performance status (0-1) for whom all available standard therapies had failed were eligible for the study.  Patients were randomly assigned (1:1) to receive placebo or napabucasin through a web-based system with a permuted block method, after stratification by ECOG performance status, KRAS status, previous VEGF inhibitor treatment, and time from diagnosis of metastatic disease.  Napabucasin 480 mg or matching placebo was taken orally every 12 h.  All patients received best supportive care.  The primary endpoint was overall survival assessed in an intention-to-treat analysis.  This is the final analysis of this trial, which is registered at ClinicalTrials.gov, number NCT01830621.  FINDINGS:  Accrual began on April 15, 2013, and was stopped for futility on May 23, 2014, at which point 282 patients had undergone randomisation (138 assigned to the napabucasin group and 144 to the placebo group).  Overall survival did not differ significantly between groups: median overall survival was 4·4 months (95% CI 3·7-4·9) in the napabucasin group and 4·8 months (4·0-5·3) in the placebo group (adjusted hazard ratio [HR] 1·13, 95% CI 0·88-1·46, p=0·34).  The safety population included 136 patients in the napabucasin group and 144 patients in the placebo group.  More patients who received napabucasin had any grade of treatment-related diarrhoea (108 [79%] of 136 patients), nausea (69 [51%]), and anorexia (52 [38%]) than did patients who received placebo (28 [19%] of 144 patients, 35 [24%], and 23 [16%], respectively).  The most common severe (grade 3 or worse) treatment-related adverse events were abdominal pain (five [4%] patients receiving napabucasin vs five [3%] receiving placebo), diarrhoea (21 [15%] vs one [1%]), fatigue (14 [10%] vs eight [6%]), and dehydration (six [4%] vs one [1%]). 251 (89%) patients had data on pSTAT3 expression, of whom 55 (22%) had pSTAT3-positive tumours (29 in the napabucasin group, 26 in the placebo group).  In a prespecified biomarker analysis of pSTAT3-positive patients, overall survival was longer in the napabucasin group than in the placebo group (median 5·1 months [95% CI 4·0-7·5] vs 3·0 months [1·7-4·1]; HR 0·41, 0·23-0·73, p=0·0025).  INTERPRETATION:  Although there was no difference in overall survival between groups in the overall unselected population, STAT3 might be an important target for the treatment of colorectal cancer with elevated pSTAT3 expression.  Nevertheless, these results require validation.  FUNDING:  Canadian Cancer Society Research Institute and Boston Biomedical.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuAFfSZrrklxe4jJGKT5N0fW6udTcc2eYFs8WPupeyCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvntVehtQ%253D%253D&md5=8fd56d231a568dfa09655e2cbe8ac20a</span></div><a href="/servlet/linkout?suffix=cit60a&amp;dbid=16384&amp;doi=10.1016%2FS2468-1253%2818%2930009-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2468-1253%252818%252930009-8%26sid%3Dliteratum%253Aachs%26aulast%3DJonker%26aufirst%3DD.%2BJ.%26aulast%3DNott%26aufirst%3DL.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DGill%26aufirst%3DS.%26aulast%3DShapiro%26aufirst%3DJ.%26aulast%3DOhtsu%26aufirst%3DA.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DVickers%26aufirst%3DM.%2BM.%26aulast%3DWei%26aufirst%3DA.%2BC.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DTebbutt%26aufirst%3DN.%2BC.%26aulast%3DMarkman%26aufirst%3DB.%26aulast%3DPrice%26aufirst%3DT.%26aulast%3DEsaki%26aufirst%3DT.%26aulast%3DKoski%26aufirst%3DS.%26aulast%3DHitron%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMagoski%26aufirst%3DN.%2BM.%26aulast%3DLi%26aufirst%3DC.%2BJ.%26aulast%3DSimes%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DC.%2BJ.%26atitle%3DNapabucasin%2520versus%2520placebo%2520in%2520refractory%2520advanced%2520colorectal%2520cancer%253A%2520a%2520randomised%2520phase%25203%2520trial%26jtitle%3DLancet%2520Gastroenterol.%2520Hepatol.%26date%3D2018%26volume%3D3%26spage%3D263%26epage%3D270%26doi%3D10.1016%2FS2468-1253%2818%2930009-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit60b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nott, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalcberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickers, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebbutt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magoski, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Callaghan, C. J.</span></span> <span> </span><span class="NLM_article-title">A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">Suppl. 6</span>),  <span class="NLM_fpage">vi150</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw370.03</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1093%2Fannonc%2Fmdw370.03" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=vi150&issue=Suppl.+6&author=D.+J.+Jonkerauthor=L.+Nottauthor=T.+Yoshinoauthor=S.+Gillauthor=J.+Shapiroauthor=A.+Ohtsuauthor=J.+Zalcbergauthor=M.+M.+Vickersauthor=A.+Weiauthor=Y.+Gaoauthor=N.+Tebbuttauthor=B.+Markmanauthor=T.+Esakiauthor=S.+Koskiauthor=M.+Hitronauthor=N.+M.+Magoskiauthor=J.+Simesauthor=C.+Liauthor=D.+Tuauthor=C.+J.+O%E2%80%99Callaghan&title=A+randomized+phase+III+study+of+napabucasin+%5BBBI608%5D+%28NAPA%29+vs+placebo+%28PBO%29+in+patients+%28pts%29+with+pretreated+advanced+colorectal+cancer+%28ACRC%29%3A+the+CCTG%2FAGITG+CO.23+trial&doi=10.1093%2Fannonc%2Fmdw370.03"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60b&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw370.03&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw370.03%26sid%3Dliteratum%253Aachs%26aulast%3DJonker%26aufirst%3DD.%2BJ.%26aulast%3DNott%26aufirst%3DL.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DGill%26aufirst%3DS.%26aulast%3DShapiro%26aufirst%3DJ.%26aulast%3DOhtsu%26aufirst%3DA.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DVickers%26aufirst%3DM.%2BM.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DTebbutt%26aufirst%3DN.%26aulast%3DMarkman%26aufirst%3DB.%26aulast%3DEsaki%26aufirst%3DT.%26aulast%3DKoski%26aufirst%3DS.%26aulast%3DHitron%26aufirst%3DM.%26aulast%3DMagoski%26aufirst%3DN.%2BM.%26aulast%3DSimes%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DC.%2BJ.%26atitle%3DA%2520randomized%2520phase%2520III%2520study%2520of%2520napabucasin%2520%255BBBI608%255D%2520%2528NAPA%2529%2520vs%2520placebo%2520%2528PBO%2529%2520in%2520patients%2520%2528pts%2529%2520with%2520pretreated%2520advanced%2520colorectal%2520cancer%2520%2528ACRC%2529%253A%2520the%2520CCTG%252FAGITG%2520CO.23%2520trial%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26issue%3DSuppl.%25206%26spage%3Dvi150%26doi%3D10.1093%2Fannonc%2Fmdw370.03" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lordick, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebbutt, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metges, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjulandin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hays, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontaine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodyansky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Cutsem, E.</span></span> <span> </span><span class="NLM_article-title">The BRIGHTER trial: a phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">4010</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.4010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1200%2FJCO.2018.36.15_suppl.4010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=4010&author=M.+A.+Shahauthor=K.+Shitaraauthor=F.+Lordickauthor=Y.-J.+Bangauthor=N.+C.+Tebbuttauthor=J.-P.+Metgesauthor=K.+Muroauthor=L.+Shenauthor=S.+Tjulandinauthor=J.+L.+Haysauthor=R.-h.+Xuauthor=M.+Fontaineauthor=E.+Brooksauthor=B.+Xuauthor=W.+Liauthor=C.+Liauthor=L.+Borodyanskyauthor=E.+Van+Cutsem&title=The+BRIGHTER+trial%3A+a+phase+3+randomized+double-blind+study+of+napabucasin+%28NAPA%29+plus+paclitaxel+%28PTX%29+versus+placebo+%28PBO%29+plus+PTX+in+patients+%28pts%29+with+pretreated+advanced+gastric+and+gastroesophageal+junction+%28GEJ%29+adenocarcinoma&doi=10.1200%2FJCO.2018.36.15_suppl.4010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.4010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.4010%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DM.%2BA.%26aulast%3DShitara%26aufirst%3DK.%26aulast%3DLordick%26aufirst%3DF.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DTebbutt%26aufirst%3DN.%2BC.%26aulast%3DMetges%26aufirst%3DJ.-P.%26aulast%3DMuro%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DTjulandin%26aufirst%3DS.%26aulast%3DHays%26aufirst%3DJ.%2BL.%26aulast%3DXu%26aufirst%3DR.-h.%26aulast%3DFontaine%26aufirst%3DM.%26aulast%3DBrooks%26aufirst%3DE.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DBorodyansky%26aufirst%3DL.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26atitle%3DThe%2520BRIGHTER%2520trial%253A%2520a%2520phase%25203%2520randomized%2520double-blind%2520study%2520of%2520napabucasin%2520%2528NAPA%2529%2520plus%2520paclitaxel%2520%2528PTX%2529%2520versus%2520placebo%2520%2528PBO%2529%2520plus%2520PTX%2520in%2520patients%2520%2528pts%2529%2520with%2520pretreated%2520advanced%2520gastric%2520and%2520gastroesophageal%2520junction%2520%2528GEJ%2529%2520adenocarcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D4010%26doi%3D10.1200%2FJCO.2018.36.15_suppl.4010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawazoe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuboki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bando, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yodo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span> <span> </span><span class="NLM_article-title">Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1007/s00280-020-04059-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1007%2Fs00280-020-04059-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32236642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB383pvVKqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2020&pages=855-862&author=A.+Kawazoeauthor=Y.+Kubokiauthor=H.+Bandoauthor=S.+Fukuokaauthor=T.+Kojimaauthor=Y.+Naitoauthor=S.+Iinoauthor=Y.+Yodoauthor=T.+Doiauthor=K.+Shitaraauthor=T.+Yoshino&title=Phase+1+study+of+napabucasin%2C+a+cancer+stemness+inhibitor%2C+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-020-04059-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors</span></div><div class="casAuthors">Kawazoe Akihito; Kuboki Yasutoshi; Bando Hideaki; Fukuoka Shota; Kojima Takashi; Shitara Kohei; Yoshino Takayuki; Naito Yoichi; Doi Toshihiko; Iino Shuichi; Yodo Yasuhide</div><div class="citationInfo"><span class="NLM_cas:title">Cancer chemotherapy and pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">855-862</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Napabucasin is a cancer stemness inhibitor that targets a number of oncogenic pathways, including signal transducer and activator of transcription 3 (STAT3).  Phase 1/2 studies suggest tolerability and anti-tumor activity in various types of cancer; a Phase 3 study of napabucasin plus standard therapy in colorectal cancer is ongoing.  This is a Phase 1 dose-escalation study in patients with advanced solid tumors, and the first study of napabucasin in Japanese patients.  METHODS:  Patients received napabucasin 480, 960, or 1440 mg daily in 28-day cycles until disease progression or intolerable toxicity.  Primary objectives were to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and the pharmacokinetic (PK) profile of napabucasin.  Blood samples were taken for PK analysis on Days 1, 2, 8, and 15 of Cycle 1, and Days 29 and 30 of Cycle 2.  Secondary objectives were to assess napabucasin antitumor activity, and the relationship between biomarkers and antitumor activity.  JapicCTI-No: JapicCTI-132152.  RESULTS:  Enrolled were 14 patients (480 mg [n = 3], 960 mg [n = 4], 1440 mg [n = 7]).  One patient experienced a DLT (Grade 3, anorexia).  MTD was 1440 mg/day.  Most common drug-related adverse events were diarrhea (n = 9), nausea (n = 4), vomiting (n = 3), and anorexia (n = 3).  Napabucasin showed a similar PK profile to previous studies and no abnormal accumulation was observed.  Following treatment, two patients had stable disease; the remaining 12 had progressive disease.  CONCLUSION:  Napabucasin was well-tolerated at doses up to 1440 mg/day in Japanese patients with advanced solid tumors; the PK profile was comparable to that reported previously.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdA3g6eGVSrhKDYG3bNImrfW6udTcc2eae_Hti3hFftbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383pvVKqtw%253D%253D&md5=ecdfa2f874a69afe545b454d38bed775</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1007%2Fs00280-020-04059-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-020-04059-3%26sid%3Dliteratum%253Aachs%26aulast%3DKawazoe%26aufirst%3DA.%26aulast%3DKuboki%26aufirst%3DY.%26aulast%3DBando%26aufirst%3DH.%26aulast%3DFukuoka%26aufirst%3DS.%26aulast%3DKojima%26aufirst%3DT.%26aulast%3DNaito%26aufirst%3DY.%26aulast%3DIino%26aufirst%3DS.%26aulast%3DYodo%26aufirst%3DY.%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DShitara%26aufirst%3DK.%26aulast%3DYoshino%26aufirst%3DT.%26atitle%3DPhase%25201%2520study%2520of%2520napabucasin%252C%2520a%2520cancer%2520stemness%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2020%26volume%3D85%26spage%3D855%26epage%3D862%26doi%3D10.1007%2Fs00280-020-04059-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span> </span><span class="NLM_article-title">Sumitomo Dainippon Pharma Oncology. Clinical
Trials</span>. <a href="https://www.sdponcology.com/pipeline/clinical-trials/" class="extLink">https://www.sdponcology.com/pipeline/clinical-trials/</a> (accessed 2020-07-26).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Sumitomo+Dainippon+Pharma+Oncology.+Clinical%0ATrials.+https%3A%2F%2Fwww.sdponcology.com%2Fpipeline%2Fclinical-trials%2F+%28accessed+2020-07-26%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DSumitomo%2520Dainippon%2520Pharma%2520Oncology.%2520Clinical%250ATrials" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starodub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitot, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halfdanarson, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadeau, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubkus, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adesunloye, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edenfield, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodyansky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span> <span> </span><span class="NLM_article-title">Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI ± bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3529</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.35.15_suppl.3529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1200%2FJCO.2017.35.15_suppl.3529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=28796588" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=3529&author=J.+C.+Bendellauthor=J.+M.+Hubbardauthor=B.+H.+O%E2%80%99Neilauthor=D.+J.+Jonkerauthor=A.+Starodubauthor=J.+D.+Peytonauthor=H.+C.+Pitotauthor=T.+R.+Halfdanarsonauthor=B.+R.+Nadeauauthor=J.+D.+Zubkusauthor=B.+Adesunloyeauthor=W.+J.+Edenfieldauthor=Y.+Liauthor=W.+Liauthor=A.+Grotheyauthor=L.+Borodyanskyauthor=C.+Li&title=Phase+1b%2FII+study+of+cancer+stemness+inhibitor+napabucasin+%28BBI-608%29+in+combination+with+FOLFIRI+%C2%B1+bevacizumab+%28bev%29+in+metastatic+colorectal+cancer+%28mCRC%29+patients+%28pts%29&doi=10.1200%2FJCO.2017.35.15_suppl.3529"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.3529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.3529%26sid%3Dliteratum%253Aachs%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DHubbard%26aufirst%3DJ.%2BM.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DB.%2BH.%26aulast%3DJonker%26aufirst%3DD.%2BJ.%26aulast%3DStarodub%26aufirst%3DA.%26aulast%3DPeyton%26aufirst%3DJ.%2BD.%26aulast%3DPitot%26aufirst%3DH.%2BC.%26aulast%3DHalfdanarson%26aufirst%3DT.%2BR.%26aulast%3DNadeau%26aufirst%3DB.%2BR.%26aulast%3DZubkus%26aufirst%3DJ.%2BD.%26aulast%3DAdesunloye%26aufirst%3DB.%26aulast%3DEdenfield%26aufirst%3DW.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DGrothey%26aufirst%3DA.%26aulast%3DBorodyansky%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26atitle%3DPhase%25201b%252FII%2520study%2520of%2520cancer%2520stemness%2520inhibitor%2520napabucasin%2520%2528BBI-608%2529%2520in%2520combination%2520with%2520FOLFIRI%2520%25C2%25B1%2520bevacizumab%2520%2528bev%2529%2520in%2520metastatic%2520colorectal%2520cancer%2520%2528mCRC%2529%2520patients%2520%2528pts%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D3529%26doi%3D10.1200%2FJCO.2017.35.15_suppl.3529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starodub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halfdanarson, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edenfield, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Rayes, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitot, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobday, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodyansky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span> <span> </span><span class="NLM_article-title">Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI ± bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">4S</span>),  <span class="NLM_fpage">593</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.35.4_suppl.593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1200%2FJCO.2017.35.4_suppl.593" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=593&issue=4S&author=J.+C.+Bendellauthor=B.+H.+O%E2%80%99Neilauthor=A.+Starodubauthor=D.+J.+Jonkerauthor=T.+R.+Halfdanarsonauthor=W.+J.+Edenfieldauthor=B.+F.+El-Rayesauthor=J.+M.+Hubbardauthor=H.+C.+Pitotauthor=T.+J.+Hobdayauthor=Y.+Liauthor=Y.+Gaoauthor=A.+Grotheyauthor=L.+Borodyanskyauthor=C.+Li&title=Cancer+stemness+inhibition+and+chemosensitization%3A+Phase+1b%2FII+study+of+cancer+stemness+inhibitor+napabucasin+%28BBI-608%29+with+FOLFIRI+%C2%B1+bevacizumab+%28Bev%29+administered+to+colorectal+cancer+%28CRC%29+patients+%28pts%29&doi=10.1200%2FJCO.2017.35.4_suppl.593"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.4_suppl.593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.4_suppl.593%26sid%3Dliteratum%253Aachs%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DB.%2BH.%26aulast%3DStarodub%26aufirst%3DA.%26aulast%3DJonker%26aufirst%3DD.%2BJ.%26aulast%3DHalfdanarson%26aufirst%3DT.%2BR.%26aulast%3DEdenfield%26aufirst%3DW.%2BJ.%26aulast%3DEl-Rayes%26aufirst%3DB.%2BF.%26aulast%3DHubbard%26aufirst%3DJ.%2BM.%26aulast%3DPitot%26aufirst%3DH.%2BC.%26aulast%3DHobday%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGrothey%26aufirst%3DA.%26aulast%3DBorodyansky%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26atitle%3DCancer%2520stemness%2520inhibition%2520and%2520chemosensitization%253A%2520Phase%25201b%252FII%2520study%2520of%2520cancer%2520stemness%2520inhibitor%2520napabucasin%2520%2528BBI-608%2529%2520with%2520FOLFIRI%2520%25C2%25B1%2520bevacizumab%2520%2528Bev%2529%2520administered%2520to%2520colorectal%2520cancer%2520%2528CRC%2529%2520patients%2520%2528pts%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26issue%3D4S%26spage%3D593%26doi%3D10.1200%2FJCO.2017.35.4_suppl.593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span> </span><span class="NLM_article-title">A Study of DSP-0337 in Patients with Advanced
Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
(NCT03416816)</span>. <a href="https://clinicaltrials.gov/show/NCT03416816" class="extLink">https://clinicaltrials.gov/show/NCT03416816</a> (accessed 2020-10-26).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+of+DSP-0337+in+Patients+with+Advanced%0ASolid+Tumors+to+Determine+the+Safety+and+the+Pharmacokinetic+Profile%0A%28NCT03416816%29.+https%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT03416816+%28accessed+2020-10-26%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520of%2520DSP-0337%2520in%2520Patients%2520with%2520Advanced%250ASolid%2520Tumors%2520to%2520Determine%2520the%2520Safety%2520and%2520the%2520Pharmacokinetic%2520Profile%250A%2528NCT03416816%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ban, H.</span>; <span class="NLM_string-name">Kamioka, S.</span>; <span class="NLM_string-name">Sawayama, Y.</span>; <span class="NLM_string-name">Li, C. J.</span></span> <span> </span><span class="NLM_article-title">Substituted Naphtho[2,3-<i>b</i>]furans as Water-Soluble Prodrugs for Preventing and/or Treating Cancer</span>. U.S. Patent <span class="NLM_patent">20190084955 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=H.+Ban&author=S.+Kamioka&author=Y.+Sawayama&author=C.+J.+Li&title=Substituted+Naphtho%5B2%2C3-b%5Dfurans+as+Water-Soluble+Prodrugs+for+Preventing+and%2For+Treating+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBan%26aufirst%3DH.%26atitle%3DSubstituted%2520Naphtho%255B2%252C3-b%255Dfurans%2520as%2520Water-Soluble%2520Prodrugs%2520for%2520Preventing%2520and%252For%2520Treating%2520Cancer%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, Y.</span>; <span class="NLM_string-name">Kasai, M.</span>; <span class="NLM_string-name">Shoji, Y.</span>; <span class="NLM_string-name">Takeda, S.</span></span> <span> </span><span class="NLM_article-title">Anticancer Agent</span>. U.S. Patent <span class="NLM_patent">10,377,730</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Y.+Yoshimura&author=M.+Kasai&author=Y.+Shoji&author=S.+Takeda&title=Anticancer+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYoshimura%26aufirst%3DY.%26atitle%3DAnticancer%2520Agent%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, R. K.</span></span> <span> </span><span class="NLM_article-title">Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e16530</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0016530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1371%2Fjournal.pone.0016530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=21304978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFaht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&author=S.+Shankarauthor=D.+Nallauthor=S.+N.+Tangauthor=D.+Meekerauthor=J.+Passariniauthor=J.+Sharmaauthor=R.+K.+Srivastava&title=Resveratrol+inhibits+pancreatic+cancer+stem+cell+characteristics+in+human+and+KrasG12D+transgenic+mice+by+inhibiting+pluripotency+maintaining+factors+and+epithelial-mesenchymal+transition&doi=10.1371%2Fjournal.pone.0016530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol inhibits pancreatic Cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition</span></div><div class="casAuthors">Shankar, Sharmila; Nall, Dara; Tang, Su-Ni; Meeker, Daniel; Passarini, Jenna; Sharma, Jay; Srivastava, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e16530</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Cancer stem cells (CSCs) can proliferate and self-renew extensively due to their ability to express anti-apoptotic and drug resistant proteins, thus sustaining tumor growth.  Therefore, the strategy to eradicate CSCs might have significant clin. implications.  The objectives of this study were to examine the mol. mechanisms by which resveratrol inhibits stem cell characteristics of pancreatic CSCs derived from human primary tumors and KrasG12D transgenic mice.  Methodol./Principal Findings: Human pancreatic CSCs (CD133+CD44+CD24+ESA+) are highly tumorigenic and form s.c. tumors in NOD/SCID mice.  Human pancreatic CSCs expressing high levels of CD133, CD24, CD44, ESA, and aldehyde dehydrogenase also express significantly more Nanog, Oct-4, Notch1, MDR1 and ABCG2 than normal pancreatic tissues and primary pancreatic cancer cells.  Similarly, CSCs from KrasG12D mice express significantly higher levels of Nanog and Oct-4 than pancreatic tissues from Pdx-Cre mice.  Resveratrol inhibits the growth (size and wt.) and development (PanIN lesions) of pancreatic cancer in KrasG12D mice.  Resveratrol inhibits the self-renewal capacity of pancreatic CSCs derived from human primary tumors and KrasG12D mice.  Resveratrol induces apoptosis by activating capase-3/7 and inhibiting the expression of Bcl-2 and XIAP in human CSCs.  Resveratrol inhibits pluripotency maintaining factors (Nanog, Sox-2, c-Myc and Oct-4) and drug resistance gene ABCG2 in CSCs.  Inhibition of Nanog by shRNA enhances the inhibitory effects of resveratrol on self-renewal capacity of CSCs.  Finally, resveratrol inhibits CSC's migration and invasion and markers of epithelial-mesenchymal transition (Zeb-1, Slug and Snail).  Conclusions/Significance: These data suggest that resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition.  In conclusion, resveratrol can be used for the management of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-ABzxZvwvVrVg90H21EOLACvtfcHk0lh_pm5zCs4Gtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFaht70%253D&md5=b3e94d7e2104d7cdf92daa9510e075aa</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0016530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0016530%26sid%3Dliteratum%253Aachs%26aulast%3DShankar%26aufirst%3DS.%26aulast%3DNall%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DS.%2BN.%26aulast%3DMeeker%26aufirst%3DD.%26aulast%3DPassarini%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DJ.%26aulast%3DSrivastava%26aufirst%3DR.%2BK.%26atitle%3DResveratrol%2520inhibits%2520pancreatic%2520cancer%2520stem%2520cell%2520characteristics%2520in%2520human%2520and%2520KrasG12D%2520transgenic%2520mice%2520by%2520inhibiting%2520pluripotency%2520maintaining%2520factors%2520and%2520epithelial-mesenchymal%2520transition%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26doi%3D10.1371%2Fjournal.pone.0016530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.</span></span> <span> </span><span class="NLM_article-title">Resveratrol eliminates cancer stem cells of osteosarcoma by STAT3 pathway inhibition</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0205918</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0205918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1371%2Fjournal.pone.0205918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30356255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFKnurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=L.+Pengauthor=D.+Jiang&title=Resveratrol+eliminates+cancer+stem+cells+of+osteosarcoma+by+STAT3+pathway+inhibition&doi=10.1371%2Fjournal.pone.0205918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol eliminates cancer stem cells of osteosarcoma by STAT3 pathway inhibition</span></div><div class="casAuthors">Peng, Lihua; Jian, Dianming</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0205918/1-e0205918/13</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Resveratrol shows potent anti-tumor therapeutic properties in various tumors.  However, the exact effect of resveratrol on osteosarcoma cells, esp. cancer stem cells, remains unclear.  In this study, we examd. the effect of resveratrol on osteosarcoma stem cells and explored the underlying mol. mechanisms.  Resveratrol inhibited cell viability, selfrenewal ability and tumorigenesis of osteosarcoma cells, whereas showed no significant inhibition effects to normal osteoblast cells.  Mech., resveratrol treatment decreased cytokines synthesis and inhibited JAK2/STAT3 signaling, which was consistent with the decline of cancer stem cells marker, CD133.  Exogenous STAT3 activation attenuated the cancer stem cell elimination effects of resveratrol treatment.  Our results demonstrated that resveratrol inhibited osteosarcoma cell proliferation and tumorigenesis ability, which was correlated with cytokines inhibition related JAK2/STAT3 signaling blockage.  Resveratrol may be a promising therapeutic agent for osteosarcoma management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozr-eagsmWF7Vg90H21EOLACvtfcHk0liKtqoEGQNlQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFKnurk%253D&md5=0c0e2b525062666d2c03b11cf6a260c3</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0205918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0205918%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DD.%26atitle%3DResveratrol%2520eliminates%2520cancer%2520stem%2520cells%2520of%2520osteosarcoma%2520by%2520STAT3%2520pathway%2520inhibition%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0205918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafabakhsh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzaei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asemi, Z.</span></span> <span> </span><span class="NLM_article-title">Resveratrol is a promising agent for colorectal cancer prevention and treatment: focus on molecular mechanisms</span>. <i>Cancer Cell Int.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">180</span>, <span class="refDoi"> DOI: 10.1186/s12935-019-0906-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2Fs12935-019-0906-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31341423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3MvgvVykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=180&author=M.+Honariauthor=R.+Shafabakhshauthor=R.+J.+Reiterauthor=H.+Mirzaeiauthor=Z.+Asemi&title=Resveratrol+is+a+promising+agent+for+colorectal+cancer+prevention+and+treatment%3A+focus+on+molecular+mechanisms&doi=10.1186%2Fs12935-019-0906-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol is a promising agent for colorectal cancer prevention and treatment: focus on molecular mechanisms</span></div><div class="casAuthors">Honari Mohadese; Shafabakhsh Rana; Mirzaei Hamed; Asemi Zatollah; Reiter Russel J</div><div class="citationInfo"><span class="NLM_cas:title">Cancer cell international</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">180</span>
        ISSN:<span class="NLM_cas:issn">1475-2867</span>.
    </div><div class="casAbstract">Colorectal cancer (CRC) is the third most common cancer and one of the main causes of cancer death entire the world.  Environmental, dietary, and lifestyle factors including red meat consumption, cigarette smoking, alcohol intake and family history are the most important risk factors of CRC.  Multiple pathways including inflammation, oxidative stress, and apoptosis are involved in its incidence and progression.  Resveratrol, a polyphenolic compound, has different pharmacologic functions including anti-inflammation, cancer prevention, lipid-lowering effect, and hypoglycemic effect.  Many studies have proved that resveratrol might also represent a chemo preventive effect on CRC.  Thus, the aim of the current review is to depict the role of resveratrol in treatment of CRC in a molecular manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTULiM37Yxw2Jw7prLlxLOzfW6udTcc2eZ4W--yvFnb8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvgvVykuw%253D%253D&md5=fa841fa9f64f391d6478938bb6e192d9</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1186%2Fs12935-019-0906-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12935-019-0906-y%26sid%3Dliteratum%253Aachs%26aulast%3DHonari%26aufirst%3DM.%26aulast%3DShafabakhsh%26aufirst%3DR.%26aulast%3DReiter%26aufirst%3DR.%2BJ.%26aulast%3DMirzaei%26aufirst%3DH.%26aulast%3DAsemi%26aufirst%3DZ.%26atitle%3DResveratrol%2520is%2520a%2520promising%2520agent%2520for%2520colorectal%2520cancer%2520prevention%2520and%2520treatment%253A%2520focus%2520on%2520molecular%2520mechanisms%26jtitle%3DCancer%2520Cell%2520Int.%26date%3D2019%26volume%3D19%26spage%3D180%26doi%3D10.1186%2Fs12935-019-0906-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hemshekhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunitha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santhosh, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devaraja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemparaju, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanath, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niranjana, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girish, K. S.</span></span> <span> </span><span class="NLM_article-title">An overview of genus garcinia: phytochemical and therapeutic aspects</span>. <i>Phytochem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1007/s11101-011-9207-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1007%2Fs11101-011-9207-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1Smu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=325-351&author=M.+Hemshekharauthor=K.+Sunithaauthor=M.+S.+Santhoshauthor=S.+Devarajaauthor=K.+K.+Kemparajuauthor=B.+S.+Vishwanathauthor=S.+R.+Niranjanaauthor=K.+S.+Girish&title=An+overview+of+genus+garcinia%3A+phytochemical+and+therapeutic+aspects&doi=10.1007%2Fs11101-011-9207-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">An overview on genus Garcinia: Phytochemical and therapeutical aspects</span></div><div class="casAuthors">Hemshekhar, M.; Sunitha, K.; Santhosh, M. Sebastin; Devaraja, S.; Kemparaju, K.; Vishwanath, B. S.; Niranjana, S. R.; Girish, K. S.</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-351</span>CODEN:
                <span class="NLM_cas:coden">PRHEBS</span>;
        ISSN:<span class="NLM_cas:issn">1568-7767</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The genus Garcinia belongs to the family Clusiaceae and has been involved in ayurvedic prepns. to medicate various pathophysiol. disorders.  Bioactive mols. such as hydroxycitric acid (HCA), flavonoids, terpenes, polysaccharides, procyanidines and polyisoprenylated benzophenone derivs. like garcinol, xanthochymol and guttiferone isoforms have been isolated from Garcinia.  The genus has received the attention of pharmaceutical industries due to its immense remedial qualities.  HCA has been known for its hypolipidemic property.  The polyisoprenylated benzophenone and xanthone derivs. are known for their antioxidant, apoptotic, anti-cancer, anti-inflammatory, antibacterial, antiviral, antifungal, antiulcer, antiprotozoal, and HAT inhibiting properties.  Future studies on the synthesis of therapeutically important products and their analogs and evaluation of their safety and efficacy would be of great interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCgb_ZixEiKLVg90H21EOLACvtfcHk0lgwwhC_MlC4jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1Smu7c%253D&md5=8538fe76bb43fa0ecd111649b3b62891</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1007%2Fs11101-011-9207-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11101-011-9207-3%26sid%3Dliteratum%253Aachs%26aulast%3DHemshekhar%26aufirst%3DM.%26aulast%3DSunitha%26aufirst%3DK.%26aulast%3DSanthosh%26aufirst%3DM.%2BS.%26aulast%3DDevaraja%26aufirst%3DS.%26aulast%3DKemparaju%26aufirst%3DK.%2BK.%26aulast%3DVishwanath%26aufirst%3DB.%2BS.%26aulast%3DNiranjana%26aufirst%3DS.%2BR.%26aulast%3DGirish%26aufirst%3DK.%2BS.%26atitle%3DAn%2520overview%2520of%2520genus%2520garcinia%253A%2520phytochemical%2520and%2520therapeutic%2520aspects%26jtitle%3DPhytochem.%2520Rev.%26date%3D2011%26volume%3D10%26spage%3D325%26epage%3D351%26doi%3D10.1007%2Fs11101-011-9207-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schobert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biersack, B.</span></span> <span> </span><span class="NLM_article-title">Chemical and biological aspects of garcinol and isogarcinol: Recent developments</span>. <i>Chem. Biodiversity</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>, <span class="NLM_elocation-id">e1900366</span> <span class="refDoi"> DOI: 10.1002/cbdv.201900366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fcbdv.201900366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31386266" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&author=R.+Schobertauthor=B.+Biersack&title=Chemical+and+biological+aspects+of+garcinol+and+isogarcinol%3A+Recent+developments&doi=10.1002%2Fcbdv.201900366"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1002%2Fcbdv.201900366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbdv.201900366%26sid%3Dliteratum%253Aachs%26aulast%3DSchobert%26aufirst%3DR.%26aulast%3DBiersack%26aufirst%3DB.%26atitle%3DChemical%2520and%2520biological%2520aspects%2520of%2520garcinol%2520and%2520isogarcinol%253A%2520Recent%2520developments%26jtitle%3DChem.%2520Biodiversity%26date%3D2019%26volume%3D16%26doi%3D10.1002%2Fcbdv.201900366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuli, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parashar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi-Parashar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. S.</span></span> <span> </span><span class="NLM_article-title">Garcinol exhibits anti-neoplastic effects by targeting diverse oncogenic factors in tumor cells</span>. <i>Biomedicines</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">103</span>, <span class="refDoi"> DOI: 10.3390/biomedicines8050103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fbiomedicines8050103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKgsrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=103&author=V.+Aggarwalauthor=H.+S.+Tuliauthor=J.+Kaurauthor=D.+Aggarwalauthor=G.+Parasharauthor=N.+Chaturvedi-Parasharauthor=S.+Kulkarniauthor=G.+Kaurauthor=K.+Sakauthor=M.+Kumarauthor=K.+S.+Ahn&title=Garcinol+exhibits+anti-neoplastic+effects+by+targeting+diverse+oncogenic+factors+in+tumor+cells&doi=10.3390%2Fbiomedicines8050103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol exhibits anti-neoplastic effects by targeting diverse oncogenic factors in tumor cells</span></div><div class="casAuthors">Aggarwal, Vaishali; Tuli, Hardeep Singh; Kaur, Jagjit; Aggarwal, Diwakar; Parashar, Gaurav; Parashar, Nidarshana Chaturvedi; Kulkarni, Samruddhi; Kaur, Ginpreet; Sak, Katrin; Kumar, Manoj; Ahn, Kwang Seok</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicines</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">103</span>CODEN:
                <span class="NLM_cas:coden">BIOMID</span>;
        ISSN:<span class="NLM_cas:issn">2227-9059</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Garcinol, a polyisoprenylated benzophenone, is the medicinal component obtained from fruits and leaves of Garcinia indica (G. indica) and has traditionally been extensively used for its antioxidant and anti-inflammatory properties.  In addn., it has been also been exptl. illustrated to elicit anti-cancer properties.  Several in vitro and in vivo studies have illustrated the potential therapeutic efficiency of garcinol in management of different malignancies.  It mainly acts as an inhibitor of cellular processes via regulation of transcription factors NF-κB and JAK/STAT3 in tumor cells and have been demonstrated to effectively inhibit growth of malignant cell population.  Numerous studies have highlighted the anti-neoplastic potential of garcinol in different oncol. transformations including colon cancer, breast cancer, prostate cancer, head and neck cancer, hepatocellular carcinoma, etc.  However, use of garcinol is still in its pre-clin. stage and this is mainly attributed to the limitations of conclusive evaluation of pharmacol. parameters.  This necessitates evaluation of garcinol pharmacokinetics to precisely identify an appropriate dose and route of administration, tolerability, and potency under physiol. conditions along with characterization of a therapeutic index.  Hence, the research is presently ongoing in the dimension of exploring the precise metabolic mechanism of garcinol.  Despite various lacunae, garcinol has presented with promising anti-cancer effects.  Hence, this review is motivated by the constantly emerging and promising pos. anti-cancerous effects of garcinol.  This review is the first effort to summarize the mechanism of action of garcinol in modulation of anti-cancer effect via regulation of different cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeO57asMerj7Vg90H21EOLACvtfcHk0lgwwhC_MlC4jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKgsrjI&md5=c47331dcada2618f4d683b94f74205ac</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.3390%2Fbiomedicines8050103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiomedicines8050103%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DV.%26aulast%3DTuli%26aufirst%3DH.%2BS.%26aulast%3DKaur%26aufirst%3DJ.%26aulast%3DAggarwal%26aufirst%3DD.%26aulast%3DParashar%26aufirst%3DG.%26aulast%3DChaturvedi-Parashar%26aufirst%3DN.%26aulast%3DKulkarni%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DSak%26aufirst%3DK.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DK.%2BS.%26atitle%3DGarcinol%2520exhibits%2520anti-neoplastic%2520effects%2520by%2520targeting%2520diverse%2520oncogenic%2520factors%2520in%2520tumor%2520cells%26jtitle%3DBiomedicines%26date%3D2020%26volume%3D8%26spage%3D103%26doi%3D10.3390%2Fbiomedicines8050103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboukameel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padhye, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, F. H.</span></span> <span> </span><span class="NLM_article-title">Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2193</span>– <span class="NLM_lpage">2201</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0232-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1158%2F1535-7163.MCT-12-0232-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=22821148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyksr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=2193-2201&author=A.+Ahmadauthor=S.+H.+Sarkarauthor=B.+Bitarauthor=S.+Aliauthor=A.+Aboukameelauthor=S.+Sethiauthor=Y.+Liauthor=B.+Baoauthor=D.+Kongauthor=S.+Banerjeeauthor=S.+B.+Padhyeauthor=F.+H.+Sarkar&title=Garcinol+regulates+EMT+and+Wnt+signaling+pathways+in+vitro+and+in+vivo%2C+leading+to+anticancer+activity+against+breast+cancer+cells&doi=10.1158%2F1535-7163.MCT-12-0232-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol Regulates EMT and Wnt Signaling Pathways In Vitro and In Vivo, Leading to Anticancer Activity against Breast Cancer Cells</span></div><div class="casAuthors">Ahmad, Aamir; Sarkar, Sanila H.; Bitar, Bassam; Ali, Shadan; Aboukameel, Amro; Sethi, Seema; Li, Yiwei; Bao, Bin; Kong, Dejuan; Banerjee, Sanjeev; Padhye, Subhash B.; Sarkar, Fazlul H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2193-2201</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anticancer properties of Garcinia indica-derived garcinol are just beginning to be elucidated.  We have earlier reported its cancer cell-specific induction of apoptosis in breast cancer cells, which was mediated through the downregulation of NF-κB signaling pathway.  To gain further mechanistic insight, here, we show for the first time that garcinol effectively reverses epithelial-to-mesenchymal transition (EMT), i.e., it induces mesenchymal-to-epithelial transition (MET) in aggressive triple-neg. MDA-MB-231 and BT-549 breast cancer cells.  This was assocd. with upregulation of epithelial marker E-cadherin and downregulation of mesenchymal markers vimentin, ZEB-1, and ZEB-2.  We also found that garcinol upregulates the expression of miR-200 and let-7 family microRNAs (miRNAs), which provides a mol. mechanism for the obsd. reversal of EMT to MET.  Transfection of cells with NF-κB p65 subunit attenuated the effect of garcinol on apoptosis induction through reversal of MET to EMT.  Forced transfection of p65 and anti-miR-200s could also reverse the inhibitory effect of garcinol on breast cancer cell invasion.  Moreover, treatment with garcinol resulted in increased phosphorylation of β-catenin concomitant with its reduced nuclear localization.  The results were also validated in vivo in a xenograft mouse model where garcinol was found to inhibit NF-κB, miRNAs, vimentin, and nuclear β-catenin.  These novel findings suggest that the anticancer activity of garcinol against aggressive breast cancer cells is, in part, due to reversal of EMT phenotype, which is mechanistically linked with the deregulation of miR-200s, let-7s, NF-κB, and Wnt signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWiYQpeFiGubVg90H21EOLACvtfcHk0lj8QhcXYlAL3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyksr3E&md5=20db5c27a08c74042570ae5f4b03e9d9</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0232-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0232-T%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DSarkar%26aufirst%3DS.%2BH.%26aulast%3DBitar%26aufirst%3DB.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DAboukameel%26aufirst%3DA.%26aulast%3DSethi%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBao%26aufirst%3DB.%26aulast%3DKong%26aufirst%3DD.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DPadhye%26aufirst%3DS.%2BB.%26aulast%3DSarkar%26aufirst%3DF.%2BH.%26atitle%3DGarcinol%2520regulates%2520EMT%2520and%2520Wnt%2520signaling%2520pathways%2520in%2520vitro%2520and%2520in%2520vivo%252C%2520leading%2520to%2520anticancer%2520activity%2520against%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D2193%26epage%3D2201%26doi%3D10.1158%2F1535-7163.MCT-12-0232-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboukameel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biersack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seibt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schobert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padhye, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, F. H.</span></span> <span> </span><span class="NLM_article-title">Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2450</span>– <span class="NLM_lpage">2456</span>, <span class="refDoi"> DOI: 10.1093/carcin/bgs290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1093%2Fcarcin%2Fbgs290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=22971573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKrtrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=2450-2456&author=A.+Ahmadauthor=S.+H.+Sarkarauthor=A.+Aboukameelauthor=S.+Aliauthor=B.+Biersackauthor=S.+Seibtauthor=Y.+Liauthor=B.+Baoauthor=D.+Kongauthor=S.+Banerjeeauthor=R.+Schobertauthor=S.+B.+Padhyeauthor=F.+H.+Sarkar&title=Anticancer+action+of+garcinol+in+vitro+and+in+vivo+is+in+part+mediated+through+inhibition+of+STAT-3+signaling&doi=10.1093%2Fcarcin%2Fbgs290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling</span></div><div class="casAuthors">Ahmad, Aamir; Sarkar, Sanila H.; Aboukameel, Amro; Ali, Shadan; Biersack, Bernhard; Seibt, Sebastian; Li, Yiwei; Bao, Bin; Kong, Dejuan; Banerjee, Sanjeev; Schobert, Rainer; Padhye, Subhash B.; Sarkar, Fazlul H.</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2450-2456</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Garcinol, obtained from Garcinia indica, has exhibited some promising anticancer activity.  In particular, our earlier work has demonstrated its ability to inhibit cell proliferation and induction of apoptosis in multiple cancer cell lines representative of breast, prostate, as well as pancreatic cancers.  However, its exact mechanism of action remains largely unclear.  Here we show that garcinol also targets signal transducer and activator of transcription-3 (STAT-3) signaling pathway.  STAT-3 is frequently found to be activated in many cancer types and this is the first report on such action of garcinol leading to its anticancer effects.  Garcinol inhibited total, as well as phosphorylated, STAT-3 in breast, prostate and pancreatic cancer cell lines and was also found to inhibit cell invasion of all the cancer cell lines tested.  STAT-3 phosphorylation was inhibited by garcinol in a dose-dependent manner.  We also obsd. an inhibitory effect of garcinol on IL-6-induced STAT-3 phosphorylation and prodn. of urokinase-type plasminogen activator, vascular endothelial growth factor and matrix metalloproteinase-9, which might explain the reduced invasion and aggressiveness of cells treated with garcinol.  The results were further verified in vivo using MDA-MB-231 breast cancer mouse xenograft model where administration of garcinol significantly inhibited tumor growth, and western blot anal. of remnant tumor lysates showed reduced STAT-3 expression and activation.  These results suggest that garcinol may have translational potential as chemopreventive or therapeutic agent against multiple cancers and inhibition of STAT-3 signaling pathway is one of the mechanisms by which garcinol exerts its anticancer effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYyQhWi3zz37Vg90H21EOLACvtfcHk0lj8QhcXYlAL3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKrtrfM&md5=573f327b1e697fb676d690bb126ba698</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgs290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgs290%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DSarkar%26aufirst%3DS.%2BH.%26aulast%3DAboukameel%26aufirst%3DA.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DBiersack%26aufirst%3DB.%26aulast%3DSeibt%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBao%26aufirst%3DB.%26aulast%3DKong%26aufirst%3DD.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DSchobert%26aufirst%3DR.%26aulast%3DPadhye%26aufirst%3DS.%2BB.%26aulast%3DSarkar%26aufirst%3DF.%2BH.%26atitle%3DAnticancer%2520action%2520of%2520garcinol%2520in%2520vitro%2520and%2520in%2520vivo%2520is%2520in%2520part%2520mediated%2520through%2520inhibition%2520of%2520STAT-3%2520signaling%26jtitle%3DCarcinogenesis%26date%3D2012%26volume%3D33%26spage%3D2450%26epage%3D2456%26doi%3D10.1093%2Fcarcin%2Fbgs290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugam, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siveen, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swamy, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, G.</span></span> <span> </span><span class="NLM_article-title">Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">5147</span>– <span class="NLM_lpage">5163</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.18632%2Foncotarget.2881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=25762616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnjt1OltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=5147-5163&author=F.+Liauthor=M.+K.+Shanmugamauthor=K.+S.+Siveenauthor=F.+Wangauthor=T.+H.+Ongauthor=S.+Y.+Looauthor=M.+M.+Swamyauthor=S.+Mandalauthor=A.+P.+Kumarauthor=B.+C.+Gohauthor=T.+Kunduauthor=K.+S.+Ahnauthor=L.+Z.+Wangauthor=K.+M.+Huiauthor=G.+Sethi&title=Garcinol+sensitizes+human+head+and+neck+carcinoma+to+cisplatin+in+a+xenograft+mouse+model+despite+downregulation+of+proliferative+biomarkers&doi=10.18632%2Foncotarget.2881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers</span></div><div class="casAuthors">Li Feng; Shanmugam Muthu K; Siveen Kodappully Sivaraman; Wang Fan; Loo Ser Yue; Kumar Alan Prem; Goh Boon Cher; Wang Ling Zhi; Sethi Gautam; Wang Fan; Loo Ser Yue; Kumar Alan Prem; Goh Boon Cher; Wang Ling Zhi; Ong Tina H; Hui Kam Man; Loo Ser Yue; Swamy Mahadeva M M; Mandal Somnath; Kundu Tapas; Kumar Alan Prem; Sethi Gautam; Kumar Alan Prem; Goh Boon Cher; Ahn Kwang Seok</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">5147-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Platinum compounds such as cisplatin and carboplatin are frequently used as the first-line chemotherapy for the treatment of the head and neck squamous cell carcinoma (HNSCC).  In the present study, we investigated whether garcinol, a polyisoprenylated benzophenone can chemosensitize HNSCC to cisplatin.  We found that garcinol inhibited the viability of a panel of diverse HNSCC cell lines, enhanced the apoptotic effect of cisplatin, suppressed constitutive as well as cisplatin-induced NF-κB activation, and downregulated the expression of various oncogenic gene products (cyclin D1, Bcl-2, survivin and VEGF).  In vivo study showed that administration of garcinol alone (0.5 mg/kg body weight, i.p. five times/week) significantly suppressed the growth of the tumor, and this effect was further increased by cisplatin.  Both the markers of proliferation index (Ki-67) and microvessel density (CD31) were downregulated in tumor tissues by the combination of cisplatin and garcinol.  The pharmacokinetic results of garcinol indicated that good systemic exposure was achievable after i.p. administration of garcinol at 0.5 mg/kg and 2 mg/kg with mean peak concentration (Cmax) of 1825.4 and 6635.7 nM in the mouse serum, respectively.  Overall, our results suggest that garcinol can indeed potentiate the effects of cisplatin by negative regulation of various inflammatory and proliferative biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQInFgFY_9atxLDWw4HIq2sfW6udTcc2eZAQNdCT6j4m7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnjt1OltQ%253D%253D&md5=2138e0ab741d652adbe2c90a5070bba5</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2881%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DShanmugam%26aufirst%3DM.%2BK.%26aulast%3DSiveen%26aufirst%3DK.%2BS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DOng%26aufirst%3DT.%2BH.%26aulast%3DLoo%26aufirst%3DS.%2BY.%26aulast%3DSwamy%26aufirst%3DM.%2BM.%26aulast%3DMandal%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DA.%2BP.%26aulast%3DGoh%26aufirst%3DB.%2BC.%26aulast%3DKundu%26aufirst%3DT.%26aulast%3DAhn%26aufirst%3DK.%2BS.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DHui%26aufirst%3DK.%2BM.%26aulast%3DSethi%26aufirst%3DG.%26atitle%3DGarcinol%2520sensitizes%2520human%2520head%2520and%2520neck%2520carcinoma%2520to%2520cisplatin%2520in%2520a%2520xenograft%2520mouse%2520model%2520despite%2520downregulation%2520of%2520proliferative%2520biomarkers%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D5147%26epage%3D5163%26doi%3D10.18632%2Foncotarget.2881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parasramka, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deryavoush, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span> <span> </span><span class="NLM_article-title">Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures</span>. <i>Mol. Nutr. Food Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1002/mnfr.201200297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fmnfr.201200297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=23293055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslehtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=235-248&author=M.+A.+Parasramkaauthor=S.+Aliauthor=S.+Banerjeeauthor=T.+Deryavoushauthor=F.+H.+Sarkarauthor=S.+Gupta&title=Garcinol+sensitizes+human+pancreatic+adenocarcinoma+cells+to+gemcitabine+in+association+with+microRNA+signatures&doi=10.1002%2Fmnfr.201200297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures</span></div><div class="casAuthors">Parasramka, Mansi A.; Ali, Shadan; Banerjee, Sanjeev; Deryavoush, Tara; Sarkar, Fazlul H.; Gupta, SmitiV.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Nutrition & Food Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">235-248</span>CODEN:
                <span class="NLM_cas:coden">MNFRCV</span>;
        ISSN:<span class="NLM_cas:issn">1613-4125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Background. Alterations in microRNA (miRNA/miR) genes are of biol. importance in the pathophysiol. of cancers, including pancreatic cancer (PaCa).  Although growing evidence supports the role of miRNA in cancer, their response to dietary phytochems. is less known.  Previously, we showed that garcinol induces PaCa cell growth arrest and apoptosis in vitro.  The present study, discusses chemo-sensitization by garcinol in synergism with first-line PaCa drug, gemcitabine.  The miRNA expression profile of gemcitabine-resistant Panc-1 cells treated with garcinol and/or gemcitabine was also evaluated.  Methods and results. Garcinol synergizes with gemcitabine to inhibit cell proliferation and induce apoptosis in PaCa cells with significant modulation of key cancer regulators including PARP, VEGF, MMPs, ILs, caspases, and NF-κB.  In addn., biostatistical analyses, quant. reverse transcription PCR data, and in silico modeling using TargetScan5, PicTar, and DNA intelligent anal., microT-V.  B4 database showed that these two agents modulated a no. of microRNAs (miR-21, miR-196a, miR-495, miR-605, miR-638, and miR-453) linked to various canonical oncogenic signaling pathways.  Conclusion. We identified garcinol-specific miRNA biomarkers that sensitize PaCa cells to gemcitabine treatment, thus attenuating the drug-resistance phenotype.  These results prompt further interest in garcinol and gemcitabine combination strategy as a drug modality to improve treatment outcome in patients diagnosed with PaCa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk2WLWek9MV7Vg90H21EOLACvtfcHk0lg6PyOEvCmZrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslehtg%253D%253D&md5=7dbd38ddab239535a55161ef8dd0c046</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2Fmnfr.201200297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmnfr.201200297%26sid%3Dliteratum%253Aachs%26aulast%3DParasramka%26aufirst%3DM.%2BA.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DDeryavoush%26aufirst%3DT.%26aulast%3DSarkar%26aufirst%3DF.%2BH.%26aulast%3DGupta%26aufirst%3DS.%26atitle%3DGarcinol%2520sensitizes%2520human%2520pancreatic%2520adenocarcinoma%2520cells%2520to%2520gemcitabine%2520in%2520association%2520with%2520microRNA%2520signatures%26jtitle%3DMol.%2520Nutr.%2520Food%2520Res.%26date%3D2013%26volume%3D57%26spage%3D235%26epage%3D248%26doi%3D10.1002%2Fmnfr.201200297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span> <span> </span><span class="NLM_article-title">Garcinol from <i>Garcinia indica</i> downregulates cancer stem-like cell biomarker ALDH1A1 in nonsmall cell lung cancer A549 cells through DDIT3 activation</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">3675</span>– <span class="NLM_lpage">3683</span>, <span class="refDoi"> DOI: 10.1021/acs.jafc.7b00346</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jafc.7b00346" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFCnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2017&pages=3675-3683&author=J.+Wangauthor=L.+Wangauthor=C.-T.+Hoauthor=K.+Zhangauthor=Q.+Liuauthor=H.+Zhao&title=Garcinol+from+Garcinia+indica+downregulates+cancer+stem-like+cell+biomarker+ALDH1A1+in+nonsmall+cell+lung+cancer+A549+cells+through+DDIT3+activation&doi=10.1021%2Facs.jafc.7b00346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol from Garcinia indica Downregulates Cancer Stem-like Cell Biomarker ALDH1A1 in Nonsmall Cell Lung Cancer A549 Cells through DDIT3 Activation</span></div><div class="casAuthors">Wang, Jinhan; Wang, Liwen; Ho, Chi-Tang; Zhang, Kunsheng; Liu, Qiang; Zhao, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3675-3683</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonsmall cell lung cancer (NSCLC) is the predominant type of lung cancer.  Patients with NSCLC show high mortality rates because of failure to clean up cancer stem cells (CSCs).  The anticancer activity of phytochem. garcinol has been identified in various cancer cell models.  However, the effect of garcinol on NSCLC cell lines is still lacking.  Of the NSCLC cell lines we tested, A549 cells were the most sensitive to garcinol.  Interestingly, Aldehyde Dehydrogenase 1 Family Member A1 (ALDH1A1) was preferentially expressed in A549 cells and downregulated by the addn. of garcinol.  We also found that garcinol enriched DNA damage-inducible transcript 3 (DDIT3) and then altered DDIT3-CCAAT-enhancer-binding proteins beta (C/EBPβ) interaction resulting in a decreased binding of C/EBPβ to the endogenous ALDH1A1 promoter.  Furthermore, garcinol's inhibition of ALDH1A1 was identified in a xenograft mice model.  Garcinol repressed ALDH1A1 transcription in A549 cells through alterations in the interaction between DDIT3 and C/EBPβ.  Garcinol could be a potential dietary phytochem. candidate for NSCLCs patients whose tumors harbored high ALDH1A1 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEfTvmCNrY67Vg90H21EOLACvtfcHk0lg6PyOEvCmZrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFCnsbs%253D&md5=d38e7b2919e0bd0c4327af678c6e1b86</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jafc.7b00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jafc.7b00346%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHo%26aufirst%3DC.-T.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DGarcinol%2520from%2520Garcinia%2520indica%2520downregulates%2520cancer%2520stem-like%2520cell%2520biomarker%2520ALDH1A1%2520in%2520nonsmall%2520cell%2520lung%2520cancer%2520A549%2520cells%2520through%2520DDIT3%2520activation%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2017%26volume%3D65%26spage%3D3675%26epage%3D3683%26doi%3D10.1021%2Facs.jafc.7b00346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farhan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullah, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afaq, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faisal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooqi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biersack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schobert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span> <span> </span><span class="NLM_article-title">Garcinol sensitizes NSCLC cells to standard therapies by regulating EMT-modulating miRNAs</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">800</span>, <span class="refDoi"> DOI: 10.3390/ijms20040800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fijms20040800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlSiurrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=800&author=M.+Farhanauthor=A.+Malikauthor=M.+F.+Ullahauthor=S.+Afaqauthor=M.+Faisalauthor=A.+A.+Farooqiauthor=B.+Biersackauthor=R.+Schobertauthor=A.+Ahmad&title=Garcinol+sensitizes+NSCLC+cells+to+standard+therapies+by+regulating+EMT-modulating+miRNAs&doi=10.3390%2Fijms20040800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol sensitizes NSCLC cells to standard therapies by regulating EMT-modulating miRNAs</span></div><div class="casAuthors">Farhan, Mohd; Malik, Arshi; Ullah, Mohammad Fahad; Afaq, Sarah; Faisal, Mohd; Farooqi, Ammad Ahmad; Biersack, Bernhard; Schobert, Rainer; Ahmad, Aamir</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">800</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Garcinol, a dietary factor obtained from Garcinia indica, modulates several key cellular signaling pathways as well as the expression of miRNAs.  Acquired resistance to std. therapies, such as erlotinib and cisplatin, is a hallmark of non-small cell lung cancer (NSCLC) cells that often involves miRNA-regulated epithelial-to-mesenchymal transition (EMT).  We used A549 cells that were exposed to transforming growth factor beta 1 (TGF-β1), resulting in A549M cells with mesenchymal and drug resistant phenotype, and report that garcinol sensitized resistant cells with mesenchymal phenotype to erlotinib as well as cisplatin with significant decrease in their IC50 values.  It also potentiated the apoptosis-inducing activity of erlotinib in A549M and the endogenously mesenchymal H1299 NSCLC cells.  Further, garcinol significantly upregulated several key EMT-regulating miRNAs, such as miR-200b, miR-205, miR-218, and let-7c.  Antagonizing miRNAs, through anti-miRNA transfections, attenuated the EMT-modulating activity of garcinol, as detd. by mRNA expression of EMT markers, E-cadherin, vimentin, and Zinc Finger E-Box Binding Homeobox 1 (ZEB1).  This further led to repression of erlotinib as well as cisplatin sensitization, thus establishing the mechanistic role of miRNAs, particularly miR-200c and let-7c, in garcinol-mediated reversal of EMT and the resulting sensitization of NSCLC cells to std. therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOM_hTct7SC7Vg90H21EOLACvtfcHk0lgkLHl40TgBug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlSiurrE&md5=56ca5a174b09f5ae00419831d844f5af</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.3390%2Fijms20040800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20040800%26sid%3Dliteratum%253Aachs%26aulast%3DFarhan%26aufirst%3DM.%26aulast%3DMalik%26aufirst%3DA.%26aulast%3DUllah%26aufirst%3DM.%2BF.%26aulast%3DAfaq%26aufirst%3DS.%26aulast%3DFaisal%26aufirst%3DM.%26aulast%3DFarooqi%26aufirst%3DA.%2BA.%26aulast%3DBiersack%26aufirst%3DB.%26aulast%3DSchobert%26aufirst%3DR.%26aulast%3DAhmad%26aufirst%3DA.%26atitle%3DGarcinol%2520sensitizes%2520NSCLC%2520cells%2520to%2520standard%2520therapies%2520by%2520regulating%2520EMT-modulating%2520miRNAs%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D800%26doi%3D10.3390%2Fijms20040800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span> <span> </span><span class="NLM_article-title">Emerging role of garcinol in targeting cancer stem cells of non-small cell lung cancer</span>. <i>Curr. Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1007/s40495-019-00169-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1007%2Fs40495-019-00169-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVCjtLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=14-19&author=L.+Wangauthor=M.+Wangauthor=H.+Guoauthor=H.+Zhao&title=Emerging+role+of+garcinol+in+targeting+cancer+stem+cells+of+non-small+cell+lung+cancer&doi=10.1007%2Fs40495-019-00169-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging Role of Garcinol in Targeting Cancer Stem Cells of Non-small Cell Lung Cancer</span></div><div class="casAuthors">Wang, Liang; Wang, Meiyan; Guo, Hongxing; Zhao, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmacology Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-19</span>CODEN:
                <span class="NLM_cas:coden">CPRUG8</span>;
        ISSN:<span class="NLM_cas:issn">2198-641X</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Garcinol is a polyisoprenylated benzophenone analog primarily isolated from the dried rind of Garcinia indica, a tropical fruit widely grown in Southeast Asia and Central Africa.  Recent findings have well documented that garcinol is a potential dietary phytochem. candidate in the prevention and treatment of cancer and oxidative-related illness.  Herein, a brief structure-activity relationship (SAR) is summarized in this review to disclose the connection between the chem. structure of garcinol and its biol. activity.  Non-small cell lung cancer (NSCLC) is a predominant type of lung cancer, exhibiting an extremely high mortality rate as a result of failing to clean up cancer stem cells (CSCs).  Interestingly, garcinol was reported to be able to target and suppress CSCs, and both in vitro and in vivo evidences have revealed the outstanding anti-NSCLC potential of garcinol.  The mechanism may involve cellular senescence and apoptosis induction, as well as cell cycle arrest.  This paper will review the current progress of garcinol against various tumors in vitro and in vivo, particularly the effects on NSCLC, and summarize the crit. structural features of garcinol as a potent anticancer candidate.  Also, we will discuss potential future challenges in research and development of garcinol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT9oeEiWbPRLVg90H21EOLACvtfcHk0lgkLHl40TgBug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVCjtLzF&md5=c06fb07097ad11e0c453ffe96194df9a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs40495-019-00169-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40495-019-00169-6%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DEmerging%2520role%2520of%2520garcinol%2520in%2520targeting%2520cancer%2520stem%2520cells%2520of%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCurr.%2520Pharmacol.%2520Rep.%26date%3D2019%26volume%3D5%26spage%3D14%26epage%3D19%26doi%3D10.1007%2Fs40495-019-00169-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adebayo, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, C. T.</span></span> <span> </span><span class="NLM_article-title">Garcinol inhibits cancer stem cell-like phenotype via suppression of the Wnt/β-catenin/STAT3 axis signalling pathway in human non-small cell lung carcinomas</span>. <i>J. Nutr. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1016/j.jnutbio.2017.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.jnutbio.2017.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29414668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltlSlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2018&pages=140-150&author=W.+C.+Huangauthor=K.+T.+Kuoauthor=B.+O.+Adebayoauthor=C.+H.+Wangauthor=Y.+J.+Chenauthor=K.+Jinauthor=T.+H.+Tsaiauthor=C.+T.+Yeh&title=Garcinol+inhibits+cancer+stem+cell-like+phenotype+via+suppression+of+the+Wnt%2F%CE%B2-catenin%2FSTAT3+axis+signalling+pathway+in+human+non-small+cell+lung+carcinomas&doi=10.1016%2Fj.jnutbio.2017.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol inhibits cancer stem cell-like phenotype via suppression of the Wnt/β-catenin/STAT3 axis signalling pathway in human non-small cell lung carcinomas</span></div><div class="casAuthors">Huang, Wen-Chien; Kuo, Kuang-Tai; Adebayo, Bamodu Oluwaseun; Wang, Chun-Hua; Chen, Yu-Jen; Jin, Ketao; Tsai, Tung-Hu; Yeh, Chi-Tai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nutritional Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">140-150</span>CODEN:
                <span class="NLM_cas:coden">JNBIEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-2863</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Innate or acquired drug resistance and consequent tumor relapse in lung cancer patients have been linked to activities of cancer stem cells (CSCs).  Therefore, targeting CSCs is suggested as an effective approach for non-small cell lung cancer (NSCLC) therapy.  In this study, we demonstrated that garcinol, a polyisoprenylated benzophenone isolated from fruiting bodies of Garcinia indica, and possessing anti-inflammatory, antioxidant, acetyltransferase inhibitory, and anticancer activities, modulates activities of lung CSCs (LCSCs) and their assocd. aggressiveness.  Herein, we demonstrated the inhibitory effect of garcinol on the LCSC phenotype of human NSCLC cells using anal. drug cytotoxicity or cell viability, flow cytometric, and functional assay approaches.  Garcinol significantly diminished the ability of the H441 and A549 NSCLC cell lines to form spheres.  In parallel assays, garcinol inhibited differentiated lung cancer cell and LCSC viability in dose-dependent manners.  Consistent with these observations, flow cytometric data showed that garcinol reduced the putative LCSC pool, evidenced by the dose-dependent decreasing proportion of side-population (SP) cells and assocd. ALDH activity in garcinol-treated H441 cells, compared to the control group.  Addnl., functional assays showed that garcinol markedly diminished the ability of H441 and A549 cells to form colonies.  Mechanistically, garcinol impaired phosphorylation of LRP6, a co-receptor of Wnt and STAT3.  In the same assay, garcinol down-regulated β-catenin, Dvl2, Axin2, and cyclin D1 expressions in NSCLC-generated spheres, suggesting its ability to regulate the Wnt/β-catenin signaling pathway.  The results were further verified in vivo using H441 LCSC mouse xenograft model where administration of garcinol significantly inhibited tumor growth.  Taken together, we demonstrated herein that garcinol modulates the LCSC phenotype via regulation of Wnt/β-catenin signaling and inactivation of STAT3, thus showing that garcinol may be a putative novel anti-LCSC therapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkVd5bBCUGQrVg90H21EOLACvtfcHk0lgkLHl40TgBug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltlSlsr8%253D&md5=b116c523d20a68c01160fa3081038830</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.jnutbio.2017.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jnutbio.2017.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BC.%26aulast%3DKuo%26aufirst%3DK.%2BT.%26aulast%3DAdebayo%26aufirst%3DB.%2BO.%26aulast%3DWang%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DY.%2BJ.%26aulast%3DJin%26aufirst%3DK.%26aulast%3DTsai%26aufirst%3DT.%2BH.%26aulast%3DYeh%26aufirst%3DC.%2BT.%26atitle%3DGarcinol%2520inhibits%2520cancer%2520stem%2520cell-like%2520phenotype%2520via%2520suppression%2520of%2520the%2520Wnt%252F%25CE%25B2-catenin%252FSTAT3%2520axis%2520signalling%2520pathway%2520in%2520human%2520non-small%2520cell%2520lung%2520carcinomas%26jtitle%3DJ.%2520Nutr.%2520Biochem.%26date%3D2018%26volume%3D54%26spage%3D140%26epage%3D150%26doi%3D10.1016%2Fj.jnutbio.2017.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P. S.</span>; <span class="NLM_string-name">Athavale, M.</span>; <span class="NLM_string-name">Srivastava, S.</span>; <span class="NLM_string-name">Barve, K.</span></span>, <span> </span><span class="NLM_article-title">Unpublished results</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kharkar%2C+P.+S.%3B+Athavale%2C+M.%3B+Srivastava%2C+S.%3B+Barve%2C+K.%2C+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKharkar%26aufirst%3DP.%2BS.%26atitle%3DUnpublished%2520results" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vásquez-Bochm, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velázquez-Paniagua, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro-Vázquez, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero-Rodríguez, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondragon-Peralta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De La Fuente-Granada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Tapia, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Arenas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco-Velázquez, M. A.</span></span> <span> </span><span class="NLM_article-title">Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1016/j.pharep.2019.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.pharep.2019.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31026757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotFagsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2019&pages=535-544&author=L.+X.+V%C3%A1squez-Bochmauthor=M.+Vel%C3%A1zquez-Paniaguaauthor=S.+S.+Castro-V%C3%A1zquezauthor=S.+L.+Guerrero-Rodr%C3%ADguezauthor=A.+Mondragon-Peraltaauthor=M.+De+La+Fuente-Granadaauthor=S.+M.+P%C3%A9rez-Tapiaauthor=A.+Gonz%C3%A1lez-Arenasauthor=M.+A.+Velasco-Vel%C3%A1zquez&title=Transcriptome-based+identification+of+lovastatin+as+a+breast+cancer+stem+cell-targeting+drug&doi=10.1016%2Fj.pharep.2019.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug</span></div><div class="casAuthors">Vasquez-Bochm, Luz X.; Velazquez-Paniagua, Mireya; Castro-Vazquez, Sandra S.; Guerrero-Rodriguez, Sandra L.; Mondragon-Peralta, Abimael; De La Fuente-Granada, Marisol; Perez-Tapia, Sonia M.; Gonzalez-Arenas, Aliesha; Velasco-Velazquez, Marco A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">535-544</span>CODEN:
                <span class="NLM_cas:coden">PRHEDU</span>;
        ISSN:<span class="NLM_cas:issn">2299-5684</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Breast cancer is a neoplastic disease with high morbidity and mortality in women worldwide.  Breast cancer stem cells (CSCs) have a significant function in tumor growth, recurrence, and therapeutic resistance.  Thus, CSCs have been pointed as targets of new therapies for breast cancer.  Herein, we aimed to repurpose certain drugs as breast CSC-targeting agents.  We compared a consensus breast CSC signature with the transcriptomic changes that were induced by over 1300 bioactive compds. using Connectivity Map.  The effects of the selected drugs on SOX2 promoter transactivation, SOX2 expression, viability, clonogenicity, and ALDH activity in breast cancer cells were analyzed by luciferase assay, western blot, MTT assay, mammosphere formation assay, and ALDEFLUOR test, resp.  Gene Set Enrichment Anal. (GSEA) was performed using the gene expression data from mammary tumors of mice that were treated with lovastatin.  Five drugs (fasudil, pivmecillinam, ursolic acid, 16,16-dimethylprostaglandin E2, and lovastatin) induced signatures that correlated neg. with the query CSC signature.  In vitro, lovastatin inhibited SOX2 promoter transactivation, and reduced the efficiency of mammosphere formation and the percentage of ALDH+ cells.  Mevalonate mitigated the effects of lovastatin, suggesting that the targeting of CSCs by lovastatin was mediated by the inhibition of its reported target, 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR).  By GSEA, lovastatin downregulated genes that are involved in stemness and invasiveness in mammary tumors, corroborating our in vitro findings.  Lovastatin is a breast CSC-targeting drug.  The inhibition of HMGCR might develop new adjuvant therapeutic strategies for breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUpRDXdtB_ULVg90H21EOLACvtfcHk0lgZbWWl7Wx6BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotFagsLw%253D&md5=51077d2b00605cdc18051b31c723e8c3</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.pharep.2019.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharep.2019.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DV%25C3%25A1squez-Bochm%26aufirst%3DL.%2BX.%26aulast%3DVel%25C3%25A1zquez-Paniagua%26aufirst%3DM.%26aulast%3DCastro-V%25C3%25A1zquez%26aufirst%3DS.%2BS.%26aulast%3DGuerrero-Rodr%25C3%25ADguez%26aufirst%3DS.%2BL.%26aulast%3DMondragon-Peralta%26aufirst%3DA.%26aulast%3DDe%2BLa%2BFuente-Granada%26aufirst%3DM.%26aulast%3DP%25C3%25A9rez-Tapia%26aufirst%3DS.%2BM.%26aulast%3DGonz%25C3%25A1lez-Arenas%26aufirst%3DA.%26aulast%3DVelasco-Vel%25C3%25A1zquez%26aufirst%3DM.%2BA.%26atitle%3DTranscriptome-based%2520identification%2520of%2520lovastatin%2520as%2520a%2520breast%2520cancer%2520stem%2520cell-targeting%2520drug%26jtitle%3DPharmacol.%2520Rep.%26date%3D2019%26volume%3D71%26spage%3D535%26epage%3D544%26doi%3D10.1016%2Fj.pharep.2019.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsello, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natoli, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubelli, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asiedu, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahr, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirschman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donahue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liberzon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orzechowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enache, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccioni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamji, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrcic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosains, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davison, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardlie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogstrom, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenside, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read-Button, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronco, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doench, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Root, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span> <span> </span><span class="NLM_article-title">A next generation connectivity map: L1000 platform and the first 1,000,000 profiles</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">1437</span>– <span class="NLM_lpage">1452</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.10.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.cell.2017.10.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29195078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWmsbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2017&pages=1437-1452&author=A.+Subramanianauthor=R.+Narayanauthor=S.+M.+Corselloauthor=D.+D.+Peckauthor=T.+E.+Natoliauthor=X.+Luauthor=J.+Gouldauthor=J.+F.+Davisauthor=A.+A.+Tubelliauthor=J.+K.+Asieduauthor=D.+L.+Lahrauthor=J.+E.+Hirschmanauthor=Z.+Liuauthor=M.+Donahueauthor=B.+Julianauthor=M.+Khanauthor=D.+Waddenauthor=I.+C.+Smithauthor=D.+Lamauthor=A.+Liberzonauthor=C.+Toderauthor=M.+Bagulauthor=M.+Orzechowskiauthor=O.+M.+Enacheauthor=F.+Piccioniauthor=S.+A.+Johnsonauthor=N.+J.+Lyonsauthor=A.+H.+Bergerauthor=A.+F.+Shamjiauthor=A.+N.+Brooksauthor=A.+Vrcicauthor=C.+Flynnauthor=J.+Rosainsauthor=D.+Y.+Takedaauthor=R.+Huauthor=D.+Davisonauthor=J.+Lambauthor=K.+Ardlieauthor=L.+Hogstromauthor=P.+Greensideauthor=N.+S.+Grayauthor=P.+A.+Clemonsauthor=S.+Silverauthor=X.+Wuauthor=W.+N.+Zhaoauthor=W.+Read-Buttonauthor=X.+Wuauthor=S.+J.+Haggartyauthor=L.+V.+Roncoauthor=J.+S.+Boehmauthor=S.+L.+Schreiberauthor=J.+G.+Doenchauthor=J.+A.+Bittkerauthor=D.+E.+Rootauthor=B.+Wongauthor=T.+R.+Golub&title=A+next+generation+connectivity+map%3A+L1000+platform+and+the+first+1%2C000%2C000+profiles&doi=10.1016%2Fj.cell.2017.10.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85aR"><div class="casContent"><span class="casTitleNuber">85a</span><div class="casTitle"><span class="NLM_cas:atitle">A next generation connectivity map: L1000 platform and the first 1,000,000 profiles</span></div><div class="casAuthors">Subramanian, Aravind; Narayan, Rajiv; Corsello, Steven M.; Peck, David D.; Natoli, Ted E.; Lu, Xiaodong; Gould, Joshua; Davis, John F.; Tubelli, Andrew A.; Asiedu, Jacob K.; Lahr, David L.; Hirschman, Jodi E.; Liu, Zihan; Donahue, Melanie; Julian, Bina; Khan, Mariya; Wadden, David; Smith, Ian C.; Lam, Daniel; Liberzon, Arthur; Toder, Courtney; Bagul, Mukta; Orzechowski, Marek; Enache, Oana M.; Piccioni, Federica; Johnson, Sarah A.; Lyons, Nicholas J.; Berger, Alice H.; Shamji, Alykhan F.; Brooks, Angela N.; Vrcic, Anita; Flynn, Corey; Rosains, Jacqueline; Takeda, David Y.; Hu, Roger; Davison, Desiree; Lamb, Justin; Ardlie, Kristin; Hogstrom, Larson; Greenside, Peyton; Gray, Nathanael S.; Clemons, Paul A.; Silver, Serena; Wu, Xiaoyun; Zhao, Wen-Ning; Read-Button, Willis; Wu, Xiaohua; Haggarty, Stephen J.; Ronco, Lucienne V.; Boehm, Jesse S.; Schreiber, Stuart L.; Doench, John G.; Bittker, Joshua A.; Root, David E.; Wong, Bang; Golub, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1437-1452.e17</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We previously piloted the concept of a Connectivity Map (CMap), whereby genes, drugs, and disease states are connected by virtue of common gene-expression signatures.  Here, we report more than a 1000-fold scale-up of the CMap as part of the NIH LINCS Consortium, made possible by a new, low-cost, high-throughput reduced representation expression profiling method that we term L1000.  We show that L1000 is highly reproducible, comparable to RNA sequencing, and suitable for computational inference of the expression levels of 81% of non-measured transcripts.  We further show that the expanded CMap can be used to discover mechanism of action of small mols., functionally annotate genetic variants of disease genes, and inform clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIWrWy5IxY-rVg90H21EOLACvtfcHk0lgZbWWl7Wx6BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWmsbrE&md5=d2b13f2b80fe94021ac03f6a8c859a4a</span></div><a href="/servlet/linkout?suffix=cit85a&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.10.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.10.049%26sid%3Dliteratum%253Aachs%26aulast%3DSubramanian%26aufirst%3DA.%26aulast%3DNarayan%26aufirst%3DR.%26aulast%3DCorsello%26aufirst%3DS.%2BM.%26aulast%3DPeck%26aufirst%3DD.%2BD.%26aulast%3DNatoli%26aufirst%3DT.%2BE.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DGould%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DJ.%2BF.%26aulast%3DTubelli%26aufirst%3DA.%2BA.%26aulast%3DAsiedu%26aufirst%3DJ.%2BK.%26aulast%3DLahr%26aufirst%3DD.%2BL.%26aulast%3DHirschman%26aufirst%3DJ.%2BE.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DDonahue%26aufirst%3DM.%26aulast%3DJulian%26aufirst%3DB.%26aulast%3DKhan%26aufirst%3DM.%26aulast%3DWadden%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DI.%2BC.%26aulast%3DLam%26aufirst%3DD.%26aulast%3DLiberzon%26aufirst%3DA.%26aulast%3DToder%26aufirst%3DC.%26aulast%3DBagul%26aufirst%3DM.%26aulast%3DOrzechowski%26aufirst%3DM.%26aulast%3DEnache%26aufirst%3DO.%2BM.%26aulast%3DPiccioni%26aufirst%3DF.%26aulast%3DJohnson%26aufirst%3DS.%2BA.%26aulast%3DLyons%26aufirst%3DN.%2BJ.%26aulast%3DBerger%26aufirst%3DA.%2BH.%26aulast%3DShamji%26aufirst%3DA.%2BF.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DVrcic%26aufirst%3DA.%26aulast%3DFlynn%26aufirst%3DC.%26aulast%3DRosains%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DD.%2BY.%26aulast%3DHu%26aufirst%3DR.%26aulast%3DDavison%26aufirst%3DD.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DArdlie%26aufirst%3DK.%26aulast%3DHogstrom%26aufirst%3DL.%26aulast%3DGreenside%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DSilver%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DW.%2BN.%26aulast%3DRead-Button%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DRonco%26aufirst%3DL.%2BV.%26aulast%3DBoehm%26aufirst%3DJ.%2BS.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DDoench%26aufirst%3DJ.%2BG.%26aulast%3DBittker%26aufirst%3DJ.%2BA.%26aulast%3DRoot%26aufirst%3DD.%2BE.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26atitle%3DA%2520next%2520generation%2520connectivity%2520map%253A%2520L1000%2520platform%2520and%2520the%2520first%25201%252C000%252C000%2520profiles%26jtitle%3DCell%26date%3D2017%26volume%3D171%26spage%3D1437%26epage%3D1452%26doi%3D10.1016%2Fj.cell.2017.10.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit85b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modell, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobel, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunet, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hieronymus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span> <span> </span><span class="NLM_article-title">The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>313</i></span>,  <span class="NLM_fpage">1929</span>– <span class="NLM_lpage">1935</span>, <span class="refDoi"> DOI: 10.1126/science.1132939</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1126%2Fscience.1132939" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=17008526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVSnsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2006&pages=1929-1935&author=J.+Lambauthor=E.+D.+Crawfordauthor=D.+Peckauthor=J.+W.+Modellauthor=I.+C.+Blatauthor=M.+J.+Wrobelauthor=J.+Lernerauthor=J.+P.+Brunetauthor=A.+Subramanianauthor=K.+N.+Rossauthor=M.+Reichauthor=H.+Hieronymusauthor=G.+Weiauthor=S.+A.+Armstrongauthor=S.+J.+Haggartyauthor=P.+A.+Clemonsauthor=R.+Weiauthor=S.+A.+Carrauthor=E.+S.+Landerauthor=T.+R.+Golub&title=The+connectivity+map%3A+using+gene-expression+signatures+to+connect+small+molecules%2C+genes%2C+and+disease&doi=10.1126%2Fscience.1132939"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85bR"><div class="casContent"><span class="casTitleNuber">85b</span><div class="casTitle"><span class="NLM_cas:atitle">The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease</span></div><div class="casAuthors">Lamb, Justin; Crawford, Emily D.; Peck, David; Modell, Joshua W.; Blat, Irene C.; Wrobel, Matthew J.; Lerner, Jim; Brunet, Jean-Philippe; Subramanian, Aravind; Ross, Kenneth N.; Reich, Michael; Hieronymus, Haley; Wei, Guo; Armstrong, Scott A.; Haggarty, Stephen J.; Clemons, Paul A.; Wei, Ru; Carr, Steven A.; Lander, Eric S.; Golub, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">5795</span>),
    <span class="NLM_cas:pages">1929-1935</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">To pursue a systematic approach to the discovery of functional connections among diseases, genetic perturbation, and drug action, we have created the first installment of a ref. collection of gene-expression profiles from cultured human cells treated with bioactive small mols., together with pattern-matching software to mine these data.  We demonstrate that this "Connectivity Map" resource can be used to find connections among small mols. sharing a mechanism of action, chems. and physiol. processes, and diseases and drugs.  These results indicate the feasibility of the approach and suggest the value of a large-scale community Connectivity Map project.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtu0M2BUO2w7Vg90H21EOLACvtfcHk0lhlpQjhl5iHPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVSnsrbN&md5=1fad887ad515ffdd8064e526ff25a4db</span></div><a href="/servlet/linkout?suffix=cit85b&amp;dbid=16384&amp;doi=10.1126%2Fscience.1132939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1132939%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DCrawford%26aufirst%3DE.%2BD.%26aulast%3DPeck%26aufirst%3DD.%26aulast%3DModell%26aufirst%3DJ.%2BW.%26aulast%3DBlat%26aufirst%3DI.%2BC.%26aulast%3DWrobel%26aufirst%3DM.%2BJ.%26aulast%3DLerner%26aufirst%3DJ.%26aulast%3DBrunet%26aufirst%3DJ.%2BP.%26aulast%3DSubramanian%26aufirst%3DA.%26aulast%3DRoss%26aufirst%3DK.%2BN.%26aulast%3DReich%26aufirst%3DM.%26aulast%3DHieronymus%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DArmstrong%26aufirst%3DS.%2BA.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DWei%26aufirst%3DR.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26atitle%3DThe%2520connectivity%2520map%253A%2520using%2520gene-expression%2520signatures%2520to%2520connect%2520small%2520molecules%252C%2520genes%252C%2520and%2520disease%26jtitle%3DScience%26date%3D2006%26volume%3D313%26spage%3D1929%26epage%3D1935%26doi%3D10.1126%2Fscience.1132939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mok, E. H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. K. W.</span></span> <span> </span><span class="NLM_article-title">The pivotal role of the dysregulation of cholesterol homeostasis in cancer: Implications for therapeutic targets</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1410</span>, <span class="refDoi"> DOI: 10.3390/cancers12061410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcancers12061410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKnurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1410&author=E.+H.+K.+Mokauthor=T.+K.+W.+Lee&title=The+pivotal+role+of+the+dysregulation+of+cholesterol+homeostasis+in+cancer%3A+Implications+for+therapeutic+targets&doi=10.3390%2Fcancers12061410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">The pivotal role of the dysregulation of cholesterolhomeostasis in cancer: implications fortherapeutic targets</span></div><div class="casAuthors">Mok, Etienne Ho Kit; Lee, Terence Kin Wah</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1410</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Cholesterol plays an important role in cellular homeostasis by maintaining the rigidity of cell membranes, providing a medium for signaling transduction, and being converted into other vital macromols., such as sterol hormones and bile acids.  Epidemiol. studies have shown the correlation between cholesterol content and cancer incidence worldwide.  Accumulating evidence has shown the emerging roles of the dysregulation of cholesterol metab. in cancer development.  More specifically, recent reports have shown the distinct role of cholesterol in the suppression of immune cells, regulation of cell survival, and modulation of cancer stem cells in cancer.  Here, we provide a comprehensive review of the epidemiol. anal., functional roles, and mechanistic action of cholesterol homeostasis in regard to its contribution to cancer development.  Based on the existing data, cholesterol homeostasis is identified to be a new key player in cancer pathogenesis.  Lastly, we also discuss the therapeutic implications of natural compds. and cholesterol-lowering drugs in cancer prevention and treatment.  In conclusion, intervention in cholesterol metab. may offer a new therapeutic avenue for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRqsEP8TmiW7Vg90H21EOLACvtfcHk0lhlpQjhl5iHPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKnurzM&md5=6139df9e2c5d69b61f3a932a1594def1</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.3390%2Fcancers12061410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12061410%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DE.%2BH.%2BK.%26aulast%3DLee%26aufirst%3DT.%2BK.%2BW.%26atitle%3DThe%2520pivotal%2520role%2520of%2520the%2520dysregulation%2520of%2520cholesterol%2520homeostasis%2520in%2520cancer%253A%2520Implications%2520for%2520therapeutic%2520targets%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D1410%26doi%3D10.3390%2Fcancers12061410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bigelsen, S.</span></span> <span> </span><span class="NLM_article-title">Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin</span>. <i>Cancer Manage. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2003</span>– <span class="NLM_lpage">2018</span>, <span class="refDoi"> DOI: 10.2147/CMAR.S161824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.2147%2FCMAR.S161824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30034255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslGrtbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=2003-2018&author=S.+Bigelsen&title=Evidence-based+complementary+treatment+of+pancreatic+cancer%3A+a+review+of+adjunct+therapies+including+paricalcitol%2C+hydroxychloroquine%2C+intravenous+vitamin+C%2C+statins%2C+metformin%2C+curcumin%2C+and+aspirin&doi=10.2147%2FCMAR.S161824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin</span></div><div class="casAuthors">Bigelsen, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2003-2018</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Despite new and exciting research and renewed optimism about future therapy, current statistics of survival from pancreatic cancer remains dismal.  Patients seeking alternative or complementary treatments should be warned to avoid the hype and instead look to real science.  A variety of relatively safe and inexpensive treatment options that have shown success in preclin. models and/or retrospective studies are currently available.  Patients require their physicians to provide therapeutic guidance and assistance in obtaining and administrating these various therapies.  Paricalcitol, an analog of vitamin D, has been shown by researchers at the Salk Institute for Biol. Studies to break though the protective stroma surrounding tumor cells.  Hydroxychloroquine has been shown to inhibit autophagy, a process by which dying cells recycle injured organelles and internal toxins to generate needed energy for survival and reprodn.  I.v. vitamin C creates a toxic accumulation of hydrogen peroxide within cancer cells, hastening their death.  Metformin inhibits mitochondrial oxidative metab. utilized by cancer stem cells.  Statins inhibit not only cholesterol but also other factors in the same pathway that affect cancer cell growth, protein synthesis, and cell cycle progression.  A novel formulation of curcumin may prevent resistance to chemotherapy and inhibit pancreatic cancer cell proliferation.  Aspirin therapy has been shown to prevent pancreatic cancer and may be useful to prevent recurrence.  These therapies are all currently available and are reviewed in this paper with emphasis on the most recent lab. research and clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibVB4WiohfbVg90H21EOLACvtfcHk0lhlpQjhl5iHPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslGrtbvO&md5=fa34b58f748264337c896576259e0922</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.2147%2FCMAR.S161824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCMAR.S161824%26sid%3Dliteratum%253Aachs%26aulast%3DBigelsen%26aufirst%3DS.%26atitle%3DEvidence-based%2520complementary%2520treatment%2520of%2520pancreatic%2520cancer%253A%2520a%2520review%2520of%2520adjunct%2520therapies%2520including%2520paricalcitol%252C%2520hydroxychloroquine%252C%2520intravenous%2520vitamin%2520C%252C%2520statins%252C%2520metformin%252C%2520curcumin%252C%2520and%2520aspirin%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2018%26volume%3D10%26spage%3D2003%26epage%3D2018%26doi%3D10.2147%2FCMAR.S161824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehmsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terp, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arslanagic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrads, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leth-Larsen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditzel, H. J.</span></span> <span> </span><span class="NLM_article-title">Increased cholesterol biosynthesis is a key characteristic of breast cancer stem cells influencing patient outcome</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3927</span>– <span class="NLM_lpage">3938</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2019.05.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.celrep.2019.05.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31242424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Gitb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=3927-3938&author=S.+Ehmsenauthor=M.+H.+Pedersenauthor=G.+Wangauthor=M.+G.+Terpauthor=A.+Arslanagicauthor=B.+L.+Hoodauthor=T.+P.+Conradsauthor=R.+Leth-Larsenauthor=H.+J.+Ditzel&title=Increased+cholesterol+biosynthesis+is+a+key+characteristic+of+breast+cancer+stem+cells+influencing+patient+outcome&doi=10.1016%2Fj.celrep.2019.05.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Increased Cholesterol Biosynthesis Is a Key Characteristic of Breast Cancer Stem Cells Influencing Patient Outcome</span></div><div class="casAuthors">Ehmsen, Sidse; Pedersen, Martin H.; Wang, Guisong; Terp, Mikkel G.; Arslanagic, Amina; Hood, Brian L.; Conrads, Thomas P.; Leth-Larsen, Rikke; Ditzel, Henrik J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3927-3938.e6</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tumor eradication may be greatly improved by targeting cancer stem cells (CSCs), as they exhibit resistance to conventional therapy.  To gain insight into the unique biol. of CSCs, we developed patient-derived xenograft tumors (PDXs) from ER- breast cancers from which we isolated mammospheres that are enriched for CSCs.  Comparative global proteomic anal. was performed on patient tumor tissues and corresponding PDXs and mammospheres.  Mammospheres exhibited increased expression of proteins assocd. with de novo cholesterol synthesis.  The clin. relevance of increased cholesterol biosynthesis was verified in a large breast cancer cohort showing correlation with shorter relapse-free survival.  RNAi and chem. inhibition of the cholesterol biosynthesis pathway reduced mammosphere formation, which could be rescued by a downstream metabolite.  Our findings identify the cholesterol biosynthesis pathway as central for CSC propagation and a potential therapeutic target, as well as providing a mechanistic explanation for the therapeutic benefit of statins in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-bDgzBcKrk7Vg90H21EOLACvtfcHk0lggHZKMXKRvNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Gitb%252FE&md5=5ee3eacc4006fbe77d80e07eabe459f0</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2019.05.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2019.05.104%26sid%3Dliteratum%253Aachs%26aulast%3DEhmsen%26aufirst%3DS.%26aulast%3DPedersen%26aufirst%3DM.%2BH.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DTerp%26aufirst%3DM.%2BG.%26aulast%3DArslanagic%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DB.%2BL.%26aulast%3DConrads%26aufirst%3DT.%2BP.%26aulast%3DLeth-Larsen%26aufirst%3DR.%26aulast%3DDitzel%26aufirst%3DH.%2BJ.%26atitle%3DIncreased%2520cholesterol%2520biosynthesis%2520is%2520a%2520key%2520characteristic%2520of%2520breast%2520cancer%2520stem%2520cells%2520influencing%2520patient%2520outcome%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D27%26spage%3D3927%26epage%3D3938%26doi%3D10.1016%2Fj.celrep.2019.05.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jagust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Luxán-Delgado, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parejo-Alonso, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, P.</span></span> <span> </span><span class="NLM_article-title">Metabolism-based therapeutic strategies targeting cancer stem cells</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">203</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffphar.2019.00203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30967773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVCntrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=203&author=P.+Jagustauthor=B.+de+Lux%C3%A1n-Delgadoauthor=B.+Parejo-Alonsoauthor=P.+Sancho&title=Metabolism-based+therapeutic+strategies+targeting+cancer+stem+cells&doi=10.3389%2Ffphar.2019.00203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism-based therapeutic strategies targeting cancer stem cells</span></div><div class="casAuthors">Jagust, Petra; de Luxan-Delgado, Beatriz; Parejo-Alonso, Beatriz; Sancho, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">203</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Cancer heterogeneity constitutes the major source of disease progression and therapy failure.  Tumors comprise functionally diverse subpopulations, with cancer stem cells (CSCs) as the source of this heterogeneity.  Since these cells bear in vivo tumorigenicity and metastatic potential, survive chemotherapy and drive relapse, its elimination may be the only way to achieve long-term survival in patients.  Thanks to the great advances in the field over the last few years, we know now that cellular metab. and stemness are highly intertwined in normal development and cancer.  Indeed, CSCs show distinct metabolic features as compared with their more differentiated progenies, though their dominant metabolic phenotype varies across tumor entities, patients and even subclones within a tumor.  Following initial works focused on glucose metab., current studies have unveiled particularities of CSC metab. in terms of redox state, lipid metab. and use of alternative fuels, such as amino acids or ketone bodies.  In this review, we describe the different metabolic phenotypes attributed to CSCs with special focus on metab.-based therapeutic strategies tested in preclin. and clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7eSnFT9G7OLVg90H21EOLACvtfcHk0lggHZKMXKRvNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVCntrfE&md5=4f526f55599835df31c6ee24595ead16</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00203%26sid%3Dliteratum%253Aachs%26aulast%3DJagust%26aufirst%3DP.%26aulast%3Dde%2BLux%25C3%25A1n-Delgado%26aufirst%3DB.%26aulast%3DParejo-Alonso%26aufirst%3DB.%26aulast%3DSancho%26aufirst%3DP.%26atitle%3DMetabolism-based%2520therapeutic%2520strategies%2520targeting%2520cancer%2520stem%2520cells%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D203%26doi%3D10.3389%2Ffphar.2019.00203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kweon, G. R.</span></span> <span> </span><span class="NLM_article-title">L-Deprenyl exerts cytotoxicity towards acute myeloid leukemia through inhibition of mitochondrial respiration</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">3869</span>– <span class="NLM_lpage">3878</span>, <span class="refDoi"> DOI: 10.3892/or.2018.6753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3892%2For.2018.6753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30272370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFahu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2018&pages=3869-3878&author=I.+Ryuauthor=M.+J.+Ryuauthor=J.+Hanauthor=S.+J.+Kimauthor=M.+J.+Leeauthor=X.+Juauthor=B.+H.+Yooauthor=Y.+L.+Leeauthor=Y.+Jangauthor=I.+C.+Songauthor=W.+Chungauthor=E.+Ohauthor=J.+Y.+Heoauthor=G.+R.+Kweon&title=L-Deprenyl+exerts+cytotoxicity+towards+acute+myeloid+leukemia+through+inhibition+of+mitochondrial+respiration&doi=10.3892%2For.2018.6753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">L-Deprenyl exerts cytotoxicity towards acute myeloid leukemia through inhibition of mitochondrial respiration</span></div><div class="casAuthors">Ryu, Ilhwan; Ryu, Min Jeong; Han, Jeongsu; Kim, Soo Jeong; Lee, Min Joung; Ju, Xianshu; Yoo, Byeong Hyeon; Lee, Yu Lim; Jang, Yunseon; Song, Ik-Chan; Chung, Woosuk; Oh, Eungseok; Heo, Jun Young; Kweon, Gi Ryang</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3869-3878</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The identification of large nos. of genetic mutations in immature myeloid cells has made it difficult to identify specific targets for acute myeloid leukemia (AML) therapy.  Although current pharmacol. targets for controlling cancer are focused on identifying genetic mutations, it is hard to develop the specific drugs to achieve complete remission due to complex and variable genetic mutations.  To overcome the failure of the genetic mutation theory, the present study targeted mitochondrial metab. as a strategy for inducing anti.leukemic activity, based on evidence that AML cells have an abnormally high amt. of mitochondria and that somatic mutations can alter metabolic flux in cancer.  It was found that L.deprenyl, which is clin. available for the treatment of Parkinson's disease, exerts anti.mitochondria activity in KG.1α cells, as assessed by detection of oxygen consumption rate (OCR) and extracellular acidification (ECAR) using XF analyzer, resp.  Using a luciferase assay for detecting ATP (ATP) content, it was found that suppression of mitochondrial activity led to ATP depletion and was assocd. with potent cytotoxic activity.  L.deprenyl is known to target monoamine oxidase.B (MAO.B) on the outer membrane of mitochondria, therefore, the activity of MAO-A and -B was measured based on the fluorometric detection of H2O2 produced by the enzyme reaction.  Notably, MAO-A and -B activity was low in AML cells and the present findings suggested that the anticancer effect of L-deprenyl was independent of MAO-B.  Change of mitochondrial respiration. and glycolysis.related gene expression levels were measured by reverse transcription-quant. polymerase chain reaction.  Consistent with the aforementioned results, treatment with L-deprenyl reduced the mRNA level of mitochondrial respiration. and glycolysis.related genes.  Collectively, the present results identify L-deprenyl as a novel candidate for the treatment of AML through inhibition of mitochondrial respiration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxO4qJeJrAJ7Vg90H21EOLACvtfcHk0lggHZKMXKRvNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFahu73M&md5=5fb5f18450cbc7a25b85117e536dfb1c</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3892%2For.2018.6753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2018.6753%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DI.%26aulast%3DRyu%26aufirst%3DM.%2BJ.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DJu%26aufirst%3DX.%26aulast%3DYoo%26aufirst%3DB.%2BH.%26aulast%3DLee%26aufirst%3DY.%2BL.%26aulast%3DJang%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DI.%2BC.%26aulast%3DChung%26aufirst%3DW.%26aulast%3DOh%26aufirst%3DE.%26aulast%3DHeo%26aufirst%3DJ.%2BY.%26aulast%3DKweon%26aufirst%3DG.%2BR.%26atitle%3DL-Deprenyl%2520exerts%2520cytotoxicity%2520towards%2520acute%2520myeloid%2520leukemia%2520through%2520inhibition%2520of%2520mitochondrial%2520respiration%26jtitle%3DOncol.%2520Rep.%26date%3D2018%26volume%3D40%26spage%3D3869%26epage%3D3878%26doi%3D10.3892%2For.2018.6753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Thioridazine elicits potent antitumor effects in colorectal cancer stem cells</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1168</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.3892/or.2016.5313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3892%2For.2016.5313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=28000884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFyjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1168-1174&author=C.+Zhangauthor=P.+Gongauthor=P.+Liuauthor=N.+Zhouauthor=Y.+Zhouauthor=Y.+Wang&title=Thioridazine+elicits+potent+antitumor+effects+in+colorectal+cancer+stem+cells&doi=10.3892%2For.2016.5313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Thioridazine elicits potent antitumor effects in colorectal cancer stem cells</span></div><div class="casAuthors">Zhang, Chen; Gong, Ping; Liu, Pengfei; Zhou, Ning; Zhou, Yulai; Wang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1168-1174</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">As a member of the phenothiazine family, thioridazine (THIO) is a potent anti-anxiety and anti-psychotic drug.  Recent studies have reported that THIO could suppress the growth of several types of cancer cells.  However, the effect of THIO on colorectal cancer stem cells (CSCs) has not been investigated.  In the present study, we examd. the effect of THIO on viability of CSCs isolated from the human colon cancer cell line HCT116 and its colony-formation ability, along with its stem cell-specific gene expression.  The CSCs, EpCAM+ and CD44+ subpopulations from HCT116 cells were isolated using immunomagnetic beads.  After incubation with several concns. of THIO, we evaluated the proliferation and invasion ability of colon CSCs, as well as cell apoptosis.  We found that THIO significantly suppressed the proliferation and invasion of colon CSCs and induced cell apoptosis in a concn.-dependent manner.  The expression of some apoptosis genes (Bax and caspase-3) was upregulated after treatment with THIO, while that of the anti-apoptosis gene Bcl-2 was downregulated.  Moreover, the CSC mitochondrial membrane potential was downregulated.  Overall, this study showed that THIO inhibits the proliferation of CSCs derived from the HCT116 cell line through induction of apoptosis, and thus, could be a promising agent for the treatment of colon cancer and worthy of exploring in prospective clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnZ11sPRdcgbVg90H21EOLACvtfcHk0li_W8wDxKHL0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFyjtbk%253D&md5=9df4dea1fc137fdfc1b9cbdf1b031743</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.3892%2For.2016.5313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2016.5313%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DThioridazine%2520elicits%2520potent%2520antitumor%2520effects%2520in%2520colorectal%2520cancer%2520stem%2520cells%26jtitle%3DOncol.%2520Rep.%26date%3D2017%26volume%3D37%26spage%3D1168%26epage%3D1174%26doi%3D10.3892%2For.2016.5313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiou, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y. R.</span></span> <span> </span><span class="NLM_article-title">Thioridazine enhances P62-mediated autophagy and apoptosis through Wnt/β-catenin signaling pathway in glioma cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">473</span>, <span class="refDoi"> DOI: 10.3390/ijms20030473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fijms20030473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlSrs73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=473&author=C.+W.+Chuauthor=H.+J.+Koauthor=C.+H.+Chouauthor=T.+S.+Chengauthor=H.+W.+Chengauthor=Y.+H.+Liangauthor=Y.+L.+Laiauthor=C.+Y.+Linauthor=C.+Wangauthor=J.+K.+Lohauthor=J.+T.+Chengauthor=S.+J.+Chiouauthor=C.+L.+Suauthor=C.+F.+Huangauthor=Y.+R.+Hong&title=Thioridazine+enhances+P62-mediated+autophagy+and+apoptosis+through+Wnt%2F%CE%B2-catenin+signaling+pathway+in+glioma+cells&doi=10.3390%2Fijms20030473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Thioridazine enhances P62-mediated autophagy and apoptosis through Wnt/β-catenin signaling pathway in glioma cells</span></div><div class="casAuthors">Chu, Cheng-Wei; Ko, Huey-Jiun; Chou, Chia-Hua; Cheng, Tai-Shan; Cheng, Hui-Wen; Liang, Yu-Hsin; Lai, Yun-Ling; Lin, Chen-Yen; Wang, Chihuei; Loh, Joon-Khim; Cheng, Jiin-Tsuey; Chiou, Shean-Jaw; Su, Chun-Li; Huang, Chi-Ying F.; Hong, Yi-Ren</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">473</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Thioridazine (THD) is a common phenothiazine antipsychotic drug reported to suppress growth in several types of cancer cells.  We previously showed that THD acts as an antiglioblastoma and anticancer stem-like cell agent.  However, the signaling pathway underlying autophagy and apoptosis induction remains unclear.  THD treatment significantly induced autophagy with upregulated AMPK activity and engendered cell death with increased sub-G1 in glioblastoma multiform (GBM) cell lines.  Notably, through whole gene expression screening with THD treatment, frizzled (Fzd) proteins, a family of G-protein-coupled receptors, were found, suggesting the participation of Wnt/β-catenin signaling.  After THD treatment, Fzd-1 and GSK3β-S9 phosphorylation (inactivated form) was reduced to promote β-catenin degrdn., which attenuated P62 inhibition.  The autophagy marker LC3-II markedly increased when P62 was released from β-catenin inhibition.  Addnl., the P62-dependent caspase-8 activation that induced P53-independent apoptosis was confirmed by inhibiting T-cell factor/β-catenin and autophagy flux.  Moreover, treatment with THD combined with temozolomide (TMZ) engendered increased LC3-II expression and caspase-3 activity, indicating promising drug synergism.  In conclusion, THD induces autophagy in GBM cells by not only upregulating AMPK activity, but also enhancing P62-mediated autophagy and apoptosis through Wnt/β-catenin signaling.  Therefore, THD is a potential alternative therapeutic agent for drug repositioning in GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob1sZzqqhkrbVg90H21EOLACvtfcHk0li_W8wDxKHL0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlSrs73L&md5=24c6e8510f3884fc2345eb6735197b3b</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.3390%2Fijms20030473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20030473%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DC.%2BW.%26aulast%3DKo%26aufirst%3DH.%2BJ.%26aulast%3DChou%26aufirst%3DC.%2BH.%26aulast%3DCheng%26aufirst%3DT.%2BS.%26aulast%3DCheng%26aufirst%3DH.%2BW.%26aulast%3DLiang%26aufirst%3DY.%2BH.%26aulast%3DLai%26aufirst%3DY.%2BL.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLoh%26aufirst%3DJ.%2BK.%26aulast%3DCheng%26aufirst%3DJ.%2BT.%26aulast%3DChiou%26aufirst%3DS.%2BJ.%26aulast%3DSu%26aufirst%3DC.%2BL.%26aulast%3DHuang%26aufirst%3DC.%2BF.%26aulast%3DHong%26aufirst%3DY.%2BR.%26atitle%3DThioridazine%2520enhances%2520P62-mediated%2520autophagy%2520and%2520apoptosis%2520through%2520Wnt%252F%25CE%25B2-catenin%2520signaling%2520pathway%2520in%2520glioma%2520cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D473%26doi%3D10.3390%2Fijms20030473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weissenrieder, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moldovan, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koubek, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neighbors, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohl, R. J.</span></span> <span> </span><span class="NLM_article-title">The dopamine D2 receptor contributes to the spheroid formation behavior of U87 glioblastoma cells</span>. <i>Pharmacology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1159/000502562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1159%2F000502562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31645049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlWhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2020&pages=19-27&author=J.+S.+Weissenriederauthor=J.+L.+Reedauthor=M.+V.+Greenauthor=G.+L.+Moldovanauthor=E.+J.+Koubekauthor=J.+D.+Neighborsauthor=R.+J.+Hohl&title=The+dopamine+D2+receptor+contributes+to+the+spheroid+formation+behavior+of+U87+glioblastoma+cells&doi=10.1159%2F000502562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells</span></div><div class="casAuthors">Weissenrieder, Jillian S.; Reed, Jessie L.; Green, Michelle V.; Moldovan, George-Lucian; Koubek, Emily J.; Neighbors, Jeffrey D.; Hohl, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">19-27</span>CODEN:
                <span class="NLM_cas:coden">PHMGBN</span>;
        ISSN:<span class="NLM_cas:issn">0031-7012</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is a common and lethal cancer of the central nervous system.  This cancer is difficult to treat because most anticancer therapeutics do not readily penetrate into the brain due to the tight control at the cerebrovascular barrier.  Numerous studies have suggested that dopamine D2 receptor (D2R) antagonists, such as first generation antipsychotics, may have anticancer efficacy in vivo and in vitro.  The role of the D2R itself in the anticancer effects is unclear, but there is evidence suggesting that D2R activation promotes stem-like and spheroid forming behaviors in GBM.  We aimed to observe the role of the dopamine D2R and its modulators (at selective concns.) in spheroid formation and stemness of GBM cell line, U87MG, to clarify the validity of the D2R as a therapeutic target for cancer therapy.  Spheroid formation assays and Western blotting of the glioblastoma cell line, U87MG, were used to observe responses to treatment with the D2R agonists sumanirole, ropinirole, and 4-propyl-9-hydroxynaphthoxazine (PHNO); and the D2R antagonists thioridazine, pimozide, haloperidol, and remoxipride.  Extreme limiting diln. anal. was done to det. the impact of sumanirole and remoxipride treatment on sphere-forming cell frequency.  Proliferation was also measured by crystal violet staining.  Stable lentiviral transduction of DRD2 or shDRD2 was used to validate the role of the D2R in assay behaviors.  D2R antagonists thioridazine, pimozide, haloperidol, and remoxipride decrease spheroid formation behaviors at a selective 100 nmol/L concn., while D2R agonists PHNO, sumanirole, and ropinirole increase the formation of spheroids.  Similarly, 100 nmol/L remoxipride decreased sphere-forming cell frequency.  These results were recapitulated with genetic overexpression and knockdown of the D2R, and combination expts. indicate that the D2R is required for the effects of the pharmacol. modulators.  Furthermore, spheroid proliferation and invasive capacity increased under treatment with 100 nmol/L sumanirole and decreased under treatment with 100 nmol/L thioridazine.  Expression levels of the stemness markers Nestin and Sox2, as well as those of differentiation marker glial fibrillary acidic protein, were not altered by 100 nmol/L thioridazine or sumanirole for 72 h or continuous treatment with these compds. for 7 days during a spheroid formation assay.  Signaling activity of the dopamine D2R may be involved in the spheroid formation phenotype in the context of the U87MG cell line.  However, this modulation may not be due to alterations in stemness marker expression, but due to other factors that may contribute to spheroid formation, such as cell-cell adhesion or EGFR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMKGP_vHKUx7Vg90H21EOLACvtfcHk0liPl6Rq_Cdtdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlWhs7k%253D&md5=9cfd260f1553a52efc3719c730fafea0</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1159%2F000502562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000502562%26sid%3Dliteratum%253Aachs%26aulast%3DWeissenrieder%26aufirst%3DJ.%2BS.%26aulast%3DReed%26aufirst%3DJ.%2BL.%26aulast%3DGreen%26aufirst%3DM.%2BV.%26aulast%3DMoldovan%26aufirst%3DG.%2BL.%26aulast%3DKoubek%26aufirst%3DE.%2BJ.%26aulast%3DNeighbors%26aufirst%3DJ.%2BD.%26aulast%3DHohl%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520dopamine%2520D2%2520receptor%2520contributes%2520to%2520the%2520spheroid%2520formation%2520behavior%2520of%2520U87%2520glioblastoma%2520cells%26jtitle%3DPharmacology%26date%3D2020%26volume%3D105%26spage%3D19%26epage%3D27%26doi%3D10.1159%2F000502562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varga, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csonka, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csonka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molnár, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spengler, G.</span></span> <span> </span><span class="NLM_article-title">Possible biological and clinical applications of phenothiazines</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">5983</span>– <span class="NLM_lpage">5993</span>, <span class="refDoi"> DOI: 10.21873/anticanres.12045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.21873%2Fanticanres.12045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29061777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=5983-5993&author=B.+Vargaauthor=%C3%81.+Csonkaauthor=A.+Csonkaauthor=J.+Moln%C3%A1rauthor=L.+Amaralauthor=G.+Spengler&title=Possible+biological+and+clinical+applications+of+phenothiazines&doi=10.21873%2Fanticanres.12045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Possible biological and clinical applications of phenothiazines</span></div><div class="casAuthors">Varga, Borisz; Csonka, Akos; Csonka, Andrea; Molnar, Joseph; Amaral, Leonard; Spengler, Gabriella</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5983-5993</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Phenothiazines have been used in many areas of medicine, mainly in psychopharmacol.  These compds. are able to effectively inhibit dopamine, histamine, serotonin, acetylcholine, and α-adrenergic receptors; thus, their effect and side-effect profiles are extremely diverse.  Besides their antipsychotic activity, phenothiazines have a significant antimicrobial effect as well, since they can enhance the bactericidal function of macrophages and inhibit efflux pumps.  They are also able to eliminate bacteriaI resistance plasmids and destroy bacteria by their membrane-destabilizing effect.  Their antiviral, antiprotozoal, antifungal, and antiprion activities have also been described.  Phenothiazines have also been proven to destroy cancer cells and sensitize them to chemotherapy.  Anti-angiogenesis and anticancer stem cell activities have also been reported, and they might be applied as adjuvants in the treatment of infections and tumors in the future.  Finally, phenothiazines can also be effective in the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlGPaCIVQ3kLVg90H21EOLACvtfcHk0liPl6Rq_Cdtdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGqtr0%253D&md5=e3a53504392b7d0f82f8ac3f08e52ba9</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.21873%2Fanticanres.12045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21873%252Fanticanres.12045%26sid%3Dliteratum%253Aachs%26aulast%3DVarga%26aufirst%3DB.%26aulast%3DCsonka%26aufirst%3D%25C3%2581.%26aulast%3DCsonka%26aufirst%3DA.%26aulast%3DMoln%25C3%25A1r%26aufirst%3DJ.%26aulast%3DAmaral%26aufirst%3DL.%26aulast%3DSpengler%26aufirst%3DG.%26atitle%3DPossible%2520biological%2520and%2520clinical%2520applications%2520of%2520phenothiazines%26jtitle%3DAnticancer%2520Res.%26date%3D2017%26volume%3D37%26spage%3D5983%26epage%3D5993%26doi%3D10.21873%2Fanticanres.12045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oya, M.</span></span> <span> </span><span class="NLM_article-title">Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1431</span>– <span class="NLM_lpage">1441</span>, <span class="refDoi"> DOI: 10.1111/cas.13960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1111%2Fcas.13960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30719824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFOntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2019&pages=1431-1441&author=K.+Ogiharaauthor=E.+Kikuchiauthor=S.+Okazakiauthor=M.+Hagiwaraauthor=T.+Takedaauthor=K.+Matsumotoauthor=T.+Kosakaauthor=S.+Mikamiauthor=H.+Sayaauthor=M.+Oya&title=Sulfasalazine+could+modulate+the+CD44v9-xCT+system+and+enhance+cisplatin-induced+cytotoxic+effects+in+metastatic+bladder+cancer&doi=10.1111%2Fcas.13960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer</span></div><div class="casAuthors">Ogihara, Koichiro; Kikuchi, Eiji; Okazaki, Shogo; Hagiwara, Masayuki; Takeda, Toshikazu; Matsumoto, Kazuhiro; Kosaka, Takeo; Mikami, Shuji; Saya, Hideyuki; Oya, Mototsugu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1431-1441</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The prognostic role of CD44v9, a variant isoform of CD44 and a new cell surface marker of cancer stem cells, remains unclear in bladder cancer (BC) patients.  Furthermore, limited information is available on the functional role of sulfasalazine (SSZ), which could modulate the CD44v9-xCT system in order to enhance cisplatin (CDDP)-induced cytotoxicity and inhibit the metastatic potential of BC.  CD44v9 protein expression was examd. immunohistochem. in 63 muscle invasive BC (MIBC) patients who underwent radical cystectomy.  CD44v9 expression was independently assocd. with disease recurrence and cancer-specific death in MIBC.  Cytotoxic effects, glutathione levels, and reactive oxygen species prodn. by SSZ and CD44v9 and phospho-p38MAPK protein expression by SSZ with or without CDDP were assessed in MBT-2V cells with highly metastatic potential.  Sulfasalazine exerted cytotoxic effects against MBT-2V cells by inhibiting glutathione levels and inducing the prodn. of reactive oxygen species.  Sulfasalazine in combination with CDDP appeared to exert strong cytotoxic effects against MBT-2V cells by inhibiting CD44v9 expression and upregulating phospho-p38MAPK expression.  The inhibitory effects of SSZ with or without CDDP were also investigated using an MBT-2V lung metastatic model.  In the murine lung metastatic BC model, SSZ significantly prolonged animal survival.  Furthermore, the combination of SSZ with CDDP exerted stronger inhibitory effects on the establishment of lung tumor nodules than SSZ or CDDP alone.  CD44v9 expression could be a clin. biomarker for predicting poor outcomes in MIBC patients.  Sulfasalazine in combination with CDDP has potential as a novel therapy against metastatic BC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorFn5wHAFMV7Vg90H21EOLACvtfcHk0liPl6Rq_Cdtdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFOntLk%253D&md5=a69a9c62ca829f1c4aaae1e3e4687fd7</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1111%2Fcas.13960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13960%26sid%3Dliteratum%253Aachs%26aulast%3DOgihara%26aufirst%3DK.%26aulast%3DKikuchi%26aufirst%3DE.%26aulast%3DOkazaki%26aufirst%3DS.%26aulast%3DHagiwara%26aufirst%3DM.%26aulast%3DTakeda%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DMikami%26aufirst%3DS.%26aulast%3DSaya%26aufirst%3DH.%26aulast%3DOya%26aufirst%3DM.%26atitle%3DSulfasalazine%2520could%2520modulate%2520the%2520CD44v9-xCT%2520system%2520and%2520enhance%2520cisplatin-induced%2520cytotoxic%2520effects%2520in%2520metastatic%2520bladder%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2019%26volume%3D110%26spage%3D1431%26epage%3D1441%26doi%3D10.1111%2Fcas.13960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wada, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiba, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niizeki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torimura, T.</span></span> <span> </span><span class="NLM_article-title">High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: potential targets by sulfasalazine</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2801</span>– <span class="NLM_lpage">2810</span>, <span class="refDoi"> DOI: 10.1111/cas.13728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1111%2Fcas.13728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29981246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFanu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2018&pages=2801-2810&author=F.+Wadaauthor=H.+Kogaauthor=J.+Akibaauthor=T.+Niizekiauthor=H.+Iwamotoauthor=Y.+Ikezonoauthor=T.+Nakamuraauthor=M.+Abeauthor=A.+Masudaauthor=T.+Sakaueauthor=T.+Tanakaauthor=T.+Kakumaauthor=H.+Yanoauthor=T.+Torimura&title=High+expression+of+CD44v9+and+xCT+in+chemoresistant+hepatocellular+carcinoma%3A+potential+targets+by+sulfasalazine&doi=10.1111%2Fcas.13728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine</span></div><div class="casAuthors">Wada, Fumitaka; Koga, Hironori; Akiba, Jun; Niizeki, Takashi; Iwamoto, Hideki; Ikezono, Yu; Nakamura, Toru; Abe, Mitsuhiko; Masuda, Atsutaka; Sakaue, Takahiko; Tanaka, Toshimitsu; Kakuma, Tatsuyuki; Yano, Hirohisa; Torimura, Takuji</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2801-2810</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The aims of the present study were to assess: (i) expression status of CD44v9 and xCT in hepatocellular carcinoma (HCC) tissues, including those derived from patients treated with hepatic arterial infusion chemoembolization (HAIC) therapy with cisplatin (CDDP); and (ii) whether combination of CDDP with sulfasalazine (SASP), an inhibitor of xCT, was more effective on tumor cells than CDDP alone by inducing ROS-mediated apoptosis.  Twenty non-pretreated HCC tissues and 7 HCC tissues administered HAIC therapy with CDDP before surgical resection were subjected to immunohistochem. anal. of CD44v9 and xCT expression.  Human HCC cell lines HAK-1A and HAK-1B were used in this study; the latter was also used for xenograft expts. in nude mice to assess in vivo efficacy of combination treatment.  CD44v9 positivity was significantly higher in HAIC-treated tissues (5/7) than in non-pretreated tissues (2/30), suggesting the involvement of CD44v9 in the resistance to HAIC. xCT was significantly expressed in poorly differentiated HCC tissues.  Combination treatment effectively killed the CD44v9-harboring HAK-1B cells through ROS-mediated apoptosis and significantly decreased xenografted tumor growth.  In conclusion, the xCT inhibitor SASP augmented ROS-mediated apoptosis in CDDP-treated HCC cells, in which the CD44v9-xCT system functioned.  As CD44v9 is typically expressed in HAIC-resistant HCC cells, combination treatment with SASP with CDDP may overcome such drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYN0ghvFxGE7Vg90H21EOLACvtfcHk0lhUqJkEo5NoNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFanu7rE&md5=659a345da2d1d3a2fb2d4939922b05c7</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1111%2Fcas.13728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13728%26sid%3Dliteratum%253Aachs%26aulast%3DWada%26aufirst%3DF.%26aulast%3DKoga%26aufirst%3DH.%26aulast%3DAkiba%26aufirst%3DJ.%26aulast%3DNiizeki%26aufirst%3DT.%26aulast%3DIwamoto%26aufirst%3DH.%26aulast%3DIkezono%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DMasuda%26aufirst%3DA.%26aulast%3DSakaue%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKakuma%26aufirst%3DT.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DTorimura%26aufirst%3DT.%26atitle%3DHigh%2520expression%2520of%2520CD44v9%2520and%2520xCT%2520in%2520chemoresistant%2520hepatocellular%2520carcinoma%253A%2520potential%2520targets%2520by%2520sulfasalazine%26jtitle%3DCancer%2520Sci.%26date%3D2018%26volume%3D109%26spage%3D2801%26epage%3D2810%26doi%3D10.1111%2Fcas.13728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ralph, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozuhur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhulais, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Enríquez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Sánchez, R.</span></span> <span> </span><span class="NLM_article-title">Repurposing drugs as pro-oxidant redox modifiers to eliminate cancer stem cells and improve the treatment of advanced stage cancers</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2397</span>– <span class="NLM_lpage">2426</span>, <span class="refDoi"> DOI: 10.1002/med.21589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fmed.21589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31111530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3M7otVegsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=2397-2426&author=S.+J.+Ralphauthor=S.+Nozuhurauthor=R.+A.+Alhulaisauthor=S.+Rodr%C3%ADguez-Enr%C3%ADquezauthor=R.+Moreno-S%C3%A1nchez&title=Repurposing+drugs+as+pro-oxidant+redox+modifiers+to+eliminate+cancer+stem+cells+and+improve+the+treatment+of+advanced+stage+cancers&doi=10.1002%2Fmed.21589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing drugs as pro-oxidant redox modifiers to eliminate cancer stem cells and improve the treatment of advanced stage cancers</span></div><div class="casAuthors">Ralph Stephen J; Nozuhur Sam; ALHulais Reem Ali; Rodriguez-Enriquez Sara; Moreno-Sanchez Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2397-2426</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Over the last decade, three major advances have contributed in improving the response rates against cancer including, immunotherapy; greater understanding of the molecular, biochemical, and cellular mechanisms in carcinogenesis thereby providing drug targets; and identification of reliable biomarkers for early detection to facilitate the earlier stage treatment of disease.  However, no single universal cancer cure has yet been found, although combinations from the above areas have steadily improved survival outcomes.  Hence, chemotherapy remains a key component in the oncologist's arsenal for cancer therapy, despite frequent development of drug resistance and more aggressive cancers with onset of advanced stage metastases.  The focus here is to explore the repurposing of old drugs that cause pro-oxidative overload to overcome onset of resistance to chemotherapy and enhance chemotherapeutic responses, particularly against metastatic cancer.  Excellent examples of US Food and Drug Administration approved drugs suitable for repurposing are the potent and specific thioreductase inhibitor auranofin and the nonsteroidal anti-inflammatory drug, celecoxib.  Recently, both drugs were shown to selectively target and kill metastatic cancer cells and cancer stem cells (CSCs), predominantly by promoting excessive mitochondrial reactive oxygen species.  Thus, targeting intracellular redox systems of advanced stage metastatic cancer cells and CSCs can promote an overload of pro-oxidative stress to activate the intrinsic pathway for programmed cell death.  It is envisaged that more clinical studies will incorporate longer term use of repurposed drugs, such as auranofin or celecoxib, to target redox systems in cancer cells as part of common practice postcancer diagnosis, providing enhanced chemotherapeutic responses and increased cancer survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2i2MrU-cfcJSWdIdmEou5fW6udTcc2eZl9NITBW4sjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7otVegsw%253D%253D&md5=8bb0d2ecdda8689de5ce0ddb3064ea60</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1002%2Fmed.21589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21589%26sid%3Dliteratum%253Aachs%26aulast%3DRalph%26aufirst%3DS.%2BJ.%26aulast%3DNozuhur%26aufirst%3DS.%26aulast%3DAlhulais%26aufirst%3DR.%2BA.%26aulast%3DRodr%25C3%25ADguez-Enr%25C3%25ADquez%26aufirst%3DS.%26aulast%3DMoreno-S%25C3%25A1nchez%26aufirst%3DR.%26atitle%3DRepurposing%2520drugs%2520as%2520pro-oxidant%2520redox%2520modifiers%2520to%2520eliminate%2520cancer%2520stem%2520cells%2520and%2520improve%2520the%2520treatment%2520of%2520advanced%2520stage%2520cancers%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2019%26volume%3D39%26spage%3D2397%26epage%3D2426%26doi%3D10.1002%2Fmed.21589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashemi Goradel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najafi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salehi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farhood, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortezaee, K.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase-2 in cancer: a review</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">5683</span>– <span class="NLM_lpage">5699</span>, <span class="refDoi"> DOI: 10.1002/jcp.27411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fjcp.27411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30341914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKjurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2019&pages=5683-5699&author=N.+Hashemi+Goradelauthor=M.+Najafiauthor=E.+Salehiauthor=B.+Farhoodauthor=K.+Mortezaee&title=Cyclooxygenase-2+in+cancer%3A+a+review&doi=10.1002%2Fjcp.27411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase-2 in cancer: A review</span></div><div class="casAuthors">Hashemi Goradel, Nasser; Najafi, Masoud; Salehi, Eniseh; Farhood, Bagher; Mortezaee, Keywan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">5683-5699</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cyclooxygenase-2 (COX-2) is frequently expressed in many types of cancers exerting a pleiotropic and multifaceted role in genesis or promotion of carcinogenesis and cancer cell resistance to chemo- and radiotherapy.  COX-2 is released by cancer-assocd. fibroblasts (CAFs), macrophage type 2 (M2) cells, and cancer cells to the tumor microenvironment (TME).  COX-2 induces cancer stem cell (CSC)-like activity, and promotes apoptotic resistance, proliferation, angiogenesis, inflammation, invasion, and metastasis of cancer cells.  COX-2 mediated hypoxia within the TME along with its pos. interactions with YAP1 and antiapoptotic mediators are all in favor of cancer cell resistance to chemotherapeutic drugs.  COX-2 exerts most of the functions through its metabolite prostaglandin E2.  In some and limited situations, COX-2 may act as an antitumor enzyme.  Multiple signals are contributed to the functions of COX-2 on cancer cells or its regulation.  Members of mitogen-activated protein kinase (MAPK) family, epidermal growth factor receptor (EGFR), and nuclear factor-κβ are main upstream modulators for COX-2 in cancer cells.  COX-2 also has interactions with a no. of hormones within the body.  Inhibition of COX-2 provides a high possibility to exert therapeutic outcomes in cancer.  Administration of COX-2 inhibitors in a preoperative setting could reduce the risk of metastasis in cancer patients.  COX-2 inhibition also sensitizes cancer cells to treatments like radio- and chemotherapy.  Chemotherapeutic agents adversely induce COX-2 activity.  Therefore, choosing an appropriate chemotherapy drugs along with adjustment of the type and does for COX-2 inhibitors based on the type of cancer would be an effective adjuvant strategy for targeting cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGsqDfThyHLbVg90H21EOLACvtfcHk0lhUqJkEo5NoNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKjurnK&md5=e31cf4c374f72fe738e0fb5d1fbe2ab3</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1002%2Fjcp.27411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.27411%26sid%3Dliteratum%253Aachs%26aulast%3DHashemi%2BGoradel%26aufirst%3DN.%26aulast%3DNajafi%26aufirst%3DM.%26aulast%3DSalehi%26aufirst%3DE.%26aulast%3DFarhood%26aufirst%3DB.%26aulast%3DMortezaee%26aufirst%3DK.%26atitle%3DCyclooxygenase-2%2520in%2520cancer%253A%2520a%2520review%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D234%26spage%3D5683%26epage%3D5699%26doi%3D10.1002%2Fjcp.27411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, J.</span>; <span class="NLM_string-name">Jiang, Z.</span></span> <span> </span><span class="NLM_article-title">Application of Omeprazole in the Preparation of Liver Cancer Stem Cell Inhibitors</span>. Chin. Patent <span class="NLM_patent">108,685,919 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Xing&author=Z.+Jiang&title=Application+of+Omeprazole+in+the+Preparation+of+Liver+Cancer+Stem+Cell+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DJ.%26atitle%3DApplication%2520of%2520Omeprazole%2520in%2520the%2520Preparation%2520of%2520Liver%2520Cancer%2520Stem%2520Cell%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Proton pump inhibitor pantoprazole inhibits the proliferation, self-renewal and chemoresistance of gastric cancer stem cells via the EMT/β-catenin pathways</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">3207</span>– <span class="NLM_lpage">3214</span>, <span class="refDoi"> DOI: 10.3892/or.2016.5154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3892%2For.2016.5154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=27748935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1aqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=3207-3214&author=S.+Fengauthor=Z.+Zhengauthor=L.+Fengauthor=L.+Yangauthor=Z.+Chenauthor=Y.+Linauthor=Y.+Gaoauthor=Y.+Chen&title=Proton+pump+inhibitor+pantoprazole+inhibits+the+proliferation%2C+self-renewal+and+chemoresistance+of+gastric+cancer+stem+cells+via+the+EMT%2F%CE%B2-catenin+pathways&doi=10.3892%2For.2016.5154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Proton pump inhibitor pantoprazole inhibits the proliferation, self-renewal and chemoresistance of gastric cancer stem cells via the EMT/β-catenin pathways</span></div><div class="casAuthors">Feng, Shuitu; Zheng, Zhigao; Feng, Lihua; Yang, Lihong; Chen, Zuhong; Lin, Yubiao; Gao, Yingqin; Chen, Yide</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3207-3214</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The cancer stem cell (CSC) model suggests that a small subset of cancer cells possess stem cell properties and plays a crucial role in tumor initiation, metastasis and resistance to anticancer therapy.  Exploration of the specific therapies targeting at CSCs has been a crucial issue in antitumor research.  Gastric cancer (GC) cells often exist in an ischemic microenvironment with acidic conditions in vivo, thus maintenance of cellular pH homeostasis is important for the survival and function of GC cells.  Proton pump inhibitors (PPIs) may prevent intracellular proton extrusions which consequently reduce cancer cell survival under acidic conditions.  The effects of PPIs on the suppression of the viability and invasiveness of GC cells have been reported, but the functional role of pantoprazole (PPZ) in GC cells remains unknown.  In this study, we found that when cells were treated with PPZ, the 5-fluorouracil (5-FU) chemosensitivity was upregulated, meanwhile the sphere formation ability and the relative expression levels of stem cell markers CD44, CD24, ABCG2, EpCAM and Lgr5 were significantly decreased.  It was hypothesized that PPZ inhibits the GC CSCs.  Successively a sphere formation culture was performed to establish CSC models and the effect of PPZ on GC CSCs from SGC-7901 and HGC-27 cells was explored.  The addn. of PPZ reduced the relative expression of CSC markers and anti-drug markers accompanied by a decrease in proliferation, 5-FU chemoresistance and self-renewal capacity via epithelial-mesenchymal transition (EMT)/β-catenin pathways.  The study suggests that PPZ could be a promising novel specific therapeutic strategy for targeting GC CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4EV8maKK0vLVg90H21EOLACvtfcHk0liRSdH33aKsIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1aqtr0%253D&md5=0c7445b61775d373022c66a477e22f71</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.3892%2For.2016.5154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2016.5154%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DProton%2520pump%2520inhibitor%2520pantoprazole%2520inhibits%2520the%2520proliferation%252C%2520self-renewal%2520and%2520chemoresistance%2520of%2520gastric%2520cancer%2520stem%2520cells%2520via%2520the%2520EMT%252F%25CE%25B2-catenin%2520pathways%26jtitle%3DOncol.%2520Rep.%26date%3D2016%26volume%3D36%26spage%3D3207%26epage%3D3214%26doi%3D10.3892%2For.2016.5154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Negri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naponelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettuzzi, S.</span></span> <span> </span><span class="NLM_article-title">Molecular targets of epigallocatechin-gallate (EGCG): A special focus on signal transduction and cancer</span>. <i>Nutrients</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1936</span>, <span class="refDoi"> DOI: 10.3390/nu10121936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fnu10121936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlWjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1936&author=A.+Negriauthor=V.+Naponelliauthor=F.+Rizziauthor=S.+Bettuzzi&title=Molecular+targets+of+epigallocatechin-gallate+%28EGCG%29%3A+A+special+focus+on+signal+transduction+and+cancer&doi=10.3390%2Fnu10121936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular targets of epigallocatechin-gallate (egcg): a special focus on signal transduction and cancer</span></div><div class="casAuthors">Negri, Aide; Naponelli, Valeria; Rizzi, Federica; Bettuzzi, Saverio</div><div class="citationInfo"><span class="NLM_cas:title">Nutrients</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1936/1-1936/24</span>CODEN:
                <span class="NLM_cas:coden">NUTRHU</span>;
        ISSN:<span class="NLM_cas:issn">2072-6643</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Green tea is a beverage that is widely consumed worldwide and is believed to exert effects on different diseases, including cancer.  The major components of green tea are catechins, a family of polyphenols.  Among them, epigallocatechin-gallate (EGCG) is the most abundant and biol. active.  EGCG is widely studied for its anti-cancer properties.  However, the cellular and mol. mechanisms explaining its action have not been completely understood, yet.  EGCG is effective in vivo at micromolar concns., suggesting that its action is mediated by interaction with specific targets that are involved in the regulation of crucial steps of cell proliferation, survival, and metastatic spread.  Recently, several proteins have been identified as EGCG direct interactors.  Among them, the trans-membrane receptor 67LR has been identified as a high affinity EGCG receptor.  67LR is a master regulator of many pathways affecting cell proliferation or apoptosis, also regulating cancer stem cells (CSCs) activity.  EGCG was also found to be interacting directly with Pin1, TGFR-II, and metalloproteinases (MMPs) (mainly MMP2 and MMP9), which resp. regulate EGCG-dependent inhibition of NF-kB, epithelial-mesenchimal transaction (EMT) and cellular invasion.  EGCG interacts with DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), which modulates epigenetic changes.  The bulk of this novel knowledge provides information about the mechanisms of action of EGCG and may explain its onco-suppressive function.  The identification of crucial signalling pathways that are related to cancer onset and progression whose master regulators interacts with EGCG may disclose intriguing pharmacol. targets, and eventually lead to novel combined treatments in which EGCG acts synergistically with known drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF-kl3fzlnirVg90H21EOLACvtfcHk0liRSdH33aKsIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlWjtbw%253D&md5=5ec1904b1e7efc04c1b80d7b13cdf908</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.3390%2Fnu10121936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fnu10121936%26sid%3Dliteratum%253Aachs%26aulast%3DNegri%26aufirst%3DA.%26aulast%3DNaponelli%26aufirst%3DV.%26aulast%3DRizzi%26aufirst%3DF.%26aulast%3DBettuzzi%26aufirst%3DS.%26atitle%3DMolecular%2520targets%2520of%2520epigallocatechin-gallate%2520%2528EGCG%2529%253A%2520A%2520special%2520focus%2520on%2520signal%2520transduction%2520and%2520cancer%26jtitle%3DNutrients%26date%3D2018%26volume%3D10%26spage%3D1936%26doi%3D10.3390%2Fnu10121936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel human inosine 5′-monophosphate dehydrogenase 2 (<i>h</i>IMPDH2) inhibitors as potential anticancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.09.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.ejmech.2018.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30223117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslejtrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=286-301&author=C.+P.+Shahauthor=P.+S.+Kharkar&title=Discovery+of+novel+human+inosine+5%E2%80%B2-monophosphate+dehydrogenase+2+%28hIMPDH2%29+inhibitors+as+potential+anticancer+agents&doi=10.1016%2Fj.ejmech.2018.09.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102aR"><div class="casContent"><span class="casTitleNuber">102a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents</span></div><div class="casAuthors">Shah, Chetan P.; Kharkar, Prashant S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">286-301</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The enzyme IMP dehydrogenase (IMPDH) catalyzes an essential step in the de novo biosynthesis of guanine nucleotides, and thus regulates the guanine nucleotide pool required for cell proliferation.  Of the two isoforms, human IMPDH type 2 (hIMPDH2) is a validated mol. target for potential immunosuppressive, antiviral and anticancer chemotherapy.  In search of newer hIMPDH2 inhibitors as potential anticancer agents, three novel series (A: 5-aminoisobenzofuran-1(3H)-one, B: 3,4-dimethoxyaniline and C: benzo[d]-[1,3]dioxol-5-ylmethanamine) were synthesized and evaluated for in vitro and cell-based activities.  A total of 37 mols. (29-65) were screened for their in vitrohIMPDH2 inhibition, with particular emphasis on establishing their structure-activity relationship (SAR) trends.  Eight compds. (hits, 30, 31, 33-35, 37, 41 and 43) demonstrated significant enzyme inhibition (>70% @ 10 μM); esp. the A series mols. were more potent than B series (<70% inhibition @ 10 μM), while C series members were found to be inactive.  The hIMPDH2 IC50 values for the hits ranged from 0.36 to 7.38 μM.  The hits displaying >80% hIMPDH2 inhibition (30, 33, 35, 41 and 43) were further assessed for their cytotoxic activity against cancer cell lines such as MDA-MB-231 (breast adenocarcinoma), DU145 (prostate carcinoma), U87 MG (glioblastoma astrocytoma) and a normal cell line, NIH-3T3 (mouse embryonic fibroblast) using MTT assay.  Most of the compds. exhibited higher cellular potency against cancer cell lines and notably lower toxicity towards NIH-3T3 cells compared to mycophenolic acid (MPA), a prototypical hIMPDH2 inhibitor.  Two of the series A hits (30 and 35) were evaluated in human peripheral blood mononuclear cells (hPBMC) assay and found to be better tolerated than MPA.  The calcd./predicted mol. and physicochem. properties were satisfactory with ref. to drug-likeness.  The mol. docking studies clearly demonstrated crucial interactions of the hits with the cofactor-binding site of hIMPDH2, further providing crit. information for refining the design strategy.  The present study reports the design and discovery of structurally novel hIMPDH2 inhibitors as potential anticancer agents and provides a guide for further research on the development of safe and effective anticancer agents, esp. against glioblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhmbzyYpNNNLVg90H21EOLACvtfcHk0lhk4Exq9XeW_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslejtrnJ&md5=c2c2291dc8a79e7166d561f01674fb7d</span></div><a href="/servlet/linkout?suffix=cit102a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DC.%2BP.%26aulast%3DKharkar%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520novel%2520human%2520inosine%25205%25E2%2580%25B2-monophosphate%2520dehydrogenase%25202%2520%2528hIMPDH2%2529%2520inhibitors%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D158%26spage%3D286%26epage%3D301%26doi%3D10.1016%2Fj.ejmech.2018.09.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit102b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P. S.</span></span> <span> </span><span class="NLM_article-title">Newer human inosine 5′-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">972</span>– <span class="NLM_lpage">977</span>, <span class="refDoi"> DOI: 10.1080/14756366.2018.1474211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1080%2F14756366.2018.1474211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29792360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSksr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=972-977&author=C.+P.+Shahauthor=P.+S.+Kharkar&title=Newer+human+inosine+5%E2%80%B2-monophosphate+dehydrogenase+2+%28hIMPDH2%29+inhibitors+as+potential+anticancer+agents&doi=10.1080%2F14756366.2018.1474211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102bR"><div class="casContent"><span class="casTitleNuber">102b</span><div class="casTitle"><span class="NLM_cas:atitle">Newer human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents</span></div><div class="casAuthors">Shah, Chetan P.; Kharkar, Prashant S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">972-977</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Human IMP dehydrogenase 2 (hIMPDH2), being an age-old target, has attracted attention recently for anticancer drug development.  Mycophenolic acid (MPA), a well-known immunosuppressant drug, was used as a lead structure to design and develop modestly potent and selective analogs.  The steep structure-activity relationship (SAR) requirements of the lead mol. left little scope to synthesize newer analogs.  Here, newer MPA amides were designed, synthesized and evaluated for hIMPDH2 inhibition and cellular efficacy in breast, prostate and glioblastoma cell lines.  Few title compds. exhibited cellular activity profile better than MPA itself.  The obsd. differences in the overall biol. profile could be attributed to improved structural and physicochem. properties of the analogs over MPA.  This is the first report of the activity of MPA derivs. in glioblastoma, the most aggressive brain cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKuXD_2XMr0rVg90H21EOLACvtfcHk0lhk4Exq9XeW_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSksr7K&md5=0b1719ab201ab15f2b68f286229657bf</span></div><a href="/servlet/linkout?suffix=cit102b&amp;dbid=16384&amp;doi=10.1080%2F14756366.2018.1474211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2018.1474211%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DC.%2BP.%26aulast%3DKharkar%26aufirst%3DP.%2BS.%26atitle%3DNewer%2520human%2520inosine%25205%25E2%2580%25B2-monophosphate%2520dehydrogenase%25202%2520%2528hIMPDH2%2529%2520inhibitors%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2018%26volume%3D33%26spage%3D972%26epage%3D977%26doi%3D10.1080%2F14756366.2018.1474211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talukdar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emdad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span> <span> </span><span class="NLM_article-title">EGFR: an essential receptor tyrosine kinase - regulator of cancer stem cells</span>. <i>Adv. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1016/bs.acr.2020.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fbs.acr.2020.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32593400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB38nltlyhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2020&pages=161-188&author=S.+Talukdarauthor=L.+Emdadauthor=S.+K.+Dasauthor=P.+B.+Fisher&title=EGFR%3A+an+essential+receptor+tyrosine+kinase+-+regulator+of+cancer+stem+cells&doi=10.1016%2Fbs.acr.2020.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells</span></div><div class="casAuthors">Talukdar Sarmistha; Emdad Luni; Das Swadesh K; Fisher Paul B</div><div class="citationInfo"><span class="NLM_cas:title">Advances in cancer research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161-188</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Epidermal Growth Factor Receptor (EGFR) is frequently expressed at elevated levels in different forms of cancer and expression often correlates positively with cancer progression and poor prognosis.  Different mutant forms of this protein also contribute to cancer heterogeneity.  A constitutively active form of EGFR, EGFRvIII is one of the most important variants.  EGFR is responsible for the maintenance and functions of cancer stem cells (CSCs), including stemness, metabolism, immunomodulatory-activity, dormancy and therapy-resistance.  EGFR regulates these pathways through several signaling cascades, and often cooperates with other RTKs to exert further control.  Inhibitors of EGFR have been extensively studied and display some anticancer efficacy.  However, CSCs can also acquire resistance to EGFR inhibitors making effective therapy even more difficult.  To ameliorate this limitation of EGFR inhibitors when used as single agents, it may be of value to simultaneously combine multiple EGFR inhibitors or use EGFR inhibitors with regulators of other important cancer phenotype regulating molecules, such as STAT3, or involved in important processes such as DNA repair.  These combinatorial approaches require further experimental confirmation, but if successful would expand and improve therapeutic outcomes employing EGFR inhibitors as one arm of the therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhTqCS5C5LGRpyrDyM_m9cfW6udTcc2ebth8UxH2Szybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38nltlyhtg%253D%253D&md5=a91786d785a1825000b9975756ec3864</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fbs.acr.2020.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.acr.2020.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DTalukdar%26aufirst%3DS.%26aulast%3DEmdad%26aufirst%3DL.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26atitle%3DEGFR%253A%2520an%2520essential%2520receptor%2520tyrosine%2520kinase%2520-%2520regulator%2520of%2520cancer%2520stem%2520cells%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2020%26volume%3D147%26spage%3D161%26epage%3D188%26doi%3D10.1016%2Fbs.acr.2020.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P. S.</span></span> <span> </span><span class="NLM_article-title">Computational approaches for the design of (mutant-) selective tyrosine kinase inhibitors: State-of-the-art and future prospects</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1564</span>– <span class="NLM_lpage">1575</span>, <span class="refDoi"> DOI: 10.2174/1568026620666200502005853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.2174%2F1568026620666200502005853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32357816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslKjurbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=1564-1575&author=P.+S.+Kharkar&title=Computational+approaches+for+the+design+of+%28mutant-%29+selective+tyrosine+kinase+inhibitors%3A+State-of-the-art+and+future+prospects&doi=10.2174%2F1568026620666200502005853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Computational Approaches for the Design of (Mutant-)Selective Tyrosine Kinase Inhibitors: State-of-the-Art and Future Prospects</span></div><div class="casAuthors">Kharkar, Prashant S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1564-1575</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases remain one of the major attractive therapeutic targets for a large no. of indications such as cancer, rheumatoid arthritis, cardiac failure and many others.  Design and development of kinase inhibitors (ATP-competitive, allosteric or covalent) is a clin. validated and successful strategy in the pharmaceutical industry.  The perks come with limitations, particularly the development of resistance to highly potent and selective inhibitors.  When this happens, the cycle needs to be repeated, i.e., the design and development of kinase inhibitors active against the mutated forms.  Several computational approaches such as structure-, ligand-based or hybrid ones continue to live up to their potential in discovering novel kinase inhibitors.  In addn. to the conventional strategies, modern technologies (machine learning, deep learning, artificial intelligence, etc.) started yielding the results and building success stories.  Computational tools invariably played a crit. role in catalyzing the phenomenal progress in kinase drug discovery field.  The present review summarized the progress in utilizing computational methods and tools for discovering (mutant-)selective tyrosine kinase inhibitor drugs in the last three years (2017-2019).  The author believes that the enthusiastic reader will be inspired to dig out the cited literature extensively to appreciate the progress made so far and the future prospects of the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWqfC-VaBs67Vg90H21EOLACvtfcHk0lhk4Exq9XeW_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslKjurbE&md5=011a0c275b4a24d43de999ae6efc1565</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.2174%2F1568026620666200502005853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026620666200502005853%26sid%3Dliteratum%253Aachs%26aulast%3DKharkar%26aufirst%3DP.%2BS.%26atitle%3DComputational%2520approaches%2520for%2520the%2520design%2520of%2520%2528mutant-%2529%2520selective%2520tyrosine%2520kinase%2520inhibitors%253A%2520State-of-the-art%2520and%2520future%2520prospects%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2020%26volume%3D20%26spage%3D1564%26epage%3D1575%26doi%3D10.2174%2F1568026620666200502005853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.</span></span> <span> </span><span class="NLM_article-title">Regulation of Src family kinases during colorectal cancer development and its clinical implications</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1339</span>, <span class="refDoi"> DOI: 10.3390/cancers12051339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcancers12051339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVehsLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1339&author=W.+Jin&title=Regulation+of+Src+family+kinases+during+colorectal+cancer+development+and+its+clinical+implications&doi=10.3390%2Fcancers12051339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of Src family kinases during colorectal cancer development and its clinical implications</span></div><div class="casAuthors">Jin, Wook</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1339</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Src family kinases (SFKs) are non-receptor kinases that play a crit. role in the pathogenesis of colorectal cancer (CRC).  The expression and activity of SFKs are upregulated in patients with CRC.  Activation of SFKs promotes CRC cell proliferation, metastases to other organs and chemoresistance, as well as the formation of cancer stem cells (CSCs).  The enhanced expression level of Src is assocd. with decreased survival in patients with CRC.  Src-mediated regulation of CRC progression involves various membrane receptors, modulators, and suppressors, which regulate Src activation and its downstream targets through various mechanisms.  This review provides an overview of the current understanding of the correlations between Src and CRC progression, with a special focus on cancer cell proliferation, invasion, metastasis and chemoresistance, and formation of CSCs.  Addnl., this review discusses preclin. and clin. strategies to improve the therapeutic efficacy of drugs targeting Src for treating patients with CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYjUh5ZnbAubVg90H21EOLACvtfcHk0lhlg5yi1kYEGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVehsLrJ&md5=33c88dad0fb0490a3f060fe5522f74d4</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.3390%2Fcancers12051339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12051339%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DW.%26atitle%3DRegulation%2520of%2520Src%2520family%2520kinases%2520during%2520colorectal%2520cancer%2520development%2520and%2520its%2520clinical%2520implications%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D1339%26doi%3D10.3390%2Fcancers12051339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daday, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jobst, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milles, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercadante, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippig, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaub, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gräter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span> <span> </span><span class="NLM_article-title">Structural and mechanistic insights into mechanoactivation of focal adhesion kinase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">6766</span>– <span class="NLM_lpage">6774</span>, <span class="refDoi"> DOI: 10.1073/pnas.1820567116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1073%2Fpnas.1820567116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30877242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsFeqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=6766-6774&author=M.+S.+Bauerauthor=F.+Baumannauthor=C.+Dadayauthor=P.+Redondoauthor=E.+Durnerauthor=M.+A.+Jobstauthor=L.+F.+Millesauthor=D.+Mercadanteauthor=D.+A.+Pippigauthor=H.+E.+Gaubauthor=F.+Gr%C3%A4terauthor=D.+Lietha&title=Structural+and+mechanistic+insights+into+mechanoactivation+of+focal+adhesion+kinase&doi=10.1073%2Fpnas.1820567116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and mechanistic insights into mechanoactivation of focal adhesion kinase</span></div><div class="casAuthors">Bauer, Magnus Sebastian; Baumann, Fabian; Daday, Csaba; Redondo, Pilar; Durner, Ellis; Jobst, Markus Andreas; Milles, Lukas Frederik; Mercadante, Davide; Pippig, Diana Angela; Gaub, Hermann Eduard; Grater, Frauke; Lietha, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6766-6774</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a key signaling mol. regulating cell adhesion, migration, and survival.  FAK localizes into focal adhesion complexes formed at the cytoplasmic side of cell attachment to the ECM and is activated after force generation via actomyosin fibers attached to this complex.  The mechanism of translating mech. force into a biochem. signal is not understood, and it is not clear whether FAK is activated directly by force or downstream to the force signal.  We use exptl. and computational single-mol. force spectroscopy to probe the mech. properties of FAK and examine whether force can trigger activation by inducing conformational changes in FAK.  By comparison with an open and active mutant of FAK, we are able to assign mechanoactivation to an initial rupture event in the low-force range.  This activation event occurs before FAK unfolding at forces within the native range in focal adhesions.  We are also able to assign all subsequent peaks in the force landscape to partial unfolding of FAK modules.  We show that binding of ATP stabilizes the kinase domain, thereby altering the unfolding hierarchy.  Using all-atom mol. dynamics simulations, we identify intermediates along the unfolding pathway, which provide buffering to allow extension of FAK in focal adhesions without compromising functionality.  Our findings strongly support that forces in focal adhesions applied to FAK via known interactions can induce conformational changes, which in turn, trigger focal adhesion signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2-XSryEbUc7Vg90H21EOLACvtfcHk0lhlg5yi1kYEGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsFeqsrY%253D&md5=fb257abca1423f6c4434177002178c8a</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1820567116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1820567116%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DM.%2BS.%26aulast%3DBaumann%26aufirst%3DF.%26aulast%3DDaday%26aufirst%3DC.%26aulast%3DRedondo%26aufirst%3DP.%26aulast%3DDurner%26aufirst%3DE.%26aulast%3DJobst%26aufirst%3DM.%2BA.%26aulast%3DMilles%26aufirst%3DL.%2BF.%26aulast%3DMercadante%26aufirst%3DD.%26aulast%3DPippig%26aufirst%3DD.%2BA.%26aulast%3DGaub%26aufirst%3DH.%2BE.%26aulast%3DGr%25C3%25A4ter%26aufirst%3DF.%26aulast%3DLietha%26aufirst%3DD.%26atitle%3DStructural%2520and%2520mechanistic%2520insights%2520into%2520mechanoactivation%2520of%2520focal%2520adhesion%2520kinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26spage%3D6766%26epage%3D6774%26doi%3D10.1073%2Fpnas.1820567116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnawi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Khaldi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakheet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallatah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alaiya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghebeh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Alwan, M.</span></span> <span> </span><span class="NLM_article-title">Fascin activates β-catenin signaling and promotes breast cancer stem cell function mainly through focal adhesion kinase (FAK): relation with disease progression</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">440</span>, <span class="refDoi"> DOI: 10.3389/fonc.2020.00440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffonc.2020.00440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32373510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB38vjsV2muw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=440&author=R.+Barnawiauthor=S.+Al-Khaldiauthor=T.+Bakheetauthor=M.+Fallatahauthor=A.+Alaiyaauthor=H.+Ghebehauthor=M.+Al-Alwan&title=Fascin+activates+%CE%B2-catenin+signaling+and+promotes+breast+cancer+stem+cell+function+mainly+through+focal+adhesion+kinase+%28FAK%29%3A+relation+with+disease+progression&doi=10.3389%2Ffonc.2020.00440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Fascin Activates β-Catenin Signaling and Promotes Breast Cancer Stem Cell Function Mainly Through Focal Adhesion Kinase (FAK): Relation With Disease Progression</span></div><div class="casAuthors">Barnawi Rayanah; Alaiya Ayodele; Ghebeh Hazem; Al-Alwan Monther; Al-Khaldi Samiyah; Fallatah Mohannad; Bakheet Tala; Ghebeh Hazem; Al-Alwan Monther</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">440</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Cancer stem cells (CSCs), a rare population of tumor cells with high self-renewability potential, have gained increasing attention due to their contribution to chemoresistance and metastasis.  We have previously demonstrated a critical role for the actin-bundling protein (fascin) in mediating breast cancer chemoresistance through activation of focal adhesion kinase (FAK).  The latter is known to trigger the β-catenin signaling pathway.  Whether fascin activation of FAK would ultimately trigger β-catenin signaling pathway has not been elucidated.  Here, we assessed the effect of fascin manipulation in breast cancer cells on triggering β-catenin downstream targets and its dependence on FAK.  Gain and loss of fascin expression showed its direct effect on the constitutive expression of β-catenin downstream targets and enhancement of self-renewability.  In addition, fascin was essential for glycogen synthase kinase 3β inhibitor-mediated inducible expression and function of the β-catenin downstream targets.  Importantly, fascin-mediated constitutive and inducible expression of β-catenin downstream targets, as well as its subsequent effect on CSC function, was at least partially FAK dependent.  To assess the clinical relevance of the in vitro findings, we evaluated the consequence of fascin, FAK, and β-catenin downstream target coexpression on the outcome of breast cancer patient survival.  Patients with coexpression of fascin(high) and FAK(high) or high β-catenin downstream targets showed the worst survival outcome, whereas in fascin(low), patient coexpression of FAK(high) or high β-catenin targets had less significant effect on the survival.  Altogether, our data demonstrated the critical role of fascin-mediated β-catenin activation and its dependence on intact FAK signaling to promote breast CSC function.  These findings suggest that targeting of fascin-FAK-β-catenin axis may provide a novel therapeutic approach for eradication of breast cancer from the root.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0ZMud5GFokPEeosoOnpOLfW6udTcc2eZXsnp-xWLqM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38vjsV2muw%253D%253D&md5=067cb6f178e2c78e5ce966795d5a368a</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2020.00440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2020.00440%26sid%3Dliteratum%253Aachs%26aulast%3DBarnawi%26aufirst%3DR.%26aulast%3DAl-Khaldi%26aufirst%3DS.%26aulast%3DBakheet%26aufirst%3DT.%26aulast%3DFallatah%26aufirst%3DM.%26aulast%3DAlaiya%26aufirst%3DA.%26aulast%3DGhebeh%26aufirst%3DH.%26aulast%3DAl-Alwan%26aufirst%3DM.%26atitle%3DFascin%2520activates%2520%25CE%25B2-catenin%2520signaling%2520and%2520promotes%2520breast%2520cancer%2520stem%2520cell%2520function%2520mainly%2520through%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%253A%2520relation%2520with%2520disease%2520progression%26jtitle%3DFront.%2520Oncol.%26date%3D2020%26volume%3D10%26spage%3D440%26doi%3D10.3389%2Ffonc.2020.00440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolev, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, Q. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of FAK kinase activity preferentially targets cancer stem cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">51733</span>– <span class="NLM_lpage">51747</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.18517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.18632%2Foncotarget.18517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=28881682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC1cbls1yiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=51733-51747&author=V.+N.+Kolevauthor=W.+F.+Tamauthor=Q.+G.+Wrightauthor=S.+P.+McDermottauthor=C.+M.+Vidalauthor=I.+M.+Shapiroauthor=Q.+Xuauthor=M.+S.+Wichaauthor=J.+A.+Pachterauthor=D.+T.+Weaver&title=Inhibition+of+FAK+kinase+activity+preferentially+targets+cancer+stem+cells&doi=10.18632%2Foncotarget.18517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of FAK kinase activity preferentially targets cancer stem cells</span></div><div class="casAuthors">Kolev Vihren N; Tam Winnie F; Wright Quentin G; Vidal Christian M; Shapiro Irina M; Xu Qunli; Pachter Jonathan A; Weaver David T; McDermott Sean P; Wicha Max S</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">51733-51747</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting of CSCs holds promise to address these clinical challenges to cancer treatment.  VS-4718 and VS-6063 are potent inhibitors of focal adhesion kinase (FAK), a non-receptor tyrosine kinase that mediates cell signals transmitted by integrins and growth factor receptors.  We report here that inhibition of FAK kinase activity by VS-4718 or VS-6063 preferentially targets CSCs, as demonstrated by a panel of orthogonal CSC assays in cell line models and surgically resected primary breast tumor specimens cultured ex vivo.  Oral administration of VS-4718 or VS-6063 to mice bearing xenograft models of triple-negative breast cancer (TNBC) significantly reduced the proportion of CSCs in the tumors, as evidenced by a reduced tumor-initiating capability upon re-implantation in limiting dilutions of cells prepared from these tumors.  In contrast, the cytotoxic chemotherapeutic agents, paclitaxel and carboplatin, enriched for CSCs, consistent with previous reports that these cytotoxic agents preferentially target non-CSCs.  Importantly, VS-4718 and VS-6063 attenuated the chemotherapy-induced enrichment of CSCs in vitro and delayed tumor regrowth following cessation of chemotherapy.  An intriguing crosstalk between FAK and the Wnt/β-catenin pathway was revealed wherein FAK inhibition blocks β-catenin activation by reducing tyrosine 654 phosphorylation of β-catenin.  Furthermore, a constitutively active mutant form of β-catenin reversed the preferential targeting of CSCs by FAK inhibition, suggesting that this targeting is mediated, at least in part, through attenuating β-catenin activation.  The preferential targeting of cancer stem cells by FAK inhibitors provides a rationale for the clinical development of FAK inhibitors aimed to increase durable responses for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQyuSQS7mkcmr7NkxioyDXTfW6udTcc2ebZ4hn8DDqbfbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbls1yiuw%253D%253D&md5=deec42a49119828ea05923cdde632999</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.18517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.18517%26sid%3Dliteratum%253Aachs%26aulast%3DKolev%26aufirst%3DV.%2BN.%26aulast%3DTam%26aufirst%3DW.%2BF.%26aulast%3DWright%26aufirst%3DQ.%2BG.%26aulast%3DMcDermott%26aufirst%3DS.%2BP.%26aulast%3DVidal%26aufirst%3DC.%2BM.%26aulast%3DShapiro%26aufirst%3DI.%2BM.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26aulast%3DWeaver%26aufirst%3DD.%2BT.%26atitle%3DInhibition%2520of%2520FAK%2520kinase%2520activity%2520preferentially%2520targets%2520cancer%2520stem%2520cells%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D51733%26epage%3D51747%26doi%3D10.18632%2Foncotarget.18517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Verasterm
Oncology</span>. <span> </span><span class="NLM_article-title">Defactinib</span>. <a href="https://www.verastem.com/research/fak-inhibition/defactinib-fak-inhibitor/" class="extLink">https://www.verastem.com/research/fak-inhibition/defactinib-fak-inhibitor/</a> (accessed 2020-07-27).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Verasterm%0AOncology.+Defactinib.+https%3A%2F%2Fwww.verastem.com%2Fresearch%2Ffak-inhibition%2Fdefactinib-fak-inhibitor%2F+%28accessed+2020-07-27%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DDefactinib" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Regueira, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sy, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurnani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saglio, G.</span></span> <span> </span><span class="NLM_article-title">Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2064</span>– <span class="NLM_lpage">2073</span>, <span class="refDoi"> DOI: 10.1038/s41375-020-0805-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fs41375-020-0805-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32265500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsFOrsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=2064-2073&author=J.+E.+Cortesauthor=Q.+Jiangauthor=J.+Wangauthor=J.+Wengauthor=H.+Zhuauthor=X.+Liuauthor=A.+Hochhausauthor=D.+W.+Kimauthor=J.+Radichauthor=M.+Savonaauthor=P.+Martin-Regueiraauthor=O.+Syauthor=R.+Gurnaniauthor=G.+Saglio&title=Dasatinib+vs.+imatinib+in+patients+with+chronic+myeloid+leukemia+in+chronic+phase+%28CML-CP%29+who+have+not+achieved+an+optimal+response+to+3+months+of+imatinib+therapy%3A+the+DASCERN+randomized+study&doi=10.1038%2Fs41375-020-0805-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study</span></div><div class="casAuthors">Cortes, Jorge E.; Jiang, Qian; Wang, Jianxiang; Weng, Jianyu; Zhu, Huanling; Liu, Xiaoli; Hochhaus, Andreas; Kim, Dong-Wook; Radich, Jerald; Savona, Michael; Martin-Regueira, Patricia; Sy, Oumar; Gurnani, Renuka; Saglio, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2064-2073</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Early mol. response is assocd. with improved probability of deep mol. response and superior survival in patients with CML-CP.  However, ∼1 in 3 patients on first-line imatinib do not achieve this threshold.  The phase 2b DASCERN trial (NCT01593254) assessed the outcome of early switch to dasatinib in patients with suboptimal response to first-line imatinib.  Adult patients with CML-CP were randomized (2:1) to receive 100 mg dasatinib (n = 174) or continue imatinib at ≥400 mg (n = 86).  The primary endpoint was the rate of major mol. response (MMR) at 12 mo, which was 29% (dasatinib) and 13% (imatinib; P = 0.005).  After ≥2 years of follow-up, 45 patients (52%) randomized to continue imatinib had crossed over to dasatinib.  Considering treatment crossover, the 2-yr cumulative MMR rate was 64% with dasatinib and 41% with imatinib (66% and 67%, resp. by intent-to-treat).  Adverse events were consistent with the established safety profiles of both drugs.  The results of this first prospective study support early monitoring of patients treated with first-line imatinib, and suggest that switching to dasatinib in cases of suboptimal response may offer clin. benefit.  Further follow-up is needed to assess the long-term clin. benefit of early switching.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmO5ZgDLZqC7Vg90H21EOLACvtfcHk0liFzR63ZTXbVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsFOrsL0%253D&md5=677cbedae77fbcf53178119b5f7da87f</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1038%2Fs41375-020-0805-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-020-0805-1%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWeng%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRadich%26aufirst%3DJ.%26aulast%3DSavona%26aufirst%3DM.%26aulast%3DMartin-Regueira%26aufirst%3DP.%26aulast%3DSy%26aufirst%3DO.%26aulast%3DGurnani%26aufirst%3DR.%26aulast%3DSaglio%26aufirst%3DG.%26atitle%3DDasatinib%2520vs.%2520imatinib%2520in%2520patients%2520with%2520chronic%2520myeloid%2520leukemia%2520in%2520chronic%2520phase%2520%2528CML-CP%2529%2520who%2520have%2520not%2520achieved%2520an%2520optimal%2520response%2520to%25203%2520months%2520of%2520imatinib%2520therapy%253A%2520the%2520DASCERN%2520randomized%2520study%26jtitle%3DLeukemia%26date%3D2020%26volume%3D34%26spage%3D2064%26epage%3D2073%26doi%3D10.1038%2Fs41375-020-0805-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffa, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moamer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khadang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachim, I. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakdounes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebrun, J. J.</span></span> <span> </span><span class="NLM_article-title">Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1495</span>– <span class="NLM_lpage">1507</span>, <span class="refDoi"> DOI: 10.1038/s41416-018-0287-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fs41416-018-0287-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30482914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVaksL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2018&pages=1495-1507&author=J.+Tianauthor=F.+A.+Raffaauthor=M.+Daiauthor=A.+Moamerauthor=B.+Khadangauthor=I.+Y.+Hachimauthor=K.+Bakdounesauthor=S.+Aliauthor=B.+Jean-Claudeauthor=J.+J.+Lebrun&title=Dasatinib+sensitises+triple+negative+breast+cancer+cells+to+chemotherapy+by+targeting+breast+cancer+stem+cells&doi=10.1038%2Fs41416-018-0287-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells</span></div><div class="casAuthors">Tian, Jun; Raffa, Fatmah Al; Dai, Meiou; Moamer, Alaa; Khadang, Baharak; Hachim, Ibrahim Y.; Bakdounes, Khldoun; Ali, Suhad; Jean-Claude, Bertrand; Lebrun, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1495-1507</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: Patients with triple neg. breast cancer (TNBC) exhibit poor prognosis and are at high risk of tumor relapse, due to the resistance to chemotherapy.  These aggressive phenotypes are in part attributed to the presence of breast cancer stem cells (BCSCs).  Therefore, targeting BCSCs is a priority to overcoming chemotherapy failure in TNBCs.  Methods: We generated paclitaxel (pac)-resistant TNBC cells which displayed higher sphere forming potential and percentage of BCSC subpopulations compared to the parental cells.  A screen with various kinase inhibitors revealed dasatinib, a Src kinase family inhibitor, as a potent suppressor of BCSC expansion/sphere formation in pac-resistant TNBC cells.  Results: We found dasatinib to block pac-induced BCSC enrichment and Src activation in both parental and pac-resistant TNBC cells.  Interestingly, dasatinib induced an epithelial differentiation of the pac-resistant mesenchymal cells, resulting in their enhanced sensitivity to paclitaxel.  The combination treatment of dasatinib and paclitaxel not only decreased the BCSCs nos. and their sphere forming capacity but also synergistically reduced cell viability of pac-resistant cells.  Preclin. models of breast cancer further demonstrated the efficiency of the dasatinib/paclitaxel combination treatment in inhibiting tumor growth.  Conclusions: Dasatinib is a promising anti-BCSC drug that could be used in combination with paclitaxel to overcome chemoresistance in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooLMaSt2TkzbVg90H21EOLACvtfcHk0lhbGaHCgGzevg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVaksL7N&md5=c5248d79468d37a906fcd473da99dde6</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1038%2Fs41416-018-0287-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-018-0287-3%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DRaffa%26aufirst%3DF.%2BA.%26aulast%3DDai%26aufirst%3DM.%26aulast%3DMoamer%26aufirst%3DA.%26aulast%3DKhadang%26aufirst%3DB.%26aulast%3DHachim%26aufirst%3DI.%2BY.%26aulast%3DBakdounes%26aufirst%3DK.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DJean-Claude%26aufirst%3DB.%26aulast%3DLebrun%26aufirst%3DJ.%2BJ.%26atitle%3DDasatinib%2520sensitises%2520triple%2520negative%2520breast%2520cancer%2520cells%2520to%2520chemotherapy%2520by%2520targeting%2520breast%2520cancer%2520stem%2520cells%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2018%26volume%3D119%26spage%3D1495%26epage%3D1507%26doi%3D10.1038%2Fs41416-018-0287-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Yang, C.</span>; <span class="NLM_string-name">Bai, C.</span>; <span class="NLM_string-name">He, D.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Guo, Y.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Guan, W.</span>; <span class="NLM_string-name">Yu, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Thiazole-series Heterocyclic Compounds for Treating Leukemia</span>. Chin. Patent <span class="NLM_patent">106,279,143</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Rao&author=Y.+Chen&author=C.+Yang&author=C.+Bai&author=D.+He&author=Y.+Wang&author=Y.+Guo&author=Y.+Jiang&author=W.+Guan&author=J.+Yu&title=Preparation+of+Thiazole-series+Heterocyclic+Compounds+for+Treating+Leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DPreparation%2520of%2520Thiazole-series%2520Heterocyclic%2520Compounds%2520for%2520Treating%2520Leukemia%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">700</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.bmcl.2018.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29395973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFejsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=700-706&author=H.+Y.+Liauthor=D.+D.+Heauthor=X.+J.+Zhaoauthor=T.+Y.+Sunauthor=Q.+Zhangauthor=C.+G.+Baiauthor=Y.+Chen&title=Design+and+synthesis+of+novel+dasatinib+derivatives+as+inhibitors+of+leukemia+stem+cells&doi=10.1016%2Fj.bmcl.2018.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells</span></div><div class="casAuthors">Li, Hui-ying; He, Ding-Di; Zhao, Xiu-Juan; Sun, Tong-Yan; Zhang, Quan; Bai, Cui-Gai; Chen, Yue</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">700-706</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors used the concept of bioisosteres to design and synthesize a novel series of dasatinib derivs. for the treatment of leukemia.  Unfortunately, most of the dasatinib derivs. did not show appreciable inhibition against leukemia cell lines K562 and HL60.  However, acrylamide compd. had comparable inhibitory activity with dasatinib against K562 cells (IC50 = 0.039 nM vs. 0.069 nM).  And amide compd. and acrylamide compd. also had comparable inhibitory activity with dasatinib against the leukemia cell line HL60 (IC50 = 0.25 nM and 0.26 nM vs. 0.11 nM).  Against the leukemia progenitor cell line KG1a, triazole compds. and oxadiazole compds. were more potent than dasatinib.  In particular, the hydroxyl compds. were ∼64 and 180 fold more potent than dasatinib against KG1a cells (IC50 = 0.14 μM and 0.05 μM vs. 8.98 μM).  Hydroxyl compds. also inhibited colony formation in MCF-7 cells and inhibited cell migration in the cell wound scratch assay in B16BL6 cells.  Moreover, hydroxyl compds. had low toxicity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2boOwxzGkdbVg90H21EOLACvtfcHk0lhbGaHCgGzevg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFejsb8%253D&md5=cb1029f93d886749cec5f58c27b45c6d</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%2BY.%26aulast%3DHe%26aufirst%3DD.%2BD.%26aulast%3DZhao%26aufirst%3DX.%2BJ.%26aulast%3DSun%26aufirst%3DT.%2BY.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DBai%26aufirst%3DC.%2BG.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520dasatinib%2520derivatives%2520as%2520inhibitors%2520of%2520leukemia%2520stem%2520cells%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D700%26epage%3D706%26doi%3D10.1016%2Fj.bmcl.2018.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span> <span> </span><span class="NLM_article-title">Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111535</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.ejmech.2019.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31376566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFWmtL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111535&author=X.+Wangauthor=C.+Yuauthor=C.+Wangauthor=Y.+Maauthor=T.+Wangauthor=Y.+Liauthor=Z.+Huangauthor=M.+Zhouauthor=P.+Sunauthor=J.+Zhengauthor=S.+Yangauthor=Y.+Fanauthor=R.+Xiang&title=Novel+cyclin-dependent+kinase+9+%28CDK9%29+inhibitor+with+suppression+of+cancer+stemness+activity+against+non-small-cell+lung+cancer&doi=10.1016%2Fj.ejmech.2019.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer</span></div><div class="casAuthors">Wang, Xin; Yu, Chenhua; Wang, Cheng; Ma, Yakun; Wang, Tianqi; Li, Yao; Huang, Zhi; Zhou, Manqian; Sun, Peiqing; Zheng, Jianyu; Yang, Shengyong; Fan, Yan; Xiang, Rong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111535</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel, highly potent, selective CDK9 inhibitors with cancer stem cells (CSCs) inhibition activity were designed and synthesized for non-small-cell lung cancer (NSCLC) therapy.  Structure-activity relationship anal. based on enzymic and cellular activities led to the discovery of a promising inhibitor 21e(I).  I potently inhibited CDK9 with IC50 value of 11 nM and suppressed the stemness properties of NSCLC effectively.  It could decrease the stemness phenotypes of NSCLC cells, including tumor sphere formation, side-population and stemness markers abundance.  I displayed good selectivity over the CDK family kinases and kinase profiling assay against 381 kinases.  In addn., I inhibited cell proliferation, colony-formation, and cell cycle progression and induced apoptosis in NSCLC.  In H1299 xenograft mouse model, a once-daily dose of I at 20 mg/kg significantly suppressed the tumor growth without obvious toxicity.  Studies of mechanisms of action indicated that I efficiently inhibited CDK9 signaling pathway and stemness both in vitro and in vivo.  Collectively, I as a novel CDK9 inhibitor with CSCs inhibition properties could be a promising agent for the treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_2AOdlSLbIrVg90H21EOLACvtfcHk0lhbGaHCgGzevg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFWmtL3N&md5=b088226c0d124c27c921c2504a16a665</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DR.%26atitle%3DNovel%2520cyclin-dependent%2520kinase%25209%2520%2528CDK9%2529%2520inhibitor%2520with%2520suppression%2520of%2520cancer%2520stemness%2520activity%2520against%2520non-small-cell%2520lung%2520cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111535%26doi%3D10.1016%2Fj.ejmech.2019.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jirawatnotai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wattanapanitch, M.</span></span> <span> </span><span class="NLM_article-title">Role of cyclins and cyclin-dependent kinases in pluripotent stem cells and their potential as a therapeutic</span>. <i>Semin. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/j.semcdb.2020.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.semcdb.2020.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32417217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpt12gurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2020&pages=63-71&author=S.+Jirawatnotaiauthor=S.+Daltonauthor=M.+Wattanapanitch&title=Role+of+cyclins+and+cyclin-dependent+kinases+in+pluripotent+stem+cells+and+their+potential+as+a+therapeutic&doi=10.1016%2Fj.semcdb.2020.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Role of cyclins and cyclin-dependent kinases in pluripotent stem cells and their potential as a therapeutic target</span></div><div class="casAuthors">Jirawatnotai, Siwanon; Dalton, Stephen; Wattanapanitch, Methichit</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cell & Developmental Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-71</span>CODEN:
                <span class="NLM_cas:coden">SCDBFX</span>;
        ISSN:<span class="NLM_cas:issn">1084-9521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Over the last 15 years connections between cell cycle control, maintenance of pluripotency, and control of cell fate decisions have been firmly established.  With the emergence of powerful tools, such as highly-specific small mol. inhibitors for cyclin-dependent protein kinase (CDK) activity and single-cell imaging technologies, the mechanistic links between cyclins, CDKs and regulation in PSCs in mechanistic detail has been made possible.  In this review, we discuss new developments that mechanistically link the CDK regulatory network to control of cell fate decisions, including maintenance of the pluripotent state.  Overall, these findings have potential to impact the translational applications of stem cells in regenerative medicine, drug discovery and cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_uVQV9QCLRrVg90H21EOLACvtfcHk0lg3ZSkO86CwHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpt12gurg%253D&md5=f72102771fffeb729487494198029d97</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.semcdb.2020.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcdb.2020.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DJirawatnotai%26aufirst%3DS.%26aulast%3DDalton%26aufirst%3DS.%26aulast%3DWattanapanitch%26aufirst%3DM.%26atitle%3DRole%2520of%2520cyclins%2520and%2520cyclin-dependent%2520kinases%2520in%2520pluripotent%2520stem%2520cells%2520and%2520their%2520potential%2520as%2520a%2520therapeutic%26jtitle%3DSemin.%2520Cell%2520Dev.%2520Biol.%26date%3D2020%26volume%3D107%26spage%3D63%26epage%3D71%26doi%3D10.1016%2Fj.semcdb.2020.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nazio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianfanelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecconi, F.</span></span> <span> </span><span class="NLM_article-title">Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">702</span>, <span class="refDoi"> DOI: 10.1038/s41418-019-0292-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fs41418-019-0292-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30728463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFSmsLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=690-702&author=F.+Nazioauthor=M.+Bordiauthor=V.+Cianfanelliauthor=F.+Locatelliauthor=F.+Cecconi&title=Autophagy+and+cancer+stem+cells%3A+molecular+mechanisms+and+therapeutic+applications&doi=10.1038%2Fs41418-019-0292-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications</span></div><div class="casAuthors">Nazio, Francesca; Bordi, Matteo; Cianfanelli, Valentina; Locatelli, Franco; Cecconi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">690-702</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Autophagy and mitophagy act in cancer as bimodal processes, whose differential functions strictly depend on cancer ontogenesis, progression, and type.  For instance, they can act to promote cancer progression by helping cancer cells survive stress or, instead, when mutated or abnormal, to induce carcinogenesis by influencing cell signaling or promoting intracellular toxicity.  For this reason, the study of autophagy in cancer is the main focus of many researchers and several clin. trials are already ongoing to manipulate autophagy and by this way det. the outcome of disease therapy.  Since the establishment of the cancer stem cell (CSC) theory and the discovery of CSCs in individual cancer types, autophagy and mitophagy have been proposed as key mechanisms in their homeostasis, dismissal or spread, even though we still miss a comprehensive view of how and by which regulatory mols. these two processes drive cell fate.  In this review, we will dive into the deep water of autophagy, mitophagy, and CSCs and offer novel viewpoints on possible therapeutic strategies, based on the modulation of these degradative systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq9jOZkbCnH7Vg90H21EOLACvtfcHk0lg3ZSkO86CwHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFSmsLvE&md5=7a2feaaa2e09a7318fab3f1037844e6b</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fs41418-019-0292-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41418-019-0292-y%26sid%3Dliteratum%253Aachs%26aulast%3DNazio%26aufirst%3DF.%26aulast%3DBordi%26aufirst%3DM.%26aulast%3DCianfanelli%26aufirst%3DV.%26aulast%3DLocatelli%26aufirst%3DF.%26aulast%3DCecconi%26aufirst%3DF.%26atitle%3DAutophagy%2520and%2520cancer%2520stem%2520cells%253A%2520molecular%2520mechanisms%2520and%2520therapeutic%2520applications%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2019%26volume%3D26%26spage%3D690%26epage%3D702%26doi%3D10.1038%2Fs41418-019-0292-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanam, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhnerjee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastidar, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmakar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, G.</span></span> <span> </span><span class="NLM_article-title">A novel triazole, NMK-T-057, induces autophagic cell death in breast cancer cells by inhibiting γ-secretase-mediated activation of Notch signaling</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">6733</span>– <span class="NLM_lpage">6750</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA119.007671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1074%2Fjbc.RA119.007671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30824542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Slt7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=6733-6750&author=A.+Dasauthor=M.+K.+Narayanamauthor=S.+Paulauthor=P.+Mukhnerjeeauthor=S.+Ghoshauthor=D.+G.+Dastidarauthor=S.+Chakrabartyauthor=A.+Ganguliauthor=B.+Basuauthor=M.+Palauthor=U.+Chatterjiauthor=S.+K.+Banerjeeauthor=P.+Karmakarauthor=D.+Kumarauthor=G.+Chakrabarti&title=A+novel+triazole%2C+NMK-T-057%2C+induces+autophagic+cell+death+in+breast+cancer+cells+by+inhibiting+%CE%B3-secretase-mediated+activation+of+Notch+signaling&doi=10.1074%2Fjbc.RA119.007671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">A novel triazole NMK-T-057 induces autophagic cell death in breast cancer cells by inhibiting γ-secretase-mediated activation of Notch-signaling</span></div><div class="casAuthors">Das, Amlan; Narayanam, Maruthi Kumar; Paul, Santanu; Mukhnerjee, Pritha; Ghosh, Suvranil; Dastidar, Debabrata Ghosh; Chakrabarty, Subhendu; Ganguli, Arnab; Basu, Biswarup; Pal, Mahadeb; Chatterji, Urmi; Banerjee, Sushanta K.; Karmakar, Parimal; Kumar, Dalip; Chakrabarti, Gopal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6733-6751</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Notch signaling is reported to be deregulated in several malignancies, including breast, and the enzyme γ-secretase plays important role in the activation and nuclear translocation of Notch intracellular domain (NICD).  Hence, pharmacol. inhibition of γ-secretase might lead to the subsequent inhibition of Notch signaling in cancer cells.  In search of novel γ-secretase inhibitors (GSIs), we screened a series of triazole-based compds., for their potential to bind γ-secretase and we obsd. that 3-(3'4',5'-Trimethoxyphenyl)-5-(N-methyl-3'-indolyl)-1,2,4-triazole compd. (also known as NMK-T-057) can bind to γ-secretase complex.  Very interestingly, NMK-T-057 was found to inhibit proliferation, colony forming ability, motility in various breast cancer (BC) cells such as MDA-MB-231, MDA-MB-468, 4T1 (triple neg. cells) and MCF-7 (ER/PR pos. cell line), with negligible cytotoxicity against non-cancerous cells (MCF-10A and PBMC).  Further, significant induction of apoptosis and inhibition of epithelial to mesenchymal transition (EMT) and stemness were also obsd. in NMK-T-057 treated BC cells.  The in silico study revealing the affinity of NMK-T-057 towards γ-secretase, was further validated by fluorescence based γ-secretase activity assay, which confirmed inhibition of γ-secretase activity in NMK-T-057 treated BC cells.  Interestingly, it was obsd. that NMK-T-057 induced significant autophagic responses in BC cells, which lead to apoptosis.  Moreover, NMK-T-057 was found to inhibit tumor progression in 4T1-BALB/c mice model.  Hence, it may be concluded that NMK-T-057 could be potential drug candidate against BC, which can trigger autophagy-mediated cell death by inhibiting γ-secretase-mediated activation of Notch-signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMakR3ACxvarVg90H21EOLACvtfcHk0lg3ZSkO86CwHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Slt7rF&md5=5a3d25580ff89a301572d17f613b3dee</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA119.007671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA119.007671%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DA.%26aulast%3DNarayanam%26aufirst%3DM.%2BK.%26aulast%3DPaul%26aufirst%3DS.%26aulast%3DMukhnerjee%26aufirst%3DP.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DDastidar%26aufirst%3DD.%2BG.%26aulast%3DChakrabarty%26aufirst%3DS.%26aulast%3DGanguli%26aufirst%3DA.%26aulast%3DBasu%26aufirst%3DB.%26aulast%3DPal%26aufirst%3DM.%26aulast%3DChatterji%26aufirst%3DU.%26aulast%3DBanerjee%26aufirst%3DS.%2BK.%26aulast%3DKarmakar%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DD.%26aulast%3DChakrabarti%26aufirst%3DG.%26atitle%3DA%2520novel%2520triazole%252C%2520NMK-T-057%252C%2520induces%2520autophagic%2520cell%2520death%2520in%2520breast%2520cancer%2520cells%2520by%2520inhibiting%2520%25CE%25B3-secretase-mediated%2520activation%2520of%2520Notch%2520signaling%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D6733%26epage%3D6750%26doi%3D10.1074%2Fjbc.RA119.007671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Targeting the AMP-activated protein kinase for cancer prevention and therapy</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">175</span>, <span class="refDoi"> DOI: 10.3389/fonc.2013.00175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffonc.2013.00175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=23875169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC3sfivVeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=175&author=I.+Kimauthor=Y.+Y.+He&title=Targeting+the+AMP-activated+protein+kinase+for+cancer+prevention+and+therapy&doi=10.3389%2Ffonc.2013.00175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy</span></div><div class="casAuthors">Kim Inyoung; He Yu-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">175</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Despite the advances in biomedical research and clinical applications, cancer remains a leading cause of death worldwide.  Given the limitations of conventional chemotherapeutics, including serious toxicities and reduced quality of life for patients, the development of safe and efficacious alternatives with known mechanism of action is much needed.  Prevention of cancer through dietary intervention may hold promise and has been investigated extensively in the recent years.  AMP-activated protein kinase (AMPK) is an energy sensor that plays a key role in the regulation of protein and lipid metabolism in response to changes in fuel availability.  When activated, AMPK promotes energy-producing catabolic pathways while inhibiting anabolic pathways, such as cell growth and proliferation - thereby antagonizing carcinogenesis.  Other anti-cancer effects of AMPK may include promoting autophagy and DNA repair upon UVB damage.  In the last decade, interest in AMPK has grown extensively as it emerged as an attractive target molecule for cancer prevention and treatment.  Among the latest developments is the activation of AMPK by naturally occurring dietary constituents and plant products - termed phytochemicals.  Owing to their efficacy and safety, phytochemicals are considered as an alternative to the conventional harmful chemotherapy.  The rising popularity of using phytochemicals for cancer prevention and therapy is supported by a substantial progress in identifying the molecular pathways involved, including AMPK.  In this article, we review the recent progress in this budding field that suggests AMPK as a new molecular target in the prevention and treatment of cancer by phytochemicals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4H8fzaLSSUtLIORRPd5lbfW6udTcc2ebA4YGiCVLK_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfivVeltw%253D%253D&md5=f9042799e2826a9703323cecf854f7c2</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2013.00175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2013.00175%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DI.%26aulast%3DHe%26aufirst%3DY.%2BY.%26atitle%3DTargeting%2520the%2520AMP-activated%2520protein%2520kinase%2520for%2520cancer%2520prevention%2520and%2520therapy%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D3%26spage%3D175%26doi%3D10.3389%2Ffonc.2013.00175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rychahou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sviripa, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, B. M.</span></span> <span> </span><span class="NLM_article-title">Induction of AMPK activation by N,N’-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e0209392</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0209392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1371%2Fjournal.pone.0209392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30875375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFaksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&author=J.+Johnsonauthor=P.+Rychahouauthor=V.+M.+Sviripaauthor=H.+L.+Weissauthor=C.+Liuauthor=D.+S.+Wattauthor=B.+M.+Evers&title=Induction+of+AMPK+activation+by+N%2CN%E2%80%99-diarylurea+FND-4b+decreases+growth+and+increases+apoptosis+in+triple+negative+and+estrogen-receptor+positive+breast+cancers&doi=10.1371%2Fjournal.pone.0209392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers</span></div><div class="casAuthors">Johnson, Jeremy; Rychahou, Piotr; Sviripa, Vitaliy M.; Weiss, Heidi L.; Liu, Chunming; Watt, David S.; Evers, B. Mark</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0209392</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Purpose: Triple neg. breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer.  AMP-activated protein kinase (AMPK) is a major energy regulator that suppresses tumor growth, and 1-(3-chloro-4-((trifluoromethyl)thio)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea (FND-4b) is a novel AMPK activator that inhibits growth and induces apoptosis in colon cancer.  The purpose of this project was to test the effects of FND-4b on AMPK activation, proliferation, and apoptosis in breast cancer with a particular emphasis on TNBC.  Materials and methods: (i) Estrogen-receptor pos. breast cancer (ER+BC; MCF-7, and T-47D), TNBC (MDA-MB-231 and HCC-1806), and breast cancer stem cells were treated with FND-4b for 24h.  Immunoblot anal. assessed AMPK, acetyl-CoA carboxylase (ACC), ribosomal protein S6, cyclin D1, and cleaved PARP. (ii) Sulforhodamine B growth assays were performed after treating ER+BC and TNBC cells with FND-4b for 72h.  Proliferation was also assessed by counting cells after 72h of FND-4b treatment. (iii) Cell death ELISA assays were performed after treating ER+BC and TNBC cells with FND-4b for 72h.  Results: (i) FND-4b increased AMPK activation with concomitant decreases in ACC activity, phosphorylated S6, and cyclin D1 in all subtypes. (ii) FND-4b decreased proliferation in all cells, while dose-dependent growth decreases were found in ER+BC and TNBC. (iii) Increases in apoptosis were obsd. in ER+BC and the MDA-MB-231 cell line with FND-4b treatment.  Conclusions: Our findings indicate that FND-4b decreases proliferation for a variety of breast cancers by activating AMPK and has notable effects on TNBC.  The growth redns. were mediated through decreases in fatty acid synthesis (ACC), mTOR signaling (S6), and cell cycle flux (cyclin D1).  ER+BC cells were more susceptible to FND-4b-induced apoptosis, but MDA-MB-231 cells still underwent apoptosis with higher dose treatment.  Further development of FND compds. could result in a novel therapeutic for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8NCrRyPzk6LVg90H21EOLACvtfcHk0lixq_01VdKFfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFaksLw%253D&md5=2c3a1bee3025618bbf467012ebc99bd9</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0209392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0209392%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DJ.%26aulast%3DRychahou%26aufirst%3DP.%26aulast%3DSviripa%26aufirst%3DV.%2BM.%26aulast%3DWeiss%26aufirst%3DH.%2BL.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DD.%2BS.%26aulast%3DEvers%26aufirst%3DB.%2BM.%26atitle%3DInduction%2520of%2520AMPK%2520activation%2520by%2520N%252CN%25E2%2580%2599-diarylurea%2520FND-4b%2520decreases%2520growth%2520and%2520increases%2520apoptosis%2520in%2520triple%2520negative%2520and%2520estrogen-receptor%2520positive%2520breast%2520cancers%26jtitle%3DPLoS%2520One%26date%3D2019%26volume%3D14%26doi%3D10.1371%2Fjournal.pone.0209392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bort, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateos-Gómez, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vara-Ciruelos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Henche, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz-Laviada, I.</span></span> <span> </span><span class="NLM_article-title">Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1311</span>– <span class="NLM_lpage">1331</span>, <span class="refDoi"> DOI: 10.1002/1878-0261.12488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2F1878-0261.12488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30959553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKhs7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=1311-1331&author=A.+Bortauthor=B.+G.+S%C3%A1nchezauthor=P.+A.+Mateos-G%C3%B3mezauthor=D.+Vara-Ciruelosauthor=N.+Rodr%C3%ADguez-Hencheauthor=I.+D%C3%ADaz-Laviada&title=Targeting+AMP-activated+kinase+impacts+hepatocellular+cancer+stem+cells+induced+by+long-term+treatment+with+sorafenib&doi=10.1002%2F1878-0261.12488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib</span></div><div class="casAuthors">Bort, Alicia; Sanchez, Belen G.; Mateos-Gomez, Pedro A.; Vara-Ciruelos, Diana; Rodriguez-Henche, Nieves; Diaz-Laviada, Ines</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1311-1331</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1878-0261</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide.  HCC treatment is hindered by the frequent emergence of chemoresistance to the multikinase inhibitor sorafenib, which has been related to the presence of cancer stem cells (CSCs) that self-renew and often escape therapy.  The key metabolic sensor AMP-activated kinase (AMPK) has recently been recognized as a tumor growth regulator.  In this study, we aimed to elucidate the role of AMPK in the development of a stem cell phenotype in HCC cells.  To this end, we enriched the CSC population in HCC cell lines that showed increased expression of drug resistance (ALDH1A1, ABCB1A) and stem cell (CD133, Nanog, Oct4, alpha fetoprotein) markers and demonstrated their stemness phenotype.  These cells were refractory to sorafenib-induced cell death.  We report that sorafenib-resistant cells had lower levels of total and phosphorylated AMPK as well as its downstream substrate, ACC, compared with the parental cells.  Interestingly, AMPK knockdown with siRNA or inhibition with dorsomorphin increased the expression of stem cell markers in parental cells and blocked sorafenib-induced cell death.  Conversely, the upregulation of AMPK, either by transfection or by pharmacol. activation with A-769662, decreased the expression of ALDH1A1, ABCB1A, CD133, Nanog, Oct4, and alpha fetoprotein, and restored sensitivity to sorafenib.  Anal. of the underlying mechanism points to hypoxia-inducible factor HIF-1α as a regulator of stemness.  In vivo studies in a xenograft mouse model demonstrated that stem-like cells have greater tumorigenic capacity.  AMPK activation reduced xenograft tumor growth and decreased the expression of stem cell markers.  Taken together, these results indicate that AMPK may serve as a novel target to overcome chemoresistance in HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofHnzJp-loPrVg90H21EOLACvtfcHk0lip4v4WALaMyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKhs7vM&md5=40a1eb3ab6e130488e08bad3f391c421</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1002%2F1878-0261.12488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1878-0261.12488%26sid%3Dliteratum%253Aachs%26aulast%3DBort%26aufirst%3DA.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DB.%2BG.%26aulast%3DMateos-G%25C3%25B3mez%26aufirst%3DP.%2BA.%26aulast%3DVara-Ciruelos%26aufirst%3DD.%26aulast%3DRodr%25C3%25ADguez-Henche%26aufirst%3DN.%26aulast%3DD%25C3%25ADaz-Laviada%26aufirst%3DI.%26atitle%3DTargeting%2520AMP-activated%2520kinase%2520impacts%2520hepatocellular%2520cancer%2520stem%2520cells%2520induced%2520by%2520long-term%2520treatment%2520with%2520sorafenib%26jtitle%3DMol.%2520Oncol.%26date%3D2019%26volume%3D13%26spage%3D1311%26epage%3D1331%26doi%3D10.1002%2F1878-0261.12488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonini, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gantner, B. N.</span></span> <span> </span><span class="NLM_article-title">The multifaceted activities of AMPK in tumor progression--why the “one size fits all” definition does not fit at all?</span>. <i>IUBMB Life</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">896</span>, <span class="refDoi"> DOI: 10.1002/iub.1213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fiub.1213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=24265196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWnsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=889-896&author=M.+G.+Boniniauthor=B.+N.+Gantner&title=The+multifaceted+activities+of+AMPK+in+tumor+progression%2D%2Dwhy+the+%E2%80%9Cone+size+fits+all%E2%80%9D+definition+does+not+fit+at+all%3F&doi=10.1002%2Fiub.1213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">The multifaceted activities of AMPK in tumor progression-why the "one size fits all" definition does not fit at all?</span></div><div class="casAuthors">Bonini, Marcelo G.; Gantner, Benjamin N.</div><div class="citationInfo"><span class="NLM_cas:title">IUBMB Life</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">889-896</span>CODEN:
                <span class="NLM_cas:coden">IULIF8</span>;
        ISSN:<span class="NLM_cas:issn">1521-6543</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Inc.</span>)
        </div><div class="casAbstract">A review.  AMP-activated kinase (AMPK) is a central cellular energetic biosensor and regulator of a broad array of cellular metabolic routes activated by nutrient deprivation, mitochondrial dysfunction, oxidative stress, and cytokines.  The activation of AMPK maintains ATP levels in response to hypoxia, mitochondrial dysfunction, and shortage of essential metabolic fuels.  Activated AMPK turns on energy sparing pathways and promotes antiapoptotic functions thereby permitting cells to survive extremely hostile conditions for prolonged periods of time.  Cancer cells in solid tumors are generally subjected to such harsh conditions; however, they manage to efficiently survive and proliferate.  This is likely due, in great part, to a peculiar form of metab. that is heavily reliant on glycolysis and which promotes cancer cell adaptation and tumor progression.  AMPK controls the influx and utilization of glucose by cancer cells and therefore has emerged as an attractive target to treat cancer.  Investigations exploring this possibility demonstrated that activators or inhibitors of AMPK impact cancer cell viability and possibly cancer progression.  For example, the AMPK activator metformin induces apoptosis in a variety of cancer cell lines and models.  A major problem with many of the studies on metformin is that little effort has been invested in unraveling how metformin activates AMPK in the many contexts it has been tested.  This is significant because many AMPK-independent effects of metformin have been documented.  The notion that AMPK acts solely as a tumor suppressor also conflicts with findings that it confers resistance to nutrient deprivation, sustains NADPH levels in cancer cells, facilitates stress-induced gene transcription, promotes cell survival via antiapoptotic function upregulation, intermediates epithelial-to-mesenchymal transition, and increases malignant transformation.  These are all recognized steps necessary for the successful evolution of tumors.  This review highlights some of these findings and proposes that the role of AMPK in cancer should be reconsidered in light of the complex roles of AMPK under different metabolic conditions. © 2013 IUBMB Life, 65(11):889-896, 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrth4kp_QtvWLVg90H21EOLACvtfcHk0lip4v4WALaMyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWnsrrP&md5=8b35f99744010b8b9b86e7c30f362e6f</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1002%2Fiub.1213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fiub.1213%26sid%3Dliteratum%253Aachs%26aulast%3DBonini%26aufirst%3DM.%2BG.%26aulast%3DGantner%26aufirst%3DB.%2BN.%26atitle%3DThe%2520multifaceted%2520activities%2520of%2520AMPK%2520in%2520tumor%2520progression--why%2520the%2520%25E2%2580%259Cone%2520size%2520fits%2520all%25E2%2580%259D%2520definition%2520does%2520not%2520fit%2520at%2520all%253F%26jtitle%3DIUBMB%2520Life%26date%3D2013%26volume%3D65%26spage%3D889%26epage%3D896%26doi%3D10.1002%2Fiub.1213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span> <span> </span><span class="NLM_article-title">ROS/KRAS/AMPK signaling contributes to gemcitabine-induced stem-like cell properties in pancreatic cancer</span>. <i>Mol. Ther. Oncolytics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1016/j.omto.2019.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.omto.2019.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31508487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVKiu7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=299-312&author=H.+Zhaoauthor=S.+Wuauthor=H.+Liauthor=Q.+Duanauthor=Z.+Zhangauthor=Q.+Shenauthor=C.+Wangauthor=T.+Yin&title=ROS%2FKRAS%2FAMPK+signaling+contributes+to+gemcitabine-induced+stem-like+cell+properties+in+pancreatic+cancer&doi=10.1016%2Fj.omto.2019.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer</span></div><div class="casAuthors">Zhao, Hengqiang; Wu, Shihong; Li, Hehe; Duan, Qingke; Zhang, Zhengle; Shen, Qiang; Wang, Chunyou; Yin, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy--Oncolytics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">299-312</span>CODEN:
                <span class="NLM_cas:coden">MTOHDL</span>;
        ISSN:<span class="NLM_cas:issn">2372-7705</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Poor prognosis in pancreatic cancer (PanCa) is partially due to chemoresistance to gemcitabine (GEM).  Glucose metab. has been revealed to contribute to the therapeutic resistance and pluripotent state of PanCa cells.  However, few studies have focused on the effects of GEM on cancer cell metab., stemness of tumor cells, and mol. mechanisms that critically influence PanCa treatment.  We demonstrate that GEM treatment induces metabolic reprogramming, reducing mitochondrial oxidn. and upregulating aerobic glycolysis, and promotes stem-like behaviors in cancer cells.  Inhibiting aerobic glycolysis suppresses cancer cell stemness and strengthens GEM's cytotoxicity.  GEM-induced metabolic reprogramming is KRAS dependent, as knockdown of KRAS reverses the metabolic shift.  GEM-induced metabolic reprogramming also activates AMP-activated protein kinase (AMPK), which promotes glycolytic flux and cancer stemness.  In addn., GEM-induced reactive oxygen species (ROS) activate the KRAS/AMPK pathway.  This effect was validated by introducing exogenous hydrogen peroxide (H2O2).  Taken together, these findings reveal a counterproductive GEM effect during PanCa treatment.  Regulating cellular redox, targeting KRAS/AMPK signaling, or reversing metabolic reprogramming might be effective approaches to eliminate cancer stem cells (CSCs) and enhance chemosensitivity to GEM to improve the prognosis of PanCa patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquMFLClNqj8LVg90H21EOLACvtfcHk0lip4v4WALaMyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVKiu7%252FF&md5=b60dccd3a11505e23f14736673d1054b</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.omto.2019.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.omto.2019.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DDuan%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DYin%26aufirst%3DT.%26atitle%3DROS%252FKRAS%252FAMPK%2520signaling%2520contributes%2520to%2520gemcitabine-induced%2520stem-like%2520cell%2520properties%2520in%2520pancreatic%2520cancer%26jtitle%3DMol.%2520Ther.%2520Oncolytics%26date%3D2019%26volume%3D14%26spage%3D299%26epage%3D312%26doi%3D10.1016%2Fj.omto.2019.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">AMPK promotes the survival of colorectal cancer stem cells</span>. <i>Animal Model. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1002/ame2.12016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fame2.12016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30891558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3cbmtFCiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2018&pages=134-142&author=B.+Guoauthor=X.+Hanauthor=D.+Tkachauthor=S.+G.+Huangauthor=D.+Zhang&title=AMPK+promotes+the+survival+of+colorectal+cancer+stem+cells&doi=10.1002%2Fame2.12016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">AMPK promotes the survival of colorectal cancer stem cells</span></div><div class="casAuthors">Guo Bing; Han Xin; Tkach Diane; Huang Shu-Guang; Zhang Dong; Guo Bing; Zhang Dong</div><div class="citationInfo"><span class="NLM_cas:title">Animal models and experimental medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-142</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second in females worldwide in 2012.  In the past 20 years, strong evidence suggests that cancer stem cells are the main culprit of cancer metastasis, chemotherapy resistance, and relapse.  Methods:  To further understand the unique biological properties of cancer stem cells and uncover novel molecular targets to eradicate them, we first established a panel of patient-derived xenograft (PDX) tumor models using tumors surgically removed from human colorectal cancer patients.  We then isolated CRC cancer stem cells based on their ALDH activity using fluorescent-activated cell sorting (FACS) and characterized their metabolic properties.  Results:  Interestingly, we found that the CRC cancer stem cells (ie, CRC cells with higher ALDH activity, or ALDH+) express higher level of antioxidant genes and have lower level of reactive oxygen species (ROS) than non-CRC cancer stem cells (ie, CRC cells with lower ALDH activity, or ALDH-).  The CRC cancer stem cells also possess more mitochondria mass and show higher mitochondrial activity.  More intriguingly, we observed higher AMP-activated protein kinase (AMPK) activities in these CRC cancer stem cells.  Inhibition of the AMPK activity using 2 AMPK inhibitors, Compound C and Iodotubercidin, preferentially induces cell death in CRC cancer stem cells.  Conclusion:  We propose that AMPK inhibitors may help to eradicate the CRC cancer stem cells and prevent the relapse of CRCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSf6OWBoFNfYi-bLEOO4dYpfW6udTcc2eYqBDChXrlS8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbmtFCiug%253D%253D&md5=8ab4d183ec8151c17be9f55f32afcdb9</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1002%2Fame2.12016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fame2.12016%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DTkach%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DS.%2BG.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DAMPK%2520promotes%2520the%2520survival%2520of%2520colorectal%2520cancer%2520stem%2520cells%26jtitle%3DAnimal%2520Model.%2520Exp.%2520Med.%26date%3D2018%26volume%3D1%26spage%3D134%26epage%3D142%26doi%3D10.1002%2Fame2.12016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. K.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells as a potential target to overcome multidrug resistance</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">764</span>, <span class="refDoi"> DOI: 10.3389/fonc.2020.00764</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffonc.2020.00764" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32582535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB38nkt12ksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=764&author=Y.+Choauthor=Y.+K.+Kim&title=Cancer+stem+cells+as+a+potential+target+to+overcome+multidrug+resistance&doi=10.3389%2Ffonc.2020.00764"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance</span></div><div class="casAuthors">Cho Yena; Kim Yong Kee</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">764</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Multidrug resistance (MDR), which is a significant impediment to the success of cancer chemotherapy, is attributable to various defensive mechanisms in cancer.  Initially, overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp) was considered the most important mechanism for drug resistance; hence, many investigators for a long time focused on the development of specific ABC transporter inhibitors.  However, to date their efforts have failed to develop a clinically applicable drug, leaving only a number of problems.  The concept of cancer stem cells (CSCs) has provided new directions for both cancer and MDR research.  MDR is known to be one of the most important features of CSCs and thus plays a crucial role in cancer recurrence and exacerbation.  Therefore, in recent years, research targeting CSCs has been increasing rapidly in search of an effective cancer treatment.  Here, we review the drugs that have been studied and developed to overcome MDR and CSCs, and discuss the limitations and future perspectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBmJ7XxQfILV1C8OJBvdfbfW6udTcc2eYqBDChXrlS8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38nkt12ksg%253D%253D&md5=cd4df2a39f501b1ad8b26a7ad5e08046</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2020.00764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2020.00764%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DY.%2BK.%26atitle%3DCancer%2520stem%2520cells%2520as%2520a%2520potential%2520target%2520to%2520overcome%2520multidrug%2520resistance%26jtitle%3DFront.%2520Oncol.%26date%3D2020%26volume%3D10%26spage%3D764%26doi%3D10.3389%2Ffonc.2020.00764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pati, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span> <span> </span><span class="NLM_article-title">Novel metal chelators thiosemicarbazones with activity at the σ2 receptors and P-glycoprotein: an innovative strategy for resistant tumor treatment</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">103131</span>– <span class="NLM_lpage">103146</span>, <span class="refDoi"> DOI: 10.1039/C5RA19857G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1039%2FC5RA19857G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWltbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=103131-103146&author=M.+L.+Patiauthor=M.+Nisoauthor=S.+Ferorelliauthor=C.+Abateauthor=F.+Berardi&title=Novel+metal+chelators+thiosemicarbazones+with+activity+at+the+%CF%832+receptors+and+P-glycoprotein%3A+an+innovative+strategy+for+resistant+tumor+treatment&doi=10.1039%2FC5RA19857G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Novel metal chelators thiosemicarbazones with activity at the σ2 receptors and P-glycoprotein: an innovative strategy for resistant tumor treatment</span></div><div class="casAuthors">Pati, Maria Laura; Niso, Mauro; Ferorelli, Savina; Abate, Carmen; Berardi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">125</span>),
    <span class="NLM_cas:pages">103131-103146</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">To combat the emergence of drug-resistance in tumors novel strategies are urgently needed.  With this in mind we designed a novel class of thiosemicarbazones able to target simultaneously σ2 receptors and P-glycoprotein efflux pump while chelating metals such as iron.  The combined effect of these targets would lead to the activation of multiple pathways to which resistant tumors are sensitive.  Indeed, most of the novel thiosemicarbazones displayed antiproliferative activity in both parent (MCF7 breast adenocarcinoma and A549 lung carcinoma) and corresponding doxorubicin-resistant cells (MCF7dx and A549dx).  A few compds. emerged for their potent antiproliferative activity or for their more potent effect in doxorubicin-resistant cells than in the parent ones, while other compds. emerged for their remarkable P-gp modulatory activity.  These results pave the way for further studies on these targets in the oncol. field, while the availability of promising mols. for resistant tumors treatment that warrant deeper investigations was increased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6Y_9AD9FkqrVg90H21EOLACvtfcHk0lgw7n9SU_zi5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWltbrL&md5=27834cbf13e4b871abb777c95570f7af</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1039%2FC5RA19857G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5RA19857G%26sid%3Dliteratum%253Aachs%26aulast%3DPati%26aufirst%3DM.%2BL.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DBerardi%26aufirst%3DF.%26atitle%3DNovel%2520metal%2520chelators%2520thiosemicarbazones%2520with%2520activity%2520at%2520the%2520%25CF%25832%2520receptors%2520and%2520P-glycoprotein%253A%2520an%2520innovative%2520strategy%2520for%2520resistant%2520tumor%2520treatment%26jtitle%3DRSC%2520Adv.%26date%3D2015%26volume%3D5%26spage%3D103131%26epage%3D103146%26doi%3D10.1039%2FC5RA19857G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipkowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takebe, N.</span></span> <span> </span><span class="NLM_article-title">Novel apoptosis-inducing agents for the treatment of cancer, a new arsenal in the toolbox</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1087</span>, <span class="refDoi"> DOI: 10.3390/cancers11081087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcancers11081087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVKls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1087&author=B.+Limauthor=Y.+Greerauthor=S.+Lipkowitzauthor=N.+Takebe&title=Novel+apoptosis-inducing+agents+for+the+treatment+of+cancer%2C+a+new+arsenal+in+the+toolbox&doi=10.3390%2Fcancers11081087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Novel apoptosis-inducing agents for the treatment of cancer, a new arsenal in the toolbox</span></div><div class="casAuthors">Lim, Bora; Greer, Yoshimi; Lipkowitz, Stanley; Takebe, Naoko</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1087</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Evasion from apoptosis is an important hallmark of cancer cells.  Alterations of apoptosis pathways are esp. crit. as they confer resistance to conventional anti-cancer therapeutics, e.g., chemotherapy, radiotherapy, and targeted therapeutics.  Thus, successful induction of apoptosis using novel therapeutics may be a key strategy for preventing recurrence and metastasis.  Inhibitors of anti-apoptotic mols. and enhancers of pro-apoptotic mols. are being actively developed for hematol. malignancies and solid tumors in particular over the last decade.  However, due to the complicated apoptosis process caused by a multifaceted connection with cross-talk pathways, protein-protein interaction, and diverse resistance mechanisms, drug development within the category has been extremely challenging.  Careful design and development of clin. trials incorporating predictive biomarkers along with novel apoptosis-inducing agents based on rational combination strategies are needed to ensure the successful development of these mols.  Here, we review the landscape of currently available direct apoptosis-targeting agents in clin. development for cancer treatment and update the related biomarker advancement to detect and validate the efficacy of apoptosis-targeted therapies, along with strategies to combine them with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiL-nO4-7kdLVg90H21EOLACvtfcHk0lgw7n9SU_zi5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVKls7g%253D&md5=548bbc1372a2eb17a211ce9ff89277b1</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.3390%2Fcancers11081087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11081087%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DB.%26aulast%3DGreer%26aufirst%3DY.%26aulast%3DLipkowitz%26aufirst%3DS.%26aulast%3DTakebe%26aufirst%3DN.%26atitle%3DNovel%2520apoptosis-inducing%2520agents%2520for%2520the%2520treatment%2520of%2520cancer%252C%2520a%2520new%2520arsenal%2520in%2520the%2520toolbox%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26spage%3D1087%26doi%3D10.3390%2Fcancers11081087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucki, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollong, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anglin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangenberg, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skirboll, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurdak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mischel, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lairson, L. L.</span></span> <span> </span><span class="NLM_article-title">A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">6435</span>– <span class="NLM_lpage">6440</span>, <span class="refDoi"> DOI: 10.1073/pnas.1816626116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1073%2Fpnas.1816626116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30846550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFentbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=6435-6440&author=N.+C.+Luckiauthor=G.+R.+Villaauthor=N.+Verganiauthor=M.+J.+Bollongauthor=B.+A.+Beyerauthor=J.+W.+Leeauthor=J.+L.+Anglinauthor=S.+H.+Spangenbergauthor=E.+N.+Chinauthor=A.+Sharmaauthor=K.+Johnsonauthor=P.+N.+Sanderauthor=P.+Gordonauthor=S.+L.+Skirbollauthor=H.+Wurdakauthor=P.+G.+Schultzauthor=P.+S.+Mischelauthor=L.+L.+Lairson&title=A+cell+type-selective+apoptosis-inducing+small+molecule+for+the+treatment+of+brain+cancer&doi=10.1073%2Fpnas.1816626116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer</span></div><div class="casAuthors">Lucki, Natasha C.; Villa, Genaro R.; Vergani, Naja; Bollong, Michael J.; Beyer, Brittney A.; Lee, Jae Wook; Anglin, Justin L.; Spangenberg, Stephan H.; Chin, Emily N.; Sharma, Amandeep; Johnson, Kevin; Sander, Philipp N.; Gordon, Perry; Skirboll, Stephen L.; Wurdak, Heiko; Schultz, Peter G.; Mischel, Paul S.; Lairson, Luke L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6435-6440</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM; grade IV astrocytoma) is the most prevalent and aggressive form of primary brain cancer.  A subpopulation of multipotent cells termed GBM cancer stem cells (CSCs) play a crit. role in tumor initiation, tumor maintenance, metastasis, drug resistance, and recurrence following surgery.  Here we report the identification of a small mol., termed RIPGBM, from a cell-based chem. screen that selectively induces apoptosis in multiple primary patient-derived GBM CSC cultures.  The cell type-dependent selectivity of this compd. appears to arise at least in part from redox-dependent formation of a proapoptotic deriv., termed cRIPGBM, in GBM CSCs. cRIPGBM induces caspase 1-dependent apoptosis by binding to receptor-interacting protein kinase 2 (RIPK2) and acting as a mol. switch, which reduces the formation of a prosurvival RIPK2/TAK1 complex and increases the formation of a proapoptotic RIPK2/caspase 1 complex.  In an orthotopic intracranial GBM CSC tumor xenograft mouse model, RIPGBM was found to significantly suppress tumor formation in vivo.  Our chem. genetics-based approach has identified a drug candidate and a potential drug target that provide an approach to the development of treatments for this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK1-h8DEWsgrVg90H21EOLACvtfcHk0li9qLMIgwWIVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFentbs%253D&md5=7a923f1243064238e8a18924d03f3e21</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1816626116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1816626116%26sid%3Dliteratum%253Aachs%26aulast%3DLucki%26aufirst%3DN.%2BC.%26aulast%3DVilla%26aufirst%3DG.%2BR.%26aulast%3DVergani%26aufirst%3DN.%26aulast%3DBollong%26aufirst%3DM.%2BJ.%26aulast%3DBeyer%26aufirst%3DB.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DAnglin%26aufirst%3DJ.%2BL.%26aulast%3DSpangenberg%26aufirst%3DS.%2BH.%26aulast%3DChin%26aufirst%3DE.%2BN.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DSander%26aufirst%3DP.%2BN.%26aulast%3DGordon%26aufirst%3DP.%26aulast%3DSkirboll%26aufirst%3DS.%2BL.%26aulast%3DWurdak%26aufirst%3DH.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26aulast%3DLairson%26aufirst%3DL.%2BL.%26atitle%3DA%2520cell%2520type-selective%2520apoptosis-inducing%2520small%2520molecule%2520for%2520the%2520treatment%2520of%2520brain%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26spage%3D6435%26epage%3D6440%26doi%3D10.1073%2Fpnas.1816626116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of celastrol derivatives as anti-ovarian cancer stem cell agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.ejmech.2019.06.086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31279299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlejs7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=667-679&author=X.+Liauthor=J.+Dingauthor=N.+Liauthor=W.+Liuauthor=F.+Dingauthor=H.+Zhengauthor=Y.+Ningauthor=H.+Wangauthor=R.+Liuauthor=S.+Ren&title=Synthesis+and+biological+evaluation+of+celastrol+derivatives+as+anti-ovarian+cancer+stem+cell+agents&doi=10.1016%2Fj.ejmech.2019.06.086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of celastrol derivatives as anti-ovarian cancer stem cell agents</span></div><div class="casAuthors">Li, Xiaojing; Ding, Jie; Li, Ning; Liu, Wenxia; Ding, Fuhao; Zheng, Huijuan; Ning, Yanyan; Wang, Hongmin; Liu, Renmin; Ren, Shaoda</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">667-679</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Ovarian cancer is assocd. with a high percentage of recurrence of tumors and resistance to chemotherapy.  Cancer stem cells (CSCs) are responsible for cancer progression, tumor recurrence, metastasis, and chemoresistance.  Thus, developing CSC-targeting therapy is an urgent need in cancer research and clin. application.  In an attempt to achieve potent and selective anti-CSC agents, a series of celastrol derivs. with cinnamamide chains were synthesized and evaluated for their anti-ovarian cancer activities.  Most of the compds. exhibited stronger antiproliferative activity than celastrol; and celastrol deriv. I, with a 3,4,5-trimethoxycinnamamide side chain, was found to be the most potent antiproliferative agent against ovarian cancer cells with an IC50 value of 0.6 μM.  Addnl., compd. I significantly inhibited the colony formation ability and reduced the no. of tumor spheres.  Furthermore, compd. I decreased the percentage of CD44+, CD133+ and ALDH+ cells.  Thus, compd. I is a promising anti-CSC agent and could serve as a candidate for the development of new anti-ovarian cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3ZSsmsTyOMrVg90H21EOLACvtfcHk0li9qLMIgwWIVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlejs7%252FO&md5=9b19ac7d29fc4a702eac533323c55b9d</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.086%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DF.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DRen%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520celastrol%2520derivatives%2520as%2520anti-ovarian%2520cancer%2520stem%2520cell%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D179%26spage%3D667%26epage%3D679%26doi%3D10.1016%2Fj.ejmech.2019.06.086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Regina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naccarato, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biagioni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baiocchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pastena, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Magno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canettieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestri, R.</span></span> <span> </span><span class="NLM_article-title">Drug design and synthesis of first in class PDZ1 targeting NHERF1 inhibitors as anticancer agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">499</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00532</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00532" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFKiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=499&author=A.+Colucciaauthor=G.+La+Reginaauthor=V.+Naccaratoauthor=M.+Nalliauthor=V.+Orlandoauthor=S.+Biagioniauthor=M.+L.+De+Angelisauthor=M.+Baiocchiauthor=C.+Gautierauthor=S.+Gianniauthor=F.+Di+Pastenaauthor=L.+Di+Magnoauthor=G.+Canettieriauthor=A.+M.+L.+Colucciaauthor=R.+Silvestri&title=Drug+design+and+synthesis+of+first+in+class+PDZ1+targeting+NHERF1+inhibitors+as+anticancer+agents&doi=10.1021%2Facsmedchemlett.8b00532"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Design and Synthesis of First in Class PDZ1 Targeting NHERF1 Inhibitors as Anticancer Agents</span></div><div class="casAuthors">Coluccia, Antonio; La Regina, Giuseppe; Naccarato, Valentina; Nalli, Marianna; Orlando, Viviana; Biagioni, Stefano; De Angelis, Maria Laura; Baiocchi, Marta; Gautier, Candice; Gianni, Stefano; Di Pastena, Fiorella; Di Magno, Laura; Canettieri, Gianluca; Coluccia, Addolorata Maria Luce; Silvestri, Romano</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">499-503</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeted approaches aiming at modulating NHERF1 activity, rather than its overall expression, would be preferred to preserve the normal functions of this versatile protein.  We focused our attention on the NHERF1/PDZ1 domain that governs its membrane recruitment/displacement through a transient phosphorylation switch.  We herein report the design and synthesis of novel NHERF1 PDZ1 domain inhibitors.  These compds. have potential therapeutic value when used in combination with antagonists of β-catenin to augment apoptotic death of colorectal cancer cells refractory to currently available Wnt/β-catenin-targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDgdVlg2JYNLVg90H21EOLACvtfcHk0lgUOCAQ5UouUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFKiuw%253D%253D&md5=77a678697987a8c75e865f2532baae41</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00532%26sid%3Dliteratum%253Aachs%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DLa%2BRegina%26aufirst%3DG.%26aulast%3DNaccarato%26aufirst%3DV.%26aulast%3DNalli%26aufirst%3DM.%26aulast%3DOrlando%26aufirst%3DV.%26aulast%3DBiagioni%26aufirst%3DS.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%2BL.%26aulast%3DBaiocchi%26aufirst%3DM.%26aulast%3DGautier%26aufirst%3DC.%26aulast%3DGianni%26aufirst%3DS.%26aulast%3DDi%2BPastena%26aufirst%3DF.%26aulast%3DDi%2BMagno%26aufirst%3DL.%26aulast%3DCanettieri%26aufirst%3DG.%26aulast%3DColuccia%26aufirst%3DA.%2BM.%2BL.%26aulast%3DSilvestri%26aufirst%3DR.%26atitle%3DDrug%2520design%2520and%2520synthesis%2520of%2520first%2520in%2520class%2520PDZ1%2520targeting%2520NHERF1%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D499%26doi%3D10.1021%2Facsmedchemlett.8b00532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, A.</span></span> <span> </span><span class="NLM_article-title">Targeting stem cells in the realm of drug-resistant breast cancer</span>. <i>Breast Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.2147/BCTT.S189224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.2147%2FBCTT.S189224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12qs73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=115-135&author=P.+Deyauthor=M.+Rathodauthor=A.+De&title=Targeting+stem+cells+in+the+realm+of+drug-resistant+breast+cancer&doi=10.2147%2FBCTT.S189224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130aR"><div class="casContent"><span class="casTitleNuber">130a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting stem cells in the realm of drug-resistant breast cancer</span></div><div class="casAuthors">Dey, Pranay; Rathod, Maitreyi; De, Abhijit</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">115-135</span>CODEN:
                <span class="NLM_cas:coden">BCTTA9</span>;
        ISSN:<span class="NLM_cas:issn">1179-1314</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Since its first documentation, breast cancer (BC) has been a conundrum that ails millions of women every year.  This cancer has been well studied by researchers all over the world, which has improved the patient outcome significantly.  There are many diagnostic markers to identify the disease, but early detection and then subclassification of this cancer remain dubious.  Even after the correct diagnosis, more than half the patients come back with a more aggressive and metastatic tumor.  The underpinning mechanism that governs the resistance includes over-amplification of receptors, mutations in key gene targets, and activation of different signaling.  A plethora of drugs have been devised that have shown promising results in clin. settings.  However, in recent times, the role played by cancer stem cells in disease progression and their interaction in mediating the resistance to cellular insults have come into the limelight.  As breast cancer stem cells (BCSCs) are dormant in nature, it is highly likely that they fail to directly respond to the cytotoxic drugs which are meant for ablating rapidly proliferating cells.  Furthermore, the absence of well-characterized, drug-able surface markers to date, has limited the application of targeted therapies in complete eradication of the disease.  In this review, our intent is to discuss versatile therapeutics in practice followed by discussing the upcoming therapy strategies in the pipeline for BC.  Furthermore, we focus on the roles played by BCSCs in mediating the resistance, and therefore, the aspects of new therapeutics against BCSCs under development that may ease the burden in future has also been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbMU0R2TKw_LVg90H21EOLACvtfcHk0lgUOCAQ5UouUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit12qs73J&md5=8782b01d078ee556ad75e22776e680a9</span></div><a href="/servlet/linkout?suffix=cit130a&amp;dbid=16384&amp;doi=10.2147%2FBCTT.S189224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FBCTT.S189224%26sid%3Dliteratum%253Aachs%26aulast%3DDey%26aufirst%3DP.%26aulast%3DRathod%26aufirst%3DM.%26aulast%3DDe%26aufirst%3DA.%26atitle%3DTargeting%2520stem%2520cells%2520in%2520the%2520realm%2520of%2520drug-resistant%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2019%26volume%3D11%26spage%3D115%26epage%3D135%26doi%3D10.2147%2FBCTT.S189224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit130b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollmén, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proulx, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detmar, M.</span></span> <span> </span><span class="NLM_article-title">New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1007</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.18632%2Foncotarget.13537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=27894093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC2sjhtFSmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1007-1022&author=J.+Cuiauthor=M.+Hollm%C3%A9nauthor=L.+Liauthor=Y.+Chenauthor=S.+T.+Proulxauthor=D.+Rekerauthor=G.+Schneiderauthor=M.+Detmar&title=New+use+of+an+old+drug%3A+inhibition+of+breast+cancer+stem+cells+by+benztropine+mesylate&doi=10.18632%2Foncotarget.13537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130bR"><div class="casContent"><span class="casTitleNuber">130b</span><div class="casTitle"><span class="NLM_cas:atitle">New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate</span></div><div class="casAuthors">Cui Jihong; Hollmen Maija; Li Lina; Chen Yong; Proulx Steven T; Reker Daniel; Schneider Gisbert; Detmar Michael</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1007-1022</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer stem cells (CSCs) play major roles in cancer initiation, metastasis, recurrence and therapeutic resistance.  Targeting CSCs represents a promising strategy for cancer treatment.  The purpose of this study was to identify selective inhibitors of breast CSCs (BCSCs).  We carried out a cell-based phenotypic screening with cell viability as a primary endpoint, using a collection of 2,546 FDA-approved drugs and drug-like molecules in spheres formed by malignant human breast gland-derived cells (HMLER-shEcad cells, representing BCSCs) and control immortalized non-tumorigenic human mammary cells (HMLE cells, representing normal stem cells). 19 compounds were identified from screening.  The chemically related molecules benztropine mesylate and deptropine citrate were selected for further validation and both potently inhibited sphere formation and self-renewal of BCSCs in vitro.  Benztropine mesylate treatment decreased cell subpopulations with high ALDH activity and with a CD44+/CD24- phenotype.  In vivo, benztropine mesylate inhibited tumor-initiating potential in a 4T1 mouse model.  Functional studies indicated that benztropine mesylate inhibits functions of CSCs via the acetylcholine receptors, dopamine transporters/receptors, and/or histamine receptors.  In summary, our findings identify benztropine mesylate as an inhibitor of BCSCs in vitro and in vivo.  This study also provides a screening platform for identification of additional anti-CSC agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTncrZn-RnoSkH3Rlp_k91zfW6udTcc2eaq7Dj4dROr5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjhtFSmug%253D%253D&md5=10aa69b330084b006ad6a3e3b7bf27bb</span></div><a href="/servlet/linkout?suffix=cit130b&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13537%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DHollm%25C3%25A9n%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DProulx%26aufirst%3DS.%2BT.%26aulast%3DReker%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DDetmar%26aufirst%3DM.%26atitle%3DNew%2520use%2520of%2520an%2520old%2520drug%253A%2520inhibition%2520of%2520breast%2520cancer%2520stem%2520cells%2520by%2520benztropine%2520mesylate%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D1007%26epage%3D1022%26doi%3D10.18632%2Foncotarget.13537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheu, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suk, F. M.</span></span> <span> </span><span class="NLM_article-title">The antihistamine deptropine induces hepatoma cell death through blocking autophagosome-lysosome fusion</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1610</span>, <span class="refDoi"> DOI: 10.3390/cancers12061610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcancers12061610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVehtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1610&author=Y.+C.+Liangauthor=C.+C.+Changauthor=M.+T.+Sheuauthor=S.+Y.+Linauthor=C.+C.+Chungauthor=C.+T.+Tengauthor=F.+M.+Suk&title=The+antihistamine+deptropine+induces+hepatoma+cell+death+through+blocking+autophagosome-lysosome+fusion&doi=10.3390%2Fcancers12061610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">The antihistamine deptropine induces hepatoma cell death through blocking autophagosome-lysosome fusion</span></div><div class="casAuthors">Liang, Yu-Chih; Chang, Chi-Ching; Sheu, Ming-Thau; Lin, Shyr-Yi; Chung, Chia-Chen; Teng, Chang-Ting; Suk, Fat-Moon</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1610</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Some antihistamines have exhibited significant antitumor activity alone or in combination with other therapies in in vitro and clin. studies.  However, the underlying mechanisms of how antihistamines inhibit hepatocellular carcinoma proliferation are still unknown.  We first screened the antiproliferation activity of 12 benzocycloheptene structural-analog drugs, and results showed that deptropine was the most potent inhibitor of both Hep3B and HepG2 human hepatoma cells.  Deptropine significantly increased light chain 3B-II (LC3B-II) expression but did not induce sequestosome 1 (SQSTM1/p62) degrdn. in either cell line.  Interestingly, other autophagy-related proteins, such as autophagy-related 7 (ATG7), vacuolar protein sorting 34 (VPS34), phosphorylated AMP-activated protein kinase (AMPK), and phosphorylated protein kinase B (PKB, also known as Akt), exhibited no significant change in either deptropine-treated cell line.  Deptropine also inhibited the processing of cathepsin L from its precursor form to its mature form.  Immunofluorescence microscopy showed an increase of autophagosomes in deptropine-treated cells, but deptropine blocked the fusion between autophagosomes and lysosomes.  In a xenograft nude mice model, 2.5 mg/kg deptropine showed a great inhibitory effect on Hep3B tumor growth.  These results suggest that deptropine can induce in vitro and in vivo hepatoma cell death, and the underlying mechanisms might be mediated through inhibiting autophagy by blocking autophagosome-lysosome fusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBZltrdlx2iLVg90H21EOLACvtfcHk0lj17VQEDczLrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVehtLnL&md5=072cd8903e5ab8274e47382efb041f17</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.3390%2Fcancers12061610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12061610%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.%2BC.%26aulast%3DChang%26aufirst%3DC.%2BC.%26aulast%3DSheu%26aufirst%3DM.%2BT.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DChung%26aufirst%3DC.%2BC.%26aulast%3DTeng%26aufirst%3DC.%2BT.%26aulast%3DSuk%26aufirst%3DF.%2BM.%26atitle%3DThe%2520antihistamine%2520deptropine%2520induces%2520hepatoma%2520cell%2520death%2520through%2520blocking%2520autophagosome-lysosome%2520fusion%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D1610%26doi%3D10.3390%2Fcancers12061610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, X.</span></span> <span> </span><span class="NLM_article-title">Identification of PGRMC1 as a candidate oncogene for head and neck cancers and its involvement in metabolic activities</span>. <i>Front. Bioeng. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">438</span>, <span class="refDoi"> DOI: 10.3389/fbioe.2019.00438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffbioe.2019.00438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31970154" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2020&pages=438&author=Y.+Zhaoauthor=X.+Ruan&title=Identification+of+PGRMC1+as+a+candidate+oncogene+for+head+and+neck+cancers+and+its+involvement+in+metabolic+activities&doi=10.3389%2Ffbioe.2019.00438"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.3389%2Ffbioe.2019.00438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffbioe.2019.00438%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DRuan%26aufirst%3DX.%26atitle%3DIdentification%2520of%2520PGRMC1%2520as%2520a%2520candidate%2520oncogene%2520for%2520head%2520and%2520neck%2520cancers%2520and%2520its%2520involvement%2520in%2520metabolic%2520activities%26jtitle%3DFront.%2520Bioeng.%2520Biotechnol.%26date%3D2020%26volume%3D7%26spage%3D438%26doi%3D10.3389%2Ffbioe.2019.00438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craven, R. J.</span></span> <span> </span><span class="NLM_article-title">AG-205 for the Treatment of Breast Cancer</span>. U.S. Patent <span class="NLM_patent">9,724,337</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=R.+J.+Craven&title=AG-205+for+the+Treatment+of+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCraven%26aufirst%3DR.%2BJ.%26atitle%3DAG-205%2520for%2520the%2520Treatment%2520of%2520Breast%2520Cancer%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Padhariya, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Athavale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P. S.</span></span> <span> </span><span class="NLM_article-title">Substituted chloroacetamides as potential cancer stem cell inhibitors: Synthesis and biological evaluation</span>. <i>Drug Dev. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">356</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1002/ddr.21628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fddr.21628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31800121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1yjtr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2020&pages=356-365&author=K.+N.+Padhariyaauthor=M.+Athavaleauthor=S.+Srivastavaauthor=P.+S.+Kharkar&title=Substituted+chloroacetamides+as+potential+cancer+stem+cell+inhibitors%3A+Synthesis+and+biological+evaluation&doi=10.1002%2Fddr.21628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted chloroacetamides as potential cancer stem cell inhibitors: Synthesis and biological evaluation</span></div><div class="casAuthors">Padhariya, Komal N.; Athavale, Maithili; Srivastava, Sangeeta; Kharkar, Prashant S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Development Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">356-365</span>CODEN:
                <span class="NLM_cas:coden">DDREDK</span>;
        ISSN:<span class="NLM_cas:issn">0272-4391</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Cancer kills, irresp. of geog. and cultural origin.  Novel modalities for treating cancer are desperately needed.  Cancer stem cells (CSCs), main culprits behind chemoresistance and tumor relapse, are one of the few logical choices.  Herein, we report the synthesis and biol. evaluation of small mols. with chloroacetamide war-head.  These mols. were screened for viability against various breast, prostate, and oral cancer cell lines using MTT and soft-agar assays.  Further, promising hits were screened in sphere-forming assay with the aim of discovering potential anti-CSC agents.  Our optimism yielded four hits inhibiting self-renewal of cancer cells with stem-like characters in vitro.  Finally, the hits were evaluated for in vitro toxicity against human peripheral blood mononuclear cells and mouse embryonic fibroblast cell line.  Overall, these preliminary investigations yielded three hits exhibiting promising anti-CSC potential with little or no toxicity against normal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6RnOgvbEyFrVg90H21EOLACvtfcHk0lj17VQEDczLrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1yjtr3M&md5=6fb108e88b603a7d525170f9cc075710</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1002%2Fddr.21628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fddr.21628%26sid%3Dliteratum%253Aachs%26aulast%3DPadhariya%26aufirst%3DK.%2BN.%26aulast%3DAthavale%26aufirst%3DM.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DKharkar%26aufirst%3DP.%2BS.%26atitle%3DSubstituted%2520chloroacetamides%2520as%2520potential%2520cancer%2520stem%2520cell%2520inhibitors%253A%2520Synthesis%2520and%2520biological%2520evaluation%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D2020%26volume%3D81%26spage%3D356%26epage%3D365%26doi%3D10.1002%2Fddr.21628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Padhariya, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Athavale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P. S.</span></span> <span> </span><span class="NLM_article-title">A novel series of substituted 1,2,3-triazoles as cancer stem cell inhibitors: synthesis and biological evaluation</span>. <i>Drug Dev. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1002/ddr.21723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fddr.21628" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=K.+N.+Padhariyaauthor=M.+Athavaleauthor=S.+Srivastavaauthor=P.+S.+Kharkar&title=A+novel+series+of+substituted+1%2C2%2C3-triazoles+as+cancer+stem+cell+inhibitors%3A+synthesis+and+biological+evaluation&doi=10.1002%2Fddr.21723"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1002%2Fddr.21628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fddr.21628%26sid%3Dliteratum%253Aachs%26aulast%3DPadhariya%26aufirst%3DK.%2BN.%26aulast%3DAthavale%26aufirst%3DM.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DKharkar%26aufirst%3DP.%2BS.%26atitle%3DA%2520novel%2520series%2520of%2520substituted%25201%252C2%252C3-triazoles%2520as%2520cancer%2520stem%2520cell%2520inhibitors%253A%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D2020%26doi%3D10.1002%2Fddr.21723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quattrini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelardi, E. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coviello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraris, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garavaglia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Motta, C.</span></span> <span> </span><span class="NLM_article-title">Imidazo[1,2-a]pyridine derivatives as aldehyde dehydrogenase inhibitors: novel chemotypes to target glioblastoma stem cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4603</span>– <span class="NLM_lpage">4616</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01910</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01910" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlvFCht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4603-4616&author=L.+Quattriniauthor=E.+L.+M.+Gelardiauthor=V.+Covielloauthor=S.+Sartiniauthor=D.+M.+Ferrarisauthor=M.+Moriauthor=I.+Nakanoauthor=S.+Garavagliaauthor=C.+La+Motta&title=Imidazo%5B1%2C2-a%5Dpyridine+derivatives+as+aldehyde+dehydrogenase+inhibitors%3A+novel+chemotypes+to+target+glioblastoma+stem+cells&doi=10.1021%2Facs.jmedchem.9b01910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazo[1,2-a]pyridine Derivatives as Aldehyde Dehydrogenase Inhibitors: Novel Chemotypes to Target Glioblastoma Stem Cells</span></div><div class="casAuthors">Quattrini, Luca; Gelardi, Edoardo Luigi Maria; Coviello, Vito; Sartini, Stefania; Ferraris, Davide Maria; Mori, Mattia; Nakano, Ichiro; Garavaglia, Silvia; La Motta, Concettina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4603-4616</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the deadliest form of brain tumor.  It is known for its ability to escape the therapeutic options available to date thanks to the presence of a subset of cells endowed with stem-like properties and ability to resist to cytotoxic treatments.  As the cytosolic enzyme aldehyde dehydrogenase 1A3 turns out to be overexpressed in these kinds of cells, playing a key role for their vitality, treatments targeting this enzyme may represent a successful strategy to fight GBM.  In this work, we describe a novel class of imidazo[1,2-a]pyridine derivs. as aldehyde dehydrogenase 1A3 inhibitors, reporting the evidence of their significance as novel drug candidates for the treatment of GBM.  Besides showing an interesting functional profile, in terms of activity against the target enzyme and selectivity toward highly homologous isoenzymes, representative examples of the series also showed a nanomolar to picomolar efficacy against patient-derived GBM stem-like cells, thus proving the concept that targeting aldehyde dehydrogenase might represent a novel and promising way to combat GBM by striking its ability to divide immortally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrStxZKnoYSiLVg90H21EOLACvtfcHk0lh_y0pAgpfAgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlvFCht7k%253D&md5=47a29fe886d2dd95540b22154e9b7f0b</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01910%26sid%3Dliteratum%253Aachs%26aulast%3DQuattrini%26aufirst%3DL.%26aulast%3DGelardi%26aufirst%3DE.%2BL.%2BM.%26aulast%3DCoviello%26aufirst%3DV.%26aulast%3DSartini%26aufirst%3DS.%26aulast%3DFerraris%26aufirst%3DD.%2BM.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DNakano%26aufirst%3DI.%26aulast%3DGaravaglia%26aufirst%3DS.%26aulast%3DLa%2BMotta%26aufirst%3DC.%26atitle%3DImidazo%255B1%252C2-a%255Dpyridine%2520derivatives%2520as%2520aldehyde%2520dehydrogenase%2520inhibitors%253A%2520novel%2520chemotypes%2520to%2520target%2520glioblastoma%2520stem%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4603%26epage%3D4616%26doi%3D10.1021%2Facs.jmedchem.9b01910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quattrini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelardi, E. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrarolo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraris, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picarazzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garavaglia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Motta, C.</span></span> <span> </span><span class="NLM_article-title">Progress in the field of aldehyde dehydrogenase inhibitors: Novel imidazo[1,2-a]pyridines against the 1A family</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">970</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXls1CjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=963-970&author=L.+Quattriniauthor=E.+L.+M.+Gelardiauthor=G.+Petraroloauthor=G.+Colomboauthor=D.+M.+Ferrarisauthor=F.+Picarazziauthor=M.+Rizziauthor=S.+Garavagliaauthor=C.+La+Motta&title=Progress+in+the+field+of+aldehyde+dehydrogenase+inhibitors%3A+Novel+imidazo%5B1%2C2-a%5Dpyridines+against+the+1A+family&doi=10.1021%2Facsmedchemlett.9b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the Field of Aldehyde Dehydrogenase Inhibitors: Novel Imidazo[1,2-a]pyridines against the 1A Family</span></div><div class="casAuthors">Quattrini, Luca; Gelardi, Edoardo Luigi Maria; Petrarolo, Giovanni; Colombo, Giorgia; Ferraris, Davide Maria; Picarazzi, Francesca; Rizzi, Menico; Garavaglia, Silvia; La Motta, Concettina</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">963-970</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Members of the aldehyde dehydrogenase 1A family are commonly acknowledged as hallmarks of cancer stem cells, and their overexpression is significantly assocd. with poor prognosis in different types of malignancies.  Accordingly, treatments targeting these enzymes may represent a successful strategy to fight cancer.  In this work we describe a novel series of imidazo[1,2-a]pyridines, designed as aldehyde dehydrogenase inhibitors by means of a structure-based optimization of a previously developed lead.  The novel compds. were evaluated in vitro for their activity and selectivity against the three isoforms of the ALDH1A family and investigated through crystn. and modeling studies for their ability to interact with the catalytic site of the 1A3 isoform.  Compd. 3f emerged as the first in class submicromolar competitive inhibitor of the target enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTHLr4ZUbTFLVg90H21EOLACvtfcHk0lh_y0pAgpfAgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXls1CjtLk%253D&md5=bd4c5d127bd06d5d1bd72d7f62442bd7</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00686%26sid%3Dliteratum%253Aachs%26aulast%3DQuattrini%26aufirst%3DL.%26aulast%3DGelardi%26aufirst%3DE.%2BL.%2BM.%26aulast%3DPetrarolo%26aufirst%3DG.%26aulast%3DColombo%26aufirst%3DG.%26aulast%3DFerraris%26aufirst%3DD.%2BM.%26aulast%3DPicarazzi%26aufirst%3DF.%26aulast%3DRizzi%26aufirst%3DM.%26aulast%3DGaravaglia%26aufirst%3DS.%26aulast%3DLa%2BMotta%26aufirst%3DC.%26atitle%3DProgress%2520in%2520the%2520field%2520of%2520aldehyde%2520dehydrogenase%2520inhibitors%253A%2520Novel%2520imidazo%255B1%252C2-a%255Dpyridines%2520against%2520the%25201A%2520family%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D963%26epage%3D970%26doi%3D10.1021%2Facsmedchemlett.9b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span> <span> </span><span class="NLM_article-title">Mediating K<sup>+</sup>/H<sup>+</sup> transport on organelle membranes to selectively eradicate cancer stem cells with a small molecule</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">10769</span>– <span class="NLM_lpage">10779</span>, <span class="refDoi"> DOI: 10.1021/jacs.0c02134</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.0c02134" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVShtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=10769-10779&author=F.+F.+Shenauthor=S.+Y.+Daiauthor=N.+K.+Wongauthor=S.+Dengauthor=A.+S.+Wongauthor=D.+Yang&title=Mediating+K%2B%2FH%2B+transport+on+organelle+membranes+to+selectively+eradicate+cancer+stem+cells+with+a+small+molecule&doi=10.1021%2Fjacs.0c02134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Mediating K+/H+ Transport on Organelle Membranes to Selectively Eradicate Cancer Stem Cells with a Small Molecule</span></div><div class="casAuthors">Shen, Fang-Fang; Dai, Sheng-Yao; Wong, Nai-Kei; Deng, Shan; Wong, Alice Sze-Tsai; Yang, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10769-10779</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mols. that are capable of disrupting cellular ion homeostasis offer unique opportunities to treat cancer.  However, previously reported synthetic ion transporters showed limited value, as promiscuous ionic disruption caused toxicity to both healthy cells and cancer cells indiscriminately.  Here we report a simple yet efficient synthetic K+ transporter that takes advantage of the endogenous subcellular pH gradient and membrane potential to site-selectively mediate K+/H+ transport on the mitochondrial and lysosomal membranes in living cells.  Consequent mitochondrial and lysosomal damages enhanced cytotoxicity to chemo-resistant ovarian cancer stem cells (CSCs) via apoptosis induction and autophagy suppression with remarkable selectivity (up to 47-fold).  The eradication of CSCs blunted tumor formation in mice.  We believe this strategy can be exploited in the structural design and applications of next-generation synthetic cation transporters for the treatment of cancer and other diseases related to dysfunctional K+ channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2ZJhSC336zrVg90H21EOLACvtfcHk0lh_y0pAgpfAgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVShtrnO&md5=09de6c15ee329e509d80708bf7ecc18c</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Fjacs.0c02134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.0c02134%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DF.%2BF.%26aulast%3DDai%26aufirst%3DS.%2BY.%26aulast%3DWong%26aufirst%3DN.%2BK.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DA.%2BS.%26aulast%3DYang%26aufirst%3DD.%26atitle%3DMediating%2520K%252B%252FH%252B%2520transport%2520on%2520organelle%2520membranes%2520to%2520selectively%2520eradicate%2520cancer%2520stem%2520cells%2520with%2520a%2520small%2520molecule%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26spage%3D10769%26epage%3D10779%26doi%3D10.1021%2Fjacs.0c02134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santamaria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Sanz, J. A.</span></span> <span> </span><span class="NLM_article-title">Will a mAb-based immunotherapy directed against cancer stem cells be feasible?</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1509</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2017.01509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffimmu.2017.01509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29170667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFemsbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1509&author=S.+Santamariaauthor=M.+Delgadoauthor=L.+Kremerauthor=J.+A.+Garcia-Sanz&title=Will+a+mAb-based+immunotherapy+directed+against+cancer+stem+cells+be+feasible%3F&doi=10.3389%2Ffimmu.2017.01509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Will a mAb-based immunotherapy directed against cancer stem cells be feasible?</span></div><div class="casAuthors">Santamaria, Silvia; Delgado, Marisa; Kremer, Leonor; Garcia-Sanz, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1509/1-1509/8</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The cancer stem cell (CSC) hypothesis suggests that within a tumor, there is a small subpopulation of cells with stem cell properties responsible for tumor maintenance and metastasis generation.  This hypothesis also implies that new antitumor drugs, rather than targeting the bulk of the tumor mass, would be more effective if they directly targeted the CSC subpopulation.  The CSCs from several types of tumors have been identified with mAbs recognizing surface antigens in these cells; however, antigens specifically or exclusively expressed in the CSC population have not yet been identified.  Thus, questioning the possibility of using therapeutic antibodies directed against the CSCs.  Here, we review the possibilities of using antibodies directly targeting the CSCs as therapeutic agents in the form of naked antibodies, antibodies conjugated to nanoparticles, or antibody cocktails.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGVLhN0__8c7Vg90H21EOLACvtfcHk0lhfScnEF2mjzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFemsbrE&md5=63c56bbb4a6ed75af957a7feba2afa59</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.01509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.01509%26sid%3Dliteratum%253Aachs%26aulast%3DSantamaria%26aufirst%3DS.%26aulast%3DDelgado%26aufirst%3DM.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DGarcia-Sanz%26aufirst%3DJ.%2BA.%26atitle%3DWill%2520a%2520mAb-based%2520immunotherapy%2520directed%2520against%2520cancer%2520stem%2520cells%2520be%2520feasible%253F%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D1509%26doi%3D10.3389%2Ffimmu.2017.01509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widhopf, G. F.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">1370</span>– <span class="NLM_lpage">1377</span>, <span class="refDoi"> DOI: 10.1073/pnas.1816262116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1073%2Fpnas.1816262116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30622177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2msrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=1370-1377&author=S.+Zhangauthor=H.+Zhangauthor=E.+M.+Ghiaauthor=J.+Huangauthor=L.+Wuauthor=J.+Zhangauthor=S.+Lamauthor=Y.+Leiauthor=J.+Heauthor=B.+Cuiauthor=G.+F.+Widhopfauthor=J.+Yuauthor=R.+Schwabauthor=K.+Messerauthor=W.+Jiangauthor=B.+A.+Parkerauthor=D.+A.+Carsonauthor=T.+J.+Kipps&title=Inhibition+of+chemotherapy+resistant+breast+cancer+stem+cells+by+a+ROR1+specific+antibody&doi=10.1073%2Fpnas.1816262116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody</span></div><div class="casAuthors">Zhang, Suping; Zhang, Han; Ghia, Emanuela M.; Huang, Jiajia; Wu, Liufeng; Zhang, Jianchao; Lam, Sharon; Lei, Yang; He, Jinsong; Cui, Bing; Widhopf, George F., II; Yu, Jian; Schwab, Richard; Messer, Karen; Jiang, Wenqi; Parker, Barbara A.; Carson, Dennis A.; Kipps, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1370-1377</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Breast cancers enduring treatment with chemotherapy may be enriched for cancer stem cells or tumor-initiating cells, which have an enhanced capacity for self-renewal, tumor initiation, and/or metastasis.  Breast cancer cells that express the type I tyrosine kinaselike orphan receptor ROR1 also may have such features.  Here we find that the expression of ROR1 increased in breast cancer cells following treatment with chemotherapy, which also enhanced expression of genes induced by the activation of Rho-GTPases, Hippo-YAP/TAZ, or B lymphoma Mo-MLV insertion region 1 homolog (BMI1).  Expression of ROR1 also enhanced the capacity of breast cancer cells to invade Matrigel, form spheroids, engraft in Rag2a$$Hat$$  /a$$Hat$$  I$$Hat$$3ca$$Hat$$  /a$$Hat$$   mice, or survive treatment with paclitaxel.  Treatment of mice bearing breast cancer patient-derived xenografts (PDXs) with the humanized anti-ROR1 monoclonal antibody cirmtuzumab repressed expression of genes assocd. with breast cancer stemness, reduced activation of Rho-GTPases, Hippo-YAP/TAZ, or BMI1, and impaired the capacity of breast cancer PDXs to metastasize or reengraft Rag2a$$Hat$$  /a$$Hat$$  I$$Hat$$3ca$$Hat$$  /a$$Hat$$   mice.  Finally, treatment of PDX-bearing mice with cirmtuzumab and paclitaxel was more effective than treatment with either alone in eradicating breast cancer PDXs.  These results indicate that targeting ROR1 may improve the response to chemotherapy of patients with breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCYEZNkKl69bVg90H21EOLACvtfcHk0lhfScnEF2mjzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2msrw%253D&md5=1abb994f31573939f2cf01b762555e22</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1816262116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1816262116%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGhia%26aufirst%3DE.%2BM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLam%26aufirst%3DS.%26aulast%3DLei%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DB.%26aulast%3DWidhopf%26aufirst%3DG.%2BF.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DSchwab%26aufirst%3DR.%26aulast%3DMesser%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DParker%26aufirst%3DB.%2BA.%26aulast%3DCarson%26aufirst%3DD.%2BA.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26atitle%3DInhibition%2520of%2520chemotherapy%2520resistant%2520breast%2520cancer%2520stem%2520cells%2520by%2520a%2520ROR1%2520specific%2520antibody%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26spage%3D1370%26epage%3D1377%26doi%3D10.1073%2Fpnas.1816262116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowska-Borowczyk, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ga̧bka-Buszek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackiewicz, A.</span></span> <span> </span><span class="NLM_article-title">Immunotargeting of cancer stem cells</span>. <i>Wspolczesna Onkol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">A52</span>– <span class="NLM_lpage">A59</span>, <span class="refDoi"> DOI: 10.5114/wo.2014.47129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.5114%2Fwo.2014.47129" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=A52-A59&author=E.+P.+Kwiatkowska-Borowczykauthor=A.+Ga%CC%A7bka-Buszekauthor=J.+Jankowskiauthor=A.+Mackiewicz&title=Immunotargeting+of+cancer+stem+cells&doi=10.5114%2Fwo.2014.47129"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.5114%2Fwo.2014.47129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5114%252Fwo.2014.47129%26sid%3Dliteratum%253Aachs%26aulast%3DKwiatkowska-Borowczyk%26aufirst%3DE.%2BP.%26aulast%3DGa%25CC%25A7bka-Buszek%26aufirst%3DA.%26aulast%3DJankowski%26aufirst%3DJ.%26aulast%3DMackiewicz%26aufirst%3DA.%26atitle%3DImmunotargeting%2520of%2520cancer%2520stem%2520cells%26jtitle%3DWspolczesna%2520Onkol.%26date%3D2015%26volume%3D19%26spage%3DA52%26epage%3DA59%26doi%3D10.5114%2Fwo.2014.47129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClements, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, T.</span></span> <span> </span><span class="NLM_article-title">Top Notch targeting strategies in cancer: A detailed overview of recent insights and current perspectives</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1503</span>, <span class="refDoi"> DOI: 10.3390/cells9061503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcells9061503" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=1503&author=G.+Mooreauthor=S.+Annettauthor=L.+McClementsauthor=T.+Robson&title=Top+Notch+targeting+strategies+in+cancer%3A+A+detailed+overview+of+recent+insights+and+current+perspectives&doi=10.3390%2Fcells9061503"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.3390%2Fcells9061503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells9061503%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DG.%26aulast%3DAnnett%26aufirst%3DS.%26aulast%3DMcClements%26aufirst%3DL.%26aulast%3DRobson%26aufirst%3DT.%26atitle%3DTop%2520Notch%2520targeting%2520strategies%2520in%2520cancer%253A%2520A%2520detailed%2520overview%2520of%2520recent%2520insights%2520and%2520current%2520perspectives%26jtitle%3DCells%26date%3D2020%26volume%3D9%26spage%3D1503%26doi%3D10.3390%2Fcells9061503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casulo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diefenbach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaven, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faoro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span> <span> </span><span class="NLM_article-title">Safety and preliminary efficacy results of a phase I first-in-human study of the novel Notch-1 targeting antibody brontictuzumab (OMP-52M51) administered intravenously to patients with hematologic malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">5108</span>, <span class="refDoi"> DOI: 10.1182/blood.V128.22.5108.5108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1182%2Fblood.V128.22.5108.5108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=5108&author=C.+Casuloauthor=J.+Ruanauthor=N.+H.+Dangauthor=L.+Goreauthor=C.+Diefenbachauthor=A.+W.+Beavenauthor=J.+E.+Castroauthor=P.+Porcuauthor=L.+Faoroauthor=J.+Dupontauthor=A.+Kapounauthor=M.+Wangauthor=K.+McGuireauthor=I.+W.+Flinn&title=Safety+and+preliminary+efficacy+results+of+a+phase+I+first-in-human+study+of+the+novel+Notch-1+targeting+antibody+brontictuzumab+%28OMP-52M51%29+administered+intravenously+to+patients+with+hematologic+malignancies&doi=10.1182%2Fblood.V128.22.5108.5108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1182%2Fblood.V128.22.5108.5108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V128.22.5108.5108%26sid%3Dliteratum%253Aachs%26aulast%3DCasulo%26aufirst%3DC.%26aulast%3DRuan%26aufirst%3DJ.%26aulast%3DDang%26aufirst%3DN.%2BH.%26aulast%3DGore%26aufirst%3DL.%26aulast%3DDiefenbach%26aufirst%3DC.%26aulast%3DBeaven%26aufirst%3DA.%2BW.%26aulast%3DCastro%26aufirst%3DJ.%2BE.%26aulast%3DPorcu%26aufirst%3DP.%26aulast%3DFaoro%26aufirst%3DL.%26aulast%3DDupont%26aufirst%3DJ.%26aulast%3DKapoun%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DMcGuire%26aufirst%3DK.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26atitle%3DSafety%2520and%2520preliminary%2520efficacy%2520results%2520of%2520a%2520phase%2520I%2520first-in-human%2520study%2520of%2520the%2520novel%2520Notch-1%2520targeting%2520antibody%2520brontictuzumab%2520%2528OMP-52M51%2529%2520administered%2520intravenously%2520to%2520patients%2520with%2520hematologic%2520malignancies%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D5108%26doi%3D10.1182%2Fblood.V128.22.5108.5108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chugh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoun, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A.</span></span> <span> </span><span class="NLM_article-title">A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1007/s10637-018-0714-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1007%2Fs10637-018-0714-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30591982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1WhtL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=722-730&author=D.+C.+Smithauthor=R.+Chughauthor=A.+Patnaikauthor=K.+P.+Papadopoulosauthor=M.+Wangauthor=A.+M.+Kapounauthor=L.+Xuauthor=J.+Dupontauthor=R.+J.+Staggauthor=A.+Tolcher&title=A+phase+1+dose+escalation+and+expansion+study+of+Tarextumab+%28OMP-59R5%29+in+patients+with+solid+tumors&doi=10.1007%2Fs10637-018-0714-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors</span></div><div class="casAuthors">Smith, David C.; Chugh, Rashmi; Patnaik, Amita; Papadopoulos, Kyriakos P.; Wang, Min; Kapoun, Ann M.; Xu, Lu; Dupont, Jakob; Stagg, Robert J.; Tolcher, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">722-730</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose This Phase I trial evaluated the max. tolerated dose, safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of tarextumab (OMP-5948), a novel cross-reactive antibody which binds and selectively inhibits signaling via both Notch2 and Notch3, in adult patients with advanced malignancies.  Methods Std. 3 + 3 design with tarextumab 0.5, 1, 2.5, or 5 mg/kg weekly, or 5, 7.5, or 10 mg/kg every other week, or 7.5 mg every 3 wk.  Dose-limiting toxicities (DLT) were assessed during the first 28 days.  Results Forty-two patients received tarextumab (21 weekly, 15 every other week, 6 every three weeks). 2/6 subjects at the 5 mg/kg weekly dose, 2/3 at 10 mg/kg every other week, and 0/6 at 7.5 mg/kg every three weeks had a DLT.  The max. tolerated dose (MTD) was 2.5 mg/kg weekly, and 7.5 mg/kg on the every other and every three week schedules.  Gastrointestinal (GI) toxicity was the most common adverse event with diarrhea (81%), fatigue (48%), nausea (45%), anorexia (38%), and vomiting (38%) and abdominal pain and constipation (24% each).  Biomarker anal. showed regulation of stem cell and Notch gene signaling.  Conclusion Tarextumab was generally well-tolerated at doses <2.5 mg weekly and 7.5 mg/kg every other and every third week.  Diarrhea was dose-limiting above these levels, but relatively easily managed at lower doses.  Inhibition of Notch pathway signaling was demonstrated at these doses.  ClinicalTrials.gov Identifier: NCT01277146.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl7727zknLwrVg90H21EOLACvtfcHk0ljtYVx7NloYHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1WhtL3O&md5=b3cad202d5896c87b351000040cfc7e4</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1007%2Fs10637-018-0714-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-018-0714-6%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BC.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DKapoun%26aufirst%3DA.%2BM.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DDupont%26aufirst%3DJ.%26aulast%3DStagg%26aufirst%3DR.%2BJ.%26aulast%3DTolcher%26aufirst%3DA.%26atitle%3DA%2520phase%25201%2520dose%2520escalation%2520and%2520expansion%2520study%2520of%2520Tarextumab%2520%2528OMP-59R5%2529%2520in%2520patients%2520with%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2019%26volume%3D37%26spage%3D722%26epage%3D730%26doi%3D10.1007%2Fs10637-018-0714-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chugh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aljumaily, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoun, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. C.</span></span> <span> </span><span class="NLM_article-title">A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1007/s10637-018-0665-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1007%2Fs10637-018-0665-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30229512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCjur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=461-472&author=A.+Jimenoauthor=K.+N.+Mooreauthor=M.+Gordonauthor=R.+Chughauthor=J.+R.+Diamondauthor=R.+Aljumailyauthor=D.+Mendelsonauthor=A.+M.+Kapounauthor=L.+Xuauthor=R.+Staggauthor=D.+C.+Smith&title=A+first-in-human+phase+1a+study+of+the+bispecific+anti-DLL4%2Fanti-VEGF+antibody+navicixizumab+%28OMP-305B83%29+in+patients+with+previously+treated+solid+tumors&doi=10.1007%2Fs10637-018-0665-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors</span></div><div class="casAuthors">Jimeno, Antonio; Moore, Kathleen N.; Gordon, Michael; Chugh, Rashmi; Diamond, Jennifer R.; Aljumaily, Raid; Mendelson, David; Kapoun, Ann M.; Xu, Lu; Stagg, Robert; Smith, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-472</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Navicixizumab (OMP-305B83) is a bispecific antibody that inhibits delta-like ligand 4 and vascular endothelial growth factor.  This Phase 1a trial assessed escalating doses of navicixizumab in refractory solid tumors patients.  Design A 3 + 3 dose escalation design was used followed by the treatment of addnl. patients in an expansion cohort.  Study objectives were detn. of the max. tolerated dose, safety, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy.  Results: Sixty-six patients were treated once every 3 wk in 8 dose-escalation cohorts (0.5, 1, 2.5, 3.5, 5, 7.5, 10, and 12.5 mg/kg) and an expansion cohort (7.5 mg/kg).  The median age was 60 years and 68% of the patients were female.  The most commonly enrolled tumor types were ovarian (12), colorectal (11) and breast, pancreatic, uterine and endometrial (4 each) cancers.  As only 1 dose limiting toxicity occurred, the max. tolerated dose was not reached, but 7.5 mg/kg was chosen as the dose for the expansion cohort.  The treatment related adverse events (≥15% of patients) were hypertension (57.6%), headache (28.8%), fatigue (25.8%), and pulmonary hypertension (18.2%).  Pulmonary hypertension was mostly asymptomatic at doses ≤5 mg/kg (6 Gr1, 1 Gr2), but was more severe at higher doses (4 Gr2, 1 Gr3).  Navicixizumab's half-life was 11.4 days and there was a moderate (29%) incidence of anti-drug antibody formation.  Four patients (3 ovarian cancer, 1 uterine carcinosarcoma) had a partial response and 17 patients had stable disease.  Nineteen patients had a redn. in the size of their target lesions including 7/11 patients with ovarian cancer.  Four patients remained on study for >300 days and 2 of these patients were on study for >500 days.  Conclusions: Navicixizumab can be safely administered with manageable toxicities and these data showed preliminary signs of antitumor activity in multiple tumor types, but was most promising in ovarian cancer.  As a result these data justify its continued development in combination Phase 1b clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQP8R5wA0cD7Vg90H21EOLACvtfcHk0ljtYVx7NloYHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslCjur%252FI&md5=1e8e15a5702e31bdee2a292d5f20260a</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1007%2Fs10637-018-0665-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-018-0665-y%26sid%3Dliteratum%253Aachs%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DK.%2BN.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DDiamond%26aufirst%3DJ.%2BR.%26aulast%3DAljumaily%26aufirst%3DR.%26aulast%3DMendelson%26aufirst%3DD.%26aulast%3DKapoun%26aufirst%3DA.%2BM.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DStagg%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.%2BC.%26atitle%3DA%2520first-in-human%2520phase%25201a%2520study%2520of%2520the%2520bispecific%2520anti-DLL4%252Fanti-VEGF%2520antibody%2520navicixizumab%2520%2528OMP-305B83%2529%2520in%2520patients%2520with%2520previously%2520treated%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2019%26volume%3D37%26spage%3D461%26epage%3D472%26doi%3D10.1007%2Fs10637-018-0665-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caserta, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romeo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rumio, C.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates (ADC) against cancer stem-like cells (CSC) - is there still room for optimizm?</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">167</span>, <span class="refDoi"> DOI: 10.3389/fonc.2019.00167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffonc.2019.00167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30984612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252Fltl2qsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=167&author=F.+Marcucciauthor=C.+A.+Casertaauthor=E.+Romeoauthor=C.+Rumio&title=Antibody-drug+conjugates+%28ADC%29+against+cancer+stem-like+cells+%28CSC%29+-+is+there+still+room+for+optimizm%3F&doi=10.3389%2Ffonc.2019.00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates (ADC) Against Cancer Stem-Like Cells (CSC)-Is There Still Room for Optimism?</span></div><div class="casAuthors">Marcucci Fabrizio; Rumio Cristiano; Caserta Carmelo Antonio; Romeo Elisabetta</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Cancer stem-like cells (CSC) represent a subpopulation of tumor cells with peculiar functionalities that distinguish them from the bulk of tumor cells, most notably their tumor-initiating potential and drug resistance.  Given these properties, it appears logical that CSCs have become an important target for many pharma companies.  Antibody-drug conjugates (ADC) have emerged over the last decade as one of the most promising new tools for the selective ablation of tumor cells.  Three ADCs have already received regulatory approval and many others are in different phases of clinical development.  Not surprisingly, also a considerable number of anti-CSC ADCs have been described in the literature and some of these have entered clinical development.  Several of these ADCs, however, have yielded disappointing results in clinical studies.  This is similar to the results obtained with other anti-CSC drug candidates, including native antibodies, that have been investigated in the clinic.  In this article we review the anti-CSC ADCs that have been described in the literature and, in the following, we discuss reasons that may underlie the failures in clinical trials that have been observed.  Possible reasons relate to the biology of CSCs themselves, including their heterogeneity, the lack of strictly CSC-specific markers, and the capacity to interconvert between CSCs and non-CSCs; second, inherent limitations of some classes of cytotoxins that have been used for the construction of ADCs; third, the inadequacy of animal models in predicting efficacy in humans.  We conclude suggesting some possibilities to address these limitations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQNmb2epERaK4xhnOQkIHOxfW6udTcc2eY6hcZWDg_cXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252Fltl2qsw%253D%253D&md5=247908f0068097da43e894ca0bcae337</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2019.00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2019.00167%26sid%3Dliteratum%253Aachs%26aulast%3DMarcucci%26aufirst%3DF.%26aulast%3DCaserta%26aufirst%3DC.%2BA.%26aulast%3DRomeo%26aufirst%3DE.%26aulast%3DRumio%26aufirst%3DC.%26atitle%3DAntibody-drug%2520conjugates%2520%2528ADC%2529%2520against%2520cancer%2520stem-like%2520cells%2520%2528CSC%2529%2520-%2520is%2520there%2520still%2520room%2520for%2520optimizm%253F%26jtitle%3DFront.%2520Oncol.%26date%3D2019%26volume%3D9%26spage%3D167%26doi%3D10.3389%2Ffonc.2019.00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ponziani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Vittorio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flavell, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ippoliti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giansanti, F.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates: the new frontier of chemotherapy</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5510</span>, <span class="refDoi"> DOI: 10.3390/ijms21155510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fijms21155510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitValt73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=5510&author=S.+Ponzianiauthor=G.+Di+Vittorioauthor=G.+Pitariauthor=A.+M.+Ciminiauthor=M.+Ardiniauthor=R.+Gentileauthor=S.+Iacobelliauthor=G.+Salaauthor=E.+Caponeauthor=D.+J.+Flavellauthor=R.+Ippolitiauthor=F.+Giansanti&title=Antibody-drug+conjugates%3A+the+new+frontier+of+chemotherapy&doi=10.3390%2Fijms21155510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates: the new frontier of chemotherapy</span></div><div class="casAuthors">Ponziani, Sara; Di Vittorio, Giulia; Pitari, Giuseppina; Cimini, Anna Maria; Ardini, Matteo; Gentile, Roberta; Iacobelli, Stefano; Sala, Gianluca; Capone, Emily; Flavell, David J.; Ippoliti, Rodolfo; Giansanti, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5510</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  In recent years, antibody-drug conjugates (ADCs) have become promising antitumor agents to be used as one of the tools in personalized cancer medicine.  ADCs are comprised of a drug with cytotoxic activity crosslinked to a monoclonal antibody, targeting antigens expressed at higher levels on tumor cells than on normal cells.  By providing a selective targeting mechanism for cytotoxic drugs, ADCs improve the therapeutic index in clin. practice.  In this review, the chem. of ADC linker conjugation together with strategies adopted to improve antibody tolerability (by reducing antigenicity) are examd., with particular attention to ADCs approved by the regulatory agencies the U.S.  Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treating cancer patients.  Recent developments in engineering Ig (Ig) genes and antibody humanization have greatly reduced some of the problems of the first generation of ADCs, beset by problems, such as random coupling of the payload and immunogenicity of the antibody.  ADC development and clin. use is a fast, evolving area, and will likely prove an important modality for the treatment of cancer in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAe6_XsKEiBbVg90H21EOLACvtfcHk0liHa9ue9u4fdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitValt73P&md5=15bc464b864e8ea8d6e0d481b5d15704</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.3390%2Fijms21155510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21155510%26sid%3Dliteratum%253Aachs%26aulast%3DPonziani%26aufirst%3DS.%26aulast%3DDi%2BVittorio%26aufirst%3DG.%26aulast%3DPitari%26aufirst%3DG.%26aulast%3DCimini%26aufirst%3DA.%2BM.%26aulast%3DArdini%26aufirst%3DM.%26aulast%3DGentile%26aufirst%3DR.%26aulast%3DIacobelli%26aufirst%3DS.%26aulast%3DSala%26aufirst%3DG.%26aulast%3DCapone%26aufirst%3DE.%26aulast%3DFlavell%26aufirst%3DD.%2BJ.%26aulast%3DIppoliti%26aufirst%3DR.%26aulast%3DGiansanti%26aufirst%3DF.%26atitle%3DAntibody-drug%2520conjugates%253A%2520the%2520new%2520frontier%2520of%2520chemotherapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D5510%26doi%3D10.3390%2Fijms21155510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ning, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teitz-Tennenbaum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginestier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prince, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cell vaccination confers significant antitumor immunity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1853</span>– <span class="NLM_lpage">1864</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1158%2F0008-5472.CAN-11-1400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=22473314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVeltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1853-1864&author=N.+Ningauthor=Q.+Panauthor=F.+Zhengauthor=S.+Teitz-Tennenbaumauthor=M.+Egentiauthor=J.+Yetauthor=M.+Liauthor=C.+Ginestierauthor=M.+S.+Wichaauthor=J.+S.+Moyerauthor=M.+E.+Princeauthor=Y.+Xuauthor=X.+L.+Zhangauthor=S.+Huangauthor=A.+E.+Changauthor=Q.+Li&title=Cancer+stem+cell+vaccination+confers+significant+antitumor+immunity&doi=10.1158%2F0008-5472.CAN-11-1400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Stem Cell Vaccination Confers Significant Antitumor Immunity</span></div><div class="casAuthors">Ning, Ning; Pan, Qin; Zheng, Fang; Teitz-Tennenbaum, Seagal; Egenti, Martin; Yet, Ji; Li, Mu; Ginestier, Christophe; Wicha, Max S.; Moyer, Jeffrey S.; Prince, Mark E. P.; Xu, Yingxin; Zhang, Xiao-Lian; Huang, Shiang; Chang, Alfred E.; Li, Qiao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1853-1864</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most studies of cancer stem cells (CSC) involve the inoculation of cells from human tumors into immunosuppressed mice, preventing an assessment on the immunol. interactions and effects of CSCs.  In this study, we examd. the vaccination effects produced by CSC-enriched populations from histol. distinct murine tumors after their inoculation into different syngeneic immunocompetent hosts.  Enriched CSCs were immunogenic and more effective as an antigen source than unselected tumor cells in inducing protective antitumor immunity.  Immune sera from CSC-vaccinated hosts contained high levels of IgG which bound to CSCs, resulting in CSC lysis in the presence of complement.  CTLs generated from peripheral blood mononuclear cells or splenocytes harvested from CSC-vaccinated hosts were capable of killing CSCs in vitro.  Mechanistic investigations established that CSC-primed antibodies and T cells were capable of selective targeting CSCs and conferring antitumor immunity.  Together, these proof-of-concept results provide a rationale for a new type of cancer immunotherapy based on the development of CSC vaccines that can specifically target CSCs.  Cancer Res; 72(7); 1853-64.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSwxQTYmY5PbVg90H21EOLACvtfcHk0lh_f9Pa_llEnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVeltrk%253D&md5=7b09dd6937b55ce9f8d3b440eef7bd58</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1400%26sid%3Dliteratum%253Aachs%26aulast%3DNing%26aufirst%3DN.%26aulast%3DPan%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DF.%26aulast%3DTeitz-Tennenbaum%26aufirst%3DS.%26aulast%3DEgenti%26aufirst%3DM.%26aulast%3DYet%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGinestier%26aufirst%3DC.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26aulast%3DMoyer%26aufirst%3DJ.%2BS.%26aulast%3DPrince%26aufirst%3DM.%2BE.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%2BL.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DA.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26atitle%3DCancer%2520stem%2520cell%2520vaccination%2520confers%2520significant%2520antitumor%2520immunity%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1853%26epage%3D1864%26doi%3D10.1158%2F0008-5472.CAN-11-1400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span> <span> </span><span class="NLM_article-title">Development and application of cancer stem cell-targeted vaccine in cancer immunotherapy</span>. <i>J. Vaccines Vaccination</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">371</span>, <span class="refDoi"> DOI: 10.4172/2157-7560.1000371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.4172%2F2157-7560.1000371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29423335" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=371&author=M.+Linauthor=A.+E.+Changauthor=M.+Wichaauthor=Q.+Liauthor=S.+Huang&title=Development+and+application+of+cancer+stem+cell-targeted+vaccine+in+cancer+immunotherapy&doi=10.4172%2F2157-7560.1000371"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.4172%2F2157-7560.1000371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2157-7560.1000371%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DA.%2BE.%26aulast%3DWicha%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DS.%26atitle%3DDevelopment%2520and%2520application%2520of%2520cancer%2520stem%2520cell-targeted%2520vaccine%2520in%2520cancer%2520immunotherapy%26jtitle%3DJ.%2520Vaccines%2520Vaccination%26date%3D2017%26volume%3D8%26spage%3D371%26doi%3D10.4172%2F2157-7560.1000371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szaryńska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olejniczak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobiela, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Łaski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Śledziński, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kmieć, Z.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells as targets for DC-based immunotherapy of colorectal cancer</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">12042</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-30525-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fs41598-018-30525-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30104575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3c7nslylsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=12042&author=M.+Szary%C5%84skaauthor=A.+Olejniczakauthor=J.+Kobielaauthor=D.+%C5%81askiauthor=Z.+%C5%9Aledzi%C5%84skiauthor=Z.+Kmie%C4%87&title=Cancer+stem+cells+as+targets+for+DC-based+immunotherapy+of+colorectal+cancer&doi=10.1038%2Fs41598-018-30525-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells as targets for DC-based immunotherapy of colorectal cancer</span></div><div class="casAuthors">Szarynska Magdalena; Olejniczak Agata; Kmiec Zbigniew; Kobiela Jaroslaw; Laski Dariusz; Sledzinski Zbigniew</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12042</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The therapy of colorectal cancer (CRC) patients is often unsuccessful because of the presence of cancer stem cells (CSCs) resistant to conventional approaches.  Dendritic cells (DC)-based protocols are believed to effectively supplement CRC therapy.  Our study was aimed to assess how the number and properties of CSCs isolated from tumor tissue of CRC patients will affect the biological characteristics of in vitro modified DCs.  Similar procedures were conducted with the using of CRC HCT116 and HT29 cell lines.  We found that the detailed configuration of CSC-like markers significantly influenced the maturation and activation of DCs after stimulation with cancer cells lysates or culture supernatants.  This basic stimulatory effect was enhanced by LPS that is normally present in CRC CSCs niche.  The increased number of CD29(+) and CD44(+) CSCs presented the opposite impact on treated DCs as showed by many significant correlations.  The CD133(+) CSCs seemed to impair the functions of DCs.  The more CD133(+) CSCs in tumor sample the lower number of activated DCs evidenced after stimulation.  Moreover, our results showed superiority of the spherical culture model over the adherent one since spherical HCT116 and HT29 cells presented similar influence on DCs properties as CRC patients cancer cells.  We concluded that the DCs features may depend directly on the properties of CSCs affected by progression status of tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSH7Cfl0XFloyjiVMCqkKxVfW6udTcc2eYi3ysTNscP4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7nslylsA%253D%253D&md5=4a73c9858aa2e14b5d4e0da6b5e4473a</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-30525-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-30525-3%26sid%3Dliteratum%253Aachs%26aulast%3DSzary%25C5%2584ska%26aufirst%3DM.%26aulast%3DOlejniczak%26aufirst%3DA.%26aulast%3DKobiela%26aufirst%3DJ.%26aulast%3D%25C5%2581aski%26aufirst%3DD.%26aulast%3D%25C5%259Aledzi%25C5%2584ski%26aufirst%3DZ.%26aulast%3DKmie%25C4%2587%26aufirst%3DZ.%26atitle%3DCancer%2520stem%2520cells%2520as%2520targets%2520for%2520DC-based%2520immunotherapy%2520of%2520colorectal%2520cancer%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D12042%26doi%3D10.1038%2Fs41598-018-30525-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cell vaccination with PD-L1 and CTLA-4 blockades enhances the eradication of melanoma stem cells in a mouse tumor model</span>. <i>J. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">368</span>, <span class="refDoi"> DOI: 10.1097/CJI.0000000000000242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1097%2FCJI.0000000000000242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30063587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1GmtrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=361-368&author=F.+Zhengauthor=J.+Dangauthor=H.+Zhangauthor=F.+Xuauthor=D.+Baauthor=B.+Zhangauthor=F.+Chengauthor=A.+E.+Changauthor=M.+S.+Wichaauthor=Q.+Li&title=Cancer+stem+cell+vaccination+with+PD-L1+and+CTLA-4+blockades+enhances+the+eradication+of+melanoma+stem+cells+in+a+mouse+tumor+model&doi=10.1097%2FCJI.0000000000000242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model</span></div><div class="casAuthors">Zheng, Fang; Dang, Jianzhong; Zhang, Hongyu; Xu, Fangzhou; Ba, Diandian; Zhang, Bingyu; Cheng, Fanjun; Chang, Alfred E.; Wicha, Max S.; Li, Qiao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">361-368</span>CODEN:
                <span class="NLM_cas:coden">JOIMF8</span>;
        ISSN:<span class="NLM_cas:issn">1524-9557</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Immune checkpoint inhibitors and monoclonal antibodies reinvigorate cancer immunotherapy.  However, these immunotherapies only benefit a subset of patients.  We previously reported that ALDH tumor cells were highly enriched for cancer stem cells (CSCs), and ALDH CSC lysate-pulsed dendritic cell (CSC-DC) vaccine was shown to induce CSC-specific cytotoxic T lymphocytes.  In this study, we investigated the CSC targeting effect of the CSC-DC vaccine combined with a dual blockade of programmed death-ligand 1 and cytotoxic T-lymphocyte-assocd. protein (CTLA-4) in B16-F10 murine melanoma tumor model.  Our data showed that animals treated with the dual blockade of programmed death-ligand 1 and CTLA-4 and CSC-DC vaccine conferred significantly more tumor regression than the CSC-DC vaccine alone.  Importantly, the triple combination treatment dramatically eliminated ALDH CSCs in vivo.  We obsd. that CSC-DC vaccine in combination with anti-PD-L1 and anti-CTLA-4 administration resulted in ∼1.7-fold fewer PD-1CD8 T cells and ∼2.5-fold fewer CTLA-4CD8 T cells than the populations obsd. following the CSC-DC vaccination alone.  Moreover, significant antitumor effects and dramatically eliminated ALDH CSCs following the triple combination treatment were accompanied by significantly enhanced T-cell expansion, suppressed transforming growth factor β secretion, enhanced IFN-γ secretion, and significantly enhanced host specific CD8 T-cell response against CSCs.  Collectively, these data showed that administration of a-PD-L1 and a-CTLA-4 combined with CSC-DC vaccine may represent an effective immunotherapeutic strategy for cancer patients in clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKk3eQLgeXDbVg90H21EOLACvtfcHk0lh_f9Pa_llEnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1GmtrfN&md5=526143a18f03b93f5e482e72be0ba67b</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1097%2FCJI.0000000000000242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCJI.0000000000000242%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DF.%26aulast%3DDang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DBa%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DChang%26aufirst%3DA.%2BE.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26aulast%3DLi%26aufirst%3DQ.%26atitle%3DCancer%2520stem%2520cell%2520vaccination%2520with%2520PD-L1%2520and%2520CTLA-4%2520blockades%2520enhances%2520the%2520eradication%2520of%2520melanoma%2520stem%2520cells%2520in%2520a%2520mouse%2520tumor%2520model%26jtitle%3DJ.%2520Immunother.%26date%3D2018%26volume%3D41%26spage%3D361%26epage%3D368%26doi%3D10.1097%2FCJI.0000000000000242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wefers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreibelt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massuger, L. F. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, I. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torensma, R.</span></span> <span> </span><span class="NLM_article-title">Immune curbing of cancer stem cells by CTLs directed to NANOG</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1412</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2018.01412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffimmu.2018.01412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29971070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1KkurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1412&author=C.+Wefersauthor=G.+Schreibeltauthor=L.+F.+A.+G.+Massugerauthor=I.+J.+M.+de+Vriesauthor=R.+Torensma&title=Immune+curbing+of+cancer+stem+cells+by+CTLs+directed+to+NANOG&doi=10.3389%2Ffimmu.2018.01412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Immune curbing of cancer stem cells by CTLs directed to NANOG</span></div><div class="casAuthors">Wefers, Christina; Schreibelt, Gerty; Massuger, Leon F. A. G.; de Vries, I. Jolanda M.; Torensma, Ruurd</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1412/1-1412/10</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) have been identified as the source of tumor growth and disease recurrence.  Eradication of CSCs is thus essential to achieve durable responses, but CSCs are resistant to current anti-tumor therapies.  Novel therapeutic approaches that specifically target CSCs will, therefore, be crucial to improve patient outcome.  Immunotherapies, which boost the body's own immune system to eliminate cancerous cells, could be an alternative approach to target CSCs.  Vaccines of dendritic cells (DCs) loaded with tumor antigens can evoke highly specific anti-tumor T cell responses.  Importantly, DC vaccination also promotes immunol. memory formation, paving the way for long-term cancer control.  Here, we propose a DC vaccination that specifically targets CSCs.  DCs loaded with NANOG peptides, a protein required for maintaining stem cell properties, could evoke a potent anti-tumor immune response against CSCs.  We hypothesize that the resulting immunol. memory will also control newly formed CSCs, thereby preventing disease recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzjyxdPijxeLVg90H21EOLACvtfcHk0lhWZqZJMTlffg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1KkurvI&md5=fee01301f531ae0df4ebdae16a3aa0ea</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.01412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.01412%26sid%3Dliteratum%253Aachs%26aulast%3DWefers%26aufirst%3DC.%26aulast%3DSchreibelt%26aufirst%3DG.%26aulast%3DMassuger%26aufirst%3DL.%2BF.%2BA.%2BG.%26aulast%3Dde%2BVries%26aufirst%3DI.%2BJ.%2BM.%26aulast%3DTorensma%26aufirst%3DR.%26atitle%3DImmune%2520curbing%2520of%2520cancer%2520stem%2520cells%2520by%2520CTLs%2520directed%2520to%2520NANOG%26jtitle%3DFront.%2520Immunol.%26date%3D2018%26volume%3D9%26spage%3D1412%26doi%3D10.3389%2Ffimmu.2018.01412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto-Vila, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohama, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiya, T.</span></span> <span> </span><span class="NLM_article-title">Development of miRNA-based therapeutic approaches for cancer patients</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1140</span>– <span class="NLM_lpage">1147</span>, <span class="refDoi"> DOI: 10.1111/cas.13965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1111%2Fcas.13965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30729639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjslOgsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2019&pages=1140-1147&author=R.+U.+Takahashiauthor=M.+Prieto-Vilaauthor=I.+Kohamaauthor=T.+Ochiya&title=Development+of+miRNA-based+therapeutic+approaches+for+cancer+patients&doi=10.1111%2Fcas.13965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Development of miRNA-based therapeutic approaches for cancer patients</span></div><div class="casAuthors">Takahashi, Ryou-u; Prieto-Vila, Marta; Kohama, Isaku; Ochiya, Takahiro</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1140-1147</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Over the past few decades, siRNA and miRNA have attracted a great deal of attention from researchers and clinicians.  These mols. have been extensively studied from the standpoint of developing biopharmaceuticals against various diseases, including heart disease, diabetes and cancers. siRNA suppresses only a single target, whereas each miRNA regulates the expression of multiple target genes.  More importantly, because miRNA are also secreted from cancer cells, and their aberrant expression is assocd. with tumor development and progression, they represent not only therapeutic targets but also promising biomarkers for diagnosis and prognosis.  Therefore, miRNA may be more effective tools against cancers, in which multiple signal pathways are dysregulated.  In this review, we summarize recent progress in the development of miRNA therapeutics for the treatment of cancer patients, and describe delivery systems for oligonucleotide therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeqIcst2JCZLVg90H21EOLACvtfcHk0lhWZqZJMTlffg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjslOgsbw%253D&md5=0d53492c761a7a6c3114fd736374bd24</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1111%2Fcas.13965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13965%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DR.%2BU.%26aulast%3DPrieto-Vila%26aufirst%3DM.%26aulast%3DKohama%26aufirst%3DI.%26aulast%3DOchiya%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520miRNA-based%2520therapeutic%2520approaches%2520for%2520cancer%2520patients%26jtitle%3DCancer%2520Sci.%26date%3D2019%26volume%3D110%26spage%3D1140%26epage%3D1147%26doi%3D10.1111%2Fcas.13965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunitoshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardenas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Keuren-Jensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, A.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cell-associated miRNAs serve as prognostic biomarkers in colorectal cancer</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e125294</span> <span class="refDoi"> DOI: 10.1172/jci.insight.125294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1172%2Fjci.insight.125294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30895943" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&author=S.+Todenauthor=S.+Kunitoshiauthor=J.+Cardenasauthor=J.+Guauthor=E.+Hutchinsauthor=K.+Van+Keuren-Jensenauthor=H.+Uetakeauthor=Y.+Toiyamaauthor=A.+Goel&title=Cancer+stem+cell-associated+miRNAs+serve+as+prognostic+biomarkers+in+colorectal+cancer&doi=10.1172%2Fjci.insight.125294"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.125294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.125294%26sid%3Dliteratum%253Aachs%26aulast%3DToden%26aufirst%3DS.%26aulast%3DKunitoshi%26aufirst%3DS.%26aulast%3DCardenas%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DHutchins%26aufirst%3DE.%26aulast%3DVan%2BKeuren-Jensen%26aufirst%3DK.%26aulast%3DUetake%26aufirst%3DH.%26aulast%3DToiyama%26aufirst%3DY.%26aulast%3DGoel%26aufirst%3DA.%26atitle%3DCancer%2520stem%2520cell-associated%2520miRNAs%2520serve%2520as%2520prognostic%2520biomarkers%2520in%2520colorectal%2520cancer%26jtitle%3DJCI%2520Insight%26date%3D2019%26volume%3D4%26doi%3D10.1172%2Fjci.insight.125294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuh, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. K.</span></span> <span> </span><span class="NLM_article-title">MicroRNA-based combinatorial cancer therapy: Effects of microRNAs on the efficacy of anti-cancer therapies</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.3390/cells9010029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcells9010029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVygu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=29&author=H.+A.+Seoauthor=S.+Moengauthor=S.+Simauthor=H.+J.+Kuhauthor=S.+Y.+Choiauthor=J.+K.+Park&title=MicroRNA-based+combinatorial+cancer+therapy%3A+Effects+of+microRNAs+on+the+efficacy+of+anti-cancer+therapies&doi=10.3390%2Fcells9010029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">MicroRNA-Based combinatorial cancer therapy: effects of micrornas on the efficacy of anti-cancer therapies</span></div><div class="casAuthors">Seo, Hyun Ah; Moeng, Sokviseth; Sim, Seokmin; Kuh, Hyo Jeong; Choi, Soo Young; Park, Jong Kook</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The susceptibility of cancer cells to different types of treatments can be restricted by intrinsic and acquired therapeutic resistance, leading to the failure of cancer regression and remission.  To overcome this problem, a combination therapy has been proposed as a fundamental strategy to improve therapeutic responses; however, resistance is still unavoidable.  MicroRNA (miRNAs) are assocd. with cancer therapeutic resistance.  The modulation of dysregulated miRNA levels through miRNA-based therapy comprising a replacement or inhibition approach has been proposed to sensitize cancer cells to other anti-cancer therapies.  The combination of miRNA-based therapy with other anti-cancer therapies (miRNA-based combinatorial cancer therapy) is attractive, due to the ability of miRNAs to target multiple genes assocd. with the signaling pathways controlling therapeutic resistance.  In this article, we present an overview of recent findings on the role of therapeutic resistance-related miRNAs in different types of cancer.  We review the feasibility of utilizing dysregulated miRNAs in cancer cells and extracellular vesicles as potential candidates for miRNA-based combinatorial cancer therapy.  We also discuss innate properties of miRNAs that need to be considered for more effective combinatorial cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdjAjUwXVWFLVg90H21EOLACvtfcHk0liDISnkdEqO1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVygu7vK&md5=6155ce044ae3f40f7923013bad965cf1</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.3390%2Fcells9010029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells9010029%26sid%3Dliteratum%253Aachs%26aulast%3DSeo%26aufirst%3DH.%2BA.%26aulast%3DMoeng%26aufirst%3DS.%26aulast%3DSim%26aufirst%3DS.%26aulast%3DKuh%26aufirst%3DH.%2BJ.%26aulast%3DChoi%26aufirst%3DS.%2BY.%26aulast%3DPark%26aufirst%3DJ.%2BK.%26atitle%3DMicroRNA-based%2520combinatorial%2520cancer%2520therapy%253A%2520Effects%2520of%2520microRNAs%2520on%2520the%2520efficacy%2520of%2520anti-cancer%2520therapies%26jtitle%3DCells%26date%3D2020%26volume%3D9%26spage%3D29%26doi%3D10.3390%2Fcells9010029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nascimento, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogusuku, I. E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lameu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, H.</span></span> <span> </span><span class="NLM_article-title">Aptamers: novelty tools for cancer biology</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">26934</span>– <span class="NLM_lpage">26953</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.25260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.18632%2Foncotarget.25260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29928493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC1MbpvFWitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=26934-26953&author=R.+L.+Pereiraauthor=I.+C.+Nascimentoauthor=A.+P.+Santosauthor=I.+E.+Y.+Ogusukuauthor=C.+Lameuauthor=G.+Mayerauthor=H.+Ulrich&title=Aptamers%3A+novelty+tools+for+cancer+biology&doi=10.18632%2Foncotarget.25260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Aptamers: novelty tools for cancer biology</span></div><div class="casAuthors">Pereira Ricardo L; Nascimento Isis C; Santos Ana P; Ogusuku Isabella E Y; Lameu Claudiana; Ulrich Henning; Mayer Gunter; Mayer Gunter</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">26934-26953</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although the term 'cancer' was still over two thousand years away of being coined, the first known cases of the disease date back to about 3000BC, in ancient Egypt.  Five thousand years later, still lacking a cure, it has become one of the leading causes of death, killing over half a dozen million people yearly.  So far, monoclonal antibodies are the most successful immune-therapy tools when it comes to fighting cancer.  The number of clinical trials that use them has been increasing steadily during the past few years, especially since the Food and Drug Administration greenlit the use of the first immune-checkpoint blockade antibodies.  However, albeit successful, this approach does come with the cost of auto-inflammatory toxicity.  Taking this into account, the development of new therapeutic reagents with low toxicity becomes evident, particularly ones acting in tandem with the tools currently at our disposal.  Ever since its discovery in the early nineties, aptamer technology has been used for a wide range of diagnostic and therapeutic applications.  With similar properties to those of monoclonal antibodies, such as high-specificity of recognition and high-affinity binding, and the advantages of being developed using in vitro selection procedures, aptamers quickly became convenient building blocks for the generation of multifunctional constructs.  In this review, we discuss the steps involved in the in vitro selection process that leads to functional aptamers - known as Systematic Evolution of Ligands by Exponential Enrichment - as well as the most recent applications of this technology in diagnostic and treatment of oncological illnesses.  Moreover, we also suggest ways to improve such use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWcmnHKmNeloJKJbLTgsvCfW6udTcc2eaHx3jussY_lbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbpvFWitQ%253D%253D&md5=44aea3e0cc3c7ca876e515a3116b262a</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.25260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.25260%26sid%3Dliteratum%253Aachs%26aulast%3DPereira%26aufirst%3DR.%2BL.%26aulast%3DNascimento%26aufirst%3DI.%2BC.%26aulast%3DSantos%26aufirst%3DA.%2BP.%26aulast%3DOgusuku%26aufirst%3DI.%2BE.%2BY.%26aulast%3DLameu%26aufirst%3DC.%26aulast%3DMayer%26aufirst%3DG.%26aulast%3DUlrich%26aufirst%3DH.%26atitle%3DAptamers%253A%2520novelty%2520tools%2520for%2520cancer%2520biology%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D26934%26epage%3D26953%26doi%3D10.18632%2Foncotarget.25260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, N.</span></span> <span> </span><span class="NLM_article-title">Aptamer selection and applications for breast cancer diagnostics and therapy</span>. <i>J. Nanobiotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">81</span>, <span class="refDoi"> DOI: 10.1186/s12951-017-0311-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2Fs12951-017-0311-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29132385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFWnsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=81&author=M.+Liuauthor=X.+Yuauthor=Z.+Chenauthor=T.+Yangauthor=D.+Yangauthor=Q.+Liuauthor=K.+Duauthor=B.+Liauthor=Z.+Wangauthor=S.+Liauthor=Y.+Dengauthor=N.+He&title=Aptamer+selection+and+applications+for+breast+cancer+diagnostics+and+therapy&doi=10.1186%2Fs12951-017-0311-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Aptamer selection and applications for breast cancer diagnostics and therapy</span></div><div class="casAuthors">Liu, Mei; Yu, Xiaocheng; Chen, Zhu; Yang, Tong; Yang, Dandan; Liu, Qianqian; Du, Keke; Li, Bo; Wang, Zhifei; Li, Song; Deng, Yan; He, Nongyue</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nanobiotechnology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">81/1-81/16</span>CODEN:
                <span class="NLM_cas:coden">JNOAAO</span>;
        ISSN:<span class="NLM_cas:issn">1477-3155</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Aptamers are short non-coding, single-stranded oligonucleotides (RNA or DNA) developed through Systematic Evolution of Ligands by Exponential enrichment (SELEX) in vitro.  Similar to antibodies, aptamers can bind to specific targets with high affinity, and are considered promising therapeutic agents as they have several advantages over antibodies, including high specificity, stability, and non-immunogenicity.  Furthermore, aptamers can be produced at a low cost and easily modified, and are, therefore, called "chem. antibodies".  In the past years, a variety of aptamers specifically bound to both breast cancer biomarkers and cells had been selected.  Besides, taking advantage of nanomaterials, there were a no. of aptamer-nanomaterial conjugates been developed and widely investigated for diagnostics and targeted therapy of breast cancer.  In this short review, we first present a systematical review of various aptamer selection methods.  Then, various aptamer-based diagnostic and therapeutic strategies of breast cancer were provided.  Finally, the current problems, challenges, and future perspectives in the field were thoroughly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppqAbuBPrCA7Vg90H21EOLACvtfcHk0liDISnkdEqO1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFWnsbjE&md5=db80ff7c1dde78c73bafd2f90cf652fb</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1186%2Fs12951-017-0311-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12951-017-0311-4%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DDu%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DN.%26atitle%3DAptamer%2520selection%2520and%2520applications%2520for%2520breast%2520cancer%2520diagnostics%2520and%2520therapy%26jtitle%3DJ.%2520Nanobiotechnol.%26date%3D2017%26volume%3D15%26spage%3D81%26doi%3D10.1186%2Fs12951-017-0311-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latchoumanin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagdesar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebbard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liddle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, L.</span></span> <span> </span><span class="NLM_article-title">Aptamer-based therapeutic approaches to target cancer stem cells</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3948</span>– <span class="NLM_lpage">3961</span>, <span class="refDoi"> DOI: 10.7150/thno.20725</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.7150%2Fthno.20725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29109790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFaitb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=3948-3961&author=G.+Zhouauthor=O.+Latchoumaninauthor=M.+Bagdesarauthor=L.+Hebbardauthor=W.+Duanauthor=C.+Liddleauthor=J.+Georgeauthor=L.+Qiao&title=Aptamer-based+therapeutic+approaches+to+target+cancer+stem+cells&doi=10.7150%2Fthno.20725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Aptamer-based therapeutic approaches to target cancer stem cells</span></div><div class="casAuthors">Zhou, Gang; Latchoumanin, Olivier; Bagdesar, Mary; Hebbard, Lionel; Duan, Wei; Liddle, Christopher; George, Jacob; Qiao, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3948-3961</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are believed to be a principal cellular source for tumor progression and therapeutic drug resistance as they are capable of self-renewal and can differentiate into cancer cells.  Importantly, CSCs acquire the ability to evade the killing effects of cytotoxic agents through changes at the genetic, epigenetic and micro-environment levels.  Therefore, therapeutic strategies targeting CSCs hold great potential as an avenue for cancer treatment.  Aptamers or "chem. antibodies" are a group of single-stranded nucleic acid (DNA or RNA) oligonucleotides with distinctive properties such as smaller size, lower toxicity and less immunogenicity compared to conventional antibodies.  They have been frequently used to deliver therapeutic payloads to cancer cells and have achieved encouraging anti-tumor effects.  This review discusses progress in CSC evolution theory and the role of aptamers to target CSCs for cancer treatment.  Challenges of aptamer-mediated CSC targeting approaches are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVXtHiOz5iLLVg90H21EOLACvtfcHk0lgURbJ1S7uQ2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFaitb7L&md5=4fbd835810b569c2d1da946e64fc1cb8</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.7150%2Fthno.20725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.20725%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DLatchoumanin%26aufirst%3DO.%26aulast%3DBagdesar%26aufirst%3DM.%26aulast%3DHebbard%26aufirst%3DL.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DLiddle%26aufirst%3DC.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DQiao%26aufirst%3DL.%26atitle%3DAptamer-based%2520therapeutic%2520approaches%2520to%2520target%2520cancer%2520stem%2520cells%26jtitle%3DTheranostics%26date%3D2017%26volume%3D7%26spage%3D3948%26epage%3D3961%26doi%3D10.7150%2Fthno.20725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span> <span> </span><span class="NLM_article-title">Targeting breast cancer stem cells</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2010.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.molonc.2010.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=20599450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFCktL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=404-419&author=S.+P.+McDermottauthor=M.+S.+Wicha&title=Targeting+breast+cancer+stem+cells&doi=10.1016%2Fj.molonc.2010.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting breast cancer stem cells</span></div><div class="casAuthors">McDermott, Sean P.; Wicha, Max S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">404-419</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The cancer stem cell (CSC) hypothesis postulates that tumors are maintained by a self-renewing CSC population that is also capable of differentiating into non-self-renewing cell populations that constitute the bulk of the tumor.  Although, the CSC hypothesis does not directly address the cell of origin of cancer, it is postulated that tissue-resident stem or progenitor cells are the most common targets of transformation.  Clin., CSCs are predicted to mediate tumor recurrence after chemo- and radiation-therapy due to the relative inability of these modalities to effectively target CSCs.  If this is the case, then CSC must be efficiently targeted to achieve a true cure.  Similarities between normal and malignant stem cells, at the levels of cell-surface proteins, mol. pathways, cell cycle quiescence, and microRNA signaling present challenges in developing CSC-specific therapeutics.  Approaches to targeting CSCs include the development of agents targeting known stem cell regulatory pathways as well as unbiased high-throughput siRNA or small mol. screening.  Based on studies of pathways present in normal stem cells, recent work has identified potential "Achilles heals" of CSC, whereas unbiased screening provides opportunities to identify new pathways utilized by CSC as well as develop potential therapeutic agents.  Here, we review both approaches and their potential to effectively target breast CSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo94TOxDX7z7bVg90H21EOLACvtfcHk0lgURbJ1S7uQ2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFCktL3N&md5=e8a85906253d19ce740a9667d792ba74</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2010.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2010.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DS.%2BP.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26atitle%3DTargeting%2520breast%2520cancer%2520stem%2520cells%26jtitle%3DMol.%2520Oncol.%26date%3D2010%26volume%3D4%26spage%3D404%26epage%3D419%26doi%3D10.1016%2Fj.molonc.2010.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rausch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallifatidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattern, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladkich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schemmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Büchler, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zöller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salnikov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herr, I.</span></span> <span> </span><span class="NLM_article-title">Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">5004</span>– <span class="NLM_lpage">5013</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-0066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1158%2F0008-5472.CAN-10-0066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=20530687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=5004-5013&author=V.+Rauschauthor=L.+Liuauthor=G.+Kallifatidisauthor=B.+Baumannauthor=J.+Matternauthor=J.+Gladkichauthor=T.+Wirthauthor=P.+Schemmerauthor=M.+W.+B%C3%BCchlerauthor=M.+Z%C3%B6llerauthor=A.+V.+Salnikovauthor=I.+Herr&title=Synergistic+activity+of+sorafenib+and+sulforaphane+abolishes+pancreatic+cancer+stem+cell+characteristics&doi=10.1158%2F0008-5472.CAN-10-0066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160aR"><div class="casContent"><span class="casTitleNuber">160a</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics</span></div><div class="casAuthors">Rausch, Vanessa; Liu, Li; Kallifatidis, Georgios; Baumann, Bernd; Mattern, Juergen; Gladkich, Jury; Wirth, Thomas; Schemmer, Peter; Buechler, Markus W.; Zoeller, Margot; Salnikov, Alexei V.; Herr, Ingrid</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5004-5013</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent evidence suggests that pancreatic cancer and other solid tumors contain a subset of tumorigenic cells capable of extensive self-renewal that contribute to metastasis and treatment resistance.  Sorafenib (SO) is a promising new multikinase inhibitor for treatment of advanced kidney and liver cancers.  We report here targeting of pancreatic cancer stem cells (CSC) by SO and the development of a strategy to enhance this effect.  Although SO administration diminished clonogenicity, spheroid formation, aldehyde dehydrogenase 1 (ALDH1) activity, growth on immunodeficient mice, proliferation, and angiogenesis and induced apoptosis, we obsd. SO-induced activation of NF-κB assocd. with survival and regrowth of spheroids.  For enhanced elimination of CSC characteristics by SO, we cotreated cells with sulforaphane (SF).  This broccoli isothiocyanate was recently described to eliminate pancreatic CSCs by downregulation of NF-κB activity without inducing toxic side effects.  On combination treatment, SF completely eradicated SO-induced NF-κB binding, which was assocd. with abrogated clonogenicity, spheroid formation, ALDH1 activity, migratory capacity, and induction of apoptosis.  In vivo, combination therapy reduced the tumor size in a synergistic manner.  This was due to induction of apoptosis, inhibition of proliferation and angiogenesis, and downregulation of SO-induced expression of proteins involved in epithelial-mesenchymal transition.  Our data suggest that SF may be suited to increase targeting of CSCs by SO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr9wc3VmL1P7Vg90H21EOLACvtfcHk0lj2wU5EMSOWgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKltLo%253D&md5=3a858ddc0831047a55faf685aed7b166</span></div><a href="/servlet/linkout?suffix=cit160a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-0066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-0066%26sid%3Dliteratum%253Aachs%26aulast%3DRausch%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DKallifatidis%26aufirst%3DG.%26aulast%3DBaumann%26aufirst%3DB.%26aulast%3DMattern%26aufirst%3DJ.%26aulast%3DGladkich%26aufirst%3DJ.%26aulast%3DWirth%26aufirst%3DT.%26aulast%3DSchemmer%26aufirst%3DP.%26aulast%3DB%25C3%25BCchler%26aufirst%3DM.%2BW.%26aulast%3DZ%25C3%25B6ller%26aufirst%3DM.%26aulast%3DSalnikov%26aufirst%3DA.%2BV.%26aulast%3DHerr%26aufirst%3DI.%26atitle%3DSynergistic%2520activity%2520of%2520sorafenib%2520and%2520sulforaphane%2520abolishes%2520pancreatic%2520cancer%2520stem%2520cell%2520characteristics%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D5004%26epage%3D5013%26doi%3D10.1158%2F0008-5472.CAN-10-0066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit160b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S.</span></span> <span> </span><span class="NLM_article-title">Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.01089.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1111%2Fj.1476-5381.2010.01089.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=20973777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhslKrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2011&pages=773-784&author=J.+H.+Kimauthor=M.+Chaeauthor=W.+K.+Kimauthor=Y.+J.+Kimauthor=H.+S.+Kangauthor=H.+S.+Kimauthor=S.+Yoon&title=Salinomycin+sensitizes+cancer+cells+to+the+effects+of+doxorubicin+and+etoposide+treatment+by+increasing+DNA+damage+and+reducing+p21+protein&doi=10.1111%2Fj.1476-5381.2010.01089.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160bR"><div class="casContent"><span class="casTitleNuber">160b</span><div class="casTitle"><span class="NLM_cas:atitle">Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein</span></div><div class="casAuthors">Kim, Ju-Hwa; Chae, Minji; Kim, Won Ki; Kim, You-Jin; Kang, Han Sung; Kim, Hyung Sik; Yoon, Sungpil</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">773-784</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Salinomycin (Sal) has recently been shown to inhibit various cancer stem cells.  Here, we investigated whether Sal could sensitize cancer cells to the effects of doxorubicin (DOX) or etoposide (ETO).  Using the Comet assay, immunocytochem. and Western blot anal., we assessed the ability of Sal to increase DNA breakage.  We performed a cell proliferation assay to det. cell viability, cellular detachment, increased pre-G1 region, Annexin V staining and TUNEL assay to measure the ability of Sal to increase apoptosis.  Sal increased DNA breakage and phosphorylated levels of p53 and H2AX.  Sal also induced the formation of DNA foci with pH2AX and 53BP1.  Furthermore, Sal increased the sensitivity of cancer cells to the apoptotic effects of DOX or ETO.  We found that pH2AX, pBRCA1, p53BP1 and pChk1 levels were greatly increased after co-treatment of Sal with DOX or ETO.  The level of anti-apoptotic p21 protein was increased by DOX or ETO but decreased by Sal, which increased proteasome activity.  This is the first study to report that Sal increases DNA damage, and this effect plays an important role in the increased apoptosis caused by Sal.  Overall, we demonstrated that the ability of Sal to sensitize cancer cells to the effects of DOX or ETO is assocd. with an increase in DNA damage and a decrease in anti-apoptotic protein p21 levels.  These results may contribute to the development of Sal-based chemotherapy for cancer patients receiving DOX or ETO treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWhLDhzdlVUbVg90H21EOLACvtfcHk0lj2wU5EMSOWgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhslKrtLY%253D&md5=6cdb2ed9d40346bcac8c7d98c1904536</span></div><a href="/servlet/linkout?suffix=cit160b&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.01089.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.01089.x%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DChae%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DW.%2BK.%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DKang%26aufirst%3DH.%2BS.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DYoon%26aufirst%3DS.%26atitle%3DSalinomycin%2520sensitizes%2520cancer%2520cells%2520to%2520the%2520effects%2520of%2520doxorubicin%2520and%2520etoposide%2520treatment%2520by%2520increasing%2520DNA%2520damage%2520and%2520reducing%2520p21%2520protein%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D162%26spage%3D773%26epage%3D784%26doi%3D10.1111%2Fj.1476-5381.2010.01089.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanaswamy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torchilin, V. P.</span></span> <span> </span><span class="NLM_article-title">Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1080/15384047.2016.1190488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1080%2F15384047.2016.1190488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=27259361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFGmurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=698-707&author=T.+Wangauthor=R.+Narayanaswamyauthor=H.+Renauthor=V.+P.+Torchilin&title=Combination+therapy+targeting+both+cancer+stem-like+cells+and+bulk+tumor+cells+for+improved+efficacy+of+breast+cancer+treatment&doi=10.1080%2F15384047.2016.1190488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment</span></div><div class="casAuthors">Wang, Tao; Narayanaswamy, Radhika; Ren, Huilan; Torchilin, Vladimir P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">698-707</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1555-8576</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Many types of tumors are organized in a hierarchy of heterogeneous cell populations.  The cancer stem-like cells (CSCs) hypothesis suggests that tumor development and metastasis are driven by a minority population of cells, which are responsible for tumor initiation, growth and recurrences.  The inability to efficiently eliminate CSCs during chemotherapy, together with CSCs being highly tumorigenic and invasive, may result in treatment failure due to cancer relapse and metastases.  CSCs are emerging as a promising target for the development of translational cancer therapies.  Ideal panacea for cancer would kill all malignant cells, including CSCs and bulk tumor cells.  Since both chemotherapy and CSCs-specific therapy are insufficient to cure cancer, we propose combination therapy with CSCs-targeted agents and chemotherapeutics for improved breast cancer treatment.  We generated in vitro mammosphere of 2 breast cancer cell lines, and demonstrated ability of mammospheres to grow and enrich cancer cells with stem-like properties, including self-renewal, multilineage differentiation and enrichment of cells expressing breast cancer stem-like cell biomarkers CD44+/CD24-/low.  The formation of mammospheres was significantly inhibited by salinomycin, validating its pharmacol. role against the cancer stem-like cells.  In contrast, paclitaxel showed a minimal effect on the proliferation and growth of breast cancer stem-like cells.  While combination therapies of salinomycin with conventional chemotherapy (paclitaxel or lipodox) showed a potential to improve tumor cell killing, different subtypes of breast cancer cells showed different patterns in response to the combination therapies.  While optimization of combination therapy is warranted, the design of combination therapy should consider phenotypic attributes of breast cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7hT2l0IJbF7Vg90H21EOLACvtfcHk0lj2wU5EMSOWgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFGmurvP&md5=8304c35da3d2a904059edfbb0b562669</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1080%2F15384047.2016.1190488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384047.2016.1190488%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DNarayanaswamy%26aufirst%3DR.%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTorchilin%26aufirst%3DV.%2BP.%26atitle%3DCombination%2520therapy%2520targeting%2520both%2520cancer%2520stem-like%2520cells%2520and%2520bulk%2520tumor%2520cells%2520for%2520improved%2520efficacy%2520of%2520breast%2520cancer%2520treatment%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2016%26volume%3D17%26spage%3D698%26epage%3D707%26doi%3D10.1080%2F15384047.2016.1190488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dzobo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthebane, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomford, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wonkam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandara, C.</span></span> <span> </span><span class="NLM_article-title">Advances in therapeutic targeting of cancer stem cells within the tumor microenvironment: an updated review</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1896</span>, <span class="refDoi"> DOI: 10.3390/cells9081896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcells9081896" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=1896&author=K.+Dzoboauthor=D.+A.+Senthebaneauthor=C.+Ganzauthor=N.+E.+Thomfordauthor=A.+Wonkamauthor=C.+Dandara&title=Advances+in+therapeutic+targeting+of+cancer+stem+cells+within+the+tumor+microenvironment%3A+an+updated+review&doi=10.3390%2Fcells9081896"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.3390%2Fcells9081896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells9081896%26sid%3Dliteratum%253Aachs%26aulast%3DDzobo%26aufirst%3DK.%26aulast%3DSenthebane%26aufirst%3DD.%2BA.%26aulast%3DGanz%26aufirst%3DC.%26aulast%3DThomford%26aufirst%3DN.%2BE.%26aulast%3DWonkam%26aufirst%3DA.%26aulast%3DDandara%26aufirst%3DC.%26atitle%3DAdvances%2520in%2520therapeutic%2520targeting%2520of%2520cancer%2520stem%2520cells%2520within%2520the%2520tumor%2520microenvironment%253A%2520an%2520updated%2520review%26jtitle%3DCells%26date%3D2020%26volume%3D9%26spage%3D1896%26doi%3D10.3390%2Fcells9081896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schott, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landis, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dontu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layman, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paskett, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrolecki, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froehlich, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranilam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. C.</span></span> <span> </span><span class="NLM_article-title">Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1512</span>– <span class="NLM_lpage">1524</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1158%2F1078-0432.CCR-11-3326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=23340294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1512-1524&author=A.+F.+Schottauthor=M.+D.+Landisauthor=G.+Dontuauthor=K.+A.+Griffithauthor=R.+M.+Laymanauthor=I.+Kropauthor=L.+A.+Paskettauthor=H.+Wongauthor=L.+E.+Dobroleckiauthor=M.+T.+Lewisauthor=A.+M.+Froehlichauthor=J.+Paranilamauthor=D.+F.+Hayesauthor=M.+S.+Wichaauthor=J.+C.+Chang&title=Preclinical+and+clinical+studies+of+gamma+secretase+inhibitors+with+docetaxel+on+human+breast+tumors&doi=10.1158%2F1078-0432.CCR-11-3326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors</span></div><div class="casAuthors">Schott, Anne F.; Landis, Melissa D.; Dontu, Gabriela; Griffith, Kent A.; Layman, Rachel M.; Krop, Ian; Paskett, Lacey A.; Wong, Helen; Dobrolecki, Lacey E.; Lewis, Michael T.; Froehlich, Amber M.; Paranilam, Jaya; Hayes, Daniel F.; Wicha, Max S.; Chang, Jenny C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1512-1524</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Accumulating evidence supports the existence of breast cancer stem cells (BCSC), which are characterized by their capacity to self-renew and divide indefinitely and resistance to conventional therapies.  The Notch pathway is important for stem cell renewal and is a potential target for BCSC-directed therapy.  Exptl. Design: Using human breast tumorgraft studies, we evaluated the impact of gamma secretase inhibitors (GSI) on the BCSC population and the efficacy of combining GSI with docetaxel treatment.  The mouse exptl. therapy paralleled a concurrent clin. trial in patients with advanced breast cancer, designed to det. the max.-tolerated dose of the GSI, MK-0752, administered sequentially with docetaxel, and to evaluate BCSC markers in serial tumor biopsies.  Results: Treatment with GSI reduced BCSCs in MC1 and BCM-2147 tumorgrafts by inhibition of the Notch pathway.  GSI enhanced the efficacy of docetaxel in preclin. studies.  In the clin. trial, 30 patients with advanced breast cancer were treated with escalating doses of MK-0752 plus docetaxel.  Clin., meaningful doses of both drugs were possible with manageable toxicity and preliminary evidence of efficacy.  A decrease in CD44+/CD24-, ALDH+, and mammosphere-forming efficiency were obsd. in tumors of patients undergoing serial biopsies.  Conclusions: These preclin. data show that pharmacol. inhibition of the Notch pathway can reduce BCSCs in breast tumorgraft models.  The clin. trial shows feasibility of combination GSI and chemotherapy, and together these results encourage further study of Notch pathway inhibitors in combination with chemotherapy in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSPyKUMdOCRrVg90H21EOLACvtfcHk0ljWWEjpyhI6ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKktL0%253D&md5=4123f8b7f5f732252f7cafb7b2ef859c</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3326%26sid%3Dliteratum%253Aachs%26aulast%3DSchott%26aufirst%3DA.%2BF.%26aulast%3DLandis%26aufirst%3DM.%2BD.%26aulast%3DDontu%26aufirst%3DG.%26aulast%3DGriffith%26aufirst%3DK.%2BA.%26aulast%3DLayman%26aufirst%3DR.%2BM.%26aulast%3DKrop%26aufirst%3DI.%26aulast%3DPaskett%26aufirst%3DL.%2BA.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DDobrolecki%26aufirst%3DL.%2BE.%26aulast%3DLewis%26aufirst%3DM.%2BT.%26aulast%3DFroehlich%26aufirst%3DA.%2BM.%26aulast%3DParanilam%26aufirst%3DJ.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26aulast%3DChang%26aufirst%3DJ.%2BC.%26atitle%3DPreclinical%2520and%2520clinical%2520studies%2520of%2520gamma%2520secretase%2520inhibitors%2520with%2520docetaxel%2520on%2520human%2520breast%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D1512%26epage%3D1524%26doi%3D10.1158%2F1078-0432.CCR-11-3326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooray, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jameson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parnis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimison, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmgren, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoun, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebbutt, N. C.</span></span> <span> </span><span class="NLM_article-title">A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) ± nab-paclitaxel in patients with pancreatic cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">341</span>, <span class="refDoi"> DOI: 10.1200/jco.2016.34.4_suppl.341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1200%2Fjco.2016.34.4_suppl.341" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=341&author=M.+Hidalgoauthor=P.+Coorayauthor=A.+Carratoauthor=M.+B.+Jamesonauthor=F.+Parnisauthor=M.+Jefferyauthor=P.+S.+Grimisonauthor=R.+J.+Staggauthor=E.+Holmgrenauthor=A.+M.+Kapounauthor=J.+Dupontauthor=N.+C.+Tebbutt&title=A+phase+1b+study+of+the+anti-cancer+stem+cell+agent+demcizumab+%28DEM%29+and+gemcitabine+%28GEM%29+%C2%B1+nab-paclitaxel+in+patients+with+pancreatic+cancer&doi=10.1200%2Fjco.2016.34.4_suppl.341"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1200%2Fjco.2016.34.4_suppl.341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2016.34.4_suppl.341%26sid%3Dliteratum%253Aachs%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DCooray%26aufirst%3DP.%26aulast%3DCarrato%26aufirst%3DA.%26aulast%3DJameson%26aufirst%3DM.%2BB.%26aulast%3DParnis%26aufirst%3DF.%26aulast%3DJeffery%26aufirst%3DM.%26aulast%3DGrimison%26aufirst%3DP.%2BS.%26aulast%3DStagg%26aufirst%3DR.%2BJ.%26aulast%3DHolmgren%26aufirst%3DE.%26aulast%3DKapoun%26aufirst%3DA.%2BM.%26aulast%3DDupont%26aufirst%3DJ.%26aulast%3DTebbutt%26aufirst%3DN.%2BC.%26atitle%3DA%2520phase%25201b%2520study%2520of%2520the%2520anti-cancer%2520stem%2520cell%2520agent%2520demcizumab%2520%2528DEM%2529%2520and%2520gemcitabine%2520%2528GEM%2529%2520%25C2%25B1%2520nab-paclitaxel%2520in%2520patients%2520with%2520pancreatic%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D341%26doi%3D10.1200%2Fjco.2016.34.4_suppl.341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qureshy, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandis, J. R.</span></span> <span> </span><span class="NLM_article-title">Targeting the JAK/STAT pathway in solid tumors</span>. <i>J. Cancer Metastasis</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">27</span>, <span class="refDoi"> DOI: 10.20517/2394-4722.2020.58</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.20517%2F2394-4722.2020.58" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisV2rur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=27&author=Z.+Qureshyauthor=D.+E.+Johnsonauthor=J.+R.+Grandis&title=Targeting+the+JAK%2FSTAT+pathway+in+solid+tumors&doi=10.20517%2F2394-4722.2020.58"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the JAK/STAT pathway in solid tumors</span></div><div class="casAuthors">Qureshy, Zoya; Johnson, Daniel E.; Grandis, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer Metastasis and Treatment</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Spec.Iss.</span>),
    <span class="NLM_cas:pages">27</span>CODEN:
                <span class="NLM_cas:coden">JCMTCU</span>;
        ISSN:<span class="NLM_cas:issn">2454-2857</span>.
    
            (<span class="NLM_cas:orgname">OAE Publishing Inc.</span>)
        </div><div class="casAbstract">Aberrant activation of signal transducer and activator of transcription (STAT) proteins is assocd. with the development and progression of solid tumors.  However, as transcription factors, these proteins are difficult to target directly.  In this review, we summarize the role of targeting Janus kinases (JAKs), upstream activators of STATs, as a strategy for decreasing STAT activation in solid tumors.  Preclin. studies in solid tumor cell line models show that JAK inhibitors decrease STAT activation, cell proliferation, and cell survival; in in vivo models, they also inhibit tumor growth.  JAK inhibitors, particularly the JAK1/2 inhibitor ruxolitinib, sensitize cell lines and murine models to chemotherapy, immunotherapy, and oncolytic viral therapy.  Ten JAK inhibitors have been or are actively being tested in clin. trials as monotherapy or in combination with other agents in patients with solid tumors; two of these inhibitors are already Food and Drug Administration (FDA) approved for the treatment of myeloproliferative disorders and rheumatoid arthritis, making them attractive agents for use in patients with solid tumors as they are known to be well-tolerated.  Four JAK inhibitors (two of which are FDA approved for other indications) have exhibited promising anti-cancer effects in preclin. studies; however, clin. studies specifically assessing their activity against the JAK/STAT pathway in solid tumors have not yet been conducted.  In summary, JAK inhibition is a viable option for targeting the JAK/STAT pathway in solid tumors and merits further testing in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHZL06wxedJrVg90H21EOLACvtfcHk0ljWWEjpyhI6ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisV2rur%252FI&md5=7468e105d344f5f6dd86d7fbc9cb3b02</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.20517%2F2394-4722.2020.58&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.20517%252F2394-4722.2020.58%26sid%3Dliteratum%253Aachs%26aulast%3DQureshy%26aufirst%3DZ.%26aulast%3DJohnson%26aufirst%3DD.%2BE.%26aulast%3DGrandis%26aufirst%3DJ.%2BR.%26atitle%3DTargeting%2520the%2520JAK%252FSTAT%2520pathway%2520in%2520solid%2520tumors%26jtitle%3DJ.%2520Cancer%2520Metastasis%26date%3D2020%26volume%3D6%26spage%3D27%26doi%3D10.20517%2F2394-4722.2020.58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span> <span> </span><span class="NLM_article-title">IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing BC</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1038/cdd.2017.162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fcdd.2017.162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29027990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CrtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=330-339&author=D.+Wangauthor=J.+Xuauthor=B.+Liuauthor=X.+Heauthor=L.+Zhouauthor=X.+Huauthor=F.+Qiaoauthor=A.+Zhangauthor=X.+Xuauthor=H.+Zhangauthor=M.+S.+Wichaauthor=L.+Zhangauthor=Z.+M.+Shaoauthor=S.+Liu&title=IL6+blockade+potentiates+the+anti-tumor+effects+of+%CE%B3-secretase+inhibitors+in+Notch3-expressing+BC&doi=10.1038%2Fcdd.2017.162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing breast cancer</span></div><div class="casAuthors">Wang, Dong; Xu, Jiahui; Liu, Bingjie; He, Xueyan; Zhou, Lei; Hu, Xin; Qiao, Feng; Zhang, Anli; Xu, Xiaojun; Zhang, Huafeng; Wicha, Max S.; Zhang, Lixing; Shao, Zhi-ming; Liu, Suling</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">330-339</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Notch pathways have important roles in carcinogenesis including pathways involving the Notch1 and Notch2 oncogenes.  Pan-Notch inhibitors, such as gamma secretase inhibitors (GSIs), have been used in the clin. trials, but the outcomes of these trials have been insufficient and have yielded unclear.  In the present study, we demonstrated that GSIs, such as MK-0752 and RO4929097, inhibit breast tumor growth, but increase the breast cancer stem cell (BCSC) population in Notch3-expressing breast cancer cells, in a process that is coupled with IL6 induction and is blocked by the IL6R antagonist Tocilizumab (TCZ).  IL6 induction results from inhibition of Notch3-Hey2 signaling through MK-0752.  Furthermore, HIF1α upregulates Notch3 expression via direct binding to the Notch3 promoter and subsequently downregulates BCSCs by decreasing the IL6 levels in Notch3-expressing breast cancer cells.  Utilizing both breast cancer cell line xenografts and patient-derived xenografts (PDX), we showed that the combination of MK-0752 and Tocilizumab significantly decreases BCSCs and inhibits tumor growth and thus might serve as a novel therapeutic strategy for treating women with Notch3-expressing breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtYbn-rNPQLLVg90H21EOLACvtfcHk0lhpy2hhxN0j7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CrtrrJ&md5=33c6f179486d412ed70c9e9d592c9d93</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2017.162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2017.162%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DQiao%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShao%26aufirst%3DZ.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26atitle%3DIL6%2520blockade%2520potentiates%2520the%2520anti-tumor%2520effects%2520of%2520%25CE%25B3-secretase%2520inhibitors%2520in%2520Notch3-expressing%2520BC%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2018%26volume%3D25%26spage%3D330%26epage%3D339%26doi%3D10.1038%2Fcdd.2017.162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruffini, P. A.</span></span> <span> </span><span class="NLM_article-title">The CXCL8-CXCR1/2 axis as a therapeutic target in BC stem-like cells</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">40</span>, <span class="refDoi"> DOI: 10.3389/fonc.2019.00040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffonc.2019.00040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30788286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3cflvVOltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=40&author=P.+A.+Ruffini&title=The+CXCL8-CXCR1%2F2+axis+as+a+therapeutic+target+in+BC+stem-like+cells&doi=10.3389%2Ffonc.2019.00040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">The CXCL8-CXCR1/2 Axis as a Therapeutic Target in Breast Cancer Stem-Like Cells</span></div><div class="casAuthors">Ruffini Pier Adelchi</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Cancer stem-like cells (CSC) have been targeted by different strategies over the last decade.  This mini review focuses on preclinical and clinical results obtained by interfering with chemokine receptors CXCR1 and CXCR2 in breast cancer.  This strategy is currently being tested in a randomized, double blind phase 2 clinical trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTydAeEg5l-0IJKJbLTgsvCfW6udTcc2eb0ZnDfztBFEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cflvVOltw%253D%253D&md5=faf0c265039b59a054c11a006d06b4de</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2019.00040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2019.00040%26sid%3Dliteratum%253Aachs%26aulast%3DRuffini%26aufirst%3DP.%2BA.%26atitle%3DThe%2520CXCL8-CXCR1%252F2%2520axis%2520as%2520a%2520therapeutic%2520target%2520in%2520BC%2520stem-like%2520cells%26jtitle%3DFront.%2520Oncol.%26date%3D2019%26volume%3D9%26spage%3D40%26doi%3D10.3389%2Ffonc.2019.00040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, E.</span></span> <span> </span><span class="NLM_article-title">Early prediction of single-cell derived sphere formation rate using convolutional neural network image analysis</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">7717</span>– <span class="NLM_lpage">7724</span>, <span class="refDoi"> DOI: 10.1021/acs.analchem.0c00710</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.analchem.0c00710" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsV2qurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2020&pages=7717-7724&author=Y.+C.+Chenauthor=Z.+Zhangauthor=E.+Yoon&title=Early+prediction+of+single-cell+derived+sphere+formation+rate+using+convolutional+neural+network+image+analysis&doi=10.1021%2Facs.analchem.0c00710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Early Prediction of Single-Cell Derived Sphere Formation Rate Using Convolutional Neural Network Image Analysis</span></div><div class="casAuthors">Chen, Yu-Chih; Zhang, Zhixiong; Yoon, Euisik</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7717-7724</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Functional identification of cancer stem-like cells (CSCs) is an established method to identify and study this cancer subpopulation crit. for cancer progression and metastasis.  The method is based on the unique capability of single CSCs to survive and grow to tumorspheres in harsh suspension culture environment.  Recent advances in microfluidic technol. have enabled isolating and culturing thousands of single cells on a chip.  However, tumorsphere assay takes a relatively long period of time, limiting the throughput of this assay.  In this work, we incorporated machine learning with single-cell anal. to expedite tumorsphere assay.  We collected 1,710 single-cell events as the database and trained a convolutional neural network model that predicts whether a single cell could grow to a tumorsphere on Day 14 based on its Day 4 image.  With this future-telling model, we precisely estd. the sphere formation rate of SUM159 breast cancer cells to be 17.8% based on Day 4 images.  The estn. was close to the ground truth of 17.6% on Day 14.  The preliminary work demonstrates not only the feasibility to significantly accelerate tumorsphere assay but also a synergistic combination between single-cell anal. with machine learning, which can be applied to many other biomedical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo91CCM1nLtn7Vg90H21EOLACvtfcHk0lhpy2hhxN0j7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsV2qurg%253D&md5=1c40f9db306eaeb5b52979dd5c13f6c2</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Facs.analchem.0c00710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.analchem.0c00710%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%2BC.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DYoon%26aufirst%3DE.%26atitle%3DEarly%2520prediction%2520of%2520single-cell%2520derived%2520sphere%2520formation%2520rate%2520using%2520convolutional%2520neural%2520network%2520image%2520analysis%26jtitle%3DAnal.%2520Chem.%26date%3D2020%26volume%3D92%26spage%3D7717%26epage%3D7724%26doi%3D10.1021%2Facs.analchem.0c00710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blenner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander-Bryant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, J.</span></span> <span> </span><span class="NLM_article-title">Polymersomes for therapeutic delivery of protein and nucleic acid macromolecules: from design to therapeutic applications</span>. <i>Biomacromolecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1327</span>– <span class="NLM_lpage">1350</span>, <span class="refDoi"> DOI: 10.1021/acs.biomac.9b01754</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biomac.9b01754" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtl2ku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=1327-1350&author=S.+Iqbalauthor=M.+Blennerauthor=A.+Alexander-Bryantauthor=J.+Larsen&title=Polymersomes+for+therapeutic+delivery+of+protein+and+nucleic+acid+macromolecules%3A+from+design+to+therapeutic+applications&doi=10.1021%2Facs.biomac.9b01754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169aR"><div class="casContent"><span class="casTitleNuber">169a</span><div class="casTitle"><span class="NLM_cas:atitle">Polymersomes for Therapeutic Delivery of Protein and Nucleic Acid Macromolecules: From Design to Therapeutic Applications</span></div><div class="casAuthors">Iqbal, Shoaib; Blenner, Mark; Alexander-Bryant, Angela; Larsen, Jessica</div><div class="citationInfo"><span class="NLM_cas:title">Biomacromolecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1327-1350</span>CODEN:
                <span class="NLM_cas:coden">BOMAF6</span>;
        ISSN:<span class="NLM_cas:issn">1525-7797</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Macromol.-based therapeutic agents, particularly proteins, antigens, monoclonal antibodies, transcription factors, nucleic acids, and gene editing enzymes, have the potential to offer cures for previously untreatable diseases.  However, they present an enormous delivery challenge due to poor absorption and rapid metab. in the body.  Polymersomes have tremendous potential in delivering these agents to their desired intracellular location due to increased circulation times, decreased macromol. degrdn., and decreased immune responses.  In this Review, we highlight the key factors in design, development, and improved performance of these vesicles for macromol. delivery.  The recent progress made toward preclin. application of these vesicles for protein and gene delivery is also covered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohNdkP4qQ6u7Vg90H21EOLACvtfcHk0liJTZ9TXTh_sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtl2ku7c%253D&md5=4ce837b1fb148acdefd44c2889a9ba65</span></div><a href="/servlet/linkout?suffix=cit169a&amp;dbid=16384&amp;doi=10.1021%2Facs.biomac.9b01754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biomac.9b01754%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DS.%26aulast%3DBlenner%26aufirst%3DM.%26aulast%3DAlexander-Bryant%26aufirst%3DA.%26aulast%3DLarsen%26aufirst%3DJ.%26atitle%3DPolymersomes%2520for%2520therapeutic%2520delivery%2520of%2520protein%2520and%2520nucleic%2520acid%2520macromolecules%253A%2520from%2520design%2520to%2520therapeutic%2520applications%26jtitle%3DBiomacromolecules%26date%3D2020%26volume%3D21%26spage%3D1327%26epage%3D1350%26doi%3D10.1021%2Facs.biomac.9b01754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit169b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">So, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreon-Asok, A. C.</span></span> <span> </span><span class="NLM_article-title">Molecular design, synthetic strategies, and applications of cationic polythio-phenes</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">11442</span>– <span class="NLM_lpage">11509</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00773</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00773" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvV2hs77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2019&pages=11442-11509&author=R.+C.+Soauthor=A.+C.+Carreon-Asok&title=Molecular+design%2C+synthetic+strategies%2C+and+applications+of+cationic+polythio-phenes&doi=10.1021%2Facs.chemrev.8b00773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169bR"><div class="casContent"><span class="casTitleNuber">169b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Design, Synthetic Strategies, and Applications of Cationic Polythiophenes</span></div><div class="casAuthors">So, Regina C.; Carreon-Asok, Analyn C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">11442-11509</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review delves on the synthesis of cationic-functionalized oligothiophenes and polythiophenes, their properties, and their diverse applications from the year 2002-2019.  Whereas, pristine polythiophene chains are hydrophobic, and are not easily converted into a form that is useful for broad applications or for device fabrications.  Functional modification on the polymer side chain esp. with cationic pendant groups imparts favorable properties to the system such as, soly. in aq. medium, affinity with anions and neg. charged species, alongside the extensive π conjugation that provides unique optoelectronic characteristics.  This review provides a detailed account of the design and the different synthetic strategies to access cationic polythiophenes (CPTs) via chem. oxidn. using iron(III) chloride (FeCl3), via metal catalyzed/initiated polymn., and via postfunctionalization approach.  CPTs have been traditionally used in sensing and as a component in optoelectronic devices, the utility of these system has been extended to biomedical applications such as, nonviral gene delivery, cell targeting and imaging, anticancer, antifungal, bactericidal, biofilm formation, and as a mol. probe.  A summary and outlook are also presented, discussing the remaining challenges and the future direction for this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXAcxDHh4DwbVg90H21EOLACvtfcHk0liJTZ9TXTh_sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvV2hs77L&md5=f85d93b1e5a9a7e9d26c6bcb4f4e5245</span></div><a href="/servlet/linkout?suffix=cit169b&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00773%26sid%3Dliteratum%253Aachs%26aulast%3DSo%26aufirst%3DR.%2BC.%26aulast%3DCarreon-Asok%26aufirst%3DA.%2BC.%26atitle%3DMolecular%2520design%252C%2520synthetic%2520strategies%252C%2520and%2520applications%2520of%2520cationic%2520polythio-phenes%26jtitle%3DChem.%2520Rev.%26date%3D2019%26volume%3D119%26spage%3D11442%26epage%3D11509%26doi%3D10.1021%2Facs.chemrev.8b00773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hossen, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, P.</span></span> <span> </span><span class="NLM_article-title">Nanoparticle interactions with the tumor microenvironment</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2247</span>– <span class="NLM_lpage">2263</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.9b00448</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.9b00448" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFOqur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=2247-2263&author=Y.+Huaiauthor=M.+N.+Hossenauthor=S.+Wilhelmauthor=R.+Bhattacharyaauthor=P.+Mukherjee&title=Nanoparticle+interactions+with+the+tumor+microenvironment&doi=10.1021%2Facs.bioconjchem.9b00448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170aR"><div class="casContent"><span class="casTitleNuber">170a</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle Interactions with the Tumor Microenvironment</span></div><div class="casAuthors">Huai, Yanyan; Hossen, Md Nazir; Wilhelm, Stefan; Bhattacharya, Resham; Mukherjee, Priyabrata</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2247-2263</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Compared to normal tissues, the tumor microenvironment (TME) has a no. of aberrant characteristics including hypoxia, acidosis, and vascular abnormalities.  Many researchers have sought to exploit these anomalous features of the TME to develop anti-cancer therapies, and several nanoparticle-based cancer therapeutics have resulted.  In this review, the authors discuss the compn. and pathophysiol. of the TME, introduce nanoparticles (NPs) used in cancer therapy, and address the interaction between the TME and NPs.  Finally, the authors outline both the potential problems that affect TME-based nanotherapy and potential strategies to overcome these challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj_m2wsdiZhrVg90H21EOLACvtfcHk0liJTZ9TXTh_sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFOqur7K&md5=87b4f6695c1bf607d18d2f3208727f84</span></div><a href="/servlet/linkout?suffix=cit170a&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.9b00448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.9b00448%26sid%3Dliteratum%253Aachs%26aulast%3DHuai%26aufirst%3DY.%26aulast%3DHossen%26aufirst%3DM.%2BN.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DBhattacharya%26aufirst%3DR.%26aulast%3DMukherjee%26aufirst%3DP.%26atitle%3DNanoparticle%2520interactions%2520with%2520the%2520tumor%2520microenvironment%26jtitle%3DBioconjugate%2520Chem.%26date%3D2019%26volume%3D30%26spage%3D2247%26epage%3D2263%26doi%3D10.1021%2Facs.bioconjchem.9b00448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit170b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Musetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span> <span> </span><span class="NLM_article-title">Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">11740</span>– <span class="NLM_lpage">11755</span>, <span class="refDoi"> DOI: 10.1021/acsnano.8b05893</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.8b05893" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlylt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=11740-11755&author=S.+Musettiauthor=L.+Huang&title=Nanoparticle-mediated+remodeling+of+the+tumor+microenvironment+to+enhance+immunotherapy&doi=10.1021%2Facsnano.8b05893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170bR"><div class="casContent"><span class="casTitleNuber">170b</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy</span></div><div class="casAuthors">Musetti, Sara; Huang, Leaf</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">11740-11755</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nanoscience has long been lauded as a method through which tumor-assocd. barriers could be overcome.  As successful as cancer immunotherapy has been, limitations assocd. with the tumor microenvironment or side effects of systemic treatment have become more apparent.  In this Review, we seek to lay out the therapeutic challenges assocd. with the tumor microenvironment and the ways in which nanoscience is being applied to remodel the tumor microenvironment and increase the susceptibility of many cancer types to immunotherapy.  We detail the nanomedicines on the cutting edge of cancer immunotherapy and how their interactions with the tumor microenvironment make them more effective than systemically administered immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbXkVfsaYW6LVg90H21EOLACvtfcHk0lihLrF8FwwLyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlylt7bJ&md5=fbde7087070895ee0f8230d757153162</span></div><a href="/servlet/linkout?suffix=cit170b&amp;dbid=16384&amp;doi=10.1021%2Facsnano.8b05893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.8b05893%26sid%3Dliteratum%253Aachs%26aulast%3DMusetti%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DL.%26atitle%3DNanoparticle-mediated%2520remodeling%2520of%2520the%2520tumor%2520microenvironment%2520to%2520enhance%2520immunotherapy%26jtitle%3DACS%2520Nano%26date%3D2018%26volume%3D12%26spage%3D11740%26epage%3D11755%26doi%3D10.1021%2Facsnano.8b05893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit170c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Emerging nano drug delivery systems targeting cancer-associated fibroblasts for improved antitumor effect and tumor drug penetration</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1028</span>– <span class="NLM_lpage">1048</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.0c00014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.0c00014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksVGmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=1028-1048&author=J.+Guoauthor=H.+Zengauthor=Y.+Chen&title=Emerging+nano+drug+delivery+systems+targeting+cancer-associated+fibroblasts+for+improved+antitumor+effect+and+tumor+drug+penetration&doi=10.1021%2Facs.molpharmaceut.0c00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170cR"><div class="casContent"><span class="casTitleNuber">170c</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging Nano Drug Delivery Systems Targeting Cancer-Associated Fibroblasts for Improved Antitumor Effect and Tumor Drug Penetration</span></div><div class="casAuthors">Guo, Jian; Zeng, Huating; Chen, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1028-1048</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Currently, clin. used antitumor nanomedicine is usually insufficient to eradicate malignancies, due to the tumor stroma exerting therapeutic resistance and phys. barriers for proper drug delivery.  As the most abundant cells in the tumor stroma, cancer-assocd. fibroblasts (CAFs) produce a crit. tumor-promoting effect and barriers preventing the phys. delivery of nanomedicines through secreting pro-tumorigenic cytokines, increasing solid tumor pressure and interstitial fluid pressure (IFP), and nonspecific internalization.  Therefore, beyond treatment centered on cancer cells, researchers are focusing on targeting CAFs to fight stromal-rich tumors.  In recent years, a series of novel nano delivery systems have been developed based on specific CAF-targeted ligands and advanced biofunctional materials.  On the one hand, CAF-targeted nano delivery systems inhibit the pro-tumor signaling pathway between CAFs and cancer cells to reverse tumorigenesis, immunosuppression, or drug resistance in the tumor microenvironment, thus improving the sensitivity to antitumor treatments.  On the other hand, nanostrategies acting on CAFs profoundly contribute to increasing the deep penetration of antitumor drugs through the decrease of solid pressure, IFP, and dense extracellular matrix generation related to the resistance to intratumoral diffusion.  In this review, we first introduce the biol. mechanisms of CAFs that interfere with nanotherapy.  The state-of-the-art passive and active strategies of nano delivery systems targeting CAFs are then summarized, focusing on the therapeutic mechanism involved and the rational design of nano delivery systems.  Addnl., the challenges of CAF-targeted nanotherapy are discussed from the perspectives of developing efficient nano delivery systems and potential clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpslk8oeESZbVg90H21EOLACvtfcHk0lihLrF8FwwLyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksVGmu78%253D&md5=691ee15daafac0155ca682eb02ca02e9</span></div><a href="/servlet/linkout?suffix=cit170c&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.0c00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.0c00014%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DEmerging%2520nano%2520drug%2520delivery%2520systems%2520targeting%2520cancer-associated%2520fibroblasts%2520for%2520improved%2520antitumor%2520effect%2520and%2520tumor%2520drug%2520penetration%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2020%26volume%3D17%26spage%3D1028%26epage%3D1048%26doi%3D10.1021%2Facs.molpharmaceut.0c00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Jamal, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulter, J. A.</span></span> <span> </span><span class="NLM_article-title">Exploiting current understanding of hypoxia mediated tumour progression for nanotherapeutic development</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1989</span>, <span class="refDoi"> DOI: 10.3390/cancers11121989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcancers11121989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVyhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1989&author=J.+Fengauthor=N.+M.+Byrneauthor=W.+Al+Jamalauthor=J.+A.+Coulter&title=Exploiting+current+understanding+of+hypoxia+mediated+tumour+progression+for+nanotherapeutic+development&doi=10.3390%2Fcancers11121989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting current understanding of hypoxia mediated tumour progression for nanotherapeutic development</span></div><div class="casAuthors">Feng, Jie; Byrne, Niall M.; Al Jamal, Wafa; Coulter, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1989</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Hypoxia is one of the most common phenotypes of malignant tumors.  Hypoxia leads to the increased activity of hypoxia-inducible factors (HIFs), which regulate the expression of genes controlling a raft of pro-tumor phenotypes.  These include maintenance of the cancer stem cell compartment, epithelial-mesenchymal transition (EMT), angiogenesis, immunosuppression, and metabolic reprogramming.  Hypoxia can also contribute to the tumor progression in a HIF-independent manner via the activation of a complex signalling network pathway, including JAK-STAT, RhoA/ROCK, NF- κB and PI3/AKT.  Recent studies suggest that nanotherapeutics offer a unique opportunity to target the hypoxic microenvironment, enhancing the therapeutic window of conventional therapeutics.  In this review, we summarise recent advances in understanding the impact of hypoxia on tumor progression, while outlining possible nanotherapeutic approaches for overcoming hypoxia-mediated resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUa32YixN5SrVg90H21EOLACvtfcHk0lihLrF8FwwLyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVyhsLs%253D&md5=f8373c6a29c0cdba9b7abe1e36653e7e</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.3390%2Fcancers11121989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11121989%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DByrne%26aufirst%3DN.%2BM.%26aulast%3DAl%2BJamal%26aufirst%3DW.%26aulast%3DCoulter%26aufirst%3DJ.%2BA.%26atitle%3DExploiting%2520current%2520understanding%2520of%2520hypoxia%2520mediated%2520tumour%2520progression%2520for%2520nanotherapeutic%2520development%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26spage%3D1989%26doi%3D10.3390%2Fcancers11121989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weeranoppanant, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Cell membrane biomimetic nanoparticles for inflammation and cancer targeting in drug delivery</span>. <i>Biomater. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">568</span>, <span class="refDoi"> DOI: 10.1039/C9BM01392J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1039%2FC9BM01392J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31769765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFamsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=552-568&author=H.+Wangauthor=Y.+Liuauthor=R.+Heauthor=D.+Xuauthor=J.+Zangauthor=N.+Weeranoppanantauthor=H.+Dongauthor=Y.+Li&title=Cell+membrane+biomimetic+nanoparticles+for+inflammation+and+cancer+targeting+in+drug+delivery&doi=10.1039%2FC9BM01392J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Cell membrane biomimetic nanoparticles for inflammation and cancer targeting in drug delivery</span></div><div class="casAuthors">Wang, Huaiji; Liu, Ying; He, Ruiqing; Xu, Dailin; Zang, Jie; Weeranoppanant, Nopphon; Dong, Haiqing; Li, Yongyong</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">552-568</span>CODEN:
                <span class="NLM_cas:coden">BSICCH</span>;
        ISSN:<span class="NLM_cas:issn">2047-4849</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Nanoparticle capture and elimination by the immune system are great obstacles for drug delivery.  Camouflaging nanoparticles with cell membrane represents a promising strategy to communicate and negotiate with the immune system.  As a novel class of nanotherapeutics, such biomimetic nanoparticles inherit specific biol. functionalities of the source cells (e.g., erythrocytes, immune cells, cancer cells and platelets) in order to evade immune elimination, prolong circulation time, and even target a disease region by virtue of the homing tendency of the cell membrane protein.  In this review, we begin with an overview of different cell membranes that can be utilized to create a biointerface on nanoparticles.  Subsequently, we elaborate on the state-of-the-art of cell membrane biomimetic nanoparticles for drug delivery.  In particular, a summary of data on circulation capacity and targeting efficiency by camouflaged nanoparticles is presented.  In addn. to cancer therapy, inflammation treatment, as an emerging application of biomimetic nanoparticles, is specifically included.  The challenges and outlook of this technol. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSYcCjiA0kIrVg90H21EOLACvtfcHk0liAXFyWsDXh_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFamsLrI&md5=b3c38b4d71cb1f8b7af01aae4278650f</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1039%2FC9BM01392J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9BM01392J%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DWeeranoppanant%26aufirst%3DN.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DCell%2520membrane%2520biomimetic%2520nanoparticles%2520for%2520inflammation%2520and%2520cancer%2520targeting%2520in%2520drug%2520delivery%26jtitle%3DBiomater.%2520Sci.%26date%3D2020%26volume%3D8%26spage%3D552%26epage%3D568%26doi%3D10.1039%2FC9BM01392J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, C. K.</span></span> <span> </span><span class="NLM_article-title">A set of cancer stem cell homing peptides associating with the glycan moieties of glycosphingolipids</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">20490</span>– <span class="NLM_lpage">20507</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.24960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.18632%2Foncotarget.24960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29755667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC1MfislWgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=20490-20507&author=Y.+H.+Suauthor=T.+Y.+Linauthor=H.+J.+Liuauthor=C.+K.+Chuang&title=A+set+of+cancer+stem+cell+homing+peptides+associating+with+the+glycan+moieties+of+glycosphingolipids&doi=10.18632%2Foncotarget.24960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">A set of cancer stem cell homing peptides associating with the glycan moieties of glycosphingolipids</span></div><div class="casAuthors">Su Yu-Hsiu; Lin Tai-Yun; Chuang Chin-Kai; Su Yu-Hsiu; Liu Hung-Jen; Liu Hung-Jen; Liu Hung-Jen</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">20490-20507</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer stem cells (CSCs) are currently believed to be involved in tumor metastasis and relapse.  And treatments against CSCs are well concerned issues.  Peptides targeting to mouse and human CSCs were screened from an M13 phage display library.  The first subset of cancer stem cell homing peptides (CSC HPs), CSC HP-1 to -12, were screened with mouse EMT6 breast cancer stem cells.  Among them, CSC HP-1, CSC HP-3, CSC HP-8, CSC HP-9, and CSC HP-10 can bind to mouse CT26 colon CSCs; CSC HP-1, CSC HP-2, CSC HP-3, and CSC HP-8 can bind to mouse Hepa1-6 liver CSCs; as well as CSC HP-1, CSC HP-2, CSC HP-3, CSC HP-8, CSC HP-9, CSC HP-10, and CSC HP-11 can bind to human PANC-1 pancreatic CSCs.  The second subset of cancer stem cell homing peptides, CSC HP-hP1 to -hP3, were screened with human PANC-1 pancreatic CSCs.  Both CSC HP-hP1 and CSC HP-hP2 were demonstrated able to bind mouse EMT6, CT26 and Hepa1-6 CSCs as well as human colorectal HT29 and lung H1650 CSCs.  CSC HP-1 and CSC HP-hP1 could strongly associate with the Globo 4 and Lewis Y glycan epitopes coupled on a microarray chip or Globo 4 and Globo H conjugated on bovine serum albumin.  CSC HP-10, CSC HP-11 and CSC HP-hP2 could associate with the disialylated saccharide Neu5Ac-α-2,6-Gal-β-1,3-(Neu5Ac-α-2,6)-GalNAc coupled on a microarray chip.  These results indicate that the CSC HPs may target to the known stem cell glycan markers GbH and Lewis Y as well as the disialylated saccharide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRT_RS39fJiZUloaUqgkFHkfW6udTcc2eZE4Ix5ov4Mv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfislWgtw%253D%253D&md5=895879c4659087efacb2e14f05339933</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.24960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.24960%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DY.%2BH.%26aulast%3DLin%26aufirst%3DT.%2BY.%26aulast%3DLiu%26aufirst%3DH.%2BJ.%26aulast%3DChuang%26aufirst%3DC.%2BK.%26atitle%3DA%2520set%2520of%2520cancer%2520stem%2520cell%2520homing%2520peptides%2520associating%2520with%2520the%2520glycan%2520moieties%2520of%2520glycosphingolipids%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D20490%26epage%3D20507%26doi%3D10.18632%2Foncotarget.24960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, C.-K.</span>; <span class="NLM_string-name">Su, Y.-H.</span>; <span class="NLM_string-name">Lin, T.-Y.</span></span> <span> </span><span class="NLM_article-title">Cancer Stem Cell Targeting Peptide and Use Thereof</span>. U.S. Patent <span class="NLM_patent">20170158737 A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.-K.+Chuang&author=Y.-H.+Su&author=T.-Y.+Lin&title=Cancer+Stem+Cell+Targeting+Peptide+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChuang%26aufirst%3DC.-K.%26atitle%3DCancer%2520Stem%2520Cell%2520Targeting%2520Peptide%2520and%2520Use%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truchan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span> <span> </span><span class="NLM_article-title">Albumin nanoparticle of paclitaxel (Abraxane) decreases while taxol increases breast cancer stem cells in treatment of triple negative breast cancer</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2275</span>– <span class="NLM_lpage">2286</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.9b01221</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.9b01221" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVGntbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=2275-2286&author=H.+Yuanauthor=H.+Guoauthor=X.+Luanauthor=M.+Heauthor=F.+Liauthor=J.+Burnettauthor=N.+Truchanauthor=D.+Sun&title=Albumin+nanoparticle+of+paclitaxel+%28Abraxane%29+decreases+while+taxol+increases+breast+cancer+stem+cells+in+treatment+of+triple+negative+breast+cancer&doi=10.1021%2Facs.molpharmaceut.9b01221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer</span></div><div class="casAuthors">Yuan, Hebao; Guo, Hongwei; Luan, Xin; He, Miao; Li, Feng; Burnett, Joseph; Truchan, Nathan; Sun, Duxin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2275-2286</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) has a high rate of metastasis, which is assocd. with breast cancer stem-like cells (CSCs).  Although Taxol (micelle formulation of paclitaxel) is the first line chemotherapy to treat TNBC, it increases CSCs in residual tumors.  Abraxane, albumin nanoparticle of paclitaxel, showed lower plasma concn. compared to Taxol in both human and animal models, but it is not clear why Abraxane showed superior efficacy to Taxol in treatment of metastatic breast cancer in humans.  In this study, we intend to investigate if Abraxane eliminates CSCs for its better efficacy.  The results showed that Abraxane showed similar cytotoxicity in SUM149 cells in comparison with Taxol.  Although Abraxane showed 3- to 5-fold lower blood drug concn. compared to Taxol, it achieved similar tumor drug concn. and 10-fold higher tumor/plasma ratio in SUM149 xenograft NOD/SCID mouse model.  In addn., Abraxane and Taxol showed similar efficacy to shrink the tumor size in orthotopic breast cancer NOD/SCID mouse model.  However, Abraxane decreased breast CSCs frequency by 3- to 9-fold, while Taxol increased breast CSCs frequency in an orthotopic breast cancer NOD/SCID mouse model.  Furthermore, Abraxane increased 3- to 15-fold intracellular uptake in both ALDH+ CSCs and differentiated ALDH- cells in comparison with Taxol, which provides a mechanism for Abraxane's superior efficacy to eliminate CSCs in comparison with Taxol.  Our data suggest albumin nanoparticle Abraxane may have a broad implication to enhance drug's efficacy by eliminating breast cancer stem cells for treatment of metastatic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLV-4XqrWu17Vg90H21EOLACvtfcHk0liAXFyWsDXh_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVGntbnN&md5=60408c2d8dde9b94dc5838cd771b406f</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.9b01221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.9b01221%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLuan%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DBurnett%26aufirst%3DJ.%26aulast%3DTruchan%26aufirst%3DN.%26aulast%3DSun%26aufirst%3DD.%26atitle%3DAlbumin%2520nanoparticle%2520of%2520paclitaxel%2520%2528Abraxane%2529%2520decreases%2520while%2520taxol%2520increases%2520breast%2520cancer%2520stem%2520cells%2520in%2520treatment%2520of%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2020%26volume%3D17%26spage%3D2275%26epage%3D2286%26doi%3D10.1021%2Facs.molpharmaceut.9b01221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Bertoni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozielski, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaughan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihelson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhart, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laterra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. J.</span></span> <span> </span><span class="NLM_article-title">Bioreducible polymeric nanoparticles containing multiplexed cancer stem cell regulating miRNAs inhibit glioblastoma growth and prolong survival</span>. <i>Nano Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4086</span>– <span class="NLM_lpage">4094</span>, <span class="refDoi"> DOI: 10.1021/acs.nanolett.8b00390</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.nanolett.8b00390" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFyqt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=4086-4094&author=H.+Lopez-Bertoniauthor=K.+L.+Kozielskiauthor=Y.+Ruiauthor=B.+Lalauthor=H.+Vaughanauthor=D.+R.+Wilsonauthor=N.+Mihelsonauthor=C.+G.+Eberhartauthor=J.+Laterraauthor=J.+J.+Green&title=Bioreducible+polymeric+nanoparticles+containing+multiplexed+cancer+stem+cell+regulating+miRNAs+inhibit+glioblastoma+growth+and+prolong+survival&doi=10.1021%2Facs.nanolett.8b00390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival</span></div><div class="casAuthors">Lopez-Bertoni, Hernando; Kozielski, Kristen L.; Rui, Yuan; Lal, Bachchu; Vaughan, Hannah; Wilson, David R.; Mihelson, Nicole; Eberhart, Charles G.; Laterra, John; Green, Jordan J.</div><div class="citationInfo"><span class="NLM_cas:title">Nano Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4086-4094</span>CODEN:
                <span class="NLM_cas:coden">NALEFD</span>;
        ISSN:<span class="NLM_cas:issn">1530-6984</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite our growing mol.-level understanding of glioblastoma (GBM), treatment modalities remain limited.  Recent developments in the mechanisms of cell fate regulation and nanomedicine provide new avenues by which to treat and manage brain tumors via the delivery of mol. therapeutics.  Here, we have developed bioreducible poly(β-amino ester) nanoparticles that demonstrate high intracellular delivery efficacy, low cytotoxicity, escape from endosomes, and promotion of cytosol-targeted environmentally triggered cargo release for miRNA delivery to tumor-propagating human cancer stem cells.  In this report, we combined this nanobiotechnol. with newly discovered cancer stem cell inhibiting miRNAs to develop self-assembled miRNA-contg. polymeric nanoparticles (nano-miRs) to treat gliomas.  We show that these nano-miRs effectively intracellularly deliver single and combination miRNA mimics that inhibit the stem cell phenotype of human GBM cells in vitro.  Following direct intratumoral infusion, these nano-miRs were found to distribute through the tumors, inhibit the growth of established orthotopic human GBM xenografts, and cooperatively enhance the response to std.-of-care γ radiation.  Co-delivery of two miRNAs, miR-148a and miR-296-5p, within the bioreducible nano-miR particles enabled long-term survival from GBM in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzu2F4Tq9m87Vg90H21EOLACvtfcHk0lgv12uyVmUaGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFyqt7rN&md5=980ccb688441948880685d5c69fc898a</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Facs.nanolett.8b00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.nanolett.8b00390%26sid%3Dliteratum%253Aachs%26aulast%3DLopez-Bertoni%26aufirst%3DH.%26aulast%3DKozielski%26aufirst%3DK.%2BL.%26aulast%3DRui%26aufirst%3DY.%26aulast%3DLal%26aufirst%3DB.%26aulast%3DVaughan%26aufirst%3DH.%26aulast%3DWilson%26aufirst%3DD.%2BR.%26aulast%3DMihelson%26aufirst%3DN.%26aulast%3DEberhart%26aufirst%3DC.%2BG.%26aulast%3DLaterra%26aufirst%3DJ.%26aulast%3DGreen%26aufirst%3DJ.%2BJ.%26atitle%3DBioreducible%2520polymeric%2520nanoparticles%2520containing%2520multiplexed%2520cancer%2520stem%2520cell%2520regulating%2520miRNAs%2520inhibit%2520glioblastoma%2520growth%2520and%2520prolong%2520survival%26jtitle%3DNano%2520Lett.%26date%3D2018%26volume%3D18%26spage%3D4086%26epage%3D4094%26doi%3D10.1021%2Facs.nanolett.8b00390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span> <span> </span><span class="NLM_article-title">Salinomycin-loaded gold nanoparticles for treating cancer stem cells by ferroptosis-induced cell death</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2532</span>– <span class="NLM_lpage">2539</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.9b00132</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.9b00132" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvVGku74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=2532-2539&author=Y.+Zhaoauthor=W.+Zhaoauthor=Y.+C.+Limauthor=T.+Liu&title=Salinomycin-loaded+gold+nanoparticles+for+treating+cancer+stem+cells+by+ferroptosis-induced+cell+death&doi=10.1021%2Facs.molpharmaceut.9b00132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Salinomycin-Loaded Gold Nanoparticles for Treating Cancer Stem Cells by Ferroptosis-Induced Cell Death</span></div><div class="casAuthors">Zhao, Yongmei; Zhao, Wei; Lim, Yi Chieh; Liu, Tianqing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2532-2539</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are a subpopulation of tumor cells that exhibit self-renewal, differentiation, and tumorigenicity.  CSCs are highly resistant to the conventional cancer treatment and have been assocd. with metastasis.  Several studies have been shown that salinomycin (Sal) has the potential to target cancer stem cells evidenced by in vitro and in vivo tumor models.  Here, salinomycin was conjugated with biocompatible gold nanoparticles (AuNPs) coated with poly(ethylene glycol) to improve its specificity in targeting breast cancer stem cells (BCSCs).  BCSCs derived from CD24low/CD44high subpopulation showed high sensitivity to Sal-AuNP treatment.  An in-depth anal. on the mechanism of action of Sal-AuNPs indicated ferroptosis, an iron-dependent cell death, was achieved as a result of iron accumulation and inhibition of antioxidant properties.  This also led to the induction of oxidative stress, mitochondrial dysfunction, and lipid oxidn.  Our findings suggest Sal-AuNP treatment is an efficient therapeutic avenue in eliminating cancer stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKwDm7LexSrbVg90H21EOLACvtfcHk0lgv12uyVmUaGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvVGku74%253D&md5=a2622d384c5ef443603bb7b21c75a6cb</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.9b00132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.9b00132%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLim%26aufirst%3DY.%2BC.%26aulast%3DLiu%26aufirst%3DT.%26atitle%3DSalinomycin-loaded%2520gold%2520nanoparticles%2520for%2520treating%2520cancer%2520stem%2520cells%2520by%2520ferroptosis-induced%2520cell%2520death%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2019%26volume%3D16%26spage%3D2532%26epage%3D2539%26doi%3D10.1021%2Facs.molpharmaceut.9b00132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ning, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, M. J.</span></span> <span> </span><span class="NLM_article-title">Targeting colorectal cancer stem-like cells with anti-cd133 antibody-conjugated SN-38 nanoparticles</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">17793</span>– <span class="NLM_lpage">17804</span>, <span class="refDoi"> DOI: 10.1021/acsami.6b04403</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.6b04403" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKis7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=17793-17804&author=S.+T.+Ningauthor=S.+Y.+Leeauthor=M.+F.+Weiauthor=C.+L.+Pengauthor=S.+Y.+Linauthor=M.+H.+Tsaiauthor=P.+C.+Leeauthor=Y.+H.+Shihauthor=C.+Y.+Linauthor=T.+Y.+Luoauthor=M.+J.+Shieh&title=Targeting+colorectal+cancer+stem-like+cells+with+anti-cd133+antibody-conjugated+SN-38+nanoparticles&doi=10.1021%2Facsami.6b04403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles</span></div><div class="casAuthors">Ning, Sin-Tzu; Lee, Shin-Yu; Wei, Ming-Feng; Peng, Cheng-Liang; Lin, Susan Yun-Fan; Tsai, Ming-Hsien; Lee, Pei-Chi; Shih, Ying-Hsia; Lin, Chun-Yen; Luo, Tsai-Yueh; Shieh, Ming-Jium</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">17793-17804</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer stem-like cells play a key role in tumor development, and these cells are relevant to the failure of conventional chemotherapy.  To achieve favorable therapy for colorectal cancer, PEG-PCL-based nanoparticles, which possess good biol. compatibility, were fabricated as nanocarriers for the topoisomerase inhibitor, SN-38.  For cancer stem cell therapy, CD133 (prominin-1) is a theor. cancer stem-like cell (CSLC) marker for colorectal cancer and is a proposed therapeutic target.  Cells with CD133 overexpression have demonstrated enhanced tumor-initiating ability and tumor relapse probability.  To resolve the problem of chemotherapy failure, SN-38-loaded nanoparticles were conjugated with anti-CD133 antibody to target CD133-pos. (CD133+) cells.  In this study, anti-CD133 antibody-conjugated SN-38-loaded nanoparticles (CD133Ab-NPs-SN-38) efficiently bound to HCT116 cells, which overexpress CD133 glycoprotein.  The cytotoxic effect of CD133Ab-NPs-SN-38 was greater than that of nontargeted nanoparticles (NPs-SN-38) in HCT116 cells.  Furthermore, CD133Ab-NPs-SN-38 could target CD133+ cells and inhibit colony formation compared with NPs-SN-38.  In vivo studies in an HCT116 xenograft model revealed that CD133Ab-NPs-SN-38 suppressed tumor growth and retarded recurrence.  A redn. in CD133 expression in HCT116 cells treated with CD133Ab-NPs-SN-38 was also obsd. in immunohistochem. results.  Therefore, this CD133-targeting nanoparticle delivery system could eliminate CD133-pos. cells and is a potential cancer stem cell targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-eyhkT1Pc07Vg90H21EOLACvtfcHk0lgv12uyVmUaGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKis7zO&md5=2d63ca84e325d5c02ba7e83cf6383b91</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1021%2Facsami.6b04403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.6b04403%26sid%3Dliteratum%253Aachs%26aulast%3DNing%26aufirst%3DS.%2BT.%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DWei%26aufirst%3DM.%2BF.%26aulast%3DPeng%26aufirst%3DC.%2BL.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DTsai%26aufirst%3DM.%2BH.%26aulast%3DLee%26aufirst%3DP.%2BC.%26aulast%3DShih%26aufirst%3DY.%2BH.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DLuo%26aufirst%3DT.%2BY.%26aulast%3DShieh%26aufirst%3DM.%2BJ.%26atitle%3DTargeting%2520colorectal%2520cancer%2520stem-like%2520cells%2520with%2520anti-cd133%2520antibody-conjugated%2520SN-38%2520nanoparticles%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2016%26volume%3D8%26spage%3D17793%26epage%3D17804%26doi%3D10.1021%2Facsami.6b04403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarmishyn, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nhi Nguyen, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mou, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiou, S. H.</span></span> <span> </span><span class="NLM_article-title">Dual delivery of HNF4α and cisplatin by mesoporous silica nanoparticles inhibits cancer pluripotency and tumorigenicity in hepatoma-derived CD133-expressing stem cells</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">19808</span>– <span class="NLM_lpage">19818</span>, <span class="refDoi"> DOI: 10.1021/acsami.9b04474</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.9b04474" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptFyltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=19808-19818&author=P.+H.+Tsaiauthor=M.+L.+Wangauthor=J.+H.+Changauthor=A.+A.+Yarmishynauthor=P.+N.+Nhi+Nguyenauthor=W.+Chenauthor=Y.+Chienauthor=T.+I.+Huoauthor=C.+Y.+Mouauthor=S.+H.+Chiou&title=Dual+delivery+of+HNF4%CE%B1+and+cisplatin+by+mesoporous+silica+nanoparticles+inhibits+cancer+pluripotency+and+tumorigenicity+in+hepatoma-derived+CD133-expressing+stem+cells&doi=10.1021%2Facsami.9b04474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Delivery of HNF4α and Cisplatin by Mesoporous Silica Nanoparticles Inhibits Cancer Pluripotency and Tumorigenicity in Hepatoma-Derived CD133-Expressing Stem Cells</span></div><div class="casAuthors">Tsai, Ping-Hsing; Wang, Mong-Lien; Chang, Jen-Hsuan; Yarmishyn, Aliaksandr A.; Nhi Nguyen, Phan Nguyen; Chen, Wei; Chien, Yueh; Huo, Teh-Ia; Mou, Chung-Yuan; Chiou, Shih-Hwa</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">19808-19818</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is one of the most prevalent and deadly malignancies characterized by high rate of recurrence.  Tumor recurrence is often attributed to the presence of a subpopulation of cells with stem cell properties, referred to as cancer stem cells (CSCs).  Traditionally, cancer therapies target the entire bulk of tumor cells; however, they are poorly effective against CSCs, characterized by higher drug resistance.  Therefore, approaches targeting CSCs may be required in addn. to conventional chemotherapy to prevent tumor recurrence.  In this study, we investigated an approach to target HCC by combining the conventional chemotherapeutic drug, cisplatin, to target the bulk of tumor cells, and differentiation therapy by delivering the gene encoding HNF4α, an important regulator of hepatocyte differentiation, to target CSCs.  We used the Huh7 cell line as an in vitro model of HCC, which is characterized by a high proportion of CD133-expressing CSCs.  By using flow cytometry, we sepd. CD133+ and CD133- Huh7 cell subpopulations and have shown that the former has highly pronounced in vivo tumorigenic capacity in contrast to the latter, which could not generate tumors in vivo.  For the dual delivery of HNF4α-encoding plasmid and cisplatin, we used polyethyleneimine-modified mesoporous silica nanoparticles (PMSNs) as the nanocarriers.  Here, we show that the treatment of CD133-expressing Huh7 cells with HNF4α-loaded PMSNs can suppress their proliferation rate, decrease the proportion of CSCs, downregulate stemness-assocd. genes, and increase the expression of mature hepatocyte-assocd. genes.  At the same time, the treatment of Huh7 with PMSNs loaded with both HNF4α-encoding plasmid and cisplatin could block them in the S-phase of the cell cycle and cause apoptosis.  In addn., dually loaded PMSNs were the most efficient formulation in suppressing tumor growth in vivo.  To summarize, in this study, we tested the nanoparticle-based delivery system as both chemotherapy and gene-based therapy agents, which has great potential for development of effective treatment of HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2A3mQIAjgs7Vg90H21EOLACvtfcHk0ljnO1TeZ54YuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptFyltb0%253D&md5=a04bd8651acfff9324396395f6ed329e</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Facsami.9b04474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.9b04474%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DP.%2BH.%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DChang%26aufirst%3DJ.%2BH.%26aulast%3DYarmishyn%26aufirst%3DA.%2BA.%26aulast%3DNhi%2BNguyen%26aufirst%3DP.%2BN.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DChien%26aufirst%3DY.%26aulast%3DHuo%26aufirst%3DT.%2BI.%26aulast%3DMou%26aufirst%3DC.%2BY.%26aulast%3DChiou%26aufirst%3DS.%2BH.%26atitle%3DDual%2520delivery%2520of%2520HNF4%25CE%25B1%2520and%2520cisplatin%2520by%2520mesoporous%2520silica%2520nanoparticles%2520inhibits%2520cancer%2520pluripotency%2520and%2520tumorigenicity%2520in%2520hepatoma-derived%2520CD133-expressing%2520stem%2520cells%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2019%26volume%3D11%26spage%3D19808%26epage%3D19818%26doi%3D10.1021%2Facsami.9b04474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pesarrodona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-García, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seras-Franzoso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Chardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltá-Foix, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cámara-Sánchez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jara, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, S.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaverde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abasolo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, E.</span></span> <span> </span><span class="NLM_article-title">Engineering a nanostructured nucleolin-binding peptide for intracellular drug delivery in triple-negative breast cancer stem cells</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">5381</span>– <span class="NLM_lpage">5388</span>, <span class="refDoi"> DOI: 10.1021/acsami.9b15803</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.9b15803" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitl2htrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=5381-5388&author=M.+Pesarrodonaauthor=L.+S%C3%A1nchez-Garc%C3%ADaauthor=J.+Seras-Franzosoauthor=A.+S%C3%A1nchez-Chardiauthor=R.+Balt%C3%A1-Foixauthor=P.+C%C3%A1mara-S%C3%A1nchezauthor=P.+Generauthor=J.+J.+Jaraauthor=D.+Pulidoauthor=N.+Sernaauthor=S.+Schwartzauthor=M.+Royoauthor=A.+Villaverdeauthor=I.+Abasoloauthor=E.+Vazquez&title=Engineering+a+nanostructured+nucleolin-binding+peptide+for+intracellular+drug+delivery+in+triple-negative+breast+cancer+stem+cells&doi=10.1021%2Facsami.9b15803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering a Nanostructured Nucleolin-Binding Peptide for Intracellular Drug Delivery in Triple-Negative Breast Cancer Stem Cells</span></div><div class="casAuthors">Pesarrodona, Mireia; Sanchez-Garcia, Laura; Seras-Franzoso, Joaquin; Sanchez-Chardi, Alejandro; Balta-Foix, Ricardo; Camara-Sanchez, Patricia; Gener, Petra; Jara, Jose Juan; Pulido, Daniel; Serna, Naroa; Schwartz, Simo; Royo, Miriam; Villaverde, Antonio; Abasolo, Ibane; Vazquez, Esther</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">5381-5388</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Five peptide ligands of four different cell surface receptors (nucleolin, CXCR1, CMKLR1, and CD44v6) have been evaluated as targeting moieties for triple-neg. human breast cancers.  Among them, the peptide F3, derived from phage display, promotes the fast and efficient internalization of a genetically fused green fluorescent protein (GFP) inside MDA-MB-231 cancer stem cells in a specific receptor-dependent fashion.  The further engineering of this protein into the modular construct F3-RK-GFP-H6 and the subsequent construct F3-RK-PE24-H6 resulted in self-assembling polypeptides that organize as discrete and regular nanoparticles.  These materials, 15-20 nm in size, show enhanced nucleolin-dependent cell penetrability.  We show that the F3-RK-PE24-H6, based on the Pseudomonas aeruginosa exotoxin A (PE24) as a core functional domain, is highly cytotoxic over target cells.  The combination of F3, the cationic peptide (RK)n, and the toxin domain PE24 in such unusual presentation appears as a promising approach to cell-targeted drug carriers in breast cancers and addresses selective drug delivery in otherwise difficult-to-treat triple-neg. breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiOsqLbdR0e7Vg90H21EOLACvtfcHk0ljnO1TeZ54YuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitl2htrvF&md5=30248b61abc2f9b175b9c0a14ec122d0</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Facsami.9b15803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.9b15803%26sid%3Dliteratum%253Aachs%26aulast%3DPesarrodona%26aufirst%3DM.%26aulast%3DS%25C3%25A1nchez-Garc%25C3%25ADa%26aufirst%3DL.%26aulast%3DSeras-Franzoso%26aufirst%3DJ.%26aulast%3DS%25C3%25A1nchez-Chardi%26aufirst%3DA.%26aulast%3DBalt%25C3%25A1-Foix%26aufirst%3DR.%26aulast%3DC%25C3%25A1mara-S%25C3%25A1nchez%26aufirst%3DP.%26aulast%3DGener%26aufirst%3DP.%26aulast%3DJara%26aufirst%3DJ.%2BJ.%26aulast%3DPulido%26aufirst%3DD.%26aulast%3DSerna%26aufirst%3DN.%26aulast%3DSchwartz%26aufirst%3DS.%26aulast%3DRoyo%26aufirst%3DM.%26aulast%3DVillaverde%26aufirst%3DA.%26aulast%3DAbasolo%26aufirst%3DI.%26aulast%3DVazquez%26aufirst%3DE.%26atitle%3DEngineering%2520a%2520nanostructured%2520nucleolin-binding%2520peptide%2520for%2520intracellular%2520drug%2520delivery%2520in%2520triple-negative%2520breast%2520cancer%2520stem%2520cells%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2020%26volume%3D12%26spage%3D5381%26epage%3D5388%26doi%3D10.1021%2Facsami.9b15803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Confeld, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamnoon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen-Smith, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallik, S.</span></span> <span> </span><span class="NLM_article-title">Targeting the tumor core: hypoxia-responsive nanoparticles for the delivery of chemotherapy to pancreatic tumors</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2849</span>– <span class="NLM_lpage">2863</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.0c00247</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.0c00247" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFaiurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=2849-2863&author=M.+I.+Confeldauthor=B.+Mamnoonauthor=L.+Fengauthor=H.+Jensen-Smithauthor=P.+Rayauthor=J.+Frobergauthor=J.+Kimauthor=M.+A.+Hollingsworthauthor=M.+Quadirauthor=Y.+Choiauthor=S.+Mallik&title=Targeting+the+tumor+core%3A+hypoxia-responsive+nanoparticles+for+the+delivery+of+chemotherapy+to+pancreatic+tumors&doi=10.1021%2Facs.molpharmaceut.0c00247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors</span></div><div class="casAuthors">Confeld, Matthew I.; Mamnoon, Babak; Feng, Li; Jensen-Smith, Heather; Ray, Priyanka; Froberg, James; Kim, Jiha; Hollingsworth, Michael A.; Quadir, Mohiuddin; Choi, Yongki; Mallik, Sanku</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2849-2863</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In pancreatic ductal adenocarcinoma (PDAC), early onset of hypoxia triggers remodeling of the extracellular matrix, epithelial-to-mesenchymal transition, increased cell survival, the formation of cancer stem cells, and drug resistance.  Hypoxia in PDAC is also assocd. with the development of collagen-rich, fibrous extracellular stroma (desmoplasia), resulting in severely impaired drug penetration.  To overcome these daunting challenges, we created polymer nanoparticles (polymersomes) that target and penetrate pancreatic tumors, reach the hypoxic niches, undergo rapid structural destabilization, and release the encapsulated drugs.  In vitro studies indicated a high cellular uptake of the polymersomes and increased cytotoxicity of the drugs under hypoxia compared to unencapsulated drugs.  The polymersomes decreased tumor growth by nearly 250% and significantly increased necrosis within the tumors by 60% in mice compared to untreated controls.  We anticipate that these polymer nanoparticles possess a considerable translational potential for delivering drugs to solid hypoxic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTnOzJaxTzy7Vg90H21EOLACvtfcHk0liX91LiLMpL3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFaiurrM&md5=35d6a57babf6f90ca5c785b6bc0ce83d</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.0c00247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.0c00247%26sid%3Dliteratum%253Aachs%26aulast%3DConfeld%26aufirst%3DM.%2BI.%26aulast%3DMamnoon%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DJensen-Smith%26aufirst%3DH.%26aulast%3DRay%26aufirst%3DP.%26aulast%3DFroberg%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DHollingsworth%26aufirst%3DM.%2BA.%26aulast%3DQuadir%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DMallik%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520tumor%2520core%253A%2520hypoxia-responsive%2520nanoparticles%2520for%2520the%2520delivery%2520of%2520chemotherapy%2520to%2520pancreatic%2520tumors%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2020%26volume%3D17%26spage%3D2849%26epage%3D2863%26doi%3D10.1021%2Facs.molpharmaceut.0c00247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurunathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span> <span> </span><span class="NLM_article-title">Graphene oxide-silver nanocomposite enhances cytotoxic and apoptotic potential of salinomycin in human ovarian cancer stem cells (OvCSCs): a novel approach for cancer therapy</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">710</span>, <span class="refDoi"> DOI: 10.3390/ijms19030710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fijms19030710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVOntbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=710&author=Y.+J.+Choiauthor=S.+Gurunathanauthor=J.+H.+Kim&title=Graphene+oxide-silver+nanocomposite+enhances+cytotoxic+and+apoptotic+potential+of+salinomycin+in+human+ovarian+cancer+stem+cells+%28OvCSCs%29%3A+a+novel+approach+for+cancer+therapy&doi=10.3390%2Fijms19030710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Graphene oxide-silver nanocomposite enhancescytotoxic and apoptotic potential of salinomycinin human ovarian cancer stem cells (OvCSCs):a novel approach for cancer therapy</span></div><div class="casAuthors">Choi, Yun-Jung; Gurunathan, Sangiliyandi; Kim, Jin-Hoi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">710/1-710/23</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The use of graphene to target and eliminate cancer stem cells (CSCs) is an alternative approach to conventional chemotherapy.  We show the biomol.-mediated synthesis of reduced graphene oxide-silver nanoparticle nanocomposites (rGO-Ag) using R-phycoerythrin (RPE); the resulting RPE-rGO-Ag was evaluated in human ovarian cancer cells and ovarian cancer stem cells (OvCSCs).  The synthesized RPE-rGO-Ag nanocomposite (referred to as rGO-Ag) was characterized using various anal. techniques. rGO-Ag showed significant toxicity towards both ovarian cancer cells and OvCSCs.  After 3 wk of incubating OvCSCs with rGO-Ag, the no. of A2780 and ALDH+CD133+ colonies was significantly reduced. rGO-Ag was toxic to OvCSCs and reduced cell viability by mediating the generation of reactive oxygen species, leakage of lactate dehydrogenase, reduced mitochondrial membrane potential, and enhanced expression of apoptotic genes, leading to mitochondrial dysfunction and possibly triggering apoptosis. rGO-Ag showed significant cytotoxic potential towards highly tumorigenic ALDH+CD133+ cells.  The combination of rGO-Ag and salinomycin induced 5-fold higher levels of apoptosis than each treatment alone.  A combination of rGO-Ag and salinomycin at very low concns. may be suitable for selectively killing OvCSCs and sensitizing tumor cells. rGO-Ag may be a novel nano-therapeutic mol. for specific targeting of highly tumorigenic ALDH+CD133+ cells and eliminating CSCs.  This study highlights the potential for targeted therapy of tumor-initiating cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp77IFc9AfuqbVg90H21EOLACvtfcHk0liX91LiLMpL3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVOntbfL&md5=07fa5ee26a47cdc0f201b27679658f78</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.3390%2Fijms19030710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19030710%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DGurunathan%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26atitle%3DGraphene%2520oxide-silver%2520nanocomposite%2520enhances%2520cytotoxic%2520and%2520apoptotic%2520potential%2520of%2520salinomycin%2520in%2520human%2520ovarian%2520cancer%2520stem%2520cells%2520%2528OvCSCs%2529%253A%2520a%2520novel%2520approach%2520for%2520cancer%2520therapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D710%26doi%3D10.3390%2Fijms19030710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishiguro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Tuffin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, T.</span></span> <span> </span><span class="NLM_article-title">Targeting liver cancer stem cells using engineered biological nanoparticles for the treatment of hepatocellular cancer</span>. <i>Hepatol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1002/hep4.1462</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fhep4.1462" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32025612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOmtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2020&pages=298-313&author=K.+Ishiguroauthor=I.+K.+Yanauthor=L.+Lewis-Tuffinauthor=T.+Patel&title=Targeting+liver+cancer+stem+cells+using+engineered+biological+nanoparticles+for+the+treatment+of+hepatocellular+cancer&doi=10.1002%2Fhep4.1462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Liver Cancer Stem Cells Using Engineered Biological Nanoparticles for the Treatment of Hepatocellular Cancer</span></div><div class="casAuthors">Ishiguro, Kaori; Yan, Irene K.; Lewis-Tuffin, Laura; Patel, Tushar</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">298-313</span>CODEN:
                <span class="NLM_cas:coden">HCEOAJ</span>;
        ISSN:<span class="NLM_cas:issn">2471-254X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">By exploiting their biol. functions, the use of biol. nanoparticles such as extracellular vesicles can provide an efficient and effective approach for hepatic delivery of RNA-based therapeutics for the treatment of liver cancers such as hepatocellular cancer (HCC).  Targeting liver cancer stem cells (LCSC) within HCC provide an untapped opportunity to improve outcomes by enhancing therapeutic responses.  Cells with tumor-initiating capabilities such as LCSC can be identified by expression of markers such as epithelial cell adhesion mol. (EpCAM) on their cell surface.  EpCAM is a target of Wnt/β-catenin signaling, a fundamental pathway in stem-cell growth.  Moreover, mutations in the β-catenin gene are frequently obsd. in HCC and can be assocd. with constitutive activation of the Wnt/β-catenin pathway.  However, targeting these pathways for the treatment of HCC has been challenging.  Using RNA nanotechnol., we developed engineered biol. nanoparticles capable of specific and effective delivery of RNA therapeutics targeting β-catenin to LCSC.  Extracellular vesicles isolated from milk were loaded with small interfering RNA to β-catenin and decorated with RNA scaffolds to incorporate RNA aptamers capable of binding to EpCAM.  Cellular uptake of these EpCAM-targeting therapeutic milk-derived nanovesicles in vitro resulted in loss of β-catenin expression and decreased proliferation.  The uptake and therapeutic efficacy of these engineered biol. nanotherapeutics was demonstrated in vivo using tumor xenograft mouse models.  Conclusion: β-catenin can be targeted directly to control the proliferation of hepatic cancer stem cells using small interfering RNA delivered using target-specific biol. nanoparticles.  Application of this RNA nanotechnol.-based approach to engineer biol. nanotherapeutics provides a platform for developing cell-surface mol.-directed targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodTXzFrjo-47Vg90H21EOLACvtfcHk0lhs1MehBIJAbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOmtrk%253D&md5=1dd6571dd99c05cf573f255cd55adcf9</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1002%2Fhep4.1462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep4.1462%26sid%3Dliteratum%253Aachs%26aulast%3DIshiguro%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DI.%2BK.%26aulast%3DLewis-Tuffin%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DT.%26atitle%3DTargeting%2520liver%2520cancer%2520stem%2520cells%2520using%2520engineered%2520biological%2520nanoparticles%2520for%2520the%2520treatment%2520of%2520hepatocellular%2520cancer%26jtitle%3DHepatol.%2520Commun.%26date%3D2020%26volume%3D4%26spage%3D298%26epage%3D313%26doi%3D10.1002%2Fhep4.1462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2018.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.biomaterials.2018.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30352320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKit7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2019&pages=160-172&author=Y.+Liauthor=Y.+Xiaoauthor=H.+P.+Linauthor=D.+Reichelauthor=Y.+Baeauthor=E.+Y.+Leeauthor=Y.+Jiangauthor=X.+Huangauthor=C.+Yangauthor=Z.+Wang&title=In+vivo+%CE%B2-catenin+attenuation+by+the+integrin+%CE%B15-targeting+nano-delivery+strategy+suppresses+triple+negative+breast+cancer+stemness+and+metastasis&doi=10.1016%2Fj.biomaterials.2018.10.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis</span></div><div class="casAuthors">Li, Yunfei; Xiao, Yajuan; Lin, Hsuan-Pei; Reichel, Derek; Bae, Younsoo; Lee, Eun Y.; Jiang, Yiguo; Huang, Xuefei; Yang, Chengfeng; Wang, Zhishan</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">160-172</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) play pivotal roles in cancer metastasis, and strategies targeting cancer stemness may greatly reduce cancer metastasis and improve patients' survival.  The canonical Wnt/β-catenin pathway plays crit. roles in CSC generation and maintenance as well as in normal stem cells.  Non-specifically suppressing the Wnt/β-catenin pathway for cancer therapy could be deleterious to normal cells.  To achieve specific β-catenin attenuation in cancer cells, we report an integrin α5 (ITGA5)-targeting nanoparticle for treating metastatic triple neg. breast cancer (TNBC).  We found that ITGA5 is highly expressed in strongly migratory and invasive TNBC cells as well as their lung metastatic foci, which rationalizes active-targeted drug delivery to TNBC cells via ITGA5 ligands such as a commercialized ligand-RGD motif (Arg-Gly-Asp).  We modified lipid-polymer hybrid (LPH) nanoparticle for TNBC-targeted delivery of diacidic norcantharidin (NCTD), a potent anti-cancer compd. but with short half-life.  Notably, in vivo imaging anal. showed that RGD-decorated LPH (RGD-LPH) accumulated more significantly and remained much longer than LPH in nude mouse orthotopic mammary TNBC tumor and lung metastatic tumor, which implicated the feasibility of ITGA5-targeting strategy for treating metastatic TNBC.  Moreover, systemic administration of NCTD-loaded RGD-LPH (RGD-LPH-NCTD) reduced nude mouse orthotopic mammary TNBC tumor growth and metastasis more effectively than free NCTD and LPH-NCTD via down-regulating β-catenin.  These findings suggest that ITGA5-targeting nanoparticles may provide a facil and unique strategy of specially attenuating β-catenin in vivo for treating metastatic TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmm_3Z5FgrWLVg90H21EOLACvtfcHk0lhs1MehBIJAbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKit7rF&md5=5fd2f078c8174df34178e485b850ae38</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2018.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2018.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DH.%2BP.%26aulast%3DReichel%26aufirst%3DD.%26aulast%3DBae%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DE.%2BY.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DIn%2520vivo%2520%25CE%25B2-catenin%2520attenuation%2520by%2520the%2520integrin%2520%25CE%25B15-targeting%2520nano-delivery%2520strategy%2520suppresses%2520triple%2520negative%2520breast%2520cancer%2520stemness%2520and%2520metastasis%26jtitle%3DBiomaterials%26date%3D2019%26volume%3D188%26spage%3D160%26epage%3D172%26doi%3D10.1016%2Fj.biomaterials.2018.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span> <span> </span><span class="NLM_article-title">Red-emissive carbon quantum dots for nuclear drug delivery in cancer stem cells</span>. <i>J. Phys. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4345</span>, <span class="refDoi"> DOI: 10.1021/acs.jpclett.0c01408</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jpclett.0c01408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsV2qu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=4345&author=W.+Suauthor=R.+Guoauthor=F.+Yuanauthor=Y.+Liauthor=X.+Liauthor=Y.+Zhangauthor=S.+Zhouauthor=L.+Fan&title=Red-emissive+carbon+quantum+dots+for+nuclear+drug+delivery+in+cancer+stem+cells&doi=10.1021%2Facs.jpclett.0c01408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Correction to "Red-Emissive Carbon Quantum Dots for Nuclear Drug Delivery in Cancer Stem Cells"</span></div><div class="casAuthors">Su, Wen; Guo, Ruihua; Yuan, Fanglong; Li, Yunchao; Li, Xiaohong; Zhang, Yang; Zhou, Shixin; Fan, Louzhen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4345</span>CODEN:
                <span class="NLM_cas:coden">JPCLCD</span>;
        ISSN:<span class="NLM_cas:issn">1948-7185</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf6wvmpqXdxLVg90H21EOLACvtfcHk0lhs1MehBIJAbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsV2qu7c%253D&md5=a569ba6ece2848da615499a5fbf0915a</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Facs.jpclett.0c01408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jpclett.0c01408%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DL.%26atitle%3DRed-emissive%2520carbon%2520quantum%2520dots%2520for%2520nuclear%2520drug%2520delivery%2520in%2520cancer%2520stem%2520cells%26jtitle%3DJ.%2520Phys.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D4345%26doi%3D10.1021%2Facs.jpclett.0c01408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hembram, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bindhani, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, C. N.</span></span> <span> </span><span class="NLM_article-title">Quinacrine based gold hybrid nanoparticles caused apoptosis through modulating replication fork in oral cancer stem cells</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2463</span>– <span class="NLM_lpage">2472</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.0c00197</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.0c00197" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpt1Orsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=2463-2472&author=K.+C.+Hembramauthor=S.+R.+Dashauthor=B.+Dasauthor=C.+Sethyauthor=S.+Chatterjeeauthor=B.+K.+Bindhaniauthor=C.+N.+Kundu&title=Quinacrine+based+gold+hybrid+nanoparticles+caused+apoptosis+through+modulating+replication+fork+in+oral+cancer+stem+cells&doi=10.1021%2Facs.molpharmaceut.0c00197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Quinacrine Based Gold Hybrid Nanoparticles Caused Apoptosis through Modulating Replication Fork in Oral Cancer Stem Cells</span></div><div class="casAuthors">Hembram, Krushna Chandra; Dash, Somya Ranjan; Das, Biswajit; Sethy, Chinmayee; Chatterjee, Subhajit; Bindhani, Birendra Kumar; Kundu, Chanakya Nath</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2463-2472</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The presence of cancer stem cells (CSCs) in the tumor microenvironment is responsible for the development of chemoresistance and recurrence of cancer.  Our previous investigation revealed the anticancer mechanism of quinacrine-based silver and gold hybrid nanoparticles (QAgNP and QAuNP) in oral cancer cells, but to avoid cancer recurrence, it is important to study the effect of these nanoparticles (NPs) on CSCs.  Here, we developed an in vitro CSCs model using SCC-9 oral cancer cells and validated via FACS anal.  Then, 40-60% of cells were found to be CD44+/CD133+ and CD24-.  QAuNP showed excellent anti-CSC growth potential against SCC-9-cancer stem like cells (IC50 = 0.4μg/mL) with the down-regulation of representative CSC markers.  Prolonged exposure of QAuNP induced the S-phase arrest and caused re-replication shown by the extended G2/M population and apoptosis to SCC-9-CSC like cells.  Up-regulation of BAX, PARP cleavage, and simultaneous down-regulation of Bcl-xL in prolonged treatment to CSCs suggested that the majority of the cells have undergone apoptosis.  QAuNP treatment also caused a loss in DNA repair in CSCs.  Mostly, the base excision repair (BER) components (Fen-1, DNA ligase-1, Pol-β, RPA, etc.) were significantly down-regulated after QAuNP treatment, which suggested its action against DNA repair machinery.  The replication fork maintenance-related proteins, RAD 51 and BRCA-2, were also deregulated.  Very surprisingly, depletion of WRN (an interacting partner for Pre-RC and Fen-1) and a significant increase in expression of fork-degrading nuclease MRE-11 in 96 h treated NPs were obsd.  Results suggest QAuNP treatment caused excessive DNA damage and re-replication mediated replication stress (RS) and stalling of the replication fork.  Inhibition of BER components hinders the flap clearance activity of Fen-1, and it further caused RS and stopped DNA synthesis.  Overall, QAuNP treatment led to irreparable replication fork movement, and the stalled replication fork might have degraded by MRE-11, which ultimately results in apoptosis and the death of the CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2eD8S3ni3_bVg90H21EOLACvtfcHk0ljs6iuiQQud8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpt1Orsb8%253D&md5=26861c1bc25366f91ad386b3b3753c07</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.0c00197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.0c00197%26sid%3Dliteratum%253Aachs%26aulast%3DHembram%26aufirst%3DK.%2BC.%26aulast%3DDash%26aufirst%3DS.%2BR.%26aulast%3DDas%26aufirst%3DB.%26aulast%3DSethy%26aufirst%3DC.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DBindhani%26aufirst%3DB.%2BK.%26aulast%3DKundu%26aufirst%3DC.%2BN.%26atitle%3DQuinacrine%2520based%2520gold%2520hybrid%2520nanoparticles%2520caused%2520apoptosis%2520through%2520modulating%2520replication%2520fork%2520in%2520oral%2520cancer%2520stem%2520cells%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2020%26volume%3D17%26spage%3D2463%26epage%3D2472%26doi%3D10.1021%2Facs.molpharmaceut.0c00197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b','cit21c'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56a','cit56b'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60a','cit60b'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85a','cit85b'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102a','cit102b'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130a','cit130b'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160a','cit160b'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169a','cit169b'],'ref170':['cit170a','cit170b','cit170c'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Distribution of number of articles in PubMed on “Cancer Stem Cells” (1983–2021).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cell division fate of CSCs: (a) asymmetric division, (b) symmetric division, and (c) symmetric differentiation. Adapted from ref <a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a>. Copyright 2016 G. Lee et al.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Structurally Diverse CSC Inhibitors under Various Phases of Discovery and Development</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Phase 3.</p><p><span class="fn-label"><sup>b</sup></span>Phase 2.</p><p><span class="fn-label"><sup>c</sup></span>Preclinical.</p><p class="last"><span class="fn-label"><sup>d</sup></span>Biological testing.</p></p></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Major signaling pathways in CSCs and representative therapeutics targeting them.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Molecular Structures of Additional Clinical Candidates or Drugs Discussed in Recent Reports<a onclick="showRef(event, 'ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47 ref48">(39−48)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Phase 1.</p><p><span class="fn-label"><sup>b</sup></span>Phase 2.</p><p class="last"><span class="fn-label"><sup>c</sup></span>Phase 1/2.</p></p></figure><figure data-id="cht3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Chart 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 3. Molecular Structures of CSC Inhibitory Phytochemicals</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=cht3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Curcumin.</p><p><span class="fn-label"><sup>b</sup></span>Epigallocatechin gallate.</p><p><span class="fn-label"><sup>c</sup></span>Sulforaphane.</p><p><span class="fn-label"><sup>d</sup></span>Resveratrol.</p><p><span class="fn-label"><sup>e</sup></span>Genistein.</p><p><span class="fn-label"><sup>f</sup></span>Pterostilbene.</p><p><span class="fn-label"><sup>g</sup></span>Berberine.</p><p><span class="fn-label"><sup>h</sup></span>Quercetin.</p><p><span class="fn-label"><sup>i</sup></span>Ellagic acid.</p><p><span class="fn-label"><sup>j</sup></span>Koenimbine.</p><p><span class="fn-label"><sup>k</sup></span>Isonapabucasin (synthetic regioisomer of napabucasin).</p><p><span class="fn-label"><sup>l</sup></span>Garcinol.</p><p class="last"><span class="fn-label"><sup>m</sup></span>Isogarcinol.</p></p></figure><figure data-id="cht4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Chart 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 4. Napabucasin (<b>1</b>) Prodrugs Currently in the “Biological Testing” Phase</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=cht4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Chart 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 5. Molecular Structures of Drug Repurposing Candidates as CSC Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=cht5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Lovastatin.</p><p><span class="fn-label"><sup>b</sup></span>Phenformin.</p><p><span class="fn-label"><sup>c</sup></span>Menadione.</p><p><span class="fn-label"><sup>d</sup></span>Selegiline.</p><p><span class="fn-label"><sup>e</sup></span>Thioridazine.</p><p><span class="fn-label"><sup>f</sup></span>Sulfasalazine.</p><p><span class="fn-label"><sup>g</sup></span>Aurinafin.</p><p><span class="fn-label"><sup>h</sup></span>Celecoxib.</p><p class="last"><span class="fn-label"><sup>i</sup></span>Omeprazole.</p></p></figure><figure data-id="cht6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Chart 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 6. Dasatinib Analogs Currently in the “Biological Testing” Phase</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=cht6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Dasatinib.</p></p></figure><figure data-id="cht7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Chart 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 7. Representative CSC Inhibitors Reported in the Literature</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=cht7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/medium/jm0c01336_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0011.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Word cloud representing the contents of the Perspective.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01336/20201218/images/large/jm0c01336_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01336&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52650" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52650" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 186 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brower, V.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cell hypothesis evolves with emerging research</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>, <span class="NLM_elocation-id">djw139</span> <span class="refDoi"> DOI: 10.1093/jnci/djw139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1093%2Fjnci%2Fdjw139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=27130920" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&author=V.+Brower&title=Cancer+stem+cell+hypothesis+evolves+with+emerging+research&doi=10.1093%2Fjnci%2Fdjw139"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjw139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjw139%26sid%3Dliteratum%253Aachs%26aulast%3DBrower%26aufirst%3DV.%26atitle%3DCancer%2520stem%2520cell%2520hypothesis%2520evolves%2520with%2520emerging%2520research%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2016%26volume%3D108%26doi%3D10.1093%2Fjnci%2Fdjw139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartram, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeschke, J. M.</span></span> <span> </span><span class="NLM_article-title">Do cancer stem cells exist? a pilot study combining a systematic review with the hierarchy-of-hypotheses approach</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e0225898</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0225898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1371%2Fjournal.pone.0225898" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31834886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitV2ksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&author=I.+Bartramauthor=J.+M.+Jeschke&title=Do+cancer+stem+cells+exist%3F+a+pilot+study+combining+a+systematic+review+with+the+hierarchy-of-hypotheses+approach&doi=10.1371%2Fjournal.pone.0225898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Do cancer stem cells exist? A pilot study combining a systematic review with the hierarchy-of-hypotheses approach</span></div><div class="casAuthors">Bartram, Isabelle; Jeschke, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e0225898</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">A review.  The phenomenon of cancer cell heterogeneity has been explained by different hypotheses, each entailing different therapy strategies.  The most recent is the cancer stem cell model, which says that tumorigenicity and self-renewal are restricted to rare stem cell-like cancer cells.  Since its conception, conflicting evidence has been published.  In this study, we tested the applicability of a new approach developed in the field of ecol., the hierarchy-of-hypotheses approach, for the Cancer Stem Cell hypothesis.  This approach allows to structure a broad concept into more specific sub-hypotheses, which in turn can be connected to available empirical studies.  To generate a dataset with empirical studies, we conducted a systematic literature review in the Web of Science limited to the first 1000 publications returned by the search.  From this pool, 51 publications were identified that tested whether a cell sub-population had cancer stem cell properties.  By classifying the studies according to: (1) assessed indicators, (2) exptl. assays and (3) model cancer cells used, we built a hierarchical structure of sub-hypotheses.  The empirical tests from the selected studies were subsequently assigned to this hierarchy of hypotheses, and the percentage of supporting, undecided and questioning evidence was calcd. for each sub-hypothesis, as well as addnl. exptl. characteristics.  Our approach successfully allowed us to det. that within our dataset, the empirical support for the CSC hypothesis was only 49.0%.  The support of different sub-hypotheses was highly variable.  Most noticeable, the conception that putative cancer stem cells are a rare subset of cells could not be confirmed by most studies (13.5% support).  The empirical support varied also between types of cancer, animal models and cell isolation method used.  For the first time, this study showed the applicability of the hierarchy-of-hypotheses approach for synthesizing and evaluating empirical evidence for a broad hypothesis in the field of bio-medical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Eyzx9U1fSrVg90H21EOLACvtfcHk0li_AWtdxwfF9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitV2ksL0%253D&md5=ce37534e2883a2ec2dbdd32fafd31a4e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0225898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0225898%26sid%3Dliteratum%253Aachs%26aulast%3DBartram%26aufirst%3DI.%26aulast%3DJeschke%26aufirst%3DJ.%2BM.%26atitle%3DDo%2520cancer%2520stem%2520cells%2520exist%253F%2520a%2520pilot%2520study%2520combining%2520a%2520systematic%2520review%2520with%2520the%2520hierarchy-of-hypotheses%2520approach%26jtitle%3DPLoS%2520One%26date%3D2019%26volume%3D14%26doi%3D10.1371%2Fjournal.pone.0225898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">NCBI Resource Coordinators</span> <span> </span><span class="NLM_article-title">Database resources of the National
Center for Biotechnology Information</span>. <i>Nucleic
Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">D8</span>– <span class="NLM_lpage">D13</span>, <span class="refDoi"> DOI: 10.1093/nar/gkx1095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1093%2Fnar%2Fgkx1095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29140470" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=D8-D13&author=NCBI+Resource+Coordinators&title=Database+resources+of+the+National%0ACenter+for+Biotechnology+Information&doi=10.1093%2Fnar%2Fgkx1095"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkx1095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkx1095%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DDatabase%2520resources%2520of%2520the%2520National%250ACenter%2520for%2520Biotechnology%2520Information%26jtitle%3DNucleic%250AAcids%2520Res.%26date%3D2018%26volume%3D46%26spage%3DD8%26epage%3DD13%26doi%3D10.1093%2Fnar%2Fgkx1095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span> <i>SciFinder</i>, version
2020; <span class="NLM_publisher-name">Chemical Abstracts Service (CAS)</span>: <span class="NLM_publisher-loc">Columbus, OH</span>, <span class="NLM_year">2020</span> (accessed
2020-10-19).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+SciFinder%2C+version%0A2020%3B+Chemical+Abstracts+Service+%28CAS%29%3A+Columbus%2C+OH%2C+2020+%28accessed%0A2020-10-19%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DSciFinder%26pub%3DChemical%2520Abstracts%2520Service%2520%2528CAS%2529%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plaks, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span> <span> </span><span class="NLM_article-title">The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?</span>. <i>Cell Stem Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1016/j.stem.2015.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.stem.2015.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=25748930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtlGjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=225-238&author=V.+Plaksauthor=N.+Kongauthor=Z.+Werb&title=The+cancer+stem+cell+niche%3A+how+essential+is+the+niche+in+regulating+stemness+of+tumor+cells%3F&doi=10.1016%2Fj.stem.2015.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?</span></div><div class="casAuthors">Plaks, Vicki; Kong, Niwen; Werb, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Cell Stem Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-238</span>CODEN:
                <span class="NLM_cas:coden">CSCEC4</span>;
        ISSN:<span class="NLM_cas:issn">1875-9777</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Cancer stem cells (CSCs) are tumor cells that have the principal properties of self-renewal, clonal tumor initiation capacity, and clonal long-term repopulation potential.  CSCs reside in niches, which are anatomically distinct regions within the tumor microenvironment.  These niches maintain the principle properties of CSCs, preserve their phenotypic plasticity, protect them from the immune system, and facilitate their metastatic potential.  In this perspective, we focus on the CSC niche and discuss its contribution to tumor initiation and progression.  Since CSCs survive many commonly employed cancer therapies, we examine the prospects of targeting the niche components as preferable therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbJz89_n-_IbVg90H21EOLACvtfcHk0li_AWtdxwfF9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtlGjsr0%253D&md5=88070b21b2922fc2f726d5979462443f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.stem.2015.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.stem.2015.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DPlaks%26aufirst%3DV.%26aulast%3DKong%26aufirst%3DN.%26aulast%3DWerb%26aufirst%3DZ.%26atitle%3DThe%2520cancer%2520stem%2520cell%2520niche%253A%2520how%2520essential%2520is%2520the%2520niche%2520in%2520regulating%2520stemness%2520of%2520tumor%2520cells%253F%26jtitle%3DCell%2520Stem%2520Cell%26date%3D2015%26volume%3D16%26spage%3D225%26epage%3D238%26doi%3D10.1016%2Fj.stem.2015.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayob, A. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramasamy, T. S.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells as key drivers of tumour progression</span>. <i>J. Biomed. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">20</span>, <span class="refDoi"> DOI: 10.1186/s12929-018-0426-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2Fs12929-018-0426-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29506506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Sku7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=20&author=A.+Z.+Ayobauthor=T.+S.+Ramasamy&title=Cancer+stem+cells+as+key+drivers+of+tumour+progression&doi=10.1186%2Fs12929-018-0426-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells as key drivers of tumour progression</span></div><div class="casAuthors">Ayob, Ain Zubaidah; Ramasamy, Thamil Selvee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomedical Science (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20/1-20/18</span>CODEN:
                <span class="NLM_cas:coden">JBCIEA</span>;
        ISSN:<span class="NLM_cas:issn">1423-0127</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background:Cancer stem cells (CSCs) are subpopulations of cancer cells sharing similar characteristics as normal stem or progenitor cells such as self-renewal ability and multi-lineage differentiation to drive tumor growth and heterogeneity.  Throughout the cancer progression, CSC can further be induced from differentiated cancer cells via the adaptation and cross-talks with the tumor microenvironment as well as a response from therapeutic pressures, therefore contributes to their heterogeneous phenotypes.  Challengingly, conventional cancer treatments target the bulk of the tumor and are unable to target CSCs due to their highly resistance nature, leading to metastasis and tumor recurrence.  Main body: This review highlights the roles of CSCs in tumor initiation, progression and metastasis with a focus on the cellular and mol. regulators that influence their phenotypical changes and behaviors in the different stages of cancer progression.  We delineate the cross-talks between CSCs with the tumor microenvironment that support their intrinsic properties including survival, stemness, quiescence and their cellular and mol. adaptation in response to therapeutic pressure.  An insight into the distinct roles of CSCs in promoting angiogenesis and metastasis has been captured based on in vitro and in vivo evidences.  Conclusion: Given dynamic cellular events along the cancer progression and contributions of resistance nature by CSCs, understanding their mol. and cellular regulatory mechanism in a heterogeneous nature, provides significant cornerstone for the development of CSC-specific therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3nTnY6lOWyLVg90H21EOLACvtfcHk0lgYltulSmQhyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Sku7zL&md5=a4700e44e5f5cb9be8de6d03c823ad75</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1186%2Fs12929-018-0426-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12929-018-0426-4%26sid%3Dliteratum%253Aachs%26aulast%3DAyob%26aufirst%3DA.%2BZ.%26aulast%3DRamasamy%26aufirst%3DT.%2BS.%26atitle%3DCancer%2520stem%2520cells%2520as%2520key%2520drivers%2520of%2520tumour%2520progression%26jtitle%3DJ.%2520Biomed.%2520Sci.%26date%3D2018%26volume%3D25%26spage%3D20%26doi%3D10.1186%2Fs12929-018-0426-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, R. R.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, A. U.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells: cellular plasticity, niche, and its clinical relevance</span>. <i>J. Stem Cell Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">363</span>, <span class="refDoi"> DOI: 10.4172/2157-7633.1000363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.4172%2F2157-7633.1000363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=27891292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOlt7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=363&author=G.+Leeauthor=R.+R.+Hallauthor=A.+U.+Ahmed&title=Cancer+stem+cells%3A+cellular+plasticity%2C+niche%2C+and+its+clinical+relevance&doi=10.4172%2F2157-7633.1000363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells: cellular plasticity, niche, and its clinical relevance</span></div><div class="casAuthors">Lee, Gina; Hall, Robert R., III; Ahmed, Atique U.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Stem Cell Research & Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">363/1-363/9</span>CODEN:
                <span class="NLM_cas:coden">JSCRCI</span>;
        ISSN:<span class="NLM_cas:issn">2157-7633</span>.
    
            (<span class="NLM_cas:orgname">OMICS International</span>)
        </div><div class="casAbstract">Cancer handles an estd. 7.6 million deaths worldwide per annum.  A recent theory focuses on the role Cancer Stem Cells (CSCs) in driving tumorigenesis and disease progression.  This theory hypothesizes that a population of the tumor cell with similar functional and phenotypic characteristics as normal tissue stem cells are responsible for formation and advancement of many human cancers.  The CSCs subpopulation can differentiate into non-CSC tumor cells and promote phenotypic and functional heterogeneity within the tumor.  The presence of CSCs has been reported in a no. of human cancers including blood, breast, brain, colon, lung, pancreas prostate and liver.  Although the origin of CSCs remains a mystery, recent reports suggest that the phenotypic characteristics of CSCs may be plastic and are influenced by the microenvironment specific for the individual tumor.  Such factors unique to each tumor preserve the dynamic balance between CSCs to non-CSCs cell fate, as well as maintain the proper equil.  Alternating such equil. via dedifferentiation can result in aggressiveness, as CSCs are considered to be more resistant to the conventional cancer treatments of chemotherapy and radiation.  Understanding how the tumoral microenvironment affects the plasticity driven CSC niche will be crit. for developing a more effective treatment for cancer by eliminating its aggressive and recurring nature that now is believed to be perpetuated by CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEyyC8Qu2kmLVg90H21EOLACvtfcHk0lgYltulSmQhyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOlt7vL&md5=404451733e2940c236e8c93d4a2e37e0</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.4172%2F2157-7633.1000363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2157-7633.1000363%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DG.%26aulast%3DHall%26aufirst%3DR.%2BR.%26aulast%3DAhmed%26aufirst%3DA.%2BU.%26atitle%3DCancer%2520stem%2520cells%253A%2520cellular%2520plasticity%252C%2520niche%252C%2520and%2520its%2520clinical%2520relevance%26jtitle%3DJ.%2520Stem%2520Cell%2520Res.%2520Ther.%26date%3D2016%26volume%3D6%26spage%3D363%26doi%3D10.4172%2F2157-7633.1000363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lytle, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reya, T.</span></span> <span> </span><span class="NLM_article-title">Stem cell fate in cancer growth, progression and therapy resistance</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.1038/s41568-018-0056-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fs41568-018-0056-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30228301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCju77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=669-680&author=N.+K.+Lytleauthor=A.+G.+Barberauthor=T.+Reya&title=Stem+cell+fate+in+cancer+growth%2C+progression+and+therapy+resistance&doi=10.1038%2Fs41568-018-0056-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Stem cell fate in cancer growth, progression and therapy resistance</span></div><div class="casAuthors">Lytle, Nikki K.; Barber, Alison G.; Reya, Tannishtha</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">669-680</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Although we have come a long way in our understanding of the signals that drive cancer growth, and how these signals can be targeted, effective control of this disease remains a key scientific and medical challenge.  The therapy resistance and relapse that are commonly seen are driven in large part by the inherent heterogeneity within cancers that allows drugs to effectively eliminate some, but not all, malignant cells.  Here, we focus on the fundamental drivers of this heterogeneity by examg. emerging evidence that shows that these traits are often controlled by the disruption of normal cell fate and aberrant adoption of stem cell signals.  We discuss how undifferentiated cells are preferentially primed for transformation and often serve as the cell of origin for cancers.  We also consider evidence showing that activation of stem cell programs in cancers can lead to progression, therapy resistance and metastatic growth and that targeting these attributes may enable better control over a difficult disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS1xbXhKze1LVg90H21EOLACvtfcHk0lgYltulSmQhyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslCju77O&md5=d3b2025797d58c408ed5d8862b07622e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fs41568-018-0056-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-018-0056-x%26sid%3Dliteratum%253Aachs%26aulast%3DLytle%26aufirst%3DN.%2BK.%26aulast%3DBarber%26aufirst%3DA.%2BG.%26aulast%3DReya%26aufirst%3DT.%26atitle%3DStem%2520cell%2520fate%2520in%2520cancer%2520growth%252C%2520progression%2520and%2520therapy%2520resistance%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2018%26volume%3D18%26spage%3D669%26epage%3D680%26doi%3D10.1038%2Fs41568-018-0056-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamil, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, K. M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asaduzzaman, S. M.</span></span> <span> </span><span class="NLM_article-title">Stem cell and cancer stem cell: a tale of two cells</span>. <i>Progr. Stem Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.15419/psc.v3i02.124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.15419%2Fpsc.v3i02.124" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=97-108&author=M.+Rahmanauthor=H.+M.+Jamilauthor=N.+Akhtarauthor=K.+M.+T.+Rahmanauthor=R.+Islamauthor=S.+M.+Asaduzzaman&title=Stem+cell+and+cancer+stem+cell%3A+a+tale+of+two+cells&doi=10.15419%2Fpsc.v3i02.124"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.15419%2Fpsc.v3i02.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15419%252Fpsc.v3i02.124%26sid%3Dliteratum%253Aachs%26aulast%3DRahman%26aufirst%3DM.%26aulast%3DJamil%26aufirst%3DH.%2BM.%26aulast%3DAkhtar%26aufirst%3DN.%26aulast%3DRahman%26aufirst%3DK.%2BM.%2BT.%26aulast%3DIslam%26aufirst%3DR.%26aulast%3DAsaduzzaman%26aufirst%3DS.%2BM.%26atitle%3DStem%2520cell%2520and%2520cancer%2520stem%2520cell%253A%2520a%2520tale%2520of%2520two%2520cells%26jtitle%3DProgr.%2520Stem%2520Cell%26date%3D2016%26volume%3D3%26spage%3D97%26epage%3D108%26doi%3D10.15419%2Fpsc.v3i02.124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunting, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colapietro, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagutina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosveld, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakauchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, B. P.</span></span> <span> </span><span class="NLM_article-title">The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1028</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1038/nm0901-1028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fnm0901-1028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=11533706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmvFOlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1028-1034&author=S.+Zhouauthor=J.+D.+Schuetzauthor=K.+D.+Buntingauthor=A.+M.+Colapietroauthor=J.+Sampathauthor=J.+J.+Morrisauthor=I.+Lagutinaauthor=G.+C.+Grosveldauthor=M.+Osawaauthor=H.+Nakauchiauthor=B.+P.+Sorrentino&title=The+ABC+transporter+Bcrp1%2FABCG2+is+expressed+in+a+wide+variety+of+stem+cells+and+is+a+molecular+determinant+of+the+side-population+phenotype&doi=10.1038%2Fnm0901-1028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype</span></div><div class="casAuthors">Zhou, Sheng; Schuetz, John D.; Bunting, Kevin D.; Colapietro, Anne-Marie; Sampath, Janardhan; Morris, John J.; Lagutina, Irina; Grosveld, Gerard C.; Osawa, Mitsujiro; Nakauchi, Hiromitsu; Sorrentino, Brian P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1028-1034</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Stem cells from bone marrow, skeletal muscle and possibly other tissues can be identified by the 'side-population' (SP) phenotype.  Although it has been assumed that expression of ABC transporters is responsible for this phenotype, the specific mols. involved have not been defined.  Here we show that expression of the Bcrp1 (also known as Abcg2 murine/ABCG2 human) gene is a conserved feature of stem cells from a wide variety of sources.  Bcrp1 mRNA was expressed at high levels in primitive murine hematopoietic stem cells, and was sharply down regulated with differentiation.  Enforced expression of the ABCG2 cDNA directly conferred the SP phenotype to bone-marrow cells and caused a redn. in maturing progeny both in vitro and in transplantation-based assays.  These results show that expression of the Bcrp1/ABCG2 gene is an important determinant of the SP phenotype, and that it might serve as a marker for stem cells from various sources.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIKAccL-V8ibVg90H21EOLACvtfcHk0ljLf36iyHkAtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmvFOlsrk%253D&md5=3de78747ac288655cc31201553310056</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnm0901-1028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0901-1028%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DSchuetz%26aufirst%3DJ.%2BD.%26aulast%3DBunting%26aufirst%3DK.%2BD.%26aulast%3DColapietro%26aufirst%3DA.%2BM.%26aulast%3DSampath%26aufirst%3DJ.%26aulast%3DMorris%26aufirst%3DJ.%2BJ.%26aulast%3DLagutina%26aufirst%3DI.%26aulast%3DGrosveld%26aufirst%3DG.%2BC.%26aulast%3DOsawa%26aufirst%3DM.%26aulast%3DNakauchi%26aufirst%3DH.%26aulast%3DSorrentino%26aufirst%3DB.%2BP.%26atitle%3DThe%2520ABC%2520transporter%2520Bcrp1%252FABCG2%2520is%2520expressed%2520in%2520a%2520wide%2520variety%2520of%2520stem%2520cells%2520and%2520is%2520a%2520molecular%2520determinant%2520of%2520the%2520side-population%2520phenotype%26jtitle%3DNat.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D1028%26epage%3D1034%26doi%3D10.1038%2Fnm0901-1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floc’h, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flemington, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerrecher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span> <span> </span><span class="NLM_article-title">Challenges and opportunities in cancer drug resistance</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.0c00383</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.0c00383" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=R.+A.+Wardauthor=S.+Fawellauthor=N.+Floc%E2%80%99hauthor=V.+Flemingtonauthor=D.+McKerrecherauthor=P.+D.+Smith&title=Challenges+and+opportunities+in+cancer+drug+resistance&doi=10.1021%2Facs.chemrev.0c00383"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DFloc%25E2%2580%2599h%26aufirst%3DN.%26aulast%3DFlemington%26aufirst%3DV.%26aulast%3DMcKerrecher%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DChallenges%2520and%2520opportunities%2520in%2520cancer%2520drug%2520resistance%26jtitle%3DChem.%2520Rev.%26date%3D2020%26doi%3D10.1021%2Facs.chemrev.0c00383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Begicevic, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falasca, M.</span></span> <span> </span><span class="NLM_article-title">ABC transporters in cancer stem cells: beyond chemoresistance</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2362</span>, <span class="refDoi"> DOI: 10.3390/ijms18112362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fijms18112362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOgtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=2362&author=R.+R.+Begicevicauthor=M.+Falasca&title=ABC+transporters+in+cancer+stem+cells%3A+beyond+chemoresistance&doi=10.3390%2Fijms18112362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">ABC transporters in cancer stem cells: beyond chemoresistance</span></div><div class="casAuthors">Begicevic, Romana-Rea; Falasca, Marco</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2362/1-2362/23</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The efficacy of chemotherapy is one of the main challenges in cancer treatment and one of the major obstacles to overcome in achieving lasting remission and a definitive cure in patients with cancer is the emergence of cancer resistance.  Indeed, drug resistance is ultimately accountable for poor treatment outcomes and tumor relapse.  There are various mol. mechanisms involved in multidrug resistance, such as the change in the activity of membrane transporters primarily belonging to the ATP binding cassette (ABC) transporter family.  In addn., it has been proposed that this common feature could be attributed to a subpopulation of slow-cycling cancer stem cells (CSCs), endowed with enhanced tumorigenic potential and multidrug resistance.  CSCs are characterized by the overexpression of sp. surface markers that vary in different cancer cell types.  Overexpression of ABC transporters has been reported in several cancers and more predominantly in CSCs.  While the major focus on the role played by ABC transporters in cancer is polarized by their involvement in chemoresistance, emerging evidence supports a more active role of these proteins, in which they release specific bioactive mols. in the extracellular milieu.  This review will outline our current understanding of the role played by ABC transporters in CSCs, how their expression is regulated and how they support the malignant metabolic phenotype.  To summarize, we suggest that the increased expression of ABC transporters in CSCs may have precise functional roles and provide the opportunity to target, particularly these cells, by using specific ABC transporter inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOmUDkuiM2ZbVg90H21EOLACvtfcHk0ljLf36iyHkAtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOgtb7O&md5=ed113cd4ed615f8867bfe13dcd76f146</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.3390%2Fijms18112362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18112362%26sid%3Dliteratum%253Aachs%26aulast%3DBegicevic%26aufirst%3DR.%2BR.%26aulast%3DFalasca%26aufirst%3DM.%26atitle%3DABC%2520transporters%2520in%2520cancer%2520stem%2520cells%253A%2520beyond%2520chemoresistance%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D2362%26doi%3D10.3390%2Fijms18112362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muriithi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macharia, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heming, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echevarria, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyachieo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filho, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neto, V. M.</span></span> <span> </span><span class="NLM_article-title">ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance</span>. <i>Cancer Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.20892/j.issn.2095-3941.2019.0284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.20892%2Fj.issn.2095-3941.2019.0284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32587767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlalsb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=253-269&issue=2&author=W.+Muriithiauthor=L.+W.+Machariaauthor=C.+P.+Hemingauthor=J.+L.+Echevarriaauthor=A.+Nyachieoauthor=P.+N.+Filhoauthor=V.+M.+Neto&title=ABC+transporters+and+the+hallmarks+of+cancer%3A+roles+in+cancer+aggressiveness+beyond+multidrug+resistance&doi=10.20892%2Fj.issn.2095-3941.2019.0284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance</span></div><div class="casAuthors">Muriithi, Wanjiru; Macharia, Lucy Wanjiku; Heming, Carlos Pilotto; Echevarria, Juliana Lima; Nyachieo, Atunga; Filho, Paulo Niemeyer; Neto, Vivaldo Moura</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">253-269</span>CODEN:
                <span class="NLM_cas:coden">CBMADQ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Tianjin Medical University Cancer Institute and Hospital</span>)
        </div><div class="casAbstract">The ATP-binding cassette transporters (ABC transporters) have been intensely studied over the past 50 years for their involvement in the multidrug resistance (MDR) phenotype, esp. in cancer.  They are frequently overexpressed in both naive and post-treatment tumors, and hinder effective chemotherapy by reducing drug accumulation in cancer cells.  In the last decade however, several studies have established that ABC transporters have addnl., fundamental roles in tumor biol.; there is strong evidence that these proteins are involved in transporting tumor-enhancing mols. and/or in protein-protein interactions that impact cancer aggressiveness, progression, and patient prognosis.  This review highlights these studies in relation to some well-described cancer hallmarks, in an effort to re-emphasize the need for further investigation into the physiol. functions of ABC transporters that are crit. for tumor development.  Unraveling these new roles offers an opportunity to define new strategies and targets for therapy, which would include endogenous substrates or signaling pathways that regulate these proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYzAkKELKFV7Vg90H21EOLACvtfcHk0ljGxz-qiUqxSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlalsb7N&md5=a2a337daed796df412789dd797e33e73</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.20892%2Fj.issn.2095-3941.2019.0284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.20892%252Fj.issn.2095-3941.2019.0284%26sid%3Dliteratum%253Aachs%26aulast%3DMuriithi%26aufirst%3DW.%26aulast%3DMacharia%26aufirst%3DL.%2BW.%26aulast%3DHeming%26aufirst%3DC.%2BP.%26aulast%3DEchevarria%26aufirst%3DJ.%2BL.%26aulast%3DNyachieo%26aufirst%3DA.%26aulast%3DFilho%26aufirst%3DP.%2BN.%26aulast%3DNeto%26aufirst%3DV.%2BM.%26atitle%3DABC%2520transporters%2520and%2520the%2520hallmarks%2520of%2520cancer%253A%2520roles%2520in%2520cancer%2520aggressiveness%2520beyond%2520multidrug%2520resistance%26jtitle%3DCancer%2520Biol.%2520Med.%26date%3D2020%26volume%3D17%26issue%3D2%26spage%3D253%26epage%3D269%26doi%3D10.20892%2Fj.issn.2095-3941.2019.0284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span> <span> </span><span class="NLM_article-title">Radiotherapy targeting cancer stem cells “awakens” them to induce tumour relapse and metastasis in oral cancer</span>. <i>Int. J. Oral Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">19</span>, <span class="refDoi"> DOI: 10.1038/s41368-020-00087-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fs41368-020-00087-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32576817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB38njslaktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=19&author=Y.+Liuauthor=M.+Yangauthor=J.+Luoauthor=H.+Zhou&title=Radiotherapy+targeting+cancer+stem+cells+%E2%80%9Cawakens%E2%80%9D+them+to+induce+tumour+relapse+and+metastasis+in+oral+cancer&doi=10.1038%2Fs41368-020-00087-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Radiotherapy targeting cancer stem cells "awakens" them to induce tumour relapse and metastasis in oral cancer</span></div><div class="casAuthors">Liu Yangfan; Yang Miao; Zhou Hongmei; Luo Jingjing</div><div class="citationInfo"><span class="NLM_cas:title">International journal of oral science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Radiotherapy is one of the most common treatments for oral cancer.  However, in the clinic, recurrence and metastasis of oral cancer occur after radiotherapy, and the underlying mechanism remains unclear.  Cancer stem cells (CSCs), considered the "seeds" of cancer, have been confirmed to be in a quiescent state in most established tumours, with their innate radioresistance helping them survive more easily when exposed to radiation than differentiated cancer cells.  There is increasing evidence that CSCs play an important role in recurrence and metastasis post-radiotherapy in many cancers.  However, little is known about how oral CSCs cause tumour recurrence and metastasis post-radiotherapy.  In this review article, we will first summarise methods for the identification of oral CSCs and then focus on the characteristics of a CSC subpopulation induced by radiation, hereafter referred to as "awakened" CSCs, to highlight their response to radiotherapy and potential role in tumour recurrence and metastasis post-radiotherapy as well as potential therapeutics targeting CSCs.  In addition, we explore potential therapeutic strategies targeting these "awakened" CSCs to solve the serious clinical challenges of recurrence and metastasis in oral cancer after radiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQlVED3Wn4etenUz0lpNqnfW6udTcc2ea5qJOmbRl547ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38njslaktQ%253D%253D&md5=32eb4c977bc9e164c08ae88bd36f7ddb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fs41368-020-00087-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41368-020-00087-0%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DH.%26atitle%3DRadiotherapy%2520targeting%2520cancer%2520stem%2520cells%2520%25E2%2580%259Cawakens%25E2%2580%259D%2520them%2520to%2520induce%2520tumour%2520relapse%2520and%2520metastasis%2520in%2520oral%2520cancer%26jtitle%3DInt.%2520J.%2520Oral%2520Sci.%26date%3D2020%26volume%3D12%26spage%3D19%26doi%3D10.1038%2Fs41368-020-00087-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tracey, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, M. J.</span></span> <span> </span><span class="NLM_article-title">Off to a bad start: Cancer initiation by pluripotency regulator PRDM14</span>. <i>Trends Genet.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1016/j.tig.2019.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.tig.2019.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31130394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpsVOrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2019&pages=489-500&author=L.+J.+Traceyauthor=M.+J.+Justice&title=Off+to+a+bad+start%3A+Cancer+initiation+by+pluripotency+regulator+PRDM14&doi=10.1016%2Fj.tig.2019.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Off to a Bad Start: Cancer Initiation by Pluripotency Regulator PRDM14</span></div><div class="casAuthors">Tracey, Lauren J.; Justice, Monica J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Genetics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-500</span>CODEN:
                <span class="NLM_cas:coden">TRGEE2</span>;
        ISSN:<span class="NLM_cas:issn">0168-9525</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite advances in chemotherapies that improve cancer survival, most patients who relapse succumb to the disease due to the presence of cancer stem cells (CSCs), which are highly chemoresistant.  The pluripotency factor PR domain 14 (PRDM14) has a key role in initiating many types of cancer.  Normally, PRDM14 uses epigenetic mechanisms to establish and maintain the pluripotency of embryonic cells, and its role in cancer is similar.  This important link between cancer and induced pluripotency is a key revelation for how CSCs may form: pluripotency genes, such as PRDM14, can expand stem-like cells as they promote ongoing DNA damage.  PRDM14 and its protein-binding partners, the ETO/CBFA2T family, are ideal candidates for eliminating CSCs from relevant cancers, preventing relapse and improving long-term survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcfUsY53H3MLVg90H21EOLACvtfcHk0ljGxz-qiUqxSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpsVOrsbY%253D&md5=8dbba083bc11951a651139720ccb2b78</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.tig.2019.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tig.2019.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DTracey%26aufirst%3DL.%2BJ.%26aulast%3DJustice%26aufirst%3DM.%2BJ.%26atitle%3DOff%2520to%2520a%2520bad%2520start%253A%2520Cancer%2520initiation%2520by%2520pluripotency%2520regulator%2520PRDM14%26jtitle%3DTrends%2520Genet.%26date%3D2019%26volume%3D35%26spage%3D489%26epage%3D500%26doi%3D10.1016%2Fj.tig.2019.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span> <span> </span><span class="NLM_article-title">Pluripotency transcription factors and cancer stem cells: small genes make a big difference</span>. <i>Aizheng</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.5732/cjc.012.10282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.5732%2Fcjc.012.10282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=23419197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVyitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=483-487&author=A.+Liuauthor=X.+Yuauthor=S.+Liu&title=Pluripotency+transcription+factors+and+cancer+stem+cells%3A+small+genes+make+a+big+difference&doi=10.5732%2Fcjc.012.10282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Pluripotency transcription factors and cancer stem cells: small genes make a big difference</span></div><div class="casAuthors">Liu, Anfei; Yu, Xiya; Liu, Shangrong</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">483-487</span>CODEN:
                <span class="NLM_cas:coden">CJCHDJ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Sun Yat-sen University Cancer Center</span>)
        </div><div class="casAbstract">A review.  Cancer stem cells (CSCs) are thought to drive uncontrolled tumor growth, and the existence of CSCs has recently been proven by direct exptl. evidence, including tracing cell lineages within a growing tumor.  However, CSCs must be analyzed in addnl. cancer types.  Cancer stem cell-like cells (CSCLCs) are a good alternative system for the study of CSCs, which hold great promise for clin. applications.  OCT4, NANOG and SOX2 are three basic transcription factors that are expressed in both CSCLCs and embryonic stem cells (ESCs).  These transcription factors play crit. roles in maintaining the pluripotence and self-renewal characteristics of CSCLCs and ESCs.  In this review, we discuss the aberrant expression, isoforms, and pseudogenes of OCT4, NANOG, and SOX2 in the CSCLC niche, which contribute to the major differences between CSCLCs and ESCs.  We also highlight an anticancer therapy that involves killing specific cancer cells directly by repressing the expression of OCT4, NANOG, or SOX2.  Importantly, OCT4, NANOG, and SOX2 provide great promise for clin. applications because reducing their expression or blocking the pathways in which they function may inhibit tumor growth and turn-off the cancer 'switch'.  In the future, a clear understanding of transcription actor regulation will be essential for elucidating the roles of OCT4, NANOG, and SOX2 in tumorigenesis, as well as exploring their use for diagnostic and therapeutic purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohrpR4CUtaI7Vg90H21EOLACvtfcHk0lhurBz4v3VfFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVyitbg%253D&md5=96890ecefd851117efd68bffde52e328</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.5732%2Fcjc.012.10282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5732%252Fcjc.012.10282%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26atitle%3DPluripotency%2520transcription%2520factors%2520and%2520cancer%2520stem%2520cells%253A%2520small%2520genes%2520make%2520a%2520big%2520difference%26jtitle%3DAizheng%26date%3D2013%26volume%3D32%26spage%3D483%26epage%3D487%26doi%3D10.5732%2Fcjc.012.10282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span> <span> </span><span class="NLM_article-title">Dual inhibiting OCT4 and AKT potently suppresses the propagation of human cancer cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">46246</span>, <span class="refDoi"> DOI: 10.1038/srep46246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fsrep46246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=28383051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvFyiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=46246&author=W.+Liauthor=Y.+Zhouauthor=X.+Zhangauthor=Y.+Yangauthor=S.+Danauthor=T.+Suauthor=S.+Sheauthor=W.+Dongauthor=Q.+Zhaoauthor=J.+Jiaauthor=H.+Yaoauthor=M.+Zhengauthor=B.+Kangauthor=Y.+J.+Wang&title=Dual+inhibiting+OCT4+and+AKT+potently+suppresses+the+propagation+of+human+cancer+cells&doi=10.1038%2Fsrep46246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibiting OCT4 and AKT potently suppresses the propagation of human cancer cells</span></div><div class="casAuthors">Li, Wenxin; Zhou, Yanwen; Zhang, Xiaoqian; Yang, Ying; Dan, Songsong; Su, Tong; She, Shiqi; Dong, Weilai; Zhao, Qingwei; Jia, Jia; Yao, Hangping; Zheng, Min; Kang, Bo; Wang, Ying-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46246</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">AKT serves as an epigenetic modulator that links epigenetic regulation to cell survival and proliferation while the epigenetic mediator OCT4 critically controls stem cell pluripotency and self-renewal.  Emerging evidence indicated their complicated interplays in cancer cells and cancer stem cells (CSCs), and inhibiting either one may activate the other.  Thus, in this study, we propose a strategy to targeting both factors simultaneously.  Firstly, a combination of an OCT4-specific shRNA and the specific AKT inhibitor Akti-1/2 potently suppressed the propagation of human embryonal carcinoma cells, adherent cancer cells and stem-like cancer cells, establishing the proof-of-concept that dual inhibiting OCT4 and AKT can effectively target various cancer cells.  Next, we combined Akti-1/2 with metformin, a widely-prescribed drug for treating type 2 diabetes, which was reported to down-regulate OCT4 expression.  The metformin + Akti-1/2 combo significantly altered multiple signaling and epigenetic pathways, induced growth arrest and cell death of adherent and stem-like glioblastoma U87 cells, and attenuated their tumorigenicity in vivo.  Taken together, we demonstrate here that simultaneously targeting an epigenetic mediator and an epigenetic modulator, by dual inhibiting OCT4 and AKT, can have significantly improved efficacies over single treatment in suppressing the propagation of CSCs as well as the entire bulk of differentiated cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu8VxfE5dNJbVg90H21EOLACvtfcHk0lhurBz4v3VfFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvFyiu7g%253D&md5=67aa8d55d95877f148531b416123ac36</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fsrep46246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep46246%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DDan%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DT.%26aulast%3DShe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DKang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26atitle%3DDual%2520inhibiting%2520OCT4%2520and%2520AKT%2520potently%2520suppresses%2520the%2520propagation%2520of%2520human%2520cancer%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D46246%26doi%3D10.1038%2Fsrep46246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proskurina, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremova, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taranov, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostanin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernykh, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolchanov, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogachev, S. S.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells: emergent nature of tumor emergency</span>. <i>Front. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">544</span>, <span class="refDoi"> DOI: 10.3389/fgene.2018.00544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffgene.2018.00544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30505319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVems7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=544&author=Y.+R.+Efremovauthor=A.+S.+Proskurinaauthor=E.+A.+Potterauthor=E.+V.+Dolgovaauthor=O.+V.+Efremovaauthor=O.+S.+Taranovauthor=A.+A.+Ostaninauthor=E.+R.+Chernykhauthor=N.+A.+Kolchanovauthor=S.+S.+Bogachev&title=Cancer+stem+cells%3A+emergent+nature+of+tumor+emergency&doi=10.3389%2Ffgene.2018.00544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells: emergent nature of tumor emergency</span></div><div class="casAuthors">Efremov, Yaroslav R.; Proskurina, Anastasia S.; Potter, Ekaterina A.; Dolgova, Evgenia V.; Efremova, Oksana V.; Taranov, Oleg S.; Ostanin, Aleksandr A.; Chernykh, Elena R.; Kolchanov, Nikolay A.; Bogachev, Sergey S.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Genetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">544</span>CODEN:
                <span class="NLM_cas:coden">FGREBR</span>;
        ISSN:<span class="NLM_cas:issn">1664-8021</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  A functional anal. of 167 genes overexpressed in Krebs-2 tumor initiating cells was performed.  In the first part of the study, the genes were analyzed for their belonging to one or more of the three groups, which represent the three major phenotypic manifestation of malignancy of cancer cells, namely (1) proliferative self-sufficiency, (2) invasive growth and metastasis, and (3) multiple drug resistance. 96 genes out of 167 were identified as possible contributors to at least one of these fundamental properties.  It was also found that substantial part of these genes are also known as genes responsible for formation and/or maintenance of the stemness of normal pluri-/multipotent stem cells.  These results suggest that the malignancy is simply the ability to maintain the stem cell specific genes expression profile, and, as a consequence, the stemness itself regardless of the controlling effect of stem niches.  In the second part of the study, three stress factors combined into the single concept of "generalized cellular stress," which are assumed to activate the expression of these genes, were defined.  In addn., possible mechanisms for such activation were identified.  The data obtained suggest the existence of a mechanism for the de novo formation of a pluripotent/stem phenotype in the subpopulation of "committed" tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpia0s4hhtKWrVg90H21EOLACvtfcHk0lhurBz4v3VfFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVems7fP&md5=71f538a53566d49d2d7bdcd91b4860e3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3389%2Ffgene.2018.00544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffgene.2018.00544%26sid%3Dliteratum%253Aachs%26aulast%3DEfremov%26aufirst%3DY.%2BR.%26aulast%3DProskurina%26aufirst%3DA.%2BS.%26aulast%3DPotter%26aufirst%3DE.%2BA.%26aulast%3DDolgova%26aufirst%3DE.%2BV.%26aulast%3DEfremova%26aufirst%3DO.%2BV.%26aulast%3DTaranov%26aufirst%3DO.%2BS.%26aulast%3DOstanin%26aufirst%3DA.%2BA.%26aulast%3DChernykh%26aufirst%3DE.%2BR.%26aulast%3DKolchanov%26aufirst%3DN.%2BA.%26aulast%3DBogachev%26aufirst%3DS.%2BS.%26atitle%3DCancer%2520stem%2520cells%253A%2520emergent%2520nature%2520of%2520tumor%2520emergency%26jtitle%3DFront.%2520Genet.%26date%3D2018%26volume%3D9%26spage%3D544%26doi%3D10.3389%2Ffgene.2018.00544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quader, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, R.</span></span> <span> </span><span class="NLM_article-title">Interplay of EMT and CSC in cancer and the potential therapeutic strategies</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">904</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.00904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffphar.2020.00904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32625096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVWgtbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=904&author=S.+Tanabeauthor=S.+Quaderauthor=H.+Cabralauthor=R.+Ono&title=Interplay+of+EMT+and+CSC+in+cancer+and+the+potential+therapeutic+strategies&doi=10.3389%2Ffphar.2020.00904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Interplay of EMT and CSC in cancer and the potential therapeutic strategies</span></div><div class="casAuthors">Tanabe, Shihori; Quader, Sabina; Cabral, Horacio; Ono, Ryuichi</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">904</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The mechanism of epithelial-mesenchymal transition (EMT) consists of the cellular</div> phenotypic transition from epithelial to mesenchymal status.  The cells exhibiting EMT</div> exist in cancer stem cell (CSC) population, which is involved in drug resistance.  CSCs</div> demonstrating EMT feature remain after cancer treatment, which leads to drug resistance,</div> recurrence, metastasis and malignancy of cancer.  In this context, the recent advance of</div> nanotechnol. in the medical application has ascended the possibility to target CSCs</div> using nanomedicines.  In this review article, we focused on the mechanism of CSCs and</div> EMT, esp. into the signaling pathways in EMT, regulation of EMT and CSCs by</div> microRNAs and nanomedicine-based approaches to target CSCs.</div>.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjPY5-iyR5GLVg90H21EOLACvtfcHk0lg7AmRM0BiWIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVWgtbfM&md5=2c59357d85d761af3c5ab92de856b904</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.00904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.00904%26sid%3Dliteratum%253Aachs%26aulast%3DTanabe%26aufirst%3DS.%26aulast%3DQuader%26aufirst%3DS.%26aulast%3DCabral%26aufirst%3DH.%26aulast%3DOno%26aufirst%3DR.%26atitle%3DInterplay%2520of%2520EMT%2520and%2520CSC%2520in%2520cancer%2520and%2520the%2520potential%2520therapeutic%2520strategies%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D904%26doi%3D10.3389%2Ffphar.2020.00904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J. S.</span></span> <span> </span><span class="NLM_article-title">Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">965</span>, <span class="refDoi"> DOI: 10.3390/molecules21070965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fmolecules21070965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVWkt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=965&author=B.+Duauthor=J.+S.+Shim&title=Targeting+epithelial-mesenchymal+transition+%28EMT%29+to+overcome+drug+resistance+in+cancer&doi=10.3390%2Fmolecules21070965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer</span></div><div class="casAuthors">Du, Bowen; Shim, Joong Sup</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">965/1-965/15</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Epithelial-mesenchymal transition (EMT) is known to play an important role in cancer progression, metastasis and drug resistance.  Although there are controversies surrounding the causal relationship between EMT and cancer metastasis, the role of EMT in cancer drug resistance has been increasingly recognized.  Numerous EMT-related signaling pathways are involved in drug resistance in cancer cells.  Cells undergoing EMT show a feature similar to cancer stem cells (CSCs), such as an increase in drug efflux pumps and anti-apoptotic effects.  Therefore, targeting EMT has been considered a novel opportunity to overcome cancer drug resistance.  This review describes the mechanism by which EMT contributes to drug resistance in cancer cells and summarizes new advances in research in EMT-assocd. drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLrVX8vkTNGLVg90H21EOLACvtfcHk0lg7AmRM0BiWIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVWkt7rJ&md5=74f02736256323d38e647ff1416d8790</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21070965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21070965%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DB.%26aulast%3DShim%26aufirst%3DJ.%2BS.%26atitle%3DTargeting%2520epithelial-mesenchymal%2520transition%2520%2528EMT%2529%2520to%2520overcome%2520drug%2520resistance%2520in%2520cancer%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26spage%3D965%26doi%3D10.3390%2Fmolecules21070965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Stemness-related markers in cancer</span>. <i>Cancer Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.4103/ctm.ctm_69_16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.4103%2Fctm.ctm_69_16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29276782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOht7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=87-95&author=W.+Zhaoauthor=Y.+Liauthor=X.+Zhang&title=Stemness-related+markers+in+cancer&doi=10.4103%2Fctm.ctm_69_16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Stemness-related Markers in Cancer</span></div><div class="casAuthors">Zhao, Wenxiu; Li, Yvonne; Zhang, Xun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Translational Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">CTMABE</span>;
        ISSN:<span class="NLM_cas:issn">2395-3012</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs), with their self-renewal ability and multilineage differentiation potential, are a crit. subpopulation of tumor cells that can drive tumor initiation, growth, and resistance to therapy.  Like embryonic and adult stem cells, CSCs express markers that are not expressed in normal somatic cells and are thus thought to contribute toward a "stemness" phenotype.  This review summarizes the current knowledge of stemness-related markers in human cancers, with a particular focus on important transcription factors, protein surface markers, and signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQUfdLZo7mS7Vg90H21EOLACvtfcHk0lg7AmRM0BiWIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOht7fE&md5=4408ed4c8b31c8f818404c7cc712cd04</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.4103%2Fctm.ctm_69_16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252Fctm.ctm_69_16%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DStemness-related%2520markers%2520in%2520cancer%26jtitle%3DCancer%2520Transl.%2520Med.%26date%3D2017%26volume%3D3%26spage%3D87%26epage%3D95%26doi%3D10.4103%2Fctm.ctm_69_16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pádua, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueira, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesquita, P.</span></span> <span> </span><span class="NLM_article-title">The relevance of transcription factors in gastric and colorectal cancer stem cells identification and eradication</span>. <i>Front. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">442</span>, <span class="refDoi"> DOI: 10.3389/fcell.2020.00442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffcell.2020.00442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32626705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB38noslShtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=442&author=D.+P%C3%A1duaauthor=P.+Figueiraauthor=I.+Ribeiroauthor=R.+Almeidaauthor=P.+Mesquita&title=The+relevance+of+transcription+factors+in+gastric+and+colorectal+cancer+stem+cells+identification+and+eradication&doi=10.3389%2Ffcell.2020.00442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication</span></div><div class="casAuthors">Padua Diana; Figueira Paula; Ribeiro Ines; Almeida Raquel; Mesquita Patricia; Padua Diana; Figueira Paula; Ribeiro Ines; Almeida Raquel; Mesquita Patricia; Almeida Raquel; Almeida Raquel</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in cell and developmental biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">442</span>
        ISSN:<span class="NLM_cas:issn">2296-634X</span>.
    </div><div class="casAbstract">Gastric and colorectal cancers have a high incidence and mortality worldwide.  The presence of cancer stem cells (CSCs) within the tumor mass has been indicated as the main reason for tumor relapse, metastasis and therapy resistance, leading to poor overall survival.  Thus, the elimination of CSCs became a crucial goal for cancer treatment.  The identification of these cells has been performed by using cell-surface markers, a reliable approach, however it lacks specificity and usually differs among tumor type and in some cases even within the same type.  In theory, the ideal CSC markers are those that are required to maintain their stemness features.  The knowledge that CSCs exhibit characteristics comparable to normal stem cells that could be associated with the expression of similar transcription factors (TFs) including SOX2, OCT4, NANOG, KLF4 and c-Myc, and signaling pathways such as the Wnt/β-catenin, Hedgehog (Hh), Notch and PI3K/AKT/mTOR directed the attention to the use of these similarities to identify and target CSCs in different tumor types.  Several studies have demonstrated that the abnormal expression of some TFs and the dysregulation of signaling pathways are associated with tumorigenesis and CSC phenotype.  The disclosure of common and appropriate biomarkers for CSCs will provide an incredible tool for cancer prognosis and treatment.  Therefore, this review aims to gather the new insights in gastric and colorectal CSC identification specially by using TFs as biomarkers and divulge promising drugs that have been found and tested for targeting these cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKnSTGbtpJaq__Jf7-eMvJfW6udTcc2ebwTMnx-bjj-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38noslShtA%253D%253D&md5=716a3753e3b228858d1b05322f2b78ce</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.3389%2Ffcell.2020.00442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcell.2020.00442%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A1dua%26aufirst%3DD.%26aulast%3DFigueira%26aufirst%3DP.%26aulast%3DRibeiro%26aufirst%3DI.%26aulast%3DAlmeida%26aufirst%3DR.%26aulast%3DMesquita%26aufirst%3DP.%26atitle%3DThe%2520relevance%2520of%2520transcription%2520factors%2520in%2520gastric%2520and%2520colorectal%2520cancer%2520stem%2520cells%2520identification%2520and%2520eradication%26jtitle%3DFront.%2520Cell%2520Dev.%2520Biol.%26date%3D2020%26volume%3D8%26spage%3D442%26doi%3D10.3389%2Ffcell.2020.00442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muralikrishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nephew, K. P.</span></span> <span> </span><span class="NLM_article-title">Targeting aldehyde dehydrogenases to eliminate cancer stem cells in gynecologic malignancies</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">961</span>, <span class="refDoi"> DOI: 10.3390/cancers12040961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcancers12040961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKgtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=961&author=V.+Muralikrishnanauthor=T.+D.+Hurleyauthor=K.+P.+Nephew&title=Targeting+aldehyde+dehydrogenases+to+eliminate+cancer+stem+cells+in+gynecologic+malignancies&doi=10.3390%2Fcancers12040961"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting aldehyde dehydrogenases to eliminatecancer stem cells in gynecologic malignancies</span></div><div class="casAuthors">Muralikrishnan, Vaishnavi; Hurley, Thomas D.; Nephew, Kenneth P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">961</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Gynecol. cancers cause over 600,000 deaths annually in women worldwide.  The development of chemoresistance after initial rounds of chemotherapy contributes to tumor relapse and death due to gynecol. malignancies.  In this regard, cancer stem cells (CSCs), a subpopulation of stem cells with the ability to undergo self-renewal and clonal evolution, play a key role in tumor progression and drug resistance.  Aldehyde dehydrogenases (ALDH) are a group of enzymes shown to be robust CSC markers in gynecol. and other malignancies.  These enzymes also play functional roles in CSCs, including detoxification of aldehydes, scavenging of reactive oxygen species (ROS), and retinoic acid (RA) signaling, making ALDH an attractive therapeutic target in various clin. scenarios.  In this review, we discuss the crit. roles of the ALDH in driving stemness in different gynecol. malignancies.  We review inhibitors of ALDH, both general and isoform-specific, which have been used to target CSCs in gynecol. cancers.  Many of these inhibitors have been shown to be effective in preclin. models of gynecol. malignancies, supporting further development in the clinic.  Furthermore, ALDH inhibitors, including 673A and CM037, synergize with chemotherapy to reduce tumor growth.  Thus, ALDH-targeted therapies hold promise for improving patient outcomes in gynecol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0YbLEdolnPLVg90H21EOLACvtfcHk0lgVuCE182rZ2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKgtrnL&md5=98b2a7d09d7bfe5e10b93c3990ec9a81</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.3390%2Fcancers12040961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12040961%26sid%3Dliteratum%253Aachs%26aulast%3DMuralikrishnan%26aufirst%3DV.%26aulast%3DHurley%26aufirst%3DT.%2BD.%26aulast%3DNephew%26aufirst%3DK.%2BP.%26atitle%3DTargeting%2520aldehyde%2520dehydrogenases%2520to%2520eliminate%2520cancer%2520stem%2520cells%2520in%2520gynecologic%2520malignancies%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D961%26doi%3D10.3390%2Fcancers12040961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit21c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo-Guzmán, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Gallegos, Á. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Sánchez, E.</span></span> <span> </span><span class="NLM_article-title">ALDH as a stem cell marker in solid tumors</span>. <i>Curr. Stem Cell Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.2174/1574888X13666180810120012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.2174%2F1574888X13666180810120012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30095061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3c7mvVenuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=375-388&author=M.+E.+Toledo-Guzm%C3%A1nauthor=M.+I.+Hern%C3%A1ndezauthor=%C3%81.+A.+G%C3%B3mez-Gallegosauthor=E.+Ortiz-S%C3%A1nchez&title=ALDH+as+a+stem+cell+marker+in+solid+tumors&doi=10.2174%2F1574888X13666180810120012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21cR"><div class="casContent"><span class="casTitleNuber">21c</span><div class="casTitle"><span class="NLM_cas:atitle">ALDH as a Stem Cell Marker in Solid Tumors</span></div><div class="casAuthors">Toledo-Guzman Mariel E; Hernandez Miguel Ibanez; Toledo-Guzman Mariel E; Gomez-Gallegos Angel A; Ortiz-Sanchez Elizabeth; Gomez-Gallegos Angel A</div><div class="citationInfo"><span class="NLM_cas:title">Current stem cell research & therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">375-388</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aldehyde dehydrogenase (ALDH) is an enzyme that participates in important cellular mechanisms as aldehyde detoxification and retinoic acid synthesis; moreover, ALDH activity is involved in drug resistance, a characteristic of cancer stem cells (CSCs).  Even though ALDH is found in stem cells, CSCs and progenitor cells, this enzyme has been successfully used to identify and isolate cell populations with CSC properties from several tumor origins.  ALDH is allegedly involved in cell differentiation through its product, retinoic acid.  However, direct or indirect ALDH inhibition, using specific inhibitors or retinoic acid, has shown a reduction in ALDH activity, along with the loss of stem cell traits, reduction of cell proliferation, invasion, and drug sensitization.  For these reasons, ALDH and retinoic acid are promising therapeutic targets.  This review summarizes the current evidence for ALDH as a CSCs marker in solid tumors, as well as current knowledge about the functional roles of ALDH in CSCs.  We discuss the controversy of ALDH activity to maintain CSC stemness, or conversely, to promote cell differentiation.  Finally, we review the advances in using ALDH inhibitors as anti-cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQUklA8IheHWM25P7XSLhESfW6udTcc2ebwTMnx-bjj-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7mvVenuw%253D%253D&md5=ed1c99e325755b02e7ad7e9e396bc0e7</span></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.2174%2F1574888X13666180810120012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1574888X13666180810120012%26sid%3Dliteratum%253Aachs%26aulast%3DToledo-Guzm%25C3%25A1n%26aufirst%3DM.%2BE.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DM.%2BI.%26aulast%3DG%25C3%25B3mez-Gallegos%26aufirst%3D%25C3%2581.%2BA.%26aulast%3DOrtiz-S%25C3%25A1nchez%26aufirst%3DE.%26atitle%3DALDH%2520as%2520a%2520stem%2520cell%2520marker%2520in%2520solid%2520tumors%26jtitle%3DCurr.%2520Stem%2520Cell%2520Res.%2520Ther.%26date%3D2019%26volume%3D14%26spage%3D375%26epage%3D388%26doi%3D10.2174%2F1574888X13666180810120012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karsten, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goletz, S.</span></span> <span> </span><span class="NLM_article-title">What makes cancer stem cell markers different?</span>. <i>SpringerPlus</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">301</span>, <span class="refDoi"> DOI: 10.1186/2193-1801-2-301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2F2193-1801-2-301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=23888272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Wiu7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=301&author=U.+Karstenauthor=S.+Goletz&title=What+makes+cancer+stem+cell+markers+different%3F&doi=10.1186%2F2193-1801-2-301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">What makes cancer stem cell markers different?</span></div><div class="casAuthors">Karsten, Uwe; Goletz, Steffen</div><div class="citationInfo"><span class="NLM_cas:title">SpringerPlus</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">301/1-301/8, 8</span>CODEN:
                <span class="NLM_cas:coden">SPRIFB</span>;
        ISSN:<span class="NLM_cas:issn">2193-1801</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Since the cancer stem cell concept has been widely accepted, several strategies have been proposed to attack cancer stem cells (CSC).  Accordingly, stem cell markers are now preferred therapeutic targets.  However, the problem of tumor specificity has not disappeared but shifted to another question: how can cancer stem cells be distinguished from normal stem cells, or more specifically, how do CSC markers differ from normal stem cell markers.  A hypothesis is proposed which might help to solve this problem in at least a subgroup of stem cell markers.  Glycosylation may provide the key.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp0Vy6CjVTmbVg90H21EOLACvtfcHk0ljDzZt-14xfjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Wiu7%252FF&md5=b76e43970db39972f766e5cb1f3f2bd8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1186%2F2193-1801-2-301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2193-1801-2-301%26sid%3Dliteratum%253Aachs%26aulast%3DKarsten%26aufirst%3DU.%26aulast%3DGoletz%26aufirst%3DS.%26atitle%3DWhat%2520makes%2520cancer%2520stem%2520cell%2520markers%2520different%253F%26jtitle%3DSpringerPlus%26date%3D2013%26volume%3D2%26spage%3D301%26doi%3D10.1186%2F2193-1801-2-301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fatima, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span> <span> </span><span class="NLM_article-title">Clinicopathological correlation of cancer stem cell markers Oct-4 and CD133 expression as prognostic factor in malignant lesions of gallbladder: An immunohistochemical study</span>. <i>Indian J. Pathol. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.4103/IJPM.IJPM_134_19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.4103%2FIJPM.IJPM_134_19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31361225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3MvivVKmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=384-390&author=N.+Fatimaauthor=A.+N.+Srivastavaauthor=J.+Nigamauthor=N.+Tandonauthor=R.+Ahmadauthor=V.+Kumar&title=Clinicopathological+correlation+of+cancer+stem+cell+markers+Oct-4+and+CD133+expression+as+prognostic+factor+in+malignant+lesions+of+gallbladder%3A+An+immunohistochemical+study&doi=10.4103%2FIJPM.IJPM_134_19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Clinicopathological correlation of cancer stem cell markers Oct-4 and CD133 expression as prognostic factor in malignant lesions of gallbladder: An immunohistochemical study</span></div><div class="casAuthors">Fatima Naseem; Srivastava Anand Narain; Tandon Nishi; Nigam Jaya; Ahmad Rumana; Kumar Vijay</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of pathology & microbiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">384-390</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Gallbladder cancer (GBC) is the most frequent biliary tract cancer, with high morbidity and poor prognosis, and shows early metastasis and invasiveness.  No reliable biomarkers are available for detection of GBC progression.  Aim:  To investigate the immunohistochemical expression of Oct-4 and CD133 in malignant and nonneoplastic lesions of gallbladder and to analyze the clinical significance of the expressions related to clinicopathological parameters.  Settings and Design:  This is a prospective case control study, conducted in medical college background.  Materials and Methods:  A total of 103 cases of gallbladder were grouped into malignant lesions (n = 48) and nonneoplastic lesions (simple epithelial hyperplasia; n = 35 and chronic cholecystitis; n = 20).  All tissue samples were evaluated for expression of Oct-4 and CD133 using immunohistochemistry in an effort to elucidate the correlation between their expressions with clinicopathological parameters.  Statistical Analysis:  The final score was calculated by multiplying the intensity to the percentage of positive cells.  The scores ≥2 were considered as positive.  Results:  Significant positive correlation of higher expression levels of Oct-4 and CD133 were observed in malignant as compared to nonneoplastic lesions of gallbladder (P < 0.0001).  High expression of Oct-4 and CD133 were significantly associated with tumor grading (Oct-4, P = 0.04; CD133, P = 0.02), staging (Oct-4, P = 0.03; CD133, P = 0.02), and liver metastasis (Oct-4, P = 0.01; CD133, P = 0.007).  Significantly reduced survival was observed with high expression of Oct-4 (P = 0.002).  No significant correction was observed between CD 133 and survival.  Conclusion:  This study revealed that high expression level of Oct-4 may provide a new insight for the prognosis of the disease in terms of clinical staging and grade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTMu_8lyKCw9ZSWdIdmEou5fW6udTcc2eYiJ5StdrTE97ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvivVKmsw%253D%253D&md5=bb7d87c8097d28cbe07ead5d0c82ce09</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.4103%2FIJPM.IJPM_134_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252FIJPM.IJPM_134_19%26sid%3Dliteratum%253Aachs%26aulast%3DFatima%26aufirst%3DN.%26aulast%3DSrivastava%26aufirst%3DA.%2BN.%26aulast%3DNigam%26aufirst%3DJ.%26aulast%3DTandon%26aufirst%3DN.%26aulast%3DAhmad%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DV.%26atitle%3DClinicopathological%2520correlation%2520of%2520cancer%2520stem%2520cell%2520markers%2520Oct-4%2520and%2520CD133%2520expression%2520as%2520prognostic%2520factor%2520in%2520malignant%2520lesions%2520of%2520gallbladder%253A%2520An%2520immunohistochemical%2520study%26jtitle%3DIndian%2520J.%2520Pathol.%2520Microbiol.%26date%3D2019%26volume%3D62%26spage%3D384%26epage%3D390%26doi%3D10.4103%2FIJPM.IJPM_134_19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span> <span> </span><span class="NLM_article-title">Identification of new cancer stem cell markers and signaling pathways in HER-2-positive breast cancer by transcriptome sequencing</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1003</span>– <span class="NLM_lpage">1018</span>, <span class="refDoi"> DOI: 10.3892/ijo.2019.4876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3892%2Fijo.2019.4876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31545416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltVeku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=1003-1018&author=L.+Fengauthor=S.+Huangauthor=G.+Anauthor=G.+Wangauthor=S.+Guauthor=X.+Zhao&title=Identification+of+new+cancer+stem+cell+markers+and+signaling+pathways+in+HER-2-positive+breast+cancer+by+transcriptome+sequencing&doi=10.3892%2Fijo.2019.4876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of new cancer stem cell markers and signaling pathways in HER-2-positive breast cancer by transcriptome sequencing</span></div><div class="casAuthors">Feng, Lu; Huang, Shangke; An, Gaili; Wang, Guanying; Gu, Shanzhi; Zhao, Xinhan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1003-1018</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Human epidermal growth factor receptor (HER)-2-pos. breast cancer accounts for ∼25% of all breast cancer cases, and is assocd. with a poor prognosis.  In the present study, the ratio of CD44+/CD24-/low cells was almost zero in SK-BR-3 cells; however, it was >90% in MDA-MB-231 cells, as detd. by flow cytometry.  Since SK-BR-3 and MDA-MB-231 cells both exhibit a strong propensity for invasion and migration, it was hypothesized that there may be other markers of CSCs in SK-BR-3 cells.  Therefore, transcriptome sequencing was performed for SK-BR-3 and MDA-MB-231 cells.  It was obsd. that several leukocyte differentiation antigens and other CSC markers were significantly more highly expressed in SK-BR-3 cells.  Furthermore, the expression of aldehyde dehydrogenase (ALDH)1A3, CD164 and epithelial cell adhesion mol. (EpCAM) was higher in SK-BR-3 cells compared with in other subtypes of breast cell lines, as detd. by reverse transcription-polymerase chain reaction and western blot anal.  In addn., the expression levels of ALDH1A3, ALDH3B2 and EpCAM were higher in HER-2-pos. breast cancer compared with in paracancerous tissues and other subtypes of breast cancer, as detd. by immunohistochem.  The expression of β-catenin in the Wnt signaling pathway was lower in SK-BR-3 cells compared with in MDA-MB-231 cells, which may be used as a prognostic indicator for breast cancer.  These findings may help identify novel CSC markers and therapeutic targets for HER-2-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdzDidqFCAr7Vg90H21EOLACvtfcHk0ljDzZt-14xfjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltVeku78%253D&md5=ad585fbf4b88f7ecfd227e2617da9f62</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3892%2Fijo.2019.4876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2019.4876%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DAn%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DGu%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26atitle%3DIdentification%2520of%2520new%2520cancer%2520stem%2520cell%2520markers%2520and%2520signaling%2520pathways%2520in%2520HER-2-positive%2520breast%2520cancer%2520by%2520transcriptome%2520sequencing%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2019%26volume%3D55%26spage%3D1003%26epage%3D1018%26doi%3D10.3892%2Fijo.2019.4876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caglar, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biray Avci, C.</span></span> <span> </span><span class="NLM_article-title">Alterations of cell cycle genes in cancer: unmasking the role of cancer stem cells</span>. <i>Mol. Biol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">3065</span>– <span class="NLM_lpage">3076</span>, <span class="refDoi"> DOI: 10.1007/s11033-020-05341-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1007%2Fs11033-020-05341-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32112300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktFeksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2020&pages=3065-3076&author=H.+O.+Caglarauthor=C.+Biray+Avci&title=Alterations+of+cell+cycle+genes+in+cancer%3A+unmasking+the+role+of+cancer+stem+cells&doi=10.1007%2Fs11033-020-05341-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Alterations of cell cycle genes in cancer: unmasking the role of cancer stem cells</span></div><div class="casAuthors">Caglar, Hasan Onur; Biray Avci, Cigir</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">3065-3076</span>CODEN:
                <span class="NLM_cas:coden">MLBRBU</span>;
        ISSN:<span class="NLM_cas:issn">0301-4851</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Abstr.: The cell cycle is a complex and strictly controlled process, consisting of different phases.  Cell cycle regulation depends on phase-specific transcriptions of cell cycle genes.  The alterations of cell cycle genes can predispose normal cells to have a cancerous phenotype.  Indeed, several mechanisms underlying the deregulation of the cell cycle have been identified in different types of cancer.  Cancer stem cells (CSCs), a fraction of tumor cells, are selectively capable of initiating tumor development.  However, the deregulation of the cell cycle progression in CSCs still remains incompletely understood.  This review describes epigenetic alterations and aberrant transcriptional regulation of cell cycle genes in CSCs as well as cell cycle patterns of CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2T2oL7_SUvbVg90H21EOLACvtfcHk0ljDzZt-14xfjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktFeksr8%253D&md5=3cbe30a384ce330f3c20658530bf02e5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs11033-020-05341-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11033-020-05341-6%26sid%3Dliteratum%253Aachs%26aulast%3DCaglar%26aufirst%3DH.%2BO.%26aulast%3DBiray%2BAvci%26aufirst%3DC.%26atitle%3DAlterations%2520of%2520cell%2520cycle%2520genes%2520in%2520cancer%253A%2520unmasking%2520the%2520role%2520of%2520cancer%2520stem%2520cells%26jtitle%3DMol.%2520Biol.%2520Rep.%26date%3D2020%26volume%3D47%26spage%3D3065%26epage%3D3076%26doi%3D10.1007%2Fs11033-020-05341-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayob, A. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramasamy, T. S.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells as key drivers of tumour progression</span>. <i>J. Biomed. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">20</span>, <span class="refDoi"> DOI: 10.1186/s12929-018-0426-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2Fs12929-018-0426-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29506506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Sku7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=20&author=A.+Z.+Ayobauthor=T.+S.+Ramasamy&title=Cancer+stem+cells+as+key+drivers+of+tumour+progression&doi=10.1186%2Fs12929-018-0426-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells as key drivers of tumour progression</span></div><div class="casAuthors">Ayob, Ain Zubaidah; Ramasamy, Thamil Selvee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomedical Science (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20/1-20/18</span>CODEN:
                <span class="NLM_cas:coden">JBCIEA</span>;
        ISSN:<span class="NLM_cas:issn">1423-0127</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background:Cancer stem cells (CSCs) are subpopulations of cancer cells sharing similar characteristics as normal stem or progenitor cells such as self-renewal ability and multi-lineage differentiation to drive tumor growth and heterogeneity.  Throughout the cancer progression, CSC can further be induced from differentiated cancer cells via the adaptation and cross-talks with the tumor microenvironment as well as a response from therapeutic pressures, therefore contributes to their heterogeneous phenotypes.  Challengingly, conventional cancer treatments target the bulk of the tumor and are unable to target CSCs due to their highly resistance nature, leading to metastasis and tumor recurrence.  Main body: This review highlights the roles of CSCs in tumor initiation, progression and metastasis with a focus on the cellular and mol. regulators that influence their phenotypical changes and behaviors in the different stages of cancer progression.  We delineate the cross-talks between CSCs with the tumor microenvironment that support their intrinsic properties including survival, stemness, quiescence and their cellular and mol. adaptation in response to therapeutic pressure.  An insight into the distinct roles of CSCs in promoting angiogenesis and metastasis has been captured based on in vitro and in vivo evidences.  Conclusion: Given dynamic cellular events along the cancer progression and contributions of resistance nature by CSCs, understanding their mol. and cellular regulatory mechanism in a heterogeneous nature, provides significant cornerstone for the development of CSC-specific therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3nTnY6lOWyLVg90H21EOLACvtfcHk0lhAAfmKdovJmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Sku7zL&md5=a4700e44e5f5cb9be8de6d03c823ad75</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1186%2Fs12929-018-0426-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12929-018-0426-4%26sid%3Dliteratum%253Aachs%26aulast%3DAyob%26aufirst%3DA.%2BZ.%26aulast%3DRamasamy%26aufirst%3DT.%2BS.%26atitle%3DCancer%2520stem%2520cells%2520as%2520key%2520drivers%2520of%2520tumour%2520progression%26jtitle%3DJ.%2520Biomed.%2520Sci.%26date%3D2018%26volume%3D25%26spage%3D20%26doi%3D10.1186%2Fs12929-018-0426-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">López-Lázaro, M.</span></span> <span> </span><span class="NLM_article-title">The stem cell division theory of cancer</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2018.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.critrevonc.2018.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29482784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC1MrlsFCgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2018&pages=95-113&author=M.+L%C3%B3pez-L%C3%A1zaro&title=The+stem+cell+division+theory+of+cancer&doi=10.1016%2Fj.critrevonc.2018.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The stem cell division theory of cancer</span></div><div class="casAuthors">Lopez-Lazaro Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">95-113</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">All cancer registries constantly show striking differences in cancer incidence by age and among tissues.  For example, lung cancer is diagnosed hundreds of times more often at age 70 than at age 20, and lung cancer in nonsmokers occurs thousands of times more frequently than heart cancer in smokers.  An analysis of these differences using basic concepts in cell biology indicates that cancer is the end-result of the accumulation of cell divisions in stem cells.  In other words, the main determinant of carcinogenesis is the number of cell divisions that the DNA of a stem cell has accumulated in any type of cell from the zygote.  Cell division, process by which a cell copies and separates its cellular components to finally split into two cells, is necessary to produce the large number of cells required for living.  However, cell division can lead to a variety of cancer-promoting errors, such as mutations and epigenetic mistakes occurring during DNA replication, chromosome aberrations arising during mitosis, errors in the distribution of cell-fate determinants between the daughter cells, and failures to restore physical interactions with other tissue components.  Some of these errors are spontaneous, others are promoted by endogenous DNA damage occurring during quiescence, and others are influenced by pathological and environmental factors.  The cell divisions required for carcinogenesis are primarily caused by multiple local and systemic physiological signals rather than by errors in the DNA of the cells.  As carcinogenesis progresses, the accumulation of DNA errors promotes cell division and eventually triggers cell division under permissive extracellular environments.  The accumulation of cell divisions in stem cells drives not only the accumulation of the DNA alterations required for carcinogenesis, but also the formation and growth of the abnormal cell populations that characterize the disease.  This model of carcinogenesis provides a new framework for understanding the disease and has important implications for cancer prevention and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1aXaniitqqoqdXsLcGTEUfW6udTcc2ebzZeqZBq7FLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrlsFCgug%253D%253D&md5=3348665d0e4e2c7172fbe3767b8a4321</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2018.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2018.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B3pez-L%25C3%25A1zaro%26aufirst%3DM.%26atitle%3DThe%2520stem%2520cell%2520division%2520theory%2520of%2520cancer%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2018%26volume%3D123%26spage%3D95%26epage%3D113%26doi%3D10.1016%2Fj.critrevonc.2018.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lui, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obajdin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroukov, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spagnoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, F. M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms, hallmarks, and implications of stem cell quiescence</span>. <i>Stem Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1190</span>– <span class="NLM_lpage">1200</span>, <span class="refDoi"> DOI: 10.1016/j.stemcr.2019.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.stemcr.2019.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31189093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=1190-1200&author=I.+J.+Choauthor=P.+P.+Luiauthor=J.+Obajdinauthor=F.+Riccioauthor=W.+Stroukovauthor=T.+L.+Willisauthor=F.+Spagnoliauthor=F.+M.+Watt&title=Mechanisms%2C+hallmarks%2C+and+implications+of+stem+cell+quiescence&doi=10.1016%2Fj.stemcr.2019.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms, Hallmarks, and Implications of Stem Cell Quiescence</span></div><div class="casAuthors">Cho, Inchul J.; Lui, Prudence PokWai; Obajdin, Jana; Riccio, Federica; Stroukov, Wladislaw; Willis, Thea Louise; Spagnoli, Francesca; Watt, Fiona M.</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1190-1200</span>CODEN:
                <span class="NLM_cas:coden">SCRTFL</span>;
        ISSN:<span class="NLM_cas:issn">2213-6711</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Cellular quiescence is a dormant but reversible cellular state in which cell-cycle entry and proliferation are prevented.  Recent studies both in vivo and in vitro demonstrate that quiescence is actively maintained through synergistic interactions between intrinsic and extrinsic signals.  Subtypes of adult mammalian stem cells can be maintained in this poised, quiescent state, and subsequently reactivated upon tissue injury to restore homeostasis.  However, quiescence can become deregulated in pathol. settings.  In this review, we discuss the recent advances uncovering intracellular signaling pathways, transcriptional changes, and extracellular cues within the stem cell niche that control induction and exit from quiescence in tissue stem cells.  We discuss the implications of quiescence as well as the pharmacol. and genetic approaches that are being explored to either induce or prevent quiescence as a therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyjE-BlzTnArVg90H21EOLACvtfcHk0lhAAfmKdovJmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtbzI&md5=0ca821f9174662bf562862765a51a8bf</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.stemcr.2019.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.stemcr.2019.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DI.%2BJ.%26aulast%3DLui%26aufirst%3DP.%2BP.%26aulast%3DObajdin%26aufirst%3DJ.%26aulast%3DRiccio%26aufirst%3DF.%26aulast%3DStroukov%26aufirst%3DW.%26aulast%3DWillis%26aufirst%3DT.%2BL.%26aulast%3DSpagnoli%26aufirst%3DF.%26aulast%3DWatt%26aufirst%3DF.%2BM.%26atitle%3DMechanisms%252C%2520hallmarks%252C%2520and%2520implications%2520of%2520stem%2520cell%2520quiescence%26jtitle%3DStem%2520Cell%2520Rep.%26date%3D2019%26volume%3D12%26spage%3D1190%26epage%3D1200%26doi%3D10.1016%2Fj.stemcr.2019.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qemo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, L. A.</span></span> <span> </span><span class="NLM_article-title">Cell cycle dynamics in glioma cancer stem cells</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1869</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-8805-1_11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1007%2F978-1-4939-8805-1_11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30324519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFWhtLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1869&publication_year=2019&pages=117-126&author=I.+Qemoauthor=L.+A.+Porter&title=Cell+cycle+dynamics+in+glioma+cancer+stem+cells&doi=10.1007%2F978-1-4939-8805-1_11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle dynamics in glioma cancer stem cells</span></div><div class="casAuthors">Qemo, Ingrid; Porter, Lisa A.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1869</span>
        (<span class="NLM_cas:issue">Brain Tumor Stem Cells</span>),
    <span class="NLM_cas:pages">117-126</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Cancer stem cells, sometimes referred to as tumor initiating cells, play pivotal roles in tumor initiation, progression, metastasis, resistance to therapy, and relapse.  Understanding how these populations of cells expand in response to a host of conditions is crit. in detg. effective cancer therapeutics.  A defining feature of cancer stem cells is the ability to switch between modes of quiescence and sym./asym. division to protect and conserve the population, this feature is traditionally reserved for normal adult stem cell populations.  Understanding how the core cell cycle machinery responds to external cues to drive sym./asym. division vs. quiescence will reveal fundamental information about how cancer stem cell populations survive and expand.  This chapter will describe methods to study the cell cycle dynamics in brain cancer stem cell populations and how they compare to the other populations in a tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpioZEwbROLZrVg90H21EOLACvtfcHk0lj4sX-XNeRyHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFWhtLvJ&md5=9e23498568a00fee273e55f3b2972d57</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-8805-1_11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-8805-1_11%26sid%3Dliteratum%253Aachs%26aulast%3DQemo%26aufirst%3DI.%26aulast%3DPorter%26aufirst%3DL.%2BA.%26atitle%3DCell%2520cycle%2520dynamics%2520in%2520glioma%2520cancer%2520stem%2520cells%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2019%26volume%3D1869%26spage%3D117%26epage%3D126%26doi%3D10.1007%2F978-1-4939-8805-1_11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeishi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K. I.</span></span> <span> </span><span class="NLM_article-title">To wake up cancer stem cells, or to let them sleep, that is the question</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1111/cas.12958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1111%2Fcas.12958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=27116333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSgsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=875-881&author=S.+Takeishiauthor=K.+I.+Nakayama&title=To+wake+up+cancer+stem+cells%2C+or+to+let+them+sleep%2C+that+is+the+question&doi=10.1111%2Fcas.12958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">To wake up cancer stem cells, or to let them sleep, that is the question</span></div><div class="casAuthors">Takeishi, Shoichiro; Nakayama, Keiichi I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">875-881</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) generate transient-amplifying cells and thereby contribute to cancer propagation.  A fuller understanding of the biol. features of CSCs is expected to lead to the development of new anticancer therapies capable of eradicating this life-threatening disease.  Cancer stem cells are known to maintain a non-proliferative state and to enter the cell cycle only infrequently.  Given that conventional anticancer therapies preferentially target dividing cells, CSCs are resistant to such treatments, with those remaining after elimination of bulk cancer cells potentially giving rise to disease relapse and metastasis as they re-enter the cell cycle after a period of latency.  Targeting of the switch between quiescence and proliferation in CSCs is therefore a potential strategy for preventing the reinitiation of malignancy, underscoring the importance of elucidation of the mechanisms by which these cells are maintained in the quiescent state.  The fundamental properties of CSCs are thought to be governed cooperatively by internal mols. and cues from the external microenvironment (stem cell niche).  Several such intrinsic and extrinsic regulators are responsible for the control of cell cycle progression in CSCs.  In this review, we address two opposite approaches to the therapeutic targeting of CSCs - wake-up and hibernation therapies - that either promote or prevent the entry of CSCs into the cell cycle, resp., and we discuss the potential advantages and risks of each strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUgdRUXMfDcrVg90H21EOLACvtfcHk0lj4sX-XNeRyHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSgsb7K&md5=53222f246c6bd942dc3394446388e558</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1111%2Fcas.12958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12958%26sid%3Dliteratum%253Aachs%26aulast%3DTakeishi%26aufirst%3DS.%26aulast%3DNakayama%26aufirst%3DK.%2BI.%26atitle%3DTo%2520wake%2520up%2520cancer%2520stem%2520cells%252C%2520or%2520to%2520let%2520them%2520sleep%252C%2520that%2520is%2520the%2520question%26jtitle%3DCancer%2520Sci.%26date%3D2016%26volume%3D107%26spage%3D875%26epage%3D881%26doi%3D10.1111%2Fcas.12958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afify, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seno, M.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cell generation by silenced MAPK enhancing PI3K/AKT signaling</span>. <i>Med. Hypotheses</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">109742</span>, <span class="refDoi"> DOI: 10.1016/j.mehy.2020.109742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.mehy.2020.109742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32315923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXns1Cjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2020&pages=109742&author=G.+Hassanauthor=J.+Duauthor=S.+M.+Afifyauthor=A.+Senoauthor=M.+Seno&title=Cancer+stem+cell+generation+by+silenced+MAPK+enhancing+PI3K%2FAKT+signaling&doi=10.1016%2Fj.mehy.2020.109742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cell generation by silenced MAPK enhancing PI3K/AKT signaling.</span></div><div class="casAuthors">Hassan, Ghmkin; Du, Juan; Afify, Said M.; Seno, Akimasa; Seno, Masaharu</div><div class="citationInfo"><span class="NLM_cas:title">Medical Hypotheses</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109742</span>CODEN:
                <span class="NLM_cas:coden">MEHYDY</span>;
        ISSN:<span class="NLM_cas:issn">0306-9877</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cancer stem cells, which are defined by self-renewal, differentiation potential and tumorigenicity, are proposed to be responsible for cancer initiation and maintain the tumor mass.  Cancer stem cells are thought to be resistant to chemotherapy inhibiting different signaling pathways.  Typically, growth factors are known to stimulate MEK/ERK pathways, which is responsible for mitogenic activity, while the PI3K appears more related with the maintenance of stemness.  The cross-talk, even in pos. or neg. ways, between these two pathways could stimulate or accelerate the conversion of normal stem cells into cancer stem cells.  Here, we propose a new hypothesis of a mechanism for the conversion of stem cells or progenitors including induced pluripotent stem cells (iPSCs) to tissue-specific cancer stem cells.  This conversion could be prepd. by inhibiting MEK/ERK pathway and enhancing PI3K/AKT pathway exploiting conditioned media derived from cancer cell lines, which are good sources of many different cytokines, chemokines, tissues-specific factors, metabolites and so on, together with some inhibitors.  The feasibility of this combination will be explained in this hypothesis through the reports published somewhere.  Generation of cancer stem cells using embryonic stem cells/iPSCs will bring new theory in the mechanisms of tumorigenesis and assist drug screening that applies for the precision medicines for individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdAJA2g4xE7rVg90H21EOLACvtfcHk0lj4sX-XNeRyHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXns1Cjsr4%253D&md5=434416c02329c81792f038d09c3109a1</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.mehy.2020.109742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mehy.2020.109742%26sid%3Dliteratum%253Aachs%26aulast%3DHassan%26aufirst%3DG.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DAfify%26aufirst%3DS.%2BM.%26aulast%3DSeno%26aufirst%3DA.%26aulast%3DSeno%26aufirst%3DM.%26atitle%3DCancer%2520stem%2520cell%2520generation%2520by%2520silenced%2520MAPK%2520enhancing%2520PI3K%252FAKT%2520signaling%26jtitle%3DMed.%2520Hypotheses%26date%3D2020%26volume%3D141%26spage%3D109742%26doi%3D10.1016%2Fj.mehy.2020.109742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, Z.</span></span> <span> </span><span class="NLM_article-title">Inhibition of GSK3 and MEK induced cancer stem cell generation via the Wnt and MEK signaling pathways</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2013</span>, <span class="refDoi"> DOI: 10.3892/or.2018.6600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3892%2For.2018.6600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30066938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2msb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2018&pages=2005-2013&author=S.+Liaoauthor=L.+Ganauthor=W.+Qinauthor=C.+Liuauthor=Z.+Mei&title=Inhibition+of+GSK3+and+MEK+induced+cancer+stem+cell+generation+via+the+Wnt+and+MEK+signaling+pathways&doi=10.3892%2For.2018.6600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of gsk3 and mek induced cancer stem cell generation via the wnt and mek signaling pathways</span></div><div class="casAuthors">Liao, Shengtao; Gan, Li; Qin, Wanxiang; Liu, Chang; Mei, Zhechuan</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2005-2013</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are considered to be tumor-initiating cells, responsible for tumor invasive growth and dissemination to distant organ sites.  Typically, radiation treatment and chemotherapy should target CSCs.  However, current research investigating CSCs is impeded by the difficulty of isolating pure CSCs and maintaining them in vitro.  In the present study, the synergistic inhibition of glycogen synthase kinase 3 and mitogen-activated protein kinase kinase using small mols., CHIR99021 and PD184352, efficiently generated CSCs from immortalized human mammary epithelial cells (HMLEs) and resulted in the acquisition of mesenchymal traits and the expression of epithelial-mesenchymal transition markers.  The cell proliferation, invasion and migration of HMLE cells were significantly promoted by CHIR99021 and PD184352 (P<0.05).  Furthermore, the cell cycle was shifted from the G0/G1 phase to the G2/M phase, and the apoptotic rate was suppressed in HMLE cells following treatment with CHIR99021 and PD184352.  Compared with control group, the stimulated cells exhibited an increased ability to form mammospheres and regenerate a tumor.  In addn. to these properties, the induced cells also exhibited notable chemotherapy resistance.  In vivo, the treatment of cells with CHIR99021 and PD184352 promoted the growth of HMLE-engrafted tumor types.  These results provide a practical strategy for the generation of CSCs using small mols. in vitro, which provides a cell resource that may be used for drug screening.  Addnl., the present results addnl. highlighted the synergistic functions of Wnt and mitogen-activated protein kinase kinase signaling pathways in tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBe1TMiPAk4rVg90H21EOLACvtfcHk0lij4HUkDRF9Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2msb3I&md5=32750dd6170cd7e7a2f304e185cf5500</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3892%2For.2018.6600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2018.6600%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DS.%26aulast%3DGan%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DMei%26aufirst%3DZ.%26atitle%3DInhibition%2520of%2520GSK3%2520and%2520MEK%2520induced%2520cancer%2520stem%2520cell%2520generation%2520via%2520the%2520Wnt%2520and%2520MEK%2520signaling%2520pathways%26jtitle%3DOncol.%2520Rep.%26date%3D2018%26volume%3D40%26spage%3D2005%26epage%3D2013%26doi%3D10.3892%2For.2018.6600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clevers, H.</span></span> <span> </span><span class="NLM_article-title">Wnt signalling in stem cells and cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>434</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">850</span>, <span class="refDoi"> DOI: 10.1038/nature03319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fnature03319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=15829953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=843-850&author=T.+Reyaauthor=H.+Clevers&title=Wnt+signalling+in+stem+cells+and+cancer&doi=10.1038%2Fnature03319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Wnt signalling in stem cells and cancer</span></div><div class="casAuthors">Reya, Tannishtha; Clevers, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">843-850</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The canonical Wnt cascade has emerged as a crit. regulator of stem cells.  In many tissues, activation of Wnt signaling has also been assocd. with cancer.  This has raised the possibility that the tightly regulated self-renewal mediated by Wnt signaling in stem and progenitor cells is subverted in cancer cells to allow malignant proliferation.  Insights gained from understanding how the Wnt pathway is integrally involved in both stem cell and cancer cell maintenance and growth in the intestinal, epidermal and hematopoietic systems may serve as a paradigm for understanding the dual nature of self-renewal signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfhAAsTCfqJbVg90H21EOLACvtfcHk0lij4HUkDRF9Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrw%253D&md5=eeadde4e2da7fb4226164e4adfd8c8b0</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnature03319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03319%26sid%3Dliteratum%253Aachs%26aulast%3DReya%26aufirst%3DT.%26aulast%3DClevers%26aufirst%3DH.%26atitle%3DWnt%2520signalling%2520in%2520stem%2520cells%2520and%2520cancer%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D843%26epage%3D850%26doi%3D10.1038%2Fnature03319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beretov, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">618</span>, <span class="refDoi"> DOI: 10.1186/s12885-019-5824-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2Fs12885-019-5824-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31234823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3MzgtlShsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=618&author=J.+Dengauthor=X.+Baiauthor=X.+Fengauthor=J.+Niauthor=J.+Beretovauthor=P.+Grahamauthor=Y.+Li&title=Inhibition+of+PI3K%2FAkt%2FmTOR+signaling+pathway+alleviates+ovarian+cancer+chemoresistance+through+reversing+epithelial-mesenchymal+transition+and+decreasing+cancer+stem+cell+marker+expression&doi=10.1186%2Fs12885-019-5824-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression</span></div><div class="casAuthors">Deng Junli; Bai Xupeng; Feng Xiaojie; Ni Jie; Beretov Julia; Graham Peter; Li Yong; Deng Junli; Bai Xupeng; Feng Xiaojie; Ni Jie; Beretov Julia; Graham Peter; Li Yong; Deng Junli; Feng Xiaojie; Beretov Julia; Li Yong</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">618</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Ovarian cancer is the most common malignant tumor of the female reproductive tract.  Chemoresistance is a major challenge for current ovarian cancer therapy.  However, the mechanism underlying epithelial ovarian cancer (EOC) chemoresistance is not completely uncovered.  The phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling is an important intracellular pathway in regulating cell cycle, quiescence, and proliferation.  The aim of this study is to investigate the role of PI3K/Akt/mTOR signaling pathway and its association with epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) marker expression in EOC chemoresistance.  METHODS:  The expressions of EMT and CSC markers were detected by immunofluorescence, western blot, and quantitative real-time PCR.  BEZ235, a dual PI3K/mTOR inhibitor, was employed to investigate the role of PI3K/Akt/ mTOR signaling in regulating EMT and CSC marker expression.  Students' t test and one-way ANOVA with Tukey's post-hoc test were used to compare the data from different groups.  RESULTS:  We found that EMT and CSC marker expression were significantly enhanced in chemoresistant EOC cells, which was accompanied by the activation of PI3K/Akt/mTOR signaling.  Compared with single cisplatin treatment, combined treatment with BEZ235 and cisplatin significantly disrupted the colony formation ability, induced higher ROS level and more apoptosis in chemoresistant EOC cells.  Furthermore, the combination approach effectively inhibited PI3K/Akt/mTOR signaling pathway, reversed EMT, and decreased CSC marker expression in chemoresistant EOC cells compared with cisplatin mono-treatment.  CONCLUSIONS:  Our results first demonstrate that EMT and enhanced CSC marker expression triggered by activated PI3K/Akt/mTOR signaling are involved in the chemoresistance of EOC, and BEZ235 in combination with cisplatin might be a promising treatment option to reverse EOC chemoresistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7_gQlHibJTOLt9HypzAgQfW6udTcc2eYSahBhbQq287ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzgtlShsw%253D%253D&md5=e6be0ea91d642de6556e5c7e12689c47</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1186%2Fs12885-019-5824-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-019-5824-9%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DNi%26aufirst%3DJ.%26aulast%3DBeretov%26aufirst%3DJ.%26aulast%3DGraham%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DInhibition%2520of%2520PI3K%252FAkt%252FmTOR%2520signaling%2520pathway%2520alleviates%2520ovarian%2520cancer%2520chemoresistance%2520through%2520reversing%2520epithelial-mesenchymal%2520transition%2520and%2520decreasing%2520cancer%2520stem%2520cell%2520marker%2520expression%26jtitle%3DBMC%2520Cancer%26date%3D2019%26volume%3D19%26spage%3D618%26doi%3D10.1186%2Fs12885-019-5824-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vijay, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Den Hollander, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toneff, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietila, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez-Pena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werden, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shariati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobieski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sphyris, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soundararajan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, S. A.</span></span> <span> </span><span class="NLM_article-title">GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">37</span>, <span class="refDoi"> DOI: 10.1186/s13058-019-1125-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2Fs13058-019-1125-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30845991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3cbhs1ansQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=37&author=G.+V.+Vijayauthor=N.+Zhaoauthor=P.+Den+Hollanderauthor=M.+J.+Toneffauthor=R.+Josephauthor=M.+Pietilaauthor=J.+H.+Taubeauthor=T.+R.+Sarkarauthor=E.+Ramirez-Penaauthor=S.+J.+Werdenauthor=M.+Shariatiauthor=R.+Gaoauthor=M.+Sobieskiauthor=C.+C.+Stephanauthor=N.+Sphyrisauthor=N.+Miuraauthor=P.+Daviesauthor=J.+T.+Changauthor=R.+Soundararajanauthor=J.+M.+Rosenauthor=S.+A.+Mani&title=GSK3%CE%B2+regulates+epithelial-mesenchymal+transition+and+cancer+stem+cell+properties+in+triple-negative+breast+cancer&doi=10.1186%2Fs13058-019-1125-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer</span></div><div class="casAuthors">Vijay Geraldine Vidhya; Den Hollander Petra; Joseph Robiya; Ramirez-Pena Esmeralda; Werden Steven J; Shariati Maryam; Sphyris Nathalie; Soundararajan Rama; Mani Sendurai A; Zhao Na; Toneff Mike J; Rosen Jeffrey M; Pietila Mika; Taube Joseph H; Sarkar Tapasree R; Gao Ruli; Sobieski Mary; Stephan Clifford C; Davies Peter; Miura Noayuki; Chang Jeffrey T; Chang Jeffrey T; Mani Sendurai A</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Triple-negative breast cancers (TNBCs), which lack receptors for estrogen, progesterone, and amplification of epidermal growth factor receptor 2, are highly aggressive.  Consequently, patients diagnosed with TNBCs have reduced overall and disease-free survival rates compared to patients with other subtypes of breast cancer.  TNBCs are characterized by the presence of cancer cells with mesenchymal properties, indicating that the epithelial to mesenchymal transition (EMT) plays a major role in the progression of this disease.  The EMT program has also been implicated in chemoresistance, tumor recurrence, and induction of cancer stem cell (CSC) properties.  Currently, there are no targeted therapies for TNBC, and hence, it is critical to identify the novel targets to treat TNBC.  METHODS:  A library of compounds was screened for their ability to inhibit EMT in cells with mesenchymal phenotype as assessed using the previously described Z-cad reporters.  Of the several drugs tested, GSK3β inhibitors were identified as EMT inhibitors.  The effects of GSK3β inhibitors on the properties of TNBC cells with a mesenchymal phenotype were assessed using qRT-PCR, flow cytometry, western blot, mammosphere, and migration and cell viability assays.  Publicly available datasets also were analyzed to examine if the expression of GSK3β correlates with the overall survival of breast cancer patients.  RESULTS:  We identified a GSK3β inhibitor, BIO, in a drug screen as one of the most potent inhibitors of EMT.  BIO and two other GSK3β inhibitors, TWS119 and LiCl, also decreased the expression of mesenchymal markers in several different cell lines with a mesenchymal phenotype.  Further, inhibition of GSK3β reduced EMT-related migratory properties of cells with mesenchymal properties.  To determine if GSK3β inhibitors target mesenchymal-like cells by affecting the CSC population, we employed mammosphere assays and profiled the stem cell-related cell surface marker CD44+/24- in cells after exposure to GSK3β inhibitors.  We found that GSK3β inhibitors indeed decreased the CSC properties of cell types with mesenchymal properties.  We treated cells with epithelial and mesenchymal properties with GSK3β inhibitors and found that GSK3β inhibitors selectively kill cells with mesenchymal attributes while sparing cells with epithelial properties.  We analyzed patient data to identify genes predictive of poor clinical outcome that could serve as novel therapeutic targets for TNBC.  The Wnt signaling pathway is critical to EMT, but among the various factors known to be involved in Wnt signaling, only the higher expression of GSK3β correlated with poorer overall patient survival.  CONCLUSIONS:  Taken together, our data demonstrate that GSK3β is a potential target for TNBCs and suggest that GSK3β inhibitors could serve as selective inhibitors of EMT and CSC properties for the treatment of a subset of aggressive TNBC.  GSK3β inhibitors should be tested for use in combination with standard-of-care drugs in preclinical TNBC models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfVPhSJgAa6b7NkxioyDXTfW6udTcc2eY5MiKJbzKCwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbhs1ansQ%253D%253D&md5=87411c7f788208a247d10ab28803b773</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1186%2Fs13058-019-1125-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-019-1125-0%26sid%3Dliteratum%253Aachs%26aulast%3DVijay%26aufirst%3DG.%2BV.%26aulast%3DZhao%26aufirst%3DN.%26aulast%3DDen%2BHollander%26aufirst%3DP.%26aulast%3DToneff%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DR.%26aulast%3DPietila%26aufirst%3DM.%26aulast%3DTaube%26aufirst%3DJ.%2BH.%26aulast%3DSarkar%26aufirst%3DT.%2BR.%26aulast%3DRamirez-Pena%26aufirst%3DE.%26aulast%3DWerden%26aufirst%3DS.%2BJ.%26aulast%3DShariati%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DR.%26aulast%3DSobieski%26aufirst%3DM.%26aulast%3DStephan%26aufirst%3DC.%2BC.%26aulast%3DSphyris%26aufirst%3DN.%26aulast%3DMiura%26aufirst%3DN.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DJ.%2BT.%26aulast%3DSoundararajan%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DJ.%2BM.%26aulast%3DMani%26aufirst%3DS.%2BA.%26atitle%3DGSK3%25CE%25B2%2520regulates%2520epithelial-mesenchymal%2520transition%2520and%2520cancer%2520stem%2520cell%2520properties%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2019%26volume%3D21%26spage%3D37%26doi%3D10.1186%2Fs13058-019-1125-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeran, S. M.</span></span> <span> </span><span class="NLM_article-title">Epigenetics of cancer stem cells: pathways and therapeutics</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1840</i></span>,  <span class="NLM_fpage">3494</span>– <span class="NLM_lpage">3502</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2014.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.bbagen.2014.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyns7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1840&publication_year=2014&pages=3494-3502&author=S.+Shuklaauthor=S.+M.+Meeran&title=Epigenetics+of+cancer+stem+cells%3A+pathways+and+therapeutics&doi=10.1016%2Fj.bbagen.2014.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetics of cancer stem cells: Pathways and therapeutics</span></div><div class="casAuthors">Shukla, Samriddhi; Meeran, Syed Musthapa</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1840</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3494-3502</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Epigenetic alterations including DNA methylation and histone modifications are the key factors in the differentiation of stem cells into different tissue subtypes.  The generation of cancer stem cells (CSCs) in the process of carcinogenesis may also involve similar kind of epigenetic reprogramming where, in contrast, it leads to the loss of expression of genes specific to the differentiated state and regaining of stem cell-specific characteristics.  The most important predicament with treatment of cancers includes the non-responsive quiescent CSC.The distinctive capabilities of the CSCs make cancer treatment even more difficult as this population of cells tends to remain quiescent for longer intervals and then gets reactivated leading to tumor relapse.  Therefore, the current review is aimed to focus on recent advances in understanding the relation of epigenetic reprogramming to the generation, self-renewal and proliferation of CSCs.  CSC-targeted therapeutic approaches would improve the chances of patient survival by reducing the frequency of tumor relapse.  Differentiation therapy is an emerging therapeutic approach in which the CSCs are induced to differentiate from their quiescent state to a mature differentiated form, through activation of differentiation-related signaling pathways, miRNA-mediated alteration and epigenetic differentiation therapy.  Thus, understanding the origin of CSC and their epigenetic regulation is crucial to develop treatment strategy against not only for the heterogeneous population of cancer cells but also to CSCs.Characterizing the epigenetic marks of CSCs and the assocd. signaling cascades might help in developing therapeutic strategies against chemo-resistant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEAG2zhRP3ULVg90H21EOLACvtfcHk0lhnVRPgC2pq5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyns7bO&md5=afa2da448755284fdac00bda3fb7c2cd</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2014.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2014.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DMeeran%26aufirst%3DS.%2BM.%26atitle%3DEpigenetics%2520of%2520cancer%2520stem%2520cells%253A%2520pathways%2520and%2520therapeutics%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2014%26volume%3D1840%26spage%3D3494%26epage%3D3502%26doi%3D10.1016%2Fj.bbagen.2014.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turdo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veschi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaggianesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnici, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianca, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stassi, G.</span></span> <span> </span><span class="NLM_article-title">Meeting the challenge of targeting cancer stem cells</span>. <i>Front. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">16</span>, <span class="refDoi"> DOI: 10.3389/fcell.2019.00016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffcell.2019.00016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30834247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgsVKjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=16&author=A.+Turdoauthor=V.+Veschiauthor=M.+Gaggianesiauthor=A.+Chinniciauthor=P.+Biancaauthor=M.+Todaroauthor=G.+Stassi&title=Meeting+the+challenge+of+targeting+cancer+stem+cells&doi=10.3389%2Ffcell.2019.00016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Meeting the Challenge of Targeting Cancer Stem Cells</span></div><div class="casAuthors">Turdo Alice; Veschi Veronica; Gaggianesi Miriam; Chinnici Aurora; Bianca Paola; Stassi Giorgio; Todaro Matilde</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in cell and developmental biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16</span>
        ISSN:<span class="NLM_cas:issn">2296-634X</span>.
    </div><div class="casAbstract">Notwithstanding cancer patients benefit from a plethora of therapeutic alternatives, drug resistance remains a critical hurdle.  Indeed, the high mortality rate is associated with metastatic disease, which is mostly incurable due to the refractoriness of metastatic cells to current treatments.  Increasing data demonstrate that tumors contain a small subpopulation of cancer stem cells (CSCs) able to establish primary tumor and metastasis.  CSCs are endowed with multiple treatment resistance capabilities comprising a highly efficient DNA damage repair machinery, the activation of survival pathways, enhanced cellular plasticity, immune evasion and the adaptation to a hostile microenvironment.  Due to the presence of distinct cell populations within a tumor, cancer research has to face the major challenge of targeting the intra-tumoral as well as inter-tumoral heterogeneity.  Thus, targeting molecular drivers operating in CSCs, in combination with standard treatments, may improve cancer patients' outcomes, yielding long-lasting responses.  Here, we report a comprehensive overview on the most significant therapeutic advances that have changed the known paradigms of cancer treatment with a particular emphasis on newly developed compounds that selectively affect the CSC population.  Specifically, we are focusing on innovative therapeutic approaches including differentiation therapy, anti-angiogenic compounds, immunotherapy and inhibition of epigenetic enzymes and microenvironmental cues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNWC6k0csi_sERNNga7KD-fW6udTcc2eY5MiKJbzKCwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgsVKjuw%253D%253D&md5=afa42b46d117fed33f5cfed79b2936de</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3389%2Ffcell.2019.00016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcell.2019.00016%26sid%3Dliteratum%253Aachs%26aulast%3DTurdo%26aufirst%3DA.%26aulast%3DVeschi%26aufirst%3DV.%26aulast%3DGaggianesi%26aufirst%3DM.%26aulast%3DChinnici%26aufirst%3DA.%26aulast%3DBianca%26aufirst%3DP.%26aulast%3DTodaro%26aufirst%3DM.%26aulast%3DStassi%26aufirst%3DG.%26atitle%3DMeeting%2520the%2520challenge%2520of%2520targeting%2520cancer%2520stem%2520cells%26jtitle%3DFront.%2520Cell%2520Dev.%2520Biol.%26date%3D2019%26volume%3D7%26spage%3D16%26doi%3D10.3389%2Ffcell.2019.00016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhol, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panigrahi, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praharaj, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahapatra, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behera, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutia, S. K.</span></span> <span> </span><span class="NLM_article-title">Epigenetic modifications of autophagy in cancer and cancer therapeutics</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2019.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.semcancer.2019.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31158463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFyjtLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2020&pages=22-33&author=C.+S.+Bholauthor=D.+P.+Panigrahiauthor=P.+P.+Praharajauthor=K.+K.+Mahapatraauthor=S.+Patraauthor=S.+R.+Mishraauthor=B.+P.+Beheraauthor=S.+K.+Bhutia&title=Epigenetic+modifications+of+autophagy+in+cancer+and+cancer+therapeutics&doi=10.1016%2Fj.semcancer.2019.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic modifications of autophagy in cancer and cancer therapeutics</span></div><div class="casAuthors">Bhol, Chandra S.; Panigrahi, Debasna P.; Praharaj, Prakash P.; Mahapatra, Kewal K.; Patra, Srimanta; Mishra, Soumya R.; Behera, Bishnu P.; Bhutia, Sujit K.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22-33</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Epigenetic alterations, such as DNA methylation, histone modifications and miRNAs, have a significant role play in malignant cellular transformation and metastasis.  On the other hand, autophagy has been reported to perform context-dependent roles in cancer; at times, it becomes lethal and abolishes tumorigenesis, whereas, at other instances, it protects cancer cells by providing a rescue mechanism under adverse conditions.  Although epigenetics and autophagy are two important and independent cellular processes, various oncogenic and oncosuppressor proteins involve autophagy through epigenetic modifications and different signaling pathways, thereby regulating tumor growth and therapeutic response.  Moreover, the importance of epigenetic modification of autophagy in cancer is reflected through its involvement in cancer stem cell maintenance, which in turn, contributes to tumor cell viability during dormancy leading to tumor recurrence.  The effects of epigenetic modifications of autophagy in cancer is still ambiguous and less acknowledged; therefore, efforts have been made to understand its detail underlying mechanism to unveil new targets and avenues for better prognosis and diagnosis of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyB3OlPFlIy7Vg90H21EOLACvtfcHk0lhMxABqKoExQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFyjtLjL&md5=018af7507aa941ef03fdc9c8bc244508</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2019.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2019.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DBhol%26aufirst%3DC.%2BS.%26aulast%3DPanigrahi%26aufirst%3DD.%2BP.%26aulast%3DPraharaj%26aufirst%3DP.%2BP.%26aulast%3DMahapatra%26aufirst%3DK.%2BK.%26aulast%3DPatra%26aufirst%3DS.%26aulast%3DMishra%26aufirst%3DS.%2BR.%26aulast%3DBehera%26aufirst%3DB.%2BP.%26aulast%3DBhutia%26aufirst%3DS.%2BK.%26atitle%3DEpigenetic%2520modifications%2520of%2520autophagy%2520in%2520cancer%2520and%2520cancer%2520therapeutics%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2020%26volume%3D66%26spage%3D22%26epage%3D33%26doi%3D10.1016%2Fj.semcancer.2019.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span> <span> </span><span class="NLM_article-title">Targeting cancer stem cell pathways for cancer therapy</span>. <i>Signal Transduct. Target Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.1038/s41392-020-0110-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fs41392-020-0110-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32296030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB38jhtFyisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=8&author=L.+Yangauthor=P.+Shiauthor=G.+Zhaoauthor=J.+Xuauthor=W.+Pengauthor=J.+Zhangauthor=G.+Zhangauthor=X.+Wangauthor=Z.+Dongauthor=F.+Chenauthor=H.+Cui&title=Targeting+cancer+stem+cell+pathways+for+cancer+therapy&doi=10.1038%2Fs41392-020-0110-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer stem cell pathways for cancer therapy</span></div><div class="casAuthors">Yang Liqun; Shi Pengfei; Zhao Gaichao; Xu Jie; Peng Wen; Zhang Jiayi; Zhang Guanghui; Wang Xiaowen; Dong Zhen; Cui Hongjuan; Yang Liqun; Shi Pengfei; Zhao Gaichao; Xu Jie; Peng Wen; Zhang Jiayi; Zhang Guanghui; Wang Xiaowen; Dong Zhen; Cui Hongjuan; Chen Fei</div><div class="citationInfo"><span class="NLM_cas:title">Signal transduction and targeted therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been considered promising therapeutic targets for cancer therapy.  These cells have self-renewal capacity and differentiation potential and contribute to multiple tumor malignancies, such as recurrence, metastasis, heterogeneity, multidrug resistance, and radiation resistance.  The biological activities of CSCs are regulated by several pluripotent transcription factors, such as OCT4, Sox2, Nanog, KLF4, and MYC.  In addition, many intracellular signaling pathways, such as Wnt, NF-κB (nuclear factor-κB), Notch, Hedgehog, JAK-STAT (Janus kinase/signal transducers and activators of transcription), PI3K/AKT/mTOR (phosphoinositide 3-kinase/AKT/mammalian target of rapamycin), TGF (transforming growth factor)/SMAD, and PPAR (peroxisome proliferator-activated receptor), as well as extracellular factors, such as vascular niches, hypoxia, tumor-associated macrophages, cancer-associated fibroblasts, cancer-associated mesenchymal stem cells, extracellular matrix, and exosomes, have been shown to be very important regulators of CSCs.  Molecules, vaccines, antibodies, and CAR-T (chimeric antigen receptor T cell) cells have been developed to specifically target CSCs, and some of these factors are already undergoing clinical trials.  This review summarizes the characterization and identification of CSCs, depicts major factors and pathways that regulate CSC development, and discusses potential targeted therapy for CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpLB2lPAt1ijUE-swuRqsHfW6udTcc2ea7wiW2p9iznrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38jhtFyisA%253D%253D&md5=6678de50a460f118ed9fb7446edb64df</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fs41392-020-0110-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41392-020-0110-5%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DCui%26aufirst%3DH.%26atitle%3DTargeting%2520cancer%2520stem%2520cell%2520pathways%2520for%2520cancer%2520therapy%26jtitle%3DSignal%2520Transduct.%2520Target%2520Ther.%26date%3D2020%26volume%3D5%26spage%3D8%26doi%3D10.1038%2Fs41392-020-0110-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saygin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majeti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reizes, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lathia, J. D.</span></span> <span> </span><span class="NLM_article-title">Targeting cancer stemness in the clinic: from hype to hope</span>. <i>Cell Stem Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1016/j.stem.2018.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.stem.2018.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30595497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntl2l" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=25-40&author=C.+Sayginauthor=D.+Mateiauthor=R.+Majetiauthor=O.+Reizesauthor=J.+D.+Lathia&title=Targeting+cancer+stemness+in+the+clinic%3A+from+hype+to+hope&doi=10.1016%2Fj.stem.2018.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Cancer Stemness in the Clinic: From Hype to Hope</span></div><div class="casAuthors">Saygin, Caner; Matei, Daniela; Majeti, Ravindra; Reizes, Ofer; Lathia, Justin D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Stem Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-40</span>CODEN:
                <span class="NLM_cas:coden">CSCEC4</span>;
        ISSN:<span class="NLM_cas:issn">1875-9777</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Tumors are composed of non-homogeneous cell populations exhibiting varying degrees of genetic and functional heterogeneity.  Cancer stem cells (CSCs) are capable of sustaining tumors by manipulating genetic and non-genetic factors to metastasize, resist treatment, and maintain the tumor microenvironment.  Understanding the key traits and mechanisms of CSC survival provides opportunities to improve patient outcomes via improved prognostic models and therapeutics.  Here, we review the clin. significance of CSCs and results of potential CSC-targeting therapies in various cancers.  We discuss barriers to translating cues from pre-clin. models into clin. applications and propose new strategies for rational design of future anti-CSC trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuGh67NSTJgbVg90H21EOLACvtfcHk0lhMxABqKoExQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntl2l&md5=32cd80d33130f24b9ad4accbca08f716</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.stem.2018.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.stem.2018.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DSaygin%26aufirst%3DC.%26aulast%3DMatei%26aufirst%3DD.%26aulast%3DMajeti%26aufirst%3DR.%26aulast%3DReizes%26aufirst%3DO.%26aulast%3DLathia%26aufirst%3DJ.%2BD.%26atitle%3DTargeting%2520cancer%2520stemness%2520in%2520the%2520clinic%253A%2520from%2520hype%2520to%2520hope%26jtitle%3DCell%2520Stem%2520Cell%26date%3D2019%26volume%3D24%26spage%3D25%26epage%3D40%26doi%3D10.1016%2Fj.stem.2018.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fayomi, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anyaeche, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckanovich, R. J.</span></span> <span> </span><span class="NLM_article-title">An evolving paradigm of cancer stem cell hierarchies: therapeutic implications</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3083</span>– <span class="NLM_lpage">3098</span>, <span class="refDoi"> DOI: 10.7150/thno.41647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.7150%2Fthno.41647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32194856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsl2mt7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=3083-3098&author=A.+J.+Coleauthor=A.+P.+Fayomiauthor=V.+I.+Anyaecheauthor=S.+Baiauthor=R.+J.+Buckanovich&title=An+evolving+paradigm+of+cancer+stem+cell+hierarchies%3A+therapeutic+implications&doi=10.7150%2Fthno.41647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">An evolving paradigm of cancer stem cell hierarchies: therapeutic implications</span></div><div class="casAuthors">Cole, Alexander J.; Fayomi, Adetunji P.; Anyaeche, Vivian I.; Bai, Shoumei; Buckanovich, Ronald J.</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3083-3098</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">A review.  Over a decade of research has confirmed the crit. role of cancer stem-like cells (CSCs) in tumor initiation, chemoresistance, and metastasis.  Increasingly, CSC hierarchies have begun to be defined with some recurring themes.  This includes evidence that these hierarchies are 'flexible,' with both cell state transitions and dedifferentiation events possible.  These findings pose therapeutic hurdles and opportunities.  Here, we review cancer stem cell hierarchies and their interactions with the tumor microenvironment.  We also discuss the current therapeutic approaches designed to target CSC hierarchies and initial clin. trial results for CSC targeting agents.  While cancer stem cell targeted therapies are still in their infancy, we are beginning to see encouraging results that suggest a pos. outlook for CSC-targeting approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDUUo-wF4qwrVg90H21EOLACvtfcHk0lioL2fezO72fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsl2mt7jF&md5=64fa83142730948eee2340502a9dc218</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.7150%2Fthno.41647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.41647%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DA.%2BJ.%26aulast%3DFayomi%26aufirst%3DA.%2BP.%26aulast%3DAnyaeche%26aufirst%3DV.%2BI.%26aulast%3DBai%26aufirst%3DS.%26aulast%3DBuckanovich%26aufirst%3DR.%2BJ.%26atitle%3DAn%2520evolving%2520paradigm%2520of%2520cancer%2520stem%2520cell%2520hierarchies%253A%2520therapeutic%2520implications%26jtitle%3DTheranostics%26date%3D2020%26volume%3D10%26spage%3D3083%26epage%3D3098%26doi%3D10.7150%2Fthno.41647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. L.</span></span> <span> </span><span class="NLM_article-title">Targeting cancer stem cells in drug discovery: current state and future perspectives</span>. <i>World J. Stem Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">420</span>, <span class="refDoi"> DOI: 10.4252/wjsc.v11.i7.398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.4252%2Fwjsc.v11.i7.398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31396368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3MvmtlGluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=398-420&author=F.+Y.+Duauthor=Q.+F.+Zhouauthor=W.+J.+Sunauthor=G.+L.+Chen&title=Targeting+cancer+stem+cells+in+drug+discovery%3A+current+state+and+future+perspectives&doi=10.4252%2Fwjsc.v11.i7.398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer stem cells in drug discovery: Current state and future perspectives</span></div><div class="casAuthors">Du Fang-Yu; Zhou Qi-Fan; Sun Wen-Jiao; Chen Guo-Liang</div><div class="citationInfo"><span class="NLM_cas:title">World journal of stem cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">398-420</span>
        ISSN:<span class="NLM_cas:issn">1948-0210</span>.
    </div><div class="casAbstract">In recent decades, cancer stem cells (CSCs) have been increasingly identified in many malignancies.  CSC-related signaling pathways and their functions provide new strategies for treating cancer.  The aberrant activation of related signaling pathways (e.g., Wnt, Notch, and Hedgehog pathways) has been linked to multiple types of malignant tumors, which makes these pathways attractive targets for cancer therapy.  CSCs display many characteristic features, such as self-renewal, differentiation, high tumorigenicity, and drug resistance.  Therefore, there is an urgent need to develop new therapeutic strategies to target these pathways to control stem cell replication, survival, and differentiation.  Notable crosstalk occurs among different signaling pathways and potentially leads to compensatory escape.  Therefore, multitarget inhibitors will be one of the main methods to overcome the drug resistance of CSCs.  Many small molecule inhibitors of components of signaling pathways in CSCs have entered clinical trials, and some inhibitors, such as vismodegib, sonidegib, and glasdegib, have been approved.  Tumor cells are susceptible to sonidegib and vismodegib resistance due to mutations in the Smo protein.  The signal transducers and activators of transcription 3 (STAT3) inhibitor BBI608 is being evaluated in a phase III trial for a variety of cancers.  Structural derivatives of BBI608 are the main focus of STAT3 inhibitor development, which is another strategy for CSC therapy.  In addition to the potential pharmacological inhibitors targeting CSC-related signaling pathways, other methods of targeting CSCs are available, such as nano-drug delivery systems, mitochondrion targeting, autophagy, hyperthermia, immunotherapy, and CSC microenvironment targeting.  In addition, we summarize the latest advances in the clinical development of agents targeting CSC-related signaling pathways and other methods of targeting CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrJ96Nuqm0356KlWarZTAzfW6udTcc2eZY4IVDOTyDiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvmtlGluw%253D%253D&md5=09054c0eb04f640b8401d31e2b33506b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.4252%2Fwjsc.v11.i7.398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4252%252Fwjsc.v11.i7.398%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DF.%2BY.%26aulast%3DZhou%26aufirst%3DQ.%2BF.%26aulast%3DSun%26aufirst%3DW.%2BJ.%26aulast%3DChen%26aufirst%3DG.%2BL.%26atitle%3DTargeting%2520cancer%2520stem%2520cells%2520in%2520drug%2520discovery%253A%2520current%2520state%2520and%2520future%2520perspectives%26jtitle%3DWorld%2520J.%2520Stem%2520Cells%26date%3D2019%26volume%3D11%26spage%3D398%26epage%3D420%26doi%3D10.4252%2Fwjsc.v11.i7.398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajayi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavasolian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezalotfi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebrahimi, M.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells targeting; the lessons from the interaction of the immune system, the cancer stem cells and the tumor niche</span>. <i>Int. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1080/08830185.2019.1669593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1080%2F08830185.2019.1669593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31578892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSiu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=267-283&author=H.+Rajayiauthor=P.+Tavasolianauthor=A.+Rezalotfiauthor=M.+Ebrahimi&title=Cancer+stem+cells+targeting%3B+the+lessons+from+the+interaction+of+the+immune+system%2C+the+cancer+stem+cells+and+the+tumor+niche&doi=10.1080%2F08830185.2019.1669593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Stem Cells Targeting; the Lessons from the Interaction of the Immune System, the Cancer Stem Cells and the Tumor Niche</span></div><div class="casAuthors">Rajayi, Hajar; Tavasolian, Parsova; Rezalotfi, Alaleh; Ebrahimi, Marzieh</div><div class="citationInfo"><span class="NLM_cas:title">International Reviews of Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">267-283</span>CODEN:
                <span class="NLM_cas:coden">IRIMEH</span>;
        ISSN:<span class="NLM_cas:issn">0883-0185</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Failure of treatment strategies against cancers is major issue engaging many scientists to investigate the possible resistance factors.  Cancer stem cells (CSCs) subvert promising therapeutic methods by developing resistant cancers.  These pluripotent cells are located in individual microenvironments called cancer niche.  CSCs affect the immune cells and on the flip side, the immune cells in the cancer niche influence them.  Thereby, the interaction between CSCs and immune cells in cancer niche needs to be clearly studied in order to develop novel efficient methods of immune-based cancer treatment.  In this article, we review literature about the suggested methods of CSC escape from immune responses and the effect of cancer niche characteristics on the ability of CSCs to develop resistant strains of cancers.  Moreover, we discuss immune-mediated tumor targeting methods and bring in trials focused on CSC targeted therapies.  We aim to help physicians to reach a consensus about using CSC-targeted immunotherapy methods and emerge novel immunotherapy methods through disrupting the interaction between immune cells and CSCs in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlyJI0t88sQLVg90H21EOLACvtfcHk0lioL2fezO72fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSiu73M&md5=75c96b20df4a4c26fea5dc2548f66e9e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1080%2F08830185.2019.1669593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F08830185.2019.1669593%26sid%3Dliteratum%253Aachs%26aulast%3DRajayi%26aufirst%3DH.%26aulast%3DTavasolian%26aufirst%3DP.%26aulast%3DRezalotfi%26aufirst%3DA.%26aulast%3DEbrahimi%26aufirst%3DM.%26atitle%3DCancer%2520stem%2520cells%2520targeting%253B%2520the%2520lessons%2520from%2520the%2520interaction%2520of%2520the%2520immune%2520system%252C%2520the%2520cancer%2520stem%2520cells%2520and%2520the%2520tumor%2520niche%26jtitle%3DInt.%2520Rev.%2520Immunol.%26date%3D2019%26volume%3D38%26spage%3D267%26epage%3D283%26doi%3D10.1080%2F08830185.2019.1669593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoque, M. O.</span></span> <span> </span><span class="NLM_article-title">Targeting cancer stem cells: a strategy for effective eradication of cancer</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">732</span>, <span class="refDoi"> DOI: 10.3390/cancers11050732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcancers11050732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitV2mur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=732&author=M.+Shibataauthor=M.+O.+Hoque&title=Targeting+cancer+stem+cells%3A+a+strategy+for+effective+eradication+of+cancer&doi=10.3390%2Fcancers11050732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer stem cells: a strategy for effective eradication of cancer</span></div><div class="casAuthors">Shibata, Masahiro; Hoque, Mohammad Obaidul</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">732</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are subpopulations of tumor cells with the ability to self-renew, differentiate, and initiate and maintain tumor growth, and they are considered to be the main drivers of intra- and inter-tumoral heterogeneity.  While conventional chemotherapy can eradicate the majority of non-CSC tumor cells, CSCs are often drug-resistant, leading to tumor recurrence and metastasis.  The heterogeneity of CSCs is the main challenge in developing CSC-targeting therapy; therefore, we and other investigators have focused on developing novel therapeutic strategies that combine conventional chemotherapy with inhibitors of CSC-regulating pathways.  Encouraging preclin. findings have suggested that CSC pathway blockade can indeed enhance cellular sensitivity to non-targeted conventional therapy, and this work has led to several ongoing clin. trials of CSC pathway inhibitors.  Our studies in bladder cancer and lung adenocarcinoma have demonstrated a crucial role of YAP1, a transcriptional regulator of genes that promote cell survival and proliferation, in regulating CSC phenotypes.  Moreover, using cell lines and patient-derived xenograft models, we showed that inhibition of YAP1 enhances the efficacy of conventional therapies by attenuating CSC stemness features.  In this review, we summarize the therapeutic strategies for targeting CSCs in several cancers and discuss the potential and challenges of the approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxzejZFp2WPrVg90H21EOLACvtfcHk0li0iHMH8BIZwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitV2mur4%253D&md5=dd913083e1567dfdb7ca4c4dc83101ac</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.3390%2Fcancers11050732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11050732%26sid%3Dliteratum%253Aachs%26aulast%3DShibata%26aufirst%3DM.%26aulast%3DHoque%26aufirst%3DM.%2BO.%26atitle%3DTargeting%2520cancer%2520stem%2520cells%253A%2520a%2520strategy%2520for%2520effective%2520eradication%2520of%2520cancer%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26spage%3D732%26doi%3D10.3390%2Fcancers11050732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jangili, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. S.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">7856</span>– <span class="NLM_lpage">7878</span>, <span class="refDoi"> DOI: 10.1039/D0CS00379D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1039%2FD0CS00379D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32633291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlagur3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2020&pages=7856-7878&author=J.+Hanauthor=M.+Wonauthor=J.+H.+Kimauthor=E.+Jungauthor=K.+Minauthor=P.+Jangiliauthor=J.+S.+Kim&title=Cancer+stem+cell-targeted+bio-imaging+and+chemotherapeutic+perspective&doi=10.1039%2FD0CS00379D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective</span></div><div class="casAuthors">Han, Jiyou; Won, Miae; Kim, Ji Hyeon; Jung, Eugeine; Min, Kyungim; Jangili, Paramesh; Kim, Jong Seung</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7856-7878</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs), also called tumor-initiating cells (TICs), have been studied intensively due to their rapid proliferation, migration, and role in the recurrence of cancer.  In general, CSC marker-pos. cells [CD133, CD44, CD166, aldehyde dehydrogenase (ALDH), and epithelial cell adhesion mol. (EpCAM)] exhibit a 100-fold increased capacity to initiate cancer.  Within a heterogeneous tumor mass, only approx. 0.05-3% of cells are suspected to be CSCs and able to proliferate under hypoxia.  Interestingly, CSCs, cancer cells, and normal stem cells share many cytochem. properties, such as inhibition of the redox system for reactive oxygen species (ROS) prodn. and high expression of drug resistance transporters.  However, compared to normal stem cells, CSCs develop unique metabolic flexibility, which involves switching between oxidative phosphorylation (OXPHOS) and glycolysis as their main source of energy.  Due to the similarities between CSCs and other cancer cells and normal stem cells, limited chemotherapeutic and bio-imaging reagents specific for CSCs have been developed.  In this short review, we address the current knowledge regarding CSCs with a focus on designing chemotherapeutic and bio-imaging reagents that target CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsMTmA_W7FdrVg90H21EOLACvtfcHk0li0iHMH8BIZwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlagur3N&md5=791fe87c313aea6f695e8368195ed4af</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1039%2FD0CS00379D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0CS00379D%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DWon%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DJung%26aufirst%3DE.%26aulast%3DMin%26aufirst%3DK.%26aulast%3DJangili%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DJ.%2BS.%26atitle%3DCancer%2520stem%2520cell-targeted%2520bio-imaging%2520and%2520chemotherapeutic%2520perspective%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2020%26volume%3D49%26spage%3D7856%26epage%3D7878%26doi%3D10.1039%2FD0CS00379D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zu, X.</span></span> <span> </span><span class="NLM_article-title">Self-renewal signalling pathway inhibitors: perspectives on therapeutic approaches for cancer stem cells</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.2147/OTT.S224465</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.2147%2FOTT.S224465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32021295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVWlsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=525-540&author=Q.+Zhuauthor=Y.+Shenauthor=X.+Chenauthor=J.+Heauthor=J.+Liuauthor=X.+Zu&title=Self-renewal+signalling+pathway+inhibitors%3A+perspectives+on+therapeutic+approaches+for+cancer+stem+cells&doi=10.2147%2FOTT.S224465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Self-renewal signalling pathway inhibitors: perspectives on therapeutic approaches for cancer stem cells</span></div><div class="casAuthors">Zhu, Qingyun; Shen, Yingying; Chen, Xiguang; He, Jun; Liu, Jianghua; Zu, Xuyu</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">525-540</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The poor survival and prognosis of individuals with cancer are often attributed to tumor relapse and metastasis, which may be due to the presence of cancer stem cells (CSCs).  CSCs have the characteristics of self-renewal, differentiation potential, high carcinogenicity, and drug resistance.  In addn., CSCs exhibit many characteristics similar to those of embryonic or tissue stem cells while displaying persistent abnormal activation of self-renewal pathways assocd. with development and tissue homeostasis, including the Wnt, Notch, Hedgehog (Hh), TGF-β, JAK/STAT3, and NF-κB pathways.  Therefore, we can eliminate CSCs by targeting these self-renewal pathways to constrain stem cell replication, survival and differentiation.  At the same time, we cannot neglect the ping-pong effect of the tumor microenvironment, which releases cytokines and promotes self-renewal pathways in CSCs.  Recently, meaningful progress has been made in the study of inhibitors of self-renewal pathways in tumors.  This review primarily summarizes several representative and novel agents targeting these self-renewal signalling pathways and the tumor microenvironment and that represent a promising strategy for treating refractory and recurrent cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7b-ZkJAj6F7Vg90H21EOLACvtfcHk0li0iHMH8BIZwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVWlsbrN&md5=7dedc038b7491b9b017c927236c51bf7</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2147%2FOTT.S224465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S224465%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZu%26aufirst%3DX.%26atitle%3DSelf-renewal%2520signalling%2520pathway%2520inhibitors%253A%2520perspectives%2520on%2520therapeutic%2520approaches%2520for%2520cancer%2520stem%2520cells%26jtitle%3DOncoTargets%2520Ther.%26date%3D2020%26volume%3D13%26spage%3D525%26epage%3D540%26doi%3D10.2147%2FOTT.S224465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span> <span> </span><span class="NLM_article-title">Current advance of therapeutic agents in clinical trials potentially targeting tumor plasticity</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">887</span>, <span class="refDoi"> DOI: 10.3389/fonc.2019.00887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffonc.2019.00887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31552191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvVKhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=887&author=X.+G.+Yangauthor=L.+C.+Zhuauthor=Y.+J.+Wangauthor=Y.+Y.+Liauthor=D.+Wang&title=Current+advance+of+therapeutic+agents+in+clinical+trials+potentially+targeting+tumor+plasticity&doi=10.3389%2Ffonc.2019.00887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity</span></div><div class="casAuthors">Yang Xiao-Guang; Zhu Lan-Cao; Wang Yan-Jun; Li Yan-Yu; Wang Dun</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">887</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Tumor plasticity refers to tumor cell's inherent property of transforming one type of cell to different types of cells.  Tumor plasticity is the main cause of tumor relapse, metastasis and drug resistance.  Cancer stem cell (CSC) model embodies the trait of tumor plasticity.  During carcinoma progression, epithelial-mesenchymal transition (EMT) plays crucial role in the formation of CSCs and vasculogenic mimicry (VM) based on epithelial-mesenchymal plasticity.  And the unique tumor microenvironment (TME) not only provides suitable niche for CSCs but promotes the building of CSCs and VM that nourishes tumor tissue together with neoplasm metabolism by affecting tumor plasticity.  Therapeutic strategies targeting tumor plasticity are promising ways to treat malignant tumor.  In this article, we discuss the recent developments of potential drug targets related to CSCs, EMT, TME, VM, and metabolic pathways and summarize drugs that target these areas in clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSSH6BJPImEXQvupmecNw_lfW6udTcc2eamtwcIHYyAOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvVKhsA%253D%253D&md5=ca4f0603b062b3a9a8489c48496c5ed2</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2019.00887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2019.00887%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%2BG.%26aulast%3DZhu%26aufirst%3DL.%2BC.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BY.%26aulast%3DWang%26aufirst%3DD.%26atitle%3DCurrent%2520advance%2520of%2520therapeutic%2520agents%2520in%2520clinical%2520trials%2520potentially%2520targeting%2520tumor%2520plasticity%26jtitle%3DFront.%2520Oncol.%26date%3D2019%26volume%3D9%26spage%3D887%26doi%3D10.3389%2Ffonc.2019.00887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerson, S. L.</span></span> <span> </span><span class="NLM_article-title">Concise reviews: cancer stem cell targeted therapies: toward clinical success</span>. <i>Stem Cells Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1002/sctm.18-0123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fsctm.18-0123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30328686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3cvgtV2iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=75-81&author=A.+Desaiauthor=Y.+Yanauthor=S.+L.+Gerson&title=Concise+reviews%3A+cancer+stem+cell+targeted+therapies%3A+toward+clinical+success&doi=10.1002%2Fsctm.18-0123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success</span></div><div class="casAuthors">Desai Amar; Yan Yan; Gerson Stanton L; Desai Amar; Yan Yan; Gerson Stanton L</div><div class="citationInfo"><span class="NLM_cas:title">Stem cells translational medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-81</span>
        ISSN:<span class="NLM_cas:issn">2157-6564</span>.
    </div><div class="casAbstract">Cancer stem cells (CSCs) are a subpopulation of cells within tumors that possess the stem cell characteristics of self-renewal, quiescence, differentiation, and the ability to recapitulate the parental tumor when transplanted into a host.  CSCs are correlated with poor clinical outcome due to their contribution to chemotherapy resistance and metastasis.  Multiple cell surface and enzymatic markers have been characterized to identify CSCs within a heterogeneous tumor, and here we summarize ongoing preclinical and clinical efforts to therapeutically target these cells and improve patient outcomes.  Stem Cells Translational Medicine 2019;8:75-81.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRakWyb4NBDdQ20zIbnCCI3fW6udTcc2eamtwcIHYyAOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvgtV2iug%253D%253D&md5=abff02751ed183315ebab6ddc9994752</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Fsctm.18-0123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsctm.18-0123%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DA.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DGerson%26aufirst%3DS.%2BL.%26atitle%3DConcise%2520reviews%253A%2520cancer%2520stem%2520cell%2520targeted%2520therapies%253A%2520toward%2520clinical%2520success%26jtitle%3DStem%2520Cells%2520Transl.%2520Med.%26date%3D2019%26volume%3D8%26spage%3D75%26epage%3D81%26doi%3D10.1002%2Fsctm.18-0123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Cortellis</span> <span> </span><span class="NLM_article-title">Drug Discovery Intelligence</span>. <span class="NLM_publisher-name">Clarivate Analytics</span>, <span class="NLM_year">2020</span>. <a href="http://cortellis.com/drugdiscovery/home?locale=en-US" class="extLink">http://cortellis.com/drugdiscovery/home?locale=en-US</a> (accessed
2020-07-27).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Cortellis&title=Drug+Discovery+Intelligence"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DDrug%2520Discovery%2520Intelligence%26pub%3DClarivate%2520Analytics%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naujokat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, D. L.</span></span> <span> </span><span class="NLM_article-title">The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.2174/0929867327666200228110738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.2174%2F0929867327666200228110738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32107991" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=C.+Naujokatauthor=D.+L.+McKee&title=The+%E2%80%9CBig+Five%E2%80%9D+Phytochemicals+Targeting+Cancer+Stem+Cells%3A+Curcumin%2C+EGCG%2C+Sulforaphane%2C+Resveratrol+and+Genistein&doi=10.2174%2F0929867327666200228110738"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2174%2F0929867327666200228110738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867327666200228110738%26sid%3Dliteratum%253Aachs%26aulast%3DNaujokat%26aufirst%3DC.%26aulast%3DMcKee%26aufirst%3DD.%2BL.%26atitle%3DThe%2520%25E2%2580%259CBig%2520Five%25E2%2580%259D%2520Phytochemicals%2520Targeting%2520Cancer%2520Stem%2520Cells%253A%2520Curcumin%252C%2520EGCG%252C%2520Sulforaphane%252C%2520Resveratrol%2520and%2520Genistein%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.2174%2F0929867327666200228110738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liskova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubatka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlyncek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Büsselberg, D.</span></span> <span> </span><span class="NLM_article-title">Dietary phytochemicals targeting cancer stem cells</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">899</span>, <span class="refDoi"> DOI: 10.3390/molecules24050899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fmolecules24050899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos1elsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=899&author=A.+Liskovaauthor=P.+Kubatkaauthor=M.+Samecauthor=P.+Zuborauthor=M.+Mlyncekauthor=T.+Bielikauthor=S.+M.+Samuelauthor=A.+Zulliauthor=T.+K.+Kwonauthor=D.+B%C3%BCsselberg&title=Dietary+phytochemicals+targeting+cancer+stem+cells&doi=10.3390%2Fmolecules24050899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Dietary phytochemicals targeting cancer stem cells</span></div><div class="casAuthors">Liskova, Alena; Kubatka, Peter; Samec, Marek; Zubor, Pavol; Mlyncek, Milos; Bielik, Tibor; Samuel, Samson Mathews; Zulli, Anthony; Kwon, Taeg Kyu; Buesselberg, Dietrich</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">899/1-899/19</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  There is an increasing awareness of the importance of a diet rich in fruits and vegetables for human health.  Cancer stem cells (CSCs) are characterized as a subpopulation of cancer cells with aberrant regulation of self-renewal, proliferation or apoptosis leading to cancer progression, invasiveness, metastasis formation, and therapy resistance.  Anticancer effects of phytochems. are also directed to target CSCs.  Here we provide a comprehensive review of dietary phytochems. targeting CSCs.  Moreover, we evaluate and summarize studies dealing with effects of dietary phytochems. on CSCs of various malignancies in preclin. and clin. research.  Dietary phytochems. have a significant impact on CSCs which may be applied in cancer prevention and treatment.  However, anticancer effects of plant derived compds. have not yet been fully investigated in clin. research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovgRRecCNC07Vg90H21EOLACvtfcHk0liPpdlaOQvEAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos1elsbw%253D&md5=70c9a31d603166936c01cb5a789a7108</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24050899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24050899%26sid%3Dliteratum%253Aachs%26aulast%3DLiskova%26aufirst%3DA.%26aulast%3DKubatka%26aufirst%3DP.%26aulast%3DSamec%26aufirst%3DM.%26aulast%3DZubor%26aufirst%3DP.%26aulast%3DMlyncek%26aufirst%3DM.%26aulast%3DBielik%26aufirst%3DT.%26aulast%3DSamuel%26aufirst%3DS.%2BM.%26aulast%3DZulli%26aufirst%3DA.%26aulast%3DKwon%26aufirst%3DT.%2BK.%26aulast%3DB%25C3%25BCsselberg%26aufirst%3DD.%26atitle%3DDietary%2520phytochemicals%2520targeting%2520cancer%2520stem%2520cells%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D899%26doi%3D10.3390%2Fmolecules24050899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giglioli-Guivarc’h, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbasi, B. H.</span></span> <span> </span><span class="NLM_article-title">Mechanistic evaluation of phytochemicals in breast cancer remedy: current understanding and future perspectives</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">29714</span>– <span class="NLM_lpage">29744</span>, <span class="refDoi"> DOI: 10.1039/C8RA04879G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1039%2FC8RA04879G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFGlsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=29714-29744&author=M.+Younasauthor=C.+Hanoauthor=N.+Giglioli-Guivarc%E2%80%99hauthor=B.+H.+Abbasi&title=Mechanistic+evaluation+of+phytochemicals+in+breast+cancer+remedy%3A+current+understanding+and+future+perspectives&doi=10.1039%2FC8RA04879G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic evaluation of phytochemicals in breast cancer remedy: current understanding and future perspectives</span></div><div class="casAuthors">Younas, Muhammad; Hano, Christophe; Giglioli-Guivarc'h, Nathalie; Abbasi, Bilal Haider</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">29714-29744</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Breast cancer is one of the most commonly diagnosed cancers around the globe and accounts for a large proportion of fatalities in women.  Despite the advancement in therapeutic and diagnostic procedures, breast cancer still represents a major challenge.  Current anti-breast cancer approaches include surgical removal, radiotherapy, hormonal therapy and the use of various chemotherapeutic drugs.  However, drug resistance, assocd. serious adverse effects, metastasis and recurrence complications still need to be resolved which demand safe and alternative strategies.  In this scenario, phytochems. have recently gained huge attention due to their safety profile and cost-effectiveness.  These phytochems. modulate various genes, gene products and signalling pathways, thereby inhibiting breast cancer cell proliferation, invasion, angiogenesis and metastasis and inducing apoptosis.  Moreover, they also target breast cancer stem cells and overcome drug resistance problems in breast carcinomas.  Phytochems. as adjuvants with chemotherapeutic drugs have greatly enhanced their therapeutic efficacy.  This review focuses on the recently recognized mol. mechanisms underlying breast cancer chemoprevention with the use of phytochems. such as curcumin, resveratrol, silibinin, genistein, epigallocatechin gallate, secoisolariciresinol, thymoquinone, kaempferol, quercetin, parthenolide, sulforaphane, ginsenosides, naringenin, isoliquiritigenin, luteolin, benzyl isothiocyanate, α-mangostin, 3,3'-diindolylmethane, pterostilbene, vinca alkaloids and apigenin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFvkmoCMvmIrVg90H21EOLACvtfcHk0liPpdlaOQvEAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFGlsb3O&md5=41e77c9e49bb5789b3dd1365637411a6</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1039%2FC8RA04879G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8RA04879G%26sid%3Dliteratum%253Aachs%26aulast%3DYounas%26aufirst%3DM.%26aulast%3DHano%26aufirst%3DC.%26aulast%3DGiglioli-Guivarc%25E2%2580%2599h%26aufirst%3DN.%26aulast%3DAbbasi%26aufirst%3DB.%2BH.%26atitle%3DMechanistic%2520evaluation%2520of%2520phytochemicals%2520in%2520breast%2520cancer%2520remedy%253A%2520current%2520understanding%2520and%2520future%2520perspectives%26jtitle%3DRSC%2520Adv.%26date%3D2018%26volume%3D8%26spage%3D29714%26epage%3D29744%26doi%3D10.1039%2FC8RA04879G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Löcken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clamor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span> <span> </span><span class="NLM_article-title">Napabucasin and related heterocycle-fused naphthoquinones as STAT3 inhibitors with antiproliferative activity against cancer cells</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">1636</span>– <span class="NLM_lpage">1644</span>, <span class="refDoi"> DOI: 10.1021/acs.jnatprod.8b00247</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.8b00247" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FnslKisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=1636-1644&author=H.+L%C3%B6ckenauthor=C.+Clamorauthor=K.+M%C3%BCller&title=Napabucasin+and+related+heterocycle-fused+naphthoquinones+as+STAT3+inhibitors+with+antiproliferative+activity+against+cancer+cells&doi=10.1021%2Facs.jnatprod.8b00247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells</span></div><div class="casAuthors">Locken Hauke; Clamor Cinzia; Muller Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of natural products</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1636-1644</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Napabucasin (6) and its angularly anellated isomer (7), for which the synthesis is described, together with related plant-derived naphthoquinones, were evaluated in vitro against human breast cancer (MDA-MB-231) and chronic myelogenous leukemia (K562) cells.  As observed for β-lapachone (3), the active naphthoquinones all induced apoptosis in a cell-cycle-independent fashion.  In contrast to the pyran-fused β-lapachone (3), however, the most potent furan-fused naphthoquinones were able to redox cycle and generate superoxide in cell-based assays, which was independent of NAD(P)H:quinone oxido-reductase 1.  In a homogeneous time-resolved fluorescence (HTRF) assays with MDA-MB-231 cells, both napabucasin (6) and isonapabucasin (7) were identified as targeting STAT3 phosphorylation.  In addition, drug affinity responsive target stability assays were performed to validate a direct interaction of the naphthoquinones with STAT3.  Isonapabucasin (7) turned out to be twice as potent against STAT3 as napabucasin (6) in the HTRF assay, with an EC50 in the submicromolar range, which was in excellent agreement with the potency of both agents to inhibit the growth of MDA-MB-231 cells.  Moreover, molecular docking experiments predicted different binding modes to the STAT3 SH2 domain for the linearly anellated napabucasin (6) and its angularly anellated isomer (7).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSQACUhahgsEEgZCMqtRBifW6udTcc2ebb6qOB0ukDa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FnslKisw%253D%253D&md5=f7b8eca5ba22354ee3c13457409262f4</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.8b00247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.8b00247%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6cken%26aufirst%3DH.%26aulast%3DClamor%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DNapabucasin%2520and%2520related%2520heterocycle-fused%2520naphthoquinones%2520as%2520STAT3%2520inhibitors%2520with%2520antiproliferative%2520activity%2520against%2520cancer%2520cells%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2018%26volume%3D81%26spage%3D1636%26epage%3D1644%26doi%3D10.1021%2Facs.jnatprod.8b00247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Froeling, F. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swamynathan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschênes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chio, I. I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosnan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alagesan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotman, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belleau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogoff, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuveson, D. A.</span></span> <span> </span><span class="NLM_article-title">Bioactivation of napabucasin triggers reactive oxygen species-mediated cancer cell death</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">7162</span>– <span class="NLM_lpage">7174</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-0302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1158%2F1078-0432.CCR-19-0302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31527169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslWitLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=7162-7174&author=F.+E.+M.+Froelingauthor=M.+M.+Swamynathanauthor=A.+Desch%C3%AAnesauthor=I.+I.+C.+Chioauthor=E.+Brosnanauthor=M.+A.+Yaoauthor=P.+Alagesanauthor=M.+Lucitoauthor=J.+Liauthor=A.+Y.+Changauthor=L.+C.+Trotmanauthor=P.+Belleauauthor=Y.+Parkauthor=H.+A.+Rogoffauthor=J.+D.+Watsonauthor=D.+A.+Tuveson&title=Bioactivation+of+napabucasin+triggers+reactive+oxygen+species-mediated+cancer+cell+death&doi=10.1158%2F1078-0432.CCR-19-0302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactivation of napabucasin triggers reactive oxygen species-mediated cancer cell death</span></div><div class="casAuthors">Froeling, Fieke E. M.; Swamynathan, Manojit Mosur; Deschenes, Astrid; Chio, Iok In Christine; Brosnan, Erin; Yao, Melissa A.; Alagesan, Priya; Lucito, Matthew; Li, Juying; Chang, An-Yun; Trotman, Lloyd C.; Belleau, Pascal; Park, Youngkyu; Rogoff, Harry A.; Watson, James D.; Tuveson, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7162-7174</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Napabucasin (2-acetylfuro-1,4-naphthoquinone or BBI-608) is a small mol. currently being clin. evaluated in various cancer types.  It has mostly been recognized for its ability to inhibit STAT3 signaling.  However, based on its chem. structure, we hypothesized that napabucasin is a substrate for intracellular oxidoreductases and therefore may exert its anticancer effect through redox cycling, resulting in reactive oxygen species (ROS) prodn. and cell death.  Exptl. Design: Binding of napabucasin to NAD(P)H:quinone oxidoreductase-1 (NQO1), and other oxidoreductases, was measured.  Pancreatic cancer cell lines were treated with napabucasin, and cell survival, ROS generation, DNA damage, transcriptomic changes, and alterations in STAT3 activation were assayed in vitro and in vivo.  Genetic knockout or pharmacol. inhibition with dicoumarol was used to evaluate the dependency on NQO1.  Results: Napabucasin was found to bind with high affinity to NQO1 and to a lesser degree to cytochrome P 450 oxidoreductase (POR).  Treatment resulted in marked induction of ROS and DNA damage with an NQO1- and ROS-dependent decrease in STAT3 phosphorylation.  Differential cytotoxic effects were obsd., where NQO1-expressing cells generating cytotoxic levels of ROS at low napabucasin concns. were more sensitive.  Cells with low or no baseline NQO1 expression also produced ROS in response to napabucasin, albeit to a lesser extent, through the one-electron reductase POR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobkyO7Js1b7LVg90H21EOLACvtfcHk0lieykXu9usT5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslWitLvN&md5=f2bbfdc3e8673c095f1118e361e6f81d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-0302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-0302%26sid%3Dliteratum%253Aachs%26aulast%3DFroeling%26aufirst%3DF.%2BE.%2BM.%26aulast%3DSwamynathan%26aufirst%3DM.%2BM.%26aulast%3DDesch%25C3%25AAnes%26aufirst%3DA.%26aulast%3DChio%26aufirst%3DI.%2BI.%2BC.%26aulast%3DBrosnan%26aufirst%3DE.%26aulast%3DYao%26aufirst%3DM.%2BA.%26aulast%3DAlagesan%26aufirst%3DP.%26aulast%3DLucito%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DA.%2BY.%26aulast%3DTrotman%26aufirst%3DL.%2BC.%26aulast%3DBelleau%26aufirst%3DP.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DRogoff%26aufirst%3DH.%2BA.%26aulast%3DWatson%26aufirst%3DJ.%2BD.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26atitle%3DBioactivation%2520of%2520napabucasin%2520triggers%2520reactive%2520oxygen%2520species-mediated%2520cancer%2520cell%2520death%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D7162%26epage%3D7174%26doi%3D10.1158%2F1078-0432.CCR-19-0302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogoff, H. A.</span></span> <span> </span><span class="NLM_article-title">Evaluation of tumor cell-tumor microenvironment component interactions as potential predictors of patient response to napabucasin</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1429</span>– <span class="NLM_lpage">1434</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-18-1242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1158%2F1541-7786.MCR-18-1242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31043490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1KjsL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=1429-1434&author=A.+Y.+Changauthor=E.+Hsuauthor=J.+Patelauthor=Y.+Liauthor=M.+Zhangauthor=H.+Iguchiauthor=H.+A.+Rogoff&title=Evaluation+of+tumor+cell-tumor+microenvironment+component+interactions+as+potential+predictors+of+patient+response+to+napabucasin&doi=10.1158%2F1541-7786.MCR-18-1242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of tumor cell-tumor microenvironment component interactions as potential predictors of patient response to napabucasin</span></div><div class="casAuthors">Chang, An-Yun; Hsu, Eric; Patel, Jaimin; Li, Yiqun; Zhang, Minjie; Iguchi, Haruhisa; Rogoff, Harry A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1429-1434</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Napabucasin is an NAD(P)H:quinone oxidoreductase 1 (NQO1)-bioactivatable small mol. hypothesized to affect multiple oncogenic pathways.  In a prespecified, retrospective anal. of the napabucasin phase III CO.23 study, overall survival was longer for napabucasin vs. placebo in patients expressing phosphorylated STAT3 (pSTAT3) in tumor cells and cells of the tumor microenvironment (TME).  We hypothesized that a connection may exist between NQO1 expression in cancer cells and pSTAT3 in tumor cells and the TME.  In 3D spheroid cocultures of cancer cells and cancer-assocd. fibroblasts, the antitumor activity of napabucasin was NQO1 dependent.  The levels of cytokines such as IL6, CXCL10, and GM-CSF were higher in NQO1-pos. vs. NQO1-deleted cocultures.  These differentially secreted cytokines promoted STAT3 phosphorylation in tumor cells and the TME.  NQO1-expressing, napabucasin-sensitive tumor cells can modify tumor cells and the TME to promote STAT3 phosphorylation, suggesting that pSTAT3 may be used to identify a subpopulation of patients who would likely respond to napabucasin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRjLHe-89V9bVg90H21EOLACvtfcHk0lieykXu9usT5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1KjsL3O&md5=2788fe3d367fd97f4e1efb447be5d225</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-18-1242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-18-1242%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DA.%2BY.%26aulast%3DHsu%26aufirst%3DE.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DIguchi%26aufirst%3DH.%26aulast%3DRogoff%26aufirst%3DH.%2BA.%26atitle%3DEvaluation%2520of%2520tumor%2520cell-tumor%2520microenvironment%2520component%2520interactions%2520as%2520potential%2520predictors%2520of%2520patient%2520response%2520to%2520napabucasin%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2019%26volume%3D17%26spage%3D1429%26epage%3D1434%26doi%3D10.1158%2F1541-7786.MCR-18-1242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.</span></span> <span> </span><span class="NLM_article-title">Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">289</span>, <span class="refDoi"> DOI: 10.1186/s13046-019-1289-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2Fs13046-019-1289-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31277685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3MzksFOkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=289&author=D.+Hanauthor=T.+Yuauthor=N.+Dongauthor=B.+Wangauthor=F.+Sunauthor=D.+Jiang&title=Napabucasin%2C+a+novel+STAT3+inhibitor+suppresses+proliferation%2C+invasion+and+stemness+of+glioblastoma+cells&doi=10.1186%2Fs13046-019-1289-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56aR"><div class="casContent"><span class="casTitleNuber">56a</span><div class="casTitle"><span class="NLM_cas:atitle">Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells</span></div><div class="casAuthors">Han Dongfeng; Dong Nan; Wang Bo; Sun Fei; Jiang Dehua; Yu Tianfu; Yu Tianfu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">289</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Glioblastoma (GBM) cells with stem cell-like properties are called glioma stem cells (GSCs).  GSCs display highly treatment resistance and are responsible for tumor recurrence.  Napabucasin (BBI608), a novel small molecule inhibitor of STAT3, has been identified to eliminate stemness-like tumor cells in some cancers.  However, the influence of Napabucasin on GBM cells, especially on GSCs, is currently unclear.  In this study, we explored the influence and underlying mechanisms of Napabucasin on GBM cells.  METHODS:  STAT3 expression and its correlation with the glioma grade and patient survival were analyzed using CGGA and TCGA glioma databases.  The influence of Napabucasin on proliferation, stemness, the cell cycle, apoptosis, and invasion of human GBM cell lines U87MG and LN229 was tested by CCK8, EdU incorporation, colony formation, Transwell invasion, and three-dimensional spheroid assays as well as flow cytometry, qPCR, and western blot analysis.  The ability of Napabucasin to inhibit cell proliferation of U87MG tumor xenografts in mice was assessed using a live animal bioluminescence imaging system and immunohistochemistry.  RESULTS:  Napabucasin suppressed the proliferation, colony formation, and invasion of U87MG and LN229 cells.  Furthermore, Napabucasin induced cell cycle arrest and apoptosis.  More importantly, Napabucasin treatment obviously inhibited expression of stemness-associated genes including STAT3 and suppressed the spheroid formation of glioma cells in vitro.  Napabucasin also disrupted the NF-κB signaling pathway via downregulation of RelA (p65).  Finally, glioma growth was effectively impaired by Napabucasin in nude mice bearing intracranial glioma xenografts.  CONCLUSIONS:  Napabucasin treatment may be a novel approach for the treatment of GBM, particularly GSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRIKHLY7Pb48yail4HZd-ifW6udTcc2eac58gco8vChLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzksFOkuw%253D%253D&md5=8a941303a4a70d3ba1400170ab2054ee</span></div><a href="/servlet/linkout?suffix=cit56a&amp;dbid=16384&amp;doi=10.1186%2Fs13046-019-1289-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-019-1289-6%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DDong%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DD.%26atitle%3DNapabucasin%252C%2520a%2520novel%2520STAT3%2520inhibitor%2520suppresses%2520proliferation%252C%2520invasion%2520and%2520stemness%2520of%2520glioblastoma%2520cells%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D38%26spage%3D289%26doi%3D10.1186%2Fs13046-019-1289-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit56b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cafferkey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, I.</span></span> <span> </span><span class="NLM_article-title">Novel STAT 3 inhibitors for treating gastric cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1031</span>, <span class="refDoi"> DOI: 10.1080/13543784.2016.1195807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1080%2F13543784.2016.1195807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=27322026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVekurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=1023-1031&author=C.+Cafferkeyauthor=I.+Chau&title=Novel+STAT+3+inhibitors+for+treating+gastric+cancer&doi=10.1080%2F13543784.2016.1195807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56bR"><div class="casContent"><span class="casTitleNuber">56b</span><div class="casTitle"><span class="NLM_cas:atitle">Novel STAT 3 inhibitors for treating gastric cancer</span></div><div class="casAuthors">Cafferkey, Catherine; Chau, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1023-1031</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Advanced gastric cancer has a poor prognosis, with a median survival of approx. 12 mo.  There is a continued need to explore the use of novel treatments for this disease.  STAT3 inhibitors are under evaluation in a no. of early phase trials, some showing promise in gastric cancer.  This article explores the role of STAT 3 in gastric cancer and highlights some early phase clin. trials on STAT3 inhibition.  The STAT3 protein and signalling pathway are discussed.  STAT3 in the pathogenesis of gastric cancer is reviewed; pre-clin. data on the role of STAT3 in the development of cancer is presented together with early and emerging data on STAT3 inhibitors under investigation in the clin. setting.  In this review, the authors searched PubMed, clinicaltrials.gov and ASCO abstrs. on STAT3 inhibitors, focusing on trials recruiting gastric cancer patients.  Activated STAT3 in gastric cancer is correlated with poor survival.  It plays a crit. role in regulating tumor growth and metastases.  STAT3 inhibitors are emerging as an interesting drug in gastric cancer.  However, trials utilizing these agents remain in their early phase with one agent currently under evaluation in the phase III setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOJe8WolbYlbVg90H21EOLACvtfcHk0ljxPH6TqaRRxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVekurvL&md5=abbe6909fd28a5f6ea39a6c5c8aff43d</span></div><a href="/servlet/linkout?suffix=cit56b&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1195807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1195807%26sid%3Dliteratum%253Aachs%26aulast%3DCafferkey%26aufirst%3DC.%26aulast%3DChau%26aufirst%3DI.%26atitle%3DNovel%2520STAT%25203%2520inhibitors%2520for%2520treating%2520gastric%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D1023%26epage%3D1031%26doi%3D10.1080%2F13543784.2016.1195807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span> <span> </span><span class="NLM_article-title">Novel activators and small-molecule inhibitors of STAT3 in cancer</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2019.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.cytogfr.2019.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31677966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2hur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2019&pages=10-22&author=L.+Yangauthor=S.+Linauthor=L.+Xuauthor=J.+Linauthor=C.+Zhaoauthor=X.+Huang&title=Novel+activators+and+small-molecule+inhibitors+of+STAT3+in+cancer&doi=10.1016%2Fj.cytogfr.2019.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Novel activators and small-molecule inhibitors of STAT3 in cancer</span></div><div class="casAuthors">Yang, Lehe; Lin, Shichong; Xu, Lingyuan; Lin, Jiayuh; Zhao, Chengguang; Huang, Xiaoying</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-22</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Excessive activation of signal transducer and activator of transcription 3 (STAT3) signaling is obsd. in a subset of many cancers, making activated STAT3 a highly promising potential therapeutic target supported by multiple preclin. and clin. studies.  However, early-phase clin. trials have produced mixed results with STAT3-targeted cancer therapies, revealing substantial complexity to targeting aberrant STAT3 signaling.  This review discusses the diverse mechanisms of oncogenic activation of STAT3, and the small mol. inhibitors of STAT3 in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCBnwMn0yKlrVg90H21EOLACvtfcHk0ljxPH6TqaRRxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2hur7L&md5=f84f806071ba818d9056322425bf4c41</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2019.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2019.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DX.%26atitle%3DNovel%2520activators%2520and%2520small-molecule%2520inhibitors%2520of%2520STAT3%2520in%2520cancer%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2019%26volume%3D49%26spage%3D10%26epage%3D22%26doi%3D10.1016%2Fj.cytogfr.2019.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span> </span><span class="NLM_article-title">Sumitomo
Dainippon Pharma Announces Discontinuation of Phase 3 CanStem111P
Study of Investigational Anti-Cancer Agent Napabucasin in Patients
with Pancreatic Cancer Following Interim Analysis</span>; <span class="NLM_publisher-name">Sumitomo Dainippon Pharma Co., Ltd.</span>, <span class="NLM_year">2019</span>. <a href="https://www.ds-pharma.com/ir/news/2019/20190702.html" class="extLink">https://www.ds-pharma.com/ir/news/2019/20190702.html</a> (accessed
2020-10-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Sumitomo%0ADainippon+Pharma+Announces+Discontinuation+of+Phase+3+CanStem111P%0AStudy+of+Investigational+Anti-Cancer+Agent+Napabucasin+in+Patients%0Awith+Pancreatic+Cancer+Following+Interim+Analysis%3B+Sumitomo+Dainippon+Pharma+Co.%2C+Ltd.%2C+2019.+https%3A%2F%2Fwww.ds-pharma.com%2Fir%2Fnews%2F2019%2F20190702.html+%28accessed%0A2020-10-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DSumitomo%250ADainippon%2520Pharma%2520Announces%2520Discontinuation%2520of%2520Phase%25203%2520CanStem111P%250AStudy%2520of%2520Investigational%2520Anti-Cancer%2520Agent%2520Napabucasin%2520in%2520Patients%250Awith%2520Pancreatic%2520Cancer%2520Following%2520Interim%2520Analysis%26pub%3DSumitomo%2520Dainippon%2520Pharma%2520Co.%252C%2520Ltd%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayres Pereira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chio, I. I. C.</span></span> <span> </span><span class="NLM_article-title">Metastasis in pancreatic ductal adenocarcinoma: current standing and methodologies</span>. <i>Genes</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi"> DOI: 10.3390/genes11010006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fgenes11010006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=6&author=M.+Ayres+Pereiraauthor=I.+I.+C.+Chio&title=Metastasis+in+pancreatic+ductal+adenocarcinoma%3A+current+standing+and+methodologies&doi=10.3390%2Fgenes11010006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.3390%2Fgenes11010006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fgenes11010006%26sid%3Dliteratum%253Aachs%26aulast%3DAyres%2BPereira%26aufirst%3DM.%26aulast%3DChio%26aufirst%3DI.%2BI.%2BC.%26atitle%3DMetastasis%2520in%2520pancreatic%2520ductal%2520adenocarcinoma%253A%2520current%2520standing%2520and%2520methodologies%26jtitle%3DGenes%26date%3D2020%26volume%3D11%26spage%3D6%26doi%3D10.3390%2Fgenes11010006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nott, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalcberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickers, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebbutt, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magoski, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Callaghan, C. J.</span></span> <span> </span><span class="NLM_article-title">Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial</span>. <i>Lancet Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1016/S2468-1253(18)30009-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2FS2468-1253%2818%2930009-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29397354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC1MvntVehtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=263-270&author=D.+J.+Jonkerauthor=L.+Nottauthor=T.+Yoshinoauthor=S.+Gillauthor=J.+Shapiroauthor=A.+Ohtsuauthor=J.+Zalcbergauthor=M.+M.+Vickersauthor=A.+C.+Weiauthor=Y.+Gaoauthor=N.+C.+Tebbuttauthor=B.+Markmanauthor=T.+Priceauthor=T.+Esakiauthor=S.+Koskiauthor=M.+Hitronauthor=W.+Liauthor=Y.+Liauthor=N.+M.+Magoskiauthor=C.+J.+Liauthor=J.+Simesauthor=D.+Tuauthor=C.+J.+O%E2%80%99Callaghan&title=Napabucasin+versus+placebo+in+refractory+advanced+colorectal+cancer%3A+a+randomised+phase+3+trial&doi=10.1016%2FS2468-1253%2818%2930009-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60aR"><div class="casContent"><span class="casTitleNuber">60a</span><div class="casTitle"><span class="NLM_cas:atitle">Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial</span></div><div class="casAuthors">Jonker Derek J; Nott Louise; Yoshino Takayuki; Gill Sharlene; Shapiro Jeremy; Ohtsu Atsushi; Zalcberg John; Vickers Michael M; Wei Alice C; Gao Yuan; Hitron Matthew; Li Wei; Li Youzhi; Tebbutt Niall C; Markman Ben; Price Timothy; Esaki Taito; Koski Sheryl; Magoski Nadine M; Li Chiang J; Simes John; Tu Dongsheng; O'Callaghan Christopher J</div><div class="citationInfo"><span class="NLM_cas:title">The lancet. Gastroenterology & hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263-270</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Napabucasin is a first-in-class cancer stemness inhibitor that targets STAT3, which is a poor prognostic factor in colorectal cancer.  This study aimed to test napabucasin in advanced colorectal cancer.  METHODS:  This study was a double-blind randomised phase 3 trial done at 68 centres in Canada, Australia, New Zealand, and Japan.  Patients with advanced colorectal cancer with a good Eastern Cooperative Oncology Group (ECOG) performance status (0-1) for whom all available standard therapies had failed were eligible for the study.  Patients were randomly assigned (1:1) to receive placebo or napabucasin through a web-based system with a permuted block method, after stratification by ECOG performance status, KRAS status, previous VEGF inhibitor treatment, and time from diagnosis of metastatic disease.  Napabucasin 480 mg or matching placebo was taken orally every 12 h.  All patients received best supportive care.  The primary endpoint was overall survival assessed in an intention-to-treat analysis.  This is the final analysis of this trial, which is registered at ClinicalTrials.gov, number NCT01830621.  FINDINGS:  Accrual began on April 15, 2013, and was stopped for futility on May 23, 2014, at which point 282 patients had undergone randomisation (138 assigned to the napabucasin group and 144 to the placebo group).  Overall survival did not differ significantly between groups: median overall survival was 4·4 months (95% CI 3·7-4·9) in the napabucasin group and 4·8 months (4·0-5·3) in the placebo group (adjusted hazard ratio [HR] 1·13, 95% CI 0·88-1·46, p=0·34).  The safety population included 136 patients in the napabucasin group and 144 patients in the placebo group.  More patients who received napabucasin had any grade of treatment-related diarrhoea (108 [79%] of 136 patients), nausea (69 [51%]), and anorexia (52 [38%]) than did patients who received placebo (28 [19%] of 144 patients, 35 [24%], and 23 [16%], respectively).  The most common severe (grade 3 or worse) treatment-related adverse events were abdominal pain (five [4%] patients receiving napabucasin vs five [3%] receiving placebo), diarrhoea (21 [15%] vs one [1%]), fatigue (14 [10%] vs eight [6%]), and dehydration (six [4%] vs one [1%]). 251 (89%) patients had data on pSTAT3 expression, of whom 55 (22%) had pSTAT3-positive tumours (29 in the napabucasin group, 26 in the placebo group).  In a prespecified biomarker analysis of pSTAT3-positive patients, overall survival was longer in the napabucasin group than in the placebo group (median 5·1 months [95% CI 4·0-7·5] vs 3·0 months [1·7-4·1]; HR 0·41, 0·23-0·73, p=0·0025).  INTERPRETATION:  Although there was no difference in overall survival between groups in the overall unselected population, STAT3 might be an important target for the treatment of colorectal cancer with elevated pSTAT3 expression.  Nevertheless, these results require validation.  FUNDING:  Canadian Cancer Society Research Institute and Boston Biomedical.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuAFfSZrrklxe4jJGKT5N0fW6udTcc2eath-dTtIKMC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvntVehtQ%253D%253D&md5=8fd56d231a568dfa09655e2cbe8ac20a</span></div><a href="/servlet/linkout?suffix=cit60a&amp;dbid=16384&amp;doi=10.1016%2FS2468-1253%2818%2930009-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2468-1253%252818%252930009-8%26sid%3Dliteratum%253Aachs%26aulast%3DJonker%26aufirst%3DD.%2BJ.%26aulast%3DNott%26aufirst%3DL.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DGill%26aufirst%3DS.%26aulast%3DShapiro%26aufirst%3DJ.%26aulast%3DOhtsu%26aufirst%3DA.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DVickers%26aufirst%3DM.%2BM.%26aulast%3DWei%26aufirst%3DA.%2BC.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DTebbutt%26aufirst%3DN.%2BC.%26aulast%3DMarkman%26aufirst%3DB.%26aulast%3DPrice%26aufirst%3DT.%26aulast%3DEsaki%26aufirst%3DT.%26aulast%3DKoski%26aufirst%3DS.%26aulast%3DHitron%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMagoski%26aufirst%3DN.%2BM.%26aulast%3DLi%26aufirst%3DC.%2BJ.%26aulast%3DSimes%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DC.%2BJ.%26atitle%3DNapabucasin%2520versus%2520placebo%2520in%2520refractory%2520advanced%2520colorectal%2520cancer%253A%2520a%2520randomised%2520phase%25203%2520trial%26jtitle%3DLancet%2520Gastroenterol.%2520Hepatol.%26date%3D2018%26volume%3D3%26spage%3D263%26epage%3D270%26doi%3D10.1016%2FS2468-1253%2818%2930009-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit60b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nott, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalcberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickers, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebbutt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magoski, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Callaghan, C. J.</span></span> <span> </span><span class="NLM_article-title">A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">Suppl. 6</span>),  <span class="NLM_fpage">vi150</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw370.03</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1093%2Fannonc%2Fmdw370.03" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=vi150&issue=Suppl.+6&author=D.+J.+Jonkerauthor=L.+Nottauthor=T.+Yoshinoauthor=S.+Gillauthor=J.+Shapiroauthor=A.+Ohtsuauthor=J.+Zalcbergauthor=M.+M.+Vickersauthor=A.+Weiauthor=Y.+Gaoauthor=N.+Tebbuttauthor=B.+Markmanauthor=T.+Esakiauthor=S.+Koskiauthor=M.+Hitronauthor=N.+M.+Magoskiauthor=J.+Simesauthor=C.+Liauthor=D.+Tuauthor=C.+J.+O%E2%80%99Callaghan&title=A+randomized+phase+III+study+of+napabucasin+%5BBBI608%5D+%28NAPA%29+vs+placebo+%28PBO%29+in+patients+%28pts%29+with+pretreated+advanced+colorectal+cancer+%28ACRC%29%3A+the+CCTG%2FAGITG+CO.23+trial&doi=10.1093%2Fannonc%2Fmdw370.03"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60b&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw370.03&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw370.03%26sid%3Dliteratum%253Aachs%26aulast%3DJonker%26aufirst%3DD.%2BJ.%26aulast%3DNott%26aufirst%3DL.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DGill%26aufirst%3DS.%26aulast%3DShapiro%26aufirst%3DJ.%26aulast%3DOhtsu%26aufirst%3DA.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DVickers%26aufirst%3DM.%2BM.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DTebbutt%26aufirst%3DN.%26aulast%3DMarkman%26aufirst%3DB.%26aulast%3DEsaki%26aufirst%3DT.%26aulast%3DKoski%26aufirst%3DS.%26aulast%3DHitron%26aufirst%3DM.%26aulast%3DMagoski%26aufirst%3DN.%2BM.%26aulast%3DSimes%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DC.%2BJ.%26atitle%3DA%2520randomized%2520phase%2520III%2520study%2520of%2520napabucasin%2520%255BBBI608%255D%2520%2528NAPA%2529%2520vs%2520placebo%2520%2528PBO%2529%2520in%2520patients%2520%2528pts%2529%2520with%2520pretreated%2520advanced%2520colorectal%2520cancer%2520%2528ACRC%2529%253A%2520the%2520CCTG%252FAGITG%2520CO.23%2520trial%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26issue%3DSuppl.%25206%26spage%3Dvi150%26doi%3D10.1093%2Fannonc%2Fmdw370.03" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lordick, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebbutt, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metges, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjulandin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hays, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontaine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodyansky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Cutsem, E.</span></span> <span> </span><span class="NLM_article-title">The BRIGHTER trial: a phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">4010</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.4010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1200%2FJCO.2018.36.15_suppl.4010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=4010&author=M.+A.+Shahauthor=K.+Shitaraauthor=F.+Lordickauthor=Y.-J.+Bangauthor=N.+C.+Tebbuttauthor=J.-P.+Metgesauthor=K.+Muroauthor=L.+Shenauthor=S.+Tjulandinauthor=J.+L.+Haysauthor=R.-h.+Xuauthor=M.+Fontaineauthor=E.+Brooksauthor=B.+Xuauthor=W.+Liauthor=C.+Liauthor=L.+Borodyanskyauthor=E.+Van+Cutsem&title=The+BRIGHTER+trial%3A+a+phase+3+randomized+double-blind+study+of+napabucasin+%28NAPA%29+plus+paclitaxel+%28PTX%29+versus+placebo+%28PBO%29+plus+PTX+in+patients+%28pts%29+with+pretreated+advanced+gastric+and+gastroesophageal+junction+%28GEJ%29+adenocarcinoma&doi=10.1200%2FJCO.2018.36.15_suppl.4010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.4010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.4010%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DM.%2BA.%26aulast%3DShitara%26aufirst%3DK.%26aulast%3DLordick%26aufirst%3DF.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DTebbutt%26aufirst%3DN.%2BC.%26aulast%3DMetges%26aufirst%3DJ.-P.%26aulast%3DMuro%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DTjulandin%26aufirst%3DS.%26aulast%3DHays%26aufirst%3DJ.%2BL.%26aulast%3DXu%26aufirst%3DR.-h.%26aulast%3DFontaine%26aufirst%3DM.%26aulast%3DBrooks%26aufirst%3DE.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DBorodyansky%26aufirst%3DL.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26atitle%3DThe%2520BRIGHTER%2520trial%253A%2520a%2520phase%25203%2520randomized%2520double-blind%2520study%2520of%2520napabucasin%2520%2528NAPA%2529%2520plus%2520paclitaxel%2520%2528PTX%2529%2520versus%2520placebo%2520%2528PBO%2529%2520plus%2520PTX%2520in%2520patients%2520%2528pts%2529%2520with%2520pretreated%2520advanced%2520gastric%2520and%2520gastroesophageal%2520junction%2520%2528GEJ%2529%2520adenocarcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D4010%26doi%3D10.1200%2FJCO.2018.36.15_suppl.4010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawazoe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuboki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bando, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yodo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span> <span> </span><span class="NLM_article-title">Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1007/s00280-020-04059-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1007%2Fs00280-020-04059-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32236642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB383pvVKqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2020&pages=855-862&author=A.+Kawazoeauthor=Y.+Kubokiauthor=H.+Bandoauthor=S.+Fukuokaauthor=T.+Kojimaauthor=Y.+Naitoauthor=S.+Iinoauthor=Y.+Yodoauthor=T.+Doiauthor=K.+Shitaraauthor=T.+Yoshino&title=Phase+1+study+of+napabucasin%2C+a+cancer+stemness+inhibitor%2C+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-020-04059-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors</span></div><div class="casAuthors">Kawazoe Akihito; Kuboki Yasutoshi; Bando Hideaki; Fukuoka Shota; Kojima Takashi; Shitara Kohei; Yoshino Takayuki; Naito Yoichi; Doi Toshihiko; Iino Shuichi; Yodo Yasuhide</div><div class="citationInfo"><span class="NLM_cas:title">Cancer chemotherapy and pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">855-862</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Napabucasin is a cancer stemness inhibitor that targets a number of oncogenic pathways, including signal transducer and activator of transcription 3 (STAT3).  Phase 1/2 studies suggest tolerability and anti-tumor activity in various types of cancer; a Phase 3 study of napabucasin plus standard therapy in colorectal cancer is ongoing.  This is a Phase 1 dose-escalation study in patients with advanced solid tumors, and the first study of napabucasin in Japanese patients.  METHODS:  Patients received napabucasin 480, 960, or 1440 mg daily in 28-day cycles until disease progression or intolerable toxicity.  Primary objectives were to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and the pharmacokinetic (PK) profile of napabucasin.  Blood samples were taken for PK analysis on Days 1, 2, 8, and 15 of Cycle 1, and Days 29 and 30 of Cycle 2.  Secondary objectives were to assess napabucasin antitumor activity, and the relationship between biomarkers and antitumor activity.  JapicCTI-No: JapicCTI-132152.  RESULTS:  Enrolled were 14 patients (480 mg [n = 3], 960 mg [n = 4], 1440 mg [n = 7]).  One patient experienced a DLT (Grade 3, anorexia).  MTD was 1440 mg/day.  Most common drug-related adverse events were diarrhea (n = 9), nausea (n = 4), vomiting (n = 3), and anorexia (n = 3).  Napabucasin showed a similar PK profile to previous studies and no abnormal accumulation was observed.  Following treatment, two patients had stable disease; the remaining 12 had progressive disease.  CONCLUSION:  Napabucasin was well-tolerated at doses up to 1440 mg/day in Japanese patients with advanced solid tumors; the PK profile was comparable to that reported previously.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdA3g6eGVSrhKDYG3bNImrfW6udTcc2eath-dTtIKMC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383pvVKqtw%253D%253D&md5=ecdfa2f874a69afe545b454d38bed775</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1007%2Fs00280-020-04059-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-020-04059-3%26sid%3Dliteratum%253Aachs%26aulast%3DKawazoe%26aufirst%3DA.%26aulast%3DKuboki%26aufirst%3DY.%26aulast%3DBando%26aufirst%3DH.%26aulast%3DFukuoka%26aufirst%3DS.%26aulast%3DKojima%26aufirst%3DT.%26aulast%3DNaito%26aufirst%3DY.%26aulast%3DIino%26aufirst%3DS.%26aulast%3DYodo%26aufirst%3DY.%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DShitara%26aufirst%3DK.%26aulast%3DYoshino%26aufirst%3DT.%26atitle%3DPhase%25201%2520study%2520of%2520napabucasin%252C%2520a%2520cancer%2520stemness%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2020%26volume%3D85%26spage%3D855%26epage%3D862%26doi%3D10.1007%2Fs00280-020-04059-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span> </span><span class="NLM_article-title">Sumitomo Dainippon Pharma Oncology. Clinical
Trials</span>. <a href="https://www.sdponcology.com/pipeline/clinical-trials/" class="extLink">https://www.sdponcology.com/pipeline/clinical-trials/</a> (accessed 2020-07-26).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Sumitomo+Dainippon+Pharma+Oncology.+Clinical%0ATrials.+https%3A%2F%2Fwww.sdponcology.com%2Fpipeline%2Fclinical-trials%2F+%28accessed+2020-07-26%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DSumitomo%2520Dainippon%2520Pharma%2520Oncology.%2520Clinical%250ATrials" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starodub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitot, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halfdanarson, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadeau, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubkus, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adesunloye, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edenfield, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodyansky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span> <span> </span><span class="NLM_article-title">Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI ± bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3529</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.35.15_suppl.3529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1200%2FJCO.2017.35.15_suppl.3529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=28796588" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=3529&author=J.+C.+Bendellauthor=J.+M.+Hubbardauthor=B.+H.+O%E2%80%99Neilauthor=D.+J.+Jonkerauthor=A.+Starodubauthor=J.+D.+Peytonauthor=H.+C.+Pitotauthor=T.+R.+Halfdanarsonauthor=B.+R.+Nadeauauthor=J.+D.+Zubkusauthor=B.+Adesunloyeauthor=W.+J.+Edenfieldauthor=Y.+Liauthor=W.+Liauthor=A.+Grotheyauthor=L.+Borodyanskyauthor=C.+Li&title=Phase+1b%2FII+study+of+cancer+stemness+inhibitor+napabucasin+%28BBI-608%29+in+combination+with+FOLFIRI+%C2%B1+bevacizumab+%28bev%29+in+metastatic+colorectal+cancer+%28mCRC%29+patients+%28pts%29&doi=10.1200%2FJCO.2017.35.15_suppl.3529"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.3529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.3529%26sid%3Dliteratum%253Aachs%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DHubbard%26aufirst%3DJ.%2BM.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DB.%2BH.%26aulast%3DJonker%26aufirst%3DD.%2BJ.%26aulast%3DStarodub%26aufirst%3DA.%26aulast%3DPeyton%26aufirst%3DJ.%2BD.%26aulast%3DPitot%26aufirst%3DH.%2BC.%26aulast%3DHalfdanarson%26aufirst%3DT.%2BR.%26aulast%3DNadeau%26aufirst%3DB.%2BR.%26aulast%3DZubkus%26aufirst%3DJ.%2BD.%26aulast%3DAdesunloye%26aufirst%3DB.%26aulast%3DEdenfield%26aufirst%3DW.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DGrothey%26aufirst%3DA.%26aulast%3DBorodyansky%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26atitle%3DPhase%25201b%252FII%2520study%2520of%2520cancer%2520stemness%2520inhibitor%2520napabucasin%2520%2528BBI-608%2529%2520in%2520combination%2520with%2520FOLFIRI%2520%25C2%25B1%2520bevacizumab%2520%2528bev%2529%2520in%2520metastatic%2520colorectal%2520cancer%2520%2528mCRC%2529%2520patients%2520%2528pts%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D3529%26doi%3D10.1200%2FJCO.2017.35.15_suppl.3529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starodub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halfdanarson, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edenfield, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Rayes, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitot, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobday, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borodyansky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span> <span> </span><span class="NLM_article-title">Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI ± bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">4S</span>),  <span class="NLM_fpage">593</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.35.4_suppl.593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1200%2FJCO.2017.35.4_suppl.593" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=593&issue=4S&author=J.+C.+Bendellauthor=B.+H.+O%E2%80%99Neilauthor=A.+Starodubauthor=D.+J.+Jonkerauthor=T.+R.+Halfdanarsonauthor=W.+J.+Edenfieldauthor=B.+F.+El-Rayesauthor=J.+M.+Hubbardauthor=H.+C.+Pitotauthor=T.+J.+Hobdayauthor=Y.+Liauthor=Y.+Gaoauthor=A.+Grotheyauthor=L.+Borodyanskyauthor=C.+Li&title=Cancer+stemness+inhibition+and+chemosensitization%3A+Phase+1b%2FII+study+of+cancer+stemness+inhibitor+napabucasin+%28BBI-608%29+with+FOLFIRI+%C2%B1+bevacizumab+%28Bev%29+administered+to+colorectal+cancer+%28CRC%29+patients+%28pts%29&doi=10.1200%2FJCO.2017.35.4_suppl.593"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.4_suppl.593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.4_suppl.593%26sid%3Dliteratum%253Aachs%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DB.%2BH.%26aulast%3DStarodub%26aufirst%3DA.%26aulast%3DJonker%26aufirst%3DD.%2BJ.%26aulast%3DHalfdanarson%26aufirst%3DT.%2BR.%26aulast%3DEdenfield%26aufirst%3DW.%2BJ.%26aulast%3DEl-Rayes%26aufirst%3DB.%2BF.%26aulast%3DHubbard%26aufirst%3DJ.%2BM.%26aulast%3DPitot%26aufirst%3DH.%2BC.%26aulast%3DHobday%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DGrothey%26aufirst%3DA.%26aulast%3DBorodyansky%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26atitle%3DCancer%2520stemness%2520inhibition%2520and%2520chemosensitization%253A%2520Phase%25201b%252FII%2520study%2520of%2520cancer%2520stemness%2520inhibitor%2520napabucasin%2520%2528BBI-608%2529%2520with%2520FOLFIRI%2520%25C2%25B1%2520bevacizumab%2520%2528Bev%2529%2520administered%2520to%2520colorectal%2520cancer%2520%2528CRC%2529%2520patients%2520%2528pts%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26issue%3D4S%26spage%3D593%26doi%3D10.1200%2FJCO.2017.35.4_suppl.593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span> </span><span class="NLM_article-title">A Study of DSP-0337 in Patients with Advanced
Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
(NCT03416816)</span>. <a href="https://clinicaltrials.gov/show/NCT03416816" class="extLink">https://clinicaltrials.gov/show/NCT03416816</a> (accessed 2020-10-26).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+of+DSP-0337+in+Patients+with+Advanced%0ASolid+Tumors+to+Determine+the+Safety+and+the+Pharmacokinetic+Profile%0A%28NCT03416816%29.+https%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT03416816+%28accessed+2020-10-26%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520of%2520DSP-0337%2520in%2520Patients%2520with%2520Advanced%250ASolid%2520Tumors%2520to%2520Determine%2520the%2520Safety%2520and%2520the%2520Pharmacokinetic%2520Profile%250A%2528NCT03416816%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ban, H.</span>; <span class="NLM_string-name">Kamioka, S.</span>; <span class="NLM_string-name">Sawayama, Y.</span>; <span class="NLM_string-name">Li, C. J.</span></span> <span> </span><span class="NLM_article-title">Substituted Naphtho[2,3-<i>b</i>]furans as Water-Soluble Prodrugs for Preventing and/or Treating Cancer</span>. U.S. Patent <span class="NLM_patent">20190084955 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=H.+Ban&author=S.+Kamioka&author=Y.+Sawayama&author=C.+J.+Li&title=Substituted+Naphtho%5B2%2C3-b%5Dfurans+as+Water-Soluble+Prodrugs+for+Preventing+and%2For+Treating+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBan%26aufirst%3DH.%26atitle%3DSubstituted%2520Naphtho%255B2%252C3-b%255Dfurans%2520as%2520Water-Soluble%2520Prodrugs%2520for%2520Preventing%2520and%252For%2520Treating%2520Cancer%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, Y.</span>; <span class="NLM_string-name">Kasai, M.</span>; <span class="NLM_string-name">Shoji, Y.</span>; <span class="NLM_string-name">Takeda, S.</span></span> <span> </span><span class="NLM_article-title">Anticancer Agent</span>. U.S. Patent <span class="NLM_patent">10,377,730</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Y.+Yoshimura&author=M.+Kasai&author=Y.+Shoji&author=S.+Takeda&title=Anticancer+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYoshimura%26aufirst%3DY.%26atitle%3DAnticancer%2520Agent%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, R. K.</span></span> <span> </span><span class="NLM_article-title">Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e16530</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0016530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1371%2Fjournal.pone.0016530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=21304978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFaht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&author=S.+Shankarauthor=D.+Nallauthor=S.+N.+Tangauthor=D.+Meekerauthor=J.+Passariniauthor=J.+Sharmaauthor=R.+K.+Srivastava&title=Resveratrol+inhibits+pancreatic+cancer+stem+cell+characteristics+in+human+and+KrasG12D+transgenic+mice+by+inhibiting+pluripotency+maintaining+factors+and+epithelial-mesenchymal+transition&doi=10.1371%2Fjournal.pone.0016530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol inhibits pancreatic Cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition</span></div><div class="casAuthors">Shankar, Sharmila; Nall, Dara; Tang, Su-Ni; Meeker, Daniel; Passarini, Jenna; Sharma, Jay; Srivastava, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e16530</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Cancer stem cells (CSCs) can proliferate and self-renew extensively due to their ability to express anti-apoptotic and drug resistant proteins, thus sustaining tumor growth.  Therefore, the strategy to eradicate CSCs might have significant clin. implications.  The objectives of this study were to examine the mol. mechanisms by which resveratrol inhibits stem cell characteristics of pancreatic CSCs derived from human primary tumors and KrasG12D transgenic mice.  Methodol./Principal Findings: Human pancreatic CSCs (CD133+CD44+CD24+ESA+) are highly tumorigenic and form s.c. tumors in NOD/SCID mice.  Human pancreatic CSCs expressing high levels of CD133, CD24, CD44, ESA, and aldehyde dehydrogenase also express significantly more Nanog, Oct-4, Notch1, MDR1 and ABCG2 than normal pancreatic tissues and primary pancreatic cancer cells.  Similarly, CSCs from KrasG12D mice express significantly higher levels of Nanog and Oct-4 than pancreatic tissues from Pdx-Cre mice.  Resveratrol inhibits the growth (size and wt.) and development (PanIN lesions) of pancreatic cancer in KrasG12D mice.  Resveratrol inhibits the self-renewal capacity of pancreatic CSCs derived from human primary tumors and KrasG12D mice.  Resveratrol induces apoptosis by activating capase-3/7 and inhibiting the expression of Bcl-2 and XIAP in human CSCs.  Resveratrol inhibits pluripotency maintaining factors (Nanog, Sox-2, c-Myc and Oct-4) and drug resistance gene ABCG2 in CSCs.  Inhibition of Nanog by shRNA enhances the inhibitory effects of resveratrol on self-renewal capacity of CSCs.  Finally, resveratrol inhibits CSC's migration and invasion and markers of epithelial-mesenchymal transition (Zeb-1, Slug and Snail).  Conclusions/Significance: These data suggest that resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition.  In conclusion, resveratrol can be used for the management of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-ABzxZvwvVrVg90H21EOLACvtfcHk0lj8IrsfFBG_3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFaht70%253D&md5=b3e94d7e2104d7cdf92daa9510e075aa</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0016530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0016530%26sid%3Dliteratum%253Aachs%26aulast%3DShankar%26aufirst%3DS.%26aulast%3DNall%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DS.%2BN.%26aulast%3DMeeker%26aufirst%3DD.%26aulast%3DPassarini%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DJ.%26aulast%3DSrivastava%26aufirst%3DR.%2BK.%26atitle%3DResveratrol%2520inhibits%2520pancreatic%2520cancer%2520stem%2520cell%2520characteristics%2520in%2520human%2520and%2520KrasG12D%2520transgenic%2520mice%2520by%2520inhibiting%2520pluripotency%2520maintaining%2520factors%2520and%2520epithelial-mesenchymal%2520transition%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26doi%3D10.1371%2Fjournal.pone.0016530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.</span></span> <span> </span><span class="NLM_article-title">Resveratrol eliminates cancer stem cells of osteosarcoma by STAT3 pathway inhibition</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0205918</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0205918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1371%2Fjournal.pone.0205918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30356255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFKnurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=L.+Pengauthor=D.+Jiang&title=Resveratrol+eliminates+cancer+stem+cells+of+osteosarcoma+by+STAT3+pathway+inhibition&doi=10.1371%2Fjournal.pone.0205918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol eliminates cancer stem cells of osteosarcoma by STAT3 pathway inhibition</span></div><div class="casAuthors">Peng, Lihua; Jian, Dianming</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0205918/1-e0205918/13</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Resveratrol shows potent anti-tumor therapeutic properties in various tumors.  However, the exact effect of resveratrol on osteosarcoma cells, esp. cancer stem cells, remains unclear.  In this study, we examd. the effect of resveratrol on osteosarcoma stem cells and explored the underlying mol. mechanisms.  Resveratrol inhibited cell viability, selfrenewal ability and tumorigenesis of osteosarcoma cells, whereas showed no significant inhibition effects to normal osteoblast cells.  Mech., resveratrol treatment decreased cytokines synthesis and inhibited JAK2/STAT3 signaling, which was consistent with the decline of cancer stem cells marker, CD133.  Exogenous STAT3 activation attenuated the cancer stem cell elimination effects of resveratrol treatment.  Our results demonstrated that resveratrol inhibited osteosarcoma cell proliferation and tumorigenesis ability, which was correlated with cytokines inhibition related JAK2/STAT3 signaling blockage.  Resveratrol may be a promising therapeutic agent for osteosarcoma management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozr-eagsmWF7Vg90H21EOLACvtfcHk0lj8IrsfFBG_3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFKnurk%253D&md5=0c0e2b525062666d2c03b11cf6a260c3</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0205918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0205918%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DD.%26atitle%3DResveratrol%2520eliminates%2520cancer%2520stem%2520cells%2520of%2520osteosarcoma%2520by%2520STAT3%2520pathway%2520inhibition%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0205918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafabakhsh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzaei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asemi, Z.</span></span> <span> </span><span class="NLM_article-title">Resveratrol is a promising agent for colorectal cancer prevention and treatment: focus on molecular mechanisms</span>. <i>Cancer Cell Int.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">180</span>, <span class="refDoi"> DOI: 10.1186/s12935-019-0906-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2Fs12935-019-0906-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31341423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3MvgvVykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=180&author=M.+Honariauthor=R.+Shafabakhshauthor=R.+J.+Reiterauthor=H.+Mirzaeiauthor=Z.+Asemi&title=Resveratrol+is+a+promising+agent+for+colorectal+cancer+prevention+and+treatment%3A+focus+on+molecular+mechanisms&doi=10.1186%2Fs12935-019-0906-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol is a promising agent for colorectal cancer prevention and treatment: focus on molecular mechanisms</span></div><div class="casAuthors">Honari Mohadese; Shafabakhsh Rana; Mirzaei Hamed; Asemi Zatollah; Reiter Russel J</div><div class="citationInfo"><span class="NLM_cas:title">Cancer cell international</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">180</span>
        ISSN:<span class="NLM_cas:issn">1475-2867</span>.
    </div><div class="casAbstract">Colorectal cancer (CRC) is the third most common cancer and one of the main causes of cancer death entire the world.  Environmental, dietary, and lifestyle factors including red meat consumption, cigarette smoking, alcohol intake and family history are the most important risk factors of CRC.  Multiple pathways including inflammation, oxidative stress, and apoptosis are involved in its incidence and progression.  Resveratrol, a polyphenolic compound, has different pharmacologic functions including anti-inflammation, cancer prevention, lipid-lowering effect, and hypoglycemic effect.  Many studies have proved that resveratrol might also represent a chemo preventive effect on CRC.  Thus, the aim of the current review is to depict the role of resveratrol in treatment of CRC in a molecular manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTULiM37Yxw2Jw7prLlxLOzfW6udTcc2ebwRszT5Lsig7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvgvVykuw%253D%253D&md5=fa841fa9f64f391d6478938bb6e192d9</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1186%2Fs12935-019-0906-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12935-019-0906-y%26sid%3Dliteratum%253Aachs%26aulast%3DHonari%26aufirst%3DM.%26aulast%3DShafabakhsh%26aufirst%3DR.%26aulast%3DReiter%26aufirst%3DR.%2BJ.%26aulast%3DMirzaei%26aufirst%3DH.%26aulast%3DAsemi%26aufirst%3DZ.%26atitle%3DResveratrol%2520is%2520a%2520promising%2520agent%2520for%2520colorectal%2520cancer%2520prevention%2520and%2520treatment%253A%2520focus%2520on%2520molecular%2520mechanisms%26jtitle%3DCancer%2520Cell%2520Int.%26date%3D2019%26volume%3D19%26spage%3D180%26doi%3D10.1186%2Fs12935-019-0906-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hemshekhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunitha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santhosh, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devaraja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemparaju, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanath, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niranjana, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girish, K. S.</span></span> <span> </span><span class="NLM_article-title">An overview of genus garcinia: phytochemical and therapeutic aspects</span>. <i>Phytochem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1007/s11101-011-9207-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1007%2Fs11101-011-9207-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1Smu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=325-351&author=M.+Hemshekharauthor=K.+Sunithaauthor=M.+S.+Santhoshauthor=S.+Devarajaauthor=K.+K.+Kemparajuauthor=B.+S.+Vishwanathauthor=S.+R.+Niranjanaauthor=K.+S.+Girish&title=An+overview+of+genus+garcinia%3A+phytochemical+and+therapeutic+aspects&doi=10.1007%2Fs11101-011-9207-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">An overview on genus Garcinia: Phytochemical and therapeutical aspects</span></div><div class="casAuthors">Hemshekhar, M.; Sunitha, K.; Santhosh, M. Sebastin; Devaraja, S.; Kemparaju, K.; Vishwanath, B. S.; Niranjana, S. R.; Girish, K. S.</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-351</span>CODEN:
                <span class="NLM_cas:coden">PRHEBS</span>;
        ISSN:<span class="NLM_cas:issn">1568-7767</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The genus Garcinia belongs to the family Clusiaceae and has been involved in ayurvedic prepns. to medicate various pathophysiol. disorders.  Bioactive mols. such as hydroxycitric acid (HCA), flavonoids, terpenes, polysaccharides, procyanidines and polyisoprenylated benzophenone derivs. like garcinol, xanthochymol and guttiferone isoforms have been isolated from Garcinia.  The genus has received the attention of pharmaceutical industries due to its immense remedial qualities.  HCA has been known for its hypolipidemic property.  The polyisoprenylated benzophenone and xanthone derivs. are known for their antioxidant, apoptotic, anti-cancer, anti-inflammatory, antibacterial, antiviral, antifungal, antiulcer, antiprotozoal, and HAT inhibiting properties.  Future studies on the synthesis of therapeutically important products and their analogs and evaluation of their safety and efficacy would be of great interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCgb_ZixEiKLVg90H21EOLACvtfcHk0lgFJQDuhaOV_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1Smu7c%253D&md5=8538fe76bb43fa0ecd111649b3b62891</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1007%2Fs11101-011-9207-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11101-011-9207-3%26sid%3Dliteratum%253Aachs%26aulast%3DHemshekhar%26aufirst%3DM.%26aulast%3DSunitha%26aufirst%3DK.%26aulast%3DSanthosh%26aufirst%3DM.%2BS.%26aulast%3DDevaraja%26aufirst%3DS.%26aulast%3DKemparaju%26aufirst%3DK.%2BK.%26aulast%3DVishwanath%26aufirst%3DB.%2BS.%26aulast%3DNiranjana%26aufirst%3DS.%2BR.%26aulast%3DGirish%26aufirst%3DK.%2BS.%26atitle%3DAn%2520overview%2520of%2520genus%2520garcinia%253A%2520phytochemical%2520and%2520therapeutic%2520aspects%26jtitle%3DPhytochem.%2520Rev.%26date%3D2011%26volume%3D10%26spage%3D325%26epage%3D351%26doi%3D10.1007%2Fs11101-011-9207-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schobert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biersack, B.</span></span> <span> </span><span class="NLM_article-title">Chemical and biological aspects of garcinol and isogarcinol: Recent developments</span>. <i>Chem. Biodiversity</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>, <span class="NLM_elocation-id">e1900366</span> <span class="refDoi"> DOI: 10.1002/cbdv.201900366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fcbdv.201900366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31386266" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&author=R.+Schobertauthor=B.+Biersack&title=Chemical+and+biological+aspects+of+garcinol+and+isogarcinol%3A+Recent+developments&doi=10.1002%2Fcbdv.201900366"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1002%2Fcbdv.201900366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbdv.201900366%26sid%3Dliteratum%253Aachs%26aulast%3DSchobert%26aufirst%3DR.%26aulast%3DBiersack%26aufirst%3DB.%26atitle%3DChemical%2520and%2520biological%2520aspects%2520of%2520garcinol%2520and%2520isogarcinol%253A%2520Recent%2520developments%26jtitle%3DChem.%2520Biodiversity%26date%3D2019%26volume%3D16%26doi%3D10.1002%2Fcbdv.201900366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuli, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parashar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi-Parashar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. S.</span></span> <span> </span><span class="NLM_article-title">Garcinol exhibits anti-neoplastic effects by targeting diverse oncogenic factors in tumor cells</span>. <i>Biomedicines</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">103</span>, <span class="refDoi"> DOI: 10.3390/biomedicines8050103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fbiomedicines8050103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKgsrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=103&author=V.+Aggarwalauthor=H.+S.+Tuliauthor=J.+Kaurauthor=D.+Aggarwalauthor=G.+Parasharauthor=N.+Chaturvedi-Parasharauthor=S.+Kulkarniauthor=G.+Kaurauthor=K.+Sakauthor=M.+Kumarauthor=K.+S.+Ahn&title=Garcinol+exhibits+anti-neoplastic+effects+by+targeting+diverse+oncogenic+factors+in+tumor+cells&doi=10.3390%2Fbiomedicines8050103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol exhibits anti-neoplastic effects by targeting diverse oncogenic factors in tumor cells</span></div><div class="casAuthors">Aggarwal, Vaishali; Tuli, Hardeep Singh; Kaur, Jagjit; Aggarwal, Diwakar; Parashar, Gaurav; Parashar, Nidarshana Chaturvedi; Kulkarni, Samruddhi; Kaur, Ginpreet; Sak, Katrin; Kumar, Manoj; Ahn, Kwang Seok</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicines</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">103</span>CODEN:
                <span class="NLM_cas:coden">BIOMID</span>;
        ISSN:<span class="NLM_cas:issn">2227-9059</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Garcinol, a polyisoprenylated benzophenone, is the medicinal component obtained from fruits and leaves of Garcinia indica (G. indica) and has traditionally been extensively used for its antioxidant and anti-inflammatory properties.  In addn., it has been also been exptl. illustrated to elicit anti-cancer properties.  Several in vitro and in vivo studies have illustrated the potential therapeutic efficiency of garcinol in management of different malignancies.  It mainly acts as an inhibitor of cellular processes via regulation of transcription factors NF-κB and JAK/STAT3 in tumor cells and have been demonstrated to effectively inhibit growth of malignant cell population.  Numerous studies have highlighted the anti-neoplastic potential of garcinol in different oncol. transformations including colon cancer, breast cancer, prostate cancer, head and neck cancer, hepatocellular carcinoma, etc.  However, use of garcinol is still in its pre-clin. stage and this is mainly attributed to the limitations of conclusive evaluation of pharmacol. parameters.  This necessitates evaluation of garcinol pharmacokinetics to precisely identify an appropriate dose and route of administration, tolerability, and potency under physiol. conditions along with characterization of a therapeutic index.  Hence, the research is presently ongoing in the dimension of exploring the precise metabolic mechanism of garcinol.  Despite various lacunae, garcinol has presented with promising anti-cancer effects.  Hence, this review is motivated by the constantly emerging and promising pos. anti-cancerous effects of garcinol.  This review is the first effort to summarize the mechanism of action of garcinol in modulation of anti-cancer effect via regulation of different cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeO57asMerj7Vg90H21EOLACvtfcHk0lgFJQDuhaOV_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKgsrjI&md5=c47331dcada2618f4d683b94f74205ac</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.3390%2Fbiomedicines8050103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiomedicines8050103%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DV.%26aulast%3DTuli%26aufirst%3DH.%2BS.%26aulast%3DKaur%26aufirst%3DJ.%26aulast%3DAggarwal%26aufirst%3DD.%26aulast%3DParashar%26aufirst%3DG.%26aulast%3DChaturvedi-Parashar%26aufirst%3DN.%26aulast%3DKulkarni%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DSak%26aufirst%3DK.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DK.%2BS.%26atitle%3DGarcinol%2520exhibits%2520anti-neoplastic%2520effects%2520by%2520targeting%2520diverse%2520oncogenic%2520factors%2520in%2520tumor%2520cells%26jtitle%3DBiomedicines%26date%3D2020%26volume%3D8%26spage%3D103%26doi%3D10.3390%2Fbiomedicines8050103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboukameel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padhye, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, F. H.</span></span> <span> </span><span class="NLM_article-title">Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2193</span>– <span class="NLM_lpage">2201</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0232-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1158%2F1535-7163.MCT-12-0232-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=22821148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyksr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=2193-2201&author=A.+Ahmadauthor=S.+H.+Sarkarauthor=B.+Bitarauthor=S.+Aliauthor=A.+Aboukameelauthor=S.+Sethiauthor=Y.+Liauthor=B.+Baoauthor=D.+Kongauthor=S.+Banerjeeauthor=S.+B.+Padhyeauthor=F.+H.+Sarkar&title=Garcinol+regulates+EMT+and+Wnt+signaling+pathways+in+vitro+and+in+vivo%2C+leading+to+anticancer+activity+against+breast+cancer+cells&doi=10.1158%2F1535-7163.MCT-12-0232-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol Regulates EMT and Wnt Signaling Pathways In Vitro and In Vivo, Leading to Anticancer Activity against Breast Cancer Cells</span></div><div class="casAuthors">Ahmad, Aamir; Sarkar, Sanila H.; Bitar, Bassam; Ali, Shadan; Aboukameel, Amro; Sethi, Seema; Li, Yiwei; Bao, Bin; Kong, Dejuan; Banerjee, Sanjeev; Padhye, Subhash B.; Sarkar, Fazlul H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2193-2201</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anticancer properties of Garcinia indica-derived garcinol are just beginning to be elucidated.  We have earlier reported its cancer cell-specific induction of apoptosis in breast cancer cells, which was mediated through the downregulation of NF-κB signaling pathway.  To gain further mechanistic insight, here, we show for the first time that garcinol effectively reverses epithelial-to-mesenchymal transition (EMT), i.e., it induces mesenchymal-to-epithelial transition (MET) in aggressive triple-neg. MDA-MB-231 and BT-549 breast cancer cells.  This was assocd. with upregulation of epithelial marker E-cadherin and downregulation of mesenchymal markers vimentin, ZEB-1, and ZEB-2.  We also found that garcinol upregulates the expression of miR-200 and let-7 family microRNAs (miRNAs), which provides a mol. mechanism for the obsd. reversal of EMT to MET.  Transfection of cells with NF-κB p65 subunit attenuated the effect of garcinol on apoptosis induction through reversal of MET to EMT.  Forced transfection of p65 and anti-miR-200s could also reverse the inhibitory effect of garcinol on breast cancer cell invasion.  Moreover, treatment with garcinol resulted in increased phosphorylation of β-catenin concomitant with its reduced nuclear localization.  The results were also validated in vivo in a xenograft mouse model where garcinol was found to inhibit NF-κB, miRNAs, vimentin, and nuclear β-catenin.  These novel findings suggest that the anticancer activity of garcinol against aggressive breast cancer cells is, in part, due to reversal of EMT phenotype, which is mechanistically linked with the deregulation of miR-200s, let-7s, NF-κB, and Wnt signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWiYQpeFiGubVg90H21EOLACvtfcHk0lhsVdcU6-iuww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyksr3E&md5=20db5c27a08c74042570ae5f4b03e9d9</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0232-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0232-T%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DSarkar%26aufirst%3DS.%2BH.%26aulast%3DBitar%26aufirst%3DB.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DAboukameel%26aufirst%3DA.%26aulast%3DSethi%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBao%26aufirst%3DB.%26aulast%3DKong%26aufirst%3DD.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DPadhye%26aufirst%3DS.%2BB.%26aulast%3DSarkar%26aufirst%3DF.%2BH.%26atitle%3DGarcinol%2520regulates%2520EMT%2520and%2520Wnt%2520signaling%2520pathways%2520in%2520vitro%2520and%2520in%2520vivo%252C%2520leading%2520to%2520anticancer%2520activity%2520against%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D2193%26epage%3D2201%26doi%3D10.1158%2F1535-7163.MCT-12-0232-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboukameel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biersack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seibt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schobert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padhye, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, F. H.</span></span> <span> </span><span class="NLM_article-title">Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2450</span>– <span class="NLM_lpage">2456</span>, <span class="refDoi"> DOI: 10.1093/carcin/bgs290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1093%2Fcarcin%2Fbgs290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=22971573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKrtrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=2450-2456&author=A.+Ahmadauthor=S.+H.+Sarkarauthor=A.+Aboukameelauthor=S.+Aliauthor=B.+Biersackauthor=S.+Seibtauthor=Y.+Liauthor=B.+Baoauthor=D.+Kongauthor=S.+Banerjeeauthor=R.+Schobertauthor=S.+B.+Padhyeauthor=F.+H.+Sarkar&title=Anticancer+action+of+garcinol+in+vitro+and+in+vivo+is+in+part+mediated+through+inhibition+of+STAT-3+signaling&doi=10.1093%2Fcarcin%2Fbgs290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling</span></div><div class="casAuthors">Ahmad, Aamir; Sarkar, Sanila H.; Aboukameel, Amro; Ali, Shadan; Biersack, Bernhard; Seibt, Sebastian; Li, Yiwei; Bao, Bin; Kong, Dejuan; Banerjee, Sanjeev; Schobert, Rainer; Padhye, Subhash B.; Sarkar, Fazlul H.</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2450-2456</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Garcinol, obtained from Garcinia indica, has exhibited some promising anticancer activity.  In particular, our earlier work has demonstrated its ability to inhibit cell proliferation and induction of apoptosis in multiple cancer cell lines representative of breast, prostate, as well as pancreatic cancers.  However, its exact mechanism of action remains largely unclear.  Here we show that garcinol also targets signal transducer and activator of transcription-3 (STAT-3) signaling pathway.  STAT-3 is frequently found to be activated in many cancer types and this is the first report on such action of garcinol leading to its anticancer effects.  Garcinol inhibited total, as well as phosphorylated, STAT-3 in breast, prostate and pancreatic cancer cell lines and was also found to inhibit cell invasion of all the cancer cell lines tested.  STAT-3 phosphorylation was inhibited by garcinol in a dose-dependent manner.  We also obsd. an inhibitory effect of garcinol on IL-6-induced STAT-3 phosphorylation and prodn. of urokinase-type plasminogen activator, vascular endothelial growth factor and matrix metalloproteinase-9, which might explain the reduced invasion and aggressiveness of cells treated with garcinol.  The results were further verified in vivo using MDA-MB-231 breast cancer mouse xenograft model where administration of garcinol significantly inhibited tumor growth, and western blot anal. of remnant tumor lysates showed reduced STAT-3 expression and activation.  These results suggest that garcinol may have translational potential as chemopreventive or therapeutic agent against multiple cancers and inhibition of STAT-3 signaling pathway is one of the mechanisms by which garcinol exerts its anticancer effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYyQhWi3zz37Vg90H21EOLACvtfcHk0lhsVdcU6-iuww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKrtrfM&md5=573f327b1e697fb676d690bb126ba698</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgs290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgs290%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DSarkar%26aufirst%3DS.%2BH.%26aulast%3DAboukameel%26aufirst%3DA.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DBiersack%26aufirst%3DB.%26aulast%3DSeibt%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBao%26aufirst%3DB.%26aulast%3DKong%26aufirst%3DD.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DSchobert%26aufirst%3DR.%26aulast%3DPadhye%26aufirst%3DS.%2BB.%26aulast%3DSarkar%26aufirst%3DF.%2BH.%26atitle%3DAnticancer%2520action%2520of%2520garcinol%2520in%2520vitro%2520and%2520in%2520vivo%2520is%2520in%2520part%2520mediated%2520through%2520inhibition%2520of%2520STAT-3%2520signaling%26jtitle%3DCarcinogenesis%26date%3D2012%26volume%3D33%26spage%3D2450%26epage%3D2456%26doi%3D10.1093%2Fcarcin%2Fbgs290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugam, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siveen, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swamy, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, G.</span></span> <span> </span><span class="NLM_article-title">Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">5147</span>– <span class="NLM_lpage">5163</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.18632%2Foncotarget.2881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=25762616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnjt1OltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=5147-5163&author=F.+Liauthor=M.+K.+Shanmugamauthor=K.+S.+Siveenauthor=F.+Wangauthor=T.+H.+Ongauthor=S.+Y.+Looauthor=M.+M.+Swamyauthor=S.+Mandalauthor=A.+P.+Kumarauthor=B.+C.+Gohauthor=T.+Kunduauthor=K.+S.+Ahnauthor=L.+Z.+Wangauthor=K.+M.+Huiauthor=G.+Sethi&title=Garcinol+sensitizes+human+head+and+neck+carcinoma+to+cisplatin+in+a+xenograft+mouse+model+despite+downregulation+of+proliferative+biomarkers&doi=10.18632%2Foncotarget.2881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers</span></div><div class="casAuthors">Li Feng; Shanmugam Muthu K; Siveen Kodappully Sivaraman; Wang Fan; Loo Ser Yue; Kumar Alan Prem; Goh Boon Cher; Wang Ling Zhi; Sethi Gautam; Wang Fan; Loo Ser Yue; Kumar Alan Prem; Goh Boon Cher; Wang Ling Zhi; Ong Tina H; Hui Kam Man; Loo Ser Yue; Swamy Mahadeva M M; Mandal Somnath; Kundu Tapas; Kumar Alan Prem; Sethi Gautam; Kumar Alan Prem; Goh Boon Cher; Ahn Kwang Seok</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">5147-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Platinum compounds such as cisplatin and carboplatin are frequently used as the first-line chemotherapy for the treatment of the head and neck squamous cell carcinoma (HNSCC).  In the present study, we investigated whether garcinol, a polyisoprenylated benzophenone can chemosensitize HNSCC to cisplatin.  We found that garcinol inhibited the viability of a panel of diverse HNSCC cell lines, enhanced the apoptotic effect of cisplatin, suppressed constitutive as well as cisplatin-induced NF-κB activation, and downregulated the expression of various oncogenic gene products (cyclin D1, Bcl-2, survivin and VEGF).  In vivo study showed that administration of garcinol alone (0.5 mg/kg body weight, i.p. five times/week) significantly suppressed the growth of the tumor, and this effect was further increased by cisplatin.  Both the markers of proliferation index (Ki-67) and microvessel density (CD31) were downregulated in tumor tissues by the combination of cisplatin and garcinol.  The pharmacokinetic results of garcinol indicated that good systemic exposure was achievable after i.p. administration of garcinol at 0.5 mg/kg and 2 mg/kg with mean peak concentration (Cmax) of 1825.4 and 6635.7 nM in the mouse serum, respectively.  Overall, our results suggest that garcinol can indeed potentiate the effects of cisplatin by negative regulation of various inflammatory and proliferative biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQInFgFY_9atxLDWw4HIq2sfW6udTcc2eaqN7llBk7VfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnjt1OltQ%253D%253D&md5=2138e0ab741d652adbe2c90a5070bba5</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2881%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DShanmugam%26aufirst%3DM.%2BK.%26aulast%3DSiveen%26aufirst%3DK.%2BS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DOng%26aufirst%3DT.%2BH.%26aulast%3DLoo%26aufirst%3DS.%2BY.%26aulast%3DSwamy%26aufirst%3DM.%2BM.%26aulast%3DMandal%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DA.%2BP.%26aulast%3DGoh%26aufirst%3DB.%2BC.%26aulast%3DKundu%26aufirst%3DT.%26aulast%3DAhn%26aufirst%3DK.%2BS.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DHui%26aufirst%3DK.%2BM.%26aulast%3DSethi%26aufirst%3DG.%26atitle%3DGarcinol%2520sensitizes%2520human%2520head%2520and%2520neck%2520carcinoma%2520to%2520cisplatin%2520in%2520a%2520xenograft%2520mouse%2520model%2520despite%2520downregulation%2520of%2520proliferative%2520biomarkers%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D5147%26epage%3D5163%26doi%3D10.18632%2Foncotarget.2881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parasramka, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deryavoush, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span> <span> </span><span class="NLM_article-title">Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures</span>. <i>Mol. Nutr. Food Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1002/mnfr.201200297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fmnfr.201200297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=23293055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslehtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=235-248&author=M.+A.+Parasramkaauthor=S.+Aliauthor=S.+Banerjeeauthor=T.+Deryavoushauthor=F.+H.+Sarkarauthor=S.+Gupta&title=Garcinol+sensitizes+human+pancreatic+adenocarcinoma+cells+to+gemcitabine+in+association+with+microRNA+signatures&doi=10.1002%2Fmnfr.201200297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures</span></div><div class="casAuthors">Parasramka, Mansi A.; Ali, Shadan; Banerjee, Sanjeev; Deryavoush, Tara; Sarkar, Fazlul H.; Gupta, SmitiV.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Nutrition & Food Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">235-248</span>CODEN:
                <span class="NLM_cas:coden">MNFRCV</span>;
        ISSN:<span class="NLM_cas:issn">1613-4125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Background. Alterations in microRNA (miRNA/miR) genes are of biol. importance in the pathophysiol. of cancers, including pancreatic cancer (PaCa).  Although growing evidence supports the role of miRNA in cancer, their response to dietary phytochems. is less known.  Previously, we showed that garcinol induces PaCa cell growth arrest and apoptosis in vitro.  The present study, discusses chemo-sensitization by garcinol in synergism with first-line PaCa drug, gemcitabine.  The miRNA expression profile of gemcitabine-resistant Panc-1 cells treated with garcinol and/or gemcitabine was also evaluated.  Methods and results. Garcinol synergizes with gemcitabine to inhibit cell proliferation and induce apoptosis in PaCa cells with significant modulation of key cancer regulators including PARP, VEGF, MMPs, ILs, caspases, and NF-κB.  In addn., biostatistical analyses, quant. reverse transcription PCR data, and in silico modeling using TargetScan5, PicTar, and DNA intelligent anal., microT-V.  B4 database showed that these two agents modulated a no. of microRNAs (miR-21, miR-196a, miR-495, miR-605, miR-638, and miR-453) linked to various canonical oncogenic signaling pathways.  Conclusion. We identified garcinol-specific miRNA biomarkers that sensitize PaCa cells to gemcitabine treatment, thus attenuating the drug-resistance phenotype.  These results prompt further interest in garcinol and gemcitabine combination strategy as a drug modality to improve treatment outcome in patients diagnosed with PaCa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk2WLWek9MV7Vg90H21EOLACvtfcHk0lhD22tnCjveMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslehtg%253D%253D&md5=7dbd38ddab239535a55161ef8dd0c046</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2Fmnfr.201200297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmnfr.201200297%26sid%3Dliteratum%253Aachs%26aulast%3DParasramka%26aufirst%3DM.%2BA.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DDeryavoush%26aufirst%3DT.%26aulast%3DSarkar%26aufirst%3DF.%2BH.%26aulast%3DGupta%26aufirst%3DS.%26atitle%3DGarcinol%2520sensitizes%2520human%2520pancreatic%2520adenocarcinoma%2520cells%2520to%2520gemcitabine%2520in%2520association%2520with%2520microRNA%2520signatures%26jtitle%3DMol.%2520Nutr.%2520Food%2520Res.%26date%3D2013%26volume%3D57%26spage%3D235%26epage%3D248%26doi%3D10.1002%2Fmnfr.201200297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span> <span> </span><span class="NLM_article-title">Garcinol from <i>Garcinia indica</i> downregulates cancer stem-like cell biomarker ALDH1A1 in nonsmall cell lung cancer A549 cells through DDIT3 activation</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">3675</span>– <span class="NLM_lpage">3683</span>, <span class="refDoi"> DOI: 10.1021/acs.jafc.7b00346</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jafc.7b00346" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFCnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2017&pages=3675-3683&author=J.+Wangauthor=L.+Wangauthor=C.-T.+Hoauthor=K.+Zhangauthor=Q.+Liuauthor=H.+Zhao&title=Garcinol+from+Garcinia+indica+downregulates+cancer+stem-like+cell+biomarker+ALDH1A1+in+nonsmall+cell+lung+cancer+A549+cells+through+DDIT3+activation&doi=10.1021%2Facs.jafc.7b00346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol from Garcinia indica Downregulates Cancer Stem-like Cell Biomarker ALDH1A1 in Nonsmall Cell Lung Cancer A549 Cells through DDIT3 Activation</span></div><div class="casAuthors">Wang, Jinhan; Wang, Liwen; Ho, Chi-Tang; Zhang, Kunsheng; Liu, Qiang; Zhao, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3675-3683</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonsmall cell lung cancer (NSCLC) is the predominant type of lung cancer.  Patients with NSCLC show high mortality rates because of failure to clean up cancer stem cells (CSCs).  The anticancer activity of phytochem. garcinol has been identified in various cancer cell models.  However, the effect of garcinol on NSCLC cell lines is still lacking.  Of the NSCLC cell lines we tested, A549 cells were the most sensitive to garcinol.  Interestingly, Aldehyde Dehydrogenase 1 Family Member A1 (ALDH1A1) was preferentially expressed in A549 cells and downregulated by the addn. of garcinol.  We also found that garcinol enriched DNA damage-inducible transcript 3 (DDIT3) and then altered DDIT3-CCAAT-enhancer-binding proteins beta (C/EBPβ) interaction resulting in a decreased binding of C/EBPβ to the endogenous ALDH1A1 promoter.  Furthermore, garcinol's inhibition of ALDH1A1 was identified in a xenograft mice model.  Garcinol repressed ALDH1A1 transcription in A549 cells through alterations in the interaction between DDIT3 and C/EBPβ.  Garcinol could be a potential dietary phytochem. candidate for NSCLCs patients whose tumors harbored high ALDH1A1 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEfTvmCNrY67Vg90H21EOLACvtfcHk0lhD22tnCjveMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFCnsbs%253D&md5=d38e7b2919e0bd0c4327af678c6e1b86</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jafc.7b00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jafc.7b00346%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHo%26aufirst%3DC.-T.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DGarcinol%2520from%2520Garcinia%2520indica%2520downregulates%2520cancer%2520stem-like%2520cell%2520biomarker%2520ALDH1A1%2520in%2520nonsmall%2520cell%2520lung%2520cancer%2520A549%2520cells%2520through%2520DDIT3%2520activation%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2017%26volume%3D65%26spage%3D3675%26epage%3D3683%26doi%3D10.1021%2Facs.jafc.7b00346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farhan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullah, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afaq, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faisal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooqi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biersack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schobert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span> <span> </span><span class="NLM_article-title">Garcinol sensitizes NSCLC cells to standard therapies by regulating EMT-modulating miRNAs</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">800</span>, <span class="refDoi"> DOI: 10.3390/ijms20040800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fijms20040800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlSiurrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=800&author=M.+Farhanauthor=A.+Malikauthor=M.+F.+Ullahauthor=S.+Afaqauthor=M.+Faisalauthor=A.+A.+Farooqiauthor=B.+Biersackauthor=R.+Schobertauthor=A.+Ahmad&title=Garcinol+sensitizes+NSCLC+cells+to+standard+therapies+by+regulating+EMT-modulating+miRNAs&doi=10.3390%2Fijms20040800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol sensitizes NSCLC cells to standard therapies by regulating EMT-modulating miRNAs</span></div><div class="casAuthors">Farhan, Mohd; Malik, Arshi; Ullah, Mohammad Fahad; Afaq, Sarah; Faisal, Mohd; Farooqi, Ammad Ahmad; Biersack, Bernhard; Schobert, Rainer; Ahmad, Aamir</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">800</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Garcinol, a dietary factor obtained from Garcinia indica, modulates several key cellular signaling pathways as well as the expression of miRNAs.  Acquired resistance to std. therapies, such as erlotinib and cisplatin, is a hallmark of non-small cell lung cancer (NSCLC) cells that often involves miRNA-regulated epithelial-to-mesenchymal transition (EMT).  We used A549 cells that were exposed to transforming growth factor beta 1 (TGF-β1), resulting in A549M cells with mesenchymal and drug resistant phenotype, and report that garcinol sensitized resistant cells with mesenchymal phenotype to erlotinib as well as cisplatin with significant decrease in their IC50 values.  It also potentiated the apoptosis-inducing activity of erlotinib in A549M and the endogenously mesenchymal H1299 NSCLC cells.  Further, garcinol significantly upregulated several key EMT-regulating miRNAs, such as miR-200b, miR-205, miR-218, and let-7c.  Antagonizing miRNAs, through anti-miRNA transfections, attenuated the EMT-modulating activity of garcinol, as detd. by mRNA expression of EMT markers, E-cadherin, vimentin, and Zinc Finger E-Box Binding Homeobox 1 (ZEB1).  This further led to repression of erlotinib as well as cisplatin sensitization, thus establishing the mechanistic role of miRNAs, particularly miR-200c and let-7c, in garcinol-mediated reversal of EMT and the resulting sensitization of NSCLC cells to std. therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOM_hTct7SC7Vg90H21EOLACvtfcHk0lgcnwE11sWPgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlSiurrE&md5=56ca5a174b09f5ae00419831d844f5af</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.3390%2Fijms20040800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20040800%26sid%3Dliteratum%253Aachs%26aulast%3DFarhan%26aufirst%3DM.%26aulast%3DMalik%26aufirst%3DA.%26aulast%3DUllah%26aufirst%3DM.%2BF.%26aulast%3DAfaq%26aufirst%3DS.%26aulast%3DFaisal%26aufirst%3DM.%26aulast%3DFarooqi%26aufirst%3DA.%2BA.%26aulast%3DBiersack%26aufirst%3DB.%26aulast%3DSchobert%26aufirst%3DR.%26aulast%3DAhmad%26aufirst%3DA.%26atitle%3DGarcinol%2520sensitizes%2520NSCLC%2520cells%2520to%2520standard%2520therapies%2520by%2520regulating%2520EMT-modulating%2520miRNAs%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D800%26doi%3D10.3390%2Fijms20040800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span> <span> </span><span class="NLM_article-title">Emerging role of garcinol in targeting cancer stem cells of non-small cell lung cancer</span>. <i>Curr. Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1007/s40495-019-00169-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1007%2Fs40495-019-00169-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVCjtLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=14-19&author=L.+Wangauthor=M.+Wangauthor=H.+Guoauthor=H.+Zhao&title=Emerging+role+of+garcinol+in+targeting+cancer+stem+cells+of+non-small+cell+lung+cancer&doi=10.1007%2Fs40495-019-00169-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging Role of Garcinol in Targeting Cancer Stem Cells of Non-small Cell Lung Cancer</span></div><div class="casAuthors">Wang, Liang; Wang, Meiyan; Guo, Hongxing; Zhao, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmacology Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-19</span>CODEN:
                <span class="NLM_cas:coden">CPRUG8</span>;
        ISSN:<span class="NLM_cas:issn">2198-641X</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Garcinol is a polyisoprenylated benzophenone analog primarily isolated from the dried rind of Garcinia indica, a tropical fruit widely grown in Southeast Asia and Central Africa.  Recent findings have well documented that garcinol is a potential dietary phytochem. candidate in the prevention and treatment of cancer and oxidative-related illness.  Herein, a brief structure-activity relationship (SAR) is summarized in this review to disclose the connection between the chem. structure of garcinol and its biol. activity.  Non-small cell lung cancer (NSCLC) is a predominant type of lung cancer, exhibiting an extremely high mortality rate as a result of failing to clean up cancer stem cells (CSCs).  Interestingly, garcinol was reported to be able to target and suppress CSCs, and both in vitro and in vivo evidences have revealed the outstanding anti-NSCLC potential of garcinol.  The mechanism may involve cellular senescence and apoptosis induction, as well as cell cycle arrest.  This paper will review the current progress of garcinol against various tumors in vitro and in vivo, particularly the effects on NSCLC, and summarize the crit. structural features of garcinol as a potent anticancer candidate.  Also, we will discuss potential future challenges in research and development of garcinol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT9oeEiWbPRLVg90H21EOLACvtfcHk0lgcnwE11sWPgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVCjtLzF&md5=c06fb07097ad11e0c453ffe96194df9a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs40495-019-00169-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40495-019-00169-6%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DEmerging%2520role%2520of%2520garcinol%2520in%2520targeting%2520cancer%2520stem%2520cells%2520of%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCurr.%2520Pharmacol.%2520Rep.%26date%3D2019%26volume%3D5%26spage%3D14%26epage%3D19%26doi%3D10.1007%2Fs40495-019-00169-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adebayo, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, C. T.</span></span> <span> </span><span class="NLM_article-title">Garcinol inhibits cancer stem cell-like phenotype via suppression of the Wnt/β-catenin/STAT3 axis signalling pathway in human non-small cell lung carcinomas</span>. <i>J. Nutr. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1016/j.jnutbio.2017.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.jnutbio.2017.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29414668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltlSlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2018&pages=140-150&author=W.+C.+Huangauthor=K.+T.+Kuoauthor=B.+O.+Adebayoauthor=C.+H.+Wangauthor=Y.+J.+Chenauthor=K.+Jinauthor=T.+H.+Tsaiauthor=C.+T.+Yeh&title=Garcinol+inhibits+cancer+stem+cell-like+phenotype+via+suppression+of+the+Wnt%2F%CE%B2-catenin%2FSTAT3+axis+signalling+pathway+in+human+non-small+cell+lung+carcinomas&doi=10.1016%2Fj.jnutbio.2017.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol inhibits cancer stem cell-like phenotype via suppression of the Wnt/β-catenin/STAT3 axis signalling pathway in human non-small cell lung carcinomas</span></div><div class="casAuthors">Huang, Wen-Chien; Kuo, Kuang-Tai; Adebayo, Bamodu Oluwaseun; Wang, Chun-Hua; Chen, Yu-Jen; Jin, Ketao; Tsai, Tung-Hu; Yeh, Chi-Tai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nutritional Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">140-150</span>CODEN:
                <span class="NLM_cas:coden">JNBIEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-2863</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Innate or acquired drug resistance and consequent tumor relapse in lung cancer patients have been linked to activities of cancer stem cells (CSCs).  Therefore, targeting CSCs is suggested as an effective approach for non-small cell lung cancer (NSCLC) therapy.  In this study, we demonstrated that garcinol, a polyisoprenylated benzophenone isolated from fruiting bodies of Garcinia indica, and possessing anti-inflammatory, antioxidant, acetyltransferase inhibitory, and anticancer activities, modulates activities of lung CSCs (LCSCs) and their assocd. aggressiveness.  Herein, we demonstrated the inhibitory effect of garcinol on the LCSC phenotype of human NSCLC cells using anal. drug cytotoxicity or cell viability, flow cytometric, and functional assay approaches.  Garcinol significantly diminished the ability of the H441 and A549 NSCLC cell lines to form spheres.  In parallel assays, garcinol inhibited differentiated lung cancer cell and LCSC viability in dose-dependent manners.  Consistent with these observations, flow cytometric data showed that garcinol reduced the putative LCSC pool, evidenced by the dose-dependent decreasing proportion of side-population (SP) cells and assocd. ALDH activity in garcinol-treated H441 cells, compared to the control group.  Addnl., functional assays showed that garcinol markedly diminished the ability of H441 and A549 cells to form colonies.  Mechanistically, garcinol impaired phosphorylation of LRP6, a co-receptor of Wnt and STAT3.  In the same assay, garcinol down-regulated β-catenin, Dvl2, Axin2, and cyclin D1 expressions in NSCLC-generated spheres, suggesting its ability to regulate the Wnt/β-catenin signaling pathway.  The results were further verified in vivo using H441 LCSC mouse xenograft model where administration of garcinol significantly inhibited tumor growth.  Taken together, we demonstrated herein that garcinol modulates the LCSC phenotype via regulation of Wnt/β-catenin signaling and inactivation of STAT3, thus showing that garcinol may be a putative novel anti-LCSC therapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkVd5bBCUGQrVg90H21EOLACvtfcHk0lgcnwE11sWPgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltlSlsr8%253D&md5=b116c523d20a68c01160fa3081038830</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.jnutbio.2017.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jnutbio.2017.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BC.%26aulast%3DKuo%26aufirst%3DK.%2BT.%26aulast%3DAdebayo%26aufirst%3DB.%2BO.%26aulast%3DWang%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DY.%2BJ.%26aulast%3DJin%26aufirst%3DK.%26aulast%3DTsai%26aufirst%3DT.%2BH.%26aulast%3DYeh%26aufirst%3DC.%2BT.%26atitle%3DGarcinol%2520inhibits%2520cancer%2520stem%2520cell-like%2520phenotype%2520via%2520suppression%2520of%2520the%2520Wnt%252F%25CE%25B2-catenin%252FSTAT3%2520axis%2520signalling%2520pathway%2520in%2520human%2520non-small%2520cell%2520lung%2520carcinomas%26jtitle%3DJ.%2520Nutr.%2520Biochem.%26date%3D2018%26volume%3D54%26spage%3D140%26epage%3D150%26doi%3D10.1016%2Fj.jnutbio.2017.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P. S.</span>; <span class="NLM_string-name">Athavale, M.</span>; <span class="NLM_string-name">Srivastava, S.</span>; <span class="NLM_string-name">Barve, K.</span></span>, <span> </span><span class="NLM_article-title">Unpublished results</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Kharkar%2C+P.+S.%3B+Athavale%2C+M.%3B+Srivastava%2C+S.%3B+Barve%2C+K.%2C+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKharkar%26aufirst%3DP.%2BS.%26atitle%3DUnpublished%2520results" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vásquez-Bochm, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velázquez-Paniagua, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro-Vázquez, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero-Rodríguez, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondragon-Peralta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De La Fuente-Granada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Tapia, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Arenas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco-Velázquez, M. A.</span></span> <span> </span><span class="NLM_article-title">Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1016/j.pharep.2019.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.pharep.2019.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31026757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotFagsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2019&pages=535-544&author=L.+X.+V%C3%A1squez-Bochmauthor=M.+Vel%C3%A1zquez-Paniaguaauthor=S.+S.+Castro-V%C3%A1zquezauthor=S.+L.+Guerrero-Rodr%C3%ADguezauthor=A.+Mondragon-Peraltaauthor=M.+De+La+Fuente-Granadaauthor=S.+M.+P%C3%A9rez-Tapiaauthor=A.+Gonz%C3%A1lez-Arenasauthor=M.+A.+Velasco-Vel%C3%A1zquez&title=Transcriptome-based+identification+of+lovastatin+as+a+breast+cancer+stem+cell-targeting+drug&doi=10.1016%2Fj.pharep.2019.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug</span></div><div class="casAuthors">Vasquez-Bochm, Luz X.; Velazquez-Paniagua, Mireya; Castro-Vazquez, Sandra S.; Guerrero-Rodriguez, Sandra L.; Mondragon-Peralta, Abimael; De La Fuente-Granada, Marisol; Perez-Tapia, Sonia M.; Gonzalez-Arenas, Aliesha; Velasco-Velazquez, Marco A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">535-544</span>CODEN:
                <span class="NLM_cas:coden">PRHEDU</span>;
        ISSN:<span class="NLM_cas:issn">2299-5684</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Breast cancer is a neoplastic disease with high morbidity and mortality in women worldwide.  Breast cancer stem cells (CSCs) have a significant function in tumor growth, recurrence, and therapeutic resistance.  Thus, CSCs have been pointed as targets of new therapies for breast cancer.  Herein, we aimed to repurpose certain drugs as breast CSC-targeting agents.  We compared a consensus breast CSC signature with the transcriptomic changes that were induced by over 1300 bioactive compds. using Connectivity Map.  The effects of the selected drugs on SOX2 promoter transactivation, SOX2 expression, viability, clonogenicity, and ALDH activity in breast cancer cells were analyzed by luciferase assay, western blot, MTT assay, mammosphere formation assay, and ALDEFLUOR test, resp.  Gene Set Enrichment Anal. (GSEA) was performed using the gene expression data from mammary tumors of mice that were treated with lovastatin.  Five drugs (fasudil, pivmecillinam, ursolic acid, 16,16-dimethylprostaglandin E2, and lovastatin) induced signatures that correlated neg. with the query CSC signature.  In vitro, lovastatin inhibited SOX2 promoter transactivation, and reduced the efficiency of mammosphere formation and the percentage of ALDH+ cells.  Mevalonate mitigated the effects of lovastatin, suggesting that the targeting of CSCs by lovastatin was mediated by the inhibition of its reported target, 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR).  By GSEA, lovastatin downregulated genes that are involved in stemness and invasiveness in mammary tumors, corroborating our in vitro findings.  Lovastatin is a breast CSC-targeting drug.  The inhibition of HMGCR might develop new adjuvant therapeutic strategies for breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUpRDXdtB_ULVg90H21EOLACvtfcHk0lg7EPrjw1HnEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotFagsLw%253D&md5=51077d2b00605cdc18051b31c723e8c3</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.pharep.2019.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharep.2019.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DV%25C3%25A1squez-Bochm%26aufirst%3DL.%2BX.%26aulast%3DVel%25C3%25A1zquez-Paniagua%26aufirst%3DM.%26aulast%3DCastro-V%25C3%25A1zquez%26aufirst%3DS.%2BS.%26aulast%3DGuerrero-Rodr%25C3%25ADguez%26aufirst%3DS.%2BL.%26aulast%3DMondragon-Peralta%26aufirst%3DA.%26aulast%3DDe%2BLa%2BFuente-Granada%26aufirst%3DM.%26aulast%3DP%25C3%25A9rez-Tapia%26aufirst%3DS.%2BM.%26aulast%3DGonz%25C3%25A1lez-Arenas%26aufirst%3DA.%26aulast%3DVelasco-Vel%25C3%25A1zquez%26aufirst%3DM.%2BA.%26atitle%3DTranscriptome-based%2520identification%2520of%2520lovastatin%2520as%2520a%2520breast%2520cancer%2520stem%2520cell-targeting%2520drug%26jtitle%3DPharmacol.%2520Rep.%26date%3D2019%26volume%3D71%26spage%3D535%26epage%3D544%26doi%3D10.1016%2Fj.pharep.2019.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsello, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natoli, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubelli, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asiedu, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahr, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirschman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donahue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liberzon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orzechowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enache, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccioni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamji, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrcic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosains, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davison, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardlie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogstrom, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenside, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read-Button, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronco, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doench, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Root, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span> <span> </span><span class="NLM_article-title">A next generation connectivity map: L1000 platform and the first 1,000,000 profiles</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">1437</span>– <span class="NLM_lpage">1452</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.10.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.cell.2017.10.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29195078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWmsbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2017&pages=1437-1452&author=A.+Subramanianauthor=R.+Narayanauthor=S.+M.+Corselloauthor=D.+D.+Peckauthor=T.+E.+Natoliauthor=X.+Luauthor=J.+Gouldauthor=J.+F.+Davisauthor=A.+A.+Tubelliauthor=J.+K.+Asieduauthor=D.+L.+Lahrauthor=J.+E.+Hirschmanauthor=Z.+Liuauthor=M.+Donahueauthor=B.+Julianauthor=M.+Khanauthor=D.+Waddenauthor=I.+C.+Smithauthor=D.+Lamauthor=A.+Liberzonauthor=C.+Toderauthor=M.+Bagulauthor=M.+Orzechowskiauthor=O.+M.+Enacheauthor=F.+Piccioniauthor=S.+A.+Johnsonauthor=N.+J.+Lyonsauthor=A.+H.+Bergerauthor=A.+F.+Shamjiauthor=A.+N.+Brooksauthor=A.+Vrcicauthor=C.+Flynnauthor=J.+Rosainsauthor=D.+Y.+Takedaauthor=R.+Huauthor=D.+Davisonauthor=J.+Lambauthor=K.+Ardlieauthor=L.+Hogstromauthor=P.+Greensideauthor=N.+S.+Grayauthor=P.+A.+Clemonsauthor=S.+Silverauthor=X.+Wuauthor=W.+N.+Zhaoauthor=W.+Read-Buttonauthor=X.+Wuauthor=S.+J.+Haggartyauthor=L.+V.+Roncoauthor=J.+S.+Boehmauthor=S.+L.+Schreiberauthor=J.+G.+Doenchauthor=J.+A.+Bittkerauthor=D.+E.+Rootauthor=B.+Wongauthor=T.+R.+Golub&title=A+next+generation+connectivity+map%3A+L1000+platform+and+the+first+1%2C000%2C000+profiles&doi=10.1016%2Fj.cell.2017.10.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85aR"><div class="casContent"><span class="casTitleNuber">85a</span><div class="casTitle"><span class="NLM_cas:atitle">A next generation connectivity map: L1000 platform and the first 1,000,000 profiles</span></div><div class="casAuthors">Subramanian, Aravind; Narayan, Rajiv; Corsello, Steven M.; Peck, David D.; Natoli, Ted E.; Lu, Xiaodong; Gould, Joshua; Davis, John F.; Tubelli, Andrew A.; Asiedu, Jacob K.; Lahr, David L.; Hirschman, Jodi E.; Liu, Zihan; Donahue, Melanie; Julian, Bina; Khan, Mariya; Wadden, David; Smith, Ian C.; Lam, Daniel; Liberzon, Arthur; Toder, Courtney; Bagul, Mukta; Orzechowski, Marek; Enache, Oana M.; Piccioni, Federica; Johnson, Sarah A.; Lyons, Nicholas J.; Berger, Alice H.; Shamji, Alykhan F.; Brooks, Angela N.; Vrcic, Anita; Flynn, Corey; Rosains, Jacqueline; Takeda, David Y.; Hu, Roger; Davison, Desiree; Lamb, Justin; Ardlie, Kristin; Hogstrom, Larson; Greenside, Peyton; Gray, Nathanael S.; Clemons, Paul A.; Silver, Serena; Wu, Xiaoyun; Zhao, Wen-Ning; Read-Button, Willis; Wu, Xiaohua; Haggarty, Stephen J.; Ronco, Lucienne V.; Boehm, Jesse S.; Schreiber, Stuart L.; Doench, John G.; Bittker, Joshua A.; Root, David E.; Wong, Bang; Golub, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1437-1452.e17</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We previously piloted the concept of a Connectivity Map (CMap), whereby genes, drugs, and disease states are connected by virtue of common gene-expression signatures.  Here, we report more than a 1000-fold scale-up of the CMap as part of the NIH LINCS Consortium, made possible by a new, low-cost, high-throughput reduced representation expression profiling method that we term L1000.  We show that L1000 is highly reproducible, comparable to RNA sequencing, and suitable for computational inference of the expression levels of 81% of non-measured transcripts.  We further show that the expanded CMap can be used to discover mechanism of action of small mols., functionally annotate genetic variants of disease genes, and inform clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIWrWy5IxY-rVg90H21EOLACvtfcHk0lgdsBqsCNaRAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWmsbrE&md5=d2b13f2b80fe94021ac03f6a8c859a4a</span></div><a href="/servlet/linkout?suffix=cit85a&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.10.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.10.049%26sid%3Dliteratum%253Aachs%26aulast%3DSubramanian%26aufirst%3DA.%26aulast%3DNarayan%26aufirst%3DR.%26aulast%3DCorsello%26aufirst%3DS.%2BM.%26aulast%3DPeck%26aufirst%3DD.%2BD.%26aulast%3DNatoli%26aufirst%3DT.%2BE.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DGould%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DJ.%2BF.%26aulast%3DTubelli%26aufirst%3DA.%2BA.%26aulast%3DAsiedu%26aufirst%3DJ.%2BK.%26aulast%3DLahr%26aufirst%3DD.%2BL.%26aulast%3DHirschman%26aufirst%3DJ.%2BE.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DDonahue%26aufirst%3DM.%26aulast%3DJulian%26aufirst%3DB.%26aulast%3DKhan%26aufirst%3DM.%26aulast%3DWadden%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DI.%2BC.%26aulast%3DLam%26aufirst%3DD.%26aulast%3DLiberzon%26aufirst%3DA.%26aulast%3DToder%26aufirst%3DC.%26aulast%3DBagul%26aufirst%3DM.%26aulast%3DOrzechowski%26aufirst%3DM.%26aulast%3DEnache%26aufirst%3DO.%2BM.%26aulast%3DPiccioni%26aufirst%3DF.%26aulast%3DJohnson%26aufirst%3DS.%2BA.%26aulast%3DLyons%26aufirst%3DN.%2BJ.%26aulast%3DBerger%26aufirst%3DA.%2BH.%26aulast%3DShamji%26aufirst%3DA.%2BF.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DVrcic%26aufirst%3DA.%26aulast%3DFlynn%26aufirst%3DC.%26aulast%3DRosains%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DD.%2BY.%26aulast%3DHu%26aufirst%3DR.%26aulast%3DDavison%26aufirst%3DD.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DArdlie%26aufirst%3DK.%26aulast%3DHogstrom%26aufirst%3DL.%26aulast%3DGreenside%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DSilver%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DW.%2BN.%26aulast%3DRead-Button%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DRonco%26aufirst%3DL.%2BV.%26aulast%3DBoehm%26aufirst%3DJ.%2BS.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DDoench%26aufirst%3DJ.%2BG.%26aulast%3DBittker%26aufirst%3DJ.%2BA.%26aulast%3DRoot%26aufirst%3DD.%2BE.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26atitle%3DA%2520next%2520generation%2520connectivity%2520map%253A%2520L1000%2520platform%2520and%2520the%2520first%25201%252C000%252C000%2520profiles%26jtitle%3DCell%26date%3D2017%26volume%3D171%26spage%3D1437%26epage%3D1452%26doi%3D10.1016%2Fj.cell.2017.10.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit85b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modell, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobel, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunet, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hieronymus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span> <span> </span><span class="NLM_article-title">The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>313</i></span>,  <span class="NLM_fpage">1929</span>– <span class="NLM_lpage">1935</span>, <span class="refDoi"> DOI: 10.1126/science.1132939</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1126%2Fscience.1132939" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=17008526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVSnsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2006&pages=1929-1935&author=J.+Lambauthor=E.+D.+Crawfordauthor=D.+Peckauthor=J.+W.+Modellauthor=I.+C.+Blatauthor=M.+J.+Wrobelauthor=J.+Lernerauthor=J.+P.+Brunetauthor=A.+Subramanianauthor=K.+N.+Rossauthor=M.+Reichauthor=H.+Hieronymusauthor=G.+Weiauthor=S.+A.+Armstrongauthor=S.+J.+Haggartyauthor=P.+A.+Clemonsauthor=R.+Weiauthor=S.+A.+Carrauthor=E.+S.+Landerauthor=T.+R.+Golub&title=The+connectivity+map%3A+using+gene-expression+signatures+to+connect+small+molecules%2C+genes%2C+and+disease&doi=10.1126%2Fscience.1132939"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85bR"><div class="casContent"><span class="casTitleNuber">85b</span><div class="casTitle"><span class="NLM_cas:atitle">The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease</span></div><div class="casAuthors">Lamb, Justin; Crawford, Emily D.; Peck, David; Modell, Joshua W.; Blat, Irene C.; Wrobel, Matthew J.; Lerner, Jim; Brunet, Jean-Philippe; Subramanian, Aravind; Ross, Kenneth N.; Reich, Michael; Hieronymus, Haley; Wei, Guo; Armstrong, Scott A.; Haggarty, Stephen J.; Clemons, Paul A.; Wei, Ru; Carr, Steven A.; Lander, Eric S.; Golub, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">5795</span>),
    <span class="NLM_cas:pages">1929-1935</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">To pursue a systematic approach to the discovery of functional connections among diseases, genetic perturbation, and drug action, we have created the first installment of a ref. collection of gene-expression profiles from cultured human cells treated with bioactive small mols., together with pattern-matching software to mine these data.  We demonstrate that this "Connectivity Map" resource can be used to find connections among small mols. sharing a mechanism of action, chems. and physiol. processes, and diseases and drugs.  These results indicate the feasibility of the approach and suggest the value of a large-scale community Connectivity Map project.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtu0M2BUO2w7Vg90H21EOLACvtfcHk0lgdsBqsCNaRAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVSnsrbN&md5=1fad887ad515ffdd8064e526ff25a4db</span></div><a href="/servlet/linkout?suffix=cit85b&amp;dbid=16384&amp;doi=10.1126%2Fscience.1132939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1132939%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DCrawford%26aufirst%3DE.%2BD.%26aulast%3DPeck%26aufirst%3DD.%26aulast%3DModell%26aufirst%3DJ.%2BW.%26aulast%3DBlat%26aufirst%3DI.%2BC.%26aulast%3DWrobel%26aufirst%3DM.%2BJ.%26aulast%3DLerner%26aufirst%3DJ.%26aulast%3DBrunet%26aufirst%3DJ.%2BP.%26aulast%3DSubramanian%26aufirst%3DA.%26aulast%3DRoss%26aufirst%3DK.%2BN.%26aulast%3DReich%26aufirst%3DM.%26aulast%3DHieronymus%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DArmstrong%26aufirst%3DS.%2BA.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DWei%26aufirst%3DR.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26atitle%3DThe%2520connectivity%2520map%253A%2520using%2520gene-expression%2520signatures%2520to%2520connect%2520small%2520molecules%252C%2520genes%252C%2520and%2520disease%26jtitle%3DScience%26date%3D2006%26volume%3D313%26spage%3D1929%26epage%3D1935%26doi%3D10.1126%2Fscience.1132939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mok, E. H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. K. W.</span></span> <span> </span><span class="NLM_article-title">The pivotal role of the dysregulation of cholesterol homeostasis in cancer: Implications for therapeutic targets</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1410</span>, <span class="refDoi"> DOI: 10.3390/cancers12061410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcancers12061410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKnurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1410&author=E.+H.+K.+Mokauthor=T.+K.+W.+Lee&title=The+pivotal+role+of+the+dysregulation+of+cholesterol+homeostasis+in+cancer%3A+Implications+for+therapeutic+targets&doi=10.3390%2Fcancers12061410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">The pivotal role of the dysregulation of cholesterolhomeostasis in cancer: implications fortherapeutic targets</span></div><div class="casAuthors">Mok, Etienne Ho Kit; Lee, Terence Kin Wah</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1410</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Cholesterol plays an important role in cellular homeostasis by maintaining the rigidity of cell membranes, providing a medium for signaling transduction, and being converted into other vital macromols., such as sterol hormones and bile acids.  Epidemiol. studies have shown the correlation between cholesterol content and cancer incidence worldwide.  Accumulating evidence has shown the emerging roles of the dysregulation of cholesterol metab. in cancer development.  More specifically, recent reports have shown the distinct role of cholesterol in the suppression of immune cells, regulation of cell survival, and modulation of cancer stem cells in cancer.  Here, we provide a comprehensive review of the epidemiol. anal., functional roles, and mechanistic action of cholesterol homeostasis in regard to its contribution to cancer development.  Based on the existing data, cholesterol homeostasis is identified to be a new key player in cancer pathogenesis.  Lastly, we also discuss the therapeutic implications of natural compds. and cholesterol-lowering drugs in cancer prevention and treatment.  In conclusion, intervention in cholesterol metab. may offer a new therapeutic avenue for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRqsEP8TmiW7Vg90H21EOLACvtfcHk0lhnKR3AM657dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKnurzM&md5=6139df9e2c5d69b61f3a932a1594def1</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.3390%2Fcancers12061410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12061410%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DE.%2BH.%2BK.%26aulast%3DLee%26aufirst%3DT.%2BK.%2BW.%26atitle%3DThe%2520pivotal%2520role%2520of%2520the%2520dysregulation%2520of%2520cholesterol%2520homeostasis%2520in%2520cancer%253A%2520Implications%2520for%2520therapeutic%2520targets%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D1410%26doi%3D10.3390%2Fcancers12061410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bigelsen, S.</span></span> <span> </span><span class="NLM_article-title">Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin</span>. <i>Cancer Manage. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2003</span>– <span class="NLM_lpage">2018</span>, <span class="refDoi"> DOI: 10.2147/CMAR.S161824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.2147%2FCMAR.S161824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30034255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslGrtbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=2003-2018&author=S.+Bigelsen&title=Evidence-based+complementary+treatment+of+pancreatic+cancer%3A+a+review+of+adjunct+therapies+including+paricalcitol%2C+hydroxychloroquine%2C+intravenous+vitamin+C%2C+statins%2C+metformin%2C+curcumin%2C+and+aspirin&doi=10.2147%2FCMAR.S161824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin</span></div><div class="casAuthors">Bigelsen, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2003-2018</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Despite new and exciting research and renewed optimism about future therapy, current statistics of survival from pancreatic cancer remains dismal.  Patients seeking alternative or complementary treatments should be warned to avoid the hype and instead look to real science.  A variety of relatively safe and inexpensive treatment options that have shown success in preclin. models and/or retrospective studies are currently available.  Patients require their physicians to provide therapeutic guidance and assistance in obtaining and administrating these various therapies.  Paricalcitol, an analog of vitamin D, has been shown by researchers at the Salk Institute for Biol. Studies to break though the protective stroma surrounding tumor cells.  Hydroxychloroquine has been shown to inhibit autophagy, a process by which dying cells recycle injured organelles and internal toxins to generate needed energy for survival and reprodn.  I.v. vitamin C creates a toxic accumulation of hydrogen peroxide within cancer cells, hastening their death.  Metformin inhibits mitochondrial oxidative metab. utilized by cancer stem cells.  Statins inhibit not only cholesterol but also other factors in the same pathway that affect cancer cell growth, protein synthesis, and cell cycle progression.  A novel formulation of curcumin may prevent resistance to chemotherapy and inhibit pancreatic cancer cell proliferation.  Aspirin therapy has been shown to prevent pancreatic cancer and may be useful to prevent recurrence.  These therapies are all currently available and are reviewed in this paper with emphasis on the most recent lab. research and clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibVB4WiohfbVg90H21EOLACvtfcHk0lhnKR3AM657dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslGrtbvO&md5=fa34b58f748264337c896576259e0922</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.2147%2FCMAR.S161824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCMAR.S161824%26sid%3Dliteratum%253Aachs%26aulast%3DBigelsen%26aufirst%3DS.%26atitle%3DEvidence-based%2520complementary%2520treatment%2520of%2520pancreatic%2520cancer%253A%2520a%2520review%2520of%2520adjunct%2520therapies%2520including%2520paricalcitol%252C%2520hydroxychloroquine%252C%2520intravenous%2520vitamin%2520C%252C%2520statins%252C%2520metformin%252C%2520curcumin%252C%2520and%2520aspirin%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2018%26volume%3D10%26spage%3D2003%26epage%3D2018%26doi%3D10.2147%2FCMAR.S161824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehmsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terp, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arslanagic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrads, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leth-Larsen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditzel, H. J.</span></span> <span> </span><span class="NLM_article-title">Increased cholesterol biosynthesis is a key characteristic of breast cancer stem cells influencing patient outcome</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3927</span>– <span class="NLM_lpage">3938</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2019.05.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.celrep.2019.05.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31242424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Gitb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=3927-3938&author=S.+Ehmsenauthor=M.+H.+Pedersenauthor=G.+Wangauthor=M.+G.+Terpauthor=A.+Arslanagicauthor=B.+L.+Hoodauthor=T.+P.+Conradsauthor=R.+Leth-Larsenauthor=H.+J.+Ditzel&title=Increased+cholesterol+biosynthesis+is+a+key+characteristic+of+breast+cancer+stem+cells+influencing+patient+outcome&doi=10.1016%2Fj.celrep.2019.05.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Increased Cholesterol Biosynthesis Is a Key Characteristic of Breast Cancer Stem Cells Influencing Patient Outcome</span></div><div class="casAuthors">Ehmsen, Sidse; Pedersen, Martin H.; Wang, Guisong; Terp, Mikkel G.; Arslanagic, Amina; Hood, Brian L.; Conrads, Thomas P.; Leth-Larsen, Rikke; Ditzel, Henrik J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3927-3938.e6</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tumor eradication may be greatly improved by targeting cancer stem cells (CSCs), as they exhibit resistance to conventional therapy.  To gain insight into the unique biol. of CSCs, we developed patient-derived xenograft tumors (PDXs) from ER- breast cancers from which we isolated mammospheres that are enriched for CSCs.  Comparative global proteomic anal. was performed on patient tumor tissues and corresponding PDXs and mammospheres.  Mammospheres exhibited increased expression of proteins assocd. with de novo cholesterol synthesis.  The clin. relevance of increased cholesterol biosynthesis was verified in a large breast cancer cohort showing correlation with shorter relapse-free survival.  RNAi and chem. inhibition of the cholesterol biosynthesis pathway reduced mammosphere formation, which could be rescued by a downstream metabolite.  Our findings identify the cholesterol biosynthesis pathway as central for CSC propagation and a potential therapeutic target, as well as providing a mechanistic explanation for the therapeutic benefit of statins in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-bDgzBcKrk7Vg90H21EOLACvtfcHk0lhewhTKJ-thiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Gitb%252FE&md5=5ee3eacc4006fbe77d80e07eabe459f0</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2019.05.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2019.05.104%26sid%3Dliteratum%253Aachs%26aulast%3DEhmsen%26aufirst%3DS.%26aulast%3DPedersen%26aufirst%3DM.%2BH.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DTerp%26aufirst%3DM.%2BG.%26aulast%3DArslanagic%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DB.%2BL.%26aulast%3DConrads%26aufirst%3DT.%2BP.%26aulast%3DLeth-Larsen%26aufirst%3DR.%26aulast%3DDitzel%26aufirst%3DH.%2BJ.%26atitle%3DIncreased%2520cholesterol%2520biosynthesis%2520is%2520a%2520key%2520characteristic%2520of%2520breast%2520cancer%2520stem%2520cells%2520influencing%2520patient%2520outcome%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D27%26spage%3D3927%26epage%3D3938%26doi%3D10.1016%2Fj.celrep.2019.05.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jagust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Luxán-Delgado, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parejo-Alonso, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, P.</span></span> <span> </span><span class="NLM_article-title">Metabolism-based therapeutic strategies targeting cancer stem cells</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">203</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffphar.2019.00203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30967773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVCntrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=203&author=P.+Jagustauthor=B.+de+Lux%C3%A1n-Delgadoauthor=B.+Parejo-Alonsoauthor=P.+Sancho&title=Metabolism-based+therapeutic+strategies+targeting+cancer+stem+cells&doi=10.3389%2Ffphar.2019.00203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism-based therapeutic strategies targeting cancer stem cells</span></div><div class="casAuthors">Jagust, Petra; de Luxan-Delgado, Beatriz; Parejo-Alonso, Beatriz; Sancho, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">203</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Cancer heterogeneity constitutes the major source of disease progression and therapy failure.  Tumors comprise functionally diverse subpopulations, with cancer stem cells (CSCs) as the source of this heterogeneity.  Since these cells bear in vivo tumorigenicity and metastatic potential, survive chemotherapy and drive relapse, its elimination may be the only way to achieve long-term survival in patients.  Thanks to the great advances in the field over the last few years, we know now that cellular metab. and stemness are highly intertwined in normal development and cancer.  Indeed, CSCs show distinct metabolic features as compared with their more differentiated progenies, though their dominant metabolic phenotype varies across tumor entities, patients and even subclones within a tumor.  Following initial works focused on glucose metab., current studies have unveiled particularities of CSC metab. in terms of redox state, lipid metab. and use of alternative fuels, such as amino acids or ketone bodies.  In this review, we describe the different metabolic phenotypes attributed to CSCs with special focus on metab.-based therapeutic strategies tested in preclin. and clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7eSnFT9G7OLVg90H21EOLACvtfcHk0lhewhTKJ-thiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVCntrfE&md5=4f526f55599835df31c6ee24595ead16</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00203%26sid%3Dliteratum%253Aachs%26aulast%3DJagust%26aufirst%3DP.%26aulast%3Dde%2BLux%25C3%25A1n-Delgado%26aufirst%3DB.%26aulast%3DParejo-Alonso%26aufirst%3DB.%26aulast%3DSancho%26aufirst%3DP.%26atitle%3DMetabolism-based%2520therapeutic%2520strategies%2520targeting%2520cancer%2520stem%2520cells%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D203%26doi%3D10.3389%2Ffphar.2019.00203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kweon, G. R.</span></span> <span> </span><span class="NLM_article-title">L-Deprenyl exerts cytotoxicity towards acute myeloid leukemia through inhibition of mitochondrial respiration</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">3869</span>– <span class="NLM_lpage">3878</span>, <span class="refDoi"> DOI: 10.3892/or.2018.6753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3892%2For.2018.6753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30272370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFahu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2018&pages=3869-3878&author=I.+Ryuauthor=M.+J.+Ryuauthor=J.+Hanauthor=S.+J.+Kimauthor=M.+J.+Leeauthor=X.+Juauthor=B.+H.+Yooauthor=Y.+L.+Leeauthor=Y.+Jangauthor=I.+C.+Songauthor=W.+Chungauthor=E.+Ohauthor=J.+Y.+Heoauthor=G.+R.+Kweon&title=L-Deprenyl+exerts+cytotoxicity+towards+acute+myeloid+leukemia+through+inhibition+of+mitochondrial+respiration&doi=10.3892%2For.2018.6753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">L-Deprenyl exerts cytotoxicity towards acute myeloid leukemia through inhibition of mitochondrial respiration</span></div><div class="casAuthors">Ryu, Ilhwan; Ryu, Min Jeong; Han, Jeongsu; Kim, Soo Jeong; Lee, Min Joung; Ju, Xianshu; Yoo, Byeong Hyeon; Lee, Yu Lim; Jang, Yunseon; Song, Ik-Chan; Chung, Woosuk; Oh, Eungseok; Heo, Jun Young; Kweon, Gi Ryang</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3869-3878</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The identification of large nos. of genetic mutations in immature myeloid cells has made it difficult to identify specific targets for acute myeloid leukemia (AML) therapy.  Although current pharmacol. targets for controlling cancer are focused on identifying genetic mutations, it is hard to develop the specific drugs to achieve complete remission due to complex and variable genetic mutations.  To overcome the failure of the genetic mutation theory, the present study targeted mitochondrial metab. as a strategy for inducing anti.leukemic activity, based on evidence that AML cells have an abnormally high amt. of mitochondria and that somatic mutations can alter metabolic flux in cancer.  It was found that L.deprenyl, which is clin. available for the treatment of Parkinson's disease, exerts anti.mitochondria activity in KG.1α cells, as assessed by detection of oxygen consumption rate (OCR) and extracellular acidification (ECAR) using XF analyzer, resp.  Using a luciferase assay for detecting ATP (ATP) content, it was found that suppression of mitochondrial activity led to ATP depletion and was assocd. with potent cytotoxic activity.  L.deprenyl is known to target monoamine oxidase.B (MAO.B) on the outer membrane of mitochondria, therefore, the activity of MAO-A and -B was measured based on the fluorometric detection of H2O2 produced by the enzyme reaction.  Notably, MAO-A and -B activity was low in AML cells and the present findings suggested that the anticancer effect of L-deprenyl was independent of MAO-B.  Change of mitochondrial respiration. and glycolysis.related gene expression levels were measured by reverse transcription-quant. polymerase chain reaction.  Consistent with the aforementioned results, treatment with L-deprenyl reduced the mRNA level of mitochondrial respiration. and glycolysis.related genes.  Collectively, the present results identify L-deprenyl as a novel candidate for the treatment of AML through inhibition of mitochondrial respiration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxO4qJeJrAJ7Vg90H21EOLACvtfcHk0lhewhTKJ-thiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFahu73M&md5=5fb5f18450cbc7a25b85117e536dfb1c</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3892%2For.2018.6753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2018.6753%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DI.%26aulast%3DRyu%26aufirst%3DM.%2BJ.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DJu%26aufirst%3DX.%26aulast%3DYoo%26aufirst%3DB.%2BH.%26aulast%3DLee%26aufirst%3DY.%2BL.%26aulast%3DJang%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DI.%2BC.%26aulast%3DChung%26aufirst%3DW.%26aulast%3DOh%26aufirst%3DE.%26aulast%3DHeo%26aufirst%3DJ.%2BY.%26aulast%3DKweon%26aufirst%3DG.%2BR.%26atitle%3DL-Deprenyl%2520exerts%2520cytotoxicity%2520towards%2520acute%2520myeloid%2520leukemia%2520through%2520inhibition%2520of%2520mitochondrial%2520respiration%26jtitle%3DOncol.%2520Rep.%26date%3D2018%26volume%3D40%26spage%3D3869%26epage%3D3878%26doi%3D10.3892%2For.2018.6753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Thioridazine elicits potent antitumor effects in colorectal cancer stem cells</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1168</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.3892/or.2016.5313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3892%2For.2016.5313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=28000884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFyjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1168-1174&author=C.+Zhangauthor=P.+Gongauthor=P.+Liuauthor=N.+Zhouauthor=Y.+Zhouauthor=Y.+Wang&title=Thioridazine+elicits+potent+antitumor+effects+in+colorectal+cancer+stem+cells&doi=10.3892%2For.2016.5313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Thioridazine elicits potent antitumor effects in colorectal cancer stem cells</span></div><div class="casAuthors">Zhang, Chen; Gong, Ping; Liu, Pengfei; Zhou, Ning; Zhou, Yulai; Wang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1168-1174</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">As a member of the phenothiazine family, thioridazine (THIO) is a potent anti-anxiety and anti-psychotic drug.  Recent studies have reported that THIO could suppress the growth of several types of cancer cells.  However, the effect of THIO on colorectal cancer stem cells (CSCs) has not been investigated.  In the present study, we examd. the effect of THIO on viability of CSCs isolated from the human colon cancer cell line HCT116 and its colony-formation ability, along with its stem cell-specific gene expression.  The CSCs, EpCAM+ and CD44+ subpopulations from HCT116 cells were isolated using immunomagnetic beads.  After incubation with several concns. of THIO, we evaluated the proliferation and invasion ability of colon CSCs, as well as cell apoptosis.  We found that THIO significantly suppressed the proliferation and invasion of colon CSCs and induced cell apoptosis in a concn.-dependent manner.  The expression of some apoptosis genes (Bax and caspase-3) was upregulated after treatment with THIO, while that of the anti-apoptosis gene Bcl-2 was downregulated.  Moreover, the CSC mitochondrial membrane potential was downregulated.  Overall, this study showed that THIO inhibits the proliferation of CSCs derived from the HCT116 cell line through induction of apoptosis, and thus, could be a promising agent for the treatment of colon cancer and worthy of exploring in prospective clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnZ11sPRdcgbVg90H21EOLACvtfcHk0ljrHMVNREYPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFyjtbk%253D&md5=9df4dea1fc137fdfc1b9cbdf1b031743</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.3892%2For.2016.5313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2016.5313%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DThioridazine%2520elicits%2520potent%2520antitumor%2520effects%2520in%2520colorectal%2520cancer%2520stem%2520cells%26jtitle%3DOncol.%2520Rep.%26date%3D2017%26volume%3D37%26spage%3D1168%26epage%3D1174%26doi%3D10.3892%2For.2016.5313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiou, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y. R.</span></span> <span> </span><span class="NLM_article-title">Thioridazine enhances P62-mediated autophagy and apoptosis through Wnt/β-catenin signaling pathway in glioma cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">473</span>, <span class="refDoi"> DOI: 10.3390/ijms20030473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fijms20030473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlSrs73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=473&author=C.+W.+Chuauthor=H.+J.+Koauthor=C.+H.+Chouauthor=T.+S.+Chengauthor=H.+W.+Chengauthor=Y.+H.+Liangauthor=Y.+L.+Laiauthor=C.+Y.+Linauthor=C.+Wangauthor=J.+K.+Lohauthor=J.+T.+Chengauthor=S.+J.+Chiouauthor=C.+L.+Suauthor=C.+F.+Huangauthor=Y.+R.+Hong&title=Thioridazine+enhances+P62-mediated+autophagy+and+apoptosis+through+Wnt%2F%CE%B2-catenin+signaling+pathway+in+glioma+cells&doi=10.3390%2Fijms20030473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Thioridazine enhances P62-mediated autophagy and apoptosis through Wnt/β-catenin signaling pathway in glioma cells</span></div><div class="casAuthors">Chu, Cheng-Wei; Ko, Huey-Jiun; Chou, Chia-Hua; Cheng, Tai-Shan; Cheng, Hui-Wen; Liang, Yu-Hsin; Lai, Yun-Ling; Lin, Chen-Yen; Wang, Chihuei; Loh, Joon-Khim; Cheng, Jiin-Tsuey; Chiou, Shean-Jaw; Su, Chun-Li; Huang, Chi-Ying F.; Hong, Yi-Ren</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">473</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Thioridazine (THD) is a common phenothiazine antipsychotic drug reported to suppress growth in several types of cancer cells.  We previously showed that THD acts as an antiglioblastoma and anticancer stem-like cell agent.  However, the signaling pathway underlying autophagy and apoptosis induction remains unclear.  THD treatment significantly induced autophagy with upregulated AMPK activity and engendered cell death with increased sub-G1 in glioblastoma multiform (GBM) cell lines.  Notably, through whole gene expression screening with THD treatment, frizzled (Fzd) proteins, a family of G-protein-coupled receptors, were found, suggesting the participation of Wnt/β-catenin signaling.  After THD treatment, Fzd-1 and GSK3β-S9 phosphorylation (inactivated form) was reduced to promote β-catenin degrdn., which attenuated P62 inhibition.  The autophagy marker LC3-II markedly increased when P62 was released from β-catenin inhibition.  Addnl., the P62-dependent caspase-8 activation that induced P53-independent apoptosis was confirmed by inhibiting T-cell factor/β-catenin and autophagy flux.  Moreover, treatment with THD combined with temozolomide (TMZ) engendered increased LC3-II expression and caspase-3 activity, indicating promising drug synergism.  In conclusion, THD induces autophagy in GBM cells by not only upregulating AMPK activity, but also enhancing P62-mediated autophagy and apoptosis through Wnt/β-catenin signaling.  Therefore, THD is a potential alternative therapeutic agent for drug repositioning in GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob1sZzqqhkrbVg90H21EOLACvtfcHk0ljrHMVNREYPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlSrs73L&md5=24c6e8510f3884fc2345eb6735197b3b</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.3390%2Fijms20030473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20030473%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DC.%2BW.%26aulast%3DKo%26aufirst%3DH.%2BJ.%26aulast%3DChou%26aufirst%3DC.%2BH.%26aulast%3DCheng%26aufirst%3DT.%2BS.%26aulast%3DCheng%26aufirst%3DH.%2BW.%26aulast%3DLiang%26aufirst%3DY.%2BH.%26aulast%3DLai%26aufirst%3DY.%2BL.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLoh%26aufirst%3DJ.%2BK.%26aulast%3DCheng%26aufirst%3DJ.%2BT.%26aulast%3DChiou%26aufirst%3DS.%2BJ.%26aulast%3DSu%26aufirst%3DC.%2BL.%26aulast%3DHuang%26aufirst%3DC.%2BF.%26aulast%3DHong%26aufirst%3DY.%2BR.%26atitle%3DThioridazine%2520enhances%2520P62-mediated%2520autophagy%2520and%2520apoptosis%2520through%2520Wnt%252F%25CE%25B2-catenin%2520signaling%2520pathway%2520in%2520glioma%2520cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D473%26doi%3D10.3390%2Fijms20030473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weissenrieder, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moldovan, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koubek, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neighbors, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohl, R. J.</span></span> <span> </span><span class="NLM_article-title">The dopamine D2 receptor contributes to the spheroid formation behavior of U87 glioblastoma cells</span>. <i>Pharmacology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1159/000502562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1159%2F000502562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31645049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlWhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2020&pages=19-27&author=J.+S.+Weissenriederauthor=J.+L.+Reedauthor=M.+V.+Greenauthor=G.+L.+Moldovanauthor=E.+J.+Koubekauthor=J.+D.+Neighborsauthor=R.+J.+Hohl&title=The+dopamine+D2+receptor+contributes+to+the+spheroid+formation+behavior+of+U87+glioblastoma+cells&doi=10.1159%2F000502562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells</span></div><div class="casAuthors">Weissenrieder, Jillian S.; Reed, Jessie L.; Green, Michelle V.; Moldovan, George-Lucian; Koubek, Emily J.; Neighbors, Jeffrey D.; Hohl, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">19-27</span>CODEN:
                <span class="NLM_cas:coden">PHMGBN</span>;
        ISSN:<span class="NLM_cas:issn">0031-7012</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is a common and lethal cancer of the central nervous system.  This cancer is difficult to treat because most anticancer therapeutics do not readily penetrate into the brain due to the tight control at the cerebrovascular barrier.  Numerous studies have suggested that dopamine D2 receptor (D2R) antagonists, such as first generation antipsychotics, may have anticancer efficacy in vivo and in vitro.  The role of the D2R itself in the anticancer effects is unclear, but there is evidence suggesting that D2R activation promotes stem-like and spheroid forming behaviors in GBM.  We aimed to observe the role of the dopamine D2R and its modulators (at selective concns.) in spheroid formation and stemness of GBM cell line, U87MG, to clarify the validity of the D2R as a therapeutic target for cancer therapy.  Spheroid formation assays and Western blotting of the glioblastoma cell line, U87MG, were used to observe responses to treatment with the D2R agonists sumanirole, ropinirole, and 4-propyl-9-hydroxynaphthoxazine (PHNO); and the D2R antagonists thioridazine, pimozide, haloperidol, and remoxipride.  Extreme limiting diln. anal. was done to det. the impact of sumanirole and remoxipride treatment on sphere-forming cell frequency.  Proliferation was also measured by crystal violet staining.  Stable lentiviral transduction of DRD2 or shDRD2 was used to validate the role of the D2R in assay behaviors.  D2R antagonists thioridazine, pimozide, haloperidol, and remoxipride decrease spheroid formation behaviors at a selective 100 nmol/L concn., while D2R agonists PHNO, sumanirole, and ropinirole increase the formation of spheroids.  Similarly, 100 nmol/L remoxipride decreased sphere-forming cell frequency.  These results were recapitulated with genetic overexpression and knockdown of the D2R, and combination expts. indicate that the D2R is required for the effects of the pharmacol. modulators.  Furthermore, spheroid proliferation and invasive capacity increased under treatment with 100 nmol/L sumanirole and decreased under treatment with 100 nmol/L thioridazine.  Expression levels of the stemness markers Nestin and Sox2, as well as those of differentiation marker glial fibrillary acidic protein, were not altered by 100 nmol/L thioridazine or sumanirole for 72 h or continuous treatment with these compds. for 7 days during a spheroid formation assay.  Signaling activity of the dopamine D2R may be involved in the spheroid formation phenotype in the context of the U87MG cell line.  However, this modulation may not be due to alterations in stemness marker expression, but due to other factors that may contribute to spheroid formation, such as cell-cell adhesion or EGFR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMKGP_vHKUx7Vg90H21EOLACvtfcHk0lgZM3xsMGV0Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlWhs7k%253D&md5=9cfd260f1553a52efc3719c730fafea0</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1159%2F000502562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000502562%26sid%3Dliteratum%253Aachs%26aulast%3DWeissenrieder%26aufirst%3DJ.%2BS.%26aulast%3DReed%26aufirst%3DJ.%2BL.%26aulast%3DGreen%26aufirst%3DM.%2BV.%26aulast%3DMoldovan%26aufirst%3DG.%2BL.%26aulast%3DKoubek%26aufirst%3DE.%2BJ.%26aulast%3DNeighbors%26aufirst%3DJ.%2BD.%26aulast%3DHohl%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520dopamine%2520D2%2520receptor%2520contributes%2520to%2520the%2520spheroid%2520formation%2520behavior%2520of%2520U87%2520glioblastoma%2520cells%26jtitle%3DPharmacology%26date%3D2020%26volume%3D105%26spage%3D19%26epage%3D27%26doi%3D10.1159%2F000502562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varga, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csonka, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csonka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molnár, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spengler, G.</span></span> <span> </span><span class="NLM_article-title">Possible biological and clinical applications of phenothiazines</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">5983</span>– <span class="NLM_lpage">5993</span>, <span class="refDoi"> DOI: 10.21873/anticanres.12045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.21873%2Fanticanres.12045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29061777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=5983-5993&author=B.+Vargaauthor=%C3%81.+Csonkaauthor=A.+Csonkaauthor=J.+Moln%C3%A1rauthor=L.+Amaralauthor=G.+Spengler&title=Possible+biological+and+clinical+applications+of+phenothiazines&doi=10.21873%2Fanticanres.12045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Possible biological and clinical applications of phenothiazines</span></div><div class="casAuthors">Varga, Borisz; Csonka, Akos; Csonka, Andrea; Molnar, Joseph; Amaral, Leonard; Spengler, Gabriella</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5983-5993</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Phenothiazines have been used in many areas of medicine, mainly in psychopharmacol.  These compds. are able to effectively inhibit dopamine, histamine, serotonin, acetylcholine, and α-adrenergic receptors; thus, their effect and side-effect profiles are extremely diverse.  Besides their antipsychotic activity, phenothiazines have a significant antimicrobial effect as well, since they can enhance the bactericidal function of macrophages and inhibit efflux pumps.  They are also able to eliminate bacteriaI resistance plasmids and destroy bacteria by their membrane-destabilizing effect.  Their antiviral, antiprotozoal, antifungal, and antiprion activities have also been described.  Phenothiazines have also been proven to destroy cancer cells and sensitize them to chemotherapy.  Anti-angiogenesis and anticancer stem cell activities have also been reported, and they might be applied as adjuvants in the treatment of infections and tumors in the future.  Finally, phenothiazines can also be effective in the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlGPaCIVQ3kLVg90H21EOLACvtfcHk0lgZM3xsMGV0Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGqtr0%253D&md5=e3a53504392b7d0f82f8ac3f08e52ba9</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.21873%2Fanticanres.12045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21873%252Fanticanres.12045%26sid%3Dliteratum%253Aachs%26aulast%3DVarga%26aufirst%3DB.%26aulast%3DCsonka%26aufirst%3D%25C3%2581.%26aulast%3DCsonka%26aufirst%3DA.%26aulast%3DMoln%25C3%25A1r%26aufirst%3DJ.%26aulast%3DAmaral%26aufirst%3DL.%26aulast%3DSpengler%26aufirst%3DG.%26atitle%3DPossible%2520biological%2520and%2520clinical%2520applications%2520of%2520phenothiazines%26jtitle%3DAnticancer%2520Res.%26date%3D2017%26volume%3D37%26spage%3D5983%26epage%3D5993%26doi%3D10.21873%2Fanticanres.12045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oya, M.</span></span> <span> </span><span class="NLM_article-title">Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1431</span>– <span class="NLM_lpage">1441</span>, <span class="refDoi"> DOI: 10.1111/cas.13960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1111%2Fcas.13960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30719824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFOntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2019&pages=1431-1441&author=K.+Ogiharaauthor=E.+Kikuchiauthor=S.+Okazakiauthor=M.+Hagiwaraauthor=T.+Takedaauthor=K.+Matsumotoauthor=T.+Kosakaauthor=S.+Mikamiauthor=H.+Sayaauthor=M.+Oya&title=Sulfasalazine+could+modulate+the+CD44v9-xCT+system+and+enhance+cisplatin-induced+cytotoxic+effects+in+metastatic+bladder+cancer&doi=10.1111%2Fcas.13960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer</span></div><div class="casAuthors">Ogihara, Koichiro; Kikuchi, Eiji; Okazaki, Shogo; Hagiwara, Masayuki; Takeda, Toshikazu; Matsumoto, Kazuhiro; Kosaka, Takeo; Mikami, Shuji; Saya, Hideyuki; Oya, Mototsugu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1431-1441</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The prognostic role of CD44v9, a variant isoform of CD44 and a new cell surface marker of cancer stem cells, remains unclear in bladder cancer (BC) patients.  Furthermore, limited information is available on the functional role of sulfasalazine (SSZ), which could modulate the CD44v9-xCT system in order to enhance cisplatin (CDDP)-induced cytotoxicity and inhibit the metastatic potential of BC.  CD44v9 protein expression was examd. immunohistochem. in 63 muscle invasive BC (MIBC) patients who underwent radical cystectomy.  CD44v9 expression was independently assocd. with disease recurrence and cancer-specific death in MIBC.  Cytotoxic effects, glutathione levels, and reactive oxygen species prodn. by SSZ and CD44v9 and phospho-p38MAPK protein expression by SSZ with or without CDDP were assessed in MBT-2V cells with highly metastatic potential.  Sulfasalazine exerted cytotoxic effects against MBT-2V cells by inhibiting glutathione levels and inducing the prodn. of reactive oxygen species.  Sulfasalazine in combination with CDDP appeared to exert strong cytotoxic effects against MBT-2V cells by inhibiting CD44v9 expression and upregulating phospho-p38MAPK expression.  The inhibitory effects of SSZ with or without CDDP were also investigated using an MBT-2V lung metastatic model.  In the murine lung metastatic BC model, SSZ significantly prolonged animal survival.  Furthermore, the combination of SSZ with CDDP exerted stronger inhibitory effects on the establishment of lung tumor nodules than SSZ or CDDP alone.  CD44v9 expression could be a clin. biomarker for predicting poor outcomes in MIBC patients.  Sulfasalazine in combination with CDDP has potential as a novel therapy against metastatic BC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorFn5wHAFMV7Vg90H21EOLACvtfcHk0lipCe5PLo32gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFOntLk%253D&md5=a69a9c62ca829f1c4aaae1e3e4687fd7</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1111%2Fcas.13960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13960%26sid%3Dliteratum%253Aachs%26aulast%3DOgihara%26aufirst%3DK.%26aulast%3DKikuchi%26aufirst%3DE.%26aulast%3DOkazaki%26aufirst%3DS.%26aulast%3DHagiwara%26aufirst%3DM.%26aulast%3DTakeda%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DMikami%26aufirst%3DS.%26aulast%3DSaya%26aufirst%3DH.%26aulast%3DOya%26aufirst%3DM.%26atitle%3DSulfasalazine%2520could%2520modulate%2520the%2520CD44v9-xCT%2520system%2520and%2520enhance%2520cisplatin-induced%2520cytotoxic%2520effects%2520in%2520metastatic%2520bladder%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2019%26volume%3D110%26spage%3D1431%26epage%3D1441%26doi%3D10.1111%2Fcas.13960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wada, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiba, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niizeki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torimura, T.</span></span> <span> </span><span class="NLM_article-title">High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: potential targets by sulfasalazine</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2801</span>– <span class="NLM_lpage">2810</span>, <span class="refDoi"> DOI: 10.1111/cas.13728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1111%2Fcas.13728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29981246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFanu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2018&pages=2801-2810&author=F.+Wadaauthor=H.+Kogaauthor=J.+Akibaauthor=T.+Niizekiauthor=H.+Iwamotoauthor=Y.+Ikezonoauthor=T.+Nakamuraauthor=M.+Abeauthor=A.+Masudaauthor=T.+Sakaueauthor=T.+Tanakaauthor=T.+Kakumaauthor=H.+Yanoauthor=T.+Torimura&title=High+expression+of+CD44v9+and+xCT+in+chemoresistant+hepatocellular+carcinoma%3A+potential+targets+by+sulfasalazine&doi=10.1111%2Fcas.13728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine</span></div><div class="casAuthors">Wada, Fumitaka; Koga, Hironori; Akiba, Jun; Niizeki, Takashi; Iwamoto, Hideki; Ikezono, Yu; Nakamura, Toru; Abe, Mitsuhiko; Masuda, Atsutaka; Sakaue, Takahiko; Tanaka, Toshimitsu; Kakuma, Tatsuyuki; Yano, Hirohisa; Torimura, Takuji</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2801-2810</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The aims of the present study were to assess: (i) expression status of CD44v9 and xCT in hepatocellular carcinoma (HCC) tissues, including those derived from patients treated with hepatic arterial infusion chemoembolization (HAIC) therapy with cisplatin (CDDP); and (ii) whether combination of CDDP with sulfasalazine (SASP), an inhibitor of xCT, was more effective on tumor cells than CDDP alone by inducing ROS-mediated apoptosis.  Twenty non-pretreated HCC tissues and 7 HCC tissues administered HAIC therapy with CDDP before surgical resection were subjected to immunohistochem. anal. of CD44v9 and xCT expression.  Human HCC cell lines HAK-1A and HAK-1B were used in this study; the latter was also used for xenograft expts. in nude mice to assess in vivo efficacy of combination treatment.  CD44v9 positivity was significantly higher in HAIC-treated tissues (5/7) than in non-pretreated tissues (2/30), suggesting the involvement of CD44v9 in the resistance to HAIC. xCT was significantly expressed in poorly differentiated HCC tissues.  Combination treatment effectively killed the CD44v9-harboring HAK-1B cells through ROS-mediated apoptosis and significantly decreased xenografted tumor growth.  In conclusion, the xCT inhibitor SASP augmented ROS-mediated apoptosis in CDDP-treated HCC cells, in which the CD44v9-xCT system functioned.  As CD44v9 is typically expressed in HAIC-resistant HCC cells, combination treatment with SASP with CDDP may overcome such drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYN0ghvFxGE7Vg90H21EOLACvtfcHk0lipCe5PLo32gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFanu7rE&md5=659a345da2d1d3a2fb2d4939922b05c7</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1111%2Fcas.13728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13728%26sid%3Dliteratum%253Aachs%26aulast%3DWada%26aufirst%3DF.%26aulast%3DKoga%26aufirst%3DH.%26aulast%3DAkiba%26aufirst%3DJ.%26aulast%3DNiizeki%26aufirst%3DT.%26aulast%3DIwamoto%26aufirst%3DH.%26aulast%3DIkezono%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DMasuda%26aufirst%3DA.%26aulast%3DSakaue%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKakuma%26aufirst%3DT.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DTorimura%26aufirst%3DT.%26atitle%3DHigh%2520expression%2520of%2520CD44v9%2520and%2520xCT%2520in%2520chemoresistant%2520hepatocellular%2520carcinoma%253A%2520potential%2520targets%2520by%2520sulfasalazine%26jtitle%3DCancer%2520Sci.%26date%3D2018%26volume%3D109%26spage%3D2801%26epage%3D2810%26doi%3D10.1111%2Fcas.13728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ralph, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozuhur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhulais, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Enríquez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Sánchez, R.</span></span> <span> </span><span class="NLM_article-title">Repurposing drugs as pro-oxidant redox modifiers to eliminate cancer stem cells and improve the treatment of advanced stage cancers</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2397</span>– <span class="NLM_lpage">2426</span>, <span class="refDoi"> DOI: 10.1002/med.21589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fmed.21589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31111530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3M7otVegsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=2397-2426&author=S.+J.+Ralphauthor=S.+Nozuhurauthor=R.+A.+Alhulaisauthor=S.+Rodr%C3%ADguez-Enr%C3%ADquezauthor=R.+Moreno-S%C3%A1nchez&title=Repurposing+drugs+as+pro-oxidant+redox+modifiers+to+eliminate+cancer+stem+cells+and+improve+the+treatment+of+advanced+stage+cancers&doi=10.1002%2Fmed.21589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing drugs as pro-oxidant redox modifiers to eliminate cancer stem cells and improve the treatment of advanced stage cancers</span></div><div class="casAuthors">Ralph Stephen J; Nozuhur Sam; ALHulais Reem Ali; Rodriguez-Enriquez Sara; Moreno-Sanchez Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2397-2426</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Over the last decade, three major advances have contributed in improving the response rates against cancer including, immunotherapy; greater understanding of the molecular, biochemical, and cellular mechanisms in carcinogenesis thereby providing drug targets; and identification of reliable biomarkers for early detection to facilitate the earlier stage treatment of disease.  However, no single universal cancer cure has yet been found, although combinations from the above areas have steadily improved survival outcomes.  Hence, chemotherapy remains a key component in the oncologist's arsenal for cancer therapy, despite frequent development of drug resistance and more aggressive cancers with onset of advanced stage metastases.  The focus here is to explore the repurposing of old drugs that cause pro-oxidative overload to overcome onset of resistance to chemotherapy and enhance chemotherapeutic responses, particularly against metastatic cancer.  Excellent examples of US Food and Drug Administration approved drugs suitable for repurposing are the potent and specific thioreductase inhibitor auranofin and the nonsteroidal anti-inflammatory drug, celecoxib.  Recently, both drugs were shown to selectively target and kill metastatic cancer cells and cancer stem cells (CSCs), predominantly by promoting excessive mitochondrial reactive oxygen species.  Thus, targeting intracellular redox systems of advanced stage metastatic cancer cells and CSCs can promote an overload of pro-oxidative stress to activate the intrinsic pathway for programmed cell death.  It is envisaged that more clinical studies will incorporate longer term use of repurposed drugs, such as auranofin or celecoxib, to target redox systems in cancer cells as part of common practice postcancer diagnosis, providing enhanced chemotherapeutic responses and increased cancer survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2i2MrU-cfcJSWdIdmEou5fW6udTcc2eZf1tz4pa2587ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7otVegsw%253D%253D&md5=8bb0d2ecdda8689de5ce0ddb3064ea60</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1002%2Fmed.21589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21589%26sid%3Dliteratum%253Aachs%26aulast%3DRalph%26aufirst%3DS.%2BJ.%26aulast%3DNozuhur%26aufirst%3DS.%26aulast%3DAlhulais%26aufirst%3DR.%2BA.%26aulast%3DRodr%25C3%25ADguez-Enr%25C3%25ADquez%26aufirst%3DS.%26aulast%3DMoreno-S%25C3%25A1nchez%26aufirst%3DR.%26atitle%3DRepurposing%2520drugs%2520as%2520pro-oxidant%2520redox%2520modifiers%2520to%2520eliminate%2520cancer%2520stem%2520cells%2520and%2520improve%2520the%2520treatment%2520of%2520advanced%2520stage%2520cancers%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2019%26volume%3D39%26spage%3D2397%26epage%3D2426%26doi%3D10.1002%2Fmed.21589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashemi Goradel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najafi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salehi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farhood, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortezaee, K.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase-2 in cancer: a review</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">5683</span>– <span class="NLM_lpage">5699</span>, <span class="refDoi"> DOI: 10.1002/jcp.27411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fjcp.27411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30341914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKjurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2019&pages=5683-5699&author=N.+Hashemi+Goradelauthor=M.+Najafiauthor=E.+Salehiauthor=B.+Farhoodauthor=K.+Mortezaee&title=Cyclooxygenase-2+in+cancer%3A+a+review&doi=10.1002%2Fjcp.27411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase-2 in cancer: A review</span></div><div class="casAuthors">Hashemi Goradel, Nasser; Najafi, Masoud; Salehi, Eniseh; Farhood, Bagher; Mortezaee, Keywan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">5683-5699</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cyclooxygenase-2 (COX-2) is frequently expressed in many types of cancers exerting a pleiotropic and multifaceted role in genesis or promotion of carcinogenesis and cancer cell resistance to chemo- and radiotherapy.  COX-2 is released by cancer-assocd. fibroblasts (CAFs), macrophage type 2 (M2) cells, and cancer cells to the tumor microenvironment (TME).  COX-2 induces cancer stem cell (CSC)-like activity, and promotes apoptotic resistance, proliferation, angiogenesis, inflammation, invasion, and metastasis of cancer cells.  COX-2 mediated hypoxia within the TME along with its pos. interactions with YAP1 and antiapoptotic mediators are all in favor of cancer cell resistance to chemotherapeutic drugs.  COX-2 exerts most of the functions through its metabolite prostaglandin E2.  In some and limited situations, COX-2 may act as an antitumor enzyme.  Multiple signals are contributed to the functions of COX-2 on cancer cells or its regulation.  Members of mitogen-activated protein kinase (MAPK) family, epidermal growth factor receptor (EGFR), and nuclear factor-κβ are main upstream modulators for COX-2 in cancer cells.  COX-2 also has interactions with a no. of hormones within the body.  Inhibition of COX-2 provides a high possibility to exert therapeutic outcomes in cancer.  Administration of COX-2 inhibitors in a preoperative setting could reduce the risk of metastasis in cancer patients.  COX-2 inhibition also sensitizes cancer cells to treatments like radio- and chemotherapy.  Chemotherapeutic agents adversely induce COX-2 activity.  Therefore, choosing an appropriate chemotherapy drugs along with adjustment of the type and does for COX-2 inhibitors based on the type of cancer would be an effective adjuvant strategy for targeting cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGsqDfThyHLbVg90H21EOLACvtfcHk0ljZ806kz1FAcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKjurnK&md5=e31cf4c374f72fe738e0fb5d1fbe2ab3</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1002%2Fjcp.27411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.27411%26sid%3Dliteratum%253Aachs%26aulast%3DHashemi%2BGoradel%26aufirst%3DN.%26aulast%3DNajafi%26aufirst%3DM.%26aulast%3DSalehi%26aufirst%3DE.%26aulast%3DFarhood%26aufirst%3DB.%26aulast%3DMortezaee%26aufirst%3DK.%26atitle%3DCyclooxygenase-2%2520in%2520cancer%253A%2520a%2520review%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D234%26spage%3D5683%26epage%3D5699%26doi%3D10.1002%2Fjcp.27411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, J.</span>; <span class="NLM_string-name">Jiang, Z.</span></span> <span> </span><span class="NLM_article-title">Application of Omeprazole in the Preparation of Liver Cancer Stem Cell Inhibitors</span>. Chin. Patent <span class="NLM_patent">108,685,919 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Xing&author=Z.+Jiang&title=Application+of+Omeprazole+in+the+Preparation+of+Liver+Cancer+Stem+Cell+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DJ.%26atitle%3DApplication%2520of%2520Omeprazole%2520in%2520the%2520Preparation%2520of%2520Liver%2520Cancer%2520Stem%2520Cell%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Proton pump inhibitor pantoprazole inhibits the proliferation, self-renewal and chemoresistance of gastric cancer stem cells via the EMT/β-catenin pathways</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">3207</span>– <span class="NLM_lpage">3214</span>, <span class="refDoi"> DOI: 10.3892/or.2016.5154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3892%2For.2016.5154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=27748935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1aqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=3207-3214&author=S.+Fengauthor=Z.+Zhengauthor=L.+Fengauthor=L.+Yangauthor=Z.+Chenauthor=Y.+Linauthor=Y.+Gaoauthor=Y.+Chen&title=Proton+pump+inhibitor+pantoprazole+inhibits+the+proliferation%2C+self-renewal+and+chemoresistance+of+gastric+cancer+stem+cells+via+the+EMT%2F%CE%B2-catenin+pathways&doi=10.3892%2For.2016.5154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Proton pump inhibitor pantoprazole inhibits the proliferation, self-renewal and chemoresistance of gastric cancer stem cells via the EMT/β-catenin pathways</span></div><div class="casAuthors">Feng, Shuitu; Zheng, Zhigao; Feng, Lihua; Yang, Lihong; Chen, Zuhong; Lin, Yubiao; Gao, Yingqin; Chen, Yide</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3207-3214</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The cancer stem cell (CSC) model suggests that a small subset of cancer cells possess stem cell properties and plays a crucial role in tumor initiation, metastasis and resistance to anticancer therapy.  Exploration of the specific therapies targeting at CSCs has been a crucial issue in antitumor research.  Gastric cancer (GC) cells often exist in an ischemic microenvironment with acidic conditions in vivo, thus maintenance of cellular pH homeostasis is important for the survival and function of GC cells.  Proton pump inhibitors (PPIs) may prevent intracellular proton extrusions which consequently reduce cancer cell survival under acidic conditions.  The effects of PPIs on the suppression of the viability and invasiveness of GC cells have been reported, but the functional role of pantoprazole (PPZ) in GC cells remains unknown.  In this study, we found that when cells were treated with PPZ, the 5-fluorouracil (5-FU) chemosensitivity was upregulated, meanwhile the sphere formation ability and the relative expression levels of stem cell markers CD44, CD24, ABCG2, EpCAM and Lgr5 were significantly decreased.  It was hypothesized that PPZ inhibits the GC CSCs.  Successively a sphere formation culture was performed to establish CSC models and the effect of PPZ on GC CSCs from SGC-7901 and HGC-27 cells was explored.  The addn. of PPZ reduced the relative expression of CSC markers and anti-drug markers accompanied by a decrease in proliferation, 5-FU chemoresistance and self-renewal capacity via epithelial-mesenchymal transition (EMT)/β-catenin pathways.  The study suggests that PPZ could be a promising novel specific therapeutic strategy for targeting GC CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4EV8maKK0vLVg90H21EOLACvtfcHk0ljZ806kz1FAcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1aqtr0%253D&md5=0c7445b61775d373022c66a477e22f71</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.3892%2For.2016.5154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2016.5154%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DProton%2520pump%2520inhibitor%2520pantoprazole%2520inhibits%2520the%2520proliferation%252C%2520self-renewal%2520and%2520chemoresistance%2520of%2520gastric%2520cancer%2520stem%2520cells%2520via%2520the%2520EMT%252F%25CE%25B2-catenin%2520pathways%26jtitle%3DOncol.%2520Rep.%26date%3D2016%26volume%3D36%26spage%3D3207%26epage%3D3214%26doi%3D10.3892%2For.2016.5154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Negri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naponelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettuzzi, S.</span></span> <span> </span><span class="NLM_article-title">Molecular targets of epigallocatechin-gallate (EGCG): A special focus on signal transduction and cancer</span>. <i>Nutrients</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1936</span>, <span class="refDoi"> DOI: 10.3390/nu10121936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fnu10121936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlWjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1936&author=A.+Negriauthor=V.+Naponelliauthor=F.+Rizziauthor=S.+Bettuzzi&title=Molecular+targets+of+epigallocatechin-gallate+%28EGCG%29%3A+A+special+focus+on+signal+transduction+and+cancer&doi=10.3390%2Fnu10121936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular targets of epigallocatechin-gallate (egcg): a special focus on signal transduction and cancer</span></div><div class="casAuthors">Negri, Aide; Naponelli, Valeria; Rizzi, Federica; Bettuzzi, Saverio</div><div class="citationInfo"><span class="NLM_cas:title">Nutrients</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1936/1-1936/24</span>CODEN:
                <span class="NLM_cas:coden">NUTRHU</span>;
        ISSN:<span class="NLM_cas:issn">2072-6643</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Green tea is a beverage that is widely consumed worldwide and is believed to exert effects on different diseases, including cancer.  The major components of green tea are catechins, a family of polyphenols.  Among them, epigallocatechin-gallate (EGCG) is the most abundant and biol. active.  EGCG is widely studied for its anti-cancer properties.  However, the cellular and mol. mechanisms explaining its action have not been completely understood, yet.  EGCG is effective in vivo at micromolar concns., suggesting that its action is mediated by interaction with specific targets that are involved in the regulation of crucial steps of cell proliferation, survival, and metastatic spread.  Recently, several proteins have been identified as EGCG direct interactors.  Among them, the trans-membrane receptor 67LR has been identified as a high affinity EGCG receptor.  67LR is a master regulator of many pathways affecting cell proliferation or apoptosis, also regulating cancer stem cells (CSCs) activity.  EGCG was also found to be interacting directly with Pin1, TGFR-II, and metalloproteinases (MMPs) (mainly MMP2 and MMP9), which resp. regulate EGCG-dependent inhibition of NF-kB, epithelial-mesenchimal transaction (EMT) and cellular invasion.  EGCG interacts with DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), which modulates epigenetic changes.  The bulk of this novel knowledge provides information about the mechanisms of action of EGCG and may explain its onco-suppressive function.  The identification of crucial signalling pathways that are related to cancer onset and progression whose master regulators interacts with EGCG may disclose intriguing pharmacol. targets, and eventually lead to novel combined treatments in which EGCG acts synergistically with known drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF-kl3fzlnirVg90H21EOLACvtfcHk0lhCDtE1x54Tkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlWjtbw%253D&md5=5ec1904b1e7efc04c1b80d7b13cdf908</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.3390%2Fnu10121936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fnu10121936%26sid%3Dliteratum%253Aachs%26aulast%3DNegri%26aufirst%3DA.%26aulast%3DNaponelli%26aufirst%3DV.%26aulast%3DRizzi%26aufirst%3DF.%26aulast%3DBettuzzi%26aufirst%3DS.%26atitle%3DMolecular%2520targets%2520of%2520epigallocatechin-gallate%2520%2528EGCG%2529%253A%2520A%2520special%2520focus%2520on%2520signal%2520transduction%2520and%2520cancer%26jtitle%3DNutrients%26date%3D2018%26volume%3D10%26spage%3D1936%26doi%3D10.3390%2Fnu10121936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel human inosine 5′-monophosphate dehydrogenase 2 (<i>h</i>IMPDH2) inhibitors as potential anticancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.09.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.ejmech.2018.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30223117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslejtrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=286-301&author=C.+P.+Shahauthor=P.+S.+Kharkar&title=Discovery+of+novel+human+inosine+5%E2%80%B2-monophosphate+dehydrogenase+2+%28hIMPDH2%29+inhibitors+as+potential+anticancer+agents&doi=10.1016%2Fj.ejmech.2018.09.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102aR"><div class="casContent"><span class="casTitleNuber">102a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents</span></div><div class="casAuthors">Shah, Chetan P.; Kharkar, Prashant S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">286-301</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The enzyme IMP dehydrogenase (IMPDH) catalyzes an essential step in the de novo biosynthesis of guanine nucleotides, and thus regulates the guanine nucleotide pool required for cell proliferation.  Of the two isoforms, human IMPDH type 2 (hIMPDH2) is a validated mol. target for potential immunosuppressive, antiviral and anticancer chemotherapy.  In search of newer hIMPDH2 inhibitors as potential anticancer agents, three novel series (A: 5-aminoisobenzofuran-1(3H)-one, B: 3,4-dimethoxyaniline and C: benzo[d]-[1,3]dioxol-5-ylmethanamine) were synthesized and evaluated for in vitro and cell-based activities.  A total of 37 mols. (29-65) were screened for their in vitrohIMPDH2 inhibition, with particular emphasis on establishing their structure-activity relationship (SAR) trends.  Eight compds. (hits, 30, 31, 33-35, 37, 41 and 43) demonstrated significant enzyme inhibition (>70% @ 10 μM); esp. the A series mols. were more potent than B series (<70% inhibition @ 10 μM), while C series members were found to be inactive.  The hIMPDH2 IC50 values for the hits ranged from 0.36 to 7.38 μM.  The hits displaying >80% hIMPDH2 inhibition (30, 33, 35, 41 and 43) were further assessed for their cytotoxic activity against cancer cell lines such as MDA-MB-231 (breast adenocarcinoma), DU145 (prostate carcinoma), U87 MG (glioblastoma astrocytoma) and a normal cell line, NIH-3T3 (mouse embryonic fibroblast) using MTT assay.  Most of the compds. exhibited higher cellular potency against cancer cell lines and notably lower toxicity towards NIH-3T3 cells compared to mycophenolic acid (MPA), a prototypical hIMPDH2 inhibitor.  Two of the series A hits (30 and 35) were evaluated in human peripheral blood mononuclear cells (hPBMC) assay and found to be better tolerated than MPA.  The calcd./predicted mol. and physicochem. properties were satisfactory with ref. to drug-likeness.  The mol. docking studies clearly demonstrated crucial interactions of the hits with the cofactor-binding site of hIMPDH2, further providing crit. information for refining the design strategy.  The present study reports the design and discovery of structurally novel hIMPDH2 inhibitors as potential anticancer agents and provides a guide for further research on the development of safe and effective anticancer agents, esp. against glioblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhmbzyYpNNNLVg90H21EOLACvtfcHk0lhCDtE1x54Tkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslejtrnJ&md5=c2c2291dc8a79e7166d561f01674fb7d</span></div><a href="/servlet/linkout?suffix=cit102a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DC.%2BP.%26aulast%3DKharkar%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520novel%2520human%2520inosine%25205%25E2%2580%25B2-monophosphate%2520dehydrogenase%25202%2520%2528hIMPDH2%2529%2520inhibitors%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D158%26spage%3D286%26epage%3D301%26doi%3D10.1016%2Fj.ejmech.2018.09.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit102b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P. S.</span></span> <span> </span><span class="NLM_article-title">Newer human inosine 5′-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">972</span>– <span class="NLM_lpage">977</span>, <span class="refDoi"> DOI: 10.1080/14756366.2018.1474211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1080%2F14756366.2018.1474211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29792360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSksr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=972-977&author=C.+P.+Shahauthor=P.+S.+Kharkar&title=Newer+human+inosine+5%E2%80%B2-monophosphate+dehydrogenase+2+%28hIMPDH2%29+inhibitors+as+potential+anticancer+agents&doi=10.1080%2F14756366.2018.1474211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102bR"><div class="casContent"><span class="casTitleNuber">102b</span><div class="casTitle"><span class="NLM_cas:atitle">Newer human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents</span></div><div class="casAuthors">Shah, Chetan P.; Kharkar, Prashant S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">972-977</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Human IMP dehydrogenase 2 (hIMPDH2), being an age-old target, has attracted attention recently for anticancer drug development.  Mycophenolic acid (MPA), a well-known immunosuppressant drug, was used as a lead structure to design and develop modestly potent and selective analogs.  The steep structure-activity relationship (SAR) requirements of the lead mol. left little scope to synthesize newer analogs.  Here, newer MPA amides were designed, synthesized and evaluated for hIMPDH2 inhibition and cellular efficacy in breast, prostate and glioblastoma cell lines.  Few title compds. exhibited cellular activity profile better than MPA itself.  The obsd. differences in the overall biol. profile could be attributed to improved structural and physicochem. properties of the analogs over MPA.  This is the first report of the activity of MPA derivs. in glioblastoma, the most aggressive brain cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKuXD_2XMr0rVg90H21EOLACvtfcHk0lgWXmwDd2t7DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSksr7K&md5=0b1719ab201ab15f2b68f286229657bf</span></div><a href="/servlet/linkout?suffix=cit102b&amp;dbid=16384&amp;doi=10.1080%2F14756366.2018.1474211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2018.1474211%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DC.%2BP.%26aulast%3DKharkar%26aufirst%3DP.%2BS.%26atitle%3DNewer%2520human%2520inosine%25205%25E2%2580%25B2-monophosphate%2520dehydrogenase%25202%2520%2528hIMPDH2%2529%2520inhibitors%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2018%26volume%3D33%26spage%3D972%26epage%3D977%26doi%3D10.1080%2F14756366.2018.1474211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talukdar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emdad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span> <span> </span><span class="NLM_article-title">EGFR: an essential receptor tyrosine kinase - regulator of cancer stem cells</span>. <i>Adv. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1016/bs.acr.2020.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fbs.acr.2020.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32593400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB38nltlyhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2020&pages=161-188&author=S.+Talukdarauthor=L.+Emdadauthor=S.+K.+Dasauthor=P.+B.+Fisher&title=EGFR%3A+an+essential+receptor+tyrosine+kinase+-+regulator+of+cancer+stem+cells&doi=10.1016%2Fbs.acr.2020.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells</span></div><div class="casAuthors">Talukdar Sarmistha; Emdad Luni; Das Swadesh K; Fisher Paul B</div><div class="citationInfo"><span class="NLM_cas:title">Advances in cancer research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161-188</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Epidermal Growth Factor Receptor (EGFR) is frequently expressed at elevated levels in different forms of cancer and expression often correlates positively with cancer progression and poor prognosis.  Different mutant forms of this protein also contribute to cancer heterogeneity.  A constitutively active form of EGFR, EGFRvIII is one of the most important variants.  EGFR is responsible for the maintenance and functions of cancer stem cells (CSCs), including stemness, metabolism, immunomodulatory-activity, dormancy and therapy-resistance.  EGFR regulates these pathways through several signaling cascades, and often cooperates with other RTKs to exert further control.  Inhibitors of EGFR have been extensively studied and display some anticancer efficacy.  However, CSCs can also acquire resistance to EGFR inhibitors making effective therapy even more difficult.  To ameliorate this limitation of EGFR inhibitors when used as single agents, it may be of value to simultaneously combine multiple EGFR inhibitors or use EGFR inhibitors with regulators of other important cancer phenotype regulating molecules, such as STAT3, or involved in important processes such as DNA repair.  These combinatorial approaches require further experimental confirmation, but if successful would expand and improve therapeutic outcomes employing EGFR inhibitors as one arm of the therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhTqCS5C5LGRpyrDyM_m9cfW6udTcc2eb0H1Jq0ZrmGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38nltlyhtg%253D%253D&md5=a91786d785a1825000b9975756ec3864</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fbs.acr.2020.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.acr.2020.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DTalukdar%26aufirst%3DS.%26aulast%3DEmdad%26aufirst%3DL.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26atitle%3DEGFR%253A%2520an%2520essential%2520receptor%2520tyrosine%2520kinase%2520-%2520regulator%2520of%2520cancer%2520stem%2520cells%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2020%26volume%3D147%26spage%3D161%26epage%3D188%26doi%3D10.1016%2Fbs.acr.2020.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P. S.</span></span> <span> </span><span class="NLM_article-title">Computational approaches for the design of (mutant-) selective tyrosine kinase inhibitors: State-of-the-art and future prospects</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1564</span>– <span class="NLM_lpage">1575</span>, <span class="refDoi"> DOI: 10.2174/1568026620666200502005853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.2174%2F1568026620666200502005853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32357816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslKjurbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=1564-1575&author=P.+S.+Kharkar&title=Computational+approaches+for+the+design+of+%28mutant-%29+selective+tyrosine+kinase+inhibitors%3A+State-of-the-art+and+future+prospects&doi=10.2174%2F1568026620666200502005853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Computational Approaches for the Design of (Mutant-)Selective Tyrosine Kinase Inhibitors: State-of-the-Art and Future Prospects</span></div><div class="casAuthors">Kharkar, Prashant S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1564-1575</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases remain one of the major attractive therapeutic targets for a large no. of indications such as cancer, rheumatoid arthritis, cardiac failure and many others.  Design and development of kinase inhibitors (ATP-competitive, allosteric or covalent) is a clin. validated and successful strategy in the pharmaceutical industry.  The perks come with limitations, particularly the development of resistance to highly potent and selective inhibitors.  When this happens, the cycle needs to be repeated, i.e., the design and development of kinase inhibitors active against the mutated forms.  Several computational approaches such as structure-, ligand-based or hybrid ones continue to live up to their potential in discovering novel kinase inhibitors.  In addn. to the conventional strategies, modern technologies (machine learning, deep learning, artificial intelligence, etc.) started yielding the results and building success stories.  Computational tools invariably played a crit. role in catalyzing the phenomenal progress in kinase drug discovery field.  The present review summarized the progress in utilizing computational methods and tools for discovering (mutant-)selective tyrosine kinase inhibitor drugs in the last three years (2017-2019).  The author believes that the enthusiastic reader will be inspired to dig out the cited literature extensively to appreciate the progress made so far and the future prospects of the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWqfC-VaBs67Vg90H21EOLACvtfcHk0lg-5NJiQlYgxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslKjurbE&md5=011a0c275b4a24d43de999ae6efc1565</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.2174%2F1568026620666200502005853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026620666200502005853%26sid%3Dliteratum%253Aachs%26aulast%3DKharkar%26aufirst%3DP.%2BS.%26atitle%3DComputational%2520approaches%2520for%2520the%2520design%2520of%2520%2528mutant-%2529%2520selective%2520tyrosine%2520kinase%2520inhibitors%253A%2520State-of-the-art%2520and%2520future%2520prospects%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2020%26volume%3D20%26spage%3D1564%26epage%3D1575%26doi%3D10.2174%2F1568026620666200502005853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.</span></span> <span> </span><span class="NLM_article-title">Regulation of Src family kinases during colorectal cancer development and its clinical implications</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1339</span>, <span class="refDoi"> DOI: 10.3390/cancers12051339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcancers12051339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVehsLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1339&author=W.+Jin&title=Regulation+of+Src+family+kinases+during+colorectal+cancer+development+and+its+clinical+implications&doi=10.3390%2Fcancers12051339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of Src family kinases during colorectal cancer development and its clinical implications</span></div><div class="casAuthors">Jin, Wook</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1339</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Src family kinases (SFKs) are non-receptor kinases that play a crit. role in the pathogenesis of colorectal cancer (CRC).  The expression and activity of SFKs are upregulated in patients with CRC.  Activation of SFKs promotes CRC cell proliferation, metastases to other organs and chemoresistance, as well as the formation of cancer stem cells (CSCs).  The enhanced expression level of Src is assocd. with decreased survival in patients with CRC.  Src-mediated regulation of CRC progression involves various membrane receptors, modulators, and suppressors, which regulate Src activation and its downstream targets through various mechanisms.  This review provides an overview of the current understanding of the correlations between Src and CRC progression, with a special focus on cancer cell proliferation, invasion, metastasis and chemoresistance, and formation of CSCs.  Addnl., this review discusses preclin. and clin. strategies to improve the therapeutic efficacy of drugs targeting Src for treating patients with CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYjUh5ZnbAubVg90H21EOLACvtfcHk0lg-5NJiQlYgxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVehsLrJ&md5=33c88dad0fb0490a3f060fe5522f74d4</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.3390%2Fcancers12051339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12051339%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DW.%26atitle%3DRegulation%2520of%2520Src%2520family%2520kinases%2520during%2520colorectal%2520cancer%2520development%2520and%2520its%2520clinical%2520implications%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D1339%26doi%3D10.3390%2Fcancers12051339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daday, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jobst, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milles, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercadante, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippig, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaub, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gräter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span> <span> </span><span class="NLM_article-title">Structural and mechanistic insights into mechanoactivation of focal adhesion kinase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">6766</span>– <span class="NLM_lpage">6774</span>, <span class="refDoi"> DOI: 10.1073/pnas.1820567116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1073%2Fpnas.1820567116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30877242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsFeqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=6766-6774&author=M.+S.+Bauerauthor=F.+Baumannauthor=C.+Dadayauthor=P.+Redondoauthor=E.+Durnerauthor=M.+A.+Jobstauthor=L.+F.+Millesauthor=D.+Mercadanteauthor=D.+A.+Pippigauthor=H.+E.+Gaubauthor=F.+Gr%C3%A4terauthor=D.+Lietha&title=Structural+and+mechanistic+insights+into+mechanoactivation+of+focal+adhesion+kinase&doi=10.1073%2Fpnas.1820567116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and mechanistic insights into mechanoactivation of focal adhesion kinase</span></div><div class="casAuthors">Bauer, Magnus Sebastian; Baumann, Fabian; Daday, Csaba; Redondo, Pilar; Durner, Ellis; Jobst, Markus Andreas; Milles, Lukas Frederik; Mercadante, Davide; Pippig, Diana Angela; Gaub, Hermann Eduard; Grater, Frauke; Lietha, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6766-6774</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a key signaling mol. regulating cell adhesion, migration, and survival.  FAK localizes into focal adhesion complexes formed at the cytoplasmic side of cell attachment to the ECM and is activated after force generation via actomyosin fibers attached to this complex.  The mechanism of translating mech. force into a biochem. signal is not understood, and it is not clear whether FAK is activated directly by force or downstream to the force signal.  We use exptl. and computational single-mol. force spectroscopy to probe the mech. properties of FAK and examine whether force can trigger activation by inducing conformational changes in FAK.  By comparison with an open and active mutant of FAK, we are able to assign mechanoactivation to an initial rupture event in the low-force range.  This activation event occurs before FAK unfolding at forces within the native range in focal adhesions.  We are also able to assign all subsequent peaks in the force landscape to partial unfolding of FAK modules.  We show that binding of ATP stabilizes the kinase domain, thereby altering the unfolding hierarchy.  Using all-atom mol. dynamics simulations, we identify intermediates along the unfolding pathway, which provide buffering to allow extension of FAK in focal adhesions without compromising functionality.  Our findings strongly support that forces in focal adhesions applied to FAK via known interactions can induce conformational changes, which in turn, trigger focal adhesion signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2-XSryEbUc7Vg90H21EOLACvtfcHk0li4QqHjpj0prg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsFeqsrY%253D&md5=fb257abca1423f6c4434177002178c8a</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1820567116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1820567116%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DM.%2BS.%26aulast%3DBaumann%26aufirst%3DF.%26aulast%3DDaday%26aufirst%3DC.%26aulast%3DRedondo%26aufirst%3DP.%26aulast%3DDurner%26aufirst%3DE.%26aulast%3DJobst%26aufirst%3DM.%2BA.%26aulast%3DMilles%26aufirst%3DL.%2BF.%26aulast%3DMercadante%26aufirst%3DD.%26aulast%3DPippig%26aufirst%3DD.%2BA.%26aulast%3DGaub%26aufirst%3DH.%2BE.%26aulast%3DGr%25C3%25A4ter%26aufirst%3DF.%26aulast%3DLietha%26aufirst%3DD.%26atitle%3DStructural%2520and%2520mechanistic%2520insights%2520into%2520mechanoactivation%2520of%2520focal%2520adhesion%2520kinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26spage%3D6766%26epage%3D6774%26doi%3D10.1073%2Fpnas.1820567116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnawi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Khaldi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakheet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallatah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alaiya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghebeh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Alwan, M.</span></span> <span> </span><span class="NLM_article-title">Fascin activates β-catenin signaling and promotes breast cancer stem cell function mainly through focal adhesion kinase (FAK): relation with disease progression</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">440</span>, <span class="refDoi"> DOI: 10.3389/fonc.2020.00440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffonc.2020.00440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32373510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB38vjsV2muw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=440&author=R.+Barnawiauthor=S.+Al-Khaldiauthor=T.+Bakheetauthor=M.+Fallatahauthor=A.+Alaiyaauthor=H.+Ghebehauthor=M.+Al-Alwan&title=Fascin+activates+%CE%B2-catenin+signaling+and+promotes+breast+cancer+stem+cell+function+mainly+through+focal+adhesion+kinase+%28FAK%29%3A+relation+with+disease+progression&doi=10.3389%2Ffonc.2020.00440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Fascin Activates β-Catenin Signaling and Promotes Breast Cancer Stem Cell Function Mainly Through Focal Adhesion Kinase (FAK): Relation With Disease Progression</span></div><div class="casAuthors">Barnawi Rayanah; Alaiya Ayodele; Ghebeh Hazem; Al-Alwan Monther; Al-Khaldi Samiyah; Fallatah Mohannad; Bakheet Tala; Ghebeh Hazem; Al-Alwan Monther</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">440</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Cancer stem cells (CSCs), a rare population of tumor cells with high self-renewability potential, have gained increasing attention due to their contribution to chemoresistance and metastasis.  We have previously demonstrated a critical role for the actin-bundling protein (fascin) in mediating breast cancer chemoresistance through activation of focal adhesion kinase (FAK).  The latter is known to trigger the β-catenin signaling pathway.  Whether fascin activation of FAK would ultimately trigger β-catenin signaling pathway has not been elucidated.  Here, we assessed the effect of fascin manipulation in breast cancer cells on triggering β-catenin downstream targets and its dependence on FAK.  Gain and loss of fascin expression showed its direct effect on the constitutive expression of β-catenin downstream targets and enhancement of self-renewability.  In addition, fascin was essential for glycogen synthase kinase 3β inhibitor-mediated inducible expression and function of the β-catenin downstream targets.  Importantly, fascin-mediated constitutive and inducible expression of β-catenin downstream targets, as well as its subsequent effect on CSC function, was at least partially FAK dependent.  To assess the clinical relevance of the in vitro findings, we evaluated the consequence of fascin, FAK, and β-catenin downstream target coexpression on the outcome of breast cancer patient survival.  Patients with coexpression of fascin(high) and FAK(high) or high β-catenin downstream targets showed the worst survival outcome, whereas in fascin(low), patient coexpression of FAK(high) or high β-catenin targets had less significant effect on the survival.  Altogether, our data demonstrated the critical role of fascin-mediated β-catenin activation and its dependence on intact FAK signaling to promote breast CSC function.  These findings suggest that targeting of fascin-FAK-β-catenin axis may provide a novel therapeutic approach for eradication of breast cancer from the root.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0ZMud5GFokPEeosoOnpOLfW6udTcc2ebSgJbQNbxv8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38vjsV2muw%253D%253D&md5=067cb6f178e2c78e5ce966795d5a368a</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2020.00440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2020.00440%26sid%3Dliteratum%253Aachs%26aulast%3DBarnawi%26aufirst%3DR.%26aulast%3DAl-Khaldi%26aufirst%3DS.%26aulast%3DBakheet%26aufirst%3DT.%26aulast%3DFallatah%26aufirst%3DM.%26aulast%3DAlaiya%26aufirst%3DA.%26aulast%3DGhebeh%26aufirst%3DH.%26aulast%3DAl-Alwan%26aufirst%3DM.%26atitle%3DFascin%2520activates%2520%25CE%25B2-catenin%2520signaling%2520and%2520promotes%2520breast%2520cancer%2520stem%2520cell%2520function%2520mainly%2520through%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%253A%2520relation%2520with%2520disease%2520progression%26jtitle%3DFront.%2520Oncol.%26date%3D2020%26volume%3D10%26spage%3D440%26doi%3D10.3389%2Ffonc.2020.00440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolev, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, Q. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of FAK kinase activity preferentially targets cancer stem cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">51733</span>– <span class="NLM_lpage">51747</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.18517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.18632%2Foncotarget.18517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=28881682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC1cbls1yiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=51733-51747&author=V.+N.+Kolevauthor=W.+F.+Tamauthor=Q.+G.+Wrightauthor=S.+P.+McDermottauthor=C.+M.+Vidalauthor=I.+M.+Shapiroauthor=Q.+Xuauthor=M.+S.+Wichaauthor=J.+A.+Pachterauthor=D.+T.+Weaver&title=Inhibition+of+FAK+kinase+activity+preferentially+targets+cancer+stem+cells&doi=10.18632%2Foncotarget.18517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of FAK kinase activity preferentially targets cancer stem cells</span></div><div class="casAuthors">Kolev Vihren N; Tam Winnie F; Wright Quentin G; Vidal Christian M; Shapiro Irina M; Xu Qunli; Pachter Jonathan A; Weaver David T; McDermott Sean P; Wicha Max S</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">51733-51747</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting of CSCs holds promise to address these clinical challenges to cancer treatment.  VS-4718 and VS-6063 are potent inhibitors of focal adhesion kinase (FAK), a non-receptor tyrosine kinase that mediates cell signals transmitted by integrins and growth factor receptors.  We report here that inhibition of FAK kinase activity by VS-4718 or VS-6063 preferentially targets CSCs, as demonstrated by a panel of orthogonal CSC assays in cell line models and surgically resected primary breast tumor specimens cultured ex vivo.  Oral administration of VS-4718 or VS-6063 to mice bearing xenograft models of triple-negative breast cancer (TNBC) significantly reduced the proportion of CSCs in the tumors, as evidenced by a reduced tumor-initiating capability upon re-implantation in limiting dilutions of cells prepared from these tumors.  In contrast, the cytotoxic chemotherapeutic agents, paclitaxel and carboplatin, enriched for CSCs, consistent with previous reports that these cytotoxic agents preferentially target non-CSCs.  Importantly, VS-4718 and VS-6063 attenuated the chemotherapy-induced enrichment of CSCs in vitro and delayed tumor regrowth following cessation of chemotherapy.  An intriguing crosstalk between FAK and the Wnt/β-catenin pathway was revealed wherein FAK inhibition blocks β-catenin activation by reducing tyrosine 654 phosphorylation of β-catenin.  Furthermore, a constitutively active mutant form of β-catenin reversed the preferential targeting of CSCs by FAK inhibition, suggesting that this targeting is mediated, at least in part, through attenuating β-catenin activation.  The preferential targeting of cancer stem cells by FAK inhibitors provides a rationale for the clinical development of FAK inhibitors aimed to increase durable responses for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQyuSQS7mkcmr7NkxioyDXTfW6udTcc2ebSgJbQNbxv8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbls1yiuw%253D%253D&md5=deec42a49119828ea05923cdde632999</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.18517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.18517%26sid%3Dliteratum%253Aachs%26aulast%3DKolev%26aufirst%3DV.%2BN.%26aulast%3DTam%26aufirst%3DW.%2BF.%26aulast%3DWright%26aufirst%3DQ.%2BG.%26aulast%3DMcDermott%26aufirst%3DS.%2BP.%26aulast%3DVidal%26aufirst%3DC.%2BM.%26aulast%3DShapiro%26aufirst%3DI.%2BM.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26aulast%3DWeaver%26aufirst%3DD.%2BT.%26atitle%3DInhibition%2520of%2520FAK%2520kinase%2520activity%2520preferentially%2520targets%2520cancer%2520stem%2520cells%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D51733%26epage%3D51747%26doi%3D10.18632%2Foncotarget.18517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Verasterm
Oncology</span>. <span> </span><span class="NLM_article-title">Defactinib</span>. <a href="https://www.verastem.com/research/fak-inhibition/defactinib-fak-inhibitor/" class="extLink">https://www.verastem.com/research/fak-inhibition/defactinib-fak-inhibitor/</a> (accessed 2020-07-27).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Verasterm%0AOncology.+Defactinib.+https%3A%2F%2Fwww.verastem.com%2Fresearch%2Ffak-inhibition%2Fdefactinib-fak-inhibitor%2F+%28accessed+2020-07-27%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DDefactinib" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Regueira, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sy, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurnani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saglio, G.</span></span> <span> </span><span class="NLM_article-title">Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2064</span>– <span class="NLM_lpage">2073</span>, <span class="refDoi"> DOI: 10.1038/s41375-020-0805-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fs41375-020-0805-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32265500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsFOrsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=2064-2073&author=J.+E.+Cortesauthor=Q.+Jiangauthor=J.+Wangauthor=J.+Wengauthor=H.+Zhuauthor=X.+Liuauthor=A.+Hochhausauthor=D.+W.+Kimauthor=J.+Radichauthor=M.+Savonaauthor=P.+Martin-Regueiraauthor=O.+Syauthor=R.+Gurnaniauthor=G.+Saglio&title=Dasatinib+vs.+imatinib+in+patients+with+chronic+myeloid+leukemia+in+chronic+phase+%28CML-CP%29+who+have+not+achieved+an+optimal+response+to+3+months+of+imatinib+therapy%3A+the+DASCERN+randomized+study&doi=10.1038%2Fs41375-020-0805-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study</span></div><div class="casAuthors">Cortes, Jorge E.; Jiang, Qian; Wang, Jianxiang; Weng, Jianyu; Zhu, Huanling; Liu, Xiaoli; Hochhaus, Andreas; Kim, Dong-Wook; Radich, Jerald; Savona, Michael; Martin-Regueira, Patricia; Sy, Oumar; Gurnani, Renuka; Saglio, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2064-2073</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Early mol. response is assocd. with improved probability of deep mol. response and superior survival in patients with CML-CP.  However, ∼1 in 3 patients on first-line imatinib do not achieve this threshold.  The phase 2b DASCERN trial (NCT01593254) assessed the outcome of early switch to dasatinib in patients with suboptimal response to first-line imatinib.  Adult patients with CML-CP were randomized (2:1) to receive 100 mg dasatinib (n = 174) or continue imatinib at ≥400 mg (n = 86).  The primary endpoint was the rate of major mol. response (MMR) at 12 mo, which was 29% (dasatinib) and 13% (imatinib; P = 0.005).  After ≥2 years of follow-up, 45 patients (52%) randomized to continue imatinib had crossed over to dasatinib.  Considering treatment crossover, the 2-yr cumulative MMR rate was 64% with dasatinib and 41% with imatinib (66% and 67%, resp. by intent-to-treat).  Adverse events were consistent with the established safety profiles of both drugs.  The results of this first prospective study support early monitoring of patients treated with first-line imatinib, and suggest that switching to dasatinib in cases of suboptimal response may offer clin. benefit.  Further follow-up is needed to assess the long-term clin. benefit of early switching.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmO5ZgDLZqC7Vg90H21EOLACvtfcHk0liN1OWKJbCimA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsFOrsL0%253D&md5=677cbedae77fbcf53178119b5f7da87f</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1038%2Fs41375-020-0805-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-020-0805-1%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWeng%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRadich%26aufirst%3DJ.%26aulast%3DSavona%26aufirst%3DM.%26aulast%3DMartin-Regueira%26aufirst%3DP.%26aulast%3DSy%26aufirst%3DO.%26aulast%3DGurnani%26aufirst%3DR.%26aulast%3DSaglio%26aufirst%3DG.%26atitle%3DDasatinib%2520vs.%2520imatinib%2520in%2520patients%2520with%2520chronic%2520myeloid%2520leukemia%2520in%2520chronic%2520phase%2520%2528CML-CP%2529%2520who%2520have%2520not%2520achieved%2520an%2520optimal%2520response%2520to%25203%2520months%2520of%2520imatinib%2520therapy%253A%2520the%2520DASCERN%2520randomized%2520study%26jtitle%3DLeukemia%26date%3D2020%26volume%3D34%26spage%3D2064%26epage%3D2073%26doi%3D10.1038%2Fs41375-020-0805-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffa, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moamer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khadang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachim, I. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakdounes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebrun, J. J.</span></span> <span> </span><span class="NLM_article-title">Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1495</span>– <span class="NLM_lpage">1507</span>, <span class="refDoi"> DOI: 10.1038/s41416-018-0287-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fs41416-018-0287-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30482914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVaksL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2018&pages=1495-1507&author=J.+Tianauthor=F.+A.+Raffaauthor=M.+Daiauthor=A.+Moamerauthor=B.+Khadangauthor=I.+Y.+Hachimauthor=K.+Bakdounesauthor=S.+Aliauthor=B.+Jean-Claudeauthor=J.+J.+Lebrun&title=Dasatinib+sensitises+triple+negative+breast+cancer+cells+to+chemotherapy+by+targeting+breast+cancer+stem+cells&doi=10.1038%2Fs41416-018-0287-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells</span></div><div class="casAuthors">Tian, Jun; Raffa, Fatmah Al; Dai, Meiou; Moamer, Alaa; Khadang, Baharak; Hachim, Ibrahim Y.; Bakdounes, Khldoun; Ali, Suhad; Jean-Claude, Bertrand; Lebrun, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1495-1507</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: Patients with triple neg. breast cancer (TNBC) exhibit poor prognosis and are at high risk of tumor relapse, due to the resistance to chemotherapy.  These aggressive phenotypes are in part attributed to the presence of breast cancer stem cells (BCSCs).  Therefore, targeting BCSCs is a priority to overcoming chemotherapy failure in TNBCs.  Methods: We generated paclitaxel (pac)-resistant TNBC cells which displayed higher sphere forming potential and percentage of BCSC subpopulations compared to the parental cells.  A screen with various kinase inhibitors revealed dasatinib, a Src kinase family inhibitor, as a potent suppressor of BCSC expansion/sphere formation in pac-resistant TNBC cells.  Results: We found dasatinib to block pac-induced BCSC enrichment and Src activation in both parental and pac-resistant TNBC cells.  Interestingly, dasatinib induced an epithelial differentiation of the pac-resistant mesenchymal cells, resulting in their enhanced sensitivity to paclitaxel.  The combination treatment of dasatinib and paclitaxel not only decreased the BCSCs nos. and their sphere forming capacity but also synergistically reduced cell viability of pac-resistant cells.  Preclin. models of breast cancer further demonstrated the efficiency of the dasatinib/paclitaxel combination treatment in inhibiting tumor growth.  Conclusions: Dasatinib is a promising anti-BCSC drug that could be used in combination with paclitaxel to overcome chemoresistance in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooLMaSt2TkzbVg90H21EOLACvtfcHk0liN1OWKJbCimA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVaksL7N&md5=c5248d79468d37a906fcd473da99dde6</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1038%2Fs41416-018-0287-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-018-0287-3%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DRaffa%26aufirst%3DF.%2BA.%26aulast%3DDai%26aufirst%3DM.%26aulast%3DMoamer%26aufirst%3DA.%26aulast%3DKhadang%26aufirst%3DB.%26aulast%3DHachim%26aufirst%3DI.%2BY.%26aulast%3DBakdounes%26aufirst%3DK.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DJean-Claude%26aufirst%3DB.%26aulast%3DLebrun%26aufirst%3DJ.%2BJ.%26atitle%3DDasatinib%2520sensitises%2520triple%2520negative%2520breast%2520cancer%2520cells%2520to%2520chemotherapy%2520by%2520targeting%2520breast%2520cancer%2520stem%2520cells%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2018%26volume%3D119%26spage%3D1495%26epage%3D1507%26doi%3D10.1038%2Fs41416-018-0287-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Yang, C.</span>; <span class="NLM_string-name">Bai, C.</span>; <span class="NLM_string-name">He, D.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Guo, Y.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Guan, W.</span>; <span class="NLM_string-name">Yu, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Thiazole-series Heterocyclic Compounds for Treating Leukemia</span>. Chin. Patent <span class="NLM_patent">106,279,143</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Rao&author=Y.+Chen&author=C.+Yang&author=C.+Bai&author=D.+He&author=Y.+Wang&author=Y.+Guo&author=Y.+Jiang&author=W.+Guan&author=J.+Yu&title=Preparation+of+Thiazole-series+Heterocyclic+Compounds+for+Treating+Leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DPreparation%2520of%2520Thiazole-series%2520Heterocyclic%2520Compounds%2520for%2520Treating%2520Leukemia%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">700</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.bmcl.2018.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29395973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFejsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=700-706&author=H.+Y.+Liauthor=D.+D.+Heauthor=X.+J.+Zhaoauthor=T.+Y.+Sunauthor=Q.+Zhangauthor=C.+G.+Baiauthor=Y.+Chen&title=Design+and+synthesis+of+novel+dasatinib+derivatives+as+inhibitors+of+leukemia+stem+cells&doi=10.1016%2Fj.bmcl.2018.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells</span></div><div class="casAuthors">Li, Hui-ying; He, Ding-Di; Zhao, Xiu-Juan; Sun, Tong-Yan; Zhang, Quan; Bai, Cui-Gai; Chen, Yue</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">700-706</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors used the concept of bioisosteres to design and synthesize a novel series of dasatinib derivs. for the treatment of leukemia.  Unfortunately, most of the dasatinib derivs. did not show appreciable inhibition against leukemia cell lines K562 and HL60.  However, acrylamide compd. had comparable inhibitory activity with dasatinib against K562 cells (IC50 = 0.039 nM vs. 0.069 nM).  And amide compd. and acrylamide compd. also had comparable inhibitory activity with dasatinib against the leukemia cell line HL60 (IC50 = 0.25 nM and 0.26 nM vs. 0.11 nM).  Against the leukemia progenitor cell line KG1a, triazole compds. and oxadiazole compds. were more potent than dasatinib.  In particular, the hydroxyl compds. were ∼64 and 180 fold more potent than dasatinib against KG1a cells (IC50 = 0.14 μM and 0.05 μM vs. 8.98 μM).  Hydroxyl compds. also inhibited colony formation in MCF-7 cells and inhibited cell migration in the cell wound scratch assay in B16BL6 cells.  Moreover, hydroxyl compds. had low toxicity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2boOwxzGkdbVg90H21EOLACvtfcHk0lhhunZmmZDPsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFejsb8%253D&md5=cb1029f93d886749cec5f58c27b45c6d</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%2BY.%26aulast%3DHe%26aufirst%3DD.%2BD.%26aulast%3DZhao%26aufirst%3DX.%2BJ.%26aulast%3DSun%26aufirst%3DT.%2BY.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DBai%26aufirst%3DC.%2BG.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520dasatinib%2520derivatives%2520as%2520inhibitors%2520of%2520leukemia%2520stem%2520cells%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D700%26epage%3D706%26doi%3D10.1016%2Fj.bmcl.2018.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span> <span> </span><span class="NLM_article-title">Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111535</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.ejmech.2019.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31376566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFWmtL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111535&author=X.+Wangauthor=C.+Yuauthor=C.+Wangauthor=Y.+Maauthor=T.+Wangauthor=Y.+Liauthor=Z.+Huangauthor=M.+Zhouauthor=P.+Sunauthor=J.+Zhengauthor=S.+Yangauthor=Y.+Fanauthor=R.+Xiang&title=Novel+cyclin-dependent+kinase+9+%28CDK9%29+inhibitor+with+suppression+of+cancer+stemness+activity+against+non-small-cell+lung+cancer&doi=10.1016%2Fj.ejmech.2019.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer</span></div><div class="casAuthors">Wang, Xin; Yu, Chenhua; Wang, Cheng; Ma, Yakun; Wang, Tianqi; Li, Yao; Huang, Zhi; Zhou, Manqian; Sun, Peiqing; Zheng, Jianyu; Yang, Shengyong; Fan, Yan; Xiang, Rong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111535</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel, highly potent, selective CDK9 inhibitors with cancer stem cells (CSCs) inhibition activity were designed and synthesized for non-small-cell lung cancer (NSCLC) therapy.  Structure-activity relationship anal. based on enzymic and cellular activities led to the discovery of a promising inhibitor 21e(I).  I potently inhibited CDK9 with IC50 value of 11 nM and suppressed the stemness properties of NSCLC effectively.  It could decrease the stemness phenotypes of NSCLC cells, including tumor sphere formation, side-population and stemness markers abundance.  I displayed good selectivity over the CDK family kinases and kinase profiling assay against 381 kinases.  In addn., I inhibited cell proliferation, colony-formation, and cell cycle progression and induced apoptosis in NSCLC.  In H1299 xenograft mouse model, a once-daily dose of I at 20 mg/kg significantly suppressed the tumor growth without obvious toxicity.  Studies of mechanisms of action indicated that I efficiently inhibited CDK9 signaling pathway and stemness both in vitro and in vivo.  Collectively, I as a novel CDK9 inhibitor with CSCs inhibition properties could be a promising agent for the treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_2AOdlSLbIrVg90H21EOLACvtfcHk0lhhunZmmZDPsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFWmtL3N&md5=b088226c0d124c27c921c2504a16a665</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DR.%26atitle%3DNovel%2520cyclin-dependent%2520kinase%25209%2520%2528CDK9%2529%2520inhibitor%2520with%2520suppression%2520of%2520cancer%2520stemness%2520activity%2520against%2520non-small-cell%2520lung%2520cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111535%26doi%3D10.1016%2Fj.ejmech.2019.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jirawatnotai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wattanapanitch, M.</span></span> <span> </span><span class="NLM_article-title">Role of cyclins and cyclin-dependent kinases in pluripotent stem cells and their potential as a therapeutic</span>. <i>Semin. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/j.semcdb.2020.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.semcdb.2020.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32417217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpt12gurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2020&pages=63-71&author=S.+Jirawatnotaiauthor=S.+Daltonauthor=M.+Wattanapanitch&title=Role+of+cyclins+and+cyclin-dependent+kinases+in+pluripotent+stem+cells+and+their+potential+as+a+therapeutic&doi=10.1016%2Fj.semcdb.2020.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Role of cyclins and cyclin-dependent kinases in pluripotent stem cells and their potential as a therapeutic target</span></div><div class="casAuthors">Jirawatnotai, Siwanon; Dalton, Stephen; Wattanapanitch, Methichit</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cell & Developmental Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-71</span>CODEN:
                <span class="NLM_cas:coden">SCDBFX</span>;
        ISSN:<span class="NLM_cas:issn">1084-9521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Over the last 15 years connections between cell cycle control, maintenance of pluripotency, and control of cell fate decisions have been firmly established.  With the emergence of powerful tools, such as highly-specific small mol. inhibitors for cyclin-dependent protein kinase (CDK) activity and single-cell imaging technologies, the mechanistic links between cyclins, CDKs and regulation in PSCs in mechanistic detail has been made possible.  In this review, we discuss new developments that mechanistically link the CDK regulatory network to control of cell fate decisions, including maintenance of the pluripotent state.  Overall, these findings have potential to impact the translational applications of stem cells in regenerative medicine, drug discovery and cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_uVQV9QCLRrVg90H21EOLACvtfcHk0ljwtsaTkuPstg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpt12gurg%253D&md5=f72102771fffeb729487494198029d97</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.semcdb.2020.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcdb.2020.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DJirawatnotai%26aufirst%3DS.%26aulast%3DDalton%26aufirst%3DS.%26aulast%3DWattanapanitch%26aufirst%3DM.%26atitle%3DRole%2520of%2520cyclins%2520and%2520cyclin-dependent%2520kinases%2520in%2520pluripotent%2520stem%2520cells%2520and%2520their%2520potential%2520as%2520a%2520therapeutic%26jtitle%3DSemin.%2520Cell%2520Dev.%2520Biol.%26date%3D2020%26volume%3D107%26spage%3D63%26epage%3D71%26doi%3D10.1016%2Fj.semcdb.2020.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nazio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianfanelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecconi, F.</span></span> <span> </span><span class="NLM_article-title">Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">702</span>, <span class="refDoi"> DOI: 10.1038/s41418-019-0292-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fs41418-019-0292-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30728463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFSmsLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=690-702&author=F.+Nazioauthor=M.+Bordiauthor=V.+Cianfanelliauthor=F.+Locatelliauthor=F.+Cecconi&title=Autophagy+and+cancer+stem+cells%3A+molecular+mechanisms+and+therapeutic+applications&doi=10.1038%2Fs41418-019-0292-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications</span></div><div class="casAuthors">Nazio, Francesca; Bordi, Matteo; Cianfanelli, Valentina; Locatelli, Franco; Cecconi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">690-702</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Autophagy and mitophagy act in cancer as bimodal processes, whose differential functions strictly depend on cancer ontogenesis, progression, and type.  For instance, they can act to promote cancer progression by helping cancer cells survive stress or, instead, when mutated or abnormal, to induce carcinogenesis by influencing cell signaling or promoting intracellular toxicity.  For this reason, the study of autophagy in cancer is the main focus of many researchers and several clin. trials are already ongoing to manipulate autophagy and by this way det. the outcome of disease therapy.  Since the establishment of the cancer stem cell (CSC) theory and the discovery of CSCs in individual cancer types, autophagy and mitophagy have been proposed as key mechanisms in their homeostasis, dismissal or spread, even though we still miss a comprehensive view of how and by which regulatory mols. these two processes drive cell fate.  In this review, we will dive into the deep water of autophagy, mitophagy, and CSCs and offer novel viewpoints on possible therapeutic strategies, based on the modulation of these degradative systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq9jOZkbCnH7Vg90H21EOLACvtfcHk0ljwtsaTkuPstg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFSmsLvE&md5=7a2feaaa2e09a7318fab3f1037844e6b</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fs41418-019-0292-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41418-019-0292-y%26sid%3Dliteratum%253Aachs%26aulast%3DNazio%26aufirst%3DF.%26aulast%3DBordi%26aufirst%3DM.%26aulast%3DCianfanelli%26aufirst%3DV.%26aulast%3DLocatelli%26aufirst%3DF.%26aulast%3DCecconi%26aufirst%3DF.%26atitle%3DAutophagy%2520and%2520cancer%2520stem%2520cells%253A%2520molecular%2520mechanisms%2520and%2520therapeutic%2520applications%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2019%26volume%3D26%26spage%3D690%26epage%3D702%26doi%3D10.1038%2Fs41418-019-0292-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanam, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhnerjee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastidar, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmakar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, G.</span></span> <span> </span><span class="NLM_article-title">A novel triazole, NMK-T-057, induces autophagic cell death in breast cancer cells by inhibiting γ-secretase-mediated activation of Notch signaling</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">6733</span>– <span class="NLM_lpage">6750</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA119.007671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1074%2Fjbc.RA119.007671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30824542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Slt7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=6733-6750&author=A.+Dasauthor=M.+K.+Narayanamauthor=S.+Paulauthor=P.+Mukhnerjeeauthor=S.+Ghoshauthor=D.+G.+Dastidarauthor=S.+Chakrabartyauthor=A.+Ganguliauthor=B.+Basuauthor=M.+Palauthor=U.+Chatterjiauthor=S.+K.+Banerjeeauthor=P.+Karmakarauthor=D.+Kumarauthor=G.+Chakrabarti&title=A+novel+triazole%2C+NMK-T-057%2C+induces+autophagic+cell+death+in+breast+cancer+cells+by+inhibiting+%CE%B3-secretase-mediated+activation+of+Notch+signaling&doi=10.1074%2Fjbc.RA119.007671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">A novel triazole NMK-T-057 induces autophagic cell death in breast cancer cells by inhibiting γ-secretase-mediated activation of Notch-signaling</span></div><div class="casAuthors">Das, Amlan; Narayanam, Maruthi Kumar; Paul, Santanu; Mukhnerjee, Pritha; Ghosh, Suvranil; Dastidar, Debabrata Ghosh; Chakrabarty, Subhendu; Ganguli, Arnab; Basu, Biswarup; Pal, Mahadeb; Chatterji, Urmi; Banerjee, Sushanta K.; Karmakar, Parimal; Kumar, Dalip; Chakrabarti, Gopal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6733-6751</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Notch signaling is reported to be deregulated in several malignancies, including breast, and the enzyme γ-secretase plays important role in the activation and nuclear translocation of Notch intracellular domain (NICD).  Hence, pharmacol. inhibition of γ-secretase might lead to the subsequent inhibition of Notch signaling in cancer cells.  In search of novel γ-secretase inhibitors (GSIs), we screened a series of triazole-based compds., for their potential to bind γ-secretase and we obsd. that 3-(3'4',5'-Trimethoxyphenyl)-5-(N-methyl-3'-indolyl)-1,2,4-triazole compd. (also known as NMK-T-057) can bind to γ-secretase complex.  Very interestingly, NMK-T-057 was found to inhibit proliferation, colony forming ability, motility in various breast cancer (BC) cells such as MDA-MB-231, MDA-MB-468, 4T1 (triple neg. cells) and MCF-7 (ER/PR pos. cell line), with negligible cytotoxicity against non-cancerous cells (MCF-10A and PBMC).  Further, significant induction of apoptosis and inhibition of epithelial to mesenchymal transition (EMT) and stemness were also obsd. in NMK-T-057 treated BC cells.  The in silico study revealing the affinity of NMK-T-057 towards γ-secretase, was further validated by fluorescence based γ-secretase activity assay, which confirmed inhibition of γ-secretase activity in NMK-T-057 treated BC cells.  Interestingly, it was obsd. that NMK-T-057 induced significant autophagic responses in BC cells, which lead to apoptosis.  Moreover, NMK-T-057 was found to inhibit tumor progression in 4T1-BALB/c mice model.  Hence, it may be concluded that NMK-T-057 could be potential drug candidate against BC, which can trigger autophagy-mediated cell death by inhibiting γ-secretase-mediated activation of Notch-signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMakR3ACxvarVg90H21EOLACvtfcHk0ljwtsaTkuPstg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Slt7rF&md5=5a3d25580ff89a301572d17f613b3dee</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA119.007671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA119.007671%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DA.%26aulast%3DNarayanam%26aufirst%3DM.%2BK.%26aulast%3DPaul%26aufirst%3DS.%26aulast%3DMukhnerjee%26aufirst%3DP.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DDastidar%26aufirst%3DD.%2BG.%26aulast%3DChakrabarty%26aufirst%3DS.%26aulast%3DGanguli%26aufirst%3DA.%26aulast%3DBasu%26aufirst%3DB.%26aulast%3DPal%26aufirst%3DM.%26aulast%3DChatterji%26aufirst%3DU.%26aulast%3DBanerjee%26aufirst%3DS.%2BK.%26aulast%3DKarmakar%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DD.%26aulast%3DChakrabarti%26aufirst%3DG.%26atitle%3DA%2520novel%2520triazole%252C%2520NMK-T-057%252C%2520induces%2520autophagic%2520cell%2520death%2520in%2520breast%2520cancer%2520cells%2520by%2520inhibiting%2520%25CE%25B3-secretase-mediated%2520activation%2520of%2520Notch%2520signaling%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D6733%26epage%3D6750%26doi%3D10.1074%2Fjbc.RA119.007671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Targeting the AMP-activated protein kinase for cancer prevention and therapy</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">175</span>, <span class="refDoi"> DOI: 10.3389/fonc.2013.00175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffonc.2013.00175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=23875169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC3sfivVeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=175&author=I.+Kimauthor=Y.+Y.+He&title=Targeting+the+AMP-activated+protein+kinase+for+cancer+prevention+and+therapy&doi=10.3389%2Ffonc.2013.00175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy</span></div><div class="casAuthors">Kim Inyoung; He Yu-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">175</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Despite the advances in biomedical research and clinical applications, cancer remains a leading cause of death worldwide.  Given the limitations of conventional chemotherapeutics, including serious toxicities and reduced quality of life for patients, the development of safe and efficacious alternatives with known mechanism of action is much needed.  Prevention of cancer through dietary intervention may hold promise and has been investigated extensively in the recent years.  AMP-activated protein kinase (AMPK) is an energy sensor that plays a key role in the regulation of protein and lipid metabolism in response to changes in fuel availability.  When activated, AMPK promotes energy-producing catabolic pathways while inhibiting anabolic pathways, such as cell growth and proliferation - thereby antagonizing carcinogenesis.  Other anti-cancer effects of AMPK may include promoting autophagy and DNA repair upon UVB damage.  In the last decade, interest in AMPK has grown extensively as it emerged as an attractive target molecule for cancer prevention and treatment.  Among the latest developments is the activation of AMPK by naturally occurring dietary constituents and plant products - termed phytochemicals.  Owing to their efficacy and safety, phytochemicals are considered as an alternative to the conventional harmful chemotherapy.  The rising popularity of using phytochemicals for cancer prevention and therapy is supported by a substantial progress in identifying the molecular pathways involved, including AMPK.  In this article, we review the recent progress in this budding field that suggests AMPK as a new molecular target in the prevention and treatment of cancer by phytochemicals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4H8fzaLSSUtLIORRPd5lbfW6udTcc2ebF4ff__fwu8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfivVeltw%253D%253D&md5=f9042799e2826a9703323cecf854f7c2</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2013.00175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2013.00175%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DI.%26aulast%3DHe%26aufirst%3DY.%2BY.%26atitle%3DTargeting%2520the%2520AMP-activated%2520protein%2520kinase%2520for%2520cancer%2520prevention%2520and%2520therapy%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D3%26spage%3D175%26doi%3D10.3389%2Ffonc.2013.00175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rychahou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sviripa, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, B. M.</span></span> <span> </span><span class="NLM_article-title">Induction of AMPK activation by N,N’-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e0209392</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0209392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1371%2Fjournal.pone.0209392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30875375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFaksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&author=J.+Johnsonauthor=P.+Rychahouauthor=V.+M.+Sviripaauthor=H.+L.+Weissauthor=C.+Liuauthor=D.+S.+Wattauthor=B.+M.+Evers&title=Induction+of+AMPK+activation+by+N%2CN%E2%80%99-diarylurea+FND-4b+decreases+growth+and+increases+apoptosis+in+triple+negative+and+estrogen-receptor+positive+breast+cancers&doi=10.1371%2Fjournal.pone.0209392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers</span></div><div class="casAuthors">Johnson, Jeremy; Rychahou, Piotr; Sviripa, Vitaliy M.; Weiss, Heidi L.; Liu, Chunming; Watt, David S.; Evers, B. Mark</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0209392</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Purpose: Triple neg. breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer.  AMP-activated protein kinase (AMPK) is a major energy regulator that suppresses tumor growth, and 1-(3-chloro-4-((trifluoromethyl)thio)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea (FND-4b) is a novel AMPK activator that inhibits growth and induces apoptosis in colon cancer.  The purpose of this project was to test the effects of FND-4b on AMPK activation, proliferation, and apoptosis in breast cancer with a particular emphasis on TNBC.  Materials and methods: (i) Estrogen-receptor pos. breast cancer (ER+BC; MCF-7, and T-47D), TNBC (MDA-MB-231 and HCC-1806), and breast cancer stem cells were treated with FND-4b for 24h.  Immunoblot anal. assessed AMPK, acetyl-CoA carboxylase (ACC), ribosomal protein S6, cyclin D1, and cleaved PARP. (ii) Sulforhodamine B growth assays were performed after treating ER+BC and TNBC cells with FND-4b for 72h.  Proliferation was also assessed by counting cells after 72h of FND-4b treatment. (iii) Cell death ELISA assays were performed after treating ER+BC and TNBC cells with FND-4b for 72h.  Results: (i) FND-4b increased AMPK activation with concomitant decreases in ACC activity, phosphorylated S6, and cyclin D1 in all subtypes. (ii) FND-4b decreased proliferation in all cells, while dose-dependent growth decreases were found in ER+BC and TNBC. (iii) Increases in apoptosis were obsd. in ER+BC and the MDA-MB-231 cell line with FND-4b treatment.  Conclusions: Our findings indicate that FND-4b decreases proliferation for a variety of breast cancers by activating AMPK and has notable effects on TNBC.  The growth redns. were mediated through decreases in fatty acid synthesis (ACC), mTOR signaling (S6), and cell cycle flux (cyclin D1).  ER+BC cells were more susceptible to FND-4b-induced apoptosis, but MDA-MB-231 cells still underwent apoptosis with higher dose treatment.  Further development of FND compds. could result in a novel therapeutic for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8NCrRyPzk6LVg90H21EOLACvtfcHk0ljKf06Wh3qXsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFaksLw%253D&md5=2c3a1bee3025618bbf467012ebc99bd9</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0209392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0209392%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DJ.%26aulast%3DRychahou%26aufirst%3DP.%26aulast%3DSviripa%26aufirst%3DV.%2BM.%26aulast%3DWeiss%26aufirst%3DH.%2BL.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DD.%2BS.%26aulast%3DEvers%26aufirst%3DB.%2BM.%26atitle%3DInduction%2520of%2520AMPK%2520activation%2520by%2520N%252CN%25E2%2580%2599-diarylurea%2520FND-4b%2520decreases%2520growth%2520and%2520increases%2520apoptosis%2520in%2520triple%2520negative%2520and%2520estrogen-receptor%2520positive%2520breast%2520cancers%26jtitle%3DPLoS%2520One%26date%3D2019%26volume%3D14%26doi%3D10.1371%2Fjournal.pone.0209392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bort, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateos-Gómez, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vara-Ciruelos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Henche, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz-Laviada, I.</span></span> <span> </span><span class="NLM_article-title">Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1311</span>– <span class="NLM_lpage">1331</span>, <span class="refDoi"> DOI: 10.1002/1878-0261.12488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2F1878-0261.12488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30959553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKhs7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=1311-1331&author=A.+Bortauthor=B.+G.+S%C3%A1nchezauthor=P.+A.+Mateos-G%C3%B3mezauthor=D.+Vara-Ciruelosauthor=N.+Rodr%C3%ADguez-Hencheauthor=I.+D%C3%ADaz-Laviada&title=Targeting+AMP-activated+kinase+impacts+hepatocellular+cancer+stem+cells+induced+by+long-term+treatment+with+sorafenib&doi=10.1002%2F1878-0261.12488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib</span></div><div class="casAuthors">Bort, Alicia; Sanchez, Belen G.; Mateos-Gomez, Pedro A.; Vara-Ciruelos, Diana; Rodriguez-Henche, Nieves; Diaz-Laviada, Ines</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1311-1331</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1878-0261</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide.  HCC treatment is hindered by the frequent emergence of chemoresistance to the multikinase inhibitor sorafenib, which has been related to the presence of cancer stem cells (CSCs) that self-renew and often escape therapy.  The key metabolic sensor AMP-activated kinase (AMPK) has recently been recognized as a tumor growth regulator.  In this study, we aimed to elucidate the role of AMPK in the development of a stem cell phenotype in HCC cells.  To this end, we enriched the CSC population in HCC cell lines that showed increased expression of drug resistance (ALDH1A1, ABCB1A) and stem cell (CD133, Nanog, Oct4, alpha fetoprotein) markers and demonstrated their stemness phenotype.  These cells were refractory to sorafenib-induced cell death.  We report that sorafenib-resistant cells had lower levels of total and phosphorylated AMPK as well as its downstream substrate, ACC, compared with the parental cells.  Interestingly, AMPK knockdown with siRNA or inhibition with dorsomorphin increased the expression of stem cell markers in parental cells and blocked sorafenib-induced cell death.  Conversely, the upregulation of AMPK, either by transfection or by pharmacol. activation with A-769662, decreased the expression of ALDH1A1, ABCB1A, CD133, Nanog, Oct4, and alpha fetoprotein, and restored sensitivity to sorafenib.  Anal. of the underlying mechanism points to hypoxia-inducible factor HIF-1α as a regulator of stemness.  In vivo studies in a xenograft mouse model demonstrated that stem-like cells have greater tumorigenic capacity.  AMPK activation reduced xenograft tumor growth and decreased the expression of stem cell markers.  Taken together, these results indicate that AMPK may serve as a novel target to overcome chemoresistance in HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofHnzJp-loPrVg90H21EOLACvtfcHk0lhpn7crY5h3gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKhs7vM&md5=40a1eb3ab6e130488e08bad3f391c421</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1002%2F1878-0261.12488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1878-0261.12488%26sid%3Dliteratum%253Aachs%26aulast%3DBort%26aufirst%3DA.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DB.%2BG.%26aulast%3DMateos-G%25C3%25B3mez%26aufirst%3DP.%2BA.%26aulast%3DVara-Ciruelos%26aufirst%3DD.%26aulast%3DRodr%25C3%25ADguez-Henche%26aufirst%3DN.%26aulast%3DD%25C3%25ADaz-Laviada%26aufirst%3DI.%26atitle%3DTargeting%2520AMP-activated%2520kinase%2520impacts%2520hepatocellular%2520cancer%2520stem%2520cells%2520induced%2520by%2520long-term%2520treatment%2520with%2520sorafenib%26jtitle%3DMol.%2520Oncol.%26date%3D2019%26volume%3D13%26spage%3D1311%26epage%3D1331%26doi%3D10.1002%2F1878-0261.12488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonini, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gantner, B. N.</span></span> <span> </span><span class="NLM_article-title">The multifaceted activities of AMPK in tumor progression--why the “one size fits all” definition does not fit at all?</span>. <i>IUBMB Life</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">896</span>, <span class="refDoi"> DOI: 10.1002/iub.1213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fiub.1213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=24265196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWnsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=889-896&author=M.+G.+Boniniauthor=B.+N.+Gantner&title=The+multifaceted+activities+of+AMPK+in+tumor+progression%2D%2Dwhy+the+%E2%80%9Cone+size+fits+all%E2%80%9D+definition+does+not+fit+at+all%3F&doi=10.1002%2Fiub.1213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">The multifaceted activities of AMPK in tumor progression-why the "one size fits all" definition does not fit at all?</span></div><div class="casAuthors">Bonini, Marcelo G.; Gantner, Benjamin N.</div><div class="citationInfo"><span class="NLM_cas:title">IUBMB Life</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">889-896</span>CODEN:
                <span class="NLM_cas:coden">IULIF8</span>;
        ISSN:<span class="NLM_cas:issn">1521-6543</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Inc.</span>)
        </div><div class="casAbstract">A review.  AMP-activated kinase (AMPK) is a central cellular energetic biosensor and regulator of a broad array of cellular metabolic routes activated by nutrient deprivation, mitochondrial dysfunction, oxidative stress, and cytokines.  The activation of AMPK maintains ATP levels in response to hypoxia, mitochondrial dysfunction, and shortage of essential metabolic fuels.  Activated AMPK turns on energy sparing pathways and promotes antiapoptotic functions thereby permitting cells to survive extremely hostile conditions for prolonged periods of time.  Cancer cells in solid tumors are generally subjected to such harsh conditions; however, they manage to efficiently survive and proliferate.  This is likely due, in great part, to a peculiar form of metab. that is heavily reliant on glycolysis and which promotes cancer cell adaptation and tumor progression.  AMPK controls the influx and utilization of glucose by cancer cells and therefore has emerged as an attractive target to treat cancer.  Investigations exploring this possibility demonstrated that activators or inhibitors of AMPK impact cancer cell viability and possibly cancer progression.  For example, the AMPK activator metformin induces apoptosis in a variety of cancer cell lines and models.  A major problem with many of the studies on metformin is that little effort has been invested in unraveling how metformin activates AMPK in the many contexts it has been tested.  This is significant because many AMPK-independent effects of metformin have been documented.  The notion that AMPK acts solely as a tumor suppressor also conflicts with findings that it confers resistance to nutrient deprivation, sustains NADPH levels in cancer cells, facilitates stress-induced gene transcription, promotes cell survival via antiapoptotic function upregulation, intermediates epithelial-to-mesenchymal transition, and increases malignant transformation.  These are all recognized steps necessary for the successful evolution of tumors.  This review highlights some of these findings and proposes that the role of AMPK in cancer should be reconsidered in light of the complex roles of AMPK under different metabolic conditions. © 2013 IUBMB Life, 65(11):889-896, 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrth4kp_QtvWLVg90H21EOLACvtfcHk0lhpn7crY5h3gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWnsrrP&md5=8b35f99744010b8b9b86e7c30f362e6f</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1002%2Fiub.1213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fiub.1213%26sid%3Dliteratum%253Aachs%26aulast%3DBonini%26aufirst%3DM.%2BG.%26aulast%3DGantner%26aufirst%3DB.%2BN.%26atitle%3DThe%2520multifaceted%2520activities%2520of%2520AMPK%2520in%2520tumor%2520progression--why%2520the%2520%25E2%2580%259Cone%2520size%2520fits%2520all%25E2%2580%259D%2520definition%2520does%2520not%2520fit%2520at%2520all%253F%26jtitle%3DIUBMB%2520Life%26date%3D2013%26volume%3D65%26spage%3D889%26epage%3D896%26doi%3D10.1002%2Fiub.1213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span> <span> </span><span class="NLM_article-title">ROS/KRAS/AMPK signaling contributes to gemcitabine-induced stem-like cell properties in pancreatic cancer</span>. <i>Mol. Ther. Oncolytics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1016/j.omto.2019.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.omto.2019.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31508487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVKiu7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=299-312&author=H.+Zhaoauthor=S.+Wuauthor=H.+Liauthor=Q.+Duanauthor=Z.+Zhangauthor=Q.+Shenauthor=C.+Wangauthor=T.+Yin&title=ROS%2FKRAS%2FAMPK+signaling+contributes+to+gemcitabine-induced+stem-like+cell+properties+in+pancreatic+cancer&doi=10.1016%2Fj.omto.2019.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer</span></div><div class="casAuthors">Zhao, Hengqiang; Wu, Shihong; Li, Hehe; Duan, Qingke; Zhang, Zhengle; Shen, Qiang; Wang, Chunyou; Yin, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy--Oncolytics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">299-312</span>CODEN:
                <span class="NLM_cas:coden">MTOHDL</span>;
        ISSN:<span class="NLM_cas:issn">2372-7705</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Poor prognosis in pancreatic cancer (PanCa) is partially due to chemoresistance to gemcitabine (GEM).  Glucose metab. has been revealed to contribute to the therapeutic resistance and pluripotent state of PanCa cells.  However, few studies have focused on the effects of GEM on cancer cell metab., stemness of tumor cells, and mol. mechanisms that critically influence PanCa treatment.  We demonstrate that GEM treatment induces metabolic reprogramming, reducing mitochondrial oxidn. and upregulating aerobic glycolysis, and promotes stem-like behaviors in cancer cells.  Inhibiting aerobic glycolysis suppresses cancer cell stemness and strengthens GEM's cytotoxicity.  GEM-induced metabolic reprogramming is KRAS dependent, as knockdown of KRAS reverses the metabolic shift.  GEM-induced metabolic reprogramming also activates AMP-activated protein kinase (AMPK), which promotes glycolytic flux and cancer stemness.  In addn., GEM-induced reactive oxygen species (ROS) activate the KRAS/AMPK pathway.  This effect was validated by introducing exogenous hydrogen peroxide (H2O2).  Taken together, these findings reveal a counterproductive GEM effect during PanCa treatment.  Regulating cellular redox, targeting KRAS/AMPK signaling, or reversing metabolic reprogramming might be effective approaches to eliminate cancer stem cells (CSCs) and enhance chemosensitivity to GEM to improve the prognosis of PanCa patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquMFLClNqj8LVg90H21EOLACvtfcHk0lhpn7crY5h3gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVKiu7%252FF&md5=b60dccd3a11505e23f14736673d1054b</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.omto.2019.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.omto.2019.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DDuan%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DYin%26aufirst%3DT.%26atitle%3DROS%252FKRAS%252FAMPK%2520signaling%2520contributes%2520to%2520gemcitabine-induced%2520stem-like%2520cell%2520properties%2520in%2520pancreatic%2520cancer%26jtitle%3DMol.%2520Ther.%2520Oncolytics%26date%3D2019%26volume%3D14%26spage%3D299%26epage%3D312%26doi%3D10.1016%2Fj.omto.2019.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">AMPK promotes the survival of colorectal cancer stem cells</span>. <i>Animal Model. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1002/ame2.12016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fame2.12016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30891558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3cbmtFCiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2018&pages=134-142&author=B.+Guoauthor=X.+Hanauthor=D.+Tkachauthor=S.+G.+Huangauthor=D.+Zhang&title=AMPK+promotes+the+survival+of+colorectal+cancer+stem+cells&doi=10.1002%2Fame2.12016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">AMPK promotes the survival of colorectal cancer stem cells</span></div><div class="casAuthors">Guo Bing; Han Xin; Tkach Diane; Huang Shu-Guang; Zhang Dong; Guo Bing; Zhang Dong</div><div class="citationInfo"><span class="NLM_cas:title">Animal models and experimental medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-142</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second in females worldwide in 2012.  In the past 20 years, strong evidence suggests that cancer stem cells are the main culprit of cancer metastasis, chemotherapy resistance, and relapse.  Methods:  To further understand the unique biological properties of cancer stem cells and uncover novel molecular targets to eradicate them, we first established a panel of patient-derived xenograft (PDX) tumor models using tumors surgically removed from human colorectal cancer patients.  We then isolated CRC cancer stem cells based on their ALDH activity using fluorescent-activated cell sorting (FACS) and characterized their metabolic properties.  Results:  Interestingly, we found that the CRC cancer stem cells (ie, CRC cells with higher ALDH activity, or ALDH+) express higher level of antioxidant genes and have lower level of reactive oxygen species (ROS) than non-CRC cancer stem cells (ie, CRC cells with lower ALDH activity, or ALDH-).  The CRC cancer stem cells also possess more mitochondria mass and show higher mitochondrial activity.  More intriguingly, we observed higher AMP-activated protein kinase (AMPK) activities in these CRC cancer stem cells.  Inhibition of the AMPK activity using 2 AMPK inhibitors, Compound C and Iodotubercidin, preferentially induces cell death in CRC cancer stem cells.  Conclusion:  We propose that AMPK inhibitors may help to eradicate the CRC cancer stem cells and prevent the relapse of CRCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSf6OWBoFNfYi-bLEOO4dYpfW6udTcc2ebr_jVjmxibJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbmtFCiug%253D%253D&md5=8ab4d183ec8151c17be9f55f32afcdb9</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1002%2Fame2.12016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fame2.12016%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DTkach%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DS.%2BG.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DAMPK%2520promotes%2520the%2520survival%2520of%2520colorectal%2520cancer%2520stem%2520cells%26jtitle%3DAnimal%2520Model.%2520Exp.%2520Med.%26date%3D2018%26volume%3D1%26spage%3D134%26epage%3D142%26doi%3D10.1002%2Fame2.12016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. K.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells as a potential target to overcome multidrug resistance</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">764</span>, <span class="refDoi"> DOI: 10.3389/fonc.2020.00764</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffonc.2020.00764" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32582535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB38nkt12ksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=764&author=Y.+Choauthor=Y.+K.+Kim&title=Cancer+stem+cells+as+a+potential+target+to+overcome+multidrug+resistance&doi=10.3389%2Ffonc.2020.00764"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance</span></div><div class="casAuthors">Cho Yena; Kim Yong Kee</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">764</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Multidrug resistance (MDR), which is a significant impediment to the success of cancer chemotherapy, is attributable to various defensive mechanisms in cancer.  Initially, overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp) was considered the most important mechanism for drug resistance; hence, many investigators for a long time focused on the development of specific ABC transporter inhibitors.  However, to date their efforts have failed to develop a clinically applicable drug, leaving only a number of problems.  The concept of cancer stem cells (CSCs) has provided new directions for both cancer and MDR research.  MDR is known to be one of the most important features of CSCs and thus plays a crucial role in cancer recurrence and exacerbation.  Therefore, in recent years, research targeting CSCs has been increasing rapidly in search of an effective cancer treatment.  Here, we review the drugs that have been studied and developed to overcome MDR and CSCs, and discuss the limitations and future perspectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBmJ7XxQfILV1C8OJBvdfbfW6udTcc2ebr_jVjmxibJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38nkt12ksg%253D%253D&md5=cd4df2a39f501b1ad8b26a7ad5e08046</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2020.00764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2020.00764%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DY.%2BK.%26atitle%3DCancer%2520stem%2520cells%2520as%2520a%2520potential%2520target%2520to%2520overcome%2520multidrug%2520resistance%26jtitle%3DFront.%2520Oncol.%26date%3D2020%26volume%3D10%26spage%3D764%26doi%3D10.3389%2Ffonc.2020.00764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pati, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span> <span> </span><span class="NLM_article-title">Novel metal chelators thiosemicarbazones with activity at the σ2 receptors and P-glycoprotein: an innovative strategy for resistant tumor treatment</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">103131</span>– <span class="NLM_lpage">103146</span>, <span class="refDoi"> DOI: 10.1039/C5RA19857G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1039%2FC5RA19857G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWltbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=103131-103146&author=M.+L.+Patiauthor=M.+Nisoauthor=S.+Ferorelliauthor=C.+Abateauthor=F.+Berardi&title=Novel+metal+chelators+thiosemicarbazones+with+activity+at+the+%CF%832+receptors+and+P-glycoprotein%3A+an+innovative+strategy+for+resistant+tumor+treatment&doi=10.1039%2FC5RA19857G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Novel metal chelators thiosemicarbazones with activity at the σ2 receptors and P-glycoprotein: an innovative strategy for resistant tumor treatment</span></div><div class="casAuthors">Pati, Maria Laura; Niso, Mauro; Ferorelli, Savina; Abate, Carmen; Berardi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">125</span>),
    <span class="NLM_cas:pages">103131-103146</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">To combat the emergence of drug-resistance in tumors novel strategies are urgently needed.  With this in mind we designed a novel class of thiosemicarbazones able to target simultaneously σ2 receptors and P-glycoprotein efflux pump while chelating metals such as iron.  The combined effect of these targets would lead to the activation of multiple pathways to which resistant tumors are sensitive.  Indeed, most of the novel thiosemicarbazones displayed antiproliferative activity in both parent (MCF7 breast adenocarcinoma and A549 lung carcinoma) and corresponding doxorubicin-resistant cells (MCF7dx and A549dx).  A few compds. emerged for their potent antiproliferative activity or for their more potent effect in doxorubicin-resistant cells than in the parent ones, while other compds. emerged for their remarkable P-gp modulatory activity.  These results pave the way for further studies on these targets in the oncol. field, while the availability of promising mols. for resistant tumors treatment that warrant deeper investigations was increased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6Y_9AD9FkqrVg90H21EOLACvtfcHk0ljdOvxRGisGKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWltbrL&md5=27834cbf13e4b871abb777c95570f7af</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1039%2FC5RA19857G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5RA19857G%26sid%3Dliteratum%253Aachs%26aulast%3DPati%26aufirst%3DM.%2BL.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DBerardi%26aufirst%3DF.%26atitle%3DNovel%2520metal%2520chelators%2520thiosemicarbazones%2520with%2520activity%2520at%2520the%2520%25CF%25832%2520receptors%2520and%2520P-glycoprotein%253A%2520an%2520innovative%2520strategy%2520for%2520resistant%2520tumor%2520treatment%26jtitle%3DRSC%2520Adv.%26date%3D2015%26volume%3D5%26spage%3D103131%26epage%3D103146%26doi%3D10.1039%2FC5RA19857G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipkowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takebe, N.</span></span> <span> </span><span class="NLM_article-title">Novel apoptosis-inducing agents for the treatment of cancer, a new arsenal in the toolbox</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1087</span>, <span class="refDoi"> DOI: 10.3390/cancers11081087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcancers11081087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVKls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1087&author=B.+Limauthor=Y.+Greerauthor=S.+Lipkowitzauthor=N.+Takebe&title=Novel+apoptosis-inducing+agents+for+the+treatment+of+cancer%2C+a+new+arsenal+in+the+toolbox&doi=10.3390%2Fcancers11081087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Novel apoptosis-inducing agents for the treatment of cancer, a new arsenal in the toolbox</span></div><div class="casAuthors">Lim, Bora; Greer, Yoshimi; Lipkowitz, Stanley; Takebe, Naoko</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1087</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Evasion from apoptosis is an important hallmark of cancer cells.  Alterations of apoptosis pathways are esp. crit. as they confer resistance to conventional anti-cancer therapeutics, e.g., chemotherapy, radiotherapy, and targeted therapeutics.  Thus, successful induction of apoptosis using novel therapeutics may be a key strategy for preventing recurrence and metastasis.  Inhibitors of anti-apoptotic mols. and enhancers of pro-apoptotic mols. are being actively developed for hematol. malignancies and solid tumors in particular over the last decade.  However, due to the complicated apoptosis process caused by a multifaceted connection with cross-talk pathways, protein-protein interaction, and diverse resistance mechanisms, drug development within the category has been extremely challenging.  Careful design and development of clin. trials incorporating predictive biomarkers along with novel apoptosis-inducing agents based on rational combination strategies are needed to ensure the successful development of these mols.  Here, we review the landscape of currently available direct apoptosis-targeting agents in clin. development for cancer treatment and update the related biomarker advancement to detect and validate the efficacy of apoptosis-targeted therapies, along with strategies to combine them with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiL-nO4-7kdLVg90H21EOLACvtfcHk0liQsuCgK5N03A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVKls7g%253D&md5=548bbc1372a2eb17a211ce9ff89277b1</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.3390%2Fcancers11081087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11081087%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DB.%26aulast%3DGreer%26aufirst%3DY.%26aulast%3DLipkowitz%26aufirst%3DS.%26aulast%3DTakebe%26aufirst%3DN.%26atitle%3DNovel%2520apoptosis-inducing%2520agents%2520for%2520the%2520treatment%2520of%2520cancer%252C%2520a%2520new%2520arsenal%2520in%2520the%2520toolbox%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26spage%3D1087%26doi%3D10.3390%2Fcancers11081087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucki, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollong, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anglin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangenberg, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skirboll, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurdak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mischel, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lairson, L. L.</span></span> <span> </span><span class="NLM_article-title">A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">6435</span>– <span class="NLM_lpage">6440</span>, <span class="refDoi"> DOI: 10.1073/pnas.1816626116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1073%2Fpnas.1816626116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30846550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFentbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=6435-6440&author=N.+C.+Luckiauthor=G.+R.+Villaauthor=N.+Verganiauthor=M.+J.+Bollongauthor=B.+A.+Beyerauthor=J.+W.+Leeauthor=J.+L.+Anglinauthor=S.+H.+Spangenbergauthor=E.+N.+Chinauthor=A.+Sharmaauthor=K.+Johnsonauthor=P.+N.+Sanderauthor=P.+Gordonauthor=S.+L.+Skirbollauthor=H.+Wurdakauthor=P.+G.+Schultzauthor=P.+S.+Mischelauthor=L.+L.+Lairson&title=A+cell+type-selective+apoptosis-inducing+small+molecule+for+the+treatment+of+brain+cancer&doi=10.1073%2Fpnas.1816626116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer</span></div><div class="casAuthors">Lucki, Natasha C.; Villa, Genaro R.; Vergani, Naja; Bollong, Michael J.; Beyer, Brittney A.; Lee, Jae Wook; Anglin, Justin L.; Spangenberg, Stephan H.; Chin, Emily N.; Sharma, Amandeep; Johnson, Kevin; Sander, Philipp N.; Gordon, Perry; Skirboll, Stephen L.; Wurdak, Heiko; Schultz, Peter G.; Mischel, Paul S.; Lairson, Luke L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6435-6440</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM; grade IV astrocytoma) is the most prevalent and aggressive form of primary brain cancer.  A subpopulation of multipotent cells termed GBM cancer stem cells (CSCs) play a crit. role in tumor initiation, tumor maintenance, metastasis, drug resistance, and recurrence following surgery.  Here we report the identification of a small mol., termed RIPGBM, from a cell-based chem. screen that selectively induces apoptosis in multiple primary patient-derived GBM CSC cultures.  The cell type-dependent selectivity of this compd. appears to arise at least in part from redox-dependent formation of a proapoptotic deriv., termed cRIPGBM, in GBM CSCs. cRIPGBM induces caspase 1-dependent apoptosis by binding to receptor-interacting protein kinase 2 (RIPK2) and acting as a mol. switch, which reduces the formation of a prosurvival RIPK2/TAK1 complex and increases the formation of a proapoptotic RIPK2/caspase 1 complex.  In an orthotopic intracranial GBM CSC tumor xenograft mouse model, RIPGBM was found to significantly suppress tumor formation in vivo.  Our chem. genetics-based approach has identified a drug candidate and a potential drug target that provide an approach to the development of treatments for this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK1-h8DEWsgrVg90H21EOLACvtfcHk0liQsuCgK5N03A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFentbs%253D&md5=7a923f1243064238e8a18924d03f3e21</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1816626116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1816626116%26sid%3Dliteratum%253Aachs%26aulast%3DLucki%26aufirst%3DN.%2BC.%26aulast%3DVilla%26aufirst%3DG.%2BR.%26aulast%3DVergani%26aufirst%3DN.%26aulast%3DBollong%26aufirst%3DM.%2BJ.%26aulast%3DBeyer%26aufirst%3DB.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DAnglin%26aufirst%3DJ.%2BL.%26aulast%3DSpangenberg%26aufirst%3DS.%2BH.%26aulast%3DChin%26aufirst%3DE.%2BN.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DSander%26aufirst%3DP.%2BN.%26aulast%3DGordon%26aufirst%3DP.%26aulast%3DSkirboll%26aufirst%3DS.%2BL.%26aulast%3DWurdak%26aufirst%3DH.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26aulast%3DLairson%26aufirst%3DL.%2BL.%26atitle%3DA%2520cell%2520type-selective%2520apoptosis-inducing%2520small%2520molecule%2520for%2520the%2520treatment%2520of%2520brain%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26spage%3D6435%26epage%3D6440%26doi%3D10.1073%2Fpnas.1816626116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of celastrol derivatives as anti-ovarian cancer stem cell agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.ejmech.2019.06.086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31279299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlejs7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=667-679&author=X.+Liauthor=J.+Dingauthor=N.+Liauthor=W.+Liuauthor=F.+Dingauthor=H.+Zhengauthor=Y.+Ningauthor=H.+Wangauthor=R.+Liuauthor=S.+Ren&title=Synthesis+and+biological+evaluation+of+celastrol+derivatives+as+anti-ovarian+cancer+stem+cell+agents&doi=10.1016%2Fj.ejmech.2019.06.086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of celastrol derivatives as anti-ovarian cancer stem cell agents</span></div><div class="casAuthors">Li, Xiaojing; Ding, Jie; Li, Ning; Liu, Wenxia; Ding, Fuhao; Zheng, Huijuan; Ning, Yanyan; Wang, Hongmin; Liu, Renmin; Ren, Shaoda</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">667-679</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Ovarian cancer is assocd. with a high percentage of recurrence of tumors and resistance to chemotherapy.  Cancer stem cells (CSCs) are responsible for cancer progression, tumor recurrence, metastasis, and chemoresistance.  Thus, developing CSC-targeting therapy is an urgent need in cancer research and clin. application.  In an attempt to achieve potent and selective anti-CSC agents, a series of celastrol derivs. with cinnamamide chains were synthesized and evaluated for their anti-ovarian cancer activities.  Most of the compds. exhibited stronger antiproliferative activity than celastrol; and celastrol deriv. I, with a 3,4,5-trimethoxycinnamamide side chain, was found to be the most potent antiproliferative agent against ovarian cancer cells with an IC50 value of 0.6 μM.  Addnl., compd. I significantly inhibited the colony formation ability and reduced the no. of tumor spheres.  Furthermore, compd. I decreased the percentage of CD44+, CD133+ and ALDH+ cells.  Thus, compd. I is a promising anti-CSC agent and could serve as a candidate for the development of new anti-ovarian cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3ZSsmsTyOMrVg90H21EOLACvtfcHk0liASfG90a9blw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlejs7%252FO&md5=9b19ac7d29fc4a702eac533323c55b9d</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.086%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DF.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DRen%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520celastrol%2520derivatives%2520as%2520anti-ovarian%2520cancer%2520stem%2520cell%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D179%26spage%3D667%26epage%3D679%26doi%3D10.1016%2Fj.ejmech.2019.06.086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Regina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naccarato, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biagioni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baiocchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pastena, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Magno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canettieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestri, R.</span></span> <span> </span><span class="NLM_article-title">Drug design and synthesis of first in class PDZ1 targeting NHERF1 inhibitors as anticancer agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">499</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00532</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00532" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFKiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=499&author=A.+Colucciaauthor=G.+La+Reginaauthor=V.+Naccaratoauthor=M.+Nalliauthor=V.+Orlandoauthor=S.+Biagioniauthor=M.+L.+De+Angelisauthor=M.+Baiocchiauthor=C.+Gautierauthor=S.+Gianniauthor=F.+Di+Pastenaauthor=L.+Di+Magnoauthor=G.+Canettieriauthor=A.+M.+L.+Colucciaauthor=R.+Silvestri&title=Drug+design+and+synthesis+of+first+in+class+PDZ1+targeting+NHERF1+inhibitors+as+anticancer+agents&doi=10.1021%2Facsmedchemlett.8b00532"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Design and Synthesis of First in Class PDZ1 Targeting NHERF1 Inhibitors as Anticancer Agents</span></div><div class="casAuthors">Coluccia, Antonio; La Regina, Giuseppe; Naccarato, Valentina; Nalli, Marianna; Orlando, Viviana; Biagioni, Stefano; De Angelis, Maria Laura; Baiocchi, Marta; Gautier, Candice; Gianni, Stefano; Di Pastena, Fiorella; Di Magno, Laura; Canettieri, Gianluca; Coluccia, Addolorata Maria Luce; Silvestri, Romano</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">499-503</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeted approaches aiming at modulating NHERF1 activity, rather than its overall expression, would be preferred to preserve the normal functions of this versatile protein.  We focused our attention on the NHERF1/PDZ1 domain that governs its membrane recruitment/displacement through a transient phosphorylation switch.  We herein report the design and synthesis of novel NHERF1 PDZ1 domain inhibitors.  These compds. have potential therapeutic value when used in combination with antagonists of β-catenin to augment apoptotic death of colorectal cancer cells refractory to currently available Wnt/β-catenin-targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDgdVlg2JYNLVg90H21EOLACvtfcHk0liASfG90a9blw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFKiuw%253D%253D&md5=77a678697987a8c75e865f2532baae41</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00532%26sid%3Dliteratum%253Aachs%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DLa%2BRegina%26aufirst%3DG.%26aulast%3DNaccarato%26aufirst%3DV.%26aulast%3DNalli%26aufirst%3DM.%26aulast%3DOrlando%26aufirst%3DV.%26aulast%3DBiagioni%26aufirst%3DS.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%2BL.%26aulast%3DBaiocchi%26aufirst%3DM.%26aulast%3DGautier%26aufirst%3DC.%26aulast%3DGianni%26aufirst%3DS.%26aulast%3DDi%2BPastena%26aufirst%3DF.%26aulast%3DDi%2BMagno%26aufirst%3DL.%26aulast%3DCanettieri%26aufirst%3DG.%26aulast%3DColuccia%26aufirst%3DA.%2BM.%2BL.%26aulast%3DSilvestri%26aufirst%3DR.%26atitle%3DDrug%2520design%2520and%2520synthesis%2520of%2520first%2520in%2520class%2520PDZ1%2520targeting%2520NHERF1%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D499%26doi%3D10.1021%2Facsmedchemlett.8b00532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, A.</span></span> <span> </span><span class="NLM_article-title">Targeting stem cells in the realm of drug-resistant breast cancer</span>. <i>Breast Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.2147/BCTT.S189224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.2147%2FBCTT.S189224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12qs73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=115-135&author=P.+Deyauthor=M.+Rathodauthor=A.+De&title=Targeting+stem+cells+in+the+realm+of+drug-resistant+breast+cancer&doi=10.2147%2FBCTT.S189224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130aR"><div class="casContent"><span class="casTitleNuber">130a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting stem cells in the realm of drug-resistant breast cancer</span></div><div class="casAuthors">Dey, Pranay; Rathod, Maitreyi; De, Abhijit</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">115-135</span>CODEN:
                <span class="NLM_cas:coden">BCTTA9</span>;
        ISSN:<span class="NLM_cas:issn">1179-1314</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Since its first documentation, breast cancer (BC) has been a conundrum that ails millions of women every year.  This cancer has been well studied by researchers all over the world, which has improved the patient outcome significantly.  There are many diagnostic markers to identify the disease, but early detection and then subclassification of this cancer remain dubious.  Even after the correct diagnosis, more than half the patients come back with a more aggressive and metastatic tumor.  The underpinning mechanism that governs the resistance includes over-amplification of receptors, mutations in key gene targets, and activation of different signaling.  A plethora of drugs have been devised that have shown promising results in clin. settings.  However, in recent times, the role played by cancer stem cells in disease progression and their interaction in mediating the resistance to cellular insults have come into the limelight.  As breast cancer stem cells (BCSCs) are dormant in nature, it is highly likely that they fail to directly respond to the cytotoxic drugs which are meant for ablating rapidly proliferating cells.  Furthermore, the absence of well-characterized, drug-able surface markers to date, has limited the application of targeted therapies in complete eradication of the disease.  In this review, our intent is to discuss versatile therapeutics in practice followed by discussing the upcoming therapy strategies in the pipeline for BC.  Furthermore, we focus on the roles played by BCSCs in mediating the resistance, and therefore, the aspects of new therapeutics against BCSCs under development that may ease the burden in future has also been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbMU0R2TKw_LVg90H21EOLACvtfcHk0lifQewqoybkHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit12qs73J&md5=8782b01d078ee556ad75e22776e680a9</span></div><a href="/servlet/linkout?suffix=cit130a&amp;dbid=16384&amp;doi=10.2147%2FBCTT.S189224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FBCTT.S189224%26sid%3Dliteratum%253Aachs%26aulast%3DDey%26aufirst%3DP.%26aulast%3DRathod%26aufirst%3DM.%26aulast%3DDe%26aufirst%3DA.%26atitle%3DTargeting%2520stem%2520cells%2520in%2520the%2520realm%2520of%2520drug-resistant%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2019%26volume%3D11%26spage%3D115%26epage%3D135%26doi%3D10.2147%2FBCTT.S189224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit130b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollmén, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proulx, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detmar, M.</span></span> <span> </span><span class="NLM_article-title">New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1007</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.18632%2Foncotarget.13537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=27894093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC2sjhtFSmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1007-1022&author=J.+Cuiauthor=M.+Hollm%C3%A9nauthor=L.+Liauthor=Y.+Chenauthor=S.+T.+Proulxauthor=D.+Rekerauthor=G.+Schneiderauthor=M.+Detmar&title=New+use+of+an+old+drug%3A+inhibition+of+breast+cancer+stem+cells+by+benztropine+mesylate&doi=10.18632%2Foncotarget.13537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130bR"><div class="casContent"><span class="casTitleNuber">130b</span><div class="casTitle"><span class="NLM_cas:atitle">New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate</span></div><div class="casAuthors">Cui Jihong; Hollmen Maija; Li Lina; Chen Yong; Proulx Steven T; Reker Daniel; Schneider Gisbert; Detmar Michael</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1007-1022</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer stem cells (CSCs) play major roles in cancer initiation, metastasis, recurrence and therapeutic resistance.  Targeting CSCs represents a promising strategy for cancer treatment.  The purpose of this study was to identify selective inhibitors of breast CSCs (BCSCs).  We carried out a cell-based phenotypic screening with cell viability as a primary endpoint, using a collection of 2,546 FDA-approved drugs and drug-like molecules in spheres formed by malignant human breast gland-derived cells (HMLER-shEcad cells, representing BCSCs) and control immortalized non-tumorigenic human mammary cells (HMLE cells, representing normal stem cells). 19 compounds were identified from screening.  The chemically related molecules benztropine mesylate and deptropine citrate were selected for further validation and both potently inhibited sphere formation and self-renewal of BCSCs in vitro.  Benztropine mesylate treatment decreased cell subpopulations with high ALDH activity and with a CD44+/CD24- phenotype.  In vivo, benztropine mesylate inhibited tumor-initiating potential in a 4T1 mouse model.  Functional studies indicated that benztropine mesylate inhibits functions of CSCs via the acetylcholine receptors, dopamine transporters/receptors, and/or histamine receptors.  In summary, our findings identify benztropine mesylate as an inhibitor of BCSCs in vitro and in vivo.  This study also provides a screening platform for identification of additional anti-CSC agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTncrZn-RnoSkH3Rlp_k91zfW6udTcc2eaflTeX5oPgILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjhtFSmug%253D%253D&md5=10aa69b330084b006ad6a3e3b7bf27bb</span></div><a href="/servlet/linkout?suffix=cit130b&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13537%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DHollm%25C3%25A9n%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DProulx%26aufirst%3DS.%2BT.%26aulast%3DReker%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DDetmar%26aufirst%3DM.%26atitle%3DNew%2520use%2520of%2520an%2520old%2520drug%253A%2520inhibition%2520of%2520breast%2520cancer%2520stem%2520cells%2520by%2520benztropine%2520mesylate%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D1007%26epage%3D1022%26doi%3D10.18632%2Foncotarget.13537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheu, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suk, F. M.</span></span> <span> </span><span class="NLM_article-title">The antihistamine deptropine induces hepatoma cell death through blocking autophagosome-lysosome fusion</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1610</span>, <span class="refDoi"> DOI: 10.3390/cancers12061610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcancers12061610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVehtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1610&author=Y.+C.+Liangauthor=C.+C.+Changauthor=M.+T.+Sheuauthor=S.+Y.+Linauthor=C.+C.+Chungauthor=C.+T.+Tengauthor=F.+M.+Suk&title=The+antihistamine+deptropine+induces+hepatoma+cell+death+through+blocking+autophagosome-lysosome+fusion&doi=10.3390%2Fcancers12061610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">The antihistamine deptropine induces hepatoma cell death through blocking autophagosome-lysosome fusion</span></div><div class="casAuthors">Liang, Yu-Chih; Chang, Chi-Ching; Sheu, Ming-Thau; Lin, Shyr-Yi; Chung, Chia-Chen; Teng, Chang-Ting; Suk, Fat-Moon</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1610</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Some antihistamines have exhibited significant antitumor activity alone or in combination with other therapies in in vitro and clin. studies.  However, the underlying mechanisms of how antihistamines inhibit hepatocellular carcinoma proliferation are still unknown.  We first screened the antiproliferation activity of 12 benzocycloheptene structural-analog drugs, and results showed that deptropine was the most potent inhibitor of both Hep3B and HepG2 human hepatoma cells.  Deptropine significantly increased light chain 3B-II (LC3B-II) expression but did not induce sequestosome 1 (SQSTM1/p62) degrdn. in either cell line.  Interestingly, other autophagy-related proteins, such as autophagy-related 7 (ATG7), vacuolar protein sorting 34 (VPS34), phosphorylated AMP-activated protein kinase (AMPK), and phosphorylated protein kinase B (PKB, also known as Akt), exhibited no significant change in either deptropine-treated cell line.  Deptropine also inhibited the processing of cathepsin L from its precursor form to its mature form.  Immunofluorescence microscopy showed an increase of autophagosomes in deptropine-treated cells, but deptropine blocked the fusion between autophagosomes and lysosomes.  In a xenograft nude mice model, 2.5 mg/kg deptropine showed a great inhibitory effect on Hep3B tumor growth.  These results suggest that deptropine can induce in vitro and in vivo hepatoma cell death, and the underlying mechanisms might be mediated through inhibiting autophagy by blocking autophagosome-lysosome fusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBZltrdlx2iLVg90H21EOLACvtfcHk0lifQewqoybkHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVehtLnL&md5=072cd8903e5ab8274e47382efb041f17</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.3390%2Fcancers12061610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12061610%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.%2BC.%26aulast%3DChang%26aufirst%3DC.%2BC.%26aulast%3DSheu%26aufirst%3DM.%2BT.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DChung%26aufirst%3DC.%2BC.%26aulast%3DTeng%26aufirst%3DC.%2BT.%26aulast%3DSuk%26aufirst%3DF.%2BM.%26atitle%3DThe%2520antihistamine%2520deptropine%2520induces%2520hepatoma%2520cell%2520death%2520through%2520blocking%2520autophagosome-lysosome%2520fusion%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D1610%26doi%3D10.3390%2Fcancers12061610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, X.</span></span> <span> </span><span class="NLM_article-title">Identification of PGRMC1 as a candidate oncogene for head and neck cancers and its involvement in metabolic activities</span>. <i>Front. Bioeng. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">438</span>, <span class="refDoi"> DOI: 10.3389/fbioe.2019.00438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffbioe.2019.00438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31970154" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2020&pages=438&author=Y.+Zhaoauthor=X.+Ruan&title=Identification+of+PGRMC1+as+a+candidate+oncogene+for+head+and+neck+cancers+and+its+involvement+in+metabolic+activities&doi=10.3389%2Ffbioe.2019.00438"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.3389%2Ffbioe.2019.00438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffbioe.2019.00438%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DRuan%26aufirst%3DX.%26atitle%3DIdentification%2520of%2520PGRMC1%2520as%2520a%2520candidate%2520oncogene%2520for%2520head%2520and%2520neck%2520cancers%2520and%2520its%2520involvement%2520in%2520metabolic%2520activities%26jtitle%3DFront.%2520Bioeng.%2520Biotechnol.%26date%3D2020%26volume%3D7%26spage%3D438%26doi%3D10.3389%2Ffbioe.2019.00438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craven, R. J.</span></span> <span> </span><span class="NLM_article-title">AG-205 for the Treatment of Breast Cancer</span>. U.S. Patent <span class="NLM_patent">9,724,337</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=R.+J.+Craven&title=AG-205+for+the+Treatment+of+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCraven%26aufirst%3DR.%2BJ.%26atitle%3DAG-205%2520for%2520the%2520Treatment%2520of%2520Breast%2520Cancer%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Padhariya, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Athavale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P. S.</span></span> <span> </span><span class="NLM_article-title">Substituted chloroacetamides as potential cancer stem cell inhibitors: Synthesis and biological evaluation</span>. <i>Drug Dev. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">356</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1002/ddr.21628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fddr.21628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31800121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1yjtr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2020&pages=356-365&author=K.+N.+Padhariyaauthor=M.+Athavaleauthor=S.+Srivastavaauthor=P.+S.+Kharkar&title=Substituted+chloroacetamides+as+potential+cancer+stem+cell+inhibitors%3A+Synthesis+and+biological+evaluation&doi=10.1002%2Fddr.21628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted chloroacetamides as potential cancer stem cell inhibitors: Synthesis and biological evaluation</span></div><div class="casAuthors">Padhariya, Komal N.; Athavale, Maithili; Srivastava, Sangeeta; Kharkar, Prashant S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Development Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">356-365</span>CODEN:
                <span class="NLM_cas:coden">DDREDK</span>;
        ISSN:<span class="NLM_cas:issn">0272-4391</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Cancer kills, irresp. of geog. and cultural origin.  Novel modalities for treating cancer are desperately needed.  Cancer stem cells (CSCs), main culprits behind chemoresistance and tumor relapse, are one of the few logical choices.  Herein, we report the synthesis and biol. evaluation of small mols. with chloroacetamide war-head.  These mols. were screened for viability against various breast, prostate, and oral cancer cell lines using MTT and soft-agar assays.  Further, promising hits were screened in sphere-forming assay with the aim of discovering potential anti-CSC agents.  Our optimism yielded four hits inhibiting self-renewal of cancer cells with stem-like characters in vitro.  Finally, the hits were evaluated for in vitro toxicity against human peripheral blood mononuclear cells and mouse embryonic fibroblast cell line.  Overall, these preliminary investigations yielded three hits exhibiting promising anti-CSC potential with little or no toxicity against normal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6RnOgvbEyFrVg90H21EOLACvtfcHk0ljnHP2dd2PSNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1yjtr3M&md5=6fb108e88b603a7d525170f9cc075710</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1002%2Fddr.21628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fddr.21628%26sid%3Dliteratum%253Aachs%26aulast%3DPadhariya%26aufirst%3DK.%2BN.%26aulast%3DAthavale%26aufirst%3DM.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DKharkar%26aufirst%3DP.%2BS.%26atitle%3DSubstituted%2520chloroacetamides%2520as%2520potential%2520cancer%2520stem%2520cell%2520inhibitors%253A%2520Synthesis%2520and%2520biological%2520evaluation%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D2020%26volume%3D81%26spage%3D356%26epage%3D365%26doi%3D10.1002%2Fddr.21628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Padhariya, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Athavale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P. S.</span></span> <span> </span><span class="NLM_article-title">A novel series of substituted 1,2,3-triazoles as cancer stem cell inhibitors: synthesis and biological evaluation</span>. <i>Drug Dev. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1002/ddr.21723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fddr.21628" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=K.+N.+Padhariyaauthor=M.+Athavaleauthor=S.+Srivastavaauthor=P.+S.+Kharkar&title=A+novel+series+of+substituted+1%2C2%2C3-triazoles+as+cancer+stem+cell+inhibitors%3A+synthesis+and+biological+evaluation&doi=10.1002%2Fddr.21723"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1002%2Fddr.21628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fddr.21628%26sid%3Dliteratum%253Aachs%26aulast%3DPadhariya%26aufirst%3DK.%2BN.%26aulast%3DAthavale%26aufirst%3DM.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DKharkar%26aufirst%3DP.%2BS.%26atitle%3DA%2520novel%2520series%2520of%2520substituted%25201%252C2%252C3-triazoles%2520as%2520cancer%2520stem%2520cell%2520inhibitors%253A%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D2020%26doi%3D10.1002%2Fddr.21723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quattrini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelardi, E. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coviello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraris, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garavaglia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Motta, C.</span></span> <span> </span><span class="NLM_article-title">Imidazo[1,2-a]pyridine derivatives as aldehyde dehydrogenase inhibitors: novel chemotypes to target glioblastoma stem cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4603</span>– <span class="NLM_lpage">4616</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01910</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01910" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlvFCht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4603-4616&author=L.+Quattriniauthor=E.+L.+M.+Gelardiauthor=V.+Covielloauthor=S.+Sartiniauthor=D.+M.+Ferrarisauthor=M.+Moriauthor=I.+Nakanoauthor=S.+Garavagliaauthor=C.+La+Motta&title=Imidazo%5B1%2C2-a%5Dpyridine+derivatives+as+aldehyde+dehydrogenase+inhibitors%3A+novel+chemotypes+to+target+glioblastoma+stem+cells&doi=10.1021%2Facs.jmedchem.9b01910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazo[1,2-a]pyridine Derivatives as Aldehyde Dehydrogenase Inhibitors: Novel Chemotypes to Target Glioblastoma Stem Cells</span></div><div class="casAuthors">Quattrini, Luca; Gelardi, Edoardo Luigi Maria; Coviello, Vito; Sartini, Stefania; Ferraris, Davide Maria; Mori, Mattia; Nakano, Ichiro; Garavaglia, Silvia; La Motta, Concettina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4603-4616</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the deadliest form of brain tumor.  It is known for its ability to escape the therapeutic options available to date thanks to the presence of a subset of cells endowed with stem-like properties and ability to resist to cytotoxic treatments.  As the cytosolic enzyme aldehyde dehydrogenase 1A3 turns out to be overexpressed in these kinds of cells, playing a key role for their vitality, treatments targeting this enzyme may represent a successful strategy to fight GBM.  In this work, we describe a novel class of imidazo[1,2-a]pyridine derivs. as aldehyde dehydrogenase 1A3 inhibitors, reporting the evidence of their significance as novel drug candidates for the treatment of GBM.  Besides showing an interesting functional profile, in terms of activity against the target enzyme and selectivity toward highly homologous isoenzymes, representative examples of the series also showed a nanomolar to picomolar efficacy against patient-derived GBM stem-like cells, thus proving the concept that targeting aldehyde dehydrogenase might represent a novel and promising way to combat GBM by striking its ability to divide immortally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrStxZKnoYSiLVg90H21EOLACvtfcHk0ljnHP2dd2PSNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlvFCht7k%253D&md5=47a29fe886d2dd95540b22154e9b7f0b</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01910%26sid%3Dliteratum%253Aachs%26aulast%3DQuattrini%26aufirst%3DL.%26aulast%3DGelardi%26aufirst%3DE.%2BL.%2BM.%26aulast%3DCoviello%26aufirst%3DV.%26aulast%3DSartini%26aufirst%3DS.%26aulast%3DFerraris%26aufirst%3DD.%2BM.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DNakano%26aufirst%3DI.%26aulast%3DGaravaglia%26aufirst%3DS.%26aulast%3DLa%2BMotta%26aufirst%3DC.%26atitle%3DImidazo%255B1%252C2-a%255Dpyridine%2520derivatives%2520as%2520aldehyde%2520dehydrogenase%2520inhibitors%253A%2520novel%2520chemotypes%2520to%2520target%2520glioblastoma%2520stem%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4603%26epage%3D4616%26doi%3D10.1021%2Facs.jmedchem.9b01910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quattrini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelardi, E. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrarolo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraris, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picarazzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garavaglia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Motta, C.</span></span> <span> </span><span class="NLM_article-title">Progress in the field of aldehyde dehydrogenase inhibitors: Novel imidazo[1,2-a]pyridines against the 1A family</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">970</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXls1CjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=963-970&author=L.+Quattriniauthor=E.+L.+M.+Gelardiauthor=G.+Petraroloauthor=G.+Colomboauthor=D.+M.+Ferrarisauthor=F.+Picarazziauthor=M.+Rizziauthor=S.+Garavagliaauthor=C.+La+Motta&title=Progress+in+the+field+of+aldehyde+dehydrogenase+inhibitors%3A+Novel+imidazo%5B1%2C2-a%5Dpyridines+against+the+1A+family&doi=10.1021%2Facsmedchemlett.9b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the Field of Aldehyde Dehydrogenase Inhibitors: Novel Imidazo[1,2-a]pyridines against the 1A Family</span></div><div class="casAuthors">Quattrini, Luca; Gelardi, Edoardo Luigi Maria; Petrarolo, Giovanni; Colombo, Giorgia; Ferraris, Davide Maria; Picarazzi, Francesca; Rizzi, Menico; Garavaglia, Silvia; La Motta, Concettina</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">963-970</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Members of the aldehyde dehydrogenase 1A family are commonly acknowledged as hallmarks of cancer stem cells, and their overexpression is significantly assocd. with poor prognosis in different types of malignancies.  Accordingly, treatments targeting these enzymes may represent a successful strategy to fight cancer.  In this work we describe a novel series of imidazo[1,2-a]pyridines, designed as aldehyde dehydrogenase inhibitors by means of a structure-based optimization of a previously developed lead.  The novel compds. were evaluated in vitro for their activity and selectivity against the three isoforms of the ALDH1A family and investigated through crystn. and modeling studies for their ability to interact with the catalytic site of the 1A3 isoform.  Compd. 3f emerged as the first in class submicromolar competitive inhibitor of the target enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTHLr4ZUbTFLVg90H21EOLACvtfcHk0liERiSg6TxGZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXls1CjtLk%253D&md5=bd4c5d127bd06d5d1bd72d7f62442bd7</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00686%26sid%3Dliteratum%253Aachs%26aulast%3DQuattrini%26aufirst%3DL.%26aulast%3DGelardi%26aufirst%3DE.%2BL.%2BM.%26aulast%3DPetrarolo%26aufirst%3DG.%26aulast%3DColombo%26aufirst%3DG.%26aulast%3DFerraris%26aufirst%3DD.%2BM.%26aulast%3DPicarazzi%26aufirst%3DF.%26aulast%3DRizzi%26aufirst%3DM.%26aulast%3DGaravaglia%26aufirst%3DS.%26aulast%3DLa%2BMotta%26aufirst%3DC.%26atitle%3DProgress%2520in%2520the%2520field%2520of%2520aldehyde%2520dehydrogenase%2520inhibitors%253A%2520Novel%2520imidazo%255B1%252C2-a%255Dpyridines%2520against%2520the%25201A%2520family%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D963%26epage%3D970%26doi%3D10.1021%2Facsmedchemlett.9b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span> <span> </span><span class="NLM_article-title">Mediating K<sup>+</sup>/H<sup>+</sup> transport on organelle membranes to selectively eradicate cancer stem cells with a small molecule</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">10769</span>– <span class="NLM_lpage">10779</span>, <span class="refDoi"> DOI: 10.1021/jacs.0c02134</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.0c02134" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVShtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=10769-10779&author=F.+F.+Shenauthor=S.+Y.+Daiauthor=N.+K.+Wongauthor=S.+Dengauthor=A.+S.+Wongauthor=D.+Yang&title=Mediating+K%2B%2FH%2B+transport+on+organelle+membranes+to+selectively+eradicate+cancer+stem+cells+with+a+small+molecule&doi=10.1021%2Fjacs.0c02134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Mediating K+/H+ Transport on Organelle Membranes to Selectively Eradicate Cancer Stem Cells with a Small Molecule</span></div><div class="casAuthors">Shen, Fang-Fang; Dai, Sheng-Yao; Wong, Nai-Kei; Deng, Shan; Wong, Alice Sze-Tsai; Yang, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10769-10779</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mols. that are capable of disrupting cellular ion homeostasis offer unique opportunities to treat cancer.  However, previously reported synthetic ion transporters showed limited value, as promiscuous ionic disruption caused toxicity to both healthy cells and cancer cells indiscriminately.  Here we report a simple yet efficient synthetic K+ transporter that takes advantage of the endogenous subcellular pH gradient and membrane potential to site-selectively mediate K+/H+ transport on the mitochondrial and lysosomal membranes in living cells.  Consequent mitochondrial and lysosomal damages enhanced cytotoxicity to chemo-resistant ovarian cancer stem cells (CSCs) via apoptosis induction and autophagy suppression with remarkable selectivity (up to 47-fold).  The eradication of CSCs blunted tumor formation in mice.  We believe this strategy can be exploited in the structural design and applications of next-generation synthetic cation transporters for the treatment of cancer and other diseases related to dysfunctional K+ channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2ZJhSC336zrVg90H21EOLACvtfcHk0liERiSg6TxGZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVShtrnO&md5=09de6c15ee329e509d80708bf7ecc18c</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Fjacs.0c02134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.0c02134%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DF.%2BF.%26aulast%3DDai%26aufirst%3DS.%2BY.%26aulast%3DWong%26aufirst%3DN.%2BK.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DA.%2BS.%26aulast%3DYang%26aufirst%3DD.%26atitle%3DMediating%2520K%252B%252FH%252B%2520transport%2520on%2520organelle%2520membranes%2520to%2520selectively%2520eradicate%2520cancer%2520stem%2520cells%2520with%2520a%2520small%2520molecule%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26spage%3D10769%26epage%3D10779%26doi%3D10.1021%2Fjacs.0c02134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santamaria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Sanz, J. A.</span></span> <span> </span><span class="NLM_article-title">Will a mAb-based immunotherapy directed against cancer stem cells be feasible?</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1509</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2017.01509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffimmu.2017.01509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29170667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFemsbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1509&author=S.+Santamariaauthor=M.+Delgadoauthor=L.+Kremerauthor=J.+A.+Garcia-Sanz&title=Will+a+mAb-based+immunotherapy+directed+against+cancer+stem+cells+be+feasible%3F&doi=10.3389%2Ffimmu.2017.01509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Will a mAb-based immunotherapy directed against cancer stem cells be feasible?</span></div><div class="casAuthors">Santamaria, Silvia; Delgado, Marisa; Kremer, Leonor; Garcia-Sanz, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1509/1-1509/8</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The cancer stem cell (CSC) hypothesis suggests that within a tumor, there is a small subpopulation of cells with stem cell properties responsible for tumor maintenance and metastasis generation.  This hypothesis also implies that new antitumor drugs, rather than targeting the bulk of the tumor mass, would be more effective if they directly targeted the CSC subpopulation.  The CSCs from several types of tumors have been identified with mAbs recognizing surface antigens in these cells; however, antigens specifically or exclusively expressed in the CSC population have not yet been identified.  Thus, questioning the possibility of using therapeutic antibodies directed against the CSCs.  Here, we review the possibilities of using antibodies directly targeting the CSCs as therapeutic agents in the form of naked antibodies, antibodies conjugated to nanoparticles, or antibody cocktails.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGVLhN0__8c7Vg90H21EOLACvtfcHk0lgSsIbLKCNeZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFemsbrE&md5=63c56bbb4a6ed75af957a7feba2afa59</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.01509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.01509%26sid%3Dliteratum%253Aachs%26aulast%3DSantamaria%26aufirst%3DS.%26aulast%3DDelgado%26aufirst%3DM.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DGarcia-Sanz%26aufirst%3DJ.%2BA.%26atitle%3DWill%2520a%2520mAb-based%2520immunotherapy%2520directed%2520against%2520cancer%2520stem%2520cells%2520be%2520feasible%253F%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D1509%26doi%3D10.3389%2Ffimmu.2017.01509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widhopf, G. F.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">1370</span>– <span class="NLM_lpage">1377</span>, <span class="refDoi"> DOI: 10.1073/pnas.1816262116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1073%2Fpnas.1816262116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30622177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2msrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=1370-1377&author=S.+Zhangauthor=H.+Zhangauthor=E.+M.+Ghiaauthor=J.+Huangauthor=L.+Wuauthor=J.+Zhangauthor=S.+Lamauthor=Y.+Leiauthor=J.+Heauthor=B.+Cuiauthor=G.+F.+Widhopfauthor=J.+Yuauthor=R.+Schwabauthor=K.+Messerauthor=W.+Jiangauthor=B.+A.+Parkerauthor=D.+A.+Carsonauthor=T.+J.+Kipps&title=Inhibition+of+chemotherapy+resistant+breast+cancer+stem+cells+by+a+ROR1+specific+antibody&doi=10.1073%2Fpnas.1816262116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody</span></div><div class="casAuthors">Zhang, Suping; Zhang, Han; Ghia, Emanuela M.; Huang, Jiajia; Wu, Liufeng; Zhang, Jianchao; Lam, Sharon; Lei, Yang; He, Jinsong; Cui, Bing; Widhopf, George F., II; Yu, Jian; Schwab, Richard; Messer, Karen; Jiang, Wenqi; Parker, Barbara A.; Carson, Dennis A.; Kipps, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1370-1377</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Breast cancers enduring treatment with chemotherapy may be enriched for cancer stem cells or tumor-initiating cells, which have an enhanced capacity for self-renewal, tumor initiation, and/or metastasis.  Breast cancer cells that express the type I tyrosine kinaselike orphan receptor ROR1 also may have such features.  Here we find that the expression of ROR1 increased in breast cancer cells following treatment with chemotherapy, which also enhanced expression of genes induced by the activation of Rho-GTPases, Hippo-YAP/TAZ, or B lymphoma Mo-MLV insertion region 1 homolog (BMI1).  Expression of ROR1 also enhanced the capacity of breast cancer cells to invade Matrigel, form spheroids, engraft in Rag2a$$Hat$$  /a$$Hat$$  I$$Hat$$3ca$$Hat$$  /a$$Hat$$   mice, or survive treatment with paclitaxel.  Treatment of mice bearing breast cancer patient-derived xenografts (PDXs) with the humanized anti-ROR1 monoclonal antibody cirmtuzumab repressed expression of genes assocd. with breast cancer stemness, reduced activation of Rho-GTPases, Hippo-YAP/TAZ, or BMI1, and impaired the capacity of breast cancer PDXs to metastasize or reengraft Rag2a$$Hat$$  /a$$Hat$$  I$$Hat$$3ca$$Hat$$  /a$$Hat$$   mice.  Finally, treatment of PDX-bearing mice with cirmtuzumab and paclitaxel was more effective than treatment with either alone in eradicating breast cancer PDXs.  These results indicate that targeting ROR1 may improve the response to chemotherapy of patients with breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCYEZNkKl69bVg90H21EOLACvtfcHk0lgSsIbLKCNeZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2msrw%253D&md5=1abb994f31573939f2cf01b762555e22</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1816262116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1816262116%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGhia%26aufirst%3DE.%2BM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLam%26aufirst%3DS.%26aulast%3DLei%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DB.%26aulast%3DWidhopf%26aufirst%3DG.%2BF.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DSchwab%26aufirst%3DR.%26aulast%3DMesser%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DParker%26aufirst%3DB.%2BA.%26aulast%3DCarson%26aufirst%3DD.%2BA.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26atitle%3DInhibition%2520of%2520chemotherapy%2520resistant%2520breast%2520cancer%2520stem%2520cells%2520by%2520a%2520ROR1%2520specific%2520antibody%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26spage%3D1370%26epage%3D1377%26doi%3D10.1073%2Fpnas.1816262116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowska-Borowczyk, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ga̧bka-Buszek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackiewicz, A.</span></span> <span> </span><span class="NLM_article-title">Immunotargeting of cancer stem cells</span>. <i>Wspolczesna Onkol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">A52</span>– <span class="NLM_lpage">A59</span>, <span class="refDoi"> DOI: 10.5114/wo.2014.47129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.5114%2Fwo.2014.47129" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=A52-A59&author=E.+P.+Kwiatkowska-Borowczykauthor=A.+Ga%CC%A7bka-Buszekauthor=J.+Jankowskiauthor=A.+Mackiewicz&title=Immunotargeting+of+cancer+stem+cells&doi=10.5114%2Fwo.2014.47129"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.5114%2Fwo.2014.47129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5114%252Fwo.2014.47129%26sid%3Dliteratum%253Aachs%26aulast%3DKwiatkowska-Borowczyk%26aufirst%3DE.%2BP.%26aulast%3DGa%25CC%25A7bka-Buszek%26aufirst%3DA.%26aulast%3DJankowski%26aufirst%3DJ.%26aulast%3DMackiewicz%26aufirst%3DA.%26atitle%3DImmunotargeting%2520of%2520cancer%2520stem%2520cells%26jtitle%3DWspolczesna%2520Onkol.%26date%3D2015%26volume%3D19%26spage%3DA52%26epage%3DA59%26doi%3D10.5114%2Fwo.2014.47129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClements, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, T.</span></span> <span> </span><span class="NLM_article-title">Top Notch targeting strategies in cancer: A detailed overview of recent insights and current perspectives</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1503</span>, <span class="refDoi"> DOI: 10.3390/cells9061503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcells9061503" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=1503&author=G.+Mooreauthor=S.+Annettauthor=L.+McClementsauthor=T.+Robson&title=Top+Notch+targeting+strategies+in+cancer%3A+A+detailed+overview+of+recent+insights+and+current+perspectives&doi=10.3390%2Fcells9061503"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.3390%2Fcells9061503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells9061503%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DG.%26aulast%3DAnnett%26aufirst%3DS.%26aulast%3DMcClements%26aufirst%3DL.%26aulast%3DRobson%26aufirst%3DT.%26atitle%3DTop%2520Notch%2520targeting%2520strategies%2520in%2520cancer%253A%2520A%2520detailed%2520overview%2520of%2520recent%2520insights%2520and%2520current%2520perspectives%26jtitle%3DCells%26date%3D2020%26volume%3D9%26spage%3D1503%26doi%3D10.3390%2Fcells9061503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casulo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diefenbach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaven, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faoro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span> <span> </span><span class="NLM_article-title">Safety and preliminary efficacy results of a phase I first-in-human study of the novel Notch-1 targeting antibody brontictuzumab (OMP-52M51) administered intravenously to patients with hematologic malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">5108</span>, <span class="refDoi"> DOI: 10.1182/blood.V128.22.5108.5108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1182%2Fblood.V128.22.5108.5108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=5108&author=C.+Casuloauthor=J.+Ruanauthor=N.+H.+Dangauthor=L.+Goreauthor=C.+Diefenbachauthor=A.+W.+Beavenauthor=J.+E.+Castroauthor=P.+Porcuauthor=L.+Faoroauthor=J.+Dupontauthor=A.+Kapounauthor=M.+Wangauthor=K.+McGuireauthor=I.+W.+Flinn&title=Safety+and+preliminary+efficacy+results+of+a+phase+I+first-in-human+study+of+the+novel+Notch-1+targeting+antibody+brontictuzumab+%28OMP-52M51%29+administered+intravenously+to+patients+with+hematologic+malignancies&doi=10.1182%2Fblood.V128.22.5108.5108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1182%2Fblood.V128.22.5108.5108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V128.22.5108.5108%26sid%3Dliteratum%253Aachs%26aulast%3DCasulo%26aufirst%3DC.%26aulast%3DRuan%26aufirst%3DJ.%26aulast%3DDang%26aufirst%3DN.%2BH.%26aulast%3DGore%26aufirst%3DL.%26aulast%3DDiefenbach%26aufirst%3DC.%26aulast%3DBeaven%26aufirst%3DA.%2BW.%26aulast%3DCastro%26aufirst%3DJ.%2BE.%26aulast%3DPorcu%26aufirst%3DP.%26aulast%3DFaoro%26aufirst%3DL.%26aulast%3DDupont%26aufirst%3DJ.%26aulast%3DKapoun%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DMcGuire%26aufirst%3DK.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26atitle%3DSafety%2520and%2520preliminary%2520efficacy%2520results%2520of%2520a%2520phase%2520I%2520first-in-human%2520study%2520of%2520the%2520novel%2520Notch-1%2520targeting%2520antibody%2520brontictuzumab%2520%2528OMP-52M51%2529%2520administered%2520intravenously%2520to%2520patients%2520with%2520hematologic%2520malignancies%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D5108%26doi%3D10.1182%2Fblood.V128.22.5108.5108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chugh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoun, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A.</span></span> <span> </span><span class="NLM_article-title">A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1007/s10637-018-0714-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1007%2Fs10637-018-0714-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30591982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1WhtL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=722-730&author=D.+C.+Smithauthor=R.+Chughauthor=A.+Patnaikauthor=K.+P.+Papadopoulosauthor=M.+Wangauthor=A.+M.+Kapounauthor=L.+Xuauthor=J.+Dupontauthor=R.+J.+Staggauthor=A.+Tolcher&title=A+phase+1+dose+escalation+and+expansion+study+of+Tarextumab+%28OMP-59R5%29+in+patients+with+solid+tumors&doi=10.1007%2Fs10637-018-0714-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors</span></div><div class="casAuthors">Smith, David C.; Chugh, Rashmi; Patnaik, Amita; Papadopoulos, Kyriakos P.; Wang, Min; Kapoun, Ann M.; Xu, Lu; Dupont, Jakob; Stagg, Robert J.; Tolcher, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">722-730</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose This Phase I trial evaluated the max. tolerated dose, safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of tarextumab (OMP-5948), a novel cross-reactive antibody which binds and selectively inhibits signaling via both Notch2 and Notch3, in adult patients with advanced malignancies.  Methods Std. 3 + 3 design with tarextumab 0.5, 1, 2.5, or 5 mg/kg weekly, or 5, 7.5, or 10 mg/kg every other week, or 7.5 mg every 3 wk.  Dose-limiting toxicities (DLT) were assessed during the first 28 days.  Results Forty-two patients received tarextumab (21 weekly, 15 every other week, 6 every three weeks). 2/6 subjects at the 5 mg/kg weekly dose, 2/3 at 10 mg/kg every other week, and 0/6 at 7.5 mg/kg every three weeks had a DLT.  The max. tolerated dose (MTD) was 2.5 mg/kg weekly, and 7.5 mg/kg on the every other and every three week schedules.  Gastrointestinal (GI) toxicity was the most common adverse event with diarrhea (81%), fatigue (48%), nausea (45%), anorexia (38%), and vomiting (38%) and abdominal pain and constipation (24% each).  Biomarker anal. showed regulation of stem cell and Notch gene signaling.  Conclusion Tarextumab was generally well-tolerated at doses <2.5 mg weekly and 7.5 mg/kg every other and every third week.  Diarrhea was dose-limiting above these levels, but relatively easily managed at lower doses.  Inhibition of Notch pathway signaling was demonstrated at these doses.  ClinicalTrials.gov Identifier: NCT01277146.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl7727zknLwrVg90H21EOLACvtfcHk0lhVf62cDAg4Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1WhtL3O&md5=b3cad202d5896c87b351000040cfc7e4</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1007%2Fs10637-018-0714-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-018-0714-6%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BC.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DKapoun%26aufirst%3DA.%2BM.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DDupont%26aufirst%3DJ.%26aulast%3DStagg%26aufirst%3DR.%2BJ.%26aulast%3DTolcher%26aufirst%3DA.%26atitle%3DA%2520phase%25201%2520dose%2520escalation%2520and%2520expansion%2520study%2520of%2520Tarextumab%2520%2528OMP-59R5%2529%2520in%2520patients%2520with%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2019%26volume%3D37%26spage%3D722%26epage%3D730%26doi%3D10.1007%2Fs10637-018-0714-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chugh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aljumaily, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoun, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. C.</span></span> <span> </span><span class="NLM_article-title">A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1007/s10637-018-0665-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1007%2Fs10637-018-0665-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30229512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCjur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=461-472&author=A.+Jimenoauthor=K.+N.+Mooreauthor=M.+Gordonauthor=R.+Chughauthor=J.+R.+Diamondauthor=R.+Aljumailyauthor=D.+Mendelsonauthor=A.+M.+Kapounauthor=L.+Xuauthor=R.+Staggauthor=D.+C.+Smith&title=A+first-in-human+phase+1a+study+of+the+bispecific+anti-DLL4%2Fanti-VEGF+antibody+navicixizumab+%28OMP-305B83%29+in+patients+with+previously+treated+solid+tumors&doi=10.1007%2Fs10637-018-0665-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors</span></div><div class="casAuthors">Jimeno, Antonio; Moore, Kathleen N.; Gordon, Michael; Chugh, Rashmi; Diamond, Jennifer R.; Aljumaily, Raid; Mendelson, David; Kapoun, Ann M.; Xu, Lu; Stagg, Robert; Smith, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-472</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Navicixizumab (OMP-305B83) is a bispecific antibody that inhibits delta-like ligand 4 and vascular endothelial growth factor.  This Phase 1a trial assessed escalating doses of navicixizumab in refractory solid tumors patients.  Design A 3 + 3 dose escalation design was used followed by the treatment of addnl. patients in an expansion cohort.  Study objectives were detn. of the max. tolerated dose, safety, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy.  Results: Sixty-six patients were treated once every 3 wk in 8 dose-escalation cohorts (0.5, 1, 2.5, 3.5, 5, 7.5, 10, and 12.5 mg/kg) and an expansion cohort (7.5 mg/kg).  The median age was 60 years and 68% of the patients were female.  The most commonly enrolled tumor types were ovarian (12), colorectal (11) and breast, pancreatic, uterine and endometrial (4 each) cancers.  As only 1 dose limiting toxicity occurred, the max. tolerated dose was not reached, but 7.5 mg/kg was chosen as the dose for the expansion cohort.  The treatment related adverse events (≥15% of patients) were hypertension (57.6%), headache (28.8%), fatigue (25.8%), and pulmonary hypertension (18.2%).  Pulmonary hypertension was mostly asymptomatic at doses ≤5 mg/kg (6 Gr1, 1 Gr2), but was more severe at higher doses (4 Gr2, 1 Gr3).  Navicixizumab's half-life was 11.4 days and there was a moderate (29%) incidence of anti-drug antibody formation.  Four patients (3 ovarian cancer, 1 uterine carcinosarcoma) had a partial response and 17 patients had stable disease.  Nineteen patients had a redn. in the size of their target lesions including 7/11 patients with ovarian cancer.  Four patients remained on study for >300 days and 2 of these patients were on study for >500 days.  Conclusions: Navicixizumab can be safely administered with manageable toxicities and these data showed preliminary signs of antitumor activity in multiple tumor types, but was most promising in ovarian cancer.  As a result these data justify its continued development in combination Phase 1b clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQP8R5wA0cD7Vg90H21EOLACvtfcHk0lgLsU4HeN49rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslCjur%252FI&md5=1e8e15a5702e31bdee2a292d5f20260a</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1007%2Fs10637-018-0665-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-018-0665-y%26sid%3Dliteratum%253Aachs%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DK.%2BN.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DDiamond%26aufirst%3DJ.%2BR.%26aulast%3DAljumaily%26aufirst%3DR.%26aulast%3DMendelson%26aufirst%3DD.%26aulast%3DKapoun%26aufirst%3DA.%2BM.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DStagg%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.%2BC.%26atitle%3DA%2520first-in-human%2520phase%25201a%2520study%2520of%2520the%2520bispecific%2520anti-DLL4%252Fanti-VEGF%2520antibody%2520navicixizumab%2520%2528OMP-305B83%2529%2520in%2520patients%2520with%2520previously%2520treated%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2019%26volume%3D37%26spage%3D461%26epage%3D472%26doi%3D10.1007%2Fs10637-018-0665-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caserta, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romeo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rumio, C.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates (ADC) against cancer stem-like cells (CSC) - is there still room for optimizm?</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">167</span>, <span class="refDoi"> DOI: 10.3389/fonc.2019.00167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffonc.2019.00167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30984612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252Fltl2qsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=167&author=F.+Marcucciauthor=C.+A.+Casertaauthor=E.+Romeoauthor=C.+Rumio&title=Antibody-drug+conjugates+%28ADC%29+against+cancer+stem-like+cells+%28CSC%29+-+is+there+still+room+for+optimizm%3F&doi=10.3389%2Ffonc.2019.00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates (ADC) Against Cancer Stem-Like Cells (CSC)-Is There Still Room for Optimism?</span></div><div class="casAuthors">Marcucci Fabrizio; Rumio Cristiano; Caserta Carmelo Antonio; Romeo Elisabetta</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Cancer stem-like cells (CSC) represent a subpopulation of tumor cells with peculiar functionalities that distinguish them from the bulk of tumor cells, most notably their tumor-initiating potential and drug resistance.  Given these properties, it appears logical that CSCs have become an important target for many pharma companies.  Antibody-drug conjugates (ADC) have emerged over the last decade as one of the most promising new tools for the selective ablation of tumor cells.  Three ADCs have already received regulatory approval and many others are in different phases of clinical development.  Not surprisingly, also a considerable number of anti-CSC ADCs have been described in the literature and some of these have entered clinical development.  Several of these ADCs, however, have yielded disappointing results in clinical studies.  This is similar to the results obtained with other anti-CSC drug candidates, including native antibodies, that have been investigated in the clinic.  In this article we review the anti-CSC ADCs that have been described in the literature and, in the following, we discuss reasons that may underlie the failures in clinical trials that have been observed.  Possible reasons relate to the biology of CSCs themselves, including their heterogeneity, the lack of strictly CSC-specific markers, and the capacity to interconvert between CSCs and non-CSCs; second, inherent limitations of some classes of cytotoxins that have been used for the construction of ADCs; third, the inadequacy of animal models in predicting efficacy in humans.  We conclude suggesting some possibilities to address these limitations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQNmb2epERaK4xhnOQkIHOxfW6udTcc2eZiSzw6bOkBE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252Fltl2qsw%253D%253D&md5=247908f0068097da43e894ca0bcae337</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2019.00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2019.00167%26sid%3Dliteratum%253Aachs%26aulast%3DMarcucci%26aufirst%3DF.%26aulast%3DCaserta%26aufirst%3DC.%2BA.%26aulast%3DRomeo%26aufirst%3DE.%26aulast%3DRumio%26aufirst%3DC.%26atitle%3DAntibody-drug%2520conjugates%2520%2528ADC%2529%2520against%2520cancer%2520stem-like%2520cells%2520%2528CSC%2529%2520-%2520is%2520there%2520still%2520room%2520for%2520optimizm%253F%26jtitle%3DFront.%2520Oncol.%26date%3D2019%26volume%3D9%26spage%3D167%26doi%3D10.3389%2Ffonc.2019.00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ponziani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Vittorio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flavell, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ippoliti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giansanti, F.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates: the new frontier of chemotherapy</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5510</span>, <span class="refDoi"> DOI: 10.3390/ijms21155510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fijms21155510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitValt73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=5510&author=S.+Ponzianiauthor=G.+Di+Vittorioauthor=G.+Pitariauthor=A.+M.+Ciminiauthor=M.+Ardiniauthor=R.+Gentileauthor=S.+Iacobelliauthor=G.+Salaauthor=E.+Caponeauthor=D.+J.+Flavellauthor=R.+Ippolitiauthor=F.+Giansanti&title=Antibody-drug+conjugates%3A+the+new+frontier+of+chemotherapy&doi=10.3390%2Fijms21155510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates: the new frontier of chemotherapy</span></div><div class="casAuthors">Ponziani, Sara; Di Vittorio, Giulia; Pitari, Giuseppina; Cimini, Anna Maria; Ardini, Matteo; Gentile, Roberta; Iacobelli, Stefano; Sala, Gianluca; Capone, Emily; Flavell, David J.; Ippoliti, Rodolfo; Giansanti, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5510</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  In recent years, antibody-drug conjugates (ADCs) have become promising antitumor agents to be used as one of the tools in personalized cancer medicine.  ADCs are comprised of a drug with cytotoxic activity crosslinked to a monoclonal antibody, targeting antigens expressed at higher levels on tumor cells than on normal cells.  By providing a selective targeting mechanism for cytotoxic drugs, ADCs improve the therapeutic index in clin. practice.  In this review, the chem. of ADC linker conjugation together with strategies adopted to improve antibody tolerability (by reducing antigenicity) are examd., with particular attention to ADCs approved by the regulatory agencies the U.S.  Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treating cancer patients.  Recent developments in engineering Ig (Ig) genes and antibody humanization have greatly reduced some of the problems of the first generation of ADCs, beset by problems, such as random coupling of the payload and immunogenicity of the antibody.  ADC development and clin. use is a fast, evolving area, and will likely prove an important modality for the treatment of cancer in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAe6_XsKEiBbVg90H21EOLACvtfcHk0lgLsU4HeN49rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitValt73P&md5=15bc464b864e8ea8d6e0d481b5d15704</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.3390%2Fijms21155510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21155510%26sid%3Dliteratum%253Aachs%26aulast%3DPonziani%26aufirst%3DS.%26aulast%3DDi%2BVittorio%26aufirst%3DG.%26aulast%3DPitari%26aufirst%3DG.%26aulast%3DCimini%26aufirst%3DA.%2BM.%26aulast%3DArdini%26aufirst%3DM.%26aulast%3DGentile%26aufirst%3DR.%26aulast%3DIacobelli%26aufirst%3DS.%26aulast%3DSala%26aufirst%3DG.%26aulast%3DCapone%26aufirst%3DE.%26aulast%3DFlavell%26aufirst%3DD.%2BJ.%26aulast%3DIppoliti%26aufirst%3DR.%26aulast%3DGiansanti%26aufirst%3DF.%26atitle%3DAntibody-drug%2520conjugates%253A%2520the%2520new%2520frontier%2520of%2520chemotherapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D5510%26doi%3D10.3390%2Fijms21155510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ning, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teitz-Tennenbaum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginestier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prince, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cell vaccination confers significant antitumor immunity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1853</span>– <span class="NLM_lpage">1864</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1158%2F0008-5472.CAN-11-1400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=22473314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVeltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1853-1864&author=N.+Ningauthor=Q.+Panauthor=F.+Zhengauthor=S.+Teitz-Tennenbaumauthor=M.+Egentiauthor=J.+Yetauthor=M.+Liauthor=C.+Ginestierauthor=M.+S.+Wichaauthor=J.+S.+Moyerauthor=M.+E.+Princeauthor=Y.+Xuauthor=X.+L.+Zhangauthor=S.+Huangauthor=A.+E.+Changauthor=Q.+Li&title=Cancer+stem+cell+vaccination+confers+significant+antitumor+immunity&doi=10.1158%2F0008-5472.CAN-11-1400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Stem Cell Vaccination Confers Significant Antitumor Immunity</span></div><div class="casAuthors">Ning, Ning; Pan, Qin; Zheng, Fang; Teitz-Tennenbaum, Seagal; Egenti, Martin; Yet, Ji; Li, Mu; Ginestier, Christophe; Wicha, Max S.; Moyer, Jeffrey S.; Prince, Mark E. P.; Xu, Yingxin; Zhang, Xiao-Lian; Huang, Shiang; Chang, Alfred E.; Li, Qiao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1853-1864</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most studies of cancer stem cells (CSC) involve the inoculation of cells from human tumors into immunosuppressed mice, preventing an assessment on the immunol. interactions and effects of CSCs.  In this study, we examd. the vaccination effects produced by CSC-enriched populations from histol. distinct murine tumors after their inoculation into different syngeneic immunocompetent hosts.  Enriched CSCs were immunogenic and more effective as an antigen source than unselected tumor cells in inducing protective antitumor immunity.  Immune sera from CSC-vaccinated hosts contained high levels of IgG which bound to CSCs, resulting in CSC lysis in the presence of complement.  CTLs generated from peripheral blood mononuclear cells or splenocytes harvested from CSC-vaccinated hosts were capable of killing CSCs in vitro.  Mechanistic investigations established that CSC-primed antibodies and T cells were capable of selective targeting CSCs and conferring antitumor immunity.  Together, these proof-of-concept results provide a rationale for a new type of cancer immunotherapy based on the development of CSC vaccines that can specifically target CSCs.  Cancer Res; 72(7); 1853-64.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSwxQTYmY5PbVg90H21EOLACvtfcHk0litj0PW9ydsbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVeltrk%253D&md5=7b09dd6937b55ce9f8d3b440eef7bd58</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1400%26sid%3Dliteratum%253Aachs%26aulast%3DNing%26aufirst%3DN.%26aulast%3DPan%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DF.%26aulast%3DTeitz-Tennenbaum%26aufirst%3DS.%26aulast%3DEgenti%26aufirst%3DM.%26aulast%3DYet%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGinestier%26aufirst%3DC.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26aulast%3DMoyer%26aufirst%3DJ.%2BS.%26aulast%3DPrince%26aufirst%3DM.%2BE.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%2BL.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DA.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26atitle%3DCancer%2520stem%2520cell%2520vaccination%2520confers%2520significant%2520antitumor%2520immunity%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1853%26epage%3D1864%26doi%3D10.1158%2F0008-5472.CAN-11-1400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span> <span> </span><span class="NLM_article-title">Development and application of cancer stem cell-targeted vaccine in cancer immunotherapy</span>. <i>J. Vaccines Vaccination</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">371</span>, <span class="refDoi"> DOI: 10.4172/2157-7560.1000371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.4172%2F2157-7560.1000371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29423335" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=371&author=M.+Linauthor=A.+E.+Changauthor=M.+Wichaauthor=Q.+Liauthor=S.+Huang&title=Development+and+application+of+cancer+stem+cell-targeted+vaccine+in+cancer+immunotherapy&doi=10.4172%2F2157-7560.1000371"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.4172%2F2157-7560.1000371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2157-7560.1000371%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DA.%2BE.%26aulast%3DWicha%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DS.%26atitle%3DDevelopment%2520and%2520application%2520of%2520cancer%2520stem%2520cell-targeted%2520vaccine%2520in%2520cancer%2520immunotherapy%26jtitle%3DJ.%2520Vaccines%2520Vaccination%26date%3D2017%26volume%3D8%26spage%3D371%26doi%3D10.4172%2F2157-7560.1000371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szaryńska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olejniczak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobiela, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Łaski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Śledziński, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kmieć, Z.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells as targets for DC-based immunotherapy of colorectal cancer</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">12042</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-30525-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fs41598-018-30525-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30104575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3c7nslylsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=12042&author=M.+Szary%C5%84skaauthor=A.+Olejniczakauthor=J.+Kobielaauthor=D.+%C5%81askiauthor=Z.+%C5%9Aledzi%C5%84skiauthor=Z.+Kmie%C4%87&title=Cancer+stem+cells+as+targets+for+DC-based+immunotherapy+of+colorectal+cancer&doi=10.1038%2Fs41598-018-30525-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells as targets for DC-based immunotherapy of colorectal cancer</span></div><div class="casAuthors">Szarynska Magdalena; Olejniczak Agata; Kmiec Zbigniew; Kobiela Jaroslaw; Laski Dariusz; Sledzinski Zbigniew</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12042</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The therapy of colorectal cancer (CRC) patients is often unsuccessful because of the presence of cancer stem cells (CSCs) resistant to conventional approaches.  Dendritic cells (DC)-based protocols are believed to effectively supplement CRC therapy.  Our study was aimed to assess how the number and properties of CSCs isolated from tumor tissue of CRC patients will affect the biological characteristics of in vitro modified DCs.  Similar procedures were conducted with the using of CRC HCT116 and HT29 cell lines.  We found that the detailed configuration of CSC-like markers significantly influenced the maturation and activation of DCs after stimulation with cancer cells lysates or culture supernatants.  This basic stimulatory effect was enhanced by LPS that is normally present in CRC CSCs niche.  The increased number of CD29(+) and CD44(+) CSCs presented the opposite impact on treated DCs as showed by many significant correlations.  The CD133(+) CSCs seemed to impair the functions of DCs.  The more CD133(+) CSCs in tumor sample the lower number of activated DCs evidenced after stimulation.  Moreover, our results showed superiority of the spherical culture model over the adherent one since spherical HCT116 and HT29 cells presented similar influence on DCs properties as CRC patients cancer cells.  We concluded that the DCs features may depend directly on the properties of CSCs affected by progression status of tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSH7Cfl0XFloyjiVMCqkKxVfW6udTcc2eb-OetYS5sF4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7nslylsA%253D%253D&md5=4a73c9858aa2e14b5d4e0da6b5e4473a</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-30525-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-30525-3%26sid%3Dliteratum%253Aachs%26aulast%3DSzary%25C5%2584ska%26aufirst%3DM.%26aulast%3DOlejniczak%26aufirst%3DA.%26aulast%3DKobiela%26aufirst%3DJ.%26aulast%3D%25C5%2581aski%26aufirst%3DD.%26aulast%3D%25C5%259Aledzi%25C5%2584ski%26aufirst%3DZ.%26aulast%3DKmie%25C4%2587%26aufirst%3DZ.%26atitle%3DCancer%2520stem%2520cells%2520as%2520targets%2520for%2520DC-based%2520immunotherapy%2520of%2520colorectal%2520cancer%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D12042%26doi%3D10.1038%2Fs41598-018-30525-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cell vaccination with PD-L1 and CTLA-4 blockades enhances the eradication of melanoma stem cells in a mouse tumor model</span>. <i>J. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">368</span>, <span class="refDoi"> DOI: 10.1097/CJI.0000000000000242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1097%2FCJI.0000000000000242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30063587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1GmtrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=361-368&author=F.+Zhengauthor=J.+Dangauthor=H.+Zhangauthor=F.+Xuauthor=D.+Baauthor=B.+Zhangauthor=F.+Chengauthor=A.+E.+Changauthor=M.+S.+Wichaauthor=Q.+Li&title=Cancer+stem+cell+vaccination+with+PD-L1+and+CTLA-4+blockades+enhances+the+eradication+of+melanoma+stem+cells+in+a+mouse+tumor+model&doi=10.1097%2FCJI.0000000000000242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model</span></div><div class="casAuthors">Zheng, Fang; Dang, Jianzhong; Zhang, Hongyu; Xu, Fangzhou; Ba, Diandian; Zhang, Bingyu; Cheng, Fanjun; Chang, Alfred E.; Wicha, Max S.; Li, Qiao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">361-368</span>CODEN:
                <span class="NLM_cas:coden">JOIMF8</span>;
        ISSN:<span class="NLM_cas:issn">1524-9557</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Immune checkpoint inhibitors and monoclonal antibodies reinvigorate cancer immunotherapy.  However, these immunotherapies only benefit a subset of patients.  We previously reported that ALDH tumor cells were highly enriched for cancer stem cells (CSCs), and ALDH CSC lysate-pulsed dendritic cell (CSC-DC) vaccine was shown to induce CSC-specific cytotoxic T lymphocytes.  In this study, we investigated the CSC targeting effect of the CSC-DC vaccine combined with a dual blockade of programmed death-ligand 1 and cytotoxic T-lymphocyte-assocd. protein (CTLA-4) in B16-F10 murine melanoma tumor model.  Our data showed that animals treated with the dual blockade of programmed death-ligand 1 and CTLA-4 and CSC-DC vaccine conferred significantly more tumor regression than the CSC-DC vaccine alone.  Importantly, the triple combination treatment dramatically eliminated ALDH CSCs in vivo.  We obsd. that CSC-DC vaccine in combination with anti-PD-L1 and anti-CTLA-4 administration resulted in ∼1.7-fold fewer PD-1CD8 T cells and ∼2.5-fold fewer CTLA-4CD8 T cells than the populations obsd. following the CSC-DC vaccination alone.  Moreover, significant antitumor effects and dramatically eliminated ALDH CSCs following the triple combination treatment were accompanied by significantly enhanced T-cell expansion, suppressed transforming growth factor β secretion, enhanced IFN-γ secretion, and significantly enhanced host specific CD8 T-cell response against CSCs.  Collectively, these data showed that administration of a-PD-L1 and a-CTLA-4 combined with CSC-DC vaccine may represent an effective immunotherapeutic strategy for cancer patients in clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKk3eQLgeXDbVg90H21EOLACvtfcHk0li0siKNHFp8BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1GmtrfN&md5=526143a18f03b93f5e482e72be0ba67b</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1097%2FCJI.0000000000000242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCJI.0000000000000242%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DF.%26aulast%3DDang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DBa%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DChang%26aufirst%3DA.%2BE.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26aulast%3DLi%26aufirst%3DQ.%26atitle%3DCancer%2520stem%2520cell%2520vaccination%2520with%2520PD-L1%2520and%2520CTLA-4%2520blockades%2520enhances%2520the%2520eradication%2520of%2520melanoma%2520stem%2520cells%2520in%2520a%2520mouse%2520tumor%2520model%26jtitle%3DJ.%2520Immunother.%26date%3D2018%26volume%3D41%26spage%3D361%26epage%3D368%26doi%3D10.1097%2FCJI.0000000000000242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wefers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreibelt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massuger, L. F. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, I. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torensma, R.</span></span> <span> </span><span class="NLM_article-title">Immune curbing of cancer stem cells by CTLs directed to NANOG</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1412</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2018.01412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffimmu.2018.01412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29971070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1KkurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1412&author=C.+Wefersauthor=G.+Schreibeltauthor=L.+F.+A.+G.+Massugerauthor=I.+J.+M.+de+Vriesauthor=R.+Torensma&title=Immune+curbing+of+cancer+stem+cells+by+CTLs+directed+to+NANOG&doi=10.3389%2Ffimmu.2018.01412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Immune curbing of cancer stem cells by CTLs directed to NANOG</span></div><div class="casAuthors">Wefers, Christina; Schreibelt, Gerty; Massuger, Leon F. A. G.; de Vries, I. Jolanda M.; Torensma, Ruurd</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1412/1-1412/10</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) have been identified as the source of tumor growth and disease recurrence.  Eradication of CSCs is thus essential to achieve durable responses, but CSCs are resistant to current anti-tumor therapies.  Novel therapeutic approaches that specifically target CSCs will, therefore, be crucial to improve patient outcome.  Immunotherapies, which boost the body's own immune system to eliminate cancerous cells, could be an alternative approach to target CSCs.  Vaccines of dendritic cells (DCs) loaded with tumor antigens can evoke highly specific anti-tumor T cell responses.  Importantly, DC vaccination also promotes immunol. memory formation, paving the way for long-term cancer control.  Here, we propose a DC vaccination that specifically targets CSCs.  DCs loaded with NANOG peptides, a protein required for maintaining stem cell properties, could evoke a potent anti-tumor immune response against CSCs.  We hypothesize that the resulting immunol. memory will also control newly formed CSCs, thereby preventing disease recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzjyxdPijxeLVg90H21EOLACvtfcHk0li0siKNHFp8BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1KkurvI&md5=fee01301f531ae0df4ebdae16a3aa0ea</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.01412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.01412%26sid%3Dliteratum%253Aachs%26aulast%3DWefers%26aufirst%3DC.%26aulast%3DSchreibelt%26aufirst%3DG.%26aulast%3DMassuger%26aufirst%3DL.%2BF.%2BA.%2BG.%26aulast%3Dde%2BVries%26aufirst%3DI.%2BJ.%2BM.%26aulast%3DTorensma%26aufirst%3DR.%26atitle%3DImmune%2520curbing%2520of%2520cancer%2520stem%2520cells%2520by%2520CTLs%2520directed%2520to%2520NANOG%26jtitle%3DFront.%2520Immunol.%26date%3D2018%26volume%3D9%26spage%3D1412%26doi%3D10.3389%2Ffimmu.2018.01412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto-Vila, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohama, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiya, T.</span></span> <span> </span><span class="NLM_article-title">Development of miRNA-based therapeutic approaches for cancer patients</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1140</span>– <span class="NLM_lpage">1147</span>, <span class="refDoi"> DOI: 10.1111/cas.13965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1111%2Fcas.13965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30729639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjslOgsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2019&pages=1140-1147&author=R.+U.+Takahashiauthor=M.+Prieto-Vilaauthor=I.+Kohamaauthor=T.+Ochiya&title=Development+of+miRNA-based+therapeutic+approaches+for+cancer+patients&doi=10.1111%2Fcas.13965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Development of miRNA-based therapeutic approaches for cancer patients</span></div><div class="casAuthors">Takahashi, Ryou-u; Prieto-Vila, Marta; Kohama, Isaku; Ochiya, Takahiro</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1140-1147</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Over the past few decades, siRNA and miRNA have attracted a great deal of attention from researchers and clinicians.  These mols. have been extensively studied from the standpoint of developing biopharmaceuticals against various diseases, including heart disease, diabetes and cancers. siRNA suppresses only a single target, whereas each miRNA regulates the expression of multiple target genes.  More importantly, because miRNA are also secreted from cancer cells, and their aberrant expression is assocd. with tumor development and progression, they represent not only therapeutic targets but also promising biomarkers for diagnosis and prognosis.  Therefore, miRNA may be more effective tools against cancers, in which multiple signal pathways are dysregulated.  In this review, we summarize recent progress in the development of miRNA therapeutics for the treatment of cancer patients, and describe delivery systems for oligonucleotide therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeqIcst2JCZLVg90H21EOLACvtfcHk0li0siKNHFp8BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjslOgsbw%253D&md5=0d53492c761a7a6c3114fd736374bd24</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1111%2Fcas.13965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13965%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DR.%2BU.%26aulast%3DPrieto-Vila%26aufirst%3DM.%26aulast%3DKohama%26aufirst%3DI.%26aulast%3DOchiya%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520miRNA-based%2520therapeutic%2520approaches%2520for%2520cancer%2520patients%26jtitle%3DCancer%2520Sci.%26date%3D2019%26volume%3D110%26spage%3D1140%26epage%3D1147%26doi%3D10.1111%2Fcas.13965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunitoshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardenas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Keuren-Jensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, A.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cell-associated miRNAs serve as prognostic biomarkers in colorectal cancer</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e125294</span> <span class="refDoi"> DOI: 10.1172/jci.insight.125294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1172%2Fjci.insight.125294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30895943" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&author=S.+Todenauthor=S.+Kunitoshiauthor=J.+Cardenasauthor=J.+Guauthor=E.+Hutchinsauthor=K.+Van+Keuren-Jensenauthor=H.+Uetakeauthor=Y.+Toiyamaauthor=A.+Goel&title=Cancer+stem+cell-associated+miRNAs+serve+as+prognostic+biomarkers+in+colorectal+cancer&doi=10.1172%2Fjci.insight.125294"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.125294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.125294%26sid%3Dliteratum%253Aachs%26aulast%3DToden%26aufirst%3DS.%26aulast%3DKunitoshi%26aufirst%3DS.%26aulast%3DCardenas%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DHutchins%26aufirst%3DE.%26aulast%3DVan%2BKeuren-Jensen%26aufirst%3DK.%26aulast%3DUetake%26aufirst%3DH.%26aulast%3DToiyama%26aufirst%3DY.%26aulast%3DGoel%26aufirst%3DA.%26atitle%3DCancer%2520stem%2520cell-associated%2520miRNAs%2520serve%2520as%2520prognostic%2520biomarkers%2520in%2520colorectal%2520cancer%26jtitle%3DJCI%2520Insight%26date%3D2019%26volume%3D4%26doi%3D10.1172%2Fjci.insight.125294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuh, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. K.</span></span> <span> </span><span class="NLM_article-title">MicroRNA-based combinatorial cancer therapy: Effects of microRNAs on the efficacy of anti-cancer therapies</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.3390/cells9010029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcells9010029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVygu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=29&author=H.+A.+Seoauthor=S.+Moengauthor=S.+Simauthor=H.+J.+Kuhauthor=S.+Y.+Choiauthor=J.+K.+Park&title=MicroRNA-based+combinatorial+cancer+therapy%3A+Effects+of+microRNAs+on+the+efficacy+of+anti-cancer+therapies&doi=10.3390%2Fcells9010029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">MicroRNA-Based combinatorial cancer therapy: effects of micrornas on the efficacy of anti-cancer therapies</span></div><div class="casAuthors">Seo, Hyun Ah; Moeng, Sokviseth; Sim, Seokmin; Kuh, Hyo Jeong; Choi, Soo Young; Park, Jong Kook</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The susceptibility of cancer cells to different types of treatments can be restricted by intrinsic and acquired therapeutic resistance, leading to the failure of cancer regression and remission.  To overcome this problem, a combination therapy has been proposed as a fundamental strategy to improve therapeutic responses; however, resistance is still unavoidable.  MicroRNA (miRNAs) are assocd. with cancer therapeutic resistance.  The modulation of dysregulated miRNA levels through miRNA-based therapy comprising a replacement or inhibition approach has been proposed to sensitize cancer cells to other anti-cancer therapies.  The combination of miRNA-based therapy with other anti-cancer therapies (miRNA-based combinatorial cancer therapy) is attractive, due to the ability of miRNAs to target multiple genes assocd. with the signaling pathways controlling therapeutic resistance.  In this article, we present an overview of recent findings on the role of therapeutic resistance-related miRNAs in different types of cancer.  We review the feasibility of utilizing dysregulated miRNAs in cancer cells and extracellular vesicles as potential candidates for miRNA-based combinatorial cancer therapy.  We also discuss innate properties of miRNAs that need to be considered for more effective combinatorial cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdjAjUwXVWFLVg90H21EOLACvtfcHk0liF6C5Yvsgf-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVygu7vK&md5=6155ce044ae3f40f7923013bad965cf1</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.3390%2Fcells9010029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells9010029%26sid%3Dliteratum%253Aachs%26aulast%3DSeo%26aufirst%3DH.%2BA.%26aulast%3DMoeng%26aufirst%3DS.%26aulast%3DSim%26aufirst%3DS.%26aulast%3DKuh%26aufirst%3DH.%2BJ.%26aulast%3DChoi%26aufirst%3DS.%2BY.%26aulast%3DPark%26aufirst%3DJ.%2BK.%26atitle%3DMicroRNA-based%2520combinatorial%2520cancer%2520therapy%253A%2520Effects%2520of%2520microRNAs%2520on%2520the%2520efficacy%2520of%2520anti-cancer%2520therapies%26jtitle%3DCells%26date%3D2020%26volume%3D9%26spage%3D29%26doi%3D10.3390%2Fcells9010029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nascimento, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogusuku, I. E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lameu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, H.</span></span> <span> </span><span class="NLM_article-title">Aptamers: novelty tools for cancer biology</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">26934</span>– <span class="NLM_lpage">26953</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.25260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.18632%2Foncotarget.25260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29928493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC1MbpvFWitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=26934-26953&author=R.+L.+Pereiraauthor=I.+C.+Nascimentoauthor=A.+P.+Santosauthor=I.+E.+Y.+Ogusukuauthor=C.+Lameuauthor=G.+Mayerauthor=H.+Ulrich&title=Aptamers%3A+novelty+tools+for+cancer+biology&doi=10.18632%2Foncotarget.25260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Aptamers: novelty tools for cancer biology</span></div><div class="casAuthors">Pereira Ricardo L; Nascimento Isis C; Santos Ana P; Ogusuku Isabella E Y; Lameu Claudiana; Ulrich Henning; Mayer Gunter; Mayer Gunter</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">26934-26953</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although the term 'cancer' was still over two thousand years away of being coined, the first known cases of the disease date back to about 3000BC, in ancient Egypt.  Five thousand years later, still lacking a cure, it has become one of the leading causes of death, killing over half a dozen million people yearly.  So far, monoclonal antibodies are the most successful immune-therapy tools when it comes to fighting cancer.  The number of clinical trials that use them has been increasing steadily during the past few years, especially since the Food and Drug Administration greenlit the use of the first immune-checkpoint blockade antibodies.  However, albeit successful, this approach does come with the cost of auto-inflammatory toxicity.  Taking this into account, the development of new therapeutic reagents with low toxicity becomes evident, particularly ones acting in tandem with the tools currently at our disposal.  Ever since its discovery in the early nineties, aptamer technology has been used for a wide range of diagnostic and therapeutic applications.  With similar properties to those of monoclonal antibodies, such as high-specificity of recognition and high-affinity binding, and the advantages of being developed using in vitro selection procedures, aptamers quickly became convenient building blocks for the generation of multifunctional constructs.  In this review, we discuss the steps involved in the in vitro selection process that leads to functional aptamers - known as Systematic Evolution of Ligands by Exponential Enrichment - as well as the most recent applications of this technology in diagnostic and treatment of oncological illnesses.  Moreover, we also suggest ways to improve such use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWcmnHKmNeloJKJbLTgsvCfW6udTcc2eYdx3PDNq_psrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbpvFWitQ%253D%253D&md5=44aea3e0cc3c7ca876e515a3116b262a</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.25260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.25260%26sid%3Dliteratum%253Aachs%26aulast%3DPereira%26aufirst%3DR.%2BL.%26aulast%3DNascimento%26aufirst%3DI.%2BC.%26aulast%3DSantos%26aufirst%3DA.%2BP.%26aulast%3DOgusuku%26aufirst%3DI.%2BE.%2BY.%26aulast%3DLameu%26aufirst%3DC.%26aulast%3DMayer%26aufirst%3DG.%26aulast%3DUlrich%26aufirst%3DH.%26atitle%3DAptamers%253A%2520novelty%2520tools%2520for%2520cancer%2520biology%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D26934%26epage%3D26953%26doi%3D10.18632%2Foncotarget.25260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, N.</span></span> <span> </span><span class="NLM_article-title">Aptamer selection and applications for breast cancer diagnostics and therapy</span>. <i>J. Nanobiotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">81</span>, <span class="refDoi"> DOI: 10.1186/s12951-017-0311-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1186%2Fs12951-017-0311-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29132385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFWnsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=81&author=M.+Liuauthor=X.+Yuauthor=Z.+Chenauthor=T.+Yangauthor=D.+Yangauthor=Q.+Liuauthor=K.+Duauthor=B.+Liauthor=Z.+Wangauthor=S.+Liauthor=Y.+Dengauthor=N.+He&title=Aptamer+selection+and+applications+for+breast+cancer+diagnostics+and+therapy&doi=10.1186%2Fs12951-017-0311-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Aptamer selection and applications for breast cancer diagnostics and therapy</span></div><div class="casAuthors">Liu, Mei; Yu, Xiaocheng; Chen, Zhu; Yang, Tong; Yang, Dandan; Liu, Qianqian; Du, Keke; Li, Bo; Wang, Zhifei; Li, Song; Deng, Yan; He, Nongyue</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nanobiotechnology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">81/1-81/16</span>CODEN:
                <span class="NLM_cas:coden">JNOAAO</span>;
        ISSN:<span class="NLM_cas:issn">1477-3155</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Aptamers are short non-coding, single-stranded oligonucleotides (RNA or DNA) developed through Systematic Evolution of Ligands by Exponential enrichment (SELEX) in vitro.  Similar to antibodies, aptamers can bind to specific targets with high affinity, and are considered promising therapeutic agents as they have several advantages over antibodies, including high specificity, stability, and non-immunogenicity.  Furthermore, aptamers can be produced at a low cost and easily modified, and are, therefore, called "chem. antibodies".  In the past years, a variety of aptamers specifically bound to both breast cancer biomarkers and cells had been selected.  Besides, taking advantage of nanomaterials, there were a no. of aptamer-nanomaterial conjugates been developed and widely investigated for diagnostics and targeted therapy of breast cancer.  In this short review, we first present a systematical review of various aptamer selection methods.  Then, various aptamer-based diagnostic and therapeutic strategies of breast cancer were provided.  Finally, the current problems, challenges, and future perspectives in the field were thoroughly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppqAbuBPrCA7Vg90H21EOLACvtfcHk0lhThc5rHfcREg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFWnsbjE&md5=db80ff7c1dde78c73bafd2f90cf652fb</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1186%2Fs12951-017-0311-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12951-017-0311-4%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DDu%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DN.%26atitle%3DAptamer%2520selection%2520and%2520applications%2520for%2520breast%2520cancer%2520diagnostics%2520and%2520therapy%26jtitle%3DJ.%2520Nanobiotechnol.%26date%3D2017%26volume%3D15%26spage%3D81%26doi%3D10.1186%2Fs12951-017-0311-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latchoumanin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagdesar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebbard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liddle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, L.</span></span> <span> </span><span class="NLM_article-title">Aptamer-based therapeutic approaches to target cancer stem cells</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3948</span>– <span class="NLM_lpage">3961</span>, <span class="refDoi"> DOI: 10.7150/thno.20725</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.7150%2Fthno.20725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29109790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFaitb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=3948-3961&author=G.+Zhouauthor=O.+Latchoumaninauthor=M.+Bagdesarauthor=L.+Hebbardauthor=W.+Duanauthor=C.+Liddleauthor=J.+Georgeauthor=L.+Qiao&title=Aptamer-based+therapeutic+approaches+to+target+cancer+stem+cells&doi=10.7150%2Fthno.20725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Aptamer-based therapeutic approaches to target cancer stem cells</span></div><div class="casAuthors">Zhou, Gang; Latchoumanin, Olivier; Bagdesar, Mary; Hebbard, Lionel; Duan, Wei; Liddle, Christopher; George, Jacob; Qiao, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3948-3961</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are believed to be a principal cellular source for tumor progression and therapeutic drug resistance as they are capable of self-renewal and can differentiate into cancer cells.  Importantly, CSCs acquire the ability to evade the killing effects of cytotoxic agents through changes at the genetic, epigenetic and micro-environment levels.  Therefore, therapeutic strategies targeting CSCs hold great potential as an avenue for cancer treatment.  Aptamers or "chem. antibodies" are a group of single-stranded nucleic acid (DNA or RNA) oligonucleotides with distinctive properties such as smaller size, lower toxicity and less immunogenicity compared to conventional antibodies.  They have been frequently used to deliver therapeutic payloads to cancer cells and have achieved encouraging anti-tumor effects.  This review discusses progress in CSC evolution theory and the role of aptamers to target CSCs for cancer treatment.  Challenges of aptamer-mediated CSC targeting approaches are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVXtHiOz5iLLVg90H21EOLACvtfcHk0lhThc5rHfcREg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFaitb7L&md5=4fbd835810b569c2d1da946e64fc1cb8</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.7150%2Fthno.20725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.20725%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DLatchoumanin%26aufirst%3DO.%26aulast%3DBagdesar%26aufirst%3DM.%26aulast%3DHebbard%26aufirst%3DL.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DLiddle%26aufirst%3DC.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DQiao%26aufirst%3DL.%26atitle%3DAptamer-based%2520therapeutic%2520approaches%2520to%2520target%2520cancer%2520stem%2520cells%26jtitle%3DTheranostics%26date%3D2017%26volume%3D7%26spage%3D3948%26epage%3D3961%26doi%3D10.7150%2Fthno.20725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span> <span> </span><span class="NLM_article-title">Targeting breast cancer stem cells</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2010.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.molonc.2010.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=20599450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFCktL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=404-419&author=S.+P.+McDermottauthor=M.+S.+Wicha&title=Targeting+breast+cancer+stem+cells&doi=10.1016%2Fj.molonc.2010.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting breast cancer stem cells</span></div><div class="casAuthors">McDermott, Sean P.; Wicha, Max S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">404-419</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The cancer stem cell (CSC) hypothesis postulates that tumors are maintained by a self-renewing CSC population that is also capable of differentiating into non-self-renewing cell populations that constitute the bulk of the tumor.  Although, the CSC hypothesis does not directly address the cell of origin of cancer, it is postulated that tissue-resident stem or progenitor cells are the most common targets of transformation.  Clin., CSCs are predicted to mediate tumor recurrence after chemo- and radiation-therapy due to the relative inability of these modalities to effectively target CSCs.  If this is the case, then CSC must be efficiently targeted to achieve a true cure.  Similarities between normal and malignant stem cells, at the levels of cell-surface proteins, mol. pathways, cell cycle quiescence, and microRNA signaling present challenges in developing CSC-specific therapeutics.  Approaches to targeting CSCs include the development of agents targeting known stem cell regulatory pathways as well as unbiased high-throughput siRNA or small mol. screening.  Based on studies of pathways present in normal stem cells, recent work has identified potential "Achilles heals" of CSC, whereas unbiased screening provides opportunities to identify new pathways utilized by CSC as well as develop potential therapeutic agents.  Here, we review both approaches and their potential to effectively target breast CSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo94TOxDX7z7bVg90H21EOLACvtfcHk0lj_1uZZqIjyNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFCktL3N&md5=e8a85906253d19ce740a9667d792ba74</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2010.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2010.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DS.%2BP.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26atitle%3DTargeting%2520breast%2520cancer%2520stem%2520cells%26jtitle%3DMol.%2520Oncol.%26date%3D2010%26volume%3D4%26spage%3D404%26epage%3D419%26doi%3D10.1016%2Fj.molonc.2010.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rausch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallifatidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattern, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladkich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schemmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Büchler, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zöller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salnikov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herr, I.</span></span> <span> </span><span class="NLM_article-title">Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">5004</span>– <span class="NLM_lpage">5013</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-0066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1158%2F0008-5472.CAN-10-0066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=20530687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=5004-5013&author=V.+Rauschauthor=L.+Liuauthor=G.+Kallifatidisauthor=B.+Baumannauthor=J.+Matternauthor=J.+Gladkichauthor=T.+Wirthauthor=P.+Schemmerauthor=M.+W.+B%C3%BCchlerauthor=M.+Z%C3%B6llerauthor=A.+V.+Salnikovauthor=I.+Herr&title=Synergistic+activity+of+sorafenib+and+sulforaphane+abolishes+pancreatic+cancer+stem+cell+characteristics&doi=10.1158%2F0008-5472.CAN-10-0066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160aR"><div class="casContent"><span class="casTitleNuber">160a</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics</span></div><div class="casAuthors">Rausch, Vanessa; Liu, Li; Kallifatidis, Georgios; Baumann, Bernd; Mattern, Juergen; Gladkich, Jury; Wirth, Thomas; Schemmer, Peter; Buechler, Markus W.; Zoeller, Margot; Salnikov, Alexei V.; Herr, Ingrid</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5004-5013</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent evidence suggests that pancreatic cancer and other solid tumors contain a subset of tumorigenic cells capable of extensive self-renewal that contribute to metastasis and treatment resistance.  Sorafenib (SO) is a promising new multikinase inhibitor for treatment of advanced kidney and liver cancers.  We report here targeting of pancreatic cancer stem cells (CSC) by SO and the development of a strategy to enhance this effect.  Although SO administration diminished clonogenicity, spheroid formation, aldehyde dehydrogenase 1 (ALDH1) activity, growth on immunodeficient mice, proliferation, and angiogenesis and induced apoptosis, we obsd. SO-induced activation of NF-κB assocd. with survival and regrowth of spheroids.  For enhanced elimination of CSC characteristics by SO, we cotreated cells with sulforaphane (SF).  This broccoli isothiocyanate was recently described to eliminate pancreatic CSCs by downregulation of NF-κB activity without inducing toxic side effects.  On combination treatment, SF completely eradicated SO-induced NF-κB binding, which was assocd. with abrogated clonogenicity, spheroid formation, ALDH1 activity, migratory capacity, and induction of apoptosis.  In vivo, combination therapy reduced the tumor size in a synergistic manner.  This was due to induction of apoptosis, inhibition of proliferation and angiogenesis, and downregulation of SO-induced expression of proteins involved in epithelial-mesenchymal transition.  Our data suggest that SF may be suited to increase targeting of CSCs by SO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr9wc3VmL1P7Vg90H21EOLACvtfcHk0liSvKG_50Bk-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKltLo%253D&md5=3a858ddc0831047a55faf685aed7b166</span></div><a href="/servlet/linkout?suffix=cit160a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-0066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-0066%26sid%3Dliteratum%253Aachs%26aulast%3DRausch%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DKallifatidis%26aufirst%3DG.%26aulast%3DBaumann%26aufirst%3DB.%26aulast%3DMattern%26aufirst%3DJ.%26aulast%3DGladkich%26aufirst%3DJ.%26aulast%3DWirth%26aufirst%3DT.%26aulast%3DSchemmer%26aufirst%3DP.%26aulast%3DB%25C3%25BCchler%26aufirst%3DM.%2BW.%26aulast%3DZ%25C3%25B6ller%26aufirst%3DM.%26aulast%3DSalnikov%26aufirst%3DA.%2BV.%26aulast%3DHerr%26aufirst%3DI.%26atitle%3DSynergistic%2520activity%2520of%2520sorafenib%2520and%2520sulforaphane%2520abolishes%2520pancreatic%2520cancer%2520stem%2520cell%2520characteristics%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D5004%26epage%3D5013%26doi%3D10.1158%2F0008-5472.CAN-10-0066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit160b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S.</span></span> <span> </span><span class="NLM_article-title">Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.01089.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1111%2Fj.1476-5381.2010.01089.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=20973777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhslKrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2011&pages=773-784&author=J.+H.+Kimauthor=M.+Chaeauthor=W.+K.+Kimauthor=Y.+J.+Kimauthor=H.+S.+Kangauthor=H.+S.+Kimauthor=S.+Yoon&title=Salinomycin+sensitizes+cancer+cells+to+the+effects+of+doxorubicin+and+etoposide+treatment+by+increasing+DNA+damage+and+reducing+p21+protein&doi=10.1111%2Fj.1476-5381.2010.01089.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160bR"><div class="casContent"><span class="casTitleNuber">160b</span><div class="casTitle"><span class="NLM_cas:atitle">Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein</span></div><div class="casAuthors">Kim, Ju-Hwa; Chae, Minji; Kim, Won Ki; Kim, You-Jin; Kang, Han Sung; Kim, Hyung Sik; Yoon, Sungpil</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">773-784</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Salinomycin (Sal) has recently been shown to inhibit various cancer stem cells.  Here, we investigated whether Sal could sensitize cancer cells to the effects of doxorubicin (DOX) or etoposide (ETO).  Using the Comet assay, immunocytochem. and Western blot anal., we assessed the ability of Sal to increase DNA breakage.  We performed a cell proliferation assay to det. cell viability, cellular detachment, increased pre-G1 region, Annexin V staining and TUNEL assay to measure the ability of Sal to increase apoptosis.  Sal increased DNA breakage and phosphorylated levels of p53 and H2AX.  Sal also induced the formation of DNA foci with pH2AX and 53BP1.  Furthermore, Sal increased the sensitivity of cancer cells to the apoptotic effects of DOX or ETO.  We found that pH2AX, pBRCA1, p53BP1 and pChk1 levels were greatly increased after co-treatment of Sal with DOX or ETO.  The level of anti-apoptotic p21 protein was increased by DOX or ETO but decreased by Sal, which increased proteasome activity.  This is the first study to report that Sal increases DNA damage, and this effect plays an important role in the increased apoptosis caused by Sal.  Overall, we demonstrated that the ability of Sal to sensitize cancer cells to the effects of DOX or ETO is assocd. with an increase in DNA damage and a decrease in anti-apoptotic protein p21 levels.  These results may contribute to the development of Sal-based chemotherapy for cancer patients receiving DOX or ETO treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWhLDhzdlVUbVg90H21EOLACvtfcHk0lgrZcIFfKoxRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhslKrtLY%253D&md5=6cdb2ed9d40346bcac8c7d98c1904536</span></div><a href="/servlet/linkout?suffix=cit160b&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.01089.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.01089.x%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DChae%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DW.%2BK.%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DKang%26aufirst%3DH.%2BS.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DYoon%26aufirst%3DS.%26atitle%3DSalinomycin%2520sensitizes%2520cancer%2520cells%2520to%2520the%2520effects%2520of%2520doxorubicin%2520and%2520etoposide%2520treatment%2520by%2520increasing%2520DNA%2520damage%2520and%2520reducing%2520p21%2520protein%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D162%26spage%3D773%26epage%3D784%26doi%3D10.1111%2Fj.1476-5381.2010.01089.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanaswamy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torchilin, V. P.</span></span> <span> </span><span class="NLM_article-title">Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1080/15384047.2016.1190488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1080%2F15384047.2016.1190488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=27259361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFGmurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=698-707&author=T.+Wangauthor=R.+Narayanaswamyauthor=H.+Renauthor=V.+P.+Torchilin&title=Combination+therapy+targeting+both+cancer+stem-like+cells+and+bulk+tumor+cells+for+improved+efficacy+of+breast+cancer+treatment&doi=10.1080%2F15384047.2016.1190488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment</span></div><div class="casAuthors">Wang, Tao; Narayanaswamy, Radhika; Ren, Huilan; Torchilin, Vladimir P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">698-707</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1555-8576</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Many types of tumors are organized in a hierarchy of heterogeneous cell populations.  The cancer stem-like cells (CSCs) hypothesis suggests that tumor development and metastasis are driven by a minority population of cells, which are responsible for tumor initiation, growth and recurrences.  The inability to efficiently eliminate CSCs during chemotherapy, together with CSCs being highly tumorigenic and invasive, may result in treatment failure due to cancer relapse and metastases.  CSCs are emerging as a promising target for the development of translational cancer therapies.  Ideal panacea for cancer would kill all malignant cells, including CSCs and bulk tumor cells.  Since both chemotherapy and CSCs-specific therapy are insufficient to cure cancer, we propose combination therapy with CSCs-targeted agents and chemotherapeutics for improved breast cancer treatment.  We generated in vitro mammosphere of 2 breast cancer cell lines, and demonstrated ability of mammospheres to grow and enrich cancer cells with stem-like properties, including self-renewal, multilineage differentiation and enrichment of cells expressing breast cancer stem-like cell biomarkers CD44+/CD24-/low.  The formation of mammospheres was significantly inhibited by salinomycin, validating its pharmacol. role against the cancer stem-like cells.  In contrast, paclitaxel showed a minimal effect on the proliferation and growth of breast cancer stem-like cells.  While combination therapies of salinomycin with conventional chemotherapy (paclitaxel or lipodox) showed a potential to improve tumor cell killing, different subtypes of breast cancer cells showed different patterns in response to the combination therapies.  While optimization of combination therapy is warranted, the design of combination therapy should consider phenotypic attributes of breast cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7hT2l0IJbF7Vg90H21EOLACvtfcHk0lgrZcIFfKoxRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFGmurvP&md5=8304c35da3d2a904059edfbb0b562669</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1080%2F15384047.2016.1190488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384047.2016.1190488%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DNarayanaswamy%26aufirst%3DR.%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTorchilin%26aufirst%3DV.%2BP.%26atitle%3DCombination%2520therapy%2520targeting%2520both%2520cancer%2520stem-like%2520cells%2520and%2520bulk%2520tumor%2520cells%2520for%2520improved%2520efficacy%2520of%2520breast%2520cancer%2520treatment%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2016%26volume%3D17%26spage%3D698%26epage%3D707%26doi%3D10.1080%2F15384047.2016.1190488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dzobo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthebane, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomford, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wonkam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandara, C.</span></span> <span> </span><span class="NLM_article-title">Advances in therapeutic targeting of cancer stem cells within the tumor microenvironment: an updated review</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1896</span>, <span class="refDoi"> DOI: 10.3390/cells9081896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcells9081896" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=1896&author=K.+Dzoboauthor=D.+A.+Senthebaneauthor=C.+Ganzauthor=N.+E.+Thomfordauthor=A.+Wonkamauthor=C.+Dandara&title=Advances+in+therapeutic+targeting+of+cancer+stem+cells+within+the+tumor+microenvironment%3A+an+updated+review&doi=10.3390%2Fcells9081896"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.3390%2Fcells9081896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells9081896%26sid%3Dliteratum%253Aachs%26aulast%3DDzobo%26aufirst%3DK.%26aulast%3DSenthebane%26aufirst%3DD.%2BA.%26aulast%3DGanz%26aufirst%3DC.%26aulast%3DThomford%26aufirst%3DN.%2BE.%26aulast%3DWonkam%26aufirst%3DA.%26aulast%3DDandara%26aufirst%3DC.%26atitle%3DAdvances%2520in%2520therapeutic%2520targeting%2520of%2520cancer%2520stem%2520cells%2520within%2520the%2520tumor%2520microenvironment%253A%2520an%2520updated%2520review%26jtitle%3DCells%26date%3D2020%26volume%3D9%26spage%3D1896%26doi%3D10.3390%2Fcells9081896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schott, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landis, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dontu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layman, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paskett, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrolecki, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froehlich, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranilam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. C.</span></span> <span> </span><span class="NLM_article-title">Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1512</span>– <span class="NLM_lpage">1524</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1158%2F1078-0432.CCR-11-3326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=23340294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1512-1524&author=A.+F.+Schottauthor=M.+D.+Landisauthor=G.+Dontuauthor=K.+A.+Griffithauthor=R.+M.+Laymanauthor=I.+Kropauthor=L.+A.+Paskettauthor=H.+Wongauthor=L.+E.+Dobroleckiauthor=M.+T.+Lewisauthor=A.+M.+Froehlichauthor=J.+Paranilamauthor=D.+F.+Hayesauthor=M.+S.+Wichaauthor=J.+C.+Chang&title=Preclinical+and+clinical+studies+of+gamma+secretase+inhibitors+with+docetaxel+on+human+breast+tumors&doi=10.1158%2F1078-0432.CCR-11-3326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors</span></div><div class="casAuthors">Schott, Anne F.; Landis, Melissa D.; Dontu, Gabriela; Griffith, Kent A.; Layman, Rachel M.; Krop, Ian; Paskett, Lacey A.; Wong, Helen; Dobrolecki, Lacey E.; Lewis, Michael T.; Froehlich, Amber M.; Paranilam, Jaya; Hayes, Daniel F.; Wicha, Max S.; Chang, Jenny C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1512-1524</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Accumulating evidence supports the existence of breast cancer stem cells (BCSC), which are characterized by their capacity to self-renew and divide indefinitely and resistance to conventional therapies.  The Notch pathway is important for stem cell renewal and is a potential target for BCSC-directed therapy.  Exptl. Design: Using human breast tumorgraft studies, we evaluated the impact of gamma secretase inhibitors (GSI) on the BCSC population and the efficacy of combining GSI with docetaxel treatment.  The mouse exptl. therapy paralleled a concurrent clin. trial in patients with advanced breast cancer, designed to det. the max.-tolerated dose of the GSI, MK-0752, administered sequentially with docetaxel, and to evaluate BCSC markers in serial tumor biopsies.  Results: Treatment with GSI reduced BCSCs in MC1 and BCM-2147 tumorgrafts by inhibition of the Notch pathway.  GSI enhanced the efficacy of docetaxel in preclin. studies.  In the clin. trial, 30 patients with advanced breast cancer were treated with escalating doses of MK-0752 plus docetaxel.  Clin., meaningful doses of both drugs were possible with manageable toxicity and preliminary evidence of efficacy.  A decrease in CD44+/CD24-, ALDH+, and mammosphere-forming efficiency were obsd. in tumors of patients undergoing serial biopsies.  Conclusions: These preclin. data show that pharmacol. inhibition of the Notch pathway can reduce BCSCs in breast tumorgraft models.  The clin. trial shows feasibility of combination GSI and chemotherapy, and together these results encourage further study of Notch pathway inhibitors in combination with chemotherapy in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSPyKUMdOCRrVg90H21EOLACvtfcHk0linDOswxVQkIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKktL0%253D&md5=4123f8b7f5f732252f7cafb7b2ef859c</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3326%26sid%3Dliteratum%253Aachs%26aulast%3DSchott%26aufirst%3DA.%2BF.%26aulast%3DLandis%26aufirst%3DM.%2BD.%26aulast%3DDontu%26aufirst%3DG.%26aulast%3DGriffith%26aufirst%3DK.%2BA.%26aulast%3DLayman%26aufirst%3DR.%2BM.%26aulast%3DKrop%26aufirst%3DI.%26aulast%3DPaskett%26aufirst%3DL.%2BA.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DDobrolecki%26aufirst%3DL.%2BE.%26aulast%3DLewis%26aufirst%3DM.%2BT.%26aulast%3DFroehlich%26aufirst%3DA.%2BM.%26aulast%3DParanilam%26aufirst%3DJ.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26aulast%3DChang%26aufirst%3DJ.%2BC.%26atitle%3DPreclinical%2520and%2520clinical%2520studies%2520of%2520gamma%2520secretase%2520inhibitors%2520with%2520docetaxel%2520on%2520human%2520breast%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D1512%26epage%3D1524%26doi%3D10.1158%2F1078-0432.CCR-11-3326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooray, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jameson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parnis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimison, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmgren, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoun, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebbutt, N. C.</span></span> <span> </span><span class="NLM_article-title">A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) ± nab-paclitaxel in patients with pancreatic cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">341</span>, <span class="refDoi"> DOI: 10.1200/jco.2016.34.4_suppl.341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1200%2Fjco.2016.34.4_suppl.341" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=341&author=M.+Hidalgoauthor=P.+Coorayauthor=A.+Carratoauthor=M.+B.+Jamesonauthor=F.+Parnisauthor=M.+Jefferyauthor=P.+S.+Grimisonauthor=R.+J.+Staggauthor=E.+Holmgrenauthor=A.+M.+Kapounauthor=J.+Dupontauthor=N.+C.+Tebbutt&title=A+phase+1b+study+of+the+anti-cancer+stem+cell+agent+demcizumab+%28DEM%29+and+gemcitabine+%28GEM%29+%C2%B1+nab-paclitaxel+in+patients+with+pancreatic+cancer&doi=10.1200%2Fjco.2016.34.4_suppl.341"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1200%2Fjco.2016.34.4_suppl.341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2016.34.4_suppl.341%26sid%3Dliteratum%253Aachs%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DCooray%26aufirst%3DP.%26aulast%3DCarrato%26aufirst%3DA.%26aulast%3DJameson%26aufirst%3DM.%2BB.%26aulast%3DParnis%26aufirst%3DF.%26aulast%3DJeffery%26aufirst%3DM.%26aulast%3DGrimison%26aufirst%3DP.%2BS.%26aulast%3DStagg%26aufirst%3DR.%2BJ.%26aulast%3DHolmgren%26aufirst%3DE.%26aulast%3DKapoun%26aufirst%3DA.%2BM.%26aulast%3DDupont%26aufirst%3DJ.%26aulast%3DTebbutt%26aufirst%3DN.%2BC.%26atitle%3DA%2520phase%25201b%2520study%2520of%2520the%2520anti-cancer%2520stem%2520cell%2520agent%2520demcizumab%2520%2528DEM%2529%2520and%2520gemcitabine%2520%2528GEM%2529%2520%25C2%25B1%2520nab-paclitaxel%2520in%2520patients%2520with%2520pancreatic%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D341%26doi%3D10.1200%2Fjco.2016.34.4_suppl.341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qureshy, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandis, J. R.</span></span> <span> </span><span class="NLM_article-title">Targeting the JAK/STAT pathway in solid tumors</span>. <i>J. Cancer Metastasis</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">27</span>, <span class="refDoi"> DOI: 10.20517/2394-4722.2020.58</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.20517%2F2394-4722.2020.58" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisV2rur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=27&author=Z.+Qureshyauthor=D.+E.+Johnsonauthor=J.+R.+Grandis&title=Targeting+the+JAK%2FSTAT+pathway+in+solid+tumors&doi=10.20517%2F2394-4722.2020.58"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the JAK/STAT pathway in solid tumors</span></div><div class="casAuthors">Qureshy, Zoya; Johnson, Daniel E.; Grandis, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer Metastasis and Treatment</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Spec.Iss.</span>),
    <span class="NLM_cas:pages">27</span>CODEN:
                <span class="NLM_cas:coden">JCMTCU</span>;
        ISSN:<span class="NLM_cas:issn">2454-2857</span>.
    
            (<span class="NLM_cas:orgname">OAE Publishing Inc.</span>)
        </div><div class="casAbstract">Aberrant activation of signal transducer and activator of transcription (STAT) proteins is assocd. with the development and progression of solid tumors.  However, as transcription factors, these proteins are difficult to target directly.  In this review, we summarize the role of targeting Janus kinases (JAKs), upstream activators of STATs, as a strategy for decreasing STAT activation in solid tumors.  Preclin. studies in solid tumor cell line models show that JAK inhibitors decrease STAT activation, cell proliferation, and cell survival; in in vivo models, they also inhibit tumor growth.  JAK inhibitors, particularly the JAK1/2 inhibitor ruxolitinib, sensitize cell lines and murine models to chemotherapy, immunotherapy, and oncolytic viral therapy.  Ten JAK inhibitors have been or are actively being tested in clin. trials as monotherapy or in combination with other agents in patients with solid tumors; two of these inhibitors are already Food and Drug Administration (FDA) approved for the treatment of myeloproliferative disorders and rheumatoid arthritis, making them attractive agents for use in patients with solid tumors as they are known to be well-tolerated.  Four JAK inhibitors (two of which are FDA approved for other indications) have exhibited promising anti-cancer effects in preclin. studies; however, clin. studies specifically assessing their activity against the JAK/STAT pathway in solid tumors have not yet been conducted.  In summary, JAK inhibition is a viable option for targeting the JAK/STAT pathway in solid tumors and merits further testing in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHZL06wxedJrVg90H21EOLACvtfcHk0linDOswxVQkIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisV2rur%252FI&md5=7468e105d344f5f6dd86d7fbc9cb3b02</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.20517%2F2394-4722.2020.58&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.20517%252F2394-4722.2020.58%26sid%3Dliteratum%253Aachs%26aulast%3DQureshy%26aufirst%3DZ.%26aulast%3DJohnson%26aufirst%3DD.%2BE.%26aulast%3DGrandis%26aufirst%3DJ.%2BR.%26atitle%3DTargeting%2520the%2520JAK%252FSTAT%2520pathway%2520in%2520solid%2520tumors%26jtitle%3DJ.%2520Cancer%2520Metastasis%26date%3D2020%26volume%3D6%26spage%3D27%26doi%3D10.20517%2F2394-4722.2020.58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span> <span> </span><span class="NLM_article-title">IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing BC</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1038/cdd.2017.162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1038%2Fcdd.2017.162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29027990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CrtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=330-339&author=D.+Wangauthor=J.+Xuauthor=B.+Liuauthor=X.+Heauthor=L.+Zhouauthor=X.+Huauthor=F.+Qiaoauthor=A.+Zhangauthor=X.+Xuauthor=H.+Zhangauthor=M.+S.+Wichaauthor=L.+Zhangauthor=Z.+M.+Shaoauthor=S.+Liu&title=IL6+blockade+potentiates+the+anti-tumor+effects+of+%CE%B3-secretase+inhibitors+in+Notch3-expressing+BC&doi=10.1038%2Fcdd.2017.162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing breast cancer</span></div><div class="casAuthors">Wang, Dong; Xu, Jiahui; Liu, Bingjie; He, Xueyan; Zhou, Lei; Hu, Xin; Qiao, Feng; Zhang, Anli; Xu, Xiaojun; Zhang, Huafeng; Wicha, Max S.; Zhang, Lixing; Shao, Zhi-ming; Liu, Suling</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">330-339</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Notch pathways have important roles in carcinogenesis including pathways involving the Notch1 and Notch2 oncogenes.  Pan-Notch inhibitors, such as gamma secretase inhibitors (GSIs), have been used in the clin. trials, but the outcomes of these trials have been insufficient and have yielded unclear.  In the present study, we demonstrated that GSIs, such as MK-0752 and RO4929097, inhibit breast tumor growth, but increase the breast cancer stem cell (BCSC) population in Notch3-expressing breast cancer cells, in a process that is coupled with IL6 induction and is blocked by the IL6R antagonist Tocilizumab (TCZ).  IL6 induction results from inhibition of Notch3-Hey2 signaling through MK-0752.  Furthermore, HIF1α upregulates Notch3 expression via direct binding to the Notch3 promoter and subsequently downregulates BCSCs by decreasing the IL6 levels in Notch3-expressing breast cancer cells.  Utilizing both breast cancer cell line xenografts and patient-derived xenografts (PDX), we showed that the combination of MK-0752 and Tocilizumab significantly decreases BCSCs and inhibits tumor growth and thus might serve as a novel therapeutic strategy for treating women with Notch3-expressing breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtYbn-rNPQLLVg90H21EOLACvtfcHk0liU29l3PNtK3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CrtrrJ&md5=33c6f179486d412ed70c9e9d592c9d93</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2017.162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2017.162%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DQiao%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShao%26aufirst%3DZ.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26atitle%3DIL6%2520blockade%2520potentiates%2520the%2520anti-tumor%2520effects%2520of%2520%25CE%25B3-secretase%2520inhibitors%2520in%2520Notch3-expressing%2520BC%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2018%26volume%3D25%26spage%3D330%26epage%3D339%26doi%3D10.1038%2Fcdd.2017.162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruffini, P. A.</span></span> <span> </span><span class="NLM_article-title">The CXCL8-CXCR1/2 axis as a therapeutic target in BC stem-like cells</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">40</span>, <span class="refDoi"> DOI: 10.3389/fonc.2019.00040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3389%2Ffonc.2019.00040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30788286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BB3cflvVOltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=40&author=P.+A.+Ruffini&title=The+CXCL8-CXCR1%2F2+axis+as+a+therapeutic+target+in+BC+stem-like+cells&doi=10.3389%2Ffonc.2019.00040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">The CXCL8-CXCR1/2 Axis as a Therapeutic Target in Breast Cancer Stem-Like Cells</span></div><div class="casAuthors">Ruffini Pier Adelchi</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Cancer stem-like cells (CSC) have been targeted by different strategies over the last decade.  This mini review focuses on preclinical and clinical results obtained by interfering with chemokine receptors CXCR1 and CXCR2 in breast cancer.  This strategy is currently being tested in a randomized, double blind phase 2 clinical trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTydAeEg5l-0IJKJbLTgsvCfW6udTcc2eYFZqNFxVJhprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cflvVOltw%253D%253D&md5=faf0c265039b59a054c11a006d06b4de</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2019.00040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2019.00040%26sid%3Dliteratum%253Aachs%26aulast%3DRuffini%26aufirst%3DP.%2BA.%26atitle%3DThe%2520CXCL8-CXCR1%252F2%2520axis%2520as%2520a%2520therapeutic%2520target%2520in%2520BC%2520stem-like%2520cells%26jtitle%3DFront.%2520Oncol.%26date%3D2019%26volume%3D9%26spage%3D40%26doi%3D10.3389%2Ffonc.2019.00040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, E.</span></span> <span> </span><span class="NLM_article-title">Early prediction of single-cell derived sphere formation rate using convolutional neural network image analysis</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">7717</span>– <span class="NLM_lpage">7724</span>, <span class="refDoi"> DOI: 10.1021/acs.analchem.0c00710</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.analchem.0c00710" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsV2qurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2020&pages=7717-7724&author=Y.+C.+Chenauthor=Z.+Zhangauthor=E.+Yoon&title=Early+prediction+of+single-cell+derived+sphere+formation+rate+using+convolutional+neural+network+image+analysis&doi=10.1021%2Facs.analchem.0c00710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Early Prediction of Single-Cell Derived Sphere Formation Rate Using Convolutional Neural Network Image Analysis</span></div><div class="casAuthors">Chen, Yu-Chih; Zhang, Zhixiong; Yoon, Euisik</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7717-7724</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Functional identification of cancer stem-like cells (CSCs) is an established method to identify and study this cancer subpopulation crit. for cancer progression and metastasis.  The method is based on the unique capability of single CSCs to survive and grow to tumorspheres in harsh suspension culture environment.  Recent advances in microfluidic technol. have enabled isolating and culturing thousands of single cells on a chip.  However, tumorsphere assay takes a relatively long period of time, limiting the throughput of this assay.  In this work, we incorporated machine learning with single-cell anal. to expedite tumorsphere assay.  We collected 1,710 single-cell events as the database and trained a convolutional neural network model that predicts whether a single cell could grow to a tumorsphere on Day 14 based on its Day 4 image.  With this future-telling model, we precisely estd. the sphere formation rate of SUM159 breast cancer cells to be 17.8% based on Day 4 images.  The estn. was close to the ground truth of 17.6% on Day 14.  The preliminary work demonstrates not only the feasibility to significantly accelerate tumorsphere assay but also a synergistic combination between single-cell anal. with machine learning, which can be applied to many other biomedical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo91CCM1nLtn7Vg90H21EOLACvtfcHk0lhjSLVm-Cms-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsV2qurg%253D&md5=1c40f9db306eaeb5b52979dd5c13f6c2</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Facs.analchem.0c00710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.analchem.0c00710%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%2BC.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DYoon%26aufirst%3DE.%26atitle%3DEarly%2520prediction%2520of%2520single-cell%2520derived%2520sphere%2520formation%2520rate%2520using%2520convolutional%2520neural%2520network%2520image%2520analysis%26jtitle%3DAnal.%2520Chem.%26date%3D2020%26volume%3D92%26spage%3D7717%26epage%3D7724%26doi%3D10.1021%2Facs.analchem.0c00710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blenner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander-Bryant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, J.</span></span> <span> </span><span class="NLM_article-title">Polymersomes for therapeutic delivery of protein and nucleic acid macromolecules: from design to therapeutic applications</span>. <i>Biomacromolecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1327</span>– <span class="NLM_lpage">1350</span>, <span class="refDoi"> DOI: 10.1021/acs.biomac.9b01754</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biomac.9b01754" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtl2ku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=1327-1350&author=S.+Iqbalauthor=M.+Blennerauthor=A.+Alexander-Bryantauthor=J.+Larsen&title=Polymersomes+for+therapeutic+delivery+of+protein+and+nucleic+acid+macromolecules%3A+from+design+to+therapeutic+applications&doi=10.1021%2Facs.biomac.9b01754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169aR"><div class="casContent"><span class="casTitleNuber">169a</span><div class="casTitle"><span class="NLM_cas:atitle">Polymersomes for Therapeutic Delivery of Protein and Nucleic Acid Macromolecules: From Design to Therapeutic Applications</span></div><div class="casAuthors">Iqbal, Shoaib; Blenner, Mark; Alexander-Bryant, Angela; Larsen, Jessica</div><div class="citationInfo"><span class="NLM_cas:title">Biomacromolecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1327-1350</span>CODEN:
                <span class="NLM_cas:coden">BOMAF6</span>;
        ISSN:<span class="NLM_cas:issn">1525-7797</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Macromol.-based therapeutic agents, particularly proteins, antigens, monoclonal antibodies, transcription factors, nucleic acids, and gene editing enzymes, have the potential to offer cures for previously untreatable diseases.  However, they present an enormous delivery challenge due to poor absorption and rapid metab. in the body.  Polymersomes have tremendous potential in delivering these agents to their desired intracellular location due to increased circulation times, decreased macromol. degrdn., and decreased immune responses.  In this Review, we highlight the key factors in design, development, and improved performance of these vesicles for macromol. delivery.  The recent progress made toward preclin. application of these vesicles for protein and gene delivery is also covered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohNdkP4qQ6u7Vg90H21EOLACvtfcHk0lhjSLVm-Cms-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtl2ku7c%253D&md5=4ce837b1fb148acdefd44c2889a9ba65</span></div><a href="/servlet/linkout?suffix=cit169a&amp;dbid=16384&amp;doi=10.1021%2Facs.biomac.9b01754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biomac.9b01754%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DS.%26aulast%3DBlenner%26aufirst%3DM.%26aulast%3DAlexander-Bryant%26aufirst%3DA.%26aulast%3DLarsen%26aufirst%3DJ.%26atitle%3DPolymersomes%2520for%2520therapeutic%2520delivery%2520of%2520protein%2520and%2520nucleic%2520acid%2520macromolecules%253A%2520from%2520design%2520to%2520therapeutic%2520applications%26jtitle%3DBiomacromolecules%26date%3D2020%26volume%3D21%26spage%3D1327%26epage%3D1350%26doi%3D10.1021%2Facs.biomac.9b01754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit169b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">So, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreon-Asok, A. C.</span></span> <span> </span><span class="NLM_article-title">Molecular design, synthetic strategies, and applications of cationic polythio-phenes</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">11442</span>– <span class="NLM_lpage">11509</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00773</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00773" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvV2hs77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2019&pages=11442-11509&author=R.+C.+Soauthor=A.+C.+Carreon-Asok&title=Molecular+design%2C+synthetic+strategies%2C+and+applications+of+cationic+polythio-phenes&doi=10.1021%2Facs.chemrev.8b00773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169bR"><div class="casContent"><span class="casTitleNuber">169b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Design, Synthetic Strategies, and Applications of Cationic Polythiophenes</span></div><div class="casAuthors">So, Regina C.; Carreon-Asok, Analyn C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">11442-11509</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review delves on the synthesis of cationic-functionalized oligothiophenes and polythiophenes, their properties, and their diverse applications from the year 2002-2019.  Whereas, pristine polythiophene chains are hydrophobic, and are not easily converted into a form that is useful for broad applications or for device fabrications.  Functional modification on the polymer side chain esp. with cationic pendant groups imparts favorable properties to the system such as, soly. in aq. medium, affinity with anions and neg. charged species, alongside the extensive π conjugation that provides unique optoelectronic characteristics.  This review provides a detailed account of the design and the different synthetic strategies to access cationic polythiophenes (CPTs) via chem. oxidn. using iron(III) chloride (FeCl3), via metal catalyzed/initiated polymn., and via postfunctionalization approach.  CPTs have been traditionally used in sensing and as a component in optoelectronic devices, the utility of these system has been extended to biomedical applications such as, nonviral gene delivery, cell targeting and imaging, anticancer, antifungal, bactericidal, biofilm formation, and as a mol. probe.  A summary and outlook are also presented, discussing the remaining challenges and the future direction for this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXAcxDHh4DwbVg90H21EOLACvtfcHk0lhjSLVm-Cms-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvV2hs77L&md5=f85d93b1e5a9a7e9d26c6bcb4f4e5245</span></div><a href="/servlet/linkout?suffix=cit169b&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00773%26sid%3Dliteratum%253Aachs%26aulast%3DSo%26aufirst%3DR.%2BC.%26aulast%3DCarreon-Asok%26aufirst%3DA.%2BC.%26atitle%3DMolecular%2520design%252C%2520synthetic%2520strategies%252C%2520and%2520applications%2520of%2520cationic%2520polythio-phenes%26jtitle%3DChem.%2520Rev.%26date%3D2019%26volume%3D119%26spage%3D11442%26epage%3D11509%26doi%3D10.1021%2Facs.chemrev.8b00773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hossen, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, P.</span></span> <span> </span><span class="NLM_article-title">Nanoparticle interactions with the tumor microenvironment</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2247</span>– <span class="NLM_lpage">2263</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.9b00448</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.9b00448" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFOqur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=2247-2263&author=Y.+Huaiauthor=M.+N.+Hossenauthor=S.+Wilhelmauthor=R.+Bhattacharyaauthor=P.+Mukherjee&title=Nanoparticle+interactions+with+the+tumor+microenvironment&doi=10.1021%2Facs.bioconjchem.9b00448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170aR"><div class="casContent"><span class="casTitleNuber">170a</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle Interactions with the Tumor Microenvironment</span></div><div class="casAuthors">Huai, Yanyan; Hossen, Md Nazir; Wilhelm, Stefan; Bhattacharya, Resham; Mukherjee, Priyabrata</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2247-2263</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Compared to normal tissues, the tumor microenvironment (TME) has a no. of aberrant characteristics including hypoxia, acidosis, and vascular abnormalities.  Many researchers have sought to exploit these anomalous features of the TME to develop anti-cancer therapies, and several nanoparticle-based cancer therapeutics have resulted.  In this review, the authors discuss the compn. and pathophysiol. of the TME, introduce nanoparticles (NPs) used in cancer therapy, and address the interaction between the TME and NPs.  Finally, the authors outline both the potential problems that affect TME-based nanotherapy and potential strategies to overcome these challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj_m2wsdiZhrVg90H21EOLACvtfcHk0lipW4ABICHCeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFOqur7K&md5=87b4f6695c1bf607d18d2f3208727f84</span></div><a href="/servlet/linkout?suffix=cit170a&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.9b00448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.9b00448%26sid%3Dliteratum%253Aachs%26aulast%3DHuai%26aufirst%3DY.%26aulast%3DHossen%26aufirst%3DM.%2BN.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DBhattacharya%26aufirst%3DR.%26aulast%3DMukherjee%26aufirst%3DP.%26atitle%3DNanoparticle%2520interactions%2520with%2520the%2520tumor%2520microenvironment%26jtitle%3DBioconjugate%2520Chem.%26date%3D2019%26volume%3D30%26spage%3D2247%26epage%3D2263%26doi%3D10.1021%2Facs.bioconjchem.9b00448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit170b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Musetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span> <span> </span><span class="NLM_article-title">Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">11740</span>– <span class="NLM_lpage">11755</span>, <span class="refDoi"> DOI: 10.1021/acsnano.8b05893</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.8b05893" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlylt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=11740-11755&author=S.+Musettiauthor=L.+Huang&title=Nanoparticle-mediated+remodeling+of+the+tumor+microenvironment+to+enhance+immunotherapy&doi=10.1021%2Facsnano.8b05893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170bR"><div class="casContent"><span class="casTitleNuber">170b</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy</span></div><div class="casAuthors">Musetti, Sara; Huang, Leaf</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">11740-11755</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nanoscience has long been lauded as a method through which tumor-assocd. barriers could be overcome.  As successful as cancer immunotherapy has been, limitations assocd. with the tumor microenvironment or side effects of systemic treatment have become more apparent.  In this Review, we seek to lay out the therapeutic challenges assocd. with the tumor microenvironment and the ways in which nanoscience is being applied to remodel the tumor microenvironment and increase the susceptibility of many cancer types to immunotherapy.  We detail the nanomedicines on the cutting edge of cancer immunotherapy and how their interactions with the tumor microenvironment make them more effective than systemically administered immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbXkVfsaYW6LVg90H21EOLACvtfcHk0lipW4ABICHCeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlylt7bJ&md5=fbde7087070895ee0f8230d757153162</span></div><a href="/servlet/linkout?suffix=cit170b&amp;dbid=16384&amp;doi=10.1021%2Facsnano.8b05893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.8b05893%26sid%3Dliteratum%253Aachs%26aulast%3DMusetti%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DL.%26atitle%3DNanoparticle-mediated%2520remodeling%2520of%2520the%2520tumor%2520microenvironment%2520to%2520enhance%2520immunotherapy%26jtitle%3DACS%2520Nano%26date%3D2018%26volume%3D12%26spage%3D11740%26epage%3D11755%26doi%3D10.1021%2Facsnano.8b05893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit170c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Emerging nano drug delivery systems targeting cancer-associated fibroblasts for improved antitumor effect and tumor drug penetration</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1028</span>– <span class="NLM_lpage">1048</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.0c00014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.0c00014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksVGmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=1028-1048&author=J.+Guoauthor=H.+Zengauthor=Y.+Chen&title=Emerging+nano+drug+delivery+systems+targeting+cancer-associated+fibroblasts+for+improved+antitumor+effect+and+tumor+drug+penetration&doi=10.1021%2Facs.molpharmaceut.0c00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170cR"><div class="casContent"><span class="casTitleNuber">170c</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging Nano Drug Delivery Systems Targeting Cancer-Associated Fibroblasts for Improved Antitumor Effect and Tumor Drug Penetration</span></div><div class="casAuthors">Guo, Jian; Zeng, Huating; Chen, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1028-1048</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Currently, clin. used antitumor nanomedicine is usually insufficient to eradicate malignancies, due to the tumor stroma exerting therapeutic resistance and phys. barriers for proper drug delivery.  As the most abundant cells in the tumor stroma, cancer-assocd. fibroblasts (CAFs) produce a crit. tumor-promoting effect and barriers preventing the phys. delivery of nanomedicines through secreting pro-tumorigenic cytokines, increasing solid tumor pressure and interstitial fluid pressure (IFP), and nonspecific internalization.  Therefore, beyond treatment centered on cancer cells, researchers are focusing on targeting CAFs to fight stromal-rich tumors.  In recent years, a series of novel nano delivery systems have been developed based on specific CAF-targeted ligands and advanced biofunctional materials.  On the one hand, CAF-targeted nano delivery systems inhibit the pro-tumor signaling pathway between CAFs and cancer cells to reverse tumorigenesis, immunosuppression, or drug resistance in the tumor microenvironment, thus improving the sensitivity to antitumor treatments.  On the other hand, nanostrategies acting on CAFs profoundly contribute to increasing the deep penetration of antitumor drugs through the decrease of solid pressure, IFP, and dense extracellular matrix generation related to the resistance to intratumoral diffusion.  In this review, we first introduce the biol. mechanisms of CAFs that interfere with nanotherapy.  The state-of-the-art passive and active strategies of nano delivery systems targeting CAFs are then summarized, focusing on the therapeutic mechanism involved and the rational design of nano delivery systems.  Addnl., the challenges of CAF-targeted nanotherapy are discussed from the perspectives of developing efficient nano delivery systems and potential clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpslk8oeESZbVg90H21EOLACvtfcHk0lipW4ABICHCeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksVGmu78%253D&md5=691ee15daafac0155ca682eb02ca02e9</span></div><a href="/servlet/linkout?suffix=cit170c&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.0c00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.0c00014%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DEmerging%2520nano%2520drug%2520delivery%2520systems%2520targeting%2520cancer-associated%2520fibroblasts%2520for%2520improved%2520antitumor%2520effect%2520and%2520tumor%2520drug%2520penetration%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2020%26volume%3D17%26spage%3D1028%26epage%3D1048%26doi%3D10.1021%2Facs.molpharmaceut.0c00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Jamal, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulter, J. A.</span></span> <span> </span><span class="NLM_article-title">Exploiting current understanding of hypoxia mediated tumour progression for nanotherapeutic development</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1989</span>, <span class="refDoi"> DOI: 10.3390/cancers11121989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fcancers11121989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVyhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1989&author=J.+Fengauthor=N.+M.+Byrneauthor=W.+Al+Jamalauthor=J.+A.+Coulter&title=Exploiting+current+understanding+of+hypoxia+mediated+tumour+progression+for+nanotherapeutic+development&doi=10.3390%2Fcancers11121989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting current understanding of hypoxia mediated tumour progression for nanotherapeutic development</span></div><div class="casAuthors">Feng, Jie; Byrne, Niall M.; Al Jamal, Wafa; Coulter, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1989</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Hypoxia is one of the most common phenotypes of malignant tumors.  Hypoxia leads to the increased activity of hypoxia-inducible factors (HIFs), which regulate the expression of genes controlling a raft of pro-tumor phenotypes.  These include maintenance of the cancer stem cell compartment, epithelial-mesenchymal transition (EMT), angiogenesis, immunosuppression, and metabolic reprogramming.  Hypoxia can also contribute to the tumor progression in a HIF-independent manner via the activation of a complex signalling network pathway, including JAK-STAT, RhoA/ROCK, NF- κB and PI3/AKT.  Recent studies suggest that nanotherapeutics offer a unique opportunity to target the hypoxic microenvironment, enhancing the therapeutic window of conventional therapeutics.  In this review, we summarise recent advances in understanding the impact of hypoxia on tumor progression, while outlining possible nanotherapeutic approaches for overcoming hypoxia-mediated resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUa32YixN5SrVg90H21EOLACvtfcHk0lhKMBo7-gDR2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVyhsLs%253D&md5=f8373c6a29c0cdba9b7abe1e36653e7e</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.3390%2Fcancers11121989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11121989%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DByrne%26aufirst%3DN.%2BM.%26aulast%3DAl%2BJamal%26aufirst%3DW.%26aulast%3DCoulter%26aufirst%3DJ.%2BA.%26atitle%3DExploiting%2520current%2520understanding%2520of%2520hypoxia%2520mediated%2520tumour%2520progression%2520for%2520nanotherapeutic%2520development%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26spage%3D1989%26doi%3D10.3390%2Fcancers11121989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weeranoppanant, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Cell membrane biomimetic nanoparticles for inflammation and cancer targeting in drug delivery</span>. <i>Biomater. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">568</span>, <span class="refDoi"> DOI: 10.1039/C9BM01392J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1039%2FC9BM01392J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=31769765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFamsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=552-568&author=H.+Wangauthor=Y.+Liuauthor=R.+Heauthor=D.+Xuauthor=J.+Zangauthor=N.+Weeranoppanantauthor=H.+Dongauthor=Y.+Li&title=Cell+membrane+biomimetic+nanoparticles+for+inflammation+and+cancer+targeting+in+drug+delivery&doi=10.1039%2FC9BM01392J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Cell membrane biomimetic nanoparticles for inflammation and cancer targeting in drug delivery</span></div><div class="casAuthors">Wang, Huaiji; Liu, Ying; He, Ruiqing; Xu, Dailin; Zang, Jie; Weeranoppanant, Nopphon; Dong, Haiqing; Li, Yongyong</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">552-568</span>CODEN:
                <span class="NLM_cas:coden">BSICCH</span>;
        ISSN:<span class="NLM_cas:issn">2047-4849</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Nanoparticle capture and elimination by the immune system are great obstacles for drug delivery.  Camouflaging nanoparticles with cell membrane represents a promising strategy to communicate and negotiate with the immune system.  As a novel class of nanotherapeutics, such biomimetic nanoparticles inherit specific biol. functionalities of the source cells (e.g., erythrocytes, immune cells, cancer cells and platelets) in order to evade immune elimination, prolong circulation time, and even target a disease region by virtue of the homing tendency of the cell membrane protein.  In this review, we begin with an overview of different cell membranes that can be utilized to create a biointerface on nanoparticles.  Subsequently, we elaborate on the state-of-the-art of cell membrane biomimetic nanoparticles for drug delivery.  In particular, a summary of data on circulation capacity and targeting efficiency by camouflaged nanoparticles is presented.  In addn. to cancer therapy, inflammation treatment, as an emerging application of biomimetic nanoparticles, is specifically included.  The challenges and outlook of this technol. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSYcCjiA0kIrVg90H21EOLACvtfcHk0lhKMBo7-gDR2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFamsLrI&md5=b3c38b4d71cb1f8b7af01aae4278650f</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1039%2FC9BM01392J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9BM01392J%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DWeeranoppanant%26aufirst%3DN.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DCell%2520membrane%2520biomimetic%2520nanoparticles%2520for%2520inflammation%2520and%2520cancer%2520targeting%2520in%2520drug%2520delivery%26jtitle%3DBiomater.%2520Sci.%26date%3D2020%26volume%3D8%26spage%3D552%26epage%3D568%26doi%3D10.1039%2FC9BM01392J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, C. K.</span></span> <span> </span><span class="NLM_article-title">A set of cancer stem cell homing peptides associating with the glycan moieties of glycosphingolipids</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">20490</span>– <span class="NLM_lpage">20507</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.24960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.18632%2Foncotarget.24960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=29755667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A280%3ADC%252BC1MfislWgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=20490-20507&author=Y.+H.+Suauthor=T.+Y.+Linauthor=H.+J.+Liuauthor=C.+K.+Chuang&title=A+set+of+cancer+stem+cell+homing+peptides+associating+with+the+glycan+moieties+of+glycosphingolipids&doi=10.18632%2Foncotarget.24960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">A set of cancer stem cell homing peptides associating with the glycan moieties of glycosphingolipids</span></div><div class="casAuthors">Su Yu-Hsiu; Lin Tai-Yun; Chuang Chin-Kai; Su Yu-Hsiu; Liu Hung-Jen; Liu Hung-Jen; Liu Hung-Jen</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">20490-20507</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer stem cells (CSCs) are currently believed to be involved in tumor metastasis and relapse.  And treatments against CSCs are well concerned issues.  Peptides targeting to mouse and human CSCs were screened from an M13 phage display library.  The first subset of cancer stem cell homing peptides (CSC HPs), CSC HP-1 to -12, were screened with mouse EMT6 breast cancer stem cells.  Among them, CSC HP-1, CSC HP-3, CSC HP-8, CSC HP-9, and CSC HP-10 can bind to mouse CT26 colon CSCs; CSC HP-1, CSC HP-2, CSC HP-3, and CSC HP-8 can bind to mouse Hepa1-6 liver CSCs; as well as CSC HP-1, CSC HP-2, CSC HP-3, CSC HP-8, CSC HP-9, CSC HP-10, and CSC HP-11 can bind to human PANC-1 pancreatic CSCs.  The second subset of cancer stem cell homing peptides, CSC HP-hP1 to -hP3, were screened with human PANC-1 pancreatic CSCs.  Both CSC HP-hP1 and CSC HP-hP2 were demonstrated able to bind mouse EMT6, CT26 and Hepa1-6 CSCs as well as human colorectal HT29 and lung H1650 CSCs.  CSC HP-1 and CSC HP-hP1 could strongly associate with the Globo 4 and Lewis Y glycan epitopes coupled on a microarray chip or Globo 4 and Globo H conjugated on bovine serum albumin.  CSC HP-10, CSC HP-11 and CSC HP-hP2 could associate with the disialylated saccharide Neu5Ac-α-2,6-Gal-β-1,3-(Neu5Ac-α-2,6)-GalNAc coupled on a microarray chip.  These results indicate that the CSC HPs may target to the known stem cell glycan markers GbH and Lewis Y as well as the disialylated saccharide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRT_RS39fJiZUloaUqgkFHkfW6udTcc2eZEJvepFRWwK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfislWgtw%253D%253D&md5=895879c4659087efacb2e14f05339933</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.24960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.24960%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DY.%2BH.%26aulast%3DLin%26aufirst%3DT.%2BY.%26aulast%3DLiu%26aufirst%3DH.%2BJ.%26aulast%3DChuang%26aufirst%3DC.%2BK.%26atitle%3DA%2520set%2520of%2520cancer%2520stem%2520cell%2520homing%2520peptides%2520associating%2520with%2520the%2520glycan%2520moieties%2520of%2520glycosphingolipids%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D20490%26epage%3D20507%26doi%3D10.18632%2Foncotarget.24960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, C.-K.</span>; <span class="NLM_string-name">Su, Y.-H.</span>; <span class="NLM_string-name">Lin, T.-Y.</span></span> <span> </span><span class="NLM_article-title">Cancer Stem Cell Targeting Peptide and Use Thereof</span>. U.S. Patent <span class="NLM_patent">20170158737 A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.-K.+Chuang&author=Y.-H.+Su&author=T.-Y.+Lin&title=Cancer+Stem+Cell+Targeting+Peptide+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChuang%26aufirst%3DC.-K.%26atitle%3DCancer%2520Stem%2520Cell%2520Targeting%2520Peptide%2520and%2520Use%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truchan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span> <span> </span><span class="NLM_article-title">Albumin nanoparticle of paclitaxel (Abraxane) decreases while taxol increases breast cancer stem cells in treatment of triple negative breast cancer</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2275</span>– <span class="NLM_lpage">2286</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.9b01221</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.9b01221" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVGntbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=2275-2286&author=H.+Yuanauthor=H.+Guoauthor=X.+Luanauthor=M.+Heauthor=F.+Liauthor=J.+Burnettauthor=N.+Truchanauthor=D.+Sun&title=Albumin+nanoparticle+of+paclitaxel+%28Abraxane%29+decreases+while+taxol+increases+breast+cancer+stem+cells+in+treatment+of+triple+negative+breast+cancer&doi=10.1021%2Facs.molpharmaceut.9b01221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer</span></div><div class="casAuthors">Yuan, Hebao; Guo, Hongwei; Luan, Xin; He, Miao; Li, Feng; Burnett, Joseph; Truchan, Nathan; Sun, Duxin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2275-2286</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) has a high rate of metastasis, which is assocd. with breast cancer stem-like cells (CSCs).  Although Taxol (micelle formulation of paclitaxel) is the first line chemotherapy to treat TNBC, it increases CSCs in residual tumors.  Abraxane, albumin nanoparticle of paclitaxel, showed lower plasma concn. compared to Taxol in both human and animal models, but it is not clear why Abraxane showed superior efficacy to Taxol in treatment of metastatic breast cancer in humans.  In this study, we intend to investigate if Abraxane eliminates CSCs for its better efficacy.  The results showed that Abraxane showed similar cytotoxicity in SUM149 cells in comparison with Taxol.  Although Abraxane showed 3- to 5-fold lower blood drug concn. compared to Taxol, it achieved similar tumor drug concn. and 10-fold higher tumor/plasma ratio in SUM149 xenograft NOD/SCID mouse model.  In addn., Abraxane and Taxol showed similar efficacy to shrink the tumor size in orthotopic breast cancer NOD/SCID mouse model.  However, Abraxane decreased breast CSCs frequency by 3- to 9-fold, while Taxol increased breast CSCs frequency in an orthotopic breast cancer NOD/SCID mouse model.  Furthermore, Abraxane increased 3- to 15-fold intracellular uptake in both ALDH+ CSCs and differentiated ALDH- cells in comparison with Taxol, which provides a mechanism for Abraxane's superior efficacy to eliminate CSCs in comparison with Taxol.  Our data suggest albumin nanoparticle Abraxane may have a broad implication to enhance drug's efficacy by eliminating breast cancer stem cells for treatment of metastatic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLV-4XqrWu17Vg90H21EOLACvtfcHk0ljYrnQlQLTsjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVGntbnN&md5=60408c2d8dde9b94dc5838cd771b406f</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.9b01221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.9b01221%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLuan%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DBurnett%26aufirst%3DJ.%26aulast%3DTruchan%26aufirst%3DN.%26aulast%3DSun%26aufirst%3DD.%26atitle%3DAlbumin%2520nanoparticle%2520of%2520paclitaxel%2520%2528Abraxane%2529%2520decreases%2520while%2520taxol%2520increases%2520breast%2520cancer%2520stem%2520cells%2520in%2520treatment%2520of%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2020%26volume%3D17%26spage%3D2275%26epage%3D2286%26doi%3D10.1021%2Facs.molpharmaceut.9b01221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Bertoni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozielski, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaughan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihelson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhart, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laterra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. J.</span></span> <span> </span><span class="NLM_article-title">Bioreducible polymeric nanoparticles containing multiplexed cancer stem cell regulating miRNAs inhibit glioblastoma growth and prolong survival</span>. <i>Nano Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4086</span>– <span class="NLM_lpage">4094</span>, <span class="refDoi"> DOI: 10.1021/acs.nanolett.8b00390</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.nanolett.8b00390" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFyqt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=4086-4094&author=H.+Lopez-Bertoniauthor=K.+L.+Kozielskiauthor=Y.+Ruiauthor=B.+Lalauthor=H.+Vaughanauthor=D.+R.+Wilsonauthor=N.+Mihelsonauthor=C.+G.+Eberhartauthor=J.+Laterraauthor=J.+J.+Green&title=Bioreducible+polymeric+nanoparticles+containing+multiplexed+cancer+stem+cell+regulating+miRNAs+inhibit+glioblastoma+growth+and+prolong+survival&doi=10.1021%2Facs.nanolett.8b00390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival</span></div><div class="casAuthors">Lopez-Bertoni, Hernando; Kozielski, Kristen L.; Rui, Yuan; Lal, Bachchu; Vaughan, Hannah; Wilson, David R.; Mihelson, Nicole; Eberhart, Charles G.; Laterra, John; Green, Jordan J.</div><div class="citationInfo"><span class="NLM_cas:title">Nano Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4086-4094</span>CODEN:
                <span class="NLM_cas:coden">NALEFD</span>;
        ISSN:<span class="NLM_cas:issn">1530-6984</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite our growing mol.-level understanding of glioblastoma (GBM), treatment modalities remain limited.  Recent developments in the mechanisms of cell fate regulation and nanomedicine provide new avenues by which to treat and manage brain tumors via the delivery of mol. therapeutics.  Here, we have developed bioreducible poly(β-amino ester) nanoparticles that demonstrate high intracellular delivery efficacy, low cytotoxicity, escape from endosomes, and promotion of cytosol-targeted environmentally triggered cargo release for miRNA delivery to tumor-propagating human cancer stem cells.  In this report, we combined this nanobiotechnol. with newly discovered cancer stem cell inhibiting miRNAs to develop self-assembled miRNA-contg. polymeric nanoparticles (nano-miRs) to treat gliomas.  We show that these nano-miRs effectively intracellularly deliver single and combination miRNA mimics that inhibit the stem cell phenotype of human GBM cells in vitro.  Following direct intratumoral infusion, these nano-miRs were found to distribute through the tumors, inhibit the growth of established orthotopic human GBM xenografts, and cooperatively enhance the response to std.-of-care γ radiation.  Co-delivery of two miRNAs, miR-148a and miR-296-5p, within the bioreducible nano-miR particles enabled long-term survival from GBM in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzu2F4Tq9m87Vg90H21EOLACvtfcHk0ljYrnQlQLTsjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFyqt7rN&md5=980ccb688441948880685d5c69fc898a</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Facs.nanolett.8b00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.nanolett.8b00390%26sid%3Dliteratum%253Aachs%26aulast%3DLopez-Bertoni%26aufirst%3DH.%26aulast%3DKozielski%26aufirst%3DK.%2BL.%26aulast%3DRui%26aufirst%3DY.%26aulast%3DLal%26aufirst%3DB.%26aulast%3DVaughan%26aufirst%3DH.%26aulast%3DWilson%26aufirst%3DD.%2BR.%26aulast%3DMihelson%26aufirst%3DN.%26aulast%3DEberhart%26aufirst%3DC.%2BG.%26aulast%3DLaterra%26aufirst%3DJ.%26aulast%3DGreen%26aufirst%3DJ.%2BJ.%26atitle%3DBioreducible%2520polymeric%2520nanoparticles%2520containing%2520multiplexed%2520cancer%2520stem%2520cell%2520regulating%2520miRNAs%2520inhibit%2520glioblastoma%2520growth%2520and%2520prolong%2520survival%26jtitle%3DNano%2520Lett.%26date%3D2018%26volume%3D18%26spage%3D4086%26epage%3D4094%26doi%3D10.1021%2Facs.nanolett.8b00390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span> <span> </span><span class="NLM_article-title">Salinomycin-loaded gold nanoparticles for treating cancer stem cells by ferroptosis-induced cell death</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2532</span>– <span class="NLM_lpage">2539</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.9b00132</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.9b00132" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvVGku74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=2532-2539&author=Y.+Zhaoauthor=W.+Zhaoauthor=Y.+C.+Limauthor=T.+Liu&title=Salinomycin-loaded+gold+nanoparticles+for+treating+cancer+stem+cells+by+ferroptosis-induced+cell+death&doi=10.1021%2Facs.molpharmaceut.9b00132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Salinomycin-Loaded Gold Nanoparticles for Treating Cancer Stem Cells by Ferroptosis-Induced Cell Death</span></div><div class="casAuthors">Zhao, Yongmei; Zhao, Wei; Lim, Yi Chieh; Liu, Tianqing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2532-2539</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are a subpopulation of tumor cells that exhibit self-renewal, differentiation, and tumorigenicity.  CSCs are highly resistant to the conventional cancer treatment and have been assocd. with metastasis.  Several studies have been shown that salinomycin (Sal) has the potential to target cancer stem cells evidenced by in vitro and in vivo tumor models.  Here, salinomycin was conjugated with biocompatible gold nanoparticles (AuNPs) coated with poly(ethylene glycol) to improve its specificity in targeting breast cancer stem cells (BCSCs).  BCSCs derived from CD24low/CD44high subpopulation showed high sensitivity to Sal-AuNP treatment.  An in-depth anal. on the mechanism of action of Sal-AuNPs indicated ferroptosis, an iron-dependent cell death, was achieved as a result of iron accumulation and inhibition of antioxidant properties.  This also led to the induction of oxidative stress, mitochondrial dysfunction, and lipid oxidn.  Our findings suggest Sal-AuNP treatment is an efficient therapeutic avenue in eliminating cancer stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKwDm7LexSrbVg90H21EOLACvtfcHk0liljZHnn4Owfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvVGku74%253D&md5=a2622d384c5ef443603bb7b21c75a6cb</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.9b00132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.9b00132%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLim%26aufirst%3DY.%2BC.%26aulast%3DLiu%26aufirst%3DT.%26atitle%3DSalinomycin-loaded%2520gold%2520nanoparticles%2520for%2520treating%2520cancer%2520stem%2520cells%2520by%2520ferroptosis-induced%2520cell%2520death%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2019%26volume%3D16%26spage%3D2532%26epage%3D2539%26doi%3D10.1021%2Facs.molpharmaceut.9b00132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ning, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, M. J.</span></span> <span> </span><span class="NLM_article-title">Targeting colorectal cancer stem-like cells with anti-cd133 antibody-conjugated SN-38 nanoparticles</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">17793</span>– <span class="NLM_lpage">17804</span>, <span class="refDoi"> DOI: 10.1021/acsami.6b04403</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.6b04403" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKis7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=17793-17804&author=S.+T.+Ningauthor=S.+Y.+Leeauthor=M.+F.+Weiauthor=C.+L.+Pengauthor=S.+Y.+Linauthor=M.+H.+Tsaiauthor=P.+C.+Leeauthor=Y.+H.+Shihauthor=C.+Y.+Linauthor=T.+Y.+Luoauthor=M.+J.+Shieh&title=Targeting+colorectal+cancer+stem-like+cells+with+anti-cd133+antibody-conjugated+SN-38+nanoparticles&doi=10.1021%2Facsami.6b04403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles</span></div><div class="casAuthors">Ning, Sin-Tzu; Lee, Shin-Yu; Wei, Ming-Feng; Peng, Cheng-Liang; Lin, Susan Yun-Fan; Tsai, Ming-Hsien; Lee, Pei-Chi; Shih, Ying-Hsia; Lin, Chun-Yen; Luo, Tsai-Yueh; Shieh, Ming-Jium</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">17793-17804</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer stem-like cells play a key role in tumor development, and these cells are relevant to the failure of conventional chemotherapy.  To achieve favorable therapy for colorectal cancer, PEG-PCL-based nanoparticles, which possess good biol. compatibility, were fabricated as nanocarriers for the topoisomerase inhibitor, SN-38.  For cancer stem cell therapy, CD133 (prominin-1) is a theor. cancer stem-like cell (CSLC) marker for colorectal cancer and is a proposed therapeutic target.  Cells with CD133 overexpression have demonstrated enhanced tumor-initiating ability and tumor relapse probability.  To resolve the problem of chemotherapy failure, SN-38-loaded nanoparticles were conjugated with anti-CD133 antibody to target CD133-pos. (CD133+) cells.  In this study, anti-CD133 antibody-conjugated SN-38-loaded nanoparticles (CD133Ab-NPs-SN-38) efficiently bound to HCT116 cells, which overexpress CD133 glycoprotein.  The cytotoxic effect of CD133Ab-NPs-SN-38 was greater than that of nontargeted nanoparticles (NPs-SN-38) in HCT116 cells.  Furthermore, CD133Ab-NPs-SN-38 could target CD133+ cells and inhibit colony formation compared with NPs-SN-38.  In vivo studies in an HCT116 xenograft model revealed that CD133Ab-NPs-SN-38 suppressed tumor growth and retarded recurrence.  A redn. in CD133 expression in HCT116 cells treated with CD133Ab-NPs-SN-38 was also obsd. in immunohistochem. results.  Therefore, this CD133-targeting nanoparticle delivery system could eliminate CD133-pos. cells and is a potential cancer stem cell targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-eyhkT1Pc07Vg90H21EOLACvtfcHk0liljZHnn4Owfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKis7zO&md5=2d63ca84e325d5c02ba7e83cf6383b91</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1021%2Facsami.6b04403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.6b04403%26sid%3Dliteratum%253Aachs%26aulast%3DNing%26aufirst%3DS.%2BT.%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DWei%26aufirst%3DM.%2BF.%26aulast%3DPeng%26aufirst%3DC.%2BL.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DTsai%26aufirst%3DM.%2BH.%26aulast%3DLee%26aufirst%3DP.%2BC.%26aulast%3DShih%26aufirst%3DY.%2BH.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DLuo%26aufirst%3DT.%2BY.%26aulast%3DShieh%26aufirst%3DM.%2BJ.%26atitle%3DTargeting%2520colorectal%2520cancer%2520stem-like%2520cells%2520with%2520anti-cd133%2520antibody-conjugated%2520SN-38%2520nanoparticles%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2016%26volume%3D8%26spage%3D17793%26epage%3D17804%26doi%3D10.1021%2Facsami.6b04403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarmishyn, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nhi Nguyen, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mou, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiou, S. H.</span></span> <span> </span><span class="NLM_article-title">Dual delivery of HNF4α and cisplatin by mesoporous silica nanoparticles inhibits cancer pluripotency and tumorigenicity in hepatoma-derived CD133-expressing stem cells</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">19808</span>– <span class="NLM_lpage">19818</span>, <span class="refDoi"> DOI: 10.1021/acsami.9b04474</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.9b04474" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptFyltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=19808-19818&author=P.+H.+Tsaiauthor=M.+L.+Wangauthor=J.+H.+Changauthor=A.+A.+Yarmishynauthor=P.+N.+Nhi+Nguyenauthor=W.+Chenauthor=Y.+Chienauthor=T.+I.+Huoauthor=C.+Y.+Mouauthor=S.+H.+Chiou&title=Dual+delivery+of+HNF4%CE%B1+and+cisplatin+by+mesoporous+silica+nanoparticles+inhibits+cancer+pluripotency+and+tumorigenicity+in+hepatoma-derived+CD133-expressing+stem+cells&doi=10.1021%2Facsami.9b04474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Delivery of HNF4α and Cisplatin by Mesoporous Silica Nanoparticles Inhibits Cancer Pluripotency and Tumorigenicity in Hepatoma-Derived CD133-Expressing Stem Cells</span></div><div class="casAuthors">Tsai, Ping-Hsing; Wang, Mong-Lien; Chang, Jen-Hsuan; Yarmishyn, Aliaksandr A.; Nhi Nguyen, Phan Nguyen; Chen, Wei; Chien, Yueh; Huo, Teh-Ia; Mou, Chung-Yuan; Chiou, Shih-Hwa</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">19808-19818</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is one of the most prevalent and deadly malignancies characterized by high rate of recurrence.  Tumor recurrence is often attributed to the presence of a subpopulation of cells with stem cell properties, referred to as cancer stem cells (CSCs).  Traditionally, cancer therapies target the entire bulk of tumor cells; however, they are poorly effective against CSCs, characterized by higher drug resistance.  Therefore, approaches targeting CSCs may be required in addn. to conventional chemotherapy to prevent tumor recurrence.  In this study, we investigated an approach to target HCC by combining the conventional chemotherapeutic drug, cisplatin, to target the bulk of tumor cells, and differentiation therapy by delivering the gene encoding HNF4α, an important regulator of hepatocyte differentiation, to target CSCs.  We used the Huh7 cell line as an in vitro model of HCC, which is characterized by a high proportion of CD133-expressing CSCs.  By using flow cytometry, we sepd. CD133+ and CD133- Huh7 cell subpopulations and have shown that the former has highly pronounced in vivo tumorigenic capacity in contrast to the latter, which could not generate tumors in vivo.  For the dual delivery of HNF4α-encoding plasmid and cisplatin, we used polyethyleneimine-modified mesoporous silica nanoparticles (PMSNs) as the nanocarriers.  Here, we show that the treatment of CD133-expressing Huh7 cells with HNF4α-loaded PMSNs can suppress their proliferation rate, decrease the proportion of CSCs, downregulate stemness-assocd. genes, and increase the expression of mature hepatocyte-assocd. genes.  At the same time, the treatment of Huh7 with PMSNs loaded with both HNF4α-encoding plasmid and cisplatin could block them in the S-phase of the cell cycle and cause apoptosis.  In addn., dually loaded PMSNs were the most efficient formulation in suppressing tumor growth in vivo.  To summarize, in this study, we tested the nanoparticle-based delivery system as both chemotherapy and gene-based therapy agents, which has great potential for development of effective treatment of HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2A3mQIAjgs7Vg90H21EOLACvtfcHk0liDcVcl4XtMpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptFyltb0%253D&md5=a04bd8651acfff9324396395f6ed329e</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Facsami.9b04474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.9b04474%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DP.%2BH.%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DChang%26aufirst%3DJ.%2BH.%26aulast%3DYarmishyn%26aufirst%3DA.%2BA.%26aulast%3DNhi%2BNguyen%26aufirst%3DP.%2BN.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DChien%26aufirst%3DY.%26aulast%3DHuo%26aufirst%3DT.%2BI.%26aulast%3DMou%26aufirst%3DC.%2BY.%26aulast%3DChiou%26aufirst%3DS.%2BH.%26atitle%3DDual%2520delivery%2520of%2520HNF4%25CE%25B1%2520and%2520cisplatin%2520by%2520mesoporous%2520silica%2520nanoparticles%2520inhibits%2520cancer%2520pluripotency%2520and%2520tumorigenicity%2520in%2520hepatoma-derived%2520CD133-expressing%2520stem%2520cells%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2019%26volume%3D11%26spage%3D19808%26epage%3D19818%26doi%3D10.1021%2Facsami.9b04474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pesarrodona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-García, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seras-Franzoso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Chardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltá-Foix, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cámara-Sánchez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jara, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, S.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaverde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abasolo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, E.</span></span> <span> </span><span class="NLM_article-title">Engineering a nanostructured nucleolin-binding peptide for intracellular drug delivery in triple-negative breast cancer stem cells</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">5381</span>– <span class="NLM_lpage">5388</span>, <span class="refDoi"> DOI: 10.1021/acsami.9b15803</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.9b15803" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitl2htrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=5381-5388&author=M.+Pesarrodonaauthor=L.+S%C3%A1nchez-Garc%C3%ADaauthor=J.+Seras-Franzosoauthor=A.+S%C3%A1nchez-Chardiauthor=R.+Balt%C3%A1-Foixauthor=P.+C%C3%A1mara-S%C3%A1nchezauthor=P.+Generauthor=J.+J.+Jaraauthor=D.+Pulidoauthor=N.+Sernaauthor=S.+Schwartzauthor=M.+Royoauthor=A.+Villaverdeauthor=I.+Abasoloauthor=E.+Vazquez&title=Engineering+a+nanostructured+nucleolin-binding+peptide+for+intracellular+drug+delivery+in+triple-negative+breast+cancer+stem+cells&doi=10.1021%2Facsami.9b15803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering a Nanostructured Nucleolin-Binding Peptide for Intracellular Drug Delivery in Triple-Negative Breast Cancer Stem Cells</span></div><div class="casAuthors">Pesarrodona, Mireia; Sanchez-Garcia, Laura; Seras-Franzoso, Joaquin; Sanchez-Chardi, Alejandro; Balta-Foix, Ricardo; Camara-Sanchez, Patricia; Gener, Petra; Jara, Jose Juan; Pulido, Daniel; Serna, Naroa; Schwartz, Simo; Royo, Miriam; Villaverde, Antonio; Abasolo, Ibane; Vazquez, Esther</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">5381-5388</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Five peptide ligands of four different cell surface receptors (nucleolin, CXCR1, CMKLR1, and CD44v6) have been evaluated as targeting moieties for triple-neg. human breast cancers.  Among them, the peptide F3, derived from phage display, promotes the fast and efficient internalization of a genetically fused green fluorescent protein (GFP) inside MDA-MB-231 cancer stem cells in a specific receptor-dependent fashion.  The further engineering of this protein into the modular construct F3-RK-GFP-H6 and the subsequent construct F3-RK-PE24-H6 resulted in self-assembling polypeptides that organize as discrete and regular nanoparticles.  These materials, 15-20 nm in size, show enhanced nucleolin-dependent cell penetrability.  We show that the F3-RK-PE24-H6, based on the Pseudomonas aeruginosa exotoxin A (PE24) as a core functional domain, is highly cytotoxic over target cells.  The combination of F3, the cationic peptide (RK)n, and the toxin domain PE24 in such unusual presentation appears as a promising approach to cell-targeted drug carriers in breast cancers and addresses selective drug delivery in otherwise difficult-to-treat triple-neg. breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiOsqLbdR0e7Vg90H21EOLACvtfcHk0liDcVcl4XtMpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitl2htrvF&md5=30248b61abc2f9b175b9c0a14ec122d0</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Facsami.9b15803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.9b15803%26sid%3Dliteratum%253Aachs%26aulast%3DPesarrodona%26aufirst%3DM.%26aulast%3DS%25C3%25A1nchez-Garc%25C3%25ADa%26aufirst%3DL.%26aulast%3DSeras-Franzoso%26aufirst%3DJ.%26aulast%3DS%25C3%25A1nchez-Chardi%26aufirst%3DA.%26aulast%3DBalt%25C3%25A1-Foix%26aufirst%3DR.%26aulast%3DC%25C3%25A1mara-S%25C3%25A1nchez%26aufirst%3DP.%26aulast%3DGener%26aufirst%3DP.%26aulast%3DJara%26aufirst%3DJ.%2BJ.%26aulast%3DPulido%26aufirst%3DD.%26aulast%3DSerna%26aufirst%3DN.%26aulast%3DSchwartz%26aufirst%3DS.%26aulast%3DRoyo%26aufirst%3DM.%26aulast%3DVillaverde%26aufirst%3DA.%26aulast%3DAbasolo%26aufirst%3DI.%26aulast%3DVazquez%26aufirst%3DE.%26atitle%3DEngineering%2520a%2520nanostructured%2520nucleolin-binding%2520peptide%2520for%2520intracellular%2520drug%2520delivery%2520in%2520triple-negative%2520breast%2520cancer%2520stem%2520cells%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2020%26volume%3D12%26spage%3D5381%26epage%3D5388%26doi%3D10.1021%2Facsami.9b15803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Confeld, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamnoon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen-Smith, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallik, S.</span></span> <span> </span><span class="NLM_article-title">Targeting the tumor core: hypoxia-responsive nanoparticles for the delivery of chemotherapy to pancreatic tumors</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2849</span>– <span class="NLM_lpage">2863</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.0c00247</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.0c00247" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFaiurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=2849-2863&author=M.+I.+Confeldauthor=B.+Mamnoonauthor=L.+Fengauthor=H.+Jensen-Smithauthor=P.+Rayauthor=J.+Frobergauthor=J.+Kimauthor=M.+A.+Hollingsworthauthor=M.+Quadirauthor=Y.+Choiauthor=S.+Mallik&title=Targeting+the+tumor+core%3A+hypoxia-responsive+nanoparticles+for+the+delivery+of+chemotherapy+to+pancreatic+tumors&doi=10.1021%2Facs.molpharmaceut.0c00247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors</span></div><div class="casAuthors">Confeld, Matthew I.; Mamnoon, Babak; Feng, Li; Jensen-Smith, Heather; Ray, Priyanka; Froberg, James; Kim, Jiha; Hollingsworth, Michael A.; Quadir, Mohiuddin; Choi, Yongki; Mallik, Sanku</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2849-2863</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In pancreatic ductal adenocarcinoma (PDAC), early onset of hypoxia triggers remodeling of the extracellular matrix, epithelial-to-mesenchymal transition, increased cell survival, the formation of cancer stem cells, and drug resistance.  Hypoxia in PDAC is also assocd. with the development of collagen-rich, fibrous extracellular stroma (desmoplasia), resulting in severely impaired drug penetration.  To overcome these daunting challenges, we created polymer nanoparticles (polymersomes) that target and penetrate pancreatic tumors, reach the hypoxic niches, undergo rapid structural destabilization, and release the encapsulated drugs.  In vitro studies indicated a high cellular uptake of the polymersomes and increased cytotoxicity of the drugs under hypoxia compared to unencapsulated drugs.  The polymersomes decreased tumor growth by nearly 250% and significantly increased necrosis within the tumors by 60% in mice compared to untreated controls.  We anticipate that these polymer nanoparticles possess a considerable translational potential for delivering drugs to solid hypoxic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTnOzJaxTzy7Vg90H21EOLACvtfcHk0liDcVcl4XtMpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFaiurrM&md5=35d6a57babf6f90ca5c785b6bc0ce83d</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.0c00247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.0c00247%26sid%3Dliteratum%253Aachs%26aulast%3DConfeld%26aufirst%3DM.%2BI.%26aulast%3DMamnoon%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DJensen-Smith%26aufirst%3DH.%26aulast%3DRay%26aufirst%3DP.%26aulast%3DFroberg%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DHollingsworth%26aufirst%3DM.%2BA.%26aulast%3DQuadir%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DMallik%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520tumor%2520core%253A%2520hypoxia-responsive%2520nanoparticles%2520for%2520the%2520delivery%2520of%2520chemotherapy%2520to%2520pancreatic%2520tumors%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2020%26volume%3D17%26spage%3D2849%26epage%3D2863%26doi%3D10.1021%2Facs.molpharmaceut.0c00247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurunathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span> <span> </span><span class="NLM_article-title">Graphene oxide-silver nanocomposite enhances cytotoxic and apoptotic potential of salinomycin in human ovarian cancer stem cells (OvCSCs): a novel approach for cancer therapy</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">710</span>, <span class="refDoi"> DOI: 10.3390/ijms19030710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.3390%2Fijms19030710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVOntbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=710&author=Y.+J.+Choiauthor=S.+Gurunathanauthor=J.+H.+Kim&title=Graphene+oxide-silver+nanocomposite+enhances+cytotoxic+and+apoptotic+potential+of+salinomycin+in+human+ovarian+cancer+stem+cells+%28OvCSCs%29%3A+a+novel+approach+for+cancer+therapy&doi=10.3390%2Fijms19030710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Graphene oxide-silver nanocomposite enhancescytotoxic and apoptotic potential of salinomycinin human ovarian cancer stem cells (OvCSCs):a novel approach for cancer therapy</span></div><div class="casAuthors">Choi, Yun-Jung; Gurunathan, Sangiliyandi; Kim, Jin-Hoi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">710/1-710/23</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The use of graphene to target and eliminate cancer stem cells (CSCs) is an alternative approach to conventional chemotherapy.  We show the biomol.-mediated synthesis of reduced graphene oxide-silver nanoparticle nanocomposites (rGO-Ag) using R-phycoerythrin (RPE); the resulting RPE-rGO-Ag was evaluated in human ovarian cancer cells and ovarian cancer stem cells (OvCSCs).  The synthesized RPE-rGO-Ag nanocomposite (referred to as rGO-Ag) was characterized using various anal. techniques. rGO-Ag showed significant toxicity towards both ovarian cancer cells and OvCSCs.  After 3 wk of incubating OvCSCs with rGO-Ag, the no. of A2780 and ALDH+CD133+ colonies was significantly reduced. rGO-Ag was toxic to OvCSCs and reduced cell viability by mediating the generation of reactive oxygen species, leakage of lactate dehydrogenase, reduced mitochondrial membrane potential, and enhanced expression of apoptotic genes, leading to mitochondrial dysfunction and possibly triggering apoptosis. rGO-Ag showed significant cytotoxic potential towards highly tumorigenic ALDH+CD133+ cells.  The combination of rGO-Ag and salinomycin induced 5-fold higher levels of apoptosis than each treatment alone.  A combination of rGO-Ag and salinomycin at very low concns. may be suitable for selectively killing OvCSCs and sensitizing tumor cells. rGO-Ag may be a novel nano-therapeutic mol. for specific targeting of highly tumorigenic ALDH+CD133+ cells and eliminating CSCs.  This study highlights the potential for targeted therapy of tumor-initiating cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp77IFc9AfuqbVg90H21EOLACvtfcHk0lh8a9hTJPKsVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVOntbfL&md5=07fa5ee26a47cdc0f201b27679658f78</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.3390%2Fijms19030710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19030710%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DGurunathan%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26atitle%3DGraphene%2520oxide-silver%2520nanocomposite%2520enhances%2520cytotoxic%2520and%2520apoptotic%2520potential%2520of%2520salinomycin%2520in%2520human%2520ovarian%2520cancer%2520stem%2520cells%2520%2528OvCSCs%2529%253A%2520a%2520novel%2520approach%2520for%2520cancer%2520therapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D710%26doi%3D10.3390%2Fijms19030710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishiguro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Tuffin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, T.</span></span> <span> </span><span class="NLM_article-title">Targeting liver cancer stem cells using engineered biological nanoparticles for the treatment of hepatocellular cancer</span>. <i>Hepatol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1002/hep4.1462</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1002%2Fhep4.1462" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=32025612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOmtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2020&pages=298-313&author=K.+Ishiguroauthor=I.+K.+Yanauthor=L.+Lewis-Tuffinauthor=T.+Patel&title=Targeting+liver+cancer+stem+cells+using+engineered+biological+nanoparticles+for+the+treatment+of+hepatocellular+cancer&doi=10.1002%2Fhep4.1462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Liver Cancer Stem Cells Using Engineered Biological Nanoparticles for the Treatment of Hepatocellular Cancer</span></div><div class="casAuthors">Ishiguro, Kaori; Yan, Irene K.; Lewis-Tuffin, Laura; Patel, Tushar</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">298-313</span>CODEN:
                <span class="NLM_cas:coden">HCEOAJ</span>;
        ISSN:<span class="NLM_cas:issn">2471-254X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">By exploiting their biol. functions, the use of biol. nanoparticles such as extracellular vesicles can provide an efficient and effective approach for hepatic delivery of RNA-based therapeutics for the treatment of liver cancers such as hepatocellular cancer (HCC).  Targeting liver cancer stem cells (LCSC) within HCC provide an untapped opportunity to improve outcomes by enhancing therapeutic responses.  Cells with tumor-initiating capabilities such as LCSC can be identified by expression of markers such as epithelial cell adhesion mol. (EpCAM) on their cell surface.  EpCAM is a target of Wnt/β-catenin signaling, a fundamental pathway in stem-cell growth.  Moreover, mutations in the β-catenin gene are frequently obsd. in HCC and can be assocd. with constitutive activation of the Wnt/β-catenin pathway.  However, targeting these pathways for the treatment of HCC has been challenging.  Using RNA nanotechnol., we developed engineered biol. nanoparticles capable of specific and effective delivery of RNA therapeutics targeting β-catenin to LCSC.  Extracellular vesicles isolated from milk were loaded with small interfering RNA to β-catenin and decorated with RNA scaffolds to incorporate RNA aptamers capable of binding to EpCAM.  Cellular uptake of these EpCAM-targeting therapeutic milk-derived nanovesicles in vitro resulted in loss of β-catenin expression and decreased proliferation.  The uptake and therapeutic efficacy of these engineered biol. nanotherapeutics was demonstrated in vivo using tumor xenograft mouse models.  Conclusion: β-catenin can be targeted directly to control the proliferation of hepatic cancer stem cells using small interfering RNA delivered using target-specific biol. nanoparticles.  Application of this RNA nanotechnol.-based approach to engineer biol. nanotherapeutics provides a platform for developing cell-surface mol.-directed targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodTXzFrjo-47Vg90H21EOLACvtfcHk0lh8a9hTJPKsVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOmtrk%253D&md5=1dd6571dd99c05cf573f255cd55adcf9</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1002%2Fhep4.1462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep4.1462%26sid%3Dliteratum%253Aachs%26aulast%3DIshiguro%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DI.%2BK.%26aulast%3DLewis-Tuffin%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DT.%26atitle%3DTargeting%2520liver%2520cancer%2520stem%2520cells%2520using%2520engineered%2520biological%2520nanoparticles%2520for%2520the%2520treatment%2520of%2520hepatocellular%2520cancer%26jtitle%3DHepatol.%2520Commun.%26date%3D2020%26volume%3D4%26spage%3D298%26epage%3D313%26doi%3D10.1002%2Fhep4.1462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2018.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=10.1016%2Fj.biomaterials.2018.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=30352320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKit7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2019&pages=160-172&author=Y.+Liauthor=Y.+Xiaoauthor=H.+P.+Linauthor=D.+Reichelauthor=Y.+Baeauthor=E.+Y.+Leeauthor=Y.+Jiangauthor=X.+Huangauthor=C.+Yangauthor=Z.+Wang&title=In+vivo+%CE%B2-catenin+attenuation+by+the+integrin+%CE%B15-targeting+nano-delivery+strategy+suppresses+triple+negative+breast+cancer+stemness+and+metastasis&doi=10.1016%2Fj.biomaterials.2018.10.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis</span></div><div class="casAuthors">Li, Yunfei; Xiao, Yajuan; Lin, Hsuan-Pei; Reichel, Derek; Bae, Younsoo; Lee, Eun Y.; Jiang, Yiguo; Huang, Xuefei; Yang, Chengfeng; Wang, Zhishan</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">160-172</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) play pivotal roles in cancer metastasis, and strategies targeting cancer stemness may greatly reduce cancer metastasis and improve patients' survival.  The canonical Wnt/β-catenin pathway plays crit. roles in CSC generation and maintenance as well as in normal stem cells.  Non-specifically suppressing the Wnt/β-catenin pathway for cancer therapy could be deleterious to normal cells.  To achieve specific β-catenin attenuation in cancer cells, we report an integrin α5 (ITGA5)-targeting nanoparticle for treating metastatic triple neg. breast cancer (TNBC).  We found that ITGA5 is highly expressed in strongly migratory and invasive TNBC cells as well as their lung metastatic foci, which rationalizes active-targeted drug delivery to TNBC cells via ITGA5 ligands such as a commercialized ligand-RGD motif (Arg-Gly-Asp).  We modified lipid-polymer hybrid (LPH) nanoparticle for TNBC-targeted delivery of diacidic norcantharidin (NCTD), a potent anti-cancer compd. but with short half-life.  Notably, in vivo imaging anal. showed that RGD-decorated LPH (RGD-LPH) accumulated more significantly and remained much longer than LPH in nude mouse orthotopic mammary TNBC tumor and lung metastatic tumor, which implicated the feasibility of ITGA5-targeting strategy for treating metastatic TNBC.  Moreover, systemic administration of NCTD-loaded RGD-LPH (RGD-LPH-NCTD) reduced nude mouse orthotopic mammary TNBC tumor growth and metastasis more effectively than free NCTD and LPH-NCTD via down-regulating β-catenin.  These findings suggest that ITGA5-targeting nanoparticles may provide a facil and unique strategy of specially attenuating β-catenin in vivo for treating metastatic TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmm_3Z5FgrWLVg90H21EOLACvtfcHk0ljeHkHBO2fbxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKit7rF&md5=5fd2f078c8174df34178e485b850ae38</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2018.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2018.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DH.%2BP.%26aulast%3DReichel%26aufirst%3DD.%26aulast%3DBae%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DE.%2BY.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DIn%2520vivo%2520%25CE%25B2-catenin%2520attenuation%2520by%2520the%2520integrin%2520%25CE%25B15-targeting%2520nano-delivery%2520strategy%2520suppresses%2520triple%2520negative%2520breast%2520cancer%2520stemness%2520and%2520metastasis%26jtitle%3DBiomaterials%26date%3D2019%26volume%3D188%26spage%3D160%26epage%3D172%26doi%3D10.1016%2Fj.biomaterials.2018.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span> <span> </span><span class="NLM_article-title">Red-emissive carbon quantum dots for nuclear drug delivery in cancer stem cells</span>. <i>J. Phys. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4345</span>, <span class="refDoi"> DOI: 10.1021/acs.jpclett.0c01408</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jpclett.0c01408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsV2qu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=4345&author=W.+Suauthor=R.+Guoauthor=F.+Yuanauthor=Y.+Liauthor=X.+Liauthor=Y.+Zhangauthor=S.+Zhouauthor=L.+Fan&title=Red-emissive+carbon+quantum+dots+for+nuclear+drug+delivery+in+cancer+stem+cells&doi=10.1021%2Facs.jpclett.0c01408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Correction to "Red-Emissive Carbon Quantum Dots for Nuclear Drug Delivery in Cancer Stem Cells"</span></div><div class="casAuthors">Su, Wen; Guo, Ruihua; Yuan, Fanglong; Li, Yunchao; Li, Xiaohong; Zhang, Yang; Zhou, Shixin; Fan, Louzhen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4345</span>CODEN:
                <span class="NLM_cas:coden">JPCLCD</span>;
        ISSN:<span class="NLM_cas:issn">1948-7185</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf6wvmpqXdxLVg90H21EOLACvtfcHk0ljeHkHBO2fbxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsV2qu7c%253D&md5=a569ba6ece2848da615499a5fbf0915a</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Facs.jpclett.0c01408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jpclett.0c01408%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DL.%26atitle%3DRed-emissive%2520carbon%2520quantum%2520dots%2520for%2520nuclear%2520drug%2520delivery%2520in%2520cancer%2520stem%2520cells%26jtitle%3DJ.%2520Phys.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D4345%26doi%3D10.1021%2Facs.jpclett.0c01408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hembram, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bindhani, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, C. N.</span></span> <span> </span><span class="NLM_article-title">Quinacrine based gold hybrid nanoparticles caused apoptosis through modulating replication fork in oral cancer stem cells</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2463</span>– <span class="NLM_lpage">2472</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.0c00197</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.0c00197" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpt1Orsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=2463-2472&author=K.+C.+Hembramauthor=S.+R.+Dashauthor=B.+Dasauthor=C.+Sethyauthor=S.+Chatterjeeauthor=B.+K.+Bindhaniauthor=C.+N.+Kundu&title=Quinacrine+based+gold+hybrid+nanoparticles+caused+apoptosis+through+modulating+replication+fork+in+oral+cancer+stem+cells&doi=10.1021%2Facs.molpharmaceut.0c00197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Quinacrine Based Gold Hybrid Nanoparticles Caused Apoptosis through Modulating Replication Fork in Oral Cancer Stem Cells</span></div><div class="casAuthors">Hembram, Krushna Chandra; Dash, Somya Ranjan; Das, Biswajit; Sethy, Chinmayee; Chatterjee, Subhajit; Bindhani, Birendra Kumar; Kundu, Chanakya Nath</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2463-2472</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The presence of cancer stem cells (CSCs) in the tumor microenvironment is responsible for the development of chemoresistance and recurrence of cancer.  Our previous investigation revealed the anticancer mechanism of quinacrine-based silver and gold hybrid nanoparticles (QAgNP and QAuNP) in oral cancer cells, but to avoid cancer recurrence, it is important to study the effect of these nanoparticles (NPs) on CSCs.  Here, we developed an in vitro CSCs model using SCC-9 oral cancer cells and validated via FACS anal.  Then, 40-60% of cells were found to be CD44+/CD133+ and CD24-.  QAuNP showed excellent anti-CSC growth potential against SCC-9-cancer stem like cells (IC50 = 0.4μg/mL) with the down-regulation of representative CSC markers.  Prolonged exposure of QAuNP induced the S-phase arrest and caused re-replication shown by the extended G2/M population and apoptosis to SCC-9-CSC like cells.  Up-regulation of BAX, PARP cleavage, and simultaneous down-regulation of Bcl-xL in prolonged treatment to CSCs suggested that the majority of the cells have undergone apoptosis.  QAuNP treatment also caused a loss in DNA repair in CSCs.  Mostly, the base excision repair (BER) components (Fen-1, DNA ligase-1, Pol-β, RPA, etc.) were significantly down-regulated after QAuNP treatment, which suggested its action against DNA repair machinery.  The replication fork maintenance-related proteins, RAD 51 and BRCA-2, were also deregulated.  Very surprisingly, depletion of WRN (an interacting partner for Pre-RC and Fen-1) and a significant increase in expression of fork-degrading nuclease MRE-11 in 96 h treated NPs were obsd.  Results suggest QAuNP treatment caused excessive DNA damage and re-replication mediated replication stress (RS) and stalling of the replication fork.  Inhibition of BER components hinders the flap clearance activity of Fen-1, and it further caused RS and stopped DNA synthesis.  Overall, QAuNP treatment led to irreparable replication fork movement, and the stalled replication fork might have degraded by MRE-11, which ultimately results in apoptosis and the death of the CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2eD8S3ni3_bVg90H21EOLACvtfcHk0ljeHkHBO2fbxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpt1Orsb8%253D&md5=26861c1bc25366f91ad386b3b3753c07</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.0c00197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.0c00197%26sid%3Dliteratum%253Aachs%26aulast%3DHembram%26aufirst%3DK.%2BC.%26aulast%3DDash%26aufirst%3DS.%2BR.%26aulast%3DDas%26aufirst%3DB.%26aulast%3DSethy%26aufirst%3DC.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DBindhani%26aufirst%3DB.%2BK.%26aulast%3DKundu%26aufirst%3DC.%2BN.%26atitle%3DQuinacrine%2520based%2520gold%2520hybrid%2520nanoparticles%2520caused%2520apoptosis%2520through%2520modulating%2520replication%2520fork%2520in%2520oral%2520cancer%2520stem%2520cells%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2020%26volume%3D17%26spage%3D2463%26epage%3D2472%26doi%3D10.1021%2Facs.molpharmaceut.0c00197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01336&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01336" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01336" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0c6661d2d248d","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
